<SEC-DOCUMENT>0001628280-21-015248.txt : 20210803
<SEC-HEADER>0001628280-21-015248.hdr.sgml : 20210803
<ACCEPTANCE-DATETIME>20210803085616
ACCESSION NUMBER:		0001628280-21-015248
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210803
DATE AS OF CHANGE:		20210803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Esperion Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001434868
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35986
		FILM NUMBER:		211138171

	BUSINESS ADDRESS:	
		STREET 1:		3891 RANCHERO DRIVE, SUITE 150
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-887-3903

	MAIL ADDRESS:	
		STREET 1:		3891 RANCHERO DRIVE, SUITE 150
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HDL THERAPEUTICS INC
		DATE OF NAME CHANGE:	20080513
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>espr-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:d960a0e3-43c0-4beb-a690-4f9d75967096,g:902768da-5c62-49b7-8ede-3e343f3fe2f7,d:155233a9c30143f788c2cb30bf7b7a77--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:espr="http://www.esperion.com/20210630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>espr-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF8zLTEtMS0xLTA_71d97125-04bf-41b7-b76b-2f7d42b4a1ef">0001434868</ix:nonNumeric><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF80LTEtMS0xLTA_b7d94584-6c8d-4a14-831e-76f409128d63">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF81LTEtMS0xLTA_de3634b0-f29c-426b-b4bc-9c4e403285d9">2021</ix:nonNumeric><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF82LTEtMS0xLTA_2a43fe88-1dba-4215-a528-47cc96722099">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF83LTEtMS0xLTA_6b97716d-bcbb-4d32-820c-bb3e42f84e9e">false</ix:nonNumeric><ix:nonNumeric contextRef="ifbe168eb5b3940b88ace61c5db5c89a7_D20200101-20201231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xMDUxL2ZyYWc6NzVjNzVhYTFiYTAzNDRlZjliOGRkMjkyMGE2ZmVmOWEvdGV4dHJlZ2lvbjo3NWM3NWFhMWJhMDM0NGVmOWI4ZGQyOTIwYTZmZWY5YV81NDk3NTU4MTM4OTI1_560c1496-cb07-42dd-aca5-0cf59f938839">espr:AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" format="ixt-sec:durmonth" name="espr:ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182MS9mcmFnOmRjMWNhZWM3OGM2MzQ1OTc5ZGYzYTYwN2U3MzMxMjYyL3RhYmxlOjJiOWE1YjRkYzgxMTRiOWNiODhjZWVhYjBlYmE2Y2VkL3RhYmxlcmFuZ2U6MmI5YTViNGRjODExNGI5Y2I4OGNlZWFiMGViYTZjZWRfMTMtMS0xLTEtMA_b7a0c8ac-c8e6-475a-be66-e893a4c514bc">6</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="4" name="espr:PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182MS9mcmFnOmRjMWNhZWM3OGM2MzQ1OTc5ZGYzYTYwN2U3MzMxMjYyL3RhYmxlOjJiOWE1YjRkYzgxMTRiOWNiODhjZWVhYjBlYmE2Y2VkL3RhYmxlcmFuZ2U6MmI5YTViNGRjODExNGI5Y2I4OGNlZWFiMGViYTZjZWRfMTQtMS0xLTEtMA_e05aa767-a589-41d1-9e6b-9c4136cd2ce9">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="espr-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i050ee60691314e20b69ad95578d2607a_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1c209f1921c3473dbb64c2533be863bd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i056e612b26e34dd48d60f525e33d62cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id9c66ab5008d4c28a2f2a6317075fc61_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3f1e56095ca4d07a8f77cec69f8a7ba_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3555938aa014fbda7603991f689d2d4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia332deb386b74a509426822f23273e5e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i338fd57bbd8f4b7b98555b5eedfc71e5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5566a2ae4e074e8aac4a681884d52a3b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c9855747284b97950418c5661f9398_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ed1002c3524d20bc0a363b109f9831_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33200b5320234052894888a136145868_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5187a56ea64ae79ed566f657f52f0f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9d11b53c0d4fce938a87352fd5fe47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8ebc6cecb04f1dbbca266b983b0ee4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9259ac42a9d4b44a6979f88be43cf44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb7184bc40e84732a19137ba864fb6b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e0d32b36655400c85ee28b60964a4d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4782e3db8423421e942447fb17c5f321_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib43b6fdc517a411c85647b77372d9e79_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1c8ad065e5492490704fc3b9a9d9f6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib618d67da2c4453a8e65d796194636c5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399ac47076af4f908e42954eee2ad039_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8356b00716a84a1394f6e22c68047217_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608ba03464564214a1e179c94a81c70c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eaf0b1998954d038c9b487adfa44c18_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901e75a34f054bd3a4d7f6dd621b20bb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01bcadb4b56c4ca1818a0393ce077c11_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fcaca0841c046a9b25d41c5eeddd739_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb8bb66820b64eb6a3f3211d247b61e1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbb9433a1ea14fce9d9a309b864a4811_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee76b4784b044ff9b88b671a0c9db61_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e46a07eb6b45a69ba79f90d0863355_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib41c95943c0d424c87116966a66887e0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b16fd3852e84573bb807fbdf4943cb6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f619499fe244fb9ac621a6969656b01_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib097a985762a42b8972093d71e92f8b8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26cc47a532c9410ab9a72e3f56e5c255_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf5c408305464e4a81c9c0971ccc1df0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief3d178aecba4841860608f1ec04b7d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9441fa155214bfa91ca54f2b2d79fdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a70ab68542b4ee4b2ddd235713f530a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i216f52657d874071bb5e106dc1386103_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec380fc9717840dfb890dfb2ccbee359_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf0d08a05974b498b7f99693e9bb8d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4615107f61ab4ac6a24069635566da77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bae44f5d32f4368a92888cc0e7ad821_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e73edc56fe64f7eb2572e557a02f296_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36eefb9d0f774f2b9c2f8ea719313100_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6117ad9e183545289f9791c20580fa73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa3399dd3b7433b8d3557e92fc06f12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6c23d2b97143faa25a7e68488ada74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib32496abb58143b38427f1791a44f20c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d8e1fc8bdc455ba9db23447bc100f4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce9fa23f25f427eb9589454600ed4ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc069bdc067430e92abc207531d663c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i379ebd88020b47e4b6146efc5bf71137_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62e792aa7c38468e81e43fe34e5121a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d93286758fb4fb0834e3fe5467fd410_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca8b35ceea04640b7869eb9e58fee15_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12e7f1c8a5df44dda88579554a423614_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacf27721acf74d0ea561cff498784811_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2546d188d64d9d93c6334f07c8adcf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2395549626418da16b8a9ad6037264_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeed394b634a4b9fb167c86225bdd1d3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68b9a3b16a7041bd8d34d47e1359ed86_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i733c42004f7f45bf8f40d28a377fb43e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c790fd04d414722be81c66df421c95d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8adaaf631b47b48badf05858b0984f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe168eb5b3940b88ace61c5db5c89a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id125fee9cd774cad978f6ae94f446b6b_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57aa28556d54b82af658eb81d72b9fb_I20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i60ff16704c9e4a26864f51907841faaf_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica0ff70047d84bf3ac80640f0aca8a46_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4efa02bff686461abcceaa2242640380_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>espr:customer</xbrli:measure></xbrli:unit><xbrli:context id="i584f75dd199f4a379657616c6423e8f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4850b6ddab4d628848b2165151adcd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="revenue_source"><xbrli:measure>espr:revenue_source</xbrli:measure></xbrli:unit><xbrli:context id="i24321e9e8f7543f590713d54993c4653_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i272c7eba0c41457f84c261e58a1bbedc_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife3936cfd95f4b539b5a1cbb4ce8a51a_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfdd1264317a4e959d48fae350ca5f6a_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52875fa54d2d47d08f43907539a1290b_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:AmendedLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b05bb32f374749885434ca47747d1a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RegulatoryPerformanceObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib69346e757f3452d8d1aeea2c8017cfc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RegulatoryPerformanceObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5331bb6e27784c98ba83f790214f2d62_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:MilestoneMarketingAuthorizationApprovalNustendiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22044bf98171420f847fdf469c65b5ac_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:MilestoneMarketingAuthorizationApprovalNustendiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11df274bc00047b7b2522e08b61ca091_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1fbd1b685c42ffb9c49c3b31c629df_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f9230bab5b44cda5e7265c85d57b66_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:ProductSalesBulkTabletsNilemdoAndNustendiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dfde8b13e554913935ea8540925afeb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:ProductSalesBulkTabletsNilemdoAndNustendiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b353fe5393a4dc2bac419bc2aa386d6_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i232d185de48d4c6baa127c8681fe96ca_I20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d4992daffb433d85ca8fd259ed4e9d_I20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2e95112c7734a5d8292505e37d9fa7f_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if950ab2c0cae426e871485a272155dd5_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f46b3fae7942db8d62064f916bccae_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ef4d12805a94033b928a8cef22e81f6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0ea2e4cbd104e848e494a2b3378dd35_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4170f009274249bfb0d9fad65135d67a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93803d292d3b4027976e1b5d23361ad8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72ae8eed70f84e13942db9d0ab474673_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fbda9eaced641d493d9cc099814900c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95b9b936123043afb5dde0d7efbc4dfd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:CollaborativeArrangementLicenseToIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib65202acf8f242f1bd411cf05ccd2003_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f61d084882445fb054d3e384d280e9_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:SerometrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66cc3f1c51c941f2b162c47f055b97e7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0762115bc2ec4613b524e91fa9b92de0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecad91fa7424664b1f1f53f4d25e943_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85239930eaf64704995fff739a828f1c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2755a874c4a4c48a6b849306fd2464f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5495cad7e02a4bc7ac5c026e15930a48_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i022b72f313384923a430318e5e44d480_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f3eb84da08544e7858c671a0f89178b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02ebc26f1dec4284a51f47f1f7bd41c8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id696d6839c0d44a9971fc5c29b5ab6c5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79c6b9595b0e45e399fbfc89434af8ba_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3014251d4b0c415f885b37eb158bb11f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7475569334245839b63cf3cc4120cfc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84a310b3100843458cf7b9780be99be8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74320e4faa84cd1b28ec9a625c98df5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5153d021d85e4ef9b35b24ed9da916ca_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ddd957560f42ff8203389517f59eb2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba2aa44c62434cdca9106c4f4051ff24_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5581113f5e084f04997d0355ded32b7d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4033291bd05c46c28d615917d2bf3476_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b50f26d3c4740b19924787f56195caa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17ff88d17c8f4135932357759e2c4415_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a555aa890154f02bec9878d09c55db6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a780031e57403b91a7034227c9bdaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559c63b8c37f45c191813cedafe6679c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0655536ac5664cfc9f50beaeae40a963_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c5f735fcfc445e88a0357b3cff80ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66085bd7806540ba8c194ce5c0187acd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9b0a5e5b1d4b328310765a841beb27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-26</xbrli:startDate><xbrli:endDate>2019-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fefac52cc164b6e8c114422d7b945c7_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e34a6464b9342eab9af91553cce8a2c_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e0952b04e3e49f89edda6732c584442_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2090d9c5d7cd408393dabbb49aef53e9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a49799960046fabd41ee94341b6178_D20210516-20210516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-16</xbrli:startDate><xbrli:endDate>2021-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28e0c72e2cb9467a8d1097badc2d555d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b18040c5994d5fb1c1230a7479649f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5fa732b89bf4e608cb020cdbaed049c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i314c65622530486bbc90177fa464e9a2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i682526a2d76f4aad9318435409bd1702_D20190626-20190626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-26</xbrli:startDate><xbrli:endDate>2019-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54599248558d4aeabaada2313141952a_D20190626-20190626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-26</xbrli:startDate><xbrli:endDate>2019-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24cc2d3d09bf4804b7ebe4fcf96e4159_I20190626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2993300957480c8da25fe45a53a602_D20190626-20190626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-26</xbrli:startDate><xbrli:endDate>2019-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61206dad37874474a095378d715c7ddc_I20190626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3168451b6e8043e7a8c693b76d15d0bb_D20190626-20190626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-26</xbrli:startDate><xbrli:endDate>2019-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i151f5743662f4d9b94b53d5f3aebdc7b_I20190626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519246cc64e94185973aeceecf9b0714_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if16e161500f14c968dff53d7b2d6a4eb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if04054e50e094fd9b83c8ea7d483bcc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabdf33924b4c4632935947223d1b399b_D20201118-20201118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-18</xbrli:startDate><xbrli:endDate>2020-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e05ade79f0c4479b2b0adfc5aab22f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61bb4d25218d4d74956e512d85225917_D20201116-20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieab74430e0d740e2b4be6f36bf9d3cf3_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>espr:day</xbrli:measure></xbrli:unit><xbrli:context id="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c80fd5162dd43bcb17ca0bfc7e60a2b_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f1d759f487848f983aa3b9b0cfed648_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i220604fdf4934041957bde86b350d102_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f7b2751cd04b7cba61f5f9cda15259_I20201118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe5a302bf0ef4a2ca9960e5cd3087195_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d4607f308bc47208a506b88c7eb9aa4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i975b21eabca94d14af546e0ab124bf30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1d9db700df64698bb10be3cd5969a2d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93532836fe0e4502b83cb85c9fb2c31a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib008a93c1f5b4185bd24238dd3202fe2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdbc8b360e6a444da2991d43afe2a07e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5305d0a8f10c49fa886fd702e4c1cc65_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d2d467fe6c549869f5d62f5f2e70867_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69054b09ba54731a79fe2fd68c06551_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:CappedCallMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4a6340c209848789d2ead328753e5dc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f44623b0aab464f8a2a2de5879f3fc6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21cebe390d5c4ab1a9dcde2e33388077_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8fc8a8e135542e79741bc96b14f2509_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82de142173eb4c029ba076114a0d9dc2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65c8c52a3f8249128e0061ca20f07e6e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd83bfde144490abf8e977beb2d1e13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864a800b9e2f4367b5189df3691f74ed_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i059e63457ab0488a8b8926c7af529680_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898eb34514a14aaca65ddd29c2ba018f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e390bfc85947a1b2e04d2d1b168ba2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90fbea89e414e58b44494d21f429a48_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f01c8d8eec0472c8f65bc4d927a3971_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7741b1a7bd54135bcc5b59858d55156_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7123ad4d0294677ba36fc60acabdec6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057a47e17f174e828a68dcc68defe7b5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d8118dee83344708fa7b2847e3b49ae_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3300afb8e3844697bef3a62d80174c94_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada643021f094d168ae1bb38139e79f6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb9e9630412f44bab00355a379ce951e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68daaa76952c4522a02c46ae9c9b099d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf977f7283ba4421a1c44b0fd2d0dd6b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbfaf88013a0436983a4e2f8e2e3b9a9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9deb65589fd4b818e61af707066a7bd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9113bd66c9034dc5b296e6fd3676426d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f518e9c8c2e4aa58a673d03a3aca709_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie596161ef3d64bc0b3c096d1474e9499_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e64bbef76f49d187ba3ba4bb0a64ae_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a360e7e8004cb7a888a243dc4639e3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ecd3a7b914d4102b067da5c2fed3f4d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6517e0e5ba714e75aef0fa5cdffc38ea_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i594b303f27a441e79f5d86e7922bf49c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6179414809fd40c2899b2bcdf7735820_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i155233a9c30143f788c2cb30bf7b7a77_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.818%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI1_8f534bfa-0104-4afd-9920-931b50ffd8ef">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:481.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6YmNiZTEzN2IwMGJjNDI5NTk3ZGEzMjVmZDg3YmYyYjAvdGFibGVyYW5nZTpiY2JlMTM3YjAwYmM0Mjk1OTdkYTMyNWZkODdiZjJiMF8wLTAtMS0xLTA_56226219-c97f-476e-afb8-0b82efd527a9">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8xMjg_eb66e5e4-680a-4298-9c10-e91b62d9fd07">June&#160;30, 2021</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:481.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6M2Q5ZDlkYjI3MTA5NDBhM2I0ZDcwODU5YTY3YmVjNmQvdGFibGVyYW5nZTozZDlkOWRiMjcxMDk0MGEzYjRkNzA4NTlhNjdiZWM2ZF8wLTAtMS0xLTA_a108df93-7731-4983-98d8-801f8ac6e82f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI2_ecc54507-6c85-44e5-b3dd-8c428da30f69">001-35986</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTIw_e95c338c-4a26-4258-80b3-809d14564b72">Esperion Therapeutics, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6ZjZhZTg3ODQwNTg3NDkzZmEwNzM1YmJmMGRiZjcxNWEvdGFibGVyYW5nZTpmNmFlODc4NDA1ODc0OTNmYTA3MzViYmYwZGJmNzE1YV8wLTAtMS0xLTA_3cff0e3d-40c0-4abd-b54a-6c4ead1e5cdf">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6ZjZhZTg3ODQwNTg3NDkzZmEwNzM1YmJmMGRiZjcxNWEvdGFibGVyYW5nZTpmNmFlODc4NDA1ODc0OTNmYTA3MzViYmYwZGJmNzE1YV8wLTItMS0xLTA_c695612b-5744-443d-881e-49efdc9b3062">26-1870780</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTIx_7f2188b0-8d82-47c8-a5c9-879a98bc2833">3891 Ranchero Drive, Suite&#160;150</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTIy_3ebfba9d-8b55-45f9-a88b-f3445e5912fe">Ann Arbor</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI3_38e6b954-b95d-4a5b-a1bd-c48c2c4fdd98">MI</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTIz_acdadee4-ec64-45a5-aae8-333b27f4bb5d">48108</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive office) (Zip Code)</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTE3_1cb19c69-87a5-4973-a0d5-2cdbe901b958">734</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTE4_25af759e-00cc-4dc7-988b-45ab9accd0c3">887-3903</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NzBiMDhkZTQ0YWI2NGIyMzhkOTc0NTBhOTFjOGQwNGEvdGFibGVyYW5nZTo3MGIwOGRlNDRhYjY0YjIzOGQ5NzQ1MGE5MWM4ZDA0YV8xLTAtMS0xLTA_2b6108d7-10a1-4628-95d5-315c5becafd8">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NzBiMDhkZTQ0YWI2NGIyMzhkOTc0NTBhOTFjOGQwNGEvdGFibGVyYW5nZTo3MGIwOGRlNDRhYjY0YjIzOGQ5NzQ1MGE5MWM4ZDA0YV8xLTItMS0xLTA_45a8d8ea-3e48-40dc-97fe-0beaa91fdc34">ESPR</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NzBiMDhkZTQ0YWI2NGIyMzhkOTc0NTBhOTFjOGQwNGEvdGFibGVyYW5nZTo3MGIwOGRlNDRhYjY0YjIzOGQ5NzQ1MGE5MWM4ZDA0YV8xLTQtMS0xLTAvdGV4dHJlZ2lvbjowZWRiMzhjNDg3ZDk0ZmNjOTFiM2Y5MzdmMTVkMzM4NF81_7283f039-05d6-4195-b5fb-b69a7305c4ad">NASDAQ</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Market LLC</span></div></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI4_cb9aaec9-8545-48fa-be60-4597e23a948c">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI0_63d338f6-c656-4ee3-a7ee-856aba7c331b">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NGMyY2Y4NzljYmY2NDhiNGI0YmYxZjlkNzgzNjIzZGQvdGFibGVyYW5nZTo0YzJjZjg3OWNiZjY0OGI0YjRiZjFmOWQ3ODM2MjNkZF8wLTAtMS0xLTA_eeeafbf9-77fc-4a80-9edb-872b6e61a453">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NGMyY2Y4NzljYmY2NDhiNGI0YmYxZjlkNzgzNjIzZGQvdGFibGVyYW5nZTo0YzJjZjg3OWNiZjY0OGI0YjRiZjFmOWQ3ODM2MjNkZF8yLTQtMS0xLTA_de28e8a8-abda-4a47-af77-520f6a1fd00c">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NGMyY2Y4NzljYmY2NDhiNGI0YmYxZjlkNzgzNjIzZGQvdGFibGVyYW5nZTo0YzJjZjg3OWNiZjY0OGI0YjRiZjFmOWQ3ODM2MjNkZF80LTQtMS0xLTA_71e9d35e-89c8-4219-a4b0-cbc0eb1a669b">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTE5_113e641f-58d5-499b-a873-bc35110b52b0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;1, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i050ee60691314e20b69ad95578d2607a_I20210801" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMDI2_34f58981-529b-4b69-8a15-7062c1bc6134">28,277,493</ix:nonFraction> shares of the registrant&#8217;s Common Stock, $0.001 par value per share, outstanding.</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics,&#160;Inc.</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:89.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;I &#8212; FINANCIAL INFORMATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1. Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_16">Condensed Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_16">June 30, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_16">2021 and December&#160;31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_19">Condensed Statements of Operations and Comprehensive (Loss) Income for the three and six month periods ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_22">Condensed Statements of Stockholders&#8217; Equity (Deficit) for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_22"> and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_22">month periods ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_22">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_22">, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_28">Condensed Statements of Cash Flows for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_28"> three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_28">six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_28"> month periods ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_28">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_28">, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i155233a9c30143f788c2cb30bf7b7a77_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_31">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_31">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_88">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_88">24</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_112">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_112">34</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_115">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_115">34</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_118">PART&#160;II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_121">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_121">36</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_124">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_124">36</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_127">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_127">37</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_130">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_130">37</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_133">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_133">37</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_136">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_136">39</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div><span><br/></span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_13"></div><div><span><br/></span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Esperion Therapeutics, Inc.</span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNC0xLTEtMS0w_51d2bcc7-2669-4587-bcc9-36e78c1da0c6">219,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNC0zLTEtMS0w_621ad74b-a11e-412a-86c9-f4f5f7ff482e">304,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNy0xLTEtMS00NDA3_eab35158-3289-4aae-9a76-cd3f64e16576">21,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNy0zLTEtMS00NDA5_eb6777ae-58ae-4283-b66d-0da0dbe557a5">12,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" name="espr:PrepaidClinicalDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNy0xLTEtMS0w_2bded216-15db-45cf-a1f0-6fa7f3e4dcaa">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" name="espr:PrepaidClinicalDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNy0zLTEtMS0w_01065716-502e-4c5f-87ab-467a1e3d9d0a">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfOC0xLTEtMS0w_874cb797-e972-477c-b9fe-aa7c040fecdc">23,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfOC0zLTEtMS0w_50244f83-0abb-4462-8434-15238c28e58b">16,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfOS0xLTEtMS0w_aeef6936-3d3c-4501-b067-3e3dd939cc3e">9,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfOS0zLTEtMS0w_57418d79-4b27-4ac8-954c-888d0bdeb50d">11,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTAtMS0xLTEtMA_2e15a4ed-b788-4f03-8005-7a232bc6d3c3">275,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTAtMy0xLTEtMA_cb1b5e5c-b49f-4d6a-b5d9-2f01efe4629b">345,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTItMS0xLTEtMA_c8bc8ee8-7f16-4208-9f47-174032d94a52">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTItMy0xLTEtMA_34077b9b-6ca5-499d-b43b-da64343479ee">1,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTMtMS0xLTEtMA_8e159a80-c6e0-4db1-b15b-779f2c791778">4,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTMtMy0xLTEtMA_05026bd7-da87-4708-9945-f53a879c24c9">6,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTQtMS0xLTEtMA_01f08770-7d69-4b23-a6d0-31f213aa23d4">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTQtMy0xLTEtMA_58b981d6-3536-49a6-a985-b445d288cdbf">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTUtMS0xLTEtMA_32fa5540-780d-434b-9c99-693fc03aba02">280,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTUtMy0xLTEtMA_3ac820f8-6059-4de3-b105-f659ac192747">353,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTktMS0xLTEtMA_cb8ea1d6-59ef-45e1-9aee-f7d0b534823b">29,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTktMy0xLTEtMA_48f923f9-072a-4391-963f-e6567f51447f">51,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:AccruedClinicalDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjAtMS0xLTEtMA_0ff8c9c3-b0ca-4bc7-a712-84e8ec60cb13">2,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="espr:AccruedClinicalDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjAtMy0xLTEtMA_cd5a7c16-9408-4280-9d4b-8625bcea669e">7,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjEtMS0xLTEtMA_fb50d89f-bb1b-4fee-8a9b-f7bc1f503a67">31,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjEtMy0xLTEtMA_c0201084-632a-4906-bc29-a21048c1cb52">24,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:RevenueInterestLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjItMS0xLTEtMA_7df11f57-77a5-4a71-843f-9c085fa1f1a9">12,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="espr:RevenueInterestLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjItMy0xLTEtMA_b78f2c08-33e8-4aa1-b16b-4ba29b9c2675">5,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue from collaborations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjMtMS0xLTEtMA_319bc44b-4fd0-4930-8aac-7e190b8c5b61">3,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjMtMy0xLTEtMA_79daf03f-73b4-42e1-b83f-3e118fced09b">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjQtMS0xLTEtMA_e90f7135-5e00-4167-8ca6-ece533ed1365">2,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjQtMy0xLTEtMA_1ec7a198-8f7a-4015-8576-7d606694e845">2,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjUtMS0xLTEtMA_b48e92c2-ad4a-4af5-9c5b-388e838b676a">82,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjUtMy0xLTEtMA_7535a840-3475-4385-a651-00eff2e5a33a">94,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjctMS0xLTEtMA_61dd6221-e82a-414f-890a-2c292a0a4402">272,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjctMy0xLTEtMA_825fdee5-771f-458f-81d7-a3f121e2753a">179,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:RevenueInterestLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjgtMS0xLTEtMA_a63d9690-5724-4c25-8b99-0398a4d77c80">225,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="espr:RevenueInterestLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjgtMy0xLTEtMA_6b1dd928-cfd5-4d1a-bffa-dda05d5f8f2a">171,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjktMS0xLTEtMA_b473e3aa-fc6a-49f6-af00-4f12946d3265">1,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjktMy0xLTEtMA_b6183d71-b9cc-4519-bc7c-7778c9e899ad">3,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue from collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzAtMS0xLTEtMzY0NA_a04ede93-8dfb-4457-a1fb-d851f4516b55">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzAtMy0xLTEtMzY0NA_e815b89a-ec29-492d-8d9a-940788d8d8a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzAtMS0xLTEtMA_09bd0cf0-d753-4f6e-a371-a3e16c8dfb10">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzAtMy0xLTEtMA_2b462e6a-bfa9-4741-b6af-9fcceddcf821">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzEtMS0xLTEtMA_e251c82a-df6a-4ee3-88b2-ea22bf67d1d2">584,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzEtMy0xLTEtMA_cc02ef42-3a2e-4040-900f-27acbb274ea0">449,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzItMS0xLTEtMA_4d5ca52a-e58a-4031-a2aa-150c4f4f754e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzItMy0xLTEtMA_f02278f1-045d-4984-8f2b-8de747b1f21b"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzIx_430ea4cc-b355-428a-946a-653e3f5bc074"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzIx_4893ceed-10c8-4f53-b146-1ae1dff0bb7c">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzM1_3145819b-9a73-4b09-b154-05c66ace7a73"><ix:nonFraction unitRef="shares" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzM1_59b04738-8ce4-4110-93ca-6498c8e0daf6">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzYw_565ae722-6208-4617-bc2a-d9b27bf3bf28"><ix:nonFraction unitRef="shares" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzYw_7a1dd12e-a94a-4ed8-8fa9-d4fa6fb7e790"><ix:nonFraction unitRef="shares" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzYw_aa7cb2fb-83ae-4a30-b8a1-fb32fe5f9525"><ix:nonFraction unitRef="shares" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzYw_ee2ea208-ee74-425f-af34-5d558870abed">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of June&#160;30, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMS0xLTEtMA_58efbeb5-c6c4-4a43-804a-89c10d34cd5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMy0xLTEtMA_7e1f0be4-d0be-4b85-b029-52c602a861bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzE4_75f80a97-1405-4f99-8ae5-6bc017f937e8"><ix:nonFraction unitRef="usdPerShare" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzE4_894eab25-72ef-4185-9a96-d0acdae842b6">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzMy_21ff22c2-95b3-4ce0-a020-2b5cdb7933de"><ix:nonFraction unitRef="shares" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzMy_51f21f27-6ece-450e-816d-5d64019484b2">120,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2021 and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4Xzk3_504f51e6-ab07-4b78-8330-939aff5ae90d">28,268,533</ix:nonFraction> shares issued at June&#160;30, 2021 and <ix:nonFraction unitRef="shares" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzEzNg_79bebdd5-1282-4984-a02a-868b3135a472">27,910,366</ix:nonFraction> shares issued at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMS0xLTEtMA_657023f5-2ac1-45fa-bbd6-961e5d63b9cf">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMy0xLTEtMA_feb134d9-4d57-4bd1-b4fc-e8df6639206f">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzYtMS0xLTEtMA_49e22333-6e8c-4125-8fae-559cffbf02c3">722,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzYtMy0xLTEtMA_c05c7eb7-34c8-42b0-81d7-27d5f89da3a7">797,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjk2MDI1ZDlhNzdjYjRlNTJhNmQ5MzRhZmVmYTc5NTdkXzI5_25d00df4-b0e6-4e2d-b3ae-364d1e353cad"><ix:nonFraction unitRef="shares" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjk2MDI1ZDlhNzdjYjRlNTJhNmQ5MzRhZmVmYTc5NTdkXzI5_71348a69-51db-4547-a37a-dd2c55544a75">1,994,198</ix:nonFraction></ix:nonFraction> shares at June&#160;30, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzctMS0xLTEtMA_244ff2b9-b213-4c5a-9066-fcd2b274861c">54,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzctMy0xLTEtMA_dc59a6d8-17dc-4af3-bbf9-4e5297e4e74c">54,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzktMS0xLTEtMA_138c22c6-b379-4f26-88ca-a04ba7c4c7e7">971,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzktMy0xLTEtMA_ac8d9818-cfa7-4c14-9e3d-f798221fcf12">838,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNDAtMS0xLTEtMA_fc47098d-bdb3-4bbc-af9f-7012be419a6b">304,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNDAtMy0xLTEtMA_ab0f87c9-8f14-4933-a25a-b07842ec2ad3">96,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNDEtMS0xLTEtMA_23b576a9-6dbb-4305-8162-4c404a644747">280,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNDEtMy0xLTEtMA_02ddf246-867e-40dc-acfb-d7f9a3d0d258">353,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics,&#160;Inc.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations and Comprehensive (Loss) Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended                     June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c66ab5008d4c28a2f2a6317075fc61_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMy01LTEtMS0xMjU_ab7e8357-cad7-4f62-a037-0fc59c037220">10,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f1e56095ca4d07a8f77cec69f8a7ba_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMy03LTEtMS03OA_4858d109-45e5-404c-836d-a555c60e3ede">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3555938aa014fbda7603991f689d2d4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMy01LTEtMS0w_fb0f5bbc-e535-460a-b899-aa64b20a88f0">16,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia332deb386b74a509426822f23273e5e_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMy03LTEtMS0w_50d2eb7e-8203-4cfd-82b3-ce0f8560584a">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338fd57bbd8f4b7b98555b5eedfc71e5_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNC01LTEtMS0xMjg_101c1f96-ff61-4a8c-a4dc-8a8379e91007">30,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5566a2ae4e074e8aac4a681884d52a3b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNC03LTEtMS04MQ_40488eb9-460a-4a4a-bfe2-7bb5d3139ba7">211,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c9855747284b97950418c5661f9398_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNC01LTEtMS0w_9ca738c8-4f6a-4efe-a73e-493bade0d3f3">31,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ed1002c3524d20bc0a363b109f9831_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNC03LTEtMS0w_68b9284e-316c-4b04-8905-6302cc249e4b">212,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNS01LTEtMS0xMzE_8745d3ea-0a93-4213-a96e-6e3713921297">40,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNS03LTEtMS04NA_6a2587b4-baa0-4afc-852f-9ca0e1164690">212,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNS01LTEtMS0w_a9806b12-05dc-4884-b969-874c72259bae">48,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNS03LTEtMS0w_a7e4d441-6de5-4434-8017-ded1d4cea0f8">214,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOC01LTEtMS0xMzQ_5b05adb3-f709-44ea-b7c3-9524a98ae272">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOC03LTEtMS04Nw_960842dc-be12-4db0-911e-4a7a10c1f657">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOC01LTEtMS0w_5b3d5be7-789a-4276-8bdf-40d8f8e00b12">3,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOC03LTEtMS0w_945de271-dd2a-41a9-b3a2-550f5e3eebdf">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOS01LTEtMS0xMzc_8e4e5ea4-8251-4357-a7a8-f52ba0e5969d">25,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOS03LTEtMS05MQ_c972d2c0-994d-42af-8cff-db2ada29672e">34,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOS01LTEtMS0w_485a646d-4a79-4c91-9efc-b7968c4f2dc4">53,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOS03LTEtMS0w_852ba023-7f33-474d-9a6b-bf212a250ddb">69,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTAtNS0xLTEtMTQw_8e75dbc4-08fb-4c49-a02d-3631cd0d6ba1">46,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTAtNy0xLTEtOTQ_5e6b63fa-9990-490b-8f83-8694bd2cebce">47,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTAtNS0xLTEtMA_a3c14654-1ac2-4240-8016-6215ba205a57">107,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTAtNy0xLTEtMA_ef8c5b04-a910-4368-b780-8bc14e5fcc26">89,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTEtNS0xLTEtMTQz_69a41c91-3131-4c4b-9b4f-50b8d1ddda27">73,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTEtNy0xLTEtOTc_c6edf2ad-692c-4a5f-b864-0fe98fd2f92b">83,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTEtNS0xLTEtMA_04bc35a3-e273-49d4-b1e8-aeb6cefcb3b7">163,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTEtNy0xLTEtMA_cba49198-23a1-4efa-8b3f-ca0d9de8031c">159,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss) income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTMtNS0xLTEtMTQ2_e8b5278b-e5f1-461f-8d5c-e2568b4e3323">32,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTMtNy0xLTEtMTAx_6f1900d8-4ced-418a-a9fb-22968183fe0c">129,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTMtNS0xLTEtMA_fb426936-4b4b-44d1-ab04-b1ea59ddc330">115,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTMtNy0xLTEtMA_55a66ec4-c4f7-4860-94ea-d6a5a4936fa0">54,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTUtNS0xLTEtMTUz_5e70d91b-28ae-489c-9104-176fc8fe7a07">11,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTUtNy0xLTEtMTA0_98a2a26c-6f0e-4dd1-a6a5-66de7415d419">4,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTUtNS0xLTEtMA_6c25c598-d115-4030-8f00-f41a216c3780">19,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTUtNy0xLTEtMA_622e446c-060d-497f-b302-d4aca1e9a7fa">8,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTYtNS0xLTEtMTUy_8e0ef3ad-5e5b-45ed-a91e-32ad347a26e6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTYtNy0xLTEtMTA3_07edacfe-32b7-4564-ae26-8d8f5296e776">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTYtNS0xLTEtMA_499897a0-eaf3-44fb-8cd0-4c930da9c69c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTYtNy0xLTEtMA_f9dce7f2-4aed-4347-9b5f-c810c3371c93">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTctNS0xLTEtMTc4_22ba8602-8575-4ec9-a439-ce58bf7a60eb">43,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTctNy0xLTEtMTEw_f359c64c-3b95-4a88-9d88-f24a64e899ee">124,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTctNS0xLTEtMA_34cf3931-c2d3-4edf-ab12-2b09fb44d7aa">134,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTctNy0xLTEtMA_6ebc1bfb-6a67-43eb-9b04-e4d1d12fced3">46,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTktNS0xLTEtMTgx_f2601034-800d-4d00-9a9b-9de0bc3ca9dc">1.67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTktNy0xLTEtMTEz_5f199e5b-301f-4d33-b926-94cd59965fdf">4.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTktNS0xLTEtMA_62122548-1f5f-490f-9ec6-0817813324ae">5.16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTktNy0xLTEtMA_9101bce7-e85e-47c4-bcbf-85d2c980eb63">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjAtNS0xLTEtMTkwMw_e5bc23a9-274c-4811-ad61-d42d039225e4">1.67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjAtNy0xLTEtMTg5NQ_e5ea78d0-ac2b-4e26-917d-a64e53dcd327">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjAtNS0xLTEtMA_a3312486-f30b-4e9a-b5af-ead2ab4c4885">5.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjAtNy0xLTEtMA_3c6643d3-8e7f-41fa-b6a8-6023d3485a68">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjItNS0xLTEtMTg0_9c9c03de-f657-4463-aad0-66437065b2d9">26,225,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjItNy0xLTEtMTE2_61887452-5661-4d67-b581-259335bded9b">27,665,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjItNS0xLTEtMA_9ef10db2-791e-437c-948c-25fad707edbe">26,109,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjItNy0xLTEtMA_2452a97d-f78f-401e-8b95-88b744ed409f">27,592,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjMtNS0xLTEtMTkxNQ_7261d445-63d5-4996-9786-5ae78bf4ff40">26,225,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjMtNy0xLTEtMTkxNQ_ff1d3e96-1b79-439b-9570-0f1924fdf011">28,854,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjMtNS0xLTEtMA_1462d647-fcd8-45ad-b250-096d8e577428">26,109,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjMtNy0xLTEtMA_5f8d3ff2-e029-4323-8e0e-7f4c76b5ac99">28,948,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjYtNS0xLTEtMTg3_8d4dc9e0-b546-49ad-92b9-ba817c636668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjYtNy0xLTEtMTE5_b71aa2a2-89ec-4024-a09c-eebc12a9e746">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjYtNS0xLTEtMA_1c84ca42-fef5-4982-8ce0-7965a83a9b00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjYtNy0xLTEtMA_d4fb84cb-5048-43bf-aad5-3fbc7fece799">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjctNS0xLTEtMTkw_e3e8f244-0146-46d4-bb0f-adc9d264b030">43,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjctNy0xLTEtMTIy_425f0317-49b4-4ca0-b308-3f27ce79e0ce">124,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjctNS0xLTEtMA_501dd9ca-6f47-4522-b75c-1e0dc7ee1c66">134,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjctNy0xLTEtMA_e82b4710-d404-4957-8c1d-a2a5fb6d2873">46,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.290%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders' Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a5187a56ea64ae79ed566f657f52f0f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi0xLTEtMS0w_5793628e-8214-4af9-9493-bf2d3118fe7a">27,497,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5187a56ea64ae79ed566f657f52f0f_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi0zLTEtMS0w_76ce6c09-ef5c-474a-8261-3467213ae6af">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9d11b53c0d4fce938a87352fd5fe47_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi01LTEtMS0w_3a167088-523f-4f0e-8fad-80172ee7949a">715,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f8ebc6cecb04f1dbbca266b983b0ee4_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi03LTEtMS0w_52a5100a-6ee2-4a46-891b-c9e287d65c86">695,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9259ac42a9d4b44a6979f88be43cf44_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi05LTEtMS0w_046559b8-f475-4aa8-b71b-2710152894e4">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7184bc40e84732a19137ba864fb6b1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi0xMS0xLTEtMA_44047113-3c14-49d5-9c3b-f5e8ac9ac48e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0d32b36655400c85ee28b60964a4d7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi0xMy0xLTEtMA_03cdcf15-7240-4c67-9842-81e922514882">19,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4782e3db8423421e942447fb17c5f321_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMy0xLTEtMS0w_befeb83d-422d-40a3-8706-3c5275c92302">40,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4782e3db8423421e942447fb17c5f321_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMy0zLTEtMS0w_f76ebbed-0b97-4fc1-9a94-cb3a40e213bc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib43b6fdc517a411c85647b77372d9e79_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMy01LTEtMS0w_d4805886-2c5f-4f2b-8afd-29f6ffcf664c">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMy0xMy0xLTEtMA_248de341-3c01-4979-a80b-f2999324c355">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4782e3db8423421e942447fb17c5f321_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNC0xLTEtMS0w_d16606ee-d84b-40d5-a96d-593364c268b4">10,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNC0xMy0xLTEtMA_03807656-6bca-4891-b564-be87eb843607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib43b6fdc517a411c85647b77372d9e79_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNS01LTEtMS0w_96bb16ea-0c97-4a81-a9e7-78b71322aafb">7,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNS0xMy0xLTEtMA_86e5c25d-1f0c-4c54-9c17-b8f83a5fcc54">7,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c1c8ad065e5492490704fc3b9a9d9f6_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNi05LTEtMS0w_56502c16-0040-4987-9f4c-7653c5cd8e9b">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNi0xMy0xLTEtMA_771d0c55-fca4-4cdd-96bd-90314f839df0">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib618d67da2c4453a8e65d796194636c5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNy03LTEtMS0w_5038a855-93af-4ecf-bd5f-b3b1dd69abe9">78,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNy0xMy0xLTEtMA_f803e5fa-cab8-4824-bb92-5e41e24cf93c">78,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i399ac47076af4f908e42954eee2ad039_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC0xLTEtMS0w_5844fb65-5b66-4fb0-b7b5-3665a0692de0">27,548,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399ac47076af4f908e42954eee2ad039_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC0zLTEtMS0w_5a539679-3b6e-4de8-bb5b-56b09de12759">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8356b00716a84a1394f6e22c68047217_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC01LTEtMS0w_024a351e-aab8-4204-8f50-523cf046724f">723,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608ba03464564214a1e179c94a81c70c_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC03LTEtMS0w_1025ad1b-5cd3-4c98-95f8-38607ea1810d">773,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eaf0b1998954d038c9b487adfa44c18_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC05LTEtMS0w_2c4fe731-4386-4ab9-aa9e-e126f0515fd2">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901e75a34f054bd3a4d7f6dd621b20bb_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC0xMS0xLTEtMA_6d2b685f-5d72-4377-b140-f419dd8c35fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01bcadb4b56c4ca1818a0393ce077c11_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC0xMy0xLTEtMA_f86ef87b-27bd-456a-84c2-9c92557a7727">50,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fcaca0841c046a9b25d41c5eeddd739_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOS0xLTEtMS0w_ad8a6af5-aec6-47db-a7e9-b13e004283ce">160,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8bb66820b64eb6a3f3211d247b61e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOS01LTEtMS0w_970960a9-a9e7-48f0-a44c-22317c2be68e">3,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOS0xMy0xLTEtMA_fcae8125-c8db-4c11-803c-4114c4cf1c85">3,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fcaca0841c046a9b25d41c5eeddd739_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTEtMS0xLTEtMA_450ac986-eaf2-4358-b4e9-c63becac5144">43,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTEtMTMtMS0xLTA_e2fec730-c59b-4af3-92f5-8a12ccae208b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8bb66820b64eb6a3f3211d247b61e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTItNS0xLTEtMA_b1e186b2-fcb3-4e2f-9419-3ff549b0b339">7,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTItMTMtMS0xLTA_c26c5ff9-7940-4c2e-b8e3-932dd791e49b">7,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb9433a1ea14fce9d9a309b864a4811_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTMtOS0xLTEtMA_91a7a91b-54c0-4cd1-9472-0ee55e367f73">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTMtMTMtMS0xLTA_0b4c9261-6c39-4bab-8eba-d8855c7a2768">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ee76b4784b044ff9b88b671a0c9db61_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTQtNy0xLTEtMA_b13460e9-bb8e-42ea-acc9-aa6d5915e17d">124,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTQtMTMtMS0xLTA_bd4e4ca8-13bf-4307-a799-4f16a4c680e0">124,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9e46a07eb6b45a69ba79f90d0863355_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtMS0xLTEtMA_086660f0-68ff-4f5d-93ac-b90a3467a8c6">27,751,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e46a07eb6b45a69ba79f90d0863355_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtMy0xLTEtMA_037f81c3-e7bd-4fba-a834-be58dbe6ed3b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib41c95943c0d424c87116966a66887e0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtNS0xLTEtMA_77490c10-be9c-4465-90fa-9ccbbaaba005"><ix:nonFraction unitRef="usd" contextRef="ib41c95943c0d424c87116966a66887e0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtNS0xLTEtMA_ef89ac82-d342-452f-87a9-0b161f0c3950">734,365</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b16fd3852e84573bb807fbdf4943cb6_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtNy0xLTEtMA_43922aa7-41d3-4489-907c-a274122e4614">648,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f619499fe244fb9ac621a6969656b01_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtOS0xLTEtMA_5896b6d1-28fe-4e15-acf3-b9dd79eac0a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib097a985762a42b8972093d71e92f8b8_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTQtMTEtMS0xLTM3MjY_ac4f3fef-2bcb-4f25-afdb-133d665c825f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cc47a532c9410ab9a72e3f56e5c255_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtMTMtMS0xLTA_64347f4e-35b9-40bc-b847-67fc8e7660f9">85,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders' Deficit</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf5c408305464e4a81c9c0971ccc1df0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi0xLTEtMS0w_b80f96ad-1e0d-4068-97b1-4b0faae7d100">25,916,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5c408305464e4a81c9c0971ccc1df0_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi0zLTEtMS0w_7b2f819d-de5c-45e9-9a46-7c99d931a155">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief3d178aecba4841860608f1ec04b7d7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi01LTEtMS0w_ba127cc9-686a-4d5e-a635-e5aab4854425">797,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9441fa155214bfa91ca54f2b2d79fdb_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi03LTEtMS0w_754d8dec-0a89-4860-84af-23401cc810a0">838,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a70ab68542b4ee4b2ddd235713f530a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi05LTEtMS0w_4625b13d-8911-41eb-a13c-5a8fbce894ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i216f52657d874071bb5e106dc1386103_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi0xMS0xLTEtMA_0645e4e3-a1ef-4490-87c2-67fb69fb7320">54,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi0xMy0xLTEtMA_12dc7322-f0aa-4474-940f-9a1c0099960e">96,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of new accounting pronouncement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec380fc9717840dfb890dfb2ccbee359_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMy01LTEtMS0w_56a38efa-3c22-4cd5-9d4f-9f7194dac786">93,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf0d08a05974b498b7f99693e9bb8d6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMy03LTEtMS0w_12f081ca-5326-40b0-ba86-334dccc8c124">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4615107f61ab4ac6a24069635566da77_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMy0xMy0xLTEtMA_26f9d873-137a-4ca4-9429-33e1edee9738">91,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bae44f5d32f4368a92888cc0e7ad821_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC0xLTEtMS0w_ec6dd647-f50a-4910-82c3-d2eb6d492cc8">25,916,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bae44f5d32f4368a92888cc0e7ad821_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC0zLTEtMS0w_904e151e-fa7d-47af-ab95-008a1992ff65">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e73edc56fe64f7eb2572e557a02f296_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC01LTEtMS0w_63a80abc-c5d0-408a-a6ea-3839c987835b">704,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36eefb9d0f774f2b9c2f8ea719313100_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC03LTEtMS0w_fcab2caf-0415-4768-824a-9c4eecc9809c">837,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6117ad9e183545289f9791c20580fa73_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC05LTEtMS0w_b0ac7ffa-c520-4975-80d0-b8842a46aa87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8aa3399dd3b7433b8d3557e92fc06f12_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC0xMS0xLTEtMA_1c7d25c9-ed8b-4e45-ab25-e17b57e308cd">54,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6c23d2b97143faa25a7e68488ada74_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC0xMy0xLTEtMA_eced92cd-f614-49f1-b32f-d2d5e8d77d62">188,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib32496abb58143b38427f1791a44f20c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNS0xLTEtMS0w_f891f796-4b82-4ca7-a820-bb43cf9b8d14">172,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d8e1fc8bdc455ba9db23447bc100f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNS01LTEtMS0w_bd1c890b-44ed-4a59-bc6b-8c4c9b84e7aa">2,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNS0xMy0xLTEtMA_5f77da32-358d-4281-9da2-9e5e82cfba1f">2,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib32496abb58143b38427f1791a44f20c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNi0xLTEtMS0w_5d8d27ab-1a4e-4c58-9531-7d2cee25be4b">43,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNi0xMy0xLTEtMA_b0d54e56-e6f5-451a-9b3c-84aa631ccad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of ESPP Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib32496abb58143b38427f1791a44f20c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNy0xLTEtMS0w_9cfc1643-b881-4358-a277-057a90260b9b">50,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d8e1fc8bdc455ba9db23447bc100f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNy01LTEtMS0w_af7d3f69-4687-4300-8b84-ca72df7d6f77">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNy0xMy0xLTEtMA_cf4e08ca-3082-4201-af70-73dbb359baeb">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d8e1fc8bdc455ba9db23447bc100f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfOC01LTEtMS0w_91dbff2a-0f09-44b6-b9c3-84bbafedb45e">5,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfOC0xMy0xLTEtMA_a814c4d2-187b-43c6-888c-c90cd8976e31">5,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icce9fa23f25f427eb9589454600ed4ca_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTAtNy0xLTEtMA_179fb87b-597c-4c77-ba22-1a116808babb">90,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTAtMTMtMS0xLTA_ffd29394-61f6-42b7-b207-87280b27c017">90,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdc069bdc067430e92abc207531d663c_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtMS0xLTEtMA_01b9952a-237a-41fc-9e22-e45649564e36">26,182,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc069bdc067430e92abc207531d663c_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtMy0xLTEtMA_58fc7a2f-56c4-4fbe-b8ff-a3b56183ab0e">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379ebd88020b47e4b6146efc5bf71137_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtNS0xLTEtMA_bb152dbb-b254-475e-bf6c-45b4064b4de5">713,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62e792aa7c38468e81e43fe34e5121a0_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtNy0xLTEtMA_fc48090a-c7f8-4aec-8022-0c9148d7f976">928,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d93286758fb4fb0834e3fe5467fd410_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtOS0xLTEtMA_4fe57210-cb5d-4772-bdfb-330570545bbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca8b35ceea04640b7869eb9e58fee15_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtMTEtMS0xLTA_7b1604ed-b804-47bf-8e82-ec0664e2d72f">54,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12e7f1c8a5df44dda88579554a423614_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtMTMtMS0xLTA_16b092a9-496c-4807-8efa-90425593f6bd">269,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacf27721acf74d0ea561cff498784811_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTgtMS0xLTEtMA_ac9b07cc-b3b5-43d3-948a-f05470c9dd55">10,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2546d188d64d9d93c6334f07c8adcf_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTgtNS0xLTEtMA_7362a6c5-242f-4ab5-a970-a627f982e223">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTgtMTMtMS0xLTA_47b64909-b9e9-42c3-a41d-1ebfeff27b41">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacf27721acf74d0ea561cff498784811_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTktMS0xLTEtMA_425214eb-a55d-4b71-83ee-4e9505805303">81,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTktMTMtMS0xLTA_b7c7910f-9436-4fc3-98fe-ef60c22042e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2546d188d64d9d93c6334f07c8adcf_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjAtNS0xLTEtMA_ea63ce3c-cf28-4b38-afcb-20a78f405b22">8,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjAtMTMtMS0xLTA_25170b86-c63c-4963-a4c7-bac2b9e60806">8,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjEtMTMtMS0xLTA_48f57107-a518-4af4-acde-996b117dcbdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e2395549626418da16b8a9ad6037264_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjItNy0xLTEtMA_1f7dfdc1-cb7f-4c7f-9159-b7dc725d7de3">43,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjItMTMtMS0xLTA_78a3d212-c46a-4bcb-ad97-9d81c30ff35f">43,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibeed394b634a4b9fb167c86225bdd1d3_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtMS0xLTEtMA_3bbe5c6e-2154-4978-9b75-936260cf92eb">26,274,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeed394b634a4b9fb167c86225bdd1d3_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtMy0xLTEtMA_ae532617-9b64-468f-a525-a60133630bff">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b9a3b16a7041bd8d34d47e1359ed86_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtNS0xLTEtMA_7786c167-37e6-43c0-93bd-09f761be800d">722,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733c42004f7f45bf8f40d28a377fb43e_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtNy0xLTEtMA_3cc73aab-c8be-476f-9264-3e0a88af288c">971,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c790fd04d414722be81c66df421c95d_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtOS0xLTEtMA_5f967de1-6576-4322-b259-365996bf10ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b8adaaf631b47b48badf05858b0984f_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtMTEtMS0xLTE5NDM_a0901eca-df09-4af7-8378-a10f55920649">54,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtMTMtMS0xLTA_6962551c-7818-4794-a1e9-752be181c1da">304,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.426%"><tr><td style="width:1.0%"></td><td style="width:68.966%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMy0xLTEtMS0w_34cf3931-c2d3-4edf-ab12-2b09fb44d7aa">134,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMy0zLTEtMS0w_14d78907-ce5d-48ca-9c82-d6e89213f7d7">46,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNS0xLTEtMS0w_0baf7803-03e0-4174-8fc9-1608ffd44929">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNS0zLTEtMS0w_cdfcf201-64ff-4c3c-ad46-acea18d4bf41">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of premiums and discounts on investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNi0xLTEtMS0w_21a0f901-3f1d-4802-bff8-fa33500e60ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNi0zLTEtMS0w_db11e0ee-8a41-4088-ae51-69695af0eb1b">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNy0xLTEtMS0w_1afae6d4-0667-47d1-9714-ff5c97c5a6bc">804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNy0zLTEtMS0w_5d9f42cc-edac-4062-9f57-2aef7288a1c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense related to the revenue interest liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:NonCashInterestExpenseRelatedToRevenueInterestLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfOS0xLTEtMS0w_dc1f754b-82dc-4711-a8bc-f14da31a09f4">12,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="espr:NonCashInterestExpenseRelatedToRevenueInterestLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfOS0zLTEtMS0w_fe084a70-7a1c-49ea-a27b-d48a96bc5b0c">8,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTEtMS0xLTEtMA_ac326f2e-76fb-422a-ac15-77223169b987">14,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTEtMy0xLTEtMA_a921cefe-ae0e-491f-90b7-a24037b719a9">14,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTMtNS0xLTEtNDQxMw_e7757aeb-f111-4bec-bb1d-fef724142d15">9,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTMtNy0xLTEtNDQxNQ_75d111d9-c4ab-457e-9e17-c51cefb6c0d2">2,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTMtMS0xLTEtMA_ae9221da-38ed-471d-a44d-d676026baffc">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTMtMy0xLTEtMA_17a09c30-4cba-42fa-b6cb-1c361fe929ba">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTQtMS0xLTEtMA_2c269691-d09e-41f7-b3c1-c5a01359ef92">3,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTQtMy0xLTEtMA_8986405b-d5ce-4b30-af97-08ef66d24b78">1,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTUtMS0xLTEtMA_5a00f243-b96e-436a-9548-a5769bf260e3">7,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTUtMy0xLTEtMA_e245ad57-b3fa-4753-a6bf-babce37ecd3f">8,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTYtMS0xLTEtMA_0e71863e-2080-4ae9-ba9e-11593c017c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTYtMy0xLTEtMA_4c23f68c-6856-4e2c-9909-5f60d4c1dd90">1,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTctMS0xLTEtMA_c3dae4c5-2457-477b-9785-cfa2cc5c51da">22,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTctMy0xLTEtMA_9bac159b-eb84-4e37-b873-1eb2bfc89db3">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTgtMS0xLTEtMA_da7cc4a5-c276-4902-9363-40adf2b9a3af">3,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTgtMy0xLTEtMA_eb4dbbf7-64c9-4346-96dc-b447337c9ff0">12,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTktMS0xLTEtMA_394d3c70-643a-4af8-87b5-fc6050d48c5d">136,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTktMy0xLTEtMA_3d096fd2-c352-4406-8172-a9cddf05aff9">70,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjItMS0xLTEtMA_140b2d1d-990f-43a1-8d32-af18abd87a15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjItMy0xLTEtMA_da158bfc-556b-43b5-8643-7778c0a1e0af">4,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales/maturities of investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjMtMS0xLTEtMA_87b31b1f-e4a9-410f-a621-e5eb70c62bf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjMtMy0xLTEtMA_b7148ae3-a6f8-4b6e-9443-cf4586e6b66d">36,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjQtMS0xLTEtMA_d29651eb-1083-44ee-a44f-6e134bfa58f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjQtMy0xLTEtMA_d4a93dfe-0065-413e-87b4-a9c8f8038028">776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjUtMS0xLTEtMA_e64de8ae-5124-43cd-824e-3d78e4481391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjUtMy0xLTEtMA_8f0e50eb-933f-4bce-81f8-27bb2c3a0c18">31,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from revenue interest liability, net of issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjgtMS0xLTEtMA_773295ef-332a-4d3b-9965-9a06535ad477">49,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="espr:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjgtMy0xLTEtMA_8b0f5ad7-b678-4bf0-b80f-6645105ae7a3">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjktMS0xLTEtMA_5dad6dd7-a1a2-4156-8ee1-f54f9ed19698">2,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjktMy0xLTEtMA_90b4b56f-9d31-4cbf-9f53-282661540939">4,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on revenue interest liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:PaymentsFromRevenueInterestPurchaseAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzAtMS0xLTEtMA_0c26346a-bf75-4fd2-b03d-cbaf9b593dd5">1,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" name="espr:PaymentsFromRevenueInterestPurchaseAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzAtMy0xLTEtMA_ce52926e-d718-48b2-a4f3-407ccec17db3">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzEtMS0xLTEtMA_3cb79443-ef48-453b-a400-cf2228e8e17f">440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzEtMy0xLTEtMA_bfd65fe6-ff86-42ba-a18b-d3e39519dfa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzItMS0xLTEtMA_55717642-220e-45a7-8991-705a0be03f45">51,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzItMy0xLTEtMA_bc0c8c50-f09b-4268-9a9f-5bba211abafd">29,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzQtMS0xLTEtMA_84700bca-3181-4d33-bd5d-8fde1a06b5fc">85,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzQtMy0xLTEtMA_eaf801de-6305-4bb2-b11d-4ac47e3233be">131,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzUtMS0xLTEtMA_cfaa39fd-0a07-4d2c-926e-5cf251072429">304,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0d32b36655400c85ee28b60964a4d7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzUtMy0xLTEtMA_b4e006e6-8f7d-436d-bdb5-fa2e0c23428c">167,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzYtMS0xLTEtMA_9d0fb2d0-fac7-443a-a54f-64dcf8203163">219,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cc47a532c9410ab9a72e3f56e5c255_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzYtMy0xLTEtMA_ccfd4e09-2c7a-426c-8a0d-25b7d1eb4c10">298,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment not yet paid</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzgtMS0xLTEtMA_485bbe06-30dc-40f0-bd93-5942f6b0cd1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzgtMy0xLTEtMA_5121adb2-2a8a-4f14-a582-4ce05073d14a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non cash right of use asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" name="espr:NonCashRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzktMS0xLTEtMA_c4d4ba1a-380e-4178-99da-a81f79cbaa67">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" sign="-" name="espr:NonCashRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzktMy0xLTEtMA_f885a489-3fc4-4c3f-93a6-5b1549f8fa50">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_34"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfNjI1NQ_99707d76-2d79-4705-b467-0826bc6c96be" continuedAt="id468eef098124b09b8de0ae8261bdb80" escape="true">The Company and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="id468eef098124b09b8de0ae8261bdb80" continuedAt="i92e81bdf62e34d9cb8629d5efb567989"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Esperion Therapeutics, Inc. ("the Company&#8221;) is the Lipid Management Company, a pharmaceutical company singularly focused on developing and commercializing affordable, oral, once-daily, non-statin medicines for the treatment of patients struggling with elevated low density lipoprotein cholesterol ("LDL-C"). The Esperion team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. The Company's first two products were approved by the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Swiss Agency for Therapeutic Products ("Swissmedic") in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease ("ASCVD") or heterozygous familial hypercholesterolemia ("HeFH"). </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 26, 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd ("DS"). Pursuant to the agreement, the Company granted DS exclusive development and commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. The Company received an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="id125fee9cd774cad978f6ae94f446b6b_D20210501-20210531" decimals="-5" format="ixt:numdotdecimal" name="espr:UpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfMTgyNg_8825cc7a-3579-4acf-88a1-3a8f22616725">30.0</ix:nonFraction>&#160;million in May 2021 and is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="if57aa28556d54b82af658eb81d72b9fb_I20210426" decimals="-5" format="ixt:numdotdecimal" name="espr:AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfMTg4OA_711a9e0c-b461-4928-afeb-b79e239598cc">175.0</ix:nonFraction>&#160;million in sales milestones. The Company will also receive tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i60ff16704c9e4a26864f51907841faaf_D20210426-20210426" decimals="INF" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfNTQ5NzU1ODE0NTIyOQ_c6968758-3533-472b-8b3b-ebb4ed098208">5</ix:nonFraction> percent to <ix:nonFraction unitRef="number" contextRef="ica0ff70047d84bf3ac80640f0aca8a46_D20210426-20210426" decimals="INF" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfNTQ5NzU1ODE0NTIzOQ_ee53016a-9f86-4811-9359-73642067537c">20</ix:nonFraction> percent on net sales in the DS Territory. Refer to Note 3 "Collaborations with Third Parties" for further information. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2021, the Company entered into Amendment No. 2 (the &#8220;RIPA Amendment&#8221;) to the Revenue Interest Purchase Agreement with Eiger III SA LLC (&#8220;Oberland&#8221;), an affiliate of Oberland Capital LLC, as agent for the purchaser parties thereto dated as of June 26, 2019 (as amended by the Amendment No. 1 dated as of November 9, 2020, the &#8220;RIPA&#8221;). Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $<ix:nonFraction unitRef="usd" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="-6" format="ixt:numdotdecimal" name="espr:ProceedsFromRevenueInterestPurchaseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfMjU3Ng_33520b4e-fbfc-4988-a866-9d648ff8f829">50</ix:nonFraction>&#160;million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA and the related Security Agreement, which are discussed further in Note 8 "Liability Related to the Revenue Interest Purchase Agreement."</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's primary activities since incorporation have been conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. The Company received approval by the FDA in February 2020 to commercialize NEXLETOL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NEXLIZET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., and accordingly commenced principal operations on March 30, 2020 with the commercialization of NEXLETOL. The Company is subject to risks and uncertainties which include the need to successfully commercialize its products, research, develop, and clinically test therapeutic products; obtain regulatory approvals for its products; expand its management, commercial and scientific staff; and finance its operations with an ultimate goal of achieving profitable operations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has sustained annual operating losses since inception and expects such losses to continue over the foreseeable future. The Company's ability to successfully launch, commercialize and generate revenue from NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI has been and may continue to be adversely affected by the economic impact of the COVID-19 pandemic. In response to the Company&#8217;s history of operating losses and the uncertainty around the ongoing impact of COVID-19 management has initiated certain cost optimization measures and will implement additional cost reduction measures as needed if additional collaboration or capital funding is not available. Additionally, management may continue to fund operations and advance the development of the Company's products and product candidates through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, and permitted private and public equity offerings or through other sources. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available, the Company may not be able to continue the development of its current products or future product candidates, or to commercialize its current or future product candidates, if approved.</span></div><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfNjI1Ng_24b487c0-b0e9-47e4-befb-4207162efb85" continuedAt="idea67336cab046d9a3ab9a472c3c1bbf" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods presented. Certain prior year amounts have been </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i92e81bdf62e34d9cb8629d5efb567989"><ix:continuation id="idea67336cab046d9a3ab9a472c3c1bbf">reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</ix:continuation></ix:continuation></span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_40"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTM_2c1b5990-1396-44ee-b219-1b1b58b7b14b" continuedAt="ie1e8c894afd64bf2bbf95cb6407219a9" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ie1e8c894afd64bf2bbf95cb6407219a9" continuedAt="i6553ce65064d4c479ea5dfc303002577"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTQ_abc4f171-15d2-4990-9f20-4d631b5c460c" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTE_be984c76-b8df-4e84-8cb5-41c2a09c379f" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of June&#160;30, 2021 <ix:nonFraction unitRef="customer" contextRef="i584f75dd199f4a379657616c6423e8f0_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="espr:ConcentrationRiskNumberOfMajorCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfNjIy_49647e87-60c6-4ac3-bf87-4f10e908b3d5">nine</ix:nonFraction> customers accounted for all of the Company's net trade receivables and as of December 31, 2020 <ix:nonFraction unitRef="customer" contextRef="i3e4850b6ddab4d628848b2165151adcd_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="espr:ConcentrationRiskNumberOfMajorCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfNjU5NzA2OTc4MTc0MQ_6049a6ff-1d9a-4fe9-ac5b-3157fb34c428">eight</ix:nonFraction> customers accounted for all the Company's net trade receivables.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTI_423f301f-379b-46ee-95a3-1db2668a9bbc" continuedAt="i0fbc3784a8af43768fac3a0d1e8ef176" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through <ix:nonFraction unitRef="revenue_source" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="espr:NumberOfSourcesOfRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTg0NQ_d2cb9cd2-4309-4b96-968d-ed55a9d0c1d8">two</ix:nonFraction> primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="i6553ce65064d4c479ea5dfc303002577" continuedAt="ie7d3ad54d354480095c488bb5c8284d4"><ix:continuation id="i0fbc3784a8af43768fac3a0d1e8ef176" continuedAt="iee3c877c250c4093ace0967053db61ef"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#8220;API&#8221;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt">Product Sales, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $<ix:nonFraction unitRef="usd" contextRef="id9c66ab5008d4c28a2f2a6317075fc61_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTA5OTUxMTY0MjEyMw_bfe8fefb-187d-4ebc-a0e9-837833f0e306">10.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id3555938aa014fbda7603991f689d2d4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTA5OTUxMTY0MjEzMA_07756136-aeea-4a30-9d05-40c29411e395">17.0</ix:nonFraction> million for the three and six months ended June&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib3f1e56095ca4d07a8f77cec69f8a7ba_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTA5OTUxMTY0MjAxOQ_99bc8e12-0f34-4695-a25a-026c3e3c7889">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia332deb386b74a509426822f23273e5e_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTA5OTUxMTY0MjAyMw_807bbd4b-77cf-405a-ac0b-6b2c4558a716">1.5</ix:nonFraction> million for the three and six months ended June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#8217; distribution facilities, or free on board (&#8220;FOB&#8221;) destination, the terms of which are designated in the contract.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#8217;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#8220;Other accrued liabilities&#8221; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forms of Variable Consideration</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="ie7d3ad54d354480095c488bb5c8284d4"><ix:continuation id="iee3c877c250c4093ace0967053db61ef"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-pay assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company generally offers a right of return based on the product&#8217;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#8217;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#8217;s expectations regarding future payment patterns.</span></div></ix:continuation><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNDk_87b9a64a-e798-4efb-86dc-aa00795ecd28" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTA_d472eb32-3f5e-47bd-9a6b-f8c01f272b00" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Implemented Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")  2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;). This ASU simplifies the accounting for convertible instruments by removing the separation models for convertible debt with cash conversion features and convertible instruments with a beneficial conversion feature, which requires the fair value of the embedded conversion feature of convertible instruments be allocated to equity. Under ASU 2020-06, a convertible debt instrument with those features will generally be reported as a single liability at its amortized cost with no separate accounting for the embedded conversion features in equity. The adoption of this ASU resulted in the reclassification of the portion of the Company's convertible notes from equity to debt, which also reduces reported interest expense and increases reported net income. ASU 2020-06 requires the application of the if-converted method when calculating diluted earnings per share, eliminating the Company&#8217;s ability to use the treasury stock method when certain conditions are met. The ASU is effective for annual reporting periods beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company early adopted this standard as of January 1, 2021 which resulted in a net increase in the convertible notes of approximately $<ix:nonFraction unitRef="usd" contextRef="i24321e9e8f7543f590713d54993c4653_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTM4MjU_de5aa668-768c-4211-84a3-69d59b39f149">92.0</ix:nonFraction>&#160;million, an adjustment to accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i24321e9e8f7543f590713d54993c4653_I20210101" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTM4Njk_6508db37-4005-489c-8396-a7373eae702f">1.5</ix:nonFraction>&#160;million, and a reduction to additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="i24321e9e8f7543f590713d54993c4653_I20210101" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTM5MjI_68879d31-665e-4570-aff5-4e2c565820ae">93.5</ix:nonFraction>&#160;million. The tax impact of the adoption was not material.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfODM3Mg_4ffc81f0-ba52-4217-9235-2a436c63aa8e" continuedAt="ic5dee684220b4bfeb7eb54c7190aa897" escape="true">Collaborations with Third Parties</ix:nonNumeric></span></div><ix:continuation id="ic5dee684220b4bfeb7eb54c7190aa897" continuedAt="i30c76a3f77d74bae8ce84b73f1351042"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DSE Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2019, the Company entered into a license and collaboration agreement with Daiichi Sankyo Europe GmbH ("DSE"). Pursuant to the agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablets in the European Economic Area and Switzerland (&#8220;DSE Territory&#8221;). DSE will be responsible for commercialization in the DSE Territory. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the consideration consists of a $<ix:nonFraction unitRef="usd" contextRef="i272c7eba0c41457f84c261e58a1bbedc_D20190102-20190102" decimals="-5" format="ixt:numdotdecimal" name="espr:UpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNjcy_55aefc1c-c726-40a7-aea8-6112611039e0">150.0</ix:nonFraction> million upfront cash payment as well as $<ix:nonFraction unitRef="usd" contextRef="i272c7eba0c41457f84c261e58a1bbedc_D20190102-20190102" decimals="-5" format="ixt:numdotdecimal" name="espr:CashPaymentToBeReceivedUponFirstCommercialSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNzA3_1413768a-4da6-42e1-8934-4e70b5343e43">150.0</ix:nonFraction> million cash payment to the Company upon first commercial sales in the DSE Territory. The Company also is responsible to supply DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive a substantial additional regulatory milestone payment upon the grant of the marketing authorisation in the European Union for the CV risk reduction label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company will receive tiered fifteen percent (<ix:nonFraction unitRef="number" contextRef="ife3936cfd95f4b539b5a1cbb4ce8a51a_D20190102-20190102" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMTM4Mg_ee4daf96-3188-4df5-bb74-cfc852e441ec">15</ix:nonFraction>%) to twenty-five percent (<ix:nonFraction unitRef="number" contextRef="icfdd1264317a4e959d48fae350ca5f6a_D20190102-20190102" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMTQxMA_63a1f41a-4097-419f-a531-00612109d602">25</ix:nonFraction>%) royalties on net DSE Territory sales.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement calls for both parties to participate in a Joint Collaboration Committee (the &#8220;DSE JCC&#8221;). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement Terms Amendment</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2020, the Company entered into an amendment to the license and collaboration agreement with DSE, dated as of January 2, 2019. In June 2020, the Company completed the transfer of the MAAs for NILEMDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NUSTENDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pursuant to the terms of the amendment, DSE paid the Company the second $<ix:nonFraction unitRef="usd" contextRef="i52875fa54d2d47d08f43907539a1290b_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="espr:ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMjA5Ng_82700f16-5624-4a08-af88-a58f3f57ef46">150.0</ix:nonFraction> million milestone based on completion of the NUSTENDI MAA transfer rather than the first product sale in the EU, as previously agreed. Additionally, the Company and DSE have agreed to expand the DSE Territory, or the territory in which DSE has exclusive commercialization rights to NILEMDO and NUSTENDI to include Turkey. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i272c7eba0c41457f84c261e58a1bbedc_D20190102-20190102" decimals="-5" format="ixt:numdotdecimal" name="espr:UpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMjgyNQ_4a1bf8f0-ce76-4972-8fcc-a2287e9a99f9">150.0</ix:nonFraction> million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company&#8217;s intellectual property and 2) the obligation to provide ongoing regulatory and development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company&#8217;s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company&#8217;s obligation to provide ongoing regulatory and development activities. In the three and six months ended June 30, 2020, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i70b05bb32f374749885434ca47747d1a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU0MA_aa4ef7f4-08aa-42a8-b3ba-1f93dfc26d45">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib69346e757f3452d8d1aeea2c8017cfc_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU1NA_856443b6-c002-41ef-a22b-0afa3de75bf1">1.6</ix:nonFraction>&#160;million, respectively, related to the on-going performance obligation for the ongoing regulatory efforts related to the MAA in the DSE Territory, which was transferred to DSE in June 2020.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three and six months ended June 30, 2020, the Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i5331bb6e27784c98ba83f790214f2d62_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU2OA_9026b46a-a8c1-4450-ac48-005abd763b86"><ix:nonFraction unitRef="usd" contextRef="i22044bf98171420f847fdf469c65b5ac_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU2OA_d95eabc0-484c-40a8-8dac-48b8e21e65bc">150.0</ix:nonFraction></ix:nonFraction>&#160;million milestone as collaboration revenue based on the successful transfer of the NUSTENDI MAA. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the three and six months ended June&#160;30, 2021, the Company recognized collaboration revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i11df274bc00047b7b2522e08b61ca091_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMzY1OQ_69ce787d-431e-4baf-bc05-b0c6308ec1ac">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idd1fbd1b685c42ffb9c49c3b31c629df_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMTA5OTUxMTY0NzU3MQ_6b3d281b-ee28-46a4-aa96-9709d98b009c">3.6</ix:nonFraction>&#160;million related to royalty revenue from DSE following their European launch of NILEMDO and NUSTENDI as well as the sales of bulk tablets to DSE pursuant to the supply agreement that was executed with DSE. In the three and six months ended June 30, 2020, the Company recognized collaboration revenue of $<ix:nonFraction unitRef="usd" contextRef="i26f9230bab5b44cda5e7265c85d57b66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU4NA_af132915-cd14-42bf-9ee1-4ecf23f2a33e"><ix:nonFraction unitRef="usd" contextRef="i4dfde8b13e554913935ea8540925afeb_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU4NA_f0b4e64e-c3a2-4610-a281-fc91106c1017">1.0</ix:nonFraction></ix:nonFraction>&#160;million related to the sales of bulk tablets of NILEMDO and NUSTENDI to DSE.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All remaining future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to sales-based milestones will be recognized when the subsequent sales occur.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="i30c76a3f77d74bae8ce84b73f1351042" continuedAt="i05a6b5e432184b178540b28fbb0f4e90"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Otsuka Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, the Company entered into the Otsuka Agreement with Otsuka Pharmaceutical Co., Ltd. ("Otsuka"). Pursuant to the Otsuka Agreement, the Company granted Otsuka exclusive development and commercialization rights to NEXLETOL and NEXLIZET in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the consideration consists of a $<ix:nonFraction unitRef="usd" contextRef="i3b353fe5393a4dc2bac419bc2aa386d6_D20200417-20200417" decimals="-5" format="ixt:numdotdecimal" name="espr:UpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNDgxMQ_a8abecfa-f470-4395-aa3e-8c70ff222455">60.0</ix:nonFraction> million upfront cash payment and the Company will be eligible to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="i232d185de48d4c6baa127c8681fe96ca_I20200417" decimals="-5" format="ixt:numdotdecimal" name="espr:AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNDkwOA_17064aeb-e3a2-43b0-897e-484c841ef2d8">450.0</ix:nonFraction> million if certain regulatory and commercial milestones are achieved by Otsuka. The potential future milestone payments include up to $<ix:nonFraction unitRef="usd" contextRef="i42d4992daffb433d85ca8fd259ed4e9d_I20200417" decimals="-5" format="ixt:numdotdecimal" name="espr:FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTAzNw_51301812-6519-497a-a422-939768f34412">20.0</ix:nonFraction> million upon first JNDA submissions in the Otsuka Territory, up to $<ix:nonFraction unitRef="usd" contextRef="i42d4992daffb433d85ca8fd259ed4e9d_I20200417" decimals="-5" format="ixt:numdotdecimal" name="espr:FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTA5OQ_83fd63ed-cca4-4aa5-9819-96889df196ad">70.0</ix:nonFraction> million upon the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and up to $<ix:nonFraction unitRef="usd" contextRef="i42d4992daffb433d85ca8fd259ed4e9d_I20200417" decimals="-5" format="ixt:numdotdecimal" name="espr:FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTE4Mw_4b5d947a-35c8-4cd9-bd2f-8d7762859b66">50.0</ix:nonFraction> million upon the achievement of the primary major adverse cardiovascular events (&#8220;MACE&#8221;) in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments up to $<ix:nonFraction unitRef="usd" contextRef="i42d4992daffb433d85ca8fd259ed4e9d_I20200417" decimals="-5" format="ixt:numdotdecimal" name="espr:FuturePaymentMilestoneSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTUxNA_1070ba86-0839-4aff-8c2e-7d5b8c934ac6">310.0</ix:nonFraction> million related to total net sales achievements for Otsuka in Japan. Finally, the Company will receive tiered fifteen percent (<ix:nonFraction unitRef="number" contextRef="ic2e95112c7734a5d8292505e37d9fa7f_D20200417-20200417" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTYzNg_77d6e68b-04ac-48b7-9f1c-9acb7e0b69bf">15</ix:nonFraction>%) to thirty percent (<ix:nonFraction unitRef="number" contextRef="if950ab2c0cae426e871485a272155dd5_D20200417-20200417" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTY1OQ_f6f5e1e2-a877-44b8-9c51-22013adf4453">30</ix:nonFraction>%) royalties on net sales in Japan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement calls for both parties to participate in a Joint Collaboration Committee (the "Otsuka JCC"). The Otsuka JCC is comprised of executive management from each company and Otsuka will lead in all aspects related to development and commercialization in the Otsuka Territory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company did <ix:nonFraction unitRef="usd" contextRef="i42f46b3fae7942db8d62064f916bccae_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNjEyOQ_b168f620-0eb0-451d-b1e7-cf5c18641ae7"><ix:nonFraction unitRef="usd" contextRef="i9ef4d12805a94033b928a8cef22e81f6_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNjEyOQ_d02d1663-6b13-4728-8aad-a2cbfa275103">no</ix:nonFraction></ix:nonFraction>t have any collaboration revenue from the Otsuka Agreement during the three and six months ended June 30, 2021. In the three and six months ended June 30, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ic0ea2e4cbd104e848e494a2b3378dd35_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU1OA_7fdeede7-2198-46a2-a809-850ea3de11aa"><ix:nonFraction unitRef="usd" contextRef="i4170f009274249bfb0d9fad65135d67a_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU1OA_dfcda3cd-2d92-4db6-b21d-078dfa466ae8">60.0</ix:nonFraction></ix:nonFraction>&#160;million of collaboration revenue related to the $<ix:nonFraction unitRef="usd" contextRef="i3b353fe5393a4dc2bac419bc2aa386d6_D20200417-20200417" decimals="-5" format="ixt:numdotdecimal" name="espr:UpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU0MQ_3a657f63-9a11-4d88-a330-41e4b273fde9">60.0</ix:nonFraction>&#160;million upfront payment.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet recognized any revenue for milestone payments as the related regulatory and commercial milestones have not yet been achieved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Agreement Terms</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 26, 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Company, Limited ("DS Agreement"). Pursuant to the DS Agreement, the Company granted DS exclusive rights to develop and commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet (the "Products") in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible development and commercialization in these territories. In addition, DS will fund all development costs associated with the program in the DS Territory.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the consideration consists of a $<ix:nonFraction unitRef="usd" contextRef="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426" decimals="-5" format="ixt:numdotdecimal" name="espr:FutureUpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU3Mw_2e5ed9d4-8967-45f4-a18f-b9643110593e">30.0</ix:nonFraction>&#160;million upfront cash payment that is non-refundable, non-reimbursable and non-creditable. The Company will be eligible to receive additional one-time payments of up to $<ix:nonFraction unitRef="usd" contextRef="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426" decimals="-5" format="ixt:numdotdecimal" name="espr:CashPaymentToBeReceivedUponCertainCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU4OA_aafc18b2-8f4e-446c-991f-273302de899e">175.0</ix:nonFraction>&#160;million if certain commercial milestones are achieved by DS. Also, the Company will receive tiered royalties of five percent (<ix:nonFraction unitRef="number" contextRef="i60ff16704c9e4a26864f51907841faaf_D20210426-20210426" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODYwMw_bd8bf485-115a-4932-b252-8b59abf55d68">5</ix:nonFraction>%) to twenty percent (<ix:nonFraction unitRef="number" contextRef="ica0ff70047d84bf3ac80640f0aca8a46_D20210426-20210426" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODYwNw_e16bda50-aff2-4c23-8463-efda65181462">20</ix:nonFraction>%) of net sales in the DS Territory.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement requires the parties to establish a joint collaboration committee (the "Joint Collaboration Committee" or "JCC"). The Joint Collaboration Committee is composed of six (6) members, with each Party contributing three (3) representatives each who are employees of such Party with main responsibility of overseeing the Development and Commercialization activities relating to the Licensed Products in the Field in the DS Territory and other responsibilities as stated in the Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="i05a6b5e432184b178540b28fbb0f4e90"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426" decimals="-5" format="ixt:numdotdecimal" name="espr:FutureUpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODYxMg_b15ebe97-1321-4bf1-a998-4643de59ec1d">30.0</ix:nonFraction>&#160;million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company&#8217;s intellectual property and 2) the obligation to provide ongoing development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company&#8217;s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company&#8217;s obligation to provide ongoing development activities. Accordingly, for the three and six months ended June 30, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i93803d292d3b4027976e1b5d23361ad8_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU5OA_1e1376a5-6c0d-4188-845a-d6cbf3b986c8"><ix:nonFraction unitRef="usd" contextRef="i72ae8eed70f84e13942db9d0ab474673_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU5OA_6fa00703-8ab8-4545-8b28-bb0419a2d1c2">28.1</ix:nonFraction></ix:nonFraction>&#160;million of collaboration revenue related to the $<ix:nonFraction unitRef="usd" contextRef="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426" decimals="-5" format="ixt:numdotdecimal" name="espr:FutureUpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTYxMw_f53fddb5-a2fa-4545-bf18-d170d22a1c52">30.0</ix:nonFraction>&#160;million upfront payment. The $<ix:nonFraction unitRef="usd" contextRef="i1fbda9eaced641d493d9cc099814900c_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTYyOA_da61589c-49a8-4a8e-b6af-eb1f2bcf0bc1">28.1</ix:nonFraction>&#160;million relates to the performance obligations for the license to the Company&#8217;s intellectual property and a portion of ongoing regulatory and development activities conducted during the period ended June 30, 2021, in the amounts of $<ix:nonFraction unitRef="usd" contextRef="i95b9b936123043afb5dde0d7efbc4dfd_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTY0Mw_92660a45-c935-4c59-b83c-6c5397055568">28.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib65202acf8f242f1bd411cf05ccd2003_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTY1Nw_6cb618d6-e530-4b97-aa7a-d5a7ac14cb25">0.1</ix:nonFraction> million, respectively. The remaining $<ix:nonFraction unitRef="usd" contextRef="i72ae8eed70f84e13942db9d0ab474673_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="espr:DeferredUpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTY2Mw_b49bf6ba-1e19-4c86-ad84-2d66de6cb038">1.9</ix:nonFraction>&#160;million of the upfront payment was deferred as of June 30, 2021 due to an on-going performance obligation related to the developmental activities in South Korea and Taiwan. This deferred revenue will be recognized ratably over the period leading up to the completion of these developmental activities.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Agreements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2020, the Company entered into a licensing agreement with Serometrix to in-license a series of early stage compounds known as scaffolds related to its oral, small molecule PCSK9 inhibitor program. PCSK9 is an enzyme responsible for regulating LDL receptors. PCSK9 inhibitors stop LDL receptors from being broken down, increasing the number of LDL receptors present to remove cholesterol from the blood. The agreement allows the Company use of the PCSK9 compounds, which were patented by Serometrix prior to the licensing agreement, to perform further research and development with the goal of developing a small molecule oral PCSK9 inhibitor that can be taken as a tablet.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for these rights, the Company agreed to pay Serometrix an upfront payment, milestone payments and royalties on net sales of licensed products under the agreement. The Company is obligated to make milestone payments to Serometrix upon the achievement of specified development, regulatory and commercialization milestones. The development milestone payments due under the agreement depend on the licensed product being developed. As part of the agreement, the Company made an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="id2f61d084882445fb054d3e384d280e9_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="espr:UpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfODA1NA_8c61261c-bd9f-4fa1-97a9-8a1abb30d6a2">12.5</ix:nonFraction>&#160;million in December 2020, which was recorded to research and development expense, to Serometrix, with payments in future years tied to specific milestones. The Company has also agreed to pay tiered royalties based on net sales of all products licensed under the agreement of mid-single-digit to low double-digit percentages.</span></div></ix:continuation><div id="i155233a9c30143f788c2cb30bf7b7a77_46"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RleHRyZWdpb246YzcxZDA0MTU1NGU0NGMyM2IyNmQxOGFjYmMzYzM4MDJfNzU_f68e49be-0a7f-44a2-a501-6b18a2982365" continuedAt="i70fdcff336f54556b31bb2bac20dbe60" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i70fdcff336f54556b31bb2bac20dbe60"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RleHRyZWdpb246YzcxZDA0MTU1NGU0NGMyM2IyNmQxOGFjYmMzYzM4MDJfNzY_ac4849de-4e09-45eb-96d3-ccfb10a3a7dc" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMS0xLTEtMS0w_341fed23-50d8-44bc-adf4-36614be3b25f">21,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMS0zLTEtMS0w_0556f644-908f-442d-8de0-5ef7e416070c">13,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMi0xLTEtMS0w_d061b268-a720-4e33-bda8-cb8d72b4eed6">703</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMi0zLTEtMS0w_d78566ac-aa82-49f8-af60-4427ac332eaa">2,028</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMy0xLTEtMS0w_b1038810-f300-4073-9627-54eaed1c0632">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMy0zLTEtMS0w_f63cfffa-f4db-40cd-b9cc-29be457b8d91">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfNC0xLTEtMS0w_990df683-d95d-41e5-9892-b443e6f96ebe">23,714</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfNC0zLTEtMS0w_57789962-8757-464e-8230-a0a29875bd29">16,136</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div id="i155233a9c30143f788c2cb30bf7b7a77_49"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfNjAzMw_4c404908-ca89-4f8c-a1ba-c9d2add01ac3" continuedAt="ie841b2d06be44721baa090793241a72b" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-indent:18pt"><ix:continuation id="ie841b2d06be44721baa090793241a72b" continuedAt="i15f43548fcc441398d69f7276b12f3dd"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 12, 2016, a purported stockholder of the Company filed a putative class action lawsuit in the United States District Court for the Eastern District of Michigan, against the Company and Tim Mayleben, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Kevin L. Dougherty v. Esperion Therapeutics, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (No. 16-cv-10089). The lawsuit alleges that the Company and Mr. Mayleben violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by allegedly failing to disclose in an August 17, 2015, public statement that the FDA would require a cardiovascular outcomes trial before approving the Company&#8217;s lead product candidate. The lawsuit seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between August 18, 2015, and September 28, 2015, as well as attorneys&#8217; fees and costs. On May 20, 2016, an amended complaint was filed in the lawsuit and on July 5, 2016, the Company filed a motion to dismiss the amended complaint. </span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="i15f43548fcc441398d69f7276b12f3dd"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 27, 2016, the court granted the Company&#8217;s motion to dismiss with prejudice and entered judgment in the Company&#8217;s favor. On January 24, 2017, the plaintiffs in this lawsuit filed a motion to alter or amend the judgment. In May 2017, the court denied the plaintiff&#8217;s motion to alter or amend the judgment. &#160;In May 2017, the court denied the plaintiff&#8217;s motion to alter or amend the judgment. On June 19, 2017, the plaintiffs filed a notice of appeal to the Sixth Circuit Court of Appeals and on September 14, 2017, they filed their opening brief in support of the appeal. The appeal was fully briefed on December 7, 2017, and it was argued before the Sixth Circuit on March 15, 2018. On September 27, 2018, the Sixth Circuit issued an opinion in which it reversed the district court&#8217;s dismissal and remanded for further proceedings. On October 11, 2018, the Company filed a petition for rehearing en banc and, on October 23, 2018, the Sixth Circuit Court of Appeals directed plaintiffs to respond to that petition. On December 3, 2018, the Sixth Circuit denied the Company&#8217;s petition for en banc rehearing, and on December 11, 2018, the case was returned to the federal district court by mandate from the Sixth Circuit. On December 26, 2018, the Company filed an answer to the amended complaint, and on March 28, 2019, the Company filed its amended answer to the amended complaint. On September 15, 2020, the Company filed a motion for summary judgment, and the plaintiffs filed a motion for partial summary judgment, and on October 23, 2020, the parties filed oppositions to both motions for summary judgment. On November 20, 2020, the Company and plaintiffs filed replies in support of their respective motions. On March 12, 2021, the parties agreed to a settlement in principle of the securities class action, and on April 26, 2021, the parties entered into a stipulation of settlement to resolve all legal claims, in which defendants expressly deny that they have committed any act or omission giving rise to any liability under Section 10(b) of the Securities Exchange Act of 1934. Under the terms of the stipulation of settlement, which the court preliminarily approved on May 6, 2021, the Company and certain of the Company's insurance carriers will cause a payment of $<ix:nonFraction unitRef="usd" contextRef="i66cc3f1c51c941f2b162c47f055b97e7_D20210101-20210630" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfMzI3OA_0d449f7c-8c16-4449-b584-9c658f5f5bb1">18.25</ix:nonFraction>&#160;million to be made to the plaintiff class. There is no assurance that the settlement will ultimately become final. If the settlement does not occur and litigation continues, the Company intends to vigorously defend against it. As a result of this settlement agreement, during the three months ended March 31, 2021, the Company recorded a loss on settlement of $<ix:nonFraction unitRef="usd" contextRef="i0762115bc2ec4613b524e91fa9b92de0_D20210101-20210331" decimals="-4" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfMTA5OTUxMTYzNDAyNA_1dda782a-83a6-43af-8135-936bbea738ad">13.25</ix:nonFraction>&#160;million in selling, general, and administrative expenses on the condensed statement of operations, which represents the litigation settlement of $<ix:nonFraction unitRef="usd" contextRef="ifecad91fa7424664b1f1f53f4d25e943_I20210331" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfMzYzMg_3046fd9d-4e5f-4bf7-adc1-57c0d61b17b9">18.25</ix:nonFraction>&#160;million offset by $<ix:nonFraction unitRef="usd" contextRef="ifecad91fa7424664b1f1f53f4d25e943_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfMzc3NA_75c7cdc2-3718-47b5-b215-25aa53080eab">5.0</ix:nonFraction>&#160;million in insurance claim proceeds from our insurance carriers.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2016, a purported stockholder of the Company filed a derivative lawsuit in the Court of Chancery of the State of Delaware against Tim Mayleben, Roger Newton, Mary McGowan, Nicole Vitullo, Dov Goldstein, Daniel Janney, Antonio Gotto Jr., Mark McGovern, Gilbert Omenn, Scott Braunstein, and Patrick Enright. The Company is named as a nominal defendant. The lawsuit alleges that the defendants breached their fiduciary duties to the Company when they made or approved improper statements on August 17, 2015, regarding the Company&#8217;s lead product candidate&#8217;s path to FDA approval, and failed to ensure that reliable systems of internal controls were in place at the Company. On February 8, 2019, the Company and defendants filed a motion to dismiss the derivative lawsuit. On April 23, 2019, the plaintiff filed an opposition to the motion to dismiss the derivative lawsuit, and the Company filed a reply brief on May 15, 2019. On November 6, 2019, the court held a hearing on the motion to dismiss. On February 13, 2020, the court granted the motion to dismiss with prejudice and entered judgment in the Company&#8217;s favor. On March 16, 2020, the plaintiff filed a notice of appeal to the Supreme Court of Delaware. On June 1, 2020, the plaintiff filed his opening brief on appeal to the Supreme Court of Delaware. On July 1, 2020, the Company and the defendants filed an answering brief, and on July 16, 2020, the plaintiff filed a reply brief. On October 14, 2020, the Supreme Court of Delaware held oral arguments on the appeal. On October 29, 2020, the Supreme Court of Delaware issued an order affirming the judgment of the Court of Chancery. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the Company&#8217;s contractual obligations and commitments and contingencies outside the ordinary course of business from those previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 or noted above.</span></div></ix:continuation><div id="i155233a9c30143f788c2cb30bf7b7a77_52"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfNzk1_b5736904-01e2-4321-a8cc-9d1a364a07ba" continuedAt="id4a0698a4cf74c28af11497991835f6f" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="id4a0698a4cf74c28af11497991835f6f" continuedAt="id4e408f6661e409da9205ebfe44b3baa"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfNzk0_17a85700-24ca-46f5-a9d3-eee96b118288" continuedAt="ib4d44cfd8253490a8f36ccf25f0d346d" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s cash equivalents and short-term investments (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85239930eaf64704995fff739a828f1c_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfMy0xLTEtMS0w_93b552e6-3e63-4ebb-a7ee-c2708c5d0668">201,734</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85239930eaf64704995fff739a828f1c_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfMy0zLTEtMS0w_ec57f960-8fe1-4829-935b-8c8f4b617eac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85239930eaf64704995fff739a828f1c_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfMy01LTEtMS0w_579354ca-cfc0-492f-9923-df6896be91e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85239930eaf64704995fff739a828f1c_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfMy03LTEtMS0w_6c090ba5-467f-45cc-ada0-42df25631ef9">201,734</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfNi0xLTEtMS0w_b3975997-dae8-4204-a5a4-6a45c1fdb312">201,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfNi0zLTEtMS0w_bac9524e-fb50-4664-b0a1-600bcf122e78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfNi01LTEtMS0w_1bd9bf85-35a0-4b78-94b5-572bd3b889d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfNi03LTEtMS0w_f826a279-f37a-423e-8c10-7f71a442294c">201,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="id4e408f6661e409da9205ebfe44b3baa"><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="ib4d44cfd8253490a8f36ccf25f0d346d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2755a874c4a4c48a6b849306fd2464f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMy0xLTEtMS0w_c5c32b99-22c7-4500-b4e9-1b549c630fb0">281,783</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2755a874c4a4c48a6b849306fd2464f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMy0zLTEtMS0w_9c208c1b-19fb-450f-b05e-f419d505eac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2755a874c4a4c48a6b849306fd2464f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMy01LTEtMS0w_919483eb-de69-4549-b341-53777121a501">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2755a874c4a4c48a6b849306fd2464f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMy03LTEtMS0w_3016da43-0422-4f4c-a3ff-07e6bf9aadc1">281,783</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMTAtMS0xLTEtMA_9f7f83a9-47b9-4172-80d0-84f81cbbe804">281,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMTAtMy0xLTEtMA_f92c7c8c-f3bb-4aed-9871-cceb9bff6e65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMTAtNS0xLTEtMA_83993292-88c7-42a0-8f3f-ee484f3a6100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMTAtNy0xLTEtMA_8af82995-1f6f-4710-8fc8-933d0a1367d7">281,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, other income, net in the statements of operations includes interest income on investments of less than $<ix:nonFraction unitRef="usd" contextRef="i5495cad7e02a4bc7ac5c026e15930a48_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMTA5OTUxMTYyODg5Nw_08a935a5-a3de-427f-8fd1-92e70e99dc17">0.1</ix:nonFraction> million and less than $<ix:nonFraction unitRef="usd" contextRef="i022b72f313384923a430318e5e44d480_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMTA5OTUxMTYyODg0Mw_3f252af2-e911-41e6-ae50-068697c03081">0.1</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2020, other income, net in the statements of operations includes interest income on investments of $<ix:nonFraction unitRef="usd" contextRef="i0f3eb84da08544e7858c671a0f89178b_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMTA5OTUxMTYyODg4Nw_8036cfa9-6cbd-47d0-a65e-e13a3b751e18">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i02ebc26f1dec4284a51f47f1f7bd41c8_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMTA5OTUxMTYyODg3OA_5eecf62e-ca90-4f0d-b21b-0b7ebd06d304">0.5</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="id696d6839c0d44a9971fc5c29b5ab6c5_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMzA3_3b16f9a5-15d6-4ac9-bc73-fd2b1ec33656"><ix:nonFraction unitRef="usd" contextRef="i79c6b9595b0e45e399fbfc89434af8ba_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMzA3_9698b28d-e525-41a3-904c-5107febe1743"><ix:nonFraction unitRef="usd" contextRef="i3014251d4b0c415f885b37eb158bb11f_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMzA3_a7bddf5a-b42f-43cb-b85a-171a0da085bb"><ix:nonFraction unitRef="usd" contextRef="ie7475569334245839b63cf3cc4120cfc_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMzA3_d0781b0c-84a7-46db-81fd-3a943e98e063">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> unrealized gains or losses on investments reclassified from accumulated other comprehensive income (loss) to other income in the statements of operations during the three and six months ended June&#160;30, 2021 and 2020.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three and six months ended June&#160;30, 2021, there were <ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfNTQ3_033dab22-20df-42aa-b92c-31757ae110d3">no</ix:nonFraction> allowances for credit losses and all unrealized gains (losses) for available-for-sale securities were recognized in accumulated other comprehensive income (loss). As of June&#160;30, 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AccruedInvestmentIncomeReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfNzYx_78b72e21-59cf-405e-b073-4731b0524583">no</ix:nonFraction> accrued interest receivables.</span></div></ix:continuation><div id="i155233a9c30143f788c2cb30bf7b7a77_55"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RleHRyZWdpb246MGZiZDY2MTA3NWU3NDlhY2E2ZjhhMTc4YjAwZTA5MDRfNjUw_b9981599-b7ae-416f-9719-97e9496f9b65" continuedAt="ia1abae096b8b460d862c0b7fb1204d41" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ia1abae096b8b460d862c0b7fb1204d41"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three level hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1 inputs:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices for identical assets or liabilities in active markets;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2 inputs:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level&#160;1 prices, such as quoted market prices for similar assets or liabilities or other inputs that are observable or can be corroborated by market data; and</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3 inputs:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that are supported by little or no market activity and require the reporting entity to develop assumptions that market participants would use when pricing the asset or liability.</span></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RleHRyZWdpb246MGZiZDY2MTA3NWU3NDlhY2E2ZjhhMTc4YjAwZTA5MDRfNjUx_cec8b86a-21d3-4535-9e31-f8d1466ff0a8" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets that have been measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a310b3100843458cf7b9780be99be8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNC0yLTEtMS0w_0ba4e5f3-8b9a-4396-ad5b-3fdd6711fa51">201,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74320e4faa84cd1b28ec9a625c98df5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNC00LTEtMS0w_555146fc-4c3a-42ab-8b18-0867e1a97069">201,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5153d021d85e4ef9b35b24ed9da916ca_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNC02LTEtMS0w_3c86449b-f5f5-4208-a7e9-e577d16a35f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ddd957560f42ff8203389517f59eb2_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNC04LTEtMS0w_d07ae212-3382-4ea4-b7b2-93ec092cb054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2aa44c62434cdca9106c4f4051ff24_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNy0yLTEtMS0w_f71e146b-e8ed-4bc7-bbca-86a7ec0fb0b5">201,734</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5581113f5e084f04997d0355ded32b7d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNy00LTEtMS0w_5d41377f-0be1-4f2d-8791-aab797d33196">201,734</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4033291bd05c46c28d615917d2bf3476_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNy02LTEtMS0w_3cedb1c3-8ee0-4ffe-acba-f44af45187d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b50f26d3c4740b19924787f56195caa_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNy04LTEtMS0w_acd6395a-d0f3-4beb-bea1-69a6da956549">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ff88d17c8f4135932357759e2c4415_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTAtMi0xLTEtMA_0b546081-f01a-4541-b929-ad116bcabeea">281,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a555aa890154f02bec9878d09c55db6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTAtNC0xLTEtMA_fb6fde34-162d-4935-ae22-f0881de6409a">281,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a780031e57403b91a7034227c9bdaf_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTAtNi0xLTEtMA_7e34cdf1-8ea2-4bec-8811-6b03924e1271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559c63b8c37f45c191813cedafe6679c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTAtOC0xLTEtMA_77ba08b6-5f7f-4ead-b90a-f43b6c7f34b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0655536ac5664cfc9f50beaeae40a963_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTUtMi0xLTEtMA_4d9901ad-c379-4cbf-b509-d94d78e64e9f">281,783</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9c5f735fcfc445e88a0357b3cff80ac_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTUtNC0xLTEtMA_355bea3e-8ddc-4855-993d-30bfd5cd3b4d">281,783</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66085bd7806540ba8c194ce5c0187acd_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTUtNi0xLTEtMA_e70c3d7c-73ac-46a9-b5d3-97deea7151b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a9b0a5e5b1d4b328310765a841beb27_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTUtOC0xLTEtMA_91050aa6-976c-40bb-939c-50f7f2451284">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2 or 3 during the three and six months ended June&#160;30, 2021 and 2020.</span></div></ix:continuation><div id="i155233a9c30143f788c2cb30bf7b7a77_58"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNzA3Nw_a1137b40-5ded-4a32-a45d-fcf676936f92" continuedAt="ide69a59779db432e84fee9b01845d953" escape="true">Liability Related to the Revenue Interest Purchase Agreement</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ide69a59779db432e84fee9b01845d953" continuedAt="i70cbf3b558c140e3834f6efb3baa8349">On June 26, 2019, the Company entered into a RIPA with Oberland, as agent for purchasers party thereto (the &#8220;Purchasers&#8221;), and the Purchasers named therein, to obtain financing in respect to the commercialization and further </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="i70cbf3b558c140e3834f6efb3baa8349" continuedAt="iea6d539e82144a23945e80e2eb19beee"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of bempedoic acid and the bempedoic acid / ezetimibe combination tablets and other working capital needs. Pursuant to the RIPA, the Company received $<ix:nonFraction unitRef="usd" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="-5" name="espr:GrossProceedsFromRevenueInterestPurchaseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDU1_c62145fa-9036-461e-aca9-7d520a6eb0ab">125.0</ix:nonFraction> million at closing, less certain issuance costs. The Company was also entitled to receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="-5" name="espr:AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTU5_6b0c8cbd-e569-484d-9a01-b51d39475d80">75.0</ix:nonFraction> million in subsequent installments subject to the terms and conditions set forth in the RIPA: (i) $<ix:nonFraction unitRef="usd" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="-5" name="espr:AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjUy_f5491952-f766-4a15-9bec-a886bbc0cc53">25.0</ix:nonFraction> million upon certain regulatory approval of its product candidates and (ii) $<ix:nonFraction unitRef="usd" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="-5" name="espr:AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNzIz_3010fb34-4910-4864-a753-39ee978e5053">50.0</ix:nonFraction> million, at the Company&#8217;s option, upon reaching $<ix:nonFraction unitRef="usd" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="-5" name="espr:MilestoneAmountForWorldwideSalesToReceiveThirdPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNzY2_15e142d4-9ff0-40cc-a342-19bd6d990722">100.0</ix:nonFraction> million trailing worldwide six-month net sales any time prior to December 31, 2021 (the &#8220;Third Payment&#8221;). In March 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i3fefac52cc164b6e8c114422d7b945c7_D20200301-20200331" decimals="-5" name="espr:ProceedsFromRevenueInterestPurchaseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfOTAz_96237c78-aa27-4458-8ad0-160ad2765058">25.0</ix:nonFraction> million from Oberland upon receiving regulatory approval of NEXLETOL.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from the Company based upon net sales of the Company&#8217;s certain products which will be tiered payments initially ranging from <ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="3" name="espr:RevenueInterestRateTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTIyMA_5768c298-4c8d-4ec0-8d1d-d5e77c04e9b3">2.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="3" name="espr:RevenueInterestRateInitialRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTIyNg_da12a8b3-880b-4af1-84f2-931b55ed894e">7.5</ix:nonFraction>% of the Company&#8217;s net sales in the covered territory (the &#8220;Covered Territory&#8221;); provided that (a) if annual net sales equal or exceed $<ix:nonFraction unitRef="usd" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="INF" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTM2Mg_541db255-2798-4007-a16c-e5a3b09f60cd">350.0</ix:nonFraction> million by December 31, 2021 (the &#8220;Sales Threshold&#8221;), the initially tiered revenue interest rate will be decreased to a single rate of <ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="3" name="espr:RevenueInterestRateTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTQ5Mg_01aa3963-2530-4ebb-b57e-bff86751491b">2.5</ix:nonFraction>% of the Company&#8217;s net sales in the Covered Territory, beginning on January 1, 2022, and (b) if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive <ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="INF" name="espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTY3Mg_d1047e61-bd44-48bb-9c9d-3aacdc6e935b">100</ix:nonFraction>% of their invested capital by December 31, 2024, the revenue interest rate will be decreased to a single rate of <ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="3" name="espr:RevenueInterestRateTierThree" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTc4Nw_5bf66a40-c10a-46de-af80-8d2cb107bfa3">0.4</ix:nonFraction>% of the Company&#8217;s net sales in the Covered Territory beginning on January 1, 2025. If the Third Payment is drawn down by the Company, the applicable royalty rates will increase by one-third. The Covered Territory is the United States, but is subject to expand to include the world-wide net sales if the Company&#8217;s annual U.S. net sales are less than $<ix:nonFraction unitRef="usd" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="INF" format="ixt:numdotdecimal" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMjEzOA_760167d8-f7eb-449d-a8ad-6fcf37210c96">350.0</ix:nonFraction> million for the year ended December 31, 2021. The U.S. net sales milestone thresholds are not to be taken as financial guidance. The Purchasers&#8217; rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received Revenue Interests payments of <ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMjQxNA_bcc71e15-91e4-4099-b26c-76e76fc52cca">195</ix:nonFraction>% of the then aggregate purchase price (the &#8220;Cumulative Purchaser Payments&#8221;) paid to the Company, unless the RIPA is terminated earlier.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RIPA, the Company has an option (the &#8220;Call Option&#8221;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#8220;Put Option&#8221;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option is exercised prior to the first anniversary of the closing date by the Purchasers (except pursuant to a change of control), the required repurchase price will be <ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMzE3Nw_c2526fb9-70b1-4b57-9ff5-5e985ac3ecd3">120</ix:nonFraction>% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests). In all other cases, if the Put Option or the Call Option are exercised, the required repurchase price will be <ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMzQyNQ_2adde6a2-5bae-4f91-9dea-e7e9dd954678">175</ix:nonFraction>% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and <ix:nonFraction unitRef="number" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMzY0Nw_6b23dd36-fb43-4c9e-95be-89d7cd9e3e26">195</ix:nonFraction>% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the RIPA contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RIPA Amendments</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 26, 2021, the Company entered into Amendment No. 2 (the &#8220;RIPA Amendment&#8221;) to the RIPA with Oberland, as agent for the purchaser parties thereto. Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $<ix:nonFraction unitRef="usd" contextRef="i3e34a6464b9342eab9af91553cce8a2c_D20210426-20210426" decimals="-6" format="ixt:numdotdecimal" name="espr:ProceedsFromRevenueInterestPurchaseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0NzM4MA_9a98eab1-e6a1-4291-9c9a-56efe399da17">50</ix:nonFraction>&#160;million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA such that the purchasers will have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from the Company based on net sales of the Company&#8217;s certain products, once approved, which will be tiered payments ranging from <ix:nonFraction unitRef="number" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" name="espr:RevenueInterestRateTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0Nzc1NA_3162db05-ca2b-4a26-89e4-52f14fd60c35">3.33</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" name="espr:RevenueInterestRateInitialRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0Nzc2MQ_937ba7c9-5943-40d9-8dc1-602f95232528">10</ix:nonFraction>% (the &#8220;Third Payment Applicable Percentage&#8221;) of the Company&#8217;s net sales in the covered territory (the &#8220;Covered Territory&#8221;); provided that (a) prior to December 31, 2024, with respect to each country defined in the Daiichi Territory, if the percentage of net sales that Company receives from Daiichi (the &#8220;Receivables Percentage&#8221;) is less than the Third Payment Applicable Percentage, then the Revenue Interest for such country payable to the purchasers will be equal to the Receivables Percentages, (b) if annual net sales equal or exceed $<ix:nonFraction unitRef="usd" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" format="ixt:numdotdecimal" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0ODMwNw_7287b1e5-5859-4b51-90a8-799508053cd0">350</ix:nonFraction>&#160;million and if the Purchasers receive <ix:nonFraction unitRef="number" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" name="espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0ODM0MQ_aa27502a-3c13-4a69-9def-28343f8fd44b">100</ix:nonFraction>% of their invested capital (<br/>Cumulative Purchaser Payments") by December 31, 2024, the revenue interest rate will be decreased to a single rate of <ix:nonFraction unitRef="number" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" name="espr:RevenueInterestRateTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0ODQ1Nw_65083a07-c9b0-47de-8251-8cc787fcacb8">3.33</ix:nonFraction>% of the Company&#8217;s net sales in the Covered Territory for all subsequent calendar quarters and (c) if the Purchasers receive Revenue Interest payments less than <ix:nonFraction unitRef="number" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" name="espr:PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NTQ2Mw_bee654d1-bccf-4996-b128-115731955438">100</ix:nonFraction>% of Cumulative Purchaser Payments by December 31, 2024, the Third Payment Applicable Percentage will be increased to a single rate of the Company&#8217;s net sales that would have provided <ix:nonFraction unitRef="number" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" name="espr:PercentageOfCumulativePurchaserPaymentsGuarantee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NTQ2OQ_8bad2bf0-8c4d-458d-bd3a-0f5e1341c19f">100</ix:nonFraction>% of Cumulative Purchaser Payments had such rate applied from the initial funding by the Purchasers. The Covered Territory was originally the United States, but has been expanded to worldwide for all calendar years beginning on or after January 1, 2022. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the RIPA, the Company has an option (the &#8220;Call Option&#8221;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#8220;Put Option&#8221;) to terminate </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="iea6d539e82144a23945e80e2eb19beee" continuedAt="i2178b840e60346ba80edefb1f1d34bb0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price will be <ix:nonFraction unitRef="number" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0OTI1NA_7e105283-3ba0-4b3e-98d0-ae16a1bf9cc7">200</ix:nonFraction>% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and <ix:nonFraction unitRef="number" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0OTQ3Nw_1980e211-3855-47d4-be9d-f1231d19ff60">225</ix:nonFraction>% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 470&#8209;50, &#8220;Debt&#8212;Modifications and Extinguishments,&#8221; the RIPA Amendment was accounted for as a debt modification. The amendment resulted in a $<ix:nonFraction unitRef="usd" contextRef="i1e0952b04e3e49f89edda6732c584442_D20210401-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnRestructuringOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NjU0OQ_4803522d-6912-47ef-a316-8ad26004b32f"><ix:nonFraction unitRef="usd" contextRef="i2090d9c5d7cd408393dabbb49aef53e9_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnRestructuringOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NjU0OQ_c9069bc9-0bbb-422b-b2c7-99a54abd0bc3">0.1</ix:nonFraction></ix:nonFraction>&#160;million loss on modification of debt, consisting of third-party fees associated with the transaction, which is included in selling, general, and administrative expenses in the statements of operations for the three and six months ended June 30, 2021.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2021, the Company entered into an Amendment to the Security Agreement and Waiver ("Amendment and Waiver") with the same parties to the Security Agreement, by and among the Company, Eiger Partners II LP (the "Purchaser") and Eiger III SA LLC (the "Purchaser Agent"), dated as of June 26, 2019 (the "Security Agreement"). Pursuant to the Amendment and Waiver, if (i) the net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States (as reported in the Company&#8217;s financial statements as &#8220;product sales, net&#8221; in accordance with GAAP and excluding, for the avoidance of doubt, upfront or milestone payments and other collaboration revenue) (the &#8220;Specified Net Revenue&#8221;) for the calendar quarter ending September 30, 2021 does not exceed $<ix:nonFraction unitRef="usd" contextRef="if3a49799960046fabd41ee94341b6178_D20210516-20210516" decimals="-6" format="ixt:numdotdecimal" name="espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY1MTAzMA_18277cb9-279b-4bac-9e87-f73d533200fa">15.0</ix:nonFraction> million, or (ii) the Specified Net Revenue for any calendar quarter ending after September 30, 2021 does not exceed $<ix:nonFraction unitRef="usd" contextRef="if3a49799960046fabd41ee94341b6178_D20210516-20210516" decimals="-6" format="ixt:numdotdecimal" name="espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY1MTE0Mg_1edd7856-8a4e-402a-92e4-d1c55d41d8b7">15.0</ix:nonFraction> million, then the Company shall deposit $<ix:nonFraction unitRef="usd" contextRef="if3a49799960046fabd41ee94341b6178_D20210516-20210516" decimals="-6" format="ixt:numdotdecimal" name="espr:BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY1MTE3OA_c4e77bc2-eb04-4b71-9d4d-a21b268ccd28">50.0</ix:nonFraction> million in a deposit account that is subject to a block account control agreement in favor of the Purchase Agent, no later than the earlier of (x) the date the Specified Net Revenue for such calendar quarter has been determined and (y) 45 days after the last day of such calendar quarter. The Purchaser Agent shall have sole dominion and control over all funds deposited in the deposited account and such funds may be withdrawn therefrom only with the consent of the Purchaser Agent. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to apply amounts held in the deposit account in payment of certain secured obligations in the manner provided for in the Security Agreement. The Amendment and Wavier does not substitute, replace or release the Pledgors from any other obligations under the RIPA or Security Agreement.</span></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the arrangement, as of June&#160;30, 2021, the Company has recorded a liability, referred to as the &#8220;Revenue interest liability&#8221; in the condensed balance sheets, of $<ix:nonFraction unitRef="usd" contextRef="i28e0c72e2cb9467a8d1097badc2d555d_I20210630" decimals="-5" name="espr:RevenueInterestLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDIxMw_9331bdc8-a90d-485f-adf9-6e04a7118b93">238.2</ix:nonFraction> million, net of $<ix:nonFraction unitRef="usd" contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630" decimals="-5" name="espr:UnamortizedTransactionCostsOnRevenueInterestAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDIyNA_696c5d9f-7ace-4a70-b8e3-28a29a16c238">0.5</ix:nonFraction> million of capitalized issuance costs in connection with the RIPA. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The Company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant increase or decrease in net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. The Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i82b18040c5994d5fb1c1230a7479649f_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDM5ODA0NjUzNjI4OQ_877b2389-3308-49fb-8ac1-fee5d9285152">8.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDM5ODA0NjUzNjMxNw_b86f3f37-94a2-4762-9f90-a666a8a8a242">12.9</ix:nonFraction>&#160;million in interest expense related to this arrangement for the three and six months ended June&#160;30, 2021, and $<ix:nonFraction unitRef="usd" contextRef="ib5fa732b89bf4e608cb020cdbaed049c_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NjY1Ng_f6b58b3d-8c7f-4dcf-8cad-e9652c5d5bd2">4.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i314c65622530486bbc90177fa464e9a2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NjY3MA_fbc39b78-a754-4c00-8179-82f2246425ed">8.8</ix:nonFraction>&#160;million for the three and six months ended June 30, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment of the RIPA to Oberland does not have a fixed repayment schedule, rather it will be completely repaid and extinguished when the Company has repaid <ix:nonFraction unitRef="number" contextRef="i682526a2d76f4aad9318435409bd1702_D20190626-20190626" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTI5Mg_b4fffa07-bc05-46bb-a6ad-11a867c0962e">200</ix:nonFraction>% of the aggregate purchase price prior to the third anniversary of the closing date, and <ix:nonFraction unitRef="number" contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY1MjQ2OA_1980e211-3855-47d4-be9d-f1231d19ff60">225</ix:nonFraction>% of the Cumulative Purchaser Payments thereafter, unless the RIPA is terminated earlier. Since there is not a fixed repayment schedule, the Company does not project its future repayments by year. Each period, the Company estimates the future expected sales of its products in the covered territory and determines the effective annual imputed interest rate, which updates and changes the timing of the Company&#8217;s payments. Under the terms of the agreement, every $<ix:nonFraction unitRef="usd" contextRef="i54599248558d4aeabaada2313141952a_D20190626-20190626" decimals="-6" format="ixt:numdotdecimal" name="espr:HypotheticalSalesGeneratedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTczOA_ccaacd57-fda0-486c-bbba-c6a0ef66ad94">100</ix:nonFraction>&#160;million of net sales generated, less than or equal to $<ix:nonFraction unitRef="usd" contextRef="i54599248558d4aeabaada2313141952a_D20190626-20190626" decimals="INF" format="ixt:numdotdecimal" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTc4Nw_86b4f9e0-5cbc-4c7f-8cda-8876d19ae22b">250</ix:nonFraction>&#160;million in an annual aggregate year, would result in a repayment obligation of approximately $<ix:nonFraction unitRef="usd" contextRef="i24cc2d3d09bf4804b7ebe4fcf96e4159_I20190626" decimals="-5" format="ixt:numdotdecimal" name="espr:HypotheticalRepaymentObligationBasedOnSalesGenerated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTg3NQ_0de68dfd-4331-4a50-8b12-8329998fb570">10.0</ix:nonFraction>&#160;million or <ix:nonFraction unitRef="number" contextRef="i54599248558d4aeabaada2313141952a_D20190626-20190626" decimals="3" name="espr:RevenueInterestRateInitialRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTg4MQ_63810f10-47b5-498e-9532-ea1946447ea0">10.0</ix:nonFraction>% at the stated repayment rate in the first year. Annual Net Sales for a calendar year exceeding $<ix:nonFraction unitRef="usd" contextRef="i2b2993300957480c8da25fe45a53a602_D20190626-20190626" decimals="INF" format="ixt:numdotdecimal" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTk3OQ_2aba5305-b67d-4fe5-80a0-241c243d0b93">250</ix:nonFraction>&#160;million would result in a repayment obligation of approximately $<ix:nonFraction unitRef="usd" contextRef="i61206dad37874474a095378d715c7ddc_I20190626" decimals="-5" format="ixt:numdotdecimal" name="espr:HypotheticalRepaymentObligationBasedOnSalesGenerated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjAzOA_6a1da402-90ba-4a91-8ae3-906f1655a892">3.3</ix:nonFraction>&#160;million or <ix:nonFraction unitRef="number" contextRef="i2b2993300957480c8da25fe45a53a602_D20190626-20190626" decimals="3" name="espr:RevenueInterestRateTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjA0NA_b1be8964-06ba-4694-8c97-0f7671f42197">3.3</ix:nonFraction>% for every $<ix:nonFraction unitRef="usd" contextRef="i2b2993300957480c8da25fe45a53a602_D20190626-20190626" decimals="-6" format="ixt:numdotdecimal" name="espr:HypotheticalSalesGeneratedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjA1Nw_ce7d93fc-0ada-4525-9698-75280011c6da">100</ix:nonFraction>&#160;million of sales above the threshold. If the Company equals or exceeds $<ix:nonFraction unitRef="usd" contextRef="i3168451b6e8043e7a8c693b76d15d0bb_D20190626-20190626" decimals="INF" format="ixt:numdotdecimal" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjEyMw_0881d388-356a-4923-b920-d0816b2b7e94">350</ix:nonFraction>&#160;million of sales in the U.S. in 2021, then the repayment amount would drop to $<ix:nonFraction unitRef="usd" contextRef="i151f5743662f4d9b94b53d5f3aebdc7b_I20190626" decimals="-5" format="ixt:numdotdecimal" name="espr:HypotheticalRepaymentObligationBasedOnSalesGenerated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjE5Ng_4ed7c9ae-5fdb-41d8-8f2a-bbc70ea8273d">3.3</ix:nonFraction>&#160;million for every $<ix:nonFraction unitRef="usd" contextRef="i3168451b6e8043e7a8c693b76d15d0bb_D20190626-20190626" decimals="-6" format="ixt:numdotdecimal" name="espr:HypotheticalSalesGeneratedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjIwOQ_7064b6a5-06d1-4a8c-ac11-82fb1b5ef92f">100</ix:nonFraction>&#160;million of net sales starting in 2022. If the US net sales are less than $<ix:nonFraction unitRef="usd" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="INF" format="ixt:numdotdecimal" name="espr:NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjI3Nw_c1feeb13-6ca9-418f-aeca-5d8c20871d38">350</ix:nonFraction>&#160;million for the year ended December 31, 2021, then the Covered Territory is expanded to include worldwide sales beginning in 2022. The Company&#8217;s repayments of the RIPA are directly tied to the growth of its net sales, and as the Company&#8217;s net sales grow, the Company expects the related repayments of the RIPA to grow as well. The Company currently expects to repay $<ix:nonFraction unitRef="usd" contextRef="i519246cc64e94185973aeceecf9b0714_I20210630" decimals="-5" format="ixt:numdotdecimal" name="espr:RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjYzOA_0c6daf1a-5a73-43e7-ba1a-571d840e5a7e">12.5</ix:nonFraction>&#160;million in the next twelve months.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="i2178b840e60346ba80edefb1f1d34bb0"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual imputed interest rate is <ix:nonFraction unitRef="number" contextRef="if16e161500f14c968dff53d7b2d6a4eb_D20210101-20210630" decimals="3" name="espr:RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjcxNg_e63b3bfd-5041-46b6-b23a-6c306995eed0">17.2</ix:nonFraction>% as of June&#160;30, 2021. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626" decimals="-5" name="espr:UnamortizedTransactionCostsOnRevenueInterestAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjc1MA_d0f97d5f-361e-4145-9ecd-e1c2386af849">0.6</ix:nonFraction> million of issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. Payments made to Oberland as a result of the Company&#8217;s net sales will reduce the revenue interest liability.</span></div><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="espr:ScheduleOfRevenueInterestLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNzA3OA_31fabf6b-4d61-4c49-baa8-c2dd832d160c" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the six months ended June&#160;30, 2021:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04054e50e094fd9b83c8ea7d483bcc9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="espr:RevenueInterestLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfMS0xLTEtMS0w_ef8b85fb-a945-4d1e-a7bc-334c0e8c56ae">176,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;Oberland funding upon execution of Amendment No. 2, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfMi0xLTEtMS0w_65235df9-29cf-420d-b75e-e6023b13e830">49,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfMy0xLTEtMS0w_9e5529d3-f48f-401d-b8d8-9e4b3603f07f">12,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interests payments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:PaymentsFromRevenueInterestPurchaseAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfNC0xLTEtMS0w_8754821c-5fc1-404a-9b4f-2af7a726e378">1,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e0c72e2cb9467a8d1097badc2d555d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:RevenueInterestLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfNS0xLTEtMS0w_b98d12d8-5f95-46ca-8fab-b7190521d9eb">238,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_64"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTIxNzU_5263b05e-8f16-4c37-9c2a-410798062879" continuedAt="i9824dc6edd2f465f81aa53b1db7060ce" escape="true">Convertible Notes</ix:nonNumeric></span></div><ix:continuation id="i9824dc6edd2f465f81aa53b1db7060ce" continuedAt="i24450a7148244d22a74ae22d9e781c31"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjc_0d1c59a1-029e-47b4-b2c5-3ec7eb14867d">250.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTAw_3e35ae1e-74c9-49ea-9a2d-cbc2d58eff62">4.0</ix:nonFraction>% senior subordinated convertible notes due November 15, 2025. The net proceeds the Company received from the offering of the initial notes was approximately $<ix:nonFraction unitRef="usd" contextRef="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjU5_9604e8f2-f1c7-46f9-8208-b7f3c25a058c">242.0</ix:nonFraction>&#160;million, after deducting the initial purchasers&#8217; discounts and commissions and offering expenses payable by the Company. In connection with the offering of the senior subordinated convertible notes, the Company granted the initial purchasers of the senior subordinated convertible notes a 30-day option to purchase up to an additional $<ix:nonFraction unitRef="usd" contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116" decimals="INF" format="ixt:numdotdecimal" name="espr:DebtInstrumentAdditionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNTg5_0583a86f-dd45-4940-878e-2f87abb63f81">30.0</ix:nonFraction>&#160;million aggregate principal amount of the senior subordinated convertible notes on the same terms and conditions. On November 18, 2020 the option was exercised, which resulted in approximately $<ix:nonFraction unitRef="usd" contextRef="iabdf33924b4c4632935947223d1b399b_D20201118-20201118" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNzc3_b5583f83-f518-407c-b990-1d79a7fe8967">29.1</ix:nonFraction>&#160;million of additional proceeds, for total aggregate principal of $<ix:nonFraction unitRef="usd" contextRef="i1e05ade79f0c4479b2b0adfc5aab22f0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfODM3_3b2dacad-8e96-44d7-afd8-e0dd1b36bcae">280.0</ix:nonFraction>&#160;million and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1e05ade79f0c4479b2b0adfc5aab22f0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfODYw_8eb35a67-ab85-4323-9d11-f5258f2587d4">271.1</ix:nonFraction>&#160;million (the additional notes and, together with the initial notes, collectively called the &#8220;Convertible Notes&#8221;). The Company used approximately $<ix:nonFraction unitRef="usd" contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTAwMA_220feb3b-5aca-44ab-bccb-2f6c7b5b0b2f">46.0</ix:nonFraction>&#160;million of the net proceeds from the offering of the notes to pay the cost of the Capped Call (as defined below) and $<ix:nonFraction unitRef="usd" contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTExMg_e34d7f2f-3c41-47ff-99a3-97021cc83554">55.0</ix:nonFraction>&#160;million of the net proceeds from the offering of the initial notes to finance the Prepaid Forward (as defined below). The Convertible Notes are the Company's senior unsecured obligations and mature on November 15, 2025 (the &#8220;Maturity Date&#8221;), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Convertible Notes are convertible into shares of the Company&#8217;s common stock, can be repurchased for cash, or a combination thereof, at the Company&#8217;s election, at an initial conversion rate of <ix:nonFraction unitRef="number" contextRef="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTY1OA_e26e9400-02d0-4679-b61b-1b4fe1d93ff6">30.2151</ix:nonFraction> shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTgwNg_c26b99a5-299d-498c-a4d7-2601c89a1cf4">33.096</ix:nonFraction> per share of common stock, subject to adjustment. The Company will pay interest on the Convertible Notes semi-annually in arrears on May 15 and November 15 of each year.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes are general unsecured obligations of the Company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the Company&#8217;s RIPA, the revenue interests issued pursuant to such agreement, and any refinancing of the foregoing.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2025 in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended on March 31, 2021 (and only during such calendar quarter), if the last reported sale price per share of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ieab74430e0d740e2b4be6f36bf9d3cf3_I20201116" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjY3Ng_7dd3b98d-051a-49b5-8882-711ff77dbadb">0.001</ix:nonFraction> per share (&#8220;common stock&#8221;), is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjczNQ_2cd8ae41-5562-4022-a0d2-ae8de37c6135">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="day" contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjc4Mw_da927341-3d89-419c-b644-b29746922974">20</ix:nonFraction> trading days, whether or not consecutive, during the <ix:nonFraction unitRef="day" contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjgzOQ_95739343-c9d7-412c-9e94-a5ab583b9d72">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the <ix:nonFraction unitRef="day" contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116" decimals="INF" format="ixt-sec:numwordsen" name="espr:NumberOfBusinessDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjk3Ng_5310a771-1d55-46ea-81d5-cd69a8e5e63d">five</ix:nonFraction> business days after any <ix:nonFraction unitRef="day" contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116" decimals="INF" format="ixt-sec:numwordsen" name="espr:NumberOfConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMzAwMw_246f1ec0-963b-4294-a3cf-00bc5da0facf">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="day" contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116" decimals="INF" format="ixt-sec:numwordsen" name="espr:NumberOfConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMzA0Mw_e7927a01-9b47-46fb-91e6-5ed8b1370626">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116" decimals="INF" name="espr:DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMzIyOQ_69a4e89a-2d39-4cf6-b30f-a1d1048c4fd3">98</ix:nonFraction>% of the product of the last reported sale price per share of the Company&#8217;s common stock and the conversion rate for the notes on each such trading day; (3) if the Company calls such notes for redemption, any such notes that have been called for redemption may be converted at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption; and (4) upon the occurrence of specified corporate events, as provided in the Indenture.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 15, 2025, to the close of business on the second scheduled trading day immediately before the maturity date, holders may convert all or any portion of their notes at the applicable conversion rate at any time at the option of the holder regardless of the foregoing conditions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, following certain corporate events or following issuance of a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="i24450a7148244d22a74ae22d9e781c31" continuedAt="i04edf5b179044bfeac4b47d124fc20fe"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corporate event or to convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after November 20, 2023 and before the 41st scheduled trading day immediately before the maturity date, at a cash redemption price equal to <ix:nonFraction unitRef="number" contextRef="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNDcxOA_4de82f2e-7748-4512-9442-49ecd2129fab">100</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company&#8217;s common stock has been at least <ix:nonFraction unitRef="number" contextRef="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNDkxNQ_7d50ffa9-fc6f-4991-ab9a-ca884c3f62b0">130</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="day" contextRef="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNDk3MA_9cf5a5de-155f-461c-8899-983835f0b2db">20</ix:nonFraction> trading days (whether or not consecutive), including the trading day immediately preceding the date the Company sends the related redemption notice, during any <ix:nonFraction unitRef="day" contextRef="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNTEzMw_2fdfec84-1253-405a-b4ef-5111b6df458d">30</ix:nonFraction> consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company sends such redemption notice. No sinking fund is provided for the notes. If the Company redeems less than all the outstanding notes, at least $<ix:nonFraction unitRef="usd" contextRef="i2c80fd5162dd43bcb17ca0bfc7e60a2b_I20201116" decimals="INF" format="ixt:numdotdecimal" name="espr:DebtInstrumentCovenantRequiredAmountOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNTQwMw_222990a2-b561-41c1-8c5d-bfe9cf518953">125.0</ix:nonFraction>&#160;million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the Indenture), holders may require the Company to repurchase their notes for cash all or any portion of their notes at a fundamental change repurchase price equal to <ix:nonFraction unitRef="number" contextRef="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNTc2NQ_7ae69840-6229-4e43-8467-a98bc1f54af0">100</ix:nonFraction>% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. The Indenture includes customary terms and covenants, including certain events of default.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjA0Mw_fc3cc4e3-b21f-4b40-b157-d8e069302020">8.9</ix:nonFraction>&#160;million of issuance costs related to the issuance of the Convertible Notes, of which, prior to the adoption of ASU 2020-06 on January 1, 2021, $<ix:nonFraction unitRef="usd" contextRef="i8f1d759f487848f983aa3b9b0cfed648_I20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjE4MQ_dbb570c2-1a17-4b97-87aa-d62fe007e35c">5.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i220604fdf4934041957bde86b350d102_I20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjE4OA_be205d3d-dcf6-4fa2-9730-1e71ba282de5">3.1</ix:nonFraction>&#160;million were allocated and recorded to long-term debt and additional paid-in capital, respectively. The $<ix:nonFraction unitRef="usd" contextRef="i8f1d759f487848f983aa3b9b0cfed648_I20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjI4Nw_be38b466-8dc1-4aed-9166-dd2bdafcdedf">5.8</ix:nonFraction>&#160;million of issuance costs recorded as long-term debt on the condensed balance sheet are amortized over the <ix:nonNumeric contextRef="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTIxNzY_e5a19cf2-1aca-421b-8d52-1f6ad9408621">five-year</ix:nonNumeric> contractual term of the Convertible Notes using the effective interest method. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASU 2020-06 on January 1, 2021, the $<ix:nonFraction unitRef="usd" contextRef="i1e05ade79f0c4479b2b0adfc5aab22f0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjUzOA_ceebdd58-6307-4e7e-a8cd-8ccb2b5d4641">271.1</ix:nonFraction>&#160;million of proceeds received from the issuance of the Convertible Notes were allocated between long-term debt (the &#8220;liability component&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjY3NA_691ee1e4-622f-4501-871d-6103ea562e8c">177.6</ix:nonFraction>&#160;million and additional paid-in capital (the &#8220;equity component&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjczNg_0772c6f5-718c-4778-a787-7765c3204b69">93.5</ix:nonFraction>&#160;million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Convertible Notes and was included in additional paid-in capital in the condensed balance sheet and was not remeasured as long as it did not to meet the conditions for equity classification. The liability component was to be accreted up to the face value of the Convertible Notes of $<ix:nonFraction unitRef="usd" contextRef="ia9f7b2751cd04b7cba61f5f9cda15259_I20201118" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNzM0OA_43923030-1540-4bab-84ab-ab7c314f7a97">280.0</ix:nonFraction>&#160;million, which resulted in additional non-cash interest expense being recognized through the Maturity Date. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the adoption of ASU 2020-06 as of January 1, 2021, the Company reports the convertible debt liability at the aggregate principal amount less unamortized issuance costs. This resulted in the reclassification of the $<ix:nonFraction unitRef="usd" contextRef="i24321e9e8f7543f590713d54993c4653_I20210101" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNzY3MQ_aef81c25-f469-485e-8697-aa02df8bff1a">93.5</ix:nonFraction>&#160;million of the Company&#8217;s convertible notes recognized at December 31, 2020 from additional paid in capital to the convertible debt liability. The portion of interest expense previously recognized for the accretion of the convertible debt liability and the true-up of the amortization of the issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i24321e9e8f7543f590713d54993c4653_I20210101" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNzk3NQ_0de5e827-28b3-477b-859f-9a5d65b0c8c9">1.5</ix:nonFraction>&#160;million was recorded as an adjustment to accumulated deficit.  </span></div><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTIxNzc_4cc3952f-f6c4-42a0-84d6-cecc15daf48e" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the outstanding principal and debt issuance cost balances as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible note, debt balance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt issuance cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible notes, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5a302bf0ef4a2ca9960e5cd3087195_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMS0xLTEtMS0w_1473db34-9b22-44bb-96bf-c60141986011">185,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe5a302bf0ef4a2ca9960e5cd3087195_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMS0yLTEtMS0w_897598dc-4074-4b31-90bc-e58d9322a93e">5,733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5a302bf0ef4a2ca9960e5cd3087195_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMS0zLTEtMS0w_4475fda7-f909-4e3b-aa7a-4b4e12a96b3c">179,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to net principal due to adoption of ASU 2020-06</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4607f308bc47208a506b88c7eb9aa4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMi0xLTEtMS0w_04af6d86-ed7d-4b43-a2f2-87632e818b6a">94,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d4607f308bc47208a506b88c7eb9aa4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMi0yLTEtMS0w_d4cbc53f-bf32-4f7c-9dad-6a7469e9ba35">2,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4607f308bc47208a506b88c7eb9aa4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMi0zLTEtMS0w_303d39ac-231c-466e-91b0-ea4d976b107e">91,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975b21eabca94d14af546e0ab124bf30_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMy0xLTEtMS0w_0850bac5-1444-4a8c-a063-42613008aea3">280,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975b21eabca94d14af546e0ab124bf30_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMy0yLTEtMS0w_1e14c4e0-52b0-4d38-b602-6d1dbe937b6e">8,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975b21eabca94d14af546e0ab124bf30_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMy0zLTEtMS0w_53232416-f72b-4a25-984f-bd766425beac">271,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d9db700df64698bb10be3cd5969a2d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNC0xLTEtMS0w_33ab6183-6861-4465-911f-ef3ca6462b13">280,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1d9db700df64698bb10be3cd5969a2d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNC0yLTEtMS0w_d8cf1d58-fa8f-446c-9a08-1e1ffaac94e0">8,306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d9db700df64698bb10be3cd5969a2d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNC0zLTEtMS0w_58959a30-2ef2-42d3-b807-d12e06fb6cc6">271,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93532836fe0e4502b83cb85c9fb2c31a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNS0xLTEtMS0yMDg3_32734a97-9611-4431-999d-ee2bbe526ecf">280,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93532836fe0e4502b83cb85c9fb2c31a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNS0yLTEtMS0yMDg3_1a751f19-4c8f-4e71-9ccf-f0b1a24bee76">7,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93532836fe0e4502b83cb85c9fb2c31a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNS0zLTEtMS0yMDg3_29cbea43-f009-4d8f-8441-e9f5b634302f">272,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $<ix:nonFraction unitRef="usd" contextRef="ib008a93c1f5b4185bd24238dd3202fe2_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTA5OTUxMTY0MDI3OA_010c9871-a0a5-4112-97e2-2c007a47de54">3.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibdbc8b360e6a444da2991d43afe2a07e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTA5OTUxMTY0MDY0OQ_67c6e145-6d99-4fbd-8460-61baa80399f7">6.4</ix:nonFraction>&#160;million of interest expense during the three and six months ended June&#160;30, 2021, relating to the cash interest on the convertible notes due semi-annually and amortization of the debt issuance costs. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, no Convertible Notes were convertible pursuant to their terms. The estimated fair value of the Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i5305d0a8f10c49fa886fd702e4c1cc65_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfODUwMQ_8693e689-8aa4-4459-9865-cf9cc7e51b2b">233.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0d2d467fe6c549869f5d62f5f2e70867_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfODUwOA_62457195-de03-45c9-a9e7-158c1a4c0b42">283.4</ix:nonFraction>&#160;million as of June&#160;30, 2021 and December 31, 2020, respectively. The </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="i04edf5b179044bfeac4b47d124fc20fe"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. As of June&#160;30, 2021 and December 31, 2020, the if-converted value of the Convertible Notes did not exceed the principal value of those notes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capped Call Transactions</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into privately-negotiated capped call transactions with one of the initial purchasers of the convertible notes or its affiliate and certain other financial institutions. The Company used approximately $<ix:nonFraction unitRef="usd" contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfOTEzMg_52a595ac-06db-467e-8559-da1084dd17a2">46.0</ix:nonFraction>&#160;million of the net proceeds from the offering of the Convertible Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce potential dilution to the Company&#8217;s common stock upon any conversion of the Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, in the event that the market value per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the Convertible Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="id69054b09ba54731a79fe2fd68c06551_I20201116" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfOTk3OA_8d5ee224-573b-48c0-af86-059b2d7fb539">55.16</ix:nonFraction> (which represents a premium of approximately <ix:nonFraction unitRef="number" contextRef="id69054b09ba54731a79fe2fd68c06551_I20201116" decimals="INF" name="espr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTAwMjY_c5d702e9-9e6e-436a-bf82-352414253670">100</ix:nonFraction>% over the last reported sale price of the Company&#8217;s common stock on November 11, 2020), subject to certain adjustments. The capped call transactions are separate transactions, entered into by the Company and are not part of the terms of the Convertible Notes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that the transactions meet certain accounting criteria, the convertible note capped call transactions are recorded in stockholders&#8217; equity, and they are not accounted for as derivatives and are not remeasured each reporting period. As of June&#160;30, 2021 and December 31, 2020, the Company had not purchased any shares under the convertible note capped call transactions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Forward</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into a prepaid forward stock repurchase transaction (&#8220;Prepaid Forward&#8221;) with a financial institution (&#8220;Forward Counterparty&#8221;). Pursuant to the Prepaid Forward, the Company used approximately $<ix:nonFraction unitRef="usd" contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTA5NDk_46b9c005-992a-4420-a757-23365bff5c98">55.0</ix:nonFraction>&#160;million of the net proceeds from the offering of the Convertible Notes to fund the Prepaid Forward. The aggregate number of shares of the Company&#8217;s common stock underlying the Prepaid Forward was approximately <ix:nonFraction unitRef="shares" contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTExNTQ_e14b4ae2-fa3c-4a59-80b5-80642ddebb22">1,994,198</ix:nonFraction>. The expiration date for the Prepaid Forward is November 15, 2025, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders&#8217; votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company&#8217;s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.</span></div></ix:continuation><div id="i155233a9c30143f788c2cb30bf7b7a77_67"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RleHRyZWdpb246NjIyN2Q5NjIzZmZlNDYzNmI1YzhkZDA5ZjUzYzg4YjdfMTc4_b32d66e0-33f4-4a1d-b9d3-049d87020777" continuedAt="i08ac5586b95244b78f081fa8b9123465" escape="true">Other Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="i08ac5586b95244b78f081fa8b9123465"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RleHRyZWdpb246NjIyN2Q5NjIzZmZlNDYzNmI1YzhkZDA5ZjUzYzg4YjdfMTgw_533fee29-63d1-42d5-8acf-c9bace183c51" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfMi0xLTEtMS0w_c5572d45-13bb-48f0-83f1-fadfaa528d18">12,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfMi0zLTEtMS0w_d84b9f60-7156-486b-bd7f-2873e3eff2d3">15,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued variable consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:AccruedVariableConsiderationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfMy0xLTEtMS0w_d6d1561f-460e-43c9-9428-74eaec81f7b5">13,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="espr:AccruedVariableConsiderationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfMy0zLTEtMS0w_d8644c80-8af5-4d14-aaef-c74bb5c868b5">5,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNC0xLTEtMS0w_e36c1c45-ac49-4c3a-af5c-c7f13f3502be">4,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNC0zLTEtMS0w_1c0bca46-e0e3-436e-be80-90c4ce5514d2">3,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNS0xLTEtMS0w_645421c4-26fd-4808-bd8f-1da46b35bd29">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNS0zLTEtMS0w_2d129a3d-c3e5-463f-a6c0-48a99759183d">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNi0xLTEtMS0w_8d524d15-cb97-441a-b8ed-3abe3fcfd67e">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNi0zLTEtMS0w_6db4624b-a756-4b05-920b-fdeda93c00e4">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNy0xLTEtMS0w_0ed5c6dc-390e-4bb9-a0c8-3e20de2e7f9e">31,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNy0zLTEtMS0w_c269499f-9781-42f6-a4ee-3b9c339012f8">24,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI0OQ_fc7e71ca-6600-4c94-b644-7411ef2177cc" continuedAt="ib79bd0c005c4448ea6d8a455e777e7c9" escape="true">Stock Compensation</ix:nonNumeric></span></div><ix:continuation id="ib79bd0c005c4448ea6d8a455e777e7c9" continuedAt="icdec65ad2b2d4f94b400f6079769c4b9"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the board of directors approved the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") which was approved by the Company's shareholders on May 28, 2020. The ESPP allows eligible employees to authorize payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430" decimals="INF" name="espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMzI1_d3961d3e-52e4-4e18-b6b5-d9fa590a4c5f">10</ix:nonFraction>% of their base salary or wages up to $<ix:nonFraction unitRef="usd" contextRef="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430" decimals="INF" format="ixt:numdotdecimal" name="espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMzY0_8ea8d560-232b-4d16-ae5b-ce333735c417">25,000</ix:nonFraction> annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to <ix:nonFraction unitRef="number" contextRef="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430" decimals="INF" name="espr:EmployeeStockPurchasePlanPercentageDiscountOnShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNTk2_21909607-1eff-4e94-89c6-686541a0884a">15</ix:nonFraction>% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in <ix:nonNumeric contextRef="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430" format="ixt-sec:durwordsen" name="espr:EmployeeStockPurchasePlanDurationOfOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfODQ5_88d80a27-8e7c-4381-b571-0c1f59f83e56">six months</ix:nonNumeric> increments, commencing on September 1 and March 1 of each calendar year with the administrator having the right to establish different offering periods. In the three and six months ended June&#160;30, 2021, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ia4a6340c209848789d2ead328753e5dc_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA3MA_cc919743-5aea-4944-9c71-e0777aa7c219">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2f44623b0aab464f8a2a2de5879f3fc6_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTU0Mg_a4fb5308-4b49-4fe7-ac65-daef6cb507d5">0.4</ix:nonFraction>&#160;million of stock compensation expense related to the ESPP, respectively. As of June&#160;30, 2021, there have been <ix:nonFraction unitRef="shares" contextRef="i2f44623b0aab464f8a2a2de5879f3fc6_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTE2Mg_df066d07-0790-465e-9236-a523df2cb94c">50,818</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i21cebe390d5c4ab1a9dcde2e33388077_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTE4Mw_b7a8684d-2b96-49f6-9474-a0554f5ed128">774,182</ix:nonFraction> shares reserved for future issuance under the ESPP.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI1MA_544157e1-4ea4-4310-8d79-1bb81254360d" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s options to purchase common stock for the six months ended June&#160;30, 2021:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMi0xLTEtMS0w_c78e3b51-0d0b-4a20-81ee-a767c8af46c8">4,176,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMi0zLTEtMS0w_a21501a3-ca16-4f9c-8106-3eac70725a74">40.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbe168eb5b3940b88ace61c5db5c89a7_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMi01LTEtMS0w_890f0d95-fe5e-4a9d-8a6c-6eea76602fa1">5.28</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMi03LTEtMS0w_9fa08423-4211-47dd-81cc-be7ec5be5e74">18,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMy0xLTEtMS0w_80bf56bd-6233-4881-b4cf-8afcaaa635be">757,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMy0zLTEtMS0w_d14c11a8-d782-4b9e-9567-efb34dbece51">28.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited&#160;or&#160;expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNC0xLTEtMS0w_a505cc9b-a275-48f3-8be5-ef8e6a3e8010">876,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNC0zLTEtMS0w_749950f8-d90b-4c14-8b8d-d656bb3c110d">49.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNS0xLTEtMS0w_1fddd63a-7372-431e-b12e-c0b353d727b2">182,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNS0zLTEtMS0w_55f5695d-59e2-4179-8d72-942b9f061df5">15.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNi0xLTEtMS0w_4b3fade5-2412-4e57-b693-08dbed5a52de">3,875,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNi0zLTEtMS0w_38d73704-3d7c-4c40-aacf-d6dc3a95812e">36.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNi01LTEtMS0w_58fd1710-92e2-4ba7-a79a-ce5e00c98edb">5.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNi03LTEtMS0w_44e4d0cd-9967-4a6f-8396-ece0f52e1aa5">10,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI1MQ_878626ff-4dee-4627-9934-5862405fdce9" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the Company&#8217;s stock option plan as of June&#160;30, 2021:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMi0xLTEtMS0w_910fa1a5-fd64-4244-ade2-c721fc18934d">3,875,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMi0zLTEtMS0w_4a311964-64f4-48c7-a089-77f08b7d9e06">36.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMi01LTEtMS0w_102b137e-80db-49a7-8797-70e7f500427a">5.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMi03LTEtMS0w_16543bc9-6848-4896-a7a8-e0759fadab9d">10,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMy0xLTEtMS0w_c57a9984-33cf-433b-b4dc-b8c0395d8031">2,948,732</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMy0zLTEtMS0w_6e1a1543-2e9c-4b8e-b4e1-c468543c6831">36.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMy01LTEtMS0w_6297eda3-478e-4175-adc4-5d18caf9434a">3.94</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMy03LTEtMS0w_46c8ddca-b607-4574-a6ef-306aee739594">10,371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options was $<ix:nonFraction unitRef="usd" contextRef="ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTUyMg_33bcd399-fe5f-4e78-b141-bfafc45525fb">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMDA5MQ_b8d6a126-c904-468c-9f39-2caf79b9da07">9.9</ix:nonFraction> million for the three and six months ended June&#160;30, 2021, respectively, including $<ix:nonFraction unitRef="usd" contextRef="ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMDEwNw_f1cbcebf-a40d-4b0c-8826-07c2077fbc16">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMDExMQ_123e6132-91ab-4249-a316-809705977763">0.5</ix:nonFraction> million that were capitalized into inventory, and $<ix:nonFraction unitRef="usd" contextRef="ic8fc8a8e135542e79741bc96b14f2509_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTM3Mg_35253f0b-b911-4ae7-b85d-6115de571f0d">5.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82de142173eb4c029ba076114a0d9dc2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTM4Ng_6bf58fcf-e1dd-4d9c-a699-8f765e45e731">11.1</ix:nonFraction> million for the three and six months ended June&#160;30, 2020, respectively, including $<ix:nonFraction unitRef="usd" contextRef="ic8fc8a8e135542e79741bc96b14f2509_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTg2NQ_70a701da-b98f-47c1-bbc4-f699b1aa7389">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82de142173eb4c029ba076114a0d9dc2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTg4Mg_9bc2f533-2371-4145-8a6d-82c5c07db5ef">0.5</ix:nonFraction> million that were capitalized into inventory. As of June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i65c8c52a3f8249128e0061ca20f07e6e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTY2MQ_18ff31cf-b691-42a7-988e-fcec53cd48ce">20.3</ix:nonFraction> million of unrecognized stock-based compensation expense related to unvested options, which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTgwMQ_7b535588-c7e6-4c9d-9c24-bdf22eb6a40b">2.7</ix:nonNumeric> years. The increase in stock option expense for the three months ended June 30, 2021, was primarily due to an equity modification related to the CEO Departure Agreement entered into between the Company and the Company's former CEO on May 16, 2021. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="icdec65ad2b2d4f94b400f6079769c4b9" continuedAt="i9f079a857ddd472ab690c242c2f02c07"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (or RSUs)</span></div><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI1Mg_af9fa1bb-a036-4cde-a650-8dcc3fe0cc67" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s RSUs for the six months ended June&#160;30, 2021:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value Per <br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dd83bfde144490abf8e977beb2d1e13_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMS0xLTEtMS0w_ba80107f-98a8-4391-89e6-161aeb8f7005">401,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dd83bfde144490abf8e977beb2d1e13_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMS0zLTEtMS0w_2ab95e75-5e36-4e95-a6a4-2bb7e216dd35">46.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMi0xLTEtMS0w_b36ca0ec-d5af-44e2-88de-e1204da3a043">823,301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMi0zLTEtMS0w_ad216278-cb76-4c37-a4ec-7a7624860407">26.53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMy0xLTEtMS0w_d3f8b629-8ff7-4b1f-a1bd-473fb4731973">115,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMy0zLTEtMS0w_f3c11f56-8a3a-4e70-b298-7afa49022e0a">42.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfNC0xLTEtMS0w_c20a44ff-3d8e-4d7a-b29b-60df9e78351d">124,604</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfNC0zLTEtMS0w_d3e9f5b2-bf6a-411f-b449-d1898e2be9a0">45.15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i864a800b9e2f4367b5189df3691f74ed_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfNS0xLTEtMS0w_9ef8d42d-1496-4ac5-951a-d0fe4aac959e">984,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i864a800b9e2f4367b5189df3691f74ed_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfNS0zLTEtMS0w_541fad61-0e9b-49d6-b0b6-175d114715c1">30.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to RSUs was approximately $<ix:nonFraction unitRef="usd" contextRef="i059e63457ab0488a8b8926c7af529680_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTk4Ng_f08a1d10-6ecb-4e7b-82b9-67df63eb4bb2">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTk5Mw_8b0f95ad-a03b-4718-99fc-3011ba175232">4.0</ix:nonFraction> million for the three and six months ended June&#160;30, 2021, respectively, including $<ix:nonFraction unitRef="usd" contextRef="i059e63457ab0488a8b8926c7af529680_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjAzMg_63efab7f-4164-410f-a85d-8ed1a8df2d6e">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjA0OQ_52f6d008-c1d6-4001-b2a8-efaebc4504eb">0.2</ix:nonFraction> million that were capitalized into inventory, and approximately $<ix:nonFraction unitRef="usd" contextRef="i898eb34514a14aaca65ddd29c2ba018f_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMzI5ODUzNDg4NzU4MQ_2c45b7f4-13a3-411f-b0a0-53110b63849f">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01e390bfc85947a1b2e04d2d1b168ba2_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMzI5ODUzNDg4NzU5Ng_544ad3f0-99d0-42f3-ba1e-2602d91d211c">3.3</ix:nonFraction>&#160;million for the three and six months ended June 30, 2020, respectively, including $<ix:nonFraction unitRef="usd" contextRef="i898eb34514a14aaca65ddd29c2ba018f_D20200401-20200630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTkwMA_caf1df03-2309-47b4-8812-386532cfa041">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01e390bfc85947a1b2e04d2d1b168ba2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTkxNQ_96f6adab-7b7d-40ab-b74b-c4a68a12f5b2">0.1</ix:nonFraction> million that were capitalized into inventory. As of June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i864a800b9e2f4367b5189df3691f74ed_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjExMA_d32d50b9-0102-4970-bac6-0e549453999c">28.2</ix:nonFraction> million of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI0Nw_230ba33b-c2db-445b-a848-c37c1747bd7d">3.2</ix:nonNumeric> years.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based Restricted Stock Units ("PBRSUs")</span></div></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f079a857ddd472ab690c242c2f02c07">The Company's PBRSUs vest after a <ix:nonNumeric contextRef="if90fbea89e414e58b44494d21f429a48_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODkyNg_de1e4a0d-cba6-46a2-8fc0-f1320c162b82">two-year</ix:nonNumeric> performance period contingent upon the achievement of predetermined performance-based milestones based on the Company's U.S. net product sales. The actual number of units (if any) received under this award will depend on continued employment and actual performance over the <ix:nonNumeric contextRef="if90fbea89e414e58b44494d21f429a48_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODkyNw_f9de9e9e-7b78-401e-ade1-66b4f12b3249">two-year</ix:nonNumeric> performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBRSUs based on the expected performance period to achieve the performance milestone. The fair value of the PBRSUs is based on the quoted market price of our common stock on the date of grant. During the three and six months ended June 30, 2021 the Company granted <ix:nonFraction unitRef="shares" contextRef="i5f01c8d8eec0472c8f65bc4d927a3971_D20210401-20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODg1MQ_4244a602-5096-41c6-995b-6be3ebaf253a"><ix:nonFraction unitRef="shares" contextRef="if90fbea89e414e58b44494d21f429a48_D20210101-20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODg1MQ_e2586d52-3f4d-4cc1-8686-11aabba1a518">64,200</ix:nonFraction></ix:nonFraction> PBRSUs with a weighted-average fair value per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="if90fbea89e414e58b44494d21f429a48_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODg0Mw_159958e5-25c7-4b9e-abb1-777c819ec1af"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f01c8d8eec0472c8f65bc4d927a3971_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODg0Mw_20d2be34-ea81-4046-bb75-3d5f763ec418">22.52</ix:nonFraction></ix:nonFraction>. The Company expects the performance criteria to be met.</ix:continuation> </span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_73"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfNDM5_cbde8eda-8913-41f8-a2bc-1043399d1ca9" continuedAt="ia84ebd28dfab48928fbe6b0f21c9f386" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia84ebd28dfab48928fbe6b0f21c9f386">There was <ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfMzI_3f4aa625-8415-406a-8a51-7598e2320c8b"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfMzI_8e8ab965-10ae-46cf-ab8b-6674beb84251"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfMzI_9542a880-963b-4436-a014-9a77bcafc6d3"><ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfMzI_cce1f458-561b-4a89-b2fe-c8769db02423">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for income taxes for the three and six months ended June&#160;30, 2021 and 2020, because the Company has incurred annual operating losses since inception. At June&#160;30, 2021, the Company continues to conclude that it is not more likely than not that the Company will realize the benefit of its deferred tax assets due to its history of losses. Accordingly, a full valuation allowance has been applied against the net deferred tax assets.</ix:continuation></span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_76"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RleHRyZWdpb246MmE4ZWE4YjZiMDMzNGIyNDg5OWE2OWI3YjY5NThiYzJfMTA0Mg_c5a6c2fb-23a7-456b-9ea3-dc1b450ede39" continuedAt="i782c735a36144cf0bad931a0824c2162" escape="true">Net (Loss) Income Per Common Share</ix:nonNumeric></span></div><ix:continuation id="i782c735a36144cf0bad931a0824c2162" continuedAt="i28228895fefa4924a74671aa5a01c47e"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated by dividing net (loss) income by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common stock equivalents outstanding for the period, including shares that potentially could be dilutive if they were exercised or vested during the period, determined using the treasury-stock method. For purposes of this calculation, stock options, unvested RSUs, unvested PBRSUs, shares issuable under the ESPP and shares issuable upon conversion of the convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RleHRyZWdpb246MmE4ZWE4YjZiMDMzNGIyNDg5OWE2OWI3YjY5NThiYzJfNTQ5NzU1ODE0MDAzNQ_66861a14-b05e-48e4-86d6-9c7cfba30fd1" continuedAt="i93ebeca65cc8439a92577f9226ec8490" escape="true">The following table summarizes the calculation of basic and diluted net (loss) income per share:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><ix:continuation id="i28228895fefa4924a74671aa5a01c47e"><div style="margin-bottom:12pt"><ix:continuation id="i93ebeca65cc8439a92577f9226ec8490"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:43.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income (in thousands)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMi0xLTEtMS0yNTE5_22ba8602-8575-4ec9-a439-ce58bf7a60eb">43,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMi0zLTEtMS0yNTE5_f359c64c-3b95-4a88-9d88-f24a64e899ee">124,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMi01LTEtMS0yNTE5_34cf3931-c2d3-4edf-ab12-2b09fb44d7aa">134,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMi03LTEtMS0yNTE5_6ebc1bfb-6a67-43eb-9b04-e4d1d12fced3">46,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNC0xLTEtMS0yNTE5_9c9c03de-f657-4463-aad0-66437065b2d9">26,225,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNC0zLTEtMS0yNTE5_3bb9684b-dc7b-4131-b4e8-783ac7552e89">27,665,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNC01LTEtMS0yNTE5_9ef10db2-791e-437c-948c-25fad707edbe">26,109,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNC03LTEtMS0yNTE5_20691f81-ee48-4b1a-bc66-96a9ea29307c">27,592,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNy0xLTEtMS0yNTE5_38857131-9a9c-48cc-947e-a9d3e865b41a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8fc8a8e135542e79741bc96b14f2509_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNy0zLTEtMS0yNTE5_05397151-5bb9-4e4c-8d8a-f94008268da4">1,139,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNy01LTEtMS0yNTE5_4a5b7926-4475-4bad-8bad-de64a4d31eae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82de142173eb4c029ba076114a0d9dc2_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNy03LTEtMS0yNTE5_dc39e86c-def7-437f-b8e4-56f9a13a058e">1,291,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i059e63457ab0488a8b8926c7af529680_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOC0xLTEtMS0yNTE5_aaf30b78-ad40-4677-925b-4f279cd09d91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i898eb34514a14aaca65ddd29c2ba018f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOC0zLTEtMS0yNTE5_4d84cace-2f77-47a3-bb9a-158b4fcca985">49,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOC01LTEtMS0yNTE5_a9edfd7b-a8c3-4b03-ba87-0277320180fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01e390bfc85947a1b2e04d2d1b168ba2_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOC03LTEtMS0yNTE5_0048fc13-e3b8-4bc1-9889-9b516775277b">64,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOS0xLTEtMS0yNTE5_283d8d28-7f26-4562-add7-380ed4085370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOS0zLTEtMS0yNTE5_b4080040-c366-4ed9-a44c-c5c764fcf144">1,188,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOS01LTEtMS0yNTE5_92a7e080-7cf5-4c81-93bb-3fc1620dbc43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOS03LTEtMS0yNTE5_c910842a-d07e-49d2-9795-24b6f64dc96b">1,355,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTAtMS0xLTEtMjUxOQ_f53974a7-7ec9-4fd8-bbd3-54b0add273cd">26,225,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTAtMy0xLTEtMjUxOQ_99b2d5df-d578-40e8-bb28-8990e47a831c">28,854,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTAtNS0xLTEtMjUxOQ_88b4d8f6-78f3-4042-8364-59571e2a68b4">26,109,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTAtNy0xLTEtMjUxOQ_a615e86b-0623-47c0-a4a1-cb0a339aa2dc">28,948,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTItMS0xLTEtMjUxOQ_73626918-800d-4c54-9ade-28618a15628a">1.67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTItMy0xLTEtMjUxOQ_b3c4d113-7d41-460c-9ea6-d5dc7251e5eb">4.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTItNS0xLTEtMjUxOQ_4e11a946-7b1e-450f-9fc5-cdc8edd03cbe">5.16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTItNy0xLTEtMjUxOQ_6e6dcf91-f3cf-4909-8204-9d3b1deab2a3">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share - diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTMtMS0xLTEtMjUxOQ_a80a1487-146b-49b3-ae32-ab47ec58e4aa">1.67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTMtMy0xLTEtMjUxOQ_bca99bb7-6f24-4db3-8f1f-fe99d384a542">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTMtNS0xLTEtMjUxOQ_9bc49f44-4e5e-4d4f-979a-72c70458401f">5.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTMtNy0xLTEtMjUxOQ_9293fc20-a56d-4ddf-ab54-f3fe073d84eb">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RleHRyZWdpb246MmE4ZWE4YjZiMDMzNGIyNDg5OWE2OWI3YjY5NThiYzJfMTA0Mw_e1165f00-2c08-4c0f-a0b1-ddf298fd226d" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net (loss) income per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7741b1a7bd54135bcc5b59858d55156_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMi0xLTEtMS0w_d6c0727d-a50b-4b87-98e6-488227375d33">3,875,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7123ad4d0294677ba36fc60acabdec6_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMi0zLTEtMS0w_25a2e338-e2d8-4610-b055-cc50bfde9550">2,427,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i057a47e17f174e828a68dcc68defe7b5_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMi01LTEtMS0w_ee513ab6-5d3b-47b8-b28c-13e07e4365d3">3,875,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d8118dee83344708fa7b2847e3b49ae_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMi03LTEtMS0w_23b29909-0988-4657-bd1d-5702605c45c5">2,391,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3300afb8e3844697bef3a62d80174c94_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMy0xLTEtMS0w_badbd252-0a26-445c-a3c6-1801f13323fb">984,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iada643021f094d168ae1bb38139e79f6_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMy0zLTEtMS0w_17332fda-7061-4b22-b4d4-99227d287eac">295,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb9e9630412f44bab00355a379ce951e_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMy01LTEtMS0w_aa788a53-e79e-4c0d-a548-aade7ffdcb3e">984,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68daaa76952c4522a02c46ae9c9b099d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMy03LTEtMS0w_f6b5cd49-65ba-4752-9610-6aeb4094bdce">190,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested PBRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf977f7283ba4421a1c44b0fd2d0dd6b_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC0xLTEtMS00NDIw_dbf8ed2a-c42b-4f3c-bc9f-999712405868">64,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbfaf88013a0436983a4e2f8e2e3b9a9_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC0zLTEtMS00NDIy_2b204976-be51-4fe7-ab08-96d902e5c249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9deb65589fd4b818e61af707066a7bd_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC01LTEtMS00NDI2_c285d923-e7d2-40dc-85f9-5ba2d7f6572b">64,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9113bd66c9034dc5b296e6fd3676426d_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC03LTEtMS00NDI2_488b2972-ca18-41f9-9510-280c6bd72fb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable related to the ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f518e9c8c2e4aa58a673d03a3aca709_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC0xLTEtMS0w_fa8bae10-6c45-4c9a-a76d-5b65339bb63e">33,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie596161ef3d64bc0b3c096d1474e9499_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC0zLTEtMS0w_3e55c0cb-0017-468b-b670-36112ab89aa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6e64bbef76f49d187ba3ba4bb0a64ae_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC01LTEtMS0yNTQ0_681fca50-f323-4b02-98db-2d7fb915bc29">33,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9a360e7e8004cb7a888a243dc4639e3_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC03LTEtMS0yNTQ0_6f42af65-e077-430f-9b57-3417b2340080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ecd3a7b914d4102b067da5c2fed3f4d_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNS0xLTEtMS0w_d2fad463-ecde-439c-9d2c-946458f136d2">8,460,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6517e0e5ba714e75aef0fa5cdffc38ea_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNS0zLTEtMS0w_06702607-5e7d-473e-9500-582df324bc5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i594b303f27a441e79f5d86e7922bf49c_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNS01LTEtMS0yNTQ0_85ea034f-083a-4f3e-9107-4fe1e1be5e0d">8,460,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6179414809fd40c2899b2bcdf7735820_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNS03LTEtMS0yNTQ0_ac3eeae1-1b7e-4878-8d28-6cce3a22c34a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNi0xLTEtMS0w_9ad526a1-2148-47a3-bd75-2d2f98e1048e">13,417,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33200b5320234052894888a136145868_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNi0zLTEtMS0w_2c7f3cf0-2a25-4e1f-aa3e-2c72cfde8225">2,722,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNi01LTEtMS0w_8aef5e19-cdba-4165-b6c7-7451fd31ffbc">13,417,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNi03LTEtMS0w_c57a73ad-3ce9-49b3-a5f4-928bcf58b221">2,581,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed financial statements and related notes appearing elsewhere in this Quarterly Report on Form&#160;10-Q and our annual report on Form&#160;10-K for the fiscal year ended December&#160;31, 2020 and other filings that we make with the Securities and Exchange Commission.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These forward-looking statements are based on our management&#8217;s belief and assumptions and on information currently available to management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events, including our clinical development and commercialization plans, or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, including in relation to the clinical development, commercialization plans, or approval of expanded indications for bempedoic acid and the bempedoic acid / ezetimibe combination tablets to be materially different from any future results, performance or achievements, including in relation to the clinical development, commercialization plans, or approval of expanded indications for bempedoic acid and the bempedoic acid / ezetimibe combination tablets, and the impact of COVID-19 on our business, clinical activities and commercial development plans, expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements are often identified by the use of words such as, but not limited to, &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other similar terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and that could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those referred to or discussed in or incorporated by reference into the section titled &#8220;Risk Factors&#8221; included in Item 1A of Part&#160;II of this Quarterly Report on Form&#160;10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements in this report represent our views as of the date of this quarterly report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We use the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the "Company&#8221; in this report to refer to Esperion Therapeutics, Inc.</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_91"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Overview</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the Lipid Management Company, a pharmaceutical company singularly focused on developing and commercializing affordable, oral, once-daily, non-statin medicines for the treatment of patients struggling with elevated low density lipoprotein cholesterol, or LDL-C. Our team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. Our first two products were approved by the U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, and Swiss Agency for Therapeutic Products, or Swissmedic, in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease, or ASCVD, or heterozygous familial hypercholesterolemia, or HeFH. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2021, we entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd, or DS. Pursuant to the agreement, we granted DS exclusive development and commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar, or the DS Territory. The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. We </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received an upfront cash payment of $30.0 million in May 2021 and are eligible to receive up to an additional $175.0 million in sales milestones. We will also receive tiered royalties ranging from 5 percent to 20 percent on net sales in the DS Territory.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2021, we entered into Amendment No. 2, or the RIPA Amendment, to the Revenue Interest Purchase Agreement, or RIPA, with Eiger III SA LLC, or Oberland, an affiliate of Oberland Capital LLC, as agent for the purchaser parties thereto dated as of June 26, 2019 (as amended by the Amendment No. 1 dated as of November 9, 2020). Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50&#160;million payment payable to us under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA and the related Security Agreement, which are discussed further in Note 8 "Liability Related to the Revenue Interest Purchase Agreement" in our condensed financial statements included in this Form 10-Q for the quarter ended June&#160;30, 2021.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in January 2008 and commenced our operations in April 2008. Since our inception, we have focused substantially all of our efforts and financial resources on developing bempedoic acid and the bempedoic acid / ezetimibe combination tablets. In February 2020, the FDA approved NEXLETOL and NEXLIZET. NEXLETOL was commercially available in the U.S. on March 30, 2020 and NEXLIZET was commercially available in the U.S. on June 4, 2020. We have funded our operations to date primarily through proceeds from sales of preferred stock, convertible promissory notes and warrants, public offerings of common stock, the incurrence of indebtedness, through collaborations with third parties and revenue interest purchase agreements, and we have incurred losses in each year since our inception.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the three and six months ended June&#160;30, 2021, our net losses were $43.7 million and $134.6 million, respectively. In the three and six months ended June&#160;30, 2020, we recorded net income of $124.6 million and $46.4 million, respectively, which was primarily due to revenue </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">generated from our collaboration agreements with Daiichi Sankyo Europe GmbH, or DSE, and Otsuka Pharmaceutical Co., Ltd., or Otsuka. We expect to incur significant expenses and operating losses for the foreseeable future. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In response to our history of operating losses and the uncertainty around the ongoing impact of COVID-19 we have initiated certain cost optimization measures and will implement additional cost reduction measures as needed if additional collaboration or capital funding is not available. Despite such cost savings initiatives we expect to continue to incur significant expenses and operating losses for the foreseeable future in connection with our ongoing activities, including, among others:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">commercializing NEXLETOL and NEXLIZET tablets in the U.S.; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">completing the clinical development activities for the CLEAR global cardiovascular outcomes trial, or CVOT.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we may need additional financing to support our continuing operations and further the development of our products. We may seek to fund our operations and further development activities through collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, permitted public or private equity offerings or through other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy or continue operations. We will need to generate significant revenues to achieve profitability, and we may never do so.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Overview</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEXLETOL is a first-in-class ATP Citrate Lyase, or ACL, inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Completed Phase 3 studies conducted in more than 3,000 patients, with over 2,000 patients treated with NEXLETOL, demonstrated an average 18 percent placebo corrected LDL-C lowering when used in patients on moderate or high-intensity statins. NEXLETOL was approved by the FDA in February 2020 as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Phase 3 data demonstrated NEXLIZET lowered LDL-C by a mean of 38 percent compared to placebo when added on to maximally tolerated statins. NEXLIZET was approved by the FDA in February 2020 as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NILEMDO is a first-in-class ACL inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NILEMDO was approved by the EC in March 2020 for use in adults with primary hypercholesterolemia </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in adult patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies as an adjunct to diet in adult patients who are statin-intolerant, or for whom a statin is contraindicated.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. NUSTENDI was approved by the EC in March 2020 for use in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet in combination with a statin in adult patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe, alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone, or as an adjunct to diet in adult patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, we incurred $32.0 million in expenses related to our CLEAR Outcomes CVOT and other ongoing clinical studies.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2020, we incurred $33.6 million in expenses related to our CLEAR Outcomes CVOT and other ongoing clinical studies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing Clinical Studies</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Cardiovascular Outcomes Trial&#8212;CLEAR Outcomes</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLEAR Outcomes is a Phase 3, event driven, randomized, multicenter, double-blind, placebo-controlled clinical study designed to evaluate whether treatment of bempedoic acid reduces the risk of cardiovascular events in patients with statin intolerance who have cardiovascular disease or are at high risk for cardiovascular disease. The primary endpoint of the study is the effect of bempedoic acid on major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization; also referred to as "four-component MACE"). CLEAR Outcomes is designed to provide 90 percent power to detect an approximately 15 percent relative risk reduction in the primary endpoint in the bempedoic acid treatment group as compared to the placebo group and is expected to complete with a minimum of 1,620 patients experiencing the primary endpoint.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study over-enrolled with over 14,000 patients with hypercholesterolemia and high cardiovascular disease risk at over 1,200 sites in 32 countries. Eligible patients at high risk (LDL-C &gt;100 mg/dL in primary prevention) for cardiovascular disease or with cardiovascular disease (LDL-C between 100 mg/dL to 190 mg/dL in secondary prevention) and who are only able to tolerate less than the lowest approved daily starting dose of a statin and considered statin averse, were randomized to receive bempedoic acid 180 mg once-daily or placebo. The expected average baseline LDL-C level in all patients is between 135 mg/dL and 140 mg/dL.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLEAR Outcomes will conclude once the predetermined number of MACE endpoints occur. We initiated CLEAR Outcomes in December 2016 and completed enrollment in August 2019. The expected average treatment duration will be 3.75 years with a minimum treatment duration of approximately 2.25 years. Based on estimated cardiovascular event rates, we expect to meet the target number of events in the second half of 2022. The study is intended to support our submissions for a CV risk reduction indication in the U.S., Europe and other territories. During the third quarter of 2020, we accumulated 50% of the primary 4-component MACE endpoints</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic, or the future outbreak of any other highly infectious or contagious diseases, may impact our business, including our CVOT and commercialization efforts will depend on continuously changing circumstances, which are highly uncertain and cannot be predicted at this time, such as the duration of such pandemic including future waves of infection, the emergence and prevalence of more contagious variants, or the global availability of effective vaccines, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. The ongoing fluidity of this situation precludes any prediction as to the full impact of the COVID-19 pandemic but it could have a material adverse effect on our business, financial condition, and results of operations. The evolving COVID-19 pandemic may also have the effect of heightening the risks to which we are subject, including potential impacts on the progress and time to completion of our ongoing CVOT, the reliance on third parties in our supply chain for materials and manufacturing and delivery of our drugs and drug candidates, our ability to effectively promote and market our approved products, disruptions in health regulatory agencies' operations globally, the volatility of our common </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock, our ability to access capital markets, and our ability to successfully commercialize and generate revenue from our approved drugs.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to assess the long-term impact of COVID-19 on our business operations in an effort to mitigate interruption to our commercialization of our approved drugs and other business activities and to ensure the safety and well being of our employees, as well as the physicians and patients participating in our CVOT. Because COVID-19 infections have been reported throughout the U.S. and worldwide, and as new strains continue to be identified, certain national, state, and local governmental authorities have issued orders, proclamations, and/or directives aimed at minimizing the spread of COVID-19. Although some of these restrictions were eased or lifted, in response to local surges and new waves of infection, some countries, states, and local governments have reinstituted these restrictions, and additional, more restrictive orders, proclamations, and/or directives may be issued in the future. In response to the COVID-19 pandemic, we have implemented precautionary measures to protect the health and safety of our employees, partners, and patients, including encouraging all employees to work-from-home if able to perform their duties remotely, and requiring adherence to onsite occupancy limits and appropriate safety measures designed to comply with federal, state, and local guidelines.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ability to successfully launch, commercialize, and generate revenue from NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI has been and may continue to be adversely affected by the economic impact of the COVID-19 pandemic. Physicians&#8217; offices and other medical institutions continue to have limited access for non-patients, which includes our sales personnel. In addition, social distancing requirements and precautionary measures due to COVID-19 have impacted the ability of our sales personnel to interact in-person with customers. As a result, in many circumstances we have needed to limit our interactions with physicians and payors and adapt our launch strategies and tactics to a virtual model, including developing and deploying various technology-enabled platforms for virtual engagement such as remote detailing, digital and non-personal marketing channels, and social media. These circumstances have affected and may continue to adversely affect the ability of our sales professionals to effectively market our approved drugs to physicians and the rates of uptakes for our approved drugs, which may have a negative impact on our sales and our market penetration. In addition, patient visits with physicians have decreased as a result of COVID-19, due to travel restrictions, social distancing requirements, prioritization of healthcare resources to address the pandemic, and/or fear of exposure to the virus, which we believe has adversely affected and could continue to have a material adverse impact on new patient starts and overall patient treatment volume. Market disruption and unemployment caused by the COVID-19 pandemic may lead to delays in obtaining insurance coverage and reimbursement of newly approved products.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have had to optimize our cost structure in response to the evolving COVID-19 pandemic and its impact on the conventional healthcare model associated with normal health management practices, such as regular physician office visits, lab tests, and prescription fills. As a result of the impact COVID-19 has had on our business and demand, we adjusted our budgeted production plans accordingly. We also adjusted our original commercialization marketing budget and prioritized initiatives we believe have a high return on investment. We have made adjustments to our workforce for near-term growth potential and modified our sales geographies to adapt for COVID-19 hotspots and shelter-on-place orders. While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will have on our business or operations, the continued spread or future waves of COVID-19, measures taken by governments, actions taken to protect employees, and the broad impact of the pandemic on all business activities may materially and adversely affect our preclinical activities, clinical development progress, data and timelines, commercialization efforts including any revenue from sales, supply chain continuity, and general business operations, and our business, prospects, financial condition, and results of operations could be materially harmed as a result.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not experienced any interruption of our supply of drug products needed to support our ongoing clinical study and product sales. However, such interruptions may occur due to supply chain issues related to COVID-19, such as the demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, which may make it more difficult to obtain materials or manufacturing capacity at our third-party manufacturers to the products needed for our clinical trials and commercial product, which could lead to delays in our ongoing trial and/or issues with our commercial supply. We remain focused on maintaining a strong balance sheet, liquidity and financial flexibility and continue to monitor developments as we deal with the disruptions and uncertainties from a business and financial perspective relating to COVID-19. We will continue to work diligently with our partners and stakeholders to continue supporting patient access to our approved medicines, advancing our product under regulatory review as well as in our clinical studies to the extent safe to do so for patients, caregivers and healthcare practitioners, and ensuring the continuity of our manufacturing and supply chain. For additional information related to the potential impact of COVID-19 on our business, please read Part I-Item 1A, &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales, net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net is related to our sales of NEXLETOL and NEXLIZET. NEXLETOL was commercially available in the U.S. on March 30, 2020 and NEXLIZET was commercially available in the U.S. on June 4, 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is related to our collaboration agreements with DSE, Otsuka and DS. Collaboration revenue in the three and six months ended June&#160;30, 2021 was primarily related to the initial recognition of the upfront payment from our license and collaboration agreement with DS, sales of bulk tablets under supply agreements, and royalty revenue received from collaboration partners. Collaboration revenue in the three and six months ended June 30, 2020, was primarily related to the $150.0 million milestone from the MAA transfer to DSE and the $60.0 million from the upfront payment with Otsuka. Under contracted supply agreements with ex-U.S. collaborators, we may manufacture and supply quantities of active pharmaceutical ingredient, or API, or bulk tablets reasonably required by ex-U.S. collaboration partners for the development or sale of licensed products in their respective territory. We recognize revenue when the collaboration partner has obtained control of the API or bulk tablets. We also receive royalties from the commercialization of such products, and record our share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborators. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of goods sold</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our net product sales of NEXLETOL and NEXLIZET and the cost of goods sold from our supply agreements with collaboration partners. Prior to the FDA approval of NEXLETOL and NEXLIZET in February 2020, expenses associated with the manufacturing of our products were recorded as research and development expense.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist primarily of costs incurred in connection with the development of bempedoic acid and the bempedoic acid / ezetimibe combination tablets, which include:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred under agreements with consultants, contract research organizations, or CROs, and investigative sites that conduct our preclinical and clinical studies;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of acquiring, developing and manufacturing clinical study materials and commercial product manufacturing supply prior to product approval, including the procurement of ezetimibe in our continued development of our bempedoic acid / ezetimibe combination tablet;</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">employee-related expenses, including salaries, benefits, stock-based compensation and travel expenses;</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">allocated expenses for rent and maintenance of facilities, insurance and other supplies; and</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs related to compliance with regulatory requirements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. To date, substantially all of our research and development work has been related to bempedoic acid and the bempedoic acid / ezetimibe combination tablets. Costs for certain development activities, such as clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. Our direct research and development expenses consist principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical studies. We do not allocate acquiring and manufacturing clinical study materials, salaries, stock-based compensation, employee benefits or other indirect costs related to our research and development function to specific programs.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to incur research and development expenses in the foreseeable future as they relate to our ongoing CLEAR Outcomes CVOT and any other development programs or additional indications we choose to pursue. We cannot determine with certainty the duration and completion costs associated with the ongoing or future clinical studies of bempedoic acid and the bempedoic acid / ezetimibe combination tablets. The duration, costs and timing associated with the development of bempedoic acid and the bempedoic acid / ezetimibe combination tablets will depend on a variety of factors, including </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertainties associated with the results of our clinical studies and our ability to obtain regulatory approval outside the U.S. and Europe. For example, if a regulatory authority were to require us to conduct clinical studies beyond those that we currently anticipate will be required for the completion of clinical development or post-commercialization clinical studies of bempedoic acid or the bempedoic acid / ezetimibe combination tablets, we could be required to expend significant additional financial resources and time on the completion of clinical development or post-commercialization clinical studies of bempedoic acid and the bempedoic acid / ezetimibe combination tablets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses primarily consist of salaries and related costs for personnel, including stock-based compensation, associated with our sales, executive, accounting and finance, commercial, operational and other administrative functions. Other general and administrative expenses include selling expenses, facility-related costs, communication expenses and professional fees for legal, patent prosecution, protection and review, consulting and accounting services.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our selling, general and administrative expenses will increase in the future in connection with the commercialization of NEXLETOL and NEXLIZET, increases in our headcount, expansion of our information technology infrastructure, and increased expenses associated with being a public company and complying with exchange listing and Securities and Exchange Commission, or SEC, requirements. These increases will likely include higher legal, compliance, accounting and investor and public relations expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is related to our Revenue Interest Purchase Agreement, or RIPA, with Eiger III SA LLC, or Oberland, an affiliate of Oberland Capital and Convertible Notes for the three and six months ended June&#160;30, 2021. Interest expense during the three and six months ended June&#160;30, 2020 related solely to the RIPA.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, primarily relates to interest income and the accretion or amortization of premiums and discounts earned on our cash, cash equivalents and investment securities.</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_97"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events, contractual milestones and other various factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2021 and 2020</span></div><div style="text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited,&#160;in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,610&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,074&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,913)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,533)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,170&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,703)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,144)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,640)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,504)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,668)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,279)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales, net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net for the three months ended June&#160;30, 2021 was $10.6 million compared to $0.6 million for the three months ended June&#160;30, 2020, an increase of $10.0 million. The increase is primarily due to sequential prescription growth of NEXLETOL and NEXLIZET during the entire second quarter of 2021. NEXLETOL and NEXLIZET became commercially available in the U.S. on March 30, 2020 and June 4, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue recognized for the three months ended June&#160;30, 2021 was $30.0 million compared to $211.6&#160;million for the three months ended June&#160;30, 2020, a decrease of $181.6&#160;million. Collaboration revenue for the three months ended June&#160;30, 2021 was primarily related to the initial recognition of the upfront payment from our license and collaboration agreement with DS, product sales to collaboration partners under our supply agreements and royalty revenue from our collaboration agreement with DSE. Collaboration revenue for the three months ended June&#160;30, 2020 was primarily related to the $60.0 million upfront payment from the collaboration with Otsuka and $150.0 million of collaboration revenue from DSE related to the MAA transfer milestone.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of goods sold</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold for the three months ended June&#160;30, 2021 was $1.8 million compared to $0.4&#160;million for the three months ended June&#160;30, 2020, an increase of $1.4 million. The increase is primarily related to increased product sales to our collaboration partners from our supply agreements and increased net product sales of NEXLETOL and NEXLIZET. NEXLETOL and NEXLIZET became commercially available in the U.S. on March 30, 2020 and June 4, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three months ended June&#160;30, 2021, were $25.1 million, compared to $35.0 million for the three months ended June&#160;30, 2020, a decrease of $9.9 million. The decrease in research and development expenses was primarily attributable to an overall reduction in ongoing clinical research activities, including compensation costs. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the three months ended June&#160;30, 2021, were $46.3 million, compared to $47.7 million for the three months ended June&#160;30, 2020, a decrease of $1.4 million. The decrease in selling, general and administrative expenses was primarily attributable to a decrease in advertising and costs to support the initial launch of NEXLETOL and NEXLIZET in the U.S. in 2020. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended June&#160;30, 2021, was $11.1&#160;million, compared to $4.6 million for the three months ended June&#160;30, 2020, an increase of $6.5 million. The increase in interest expense was primarily due to additional interest expense attributable to the second and third installment payments from our RIPA with Oberland and the Convertible Notes entered in November 2020.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income, net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net for the three months ended June&#160;30, 2021, was less than $0.1&#160;million, compared to $0.1&#160;million for the three months ended June&#160;30, 2020, a decrease of $0.1&#160;million. The decrease is related to lower interest income on our investments due to lower interest rates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June 30, 2021 and 2020</span></div><div style="text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:58.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited,&#160;in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,357)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,724&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,081)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,269)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,811)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,458)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,965)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales, net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net for the six months ended June&#160;30, 2021 was $17.0 million compared to $1.5 million for the six months ended June&#160;30, 2020, an increase of $15.5 million. The increase is primarily due to sequential prescription growth of NEXLETOL and NEXLIZET during the entire six months ended June 30, 2021. NEXLETOL and NEXLIZET became commercially available in the U.S. on March 30, 2020 and June 4, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue recognized for the six months ended June&#160;30, 2021 was $31.7 million compared to $212.6 million for the six months ended June&#160;30, 2020, a decrease of $180.9 million. Collaboration revenue for the six months ended June&#160;30, 2021 was primarily related to the initial recognition of the upfront payment from our license and collaboration agreement with DS, product sales to collaboration partners under our supply agreements and royalty revenue from our collaboration agreement with DSE. Collaboration revenue for the six months ended June&#160;30, 2020 was primarily related to the $60.0 million upfront payment from the collaboration with Otsuka and $150.0 million of collaboration revenue from DSE related to the MAA transfer milestone.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of goods sold</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold for the six months ended June&#160;30, 2021 was $3.6&#160;million compared to $0.4 million for the six months ended June&#160;30, 2020, an increase of $3.2&#160;million. The increase is primarily related to increased product sales to our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration partners from our supply agreements and increased net product sales of NEXLETOL and NEXLIZET. NEXLETOL and NEXLIZET became commercially available in the U.S. on March 30, 2020 and June 4, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the six months ended June&#160;30, 2021, were $53.0 million, compared to $69.7 million for the six months ended June&#160;30, 2020, a decrease of $16.7 million. The decrease in research and development expenses was primarily attributable to a decline in manufacturing costs which were classified as research and development expense prior to FDA approval of NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively, as well as an overall reduction in ongoing clinical research activities, including compensation costs. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the six months ended June&#160;30, 2021, were $107.4 million, compared to $89.2 million for the six months ended June&#160;30, 2020, an increase of approximately $18.2 million. The increase in selling, general and administrative expenses was primarily attributable to a $13.3 million one-time charge associated with a legal settlement as well as increases in salaries and benefits, including stock-based compensation, from the build out of our customer-facing team and other costs to support the commercialization of NEXLETOL and NEXLIZET in the U.S.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the six months ended June&#160;30, 2021, was $19.3 million, compared to $8.8 million for the six months ended June&#160;30, 2020, an increase of approximately $10.5 million. The increase in interest expense was primarily due to additional interest expense attributable to the second and third installment payments from our RIPA with Oberland and the Convertible Notes entered in November 2020.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income, net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net for the six months ended June&#160;30, 2021, was less than $0.1 million, compared to $0.4 million for the six months ended June&#160;30, 2020, a decrease of $0.4 million. The decrease is related to lower interest income on our investments due to lower interest rates.</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_103"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded our operations to date primarily through proceeds from sales of preferred stock, convertible promissory notes and warrants, public offerings of common stock, the incurrence of indebtedness, milestone payments from collaboration agreements and revenue interest purchase agreement. Pursuant to the license and collaboration agreements with DSE and Otsuka, we are eligible for substantial additional sales and regulatory milestone payments and royalties. Pursuant to the license and collaboration agreements with DS, we received an upfront cash payment of $30.0 million in May 2021 and are eligible for substantial additional sales milestone payments and royalties. Pursuant to the amended RIPA with Oberland, we received an additional $50.0 million in May 2021 following the completion of the DS Agreement. The amended RIPA increases the revenue interest we will pay Oberland based on the net sales of our products as outlined in Note 8 "Liability Related to the Revenue Interest Purchase Agreement" in our condensed financial statements included in this Form 10-Q for the quarter ended June&#160;30, 2021. We anticipate that we will incur losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our primary sources of liquidity were our cash and cash equivalents which totaled $219.2 million. We invest our cash equivalents and investments in highly liquid, interest-bearing investment-grade and government securities to preserve principal.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the primary sources and uses of cash for the periods presented below:</span></div><div style="margin-bottom:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:67.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,699&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,776)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,431&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and expect to continue to incur, significant costs related to the commercialization of NEXLETOL and NEXLIZET and related to ongoing research and development, regulatory and other clinical study costs associated with the development of bempedoic acid and the bempedoic acid / ezetimibe combination tablets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities totaled $136.9 million for the six months ended June&#160;30, 2021, consisting of net product sales of NEXLETOL and NEXLIZET and $30.0 million in upfront fees from DS fully offset by cash used to fund the commercialization activities of NEXLETOL and NEXLIZET and the research and development costs related to bempedoic acid and the bempedoic acid / ezetimibe combination tablets, adjusted for non-cash expenses such as stock-based compensation expense, interest expense related to our RIPA with Oberland, depreciation and amortization and changes in working capital.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities totaled $70.0 million for the six months ended June 30, 2020, consisting of the $150.0 million milestone for the MAA transfer from our collaboration agreement with DSE, $60.0 million from the Otsuka collaboration agreement and net product sales of NEXLETOL and NEXLIZET offset by cash used to fund the commercialization activities of NEXLETOL and NEXLIZET and the research and development costs related to bempedoic acid and the bempedoic acid / ezetimibe combination tablets, adjusted for non-cash expenses such as stock-based compensation expense, interest expense related to our RIPA with Oberland, depreciation and amortization and changes in working capital.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have cash provided by or used in investing activities for the six months ended June&#160;30, 2021. Net cash provided by investing activities of $31.7 million for the six months ended June&#160;30, 2020, consisted primarily of proceeds from the sale and maturities of highly liquid, interest-bearing investment-grade and government securities. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $51.2 million for the six months ended June&#160;30, 2021 related primarily to $50 million in cash from our RIPA with Oberland and proceeds from exercise of our common stock, offset by payments on our revenue interest liability. Net cash provided by financing activities of $29.7 million for the six months ended June&#160;30, 2020 related primarily to the $25.0 million in cash received from the RIPA with Oberland upon regulatory approval of NEXLETOL.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan of Operations and Funding Requirements</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to incur significant expenses and operating losses for the foreseeable future in connection with our ongoing CLEAR Outcomes CVOT and commercial launch activities associated with NEXLETOL and NEXLIZET in the U.S. Pursuant to the license and collaboration agreement with DSE and Otsuka, we are eligible for substantial additional sales and regulatory milestone payments and royalties. Pursuant to the license and collaboration agreements with DS, we received an upfront cash payment of $30.0 million in May 2021 and are eligible for substantial additional sales milestone payments and royalties. Pursuant to the amended RIPA with Oberland, we received $50.0 million in May 2021. In return, Oberland will have a right to receive revenue interest payments from us based on net product sales of certain of our products. In addition, if the quarterly net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States starting with the quarter ending September 30, 2021 does not exceed $15.0 million, we are required to deposit $50.0 million in a deposit account with Oberland. Oberland shall have sole dominion and control over all funds deposited in the deposit account and such funds may be withdrawn only with the consent of Oberland. We will implement certain additional cost reduction initiatives or attempt to secure additional cash resources as needed to continue to fund the commercialization and further development of bempedoic acid and the bempedoic acid / ezetimibe combination tablets. Because of the numerous risks and uncertainties associated with the development and ongoing commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablets and the extent to which we entered and may enter into collaborations with pharmaceutical partners regarding the development and commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablets, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development and commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablets. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to successfully develop and commercialize NEXLETOL and NEXLIZET or other product candidates;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs, timing and outcomes of our CLEAR Outcomes CVOT and other ongoing clinical studies of bempedoic acid and the bempedoic acid / ezetimibe combination tablets;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the time and cost necessary to obtain regulatory approvals for bempedoic acid and the bempedoic acid / ezetimibe combination tablets outside the U.S. and Europe;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to establish any future collaboration or commercialization arrangements on favorable terms, if at all;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to realize the intended benefits of our existing and future collaboration and partnerships;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the implementation of operational and financial information technology; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:32.5pt">our ability to successfully implement certain cost reduction initiates, as needed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Until such time, if ever, as we can generate U.S. substantial product revenues, we expect to finance our cash needs through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings and equity offerings or other sources. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available and permitted under the terms of our RIPA, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners or royalty-based financing arrangements, such as the collaboration arrangements with DSE, Otsuka and DS and the RIPA with Oberland, we may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us. For instance, as part of the RIPA with Oberland, Oberland has the right to receive certain revenue interests from us based on the net sales of certain products, and we have granted Oberland a senior security interest in certain of our assets. If our cash flows and capital resources are insufficient to allow us to make required payments, we may have to reduce or delay capital expenditures, sell assets or seek additional capital. If we raise funds by selling additional equity, such sale would result in dilution to our stockholders. If we are unable to raise additional funds through equity or permitted debt financings or through collaborations, strategic alliances or licensing arrangements or permitted royalty-based financing arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market bempedoic acid and the bempedoic acid / ezetimibe combination tablets that we would otherwise prefer to develop and market ourselves.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_106"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to our contractual obligations and commitments outside the ordinary course of business from those previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 and in Note 5 &#8220;Commitments and Contingencies,&#8221; and Note 8 "Liability Related to the Revenue Interest Purchase Agreement" in our condensed financial statements included in this Form 10-Q for the quarter ended June&#160;30, 2021.</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_109"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor did we have during the periods presented, any off-balance sheet arrangements as defined by Securities and Exchange Commission rules.</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_112"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes with respect to the information appearing in Part II, Item 7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_115"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934 is (1)&#160;recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and (2)&#160;accumulated and communicated to our management, including our President and Chief Executive Officer, who is our principal executive officer, and our Chief Financial Officer, who is our principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of June&#160;30, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_121"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required with respect to this item can be found under &#8220;Commitments and Contingencies&#8221; in Note 5 to our condensed financial statements included elsewhere in this Form 10-Q and is incorporated by reference into this Item 1.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may become party to legal matters and claims arising in the ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations or cash flows.</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_124"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our potential risks and uncertainties, see the information under the heading &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, or Annual Report. There have been no significant changes from the risk factors previously disclosed in our Annual Report, except as set forth below.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our payment obligations under the Revenue Interest Purchase Agreement with Oberland may adversely affect our financial position or results of operations and our ability to raise additional capital which in turn may increase our vulnerability to adverse regulatory developments or economic or business downturns.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2019, we entered into the RIPA with Oberland and the Purchasers named therein. Pursuant to the RIPA, Oberland paid us $125.0 million on closing, less certain transaction expenses, and, Oberland paid us an additional $25.0 million in March 2020 upon receiving regulatory approval of NEXLETOL. Pursuant to the RIPA Amendment, we received the final $50.0 million. As consideration for the payments, Oberland has the right to receive certain revenue interests from us based on the net sales of certain products, once approved, which will be tiered payments initially ranging from 3.33% to 10% of our net sales in the covered territory. See in Note 8 "Liability Related to the Revenue Interest Purchase Agreement" in our condensed financial statements included in this Form 10-Q for the quarter ended June 30, 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RIPA and the revenue interest stream payable to Oberland could have important negative consequences to the holders of our securities. For example, a portion of our cash flow from operations will be needed to pay certain revenue interests to Oberland and will not be available to fund future operations. Further, if we fail to achieve the Specified Net Revenue thresholds, we will be obligated to deposit $50 million into the Blocked Account, which would reduce our unrestricted cash and could have a material adverse effect. Additionally, we may have increased vulnerability to adverse general economic and industry conditions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment requirements under the RIPA will increase our cash outflows. Our future operating performance is subject to market conditions and business factors that are beyond our control. If our cash inflows and capital resources are insufficient to allow us to make required payments, we may have to reduce or delay capital expenditures, sell assets or seek additional capital. If we raise funds by selling additional equity, such sale would result in dilution to our stockholders. There is no assurance that if we are required to secure funding we can do so on terms acceptable to us, or at all. Failure to pay certain amounts to Oberland when due would result in a default under the RIPA and result in foreclosure on certain of our assets which would have a material adverse effect.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RIPA contains customary affirmative and negative non-financial covenants and events of default, including, covenants and restrictions that among other things, grant a senior security interest in our assets and restrict our ability to incur liens, incur additional indebtedness, make loans and investments, engage in mergers and acquisitions, and engage in asset sales. Additionally, the Purchasers under the RIPA have an option (the &#8220;Put Option&#8221;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect (which can include adverse developments related to the regulatory approval of our product candidates) or a change of control. The triggering of the Put Option, including by our failure to comply with these covenants, could permit the Purchasers to declare certain amounts to be immediately due and payable. If we default under the terms of the RIPA, including by failure to make such accelerated payments, the Purchasers take control of our pledged assets. Further, if we are liquidated, the Purchasers&#8217; right to repayment would be senior to the rights of the holders of our common stock. Any triggering of the Put Option or other declaration by the Purchasers of an event of default under the RIPA could significantly harm our financial condition, business and prospects and could cause the price of our common stock to decline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_130"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Amended and Restated Bylaws</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2021, the board of directors approved an amendment and restatement of our amended and restated bylaws to designate the federal district courts of the United States of America as the exclusive forum for any action asserting a claim arising under the Securities Act of 1933, as amended, unless we consent in writing to the selection of an alternative forum.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description is not complete and is qualified in its entirety by reference to the full text of the bylaws, which is included as a part of Exhibit 3.1 filed with the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 and incorporated herein by reference.</span></div><div id="i155233a9c30143f788c2cb30bf7b7a77_133"></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed or furnished as part of this Quarterly Report on Form&#160;10-Q are set forth on the Exhibit&#160;Index, which Exhibit&#160;Index is incorporated herein by reference.</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:8.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by&#160;Reference&#160;to:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form&#160;or<br/>Schedule</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date&#160;with<br/>SEC</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File<br/>Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1434868/000162828021008918/ex31-secondamendedandresta.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1434868/000162828021008918/ex31-secondamendedandresta.htm">Second Amended and Restated Bylaws of Esperion Therapeutics, Inc. dated April 29, 2021 </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-licenseandcollaborat.htm">10.1*#</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-licenseandcollaborat.htm">License and Collaboration </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-licenseandcollaborat.htm">Agreement,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-licenseandcollaborat.htm"> by and between the Registrant and Daiichi Sankyo </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-licenseandcollaborat.htm">Company, Limited</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-licenseandcollaborat.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-licenseandcollaborat.htm">April 26,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-licenseandcollaborat.htm"> 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102-amendedkoenigemploym.htm">10.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102-amendedkoenigemploym.htm">Amended and Restated Employment Agreement by and between the Registrant and Sheldon Koenig dated May 14, 2021 </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1434868/000162828021007598/ex101ripaamendment.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1434868/000162828021007598/ex101ripaamendment.htm">Amendment No. 2 to the Revenue Interest Purchase Agreement, by and among the Registrant and the parties thereto dated April 26, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 26, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-35986</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1434868/000110465921067504/tm2116625d1_ex10-1.htm">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1434868/000110465921067504/tm2116625d1_ex10-1.htm">CEO Departure Agreement by and between the Registrant and Tim M. Mayleben dated May 15, 2021 </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 17, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-35986</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1434868/000162828021013041/ex101cmoemploymentcontract.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1434868/000162828021013041/ex101cmoemploymentcontract.htm">Employment Agreement by and between the Registrant and JoAnne Foody dated June 28, 2021 </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 28, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-35986</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex311x06302021.htm">31.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex311x06302021.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex312x06302021.htm">31.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex312x06302021.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex321x06302021.htm">32.1</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex321x06302021.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex321x06302021.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed herewith.</span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;The certification furnished in Exhibit&#160;32.1 hereto is deemed to be furnished with this Quarterly Report on Form&#160;10-Q and will not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i155233a9c30143f788c2cb30bf7b7a77_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i155233a9c30143f788c2cb30bf7b7a77_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPERION THERAPEUTICS,&#160;INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sheldon L. Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sheldon L. Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard B. Bartram</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard B. Bartram</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101-licenseandcollaborat.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i774f3bfd4beb417ab46a4620f82e2a1b_47"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">by and between</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Daiichi Sankyo Company, Limited</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESPERION THERAPEUTICS, INC.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">April 26, 2021</font></div><div id="i774f3bfd4beb417ab46a4620f82e2a1b_52"></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEFINITIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEVELOPMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGULATORY MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMMERCIALIZATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MANUFACTURE AND SUPPLY</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COLLABORATION MANAGEMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONFIDENTIALITY AND PUBLICATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LICENSES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FINANCIAL TERMS&#59; ROYALTY REPORTS&#59; PAYMENTS AND AUDITS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INDEMNIFICATION&#59; LIMITATION OF LIABILITY&#59; INSURANCE</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TERM AND TERMINATION&#59; REMEDIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MISCELLANEOUS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</font></td></tr></table></div><div id="i774f3bfd4beb417ab46a4620f82e2a1b_65"></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULES</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule  1.52            Third Party Agreements</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 1.53             Esperion Trademarks</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 1.81             Licensed Products</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 2.1.2            Agreed Development Plan</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 3.9               Safety Data Exchange Agreement</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 5.4               Quality Agreement</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 7.3               Press Release</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 10.2             Disclosure Schedule</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 10.2.4          Existing Esperion Patent Rights</font></div><div id="i774f3bfd4beb417ab46a4620f82e2a1b_33"></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This LICENSE AND COLLABORATION AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), entered into as of April 26, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), is entered into by and between Daiichi Sankyo Company, Limited, a company organized and existing under the laws of Japan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Esperion Therapeutics, Inc., a corporation organized and existing under the laws of the state of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Esperion owns or otherwise controls certain technology and information relating to Bempedoic Acid and the Licensed Products&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DS is a pharmaceutical company that conducts research, development, manufacturing and commercialization of pharmaceutical products&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Esperion desires to grant to DS exclusive rights to Develop, Manufacture and Commercialize Licensed Products in the Field in the DS Territory, and DS desires to undertake such Development, Manufacturing and Commercialization activities, each in accordance with the terms and conditions set forth herein.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">DEFINITIONS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquired Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Acquired Programs).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Future Acquisition of a Party or its Business).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Jurisdiction).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Person, any other Person which controls, is controlled by, or is under common control with the applicable Person. For purposes of this definition, &#8220;control&#8221; shall mean&#58; (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors, or otherwise having the power to control or direct the affairs of such Person&#59; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest or the power to direct the management and policies of such non-corporate entities.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreed Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development in South Korea and Taiwan).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Alliance Managers&#59; Appointment).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">API</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(s)&#8221; means the active pharmaceutical ingredient Bempedoic Acid.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Bankruptcy and Section 365(n)).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Bankruptcy and Section 365(n)). </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bempedoic Acid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk Tablets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Licensed Product in bulk tablet form packaged in drums.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31 of each calendar year, provided that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b) the first Calendar Quarter of a Royalty Term for a Licensed Product in a country shall begin on the First Commercial Sale of a Licensed Product in such country and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of a Royalty Term shall end on the last day of such Royalty Term.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means each successive period of twelve (12) months commencing on January 1 and ending on December 31, provided that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Term and (b) the first Calendar Year of a Royalty Term for a Licensed Product in a country shall begin on the First Commercial Sale of a Licensed Product in such country and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of such Royalty Term.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any of the following events&#58;  (a) any Person becomes the &#8220;beneficial owner&#8221; (as such term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder (or, in each case, any successor thereto), it being understood that a Person shall not be deemed to have &#8220;beneficial ownership&#8221; of (x) any securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or any of its Affiliates until such tendered securities are accepted for purchase or exchange thereunder, or (y) any securities if beneficial ownership in respect thereof (i) arises solely as a result of a revocable proxy delivered in response to a proxy or consent solicitation made pursuant to the applicable rules and regulations under the Exchange Act, and (ii) is not also then reportable on Schedule 13D or Schedule 13G (or any successor schedule) under the Exchange Act, directly or indirectly, of a majority of the total voting power represented by all classes of capital stock then outstanding of Esperion normally entitled to vote in elections of directors&#59; (b) (i) Esperion reorganizes, consolidates or comes under common control with, or merges into another corporation or entity, or (ii) any corporation or entity reorganizes, consolidates or comes under common control with, or merges into Esperion, in either event of the foregoing clauses (i) or (ii), where stockholders of Esperion immediately prior to the consummation of such transaction hold less than fifty percent (50%) of the securities outstanding of the surviving entity normally entitled to vote in elections of directors immediately following consummation of such transaction&#59; or (c) Esperion conveys, transfers or leases all or substantially all of its assets to any Person other than a directly or indirectly wholly owned Affiliate of Esperion.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.5pt">&#8220;cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">current Good Manufacturing Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the then-current standards for good manufacturing practices for biological or therapeutic products, as appropriate, as set forth in the FD&#38;C Act, or applicable regulations promulgated thereunder, as amended from time to time, and such standards of good manufacturing practice as are required by other Governmental Authorities in countries in which Licensed Products are intended to be manufactured or sold.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a human clinical study conducted on human subjects, including any Phase 1 Clinical Study, Phase 2 Clinical Study or Phase 3 Clinical Study that involves a test product, drug or device and that either is subject to requirements for prior submission to a Regulatory Authority or is not subject to requirements for prior submission to a Regulatory Authority but </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the results of which are intended to be submitted later to, or held for inspection by, a Regulatory Authority as part of an application for a research permit or Regulatory Approval, and includes studies relating to the safety, tolerability, pharmacological activity, pharmacokinetics, dose ranging or efficacy of the product, drug or device.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CMO Step-In Rights).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Co-Chairpersons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (JCC Co-Chairpersons).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any and all activities directed to marketing, promoting, distributing, importing, exporting, using, offering to sell, selling or having sold a product, but excluding for the avoidance of doubt, Developing and Manufacturing and including, for avoidance of doubt, the establishment and maintenance of patient registries or similar patient advocacy activities and programs.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party&#8217;s obligations that relate to the achievement of an objective related to a Licensed Product, at any given time as the case may be, efforts reasonably used by a similarly situated entity in the pharmaceutical industry of similar resources and expertise as such Party, for such similar entity&#8217;s own products (including internally developed, acquired and in-licensed products) of a similar modality with similar commercial potential at a similar stage in their lifecycle (assuming continuing development of such product), taking into consideration all Relevant Factors.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competing Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Notice of Infringement).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.14.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Acquired Programs).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any and all confidential or proprietary information and data, including Esperion Technology and Joint Technology, and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party in connection with this Agreement. Esperion Technology is the Confidential Information of Esperion. Joint Technology and the terms of this Agreement are the Confidential Information of both Parties.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Controlled by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any intellectual property right (including any Patent Right or Know-How), the possession of (whether by ownership or license, other than pursuant to this Agreement) the ability of a Person or its Affiliates to assign, transfer, or grant access to, or to grant a license or sublicense of, such right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Person would be required hereunder to assign, transfer or grant another Person such access or license or sublicense. Notwithstanding the foregoing, with respect to any Patent Right, Know-How or other intellectual property right acquired or in-licensed for which a Party would be required to make payments to any Third Party in connection with the license or access granted to the other Party under this Agreement, such intellectual property will be treated as &#8220;Controlled&#8221; by the licensing Party to the extent that, and only to the extent that and for so long as, the other Party agrees and does promptly pay to the licensing Party all such applicable payments to such Third Party arising out of the grant and exercise of the license to the other Party hereunder.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cover&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Covers&#8221; or &#8220;Covered&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means, with respect to a particular subject matter at issue and the relevant Patent Right, that, but for a license granted to a Party or a Third Party under a claim included in such Patent Right, the manufacture, use, sale, offer for sale, or importation by such Party of the subject matter at issue would infringe such claim or, in the case of a Patent Right that is a patent application, would infringe a claim in such patent application if it were to issue as a patent in a particular country or countries.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Clinical Study report.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means under this Agreement, with respect to Licensed Products, the development activities conducted before or after obtaining Regulatory Approval that are reasonably related to or leading to the development, preparation and submission of data and information to a Regulatory Authority for the purpose of obtaining, supporting or expanding a Regulatory Approval, including but not limited to all activities related to pharmacokinetic profiling, design and conduct of pre-clinical development, non-clinical development, pre-clinical studies, in vitro studies, Clinical Studies, other studies and scientific activities ordinarily conducted in the pharmaceutical industry in the DS Territory as a prerequisite to or in connection with a Clinical Study, regulatory affairs, statistical analysis, report writing and regulatory filing creation and submission, including Post-Approval Studies, but excluding, for the avoidance of doubt, Commercialization and Manufacturing.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development Plans).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DMF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Responsibility for Regulatory Matters).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any unbranded domain name(s) (but not including domain name(s) containing INNs) mutually agreed to by the Parties in writing to be used or to be protected in connection with the Commercialization of the License Products in the DS Territory.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DSE Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Andorra, Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy (incl. Vatican City), Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Slovenia, Slovakia, Spain, Sweden, Switzerland, Turkey and United Kingdom. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (General Indemnification by Esperion).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Know-How Controlled by DS or any of its Affiliates during the Term that arises out of the performance of obligations or exercise of rights hereunder, and that is necessary or useful to the Development, Manufacture or Commercialization of the Licensed Products in the Field, but excluding Joint Know-How.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Patent Rights Controlled by DS or its Affiliates on the Effective Date or during the Term, that Cover inventions that arise out of the performance of obligations or exercise of rights hereunder, and that are reasonably necessary or useful to the Development, Manufacture or Commercialization of the Licensed Products in the Field, but excluding Joint Patent Rights.  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Territory Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DS Territory Commercialization Plan).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Territory Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DS Advertising and Promotion).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means DS Know-How and DS Patent Rights.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Escrow Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Escrow).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Escrow Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Escrow).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Escrowed Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Escrow).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any branded domain name(s) and any domain name(s) containing INNs, in each case mutually agreed to by the Parties in writing to be used or to be protected in connection with the Commercialization of the License Products in the DS Territory.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (General Indemnification by DS).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Know-How Controlled by Esperion or its Affiliates on the Effective Date or during the Term that is reasonably necessary or useful to the Development, Manufacture or Commercialization of the Licensed Products in the Field in the DS Territory, but excluding Joint Know-How.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Manufacturing Know-How&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means Know-How Controlled by Esperion or its Affiliates on the Effective Date or during the Term that is reasonably necessary or useful to the Manufacture of the Licensed Products, including all relevant technical information, supplier lists, bills of material and related information, but excluding Joint Know-How.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means any Patent Right Controlled by Esperion or its Affiliates on the Effective Date or during the Term that is reasonably necessary or useful to the Development, Manufacture or Commercialization of the Licensed Products in the Field and in the DS Territory, but excluding Joint Patent Rights.  The Esperion Patent Rights existing as of the Effective Date are those Patent Rights identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 10.2.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Existing Esperion Patent Rights).  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Existing Esperion Patent Rights) shall be amended from time to time at the initiative of Esperion or the reasonable request of DS to reflect the then-current status of the Esperion Patent Rights including by adding or deleting Patent Rights as required for accuracy and completeness</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Esperion Know-How and Esperion Patent Rights.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means worldwide, excluding the DSE Territory and the DS Territory.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means such agreements between Esperion and a Third Party pursuant to which Esperion Controls Know-How or Patent Rights reasonably necessary or useful to Develop, Manufacture or Commercialize Licensed Products, as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any and all Trademarks pertaining to the Licensed Products that are owned by Esperion in the DS Territory and set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Esperion Trademarks), excluding any Esperion house marks and the name &#8220;Esperion.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the United States Federal Food, Drug and Cosmetic Act, as amended.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the use of Licensed Product in humans for the treatment of hyperlipidemia.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to a country, the first sale for end use or consumption of Licensed Product in such country, except for named patient sales, compassionate use or other patient access programs, after all Regulatory Approvals legally required for such sale have been granted by the Regulatory Authority of such country.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the respective periods of three (3) consecutive calendar months ending on June 30, September 30, December 31 and March 31, of each calendar year.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means each successive period of twelve (12) months commencing on April 1 and ending on March 31, provided that the first Fiscal Year of the Term shall begin on the Effective </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date and end on the first March 31 thereafter and the last Fiscal Year of the Term shall end on the last day of the Term. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Good Clinical Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all applicable good clinical practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials, including, as applicable, (a) as set forth in the European Commission Directive 2001&#47;20&#47;EC of April 4, 2001 relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, and brought into law by the European Commission Directive 2005&#47;28&#47;EC of April 8, 2005 laying down the principles and detailed guidelines for good clinical practice for investigational medicinal products&#59; (b) the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Harmonised Tripartite Guideline for Good Clinical Practice (CPMP&#47;ICH&#47;135&#47;95) and any other guidelines for good clinical practice for clinical trials on medicinal products in the European Union&#59; (c) the Declaration of Helsinki (1964) as last amended at the 59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> World Medical Association (WMA) General Assembly in October 2008 and any further amendments or clarifications thereto&#59; (d) the United States Code of Federal Regulations, Title 21, Parts 50 (&#8220;Protection of Human Subjects&#8221;), 56 (&#8220;Institutional Review Boards&#8221;) and 312 (&#8220;Investigational New Drug Application&#8221;), as may be amended from time to time&#59; and (e) the equivalent applicable Laws in any relevant country or jurisdiction, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance that the clinical data and reports results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to Licensed Product in a country, a pharmaceutical product that is approved for use in such country by a Regulatory Authority through a regulatory pathway referencing or relying on clinical data, or any findings of safety or efficacy, that are first submitted by DS or its Affiliates or Sublicensees for obtaining Regulatory Approval for such Licensed Product, in each case other than any Licensed Product that has been Developed, Manufactured or Commercialized under this Agreement by DS or any of its Related Parties in such country.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Branding Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Global Branding).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any applicable government authority, court, tribunal, arbitrator, agency, department, legislative body, commission or other instrumentality of (a) any government of any country or territory, (b) any nation, state, province, county, city or other political subdivision thereof or (c) any supranational body.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Good Clinical Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means International Financial Reporting Standards, consistently applied. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Investigational New Drug Application, as defined in the FD&#38;C Act, together with any rules and regulations promulgated thereunder, or similar application or submission that is required to be filed with any Regulatory Authority anywhere in the world before beginning clinical testing of an investigational drug or biological product in human subjects.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Indemnification Procedure).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infringement Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Right to Enforce).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INNs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means International Non-Proprietary Names.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Invent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the act of invention by inventors, as determined in accordance with the applicable patent laws.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Joint Collaboration Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the joint committee as more fully described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Joint Collaboration Committee).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Joint Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Know-How that is discovered, made or developed jointly in connection with the activities undertaken under this Agreement by one or more employees of Esperion or its Affiliates (or a Third Party acting on any of their behalf) and one or more employees of DS or its Affiliates (or a Third Party acting on any of their behalf).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Joint Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Patent Right that is Invented jointly in connection with the activities undertaken under this Agreement by one or more employees of Esperion or its Affiliates (or a Third Party acting on any of their behalf) together with one or more employees of DS or its Affiliates (or a Third Party acting on any of their behalf).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Joint Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Joint Know-How and Joint Patent Rights.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all chemical or biological materials and other tangible materials, inventions, improvements, practices, discoveries, developments, data, information, technology, methods, protocols, formulas, knowledge, know-how, trade secrets, processes, assays, skills, experience, techniques and results of experimentation and testing, including pharmacological, toxicological and pre-clinical and clinical data and analytical and quality control data, in all cases, whether or not proprietary or patentable, in written, electronic or any other form now known or hereafter developed, including any physical embodiments of any of the foregoing&#59; but excluding in any event any Patent Right and Trademarks.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all applicable laws, statutes, rules, regulations, orders, judgments, injunctions, ordinances or other pronouncements having the binding effect of law of any Governmental Authority, including if either Party is or becomes subject to a legal obligation to a Regulatory Authority or other Governmental Authority (such as a corporate integrity agreement or settlement agreement with a Governmental Authority) .</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Latin American Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Option to Expand the DS Territory).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Latin American Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Option to Expand the DS Territory).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Latin American Option Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Colombia and other Latin American countries to be mutually agreed to by the Parties in the Latin American Sublicense.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Latin American Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Option to Expand the DS Territory). </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Esperion Patent Rights and Joint Patent Rights.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical agent which includes Bempedoic Acid in any formulation, in any presentation and in any strength, including but not limited to the Licensed Product described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (General Indemnification by DS).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as applicable, all activities associated with the production, manufacture, process of formulating, processing, purifying, filling, finishing, packaging, labeling, shipping, importing and storage of Licensed Products, including process development, process validation, stability testing, manufacturing scale-up, pre-clinical, clinical and commercial manufacture and analytical development, product characterization, quality assurance and quality control development, testing and release.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means written, telephonic or in-person communications from or with any Regulatory Authority concerning any of the following&#58; key product quality attributes (e.g., purity) of Licensed Products, safety findings affecting a Licensed Product (e.g., Serious Adverse Events, emerging safety signals), clinical or non-clinical findings affecting patient safety, lack of efficacy, receipt </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or denial of Regulatory Approval, the design of Clinical Studies or the need for additional non-clinical studies (e.g., additional toxicology or carcinogenicity studies).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Middle East Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Option to Expand the DS Territory).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Middle East Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Option to Expand the DS Territory).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Middle East Option Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Saudi Arabia, Kuwait, Oman, United Arab Emirates, Qatar, Bahrain and Yemen.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Middle East Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Option to Expand the DS Territory).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Licensed Product, the aggregate gross invoiced sales prices from sales of all units of such Licensed Product sold by DS and its Related Parties to independent Third Parties in accordance with IFRS after deducting, if not previously deducted, from the amount invoiced or received&#58;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.17pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.73pt">&#91;***&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of any sale or other disposal for value, such as barter or counter-trade, of a Licensed Product, or part thereof, other than in an arm&#8217;s length transaction exclusively for cash, Net Sales shall be calculated &#91;***&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the following will not be included in Net Sales for a Party&#58; &#91;***&#93;.  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Bankruptcy and Section 365(n)).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Effective Date and ending &#91;***&#93; months thereafter.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Out-of-Pocket Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to certain activities hereunder, direct expenses paid or payable by either Party or its Affiliates to Third Parties and specifically identifiable and incurred (and invoiced) to conduct such activities for Licensed Product, as applicable, including payments to contract personnel&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that &#91;***&#93; will not be considered Out-of-Pocket Costs.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means DS or Esperion.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Challenges of Patent Rights).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a) all issued patents (including any extensions, restorations by any existing or future extension or registration mechanism (including patent term adjustments, patent term extensions, supplemental protection certificates or the equivalent thereof), substitutions, confirmations, re-registrations, re-examinations, reissues, patents and patent claims maintained after post grant examination (including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post grant review or opposition proceeding) and patents of addition)&#59; (b) patent applications (including all provisional applications, substitutions, requests for continuation, continuations, continuations-in-part, divisionals and renewals)&#59; (c) inventor&#8217;s certificates&#59; and (d) all equivalents of the foregoing in any country of the world.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any natural person, corporation, unincorporated organization, partnership, association, sole proprietorship, joint stock company, joint venture, limited liability company, trust or government, or Governmental Authority, or any other similar entity.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pre-Approval Clinical Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development in South Korea and Taiwan). </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post-Approval Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all studies required as a condition to the grant of Regulatory Approval for the Licensed Product, such as confirmatory trials or PASS (post approval safety study).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pricing and Reimbursement Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Licensed Product, the receipt by DS or a Related Party of DS of authorization for reimbursement or funding of such Licensed Product in the national health service or insurance from the national-level Governmental Authority responsible for authorizing reimbursement for or determining pricing for, pharmaceutical products in such country, national or supranational, as the case may be, regulatory jurisdiction.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Quality Agreement).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Taxes). </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registration Dossier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the registration dossier of technical data and information compiled by or on behalf of DS with respect to a Licensed Product submitted to a Regulatory Authority to obtaining Regulatory Approval of a Licensed Product in the Field in the DS Territory.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any and all approvals, licenses, registrations or authorizations of any Regulatory Authority that are necessary for the marketing and sale of a product in a country or group of countries, including a Registration Dossier filed with a Regulatory Authority in any country in the DS Territory, including all additions, amendments, supplements, extensions and modifications thereto, but excluding Pricing and Reimbursement Approvals.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Governmental Authority involved in granting approvals for the Development, Manufacturing, Commercialization, reimbursement or pricing of Licensed Products.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all applications, registrations, licenses, authorizations and approvals, all correspondence submitted to or received from Regulatory Authorities within the DS Territory (including Registration Dossiers, minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents, relating to the Licensed Product, and all data contained in any of the foregoing, including all clinical trial applications, Regulatory Approvals and applications therefor, regulatory drug lists, advertising and promotion documents, adverse event files and complaint files.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Licensed Product in a country, any exclusive marketing right, data exclusivity right or other status conferred by any Governmental Authority with respect to such Licensed Product in such country, other than a Patent Right, that limits or prohibits a Person from (i) relying on pivotal safety or efficacy data generated by or for the Parties with respect to a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensed Product in an application for Regulatory Approval of a Generic Product or (ii) Commercializing a Licensed Product or a Generic Product.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a Party&#8217;s Affiliates and permitted Sublicensees.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relevant Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all relevant factors that may affect the Development or Commercialization of a Licensed Product, including (as applicable), &#91;***&#93;.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remitter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Taxes). </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Responsible Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Control&#59; Cooperation).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Royalty Term).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.5pt">Safety Data Exchange Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Pharmacovigilance). </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Serious Adverse Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an adverse drug experience or circumstance that results in any of the following outcomes (a) death, (b) life-threatening event, (c) inpatient hospitalization or prolongation of existing hospitalization, (d) persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions, (e) a congenital anomaly&#47;birth defect, (f) significant intervention required to prevent permanent impairment or damage or (g) a medical event that may not result in death, be life-threatening or require hospitalization but, based on appropriate medical judgment, that may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes described in clauses (a) through (e).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a Third Party to whom a Party grants a direct or indirect sublicense under any Esperion Technology, DS Technology or Joint Technology, as the case may be, to Develop, Manufacture or Commercialize a Licensed Product in the Field pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DS Sublicense Rights) or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Esperion Sublicense Rights) or the last sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Ownership). </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sued Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Third Party Infringement Suit).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Licensed Products).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supply Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Supply Failure).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Term).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Terminated Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Consequences of Termination or Expiration of this Agreement).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a) the Esperion Territory, (b) the DSE Territory or (c) the DS Territory, singly or collectively, as applicable.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a Person other than a Party and its Affiliates.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any trademark, trade name, service mark, service name, brand, trade dress, logo, slogan or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing, but not including domain names.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transition Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.4.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Transition Activities).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the United States of America and its territories, possessions and commonwealths.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Bankruptcy and Section 365(n)).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.126</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any claim of a Licensed Patent that (a) has been granted by a patent granting authority, that is in force, and that has not been surrendered, abandoned, revoked or held invalid or unenforceable by a decision taken by an administrative or civil court in a jurisdiction, or (b) a pending claim in a Licensed Patent application, with the provision that any claim that has been pending for more than &#91;***&#93; years following the first substantive response from the patent office in a country, shall cease to be a Valid Claim in that country unless and until it becomes a granted claim fulfilling the requirements under (a) above.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">DEVELOPMENT</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25pt;text-decoration:underline">Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of this Agreement, except with respect to the Pre-Approval Clinical Studies, for each Licensed Product, DS shall be solely responsible for conducting, &#91;***&#93;, the Development activities set forth in the applicable Development Plan for such Licensed Product in the Field in the DS Territory, subject to oversight by the JCC. DS shall use Commercially Reasonable Efforts to&#58; (a) Develop each Licensed Product in the Field in the DS Territory in accordance with the applicable Development Plan&#59; and (b) pursue Regulatory Approval of each Licensed Product in the DS Territory.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25pt;text-decoration:underline">Development in South Korea and Taiwan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Notwithstanding the above </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Overview) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (License Grants to DS), Esperion shall be responsible for conducting, &#91;***&#93;, the Clinical Studies set forth in the Development Plan, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Agreed Development Plan&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), as amended from time to time in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (JCC Responsibilities) of this Agreement, in support of seeking Regulatory Approval of the Licensed Product in the Field in South Korea and Taiwan (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pre-Approval Clinical Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Esperion shall use Commercially Reasonable Efforts to conduct the Development activities set forth in the Agreed Development Plan in accordance with the timeline set forth therein. If Esperion contracts with a Third Party to provide any services related to the Pre-Approval Clinical Studies (as provided for in Section 2.2), Esperion shall use Commercially Reasonable Efforts to&#58; (1) &#91;***&#93;&#59; and (2) provide a copy of the executed contract with such Third Party to DS &#91;***&#93; days of execution.DS shall be solely responsible for Post-Approval Studies in the DS Territory in accordance with the applicable Development Plan &#91;***&#93;. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25pt;text-decoration:underline">Development Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For each Licensed Product, the Development activities to be undertaken by DS or Esperion (in the case of Esperion, the Pre-Approval Clinical Studies in South Korea and Taiwan to be conducted in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development in South Korea and Taiwan)) for such Licensed Product to obtain or maintain Regulatory Approval in the Field in the DS Territory shall be set forth in a development plan (in the case of Esperion, in the Agreed Development Plan) (each such plan, as amended from time to time in accordance with this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Development activities set forth in each Development Plan shall at all times be designed to be in compliance with all applicable Laws and in accordance with professional and ethical standards customary in the pharmaceutical industry. The initial Development Plan (other than for South Korea and Taiwan) setting forth the Development activities to be undertaken by DS for the Licensed Product to obtain Regulatory Approval in the Field in the DS Territory shall be provided by DS to Esperion &#91;***&#93; months after the Effective Date.  The initial Development Plan for South Korea and Taiwan setting forth the Pre-Approval Clinical Studies to be undertaken by Esperion shall be set forth in the Agreed Development Plan in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development in South Korea and Taiwan).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25pt;text-decoration:underline">Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS and Esperion (in the case of Esperion, with respect to the Pre-Approval Clinical Studies in South Korea and Taiwan to be conducted in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development in South Korea and Taiwan)) shall conduct all Development activities in a sound scientific manner and in compliance with applicable Law and the applicable Development Plan, as such Development </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan may be amended from time to time in accordance with this Agreement.  Notwithstanding anything to the contrary in this Agreement, the Parties shall not be obligated to undertake or continue any activity under a Development Plan if&#58; (a) the Party reasonably determines that performance of such activity would violate applicable Law&#59; or (b) with respect to any Clinical Study, (i) a Regulatory Authority or independent safety data review board for such Clinical Study has required or recommended termination or suspension of such Clinical Study or (ii)  the Party believes in good faith that termination or suspension of such Clinical Study is warranted because of safety or tolerability risks or the lack of suitable risk benefit ratio to the study subjects.  In the event that a Party determines not to undertake or continue any activity under a Development Plan in accordance with the immediately preceding sentence, such Party shall promptly notify the other Party of such determination, and shall use all reasonable efforts to notify and consult with the other Party prior to making such determination. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25pt;text-decoration:underline">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS shall be responsible &#91;***&#93; in connection with the Development of the Licensed Products in the Field in the DS Territory, except for &#91;***&#93;.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25pt;text-decoration:underline">Records, Reports and Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.07pt;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:71.23pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.5pt">DS shall maintain complete and accurate records of all Development and other scientific activities conducted by or on behalf of it in connection with each Licensed Product, including all data and other information resulting from such activities (which records shall include, as applicable, books, records, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof (e.g., samples of materials and other graphic or written data generated in connection with such Development and scientific activities)), in sufficient detail and in sound scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the performance of the Development activities and Clinical Studies with respect to each Licensed Product by DS. </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:68.46pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.5pt">Esperion shall maintain complete and accurate records of the Pre-Approval Clinical Studies and other scientific activities conducted by or on behalf of it in connection with such Pre-Approval Clinical Studies, including all data and other information resulting from such activities (which records shall include, as applicable, books, records, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof (e.g., samples of materials and other graphic or written data generated in connection with such Development and scientific activities)), in sufficient detail and in sound scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the performance of the Pre-Approval Clinical Studies by Esperion.</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">Development Activities Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS shall provide to Esperion, &#91;***&#93;basis through the JCC, a confidential written progress report that summarizes for each Licensed Product &#91;***&#93;t.  In addition, DS shall translate, &#91;***&#93;, CSRs and top-line data derived from Clinical Studies of Licensed Products as soon as practically possible into English and shall share such translated CSRs and top-line data with Esperion promptly after completion of such translation into English. Esperion shall provide to DS, &#91;***&#93; basis through the JCC, an update on the progress of the Pre-Approval Clinical Studies and the preparation for the Registration Dossiers in South Korea and Taiwan.  </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.07pt;text-decoration:underline">Access to Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At any time during the Term, Esperion shall have the right to review all records relating to such Development undertaken by DS with respect to each Licensed Product, at reasonable times, and upon prior written request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS shall be entitled to utilize the services of Third Parties to perform Development activities and Esperion shall be entitled to utilize the services of Third Parties to perform the Pre-Approval Clinical Studies in South Korea and Taiwan, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that (a) the applicable Party shall require such Third Parties to operate in a manner consistent with this Agreement, &#91;***&#93;&#59; and (b) the applicable Party shall remain at all times fully liable for its respective responsibilities and the acts and omissions of such Third Parties engaged by it under this Agreement.  The applicable Party shall require that any Third Party agreement entered into pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Third Parties) include &#91;***&#93;  The applicable Party shall be solely responsible for the direction of and communications with such Third Parties.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">REGULATORY MATTERS</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Responsibility for Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.5pt">Subject to the terms and conditions of this Agreement, including oversight by the JCC, except as set forth herein, DS shall be solely responsible, &#91;***&#93;, for all regulatory matters relating to each Licensed Product in the DS Territory, including (a) overseeing, monitoring and coordinating all regulatory actions, communications and filings with, and submissions to, the applicable Regulatory Authority with respect to Licensed Products&#59; (b) interfacing, corresponding and meeting with the applicable Regulatory Authority with respect to Licensed Products&#59; (c) seeking and maintaining all Regulatory Approvals with respect to Licensed Products, including any amendments, supplements or modifications to Regulatory Approvals&#59; and (d) maintaining and submitting all records required to be maintained or required to be submitted to the applicable Regulatory Authority with respect to Licensed Products, in each case in the DS Territory. Notwithstanding anything to the contrary in this Agreement, Esperion shall be responsible, &#91;***&#93;, for (i) preparing and maintaining the drug master file(s) for the API(s) containing data and information related to the Manufacture of the API(s) for the Licensed Products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DMF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), including any amendments (ii) providing the DMF directly to the applicable Regulatory Authority in the DS Territory, and (iii) communicating with Regulatory Authorities in the DS Territory regarding the DMF. DS shall be entitled to reference the DMF in Regulatory Documentation, including in applications for Regulatory Approval, for the Licensed Product in the DS Territory. Esperion shall provide all assistance reasonably requested by DS in connection with such preparation and filing of Regulatory Documentation and communications with Regulatory Authorities, including but not limited to responding to any queries related to the Licensed Products received from such Regulatory Authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Esperion shall not be required to &#91;***&#93; in connections therewith unless &#91;***&#93;, and, at the request of DS and at &#91;***&#93;, Esperion shall send representative(s) of Esperion to attend in-person meetings with Regulatory Authorities in the DS Territory relating to the Manufacture of API(s) or Bulk Tablets.&#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.5pt">Notwithstanding the above, Esperion shall prepare the Registration Dossiers for the Licensed Product for submission by DS to the applicable Regulatory Authorities in South Korea and Taiwan to obtain Regulatory Approval of such Licensed Product in the Field in South Korea and Taiwan, including but not limited to any translation of such Registration Dossiers into the appropriate language for submission to the applicable Regulatory Authorities in South Korea and Taiwan, &#91;***&#93; and shall transfer such Registration Dossiers to DS or DS&#8217;s Affiliate in order for DS or DS&#8217;s Affiliate to submit, &#91;***&#93;, such Registration Dossiers to the applicable Regulatory Authorities to obtain Regulatory Approval of the Licensed Product in the Field in South Korea and Taiwan. Upon such transfer, DS shall be responsible, &#91;***&#93;, for all regulatory matters, including post-approval submissions such as amendments, supplements or modifications, relating to the applicable Licensed Product as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Responsibility for Regulatory Matters)&#59; provided, however, that if the Regulatory Authority in South Korea and&#47;or Taiwan requests additional data or information arising from the Pre-Approval Clinical Studies which is not included in the Registration Dossiers, Esperion shall prepare and provide to DS or DS&#8217;s Affiliate in a timely manner, such additional data and information, including but not limited any analysis of data arising from the Pre-Approval Clinical Studies in South Korea and Taiwan, &#91;***&#93;.   </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Communications with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Communications with Regulatory Authorities) with respect to the Pre-Approval Clinical Studies to be conducted by Esperion in South Korea and Taiwan in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development in South Korea and Taiwan), DS shall be responsible for all communications with the applicable Regulatory Authority relating to the Licens</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed Products in the DS Territory.  Prior to the date of transfer of the applicable Registration Dossier to DS as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Responsibility for Regulatory Matters), Esperion shall be responsible for all communications with the applicable Regulatory Authority in South Korea and Taiwan relating to the Licensed Products. On or following the date of transfer of the applicable Registration Dossier to DS as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Responsibility for Regulatory Matters), DS shall be responsible for all communications with the applicable Regulatory Authority in South Korea and Taiwan relating to the Licensed Products. Within &#91;***&#93; business days after receipt of any Material Communication from such Regulatory Authority with respect to a Licensed Product, the Party responsible for communication with the Regulatory Authority (as described above), shall provide the other Party with a brief written description, in English, of the principal issues raised in such Material Communication with such Regulatory Authority. Upon Esperion&#8217;s reasonable request after receiving a notice from DS in accordance with the immediately preceding sentence, DS shall, at its sole cost and expense, translate such Material Communication as soon as practically possible and shall provide to Esperion such translated Material Communication promptly after completion of such translation into English. DS will allow Esperion a reasonable opportunity to review and comment on DS&#8217;s proposed response to any Material Communications with such Regulatory Authority with respect to such Licensed Product. Esperion shall send comments on such Material Communication to DS in a timely manner and DS will reasonably consider all comments timely provided by Esperion in connection therewith&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> DS shall not be required to comply with the foregoing if to do so would cause DS to fail to meet any deadline requested or required by any Regulatory Authority in the DS Territory.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Meetings with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except with respect to communications with Regulatory Authorities for which Esperion is responsible for in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Communications with Regulatory Authorities), DS shall provide Esperion with reasonable advance notice of all formal meetings and teleconferences with the applicable Regulatory Authority pertaining to any Licensed Product in the DS Territory, or with as much advance notice as practicable under the circumstances.  DS shall use reasonable efforts, to the extent reasonably practicable and not restricted or prohibited by applicable Laws or the Regulatory Authority, to permit Esperion to have, at Esperion&#8217;s expense, mutually acceptable representatives of Esperion attend, as observers, such formal meetings and teleconferences with such Regulatory Authority pertaining to such Licensed Product in the DS Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that DS shall not be obligated to change or re-schedule any such meeting in order to accommodate the schedule of Esperion&#8217;s representatives.  If Esperion requires an interpreter for its representatives attending any such Regulatory Authority meeting, Esperion shall retain, &#91;***&#93;, an interpreter who can provide simultaneous interpretation. Notwithstanding the foregoing, prior to the date of transfer of the applicable Registration Dossier to DS as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Responsibility for Regulatory Matters) with respect to communications with Regulatory Authorities for which Esperion is responsible for in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Communications with Regulatory Authorities), Esperion shall provide DS with reasonable advance notice of all formal meetings and teleconferences with the applicable Regulatory Authority pertaining to any Licensed Product in South Korea and&#47;or Taiwan, or with as much advance notice as practicable under the circumstances.  Esperion shall use reasonable efforts, to the extent reasonably practicable and not restricted or prohibited by applicable Laws or the Regulatory Authority, to permit DS or DS&#8217;s Affiliate to have, at DS&#8217;s expense, a mutually acceptable representative of DS or DS&#8217;s Affiliate attend, as observers, such formal meetings and teleconferences with such Regulatory Authority pertaining to such Licensed Product in South Korea and&#47;or Taiwan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Esperion shall not be obligated to change or re-schedule any such meeting in order to accommodate the schedule of DS&#8217;s representative. If DS requires an interpreter for its representative attending any such Regulatory Authority meeting, DS shall retain, &#91;***&#93;, an interpreter who can provide simultaneous interpretation.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Pricing and Reimbursement Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, DS shall have the sole right, &#91;***&#93;, and shall use Commercially Reasonable Efforts to timely prepare and submit or have prepared or submitted by subcontractors, as the case may be, all necessary applications and documentation to seek to acquire, hold and maintain all Pricing and Reimbursement Approvals necessary or useful to Commercialize each Licensed Product throughout the DS Territory as well as to conduct all correspondence and communications with Governmental Authorities regarding all such matters. Esperion shall reasonably cooperate with DS in connection therewith, including executing such documents as well as providing access to all necessary data in Esperion&#8217;s Control and not previously made available to DS, such as patient-level data, all Regulatory Documentation, publication plan and manuscripts under preparation, support with the necessary data-analyses (bio-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statistical analyses), as may be necessary to confirm DS&#8217;s rights to prepare, submit, and obtain such Pricing Approvals for the Licensed Product in the DS Territory.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Submissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  With respect to each Licensed Product, DS shall allow Esperion a reasonable opportunity to review and comment on all filings, including Registration Dossiers, and other submissions to Regulatory Authorities or other Governmental Authorities in the DS Territory related to such Licensed Product and for that purpose DS shall provide English versions of filings and submissions (excluding those materials provided by Esperion) to Esperion in advance of submission of any such filing. DS shall consider all comments timely provided by Esperion in connection therewith and accept such comments if reasonable, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> DS shall not be required to comply with the foregoing or delay submission of such filings, including Registration Dossiers, and other submissions to Regulatory Authorities or other Governmental Authorities if to do so would cause DS to fail to meet the filing target date set forth in the Development Plan or any deadline requested by any Regulatory Authority in the DS Territory.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Regulatory Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Within &#91;***&#93; days after the Effective Date and thereafter, upon DS&#8217;s reasonable request (with respect to Regulatory Documentation, data and information not previously provided), Esperion shall provide DS with all Regulatory Documentation, data and information (but not including the DMF) owned or Controlled by Esperion that relates to the Licensed Products to the extent necessary or useful to obtain or maintain Regulatory Approval of the Licensed Products in the Field in the DS Territory, including but not limited to the cleaning validation protocol related to the equipment used in connection with the Manufacture of the Licensed Products at Esperion&#8217;s Manufacturing sites. Notwithstanding the foregoing, within &#91;***&#93; days after the Effective Date, with respect to the eCTD, Esperion shall provide to DS a copy of the eCTD (but for clarity not including portions included within the DMF) existing as of the Effective Date and thereafter Esperion shall provide a copy of the updated eCTD following submission of the global cardiovascular outcomes trial (CVOT) data to the European Medicines Agency.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Within &#91;***&#93; days after the Effective Date, Esperion shall commence the transfer to DS or DS&#8217;s Affiliate at Esperion&#8217;s cost the analytical method transfer for the Brazilian Facility (as such term will be defined in the Supply Agreement) and the packaging blister specifications for Bulk Tablets of the Licensed Products. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Supply of Stability Study Samples</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At DS&#8217;s request, Esperion shall provide DS with Bulk Tablets for use by DS to conduct stability testing of Bulk Tablets as required for the DS Territory at the supply price agreed in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Supply Price) and in accordance with the delivery terms set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Delivery Terms)&#59; provided that DS notifies Esperion of the requested quantity of Bulk Tablets and date of delivery of such Bulk Tablets at least &#91;***&#93; before the requested date of delivery.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">  Right of Reference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party hereby grants to the other Party (as well as to the other Party&#8217;s Related Parties, when and if designated by the other Party from time to time) a non-exclusive, non-transferable right to rely upon, access, and reference all information and data (including all CMC information as well as data made, collected or otherwise generated in the conduct of any Clinical Studies or early access&#47;named patient programs for the Licensed Products) included in or used in support of any regulatory filing, Regulatory Approval, drug master file or other Regulatory Documentation, in each case, that is owned or Controlled by such Party, that relates to any Licensed Product, as necessary or useful to obtain or maintain Regulatory Approval of Licensed Products in the DS Territory or the Esperion Territory, as the case may be.  Such Party shall, if requested by the other Party, provide a signed statement that the other Party may rely upon, and the Regulatory Authority may access, in support of the other Party&#8217;s application for such Regulatory Approval in its Territory, any underlying raw data or information submitted by such Party to the Regulatory Authority with respect to any regulatory filing, Regulatory Approval, drug master file or other Regulatory Documentation (including orphan drug applications and designations) owned or controlled by such Party or its Related Parties that relates to any Licensed Product.  In addition, upon request of either Party (on behalf of itself or a Sublicensee), the other Party shall obtain and provide to the requesting Party certificates or other formal or official attestations concerning the regulatory status of the Licensed Products in the DS Territory or the Esperion Territory, as applicable (e.g., Certificates of Free Sale, Certificates for Export, Certificates to Foreign Governments).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline">  Pharmacovigilance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Within &#91;***&#93; after the Effective Date, the Parties shall enter into a Safety Data Exchange Agreement, or amend the existing Safety Data Exchange Agreement between Esperion and Daiichi Sankyo Europe GMBH for the DSE Territory, entered into on April 30, 2019, defining the pharmacovigilance responsibilities of the Parties, including safety data exchange procedures, with respect to the DS Territory, in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Safety Data Exchange Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Esperion will own and maintain the global safety database for the Licensed Products.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline">  Inspection.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If any Governmental Authority or Regulatory Authority requests to inspect Esperion or Esperion&#8217;s Manufacturing facilities, Esperion shall make reasonable efforts to support and allow such inspection.  &#91;***&#93; for the inspection &#91;***&#93; at Esperion or Esperion&#8217;s Manufacturing site shall &#91;***&#93; and &#91;***&#93; for such inspection shall be &#91;***&#93; &#91;***&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">COMMERCIALIZATION</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Responsibility, Cost and Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Esperion Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion shall be solely responsible, &#91;***&#93;, for all Commercialization activities relating to the Licensed Products in the Esperion Territory. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">DS Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, DS shall be solely responsible, &#91;***&#93;, for all Commercialization activities relating to Licensed Products in the DS Territory.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">DS Commercial Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field in the DS Territory. DS shall conduct all Commercialization activities for each Licensed Product in accordance with the applicable DS Territory Commercialization Plan and in compliance with applicable Laws and this Agreement.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Initial DS Territory Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Initial Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No later than within &#91;***&#93; months of the date of filing of the applicable application for Regulatory Approval for a Licensed Product in the Field in the applicable country in the DS Territory, DS shall deliver to the JCC an initial written plan setting forth a summary of the anticipated activities to be undertaken by DS in connection with the Commercialization of such Licensed Product in the applicable country in the DS Territory (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Territory Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), &#91;***&#93; Each DS Territory Commercialization Plan shall provide an outline of the Commercialization activities for the Licensed Product in the DS Territory, including (a) the positioning of the Licensed Product, (b) a summary of the branding and communication strategy with respect thereto, (c) a summary of the number of sales representatives and other personnel to be assigned on a country-by-country basis to sell the Licensed Product in the DS Territory, (d) a summary of the medical conferences and other presentations at which the Licensed Product will be promoted, and (e) annual sales projections. Commercialization activities set forth in each DS Territory Commercialization Plan shall at all times be designed to be in compliance with all applicable Laws and in accordance with professional and ethical standards customary in the pharmaceutical industry. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Amendments to DS Territory Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The DS Territory Commercialization Plan for a Licensed Product shall be updated and modified by DS, from time to time at its discretion but no less frequently than &#91;***&#93;, based upon, among other things, DS&#8217;s Commercialization activities with respect to such Licensed Product in the DS Territory, and including any changes required to take into account ongoing Development activities, a copy of which updated plan will be provided to the JCC.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Advertising and Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Global Branding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Esperion shall, from time to time during the Term, develop (and thereafter modify and update) a suggested global branding strategy (including global positioning, promotional messages, colors and other visual branding elements) for each Licensed Product for suggested use throughout the world (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Branding Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which will be shared in the JCC. Esperion will submit the Global </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Branding Strategy for the Licensed Products to the JCC at least &#91;***&#93;.  Esperion shall consider in good faith any comments provided by DS with respect to the Global Branding Strategy. The Global Branding Strategy is not binding upon DS or its Commercialization of the Licensed Products in the DS Territory. DS shall, following review of the Global Branding Strategy, reasonably consider implementing the Global Branding Strategy but has no obligation to do so.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">DS Advertising &#38; Promotion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  DS will be responsible for the creation, preparation, production, reproduction and filing with the applicable Regulatory Authorities, of relevant written sales, promotion and advertising materials relating to each Licensed Product for use in the DS Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Territory Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  All such DS Territory Promotional Materials will be compliant with applicable Law and in DS&#8217;s discretion, may (but shall not be required to) adopt aspects of the Global Branding Strategy for such Licensed Product in the DS Territory. DS will submit representative samples, machine translated into the English language, of its DS Territory Promotional Materials developed by it for use in the DS Territory to the JCC for information purposes &#91;***&#93;.  DS shall consider in good faith any timely comments Esperion may have with respect to such samples of DS Territory Promotional Materials.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Esperion Advertising &#38; Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. From time to time, and in any event upon the reasonable request of DS, Esperion shall provide to DS copies of Licensed Product promotional materials which have been used in countries where Esperion commercializes the Licensed Product, including the United States, in order for DS to align its promotional materials with the Global Branding Strategy.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Product Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  DS may propose and the Parties will discuss at the JCC Trademarks to be used in the Commercialization of Licensed Products in the DS Territory. Any such Trademarks that are approved by the JCC in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (JCC Decision-Making) shall be an Esperion Trademark.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Reporting Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Within &#91;***&#93; following the first Regulatory Approval of any Licensed Product in the Field in the DS Territory, DS shall provide Esperion with a written report summarizing DS&#8217;s Commercialization activities for such Licensed Product performed to date (or updating such report for activities performed since the last such report was given hereunder, as applicable).  In addition, DS shall provide Esperion with written notice of the First Commercial Sale of each Licensed Product in the DS Territory within &#91;***&#93; days after such event&#59; provided, however, that in all circumstances, DS shall inform Esperion of such event prior to public disclosure of such event by DS.  DS shall provide such other information to the JCC as Esperion may reasonably request with respect to Commercialization of such Licensed Product.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Sales and Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each Party and its Related Parties shall be responsible for booking sales in its respective Territory.  The Parties will use their good faith efforts to coordinate the timing of any public disclosure of Net Sales of the Licensed Products in the DS Territory prior to such disclosure.  Each Party and its Related Parties may warehouse Licensed Products both inside and outside of such Party&#8217;s Territory, provided that any sales with respect to such Licensed Products are booked in such Party&#8217;s Territory.  Each Party and its Related Parties shall be solely responsible for handling all returns of any Licensed Product sold in its Territory, as well as all aspects of Licensed Product order processing, invoicing and collection, distribution, inventory and receivables of Licensed Products sold in its Territory.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Ex-Territory Sales&#59; Export Monitoring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Ex-Territory Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to applicable Law, neither Party shall engage in any advertising or promotional activities relating to any Licensed Product directed primarily to customers or other buyers or users of such Licensed Product located outside its Territory or accept orders for Licensed Products from or sell Licensed Products into such other Party&#8217;s Territory for its own account, and if a Party receives any order for any Licensed Product in the other Party&#8217;s Territory, it shall refer such orders to the other Party.  &#91;***&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Export Monitoring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party and its Related Parties will use Commercially Reasonable Efforts to monitor and prevent exports of Licensed Products from its own Territory for Commercialization in the other Party&#8217;s Territory using methods permitted under applicable Law that are commonly used in the industry for such purpose (if any), and shall promptly inform the other Party of any such exports of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensed Products from its Territory, and any actions taken to prevent such exports.  Notwithstanding the agreement of the Parties in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Ex-Territory Sales), each Party agrees to take reasonable actions requested in writing by the other Party that are consistent with Law &#91;***&#93;.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Recalls, Market Withdrawals or Corrective Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Notification and Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event that any Regulatory Authority threatens or initiates any action to remove a Licensed Product from the market, the Party receiving notice thereof shall notify the other Party of such communication immediately (but in no event later than &#91;***&#93; hours after receipt thereof).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Responsibility of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  During the Term, DS shall at all times be responsible for and shall determine whether to initiate any recall, withdrawal or market notification of a Licensed Product in the Field in the DS Territory and Esperion shall at all times be responsible for and shall determine whether to initiate any recall, withdrawal or market notification of a Licensed Product in the Field in the Esperion Territory, including the scope of such recall or withdrawal (e.g., a full or partial recall, or temporary or permanent recall or market notification)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that before such responsible Party initiates a recall, withdrawal or market notification in its respective Territory, the Parties shall promptly meet in-person or by means of teleconference, videoconference or other similar communications equipment and discuss in good faith the reasons therefor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that such discussions shall not delay any action that such responsible Party believes has to be taken in relation to any recall, withdrawal or market notification.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">MANUFACTURE AND SUPPLY</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion shall have the sole right and responsibility to Manufacture the Licensed Products for the DS Territory, subject to the terms of this Agreement (including DS&#8217;s right and responsibility to conduct primary and secondary packaging of the Bulk Tablets as set forth below), the Supply Agreement and the Quality Agreement&#59; provided, however, that Esperion&#8217;s responsibility to Manufacture the Licensed Products for the DS Territory shall be limited to Manufacturing such Licensed Products in Bulk Tablet form. DS shall have the sole right and responsibility, &#91;***&#93;, for the primary and secondary packaging of the Bulk Tablets supplied by Esperion for commercial use in the DS Territory. Promptly following the Effective Date, the Parties shall negotiate in good faith and shall enter into a supply agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to which Esperion shall supply the Bulk Tablets to DS for Commercialization in the DS Territory. </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Back-Up Manufacturing Right.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Supply Failure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supply Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean a failure, in any &#91;***&#93; consecutive &#91;***&#93;, beginning at least &#91;***&#93;) months after DS&#8217;s First Commercial Sale of a Licensed Product, to supply DS with at least &#91;***&#93; percent (&#91;***&#93;%) of the aggregate quantity of Bulk Tablet ordered by DS as detailed in the Supply Agreement. A Supply Failure shall be considered a material breach of this Agreement&#59; provided that if DS, by written notice to Esperion, exercises its right to Manufacture or have Manufactured the Bulk Tablets, as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Manufacturing Rights) or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CMO Step-In Rights). </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Escrow.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parties will enter into an escrow agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Escrow Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) within &#91;***&#93;) days of the execution of this Agreement. Esperion agrees to deposit in a technology escrow account with a Third Party escrow agent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Escrow Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) under the Escrow Agreement &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Escrowed Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Esperion shall keep the Escrowed Materials current and shall deposit each new or modified item of Esperion Manufacturing Know-How as it is created, obtained or identified.  The Escrowed Materials shall be released to DS upon DS&#8217;s written demand in the event of a Supply Failure.  The Parties shall &#91;***&#93; all charges pursuant to the Escrow Agreement&#59; provided, however, that Esperion will pay all charges pursuant to the Escrow Agreement during each Calendar Year and submit an invoice to DS for &#91;***&#93; (&#91;***&#93;%) of such charges promptly following the end of each Calendar Year.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Manufacturing Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upon the occurrence of a Supply Failure, at DS&#8217;s option, such option to be exercised, if at all, by written notice to Esperion within &#91;***&#93;) days after the occurrence of such Supply Failure (or such longer period as the Parties may agree in writing), DS may Manufacture or have Manufactured, the Bulk Tablets solely for Development and Commercialization in the DS Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">CMO Step-In Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Esperion shall use Commercially Reasonable Efforts to include in each Manufacturing or supply agreement with any Third Party contract manufacturing organization that provides API and Bulk Tablet Manufacturing services (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) engaged by Esperion to Manufacture the Licensed Product for clinical or commercial distribution in the DS Territory a provision that permits DS to, at DS&#8217;s option, such option to be exercised, if at all, by written mutual agreement of the Parties within &#91;***&#93; days after the occurrence of such Supply Failure (or such longer period as the Parties may agree in writing), to engage such CMO directly under Esperion&#8217;s agreement with such CMO or enter into its own agreement with such CMO on substantially the same terms as Esperion in the case of a Supply Failure. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Supply Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS will purchase the Licensed Product at &#91;***&#93; U.S. Dollars cent &#91;***&#93;) per tablet for all SKUs in accordance with the terms and conditions set forth in the Supply Agreement, subject to increases or decreases to such price in connection with newly adopted tariffs or taxes, if any, imposed by competent authorities in the DS Territory on such purchases. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Delivery Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything in the Supply Agreement, Esperion shall deliver the Bulk Tablets to &#91;***&#93; the German Facility (as such term will be defined in the Supply Agreement) and &#91;***&#93; Piramal Facility in the UK or India.  Esperion shall ensure that the Bulk Tablets supplied by Esperion to DS shall have at least &#91;***&#93;) percent of its shelf life remaining at the time of delivery at the German Facility and the Piramal Facility in the UK or India.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Prior to delivery of any Licensed Product by Esperion to DS pursuant to the Supply Agreement, the Parties shall enter into a Quality Agreement, in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which shall govern issues related to the quality of Licensed Product supplied by Esperion under the Supply Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If there are contradictions, conflicts, or inconsistencies related to the quality assurance between the terms of this Agreement and any terms of the Quality Agreement in relation to the quality of the Bulk Tablet, the terms of the Quality Agreement shall control unless otherwise agreed to in writing between the Parties. Should Esperion wish to modify, amend or supplement the specifications of the Bulk Tablet for any reason, it shall so notify DS well in advance, before the change of specification of the Bulk Tablet, and DS shall make a reasonable effort to obtain an authorization from the Regulatory Authority with respect to such change in each country of DS Territory.  If DS cannot obtain approval from a Regulatory Authority in any country of DS Territory Esperion shall continue to provide Bulk Tablet under the approved specification in that country.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">COLLABORATION MANAGEMENT</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Joint Collaboration Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Parties shall establish a joint collaboration committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Joint Collaboration Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) within &#91;***&#93; days after the Effective Date to oversee the Development and Commercialization activities relating to the Licensed Products in the Field in the DS Territory, including reviewing and guiding implementation of the Development in the DS Territory. The JCC shall also be responsible for the enumerated responsibilities set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (JCC Responsibilities).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Composition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The JCC shall be comprised of &#91;***&#93; members, with each Party contributing &#91;***&#93; representatives who are employees of such Party. Each Party shall appoint its respective representatives to the JCC as of the Effective Date and may substitute one or more of its representatives, in its sole discretion, effective upon notice to the other Party of such change. Each Party shall have at least &#91;***&#93; JCC representative who is an executive level employee (vice president or above), and all JCC representatives shall have appropriate expertise, seniority, decision-making authority and ongoing familiarity with the Parties&#8217; activities hereunder.  Additional representatives or consultants may from time to time, by mutual consent of the Parties, be invited to attend JCC meetings, subject to such representatives and consultants (or the representative&#8217;s or consultant&#8217;s employer) undertaking confidentiality obligations, whether in a written agreement or by operation of law, no less stringent than the requirements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Nondisclosure Obligation).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">JCC Co-Chairpersons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The JCC shall be co-chaired by a representative of each of DS and Esperion (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Co-Chairpersons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the name of such representative of each Party to be communicated to the other Party prior to the first scheduled meeting of the JCC.  The Co-Chairpersons&#8217; JCC responsibilities shall include setting the agenda for meetings, conducting meetings, including, when feasible, ensuring that objectives for each meeting are set and achieved and ensuring the objectives and results of each meeting are communicated to the senior management of each Party, in each case in close consultation with the Alliance Managers. A Co-Chairperson can be an Alliance Manager at the same time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;text-decoration:underline">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Within &#91;***&#93;) days following the Effective Date, each Party will appoint (and notify the other Party of the identity of) an employee of such Party having a general understanding in matters related to pharmaceutical development, commercialization, and promotion, to act as its alliance manager under this Agreement (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The Alliance Managers shall be a participant or member, as applicable, of the JCC and will serve as a primary point of contact for the other Party and will undertake such other tasks as are detailed in this Agreement or as may be assigned by the JCC.  Each Alliance Manager shall attend each scheduled meeting of the JCC.  Each Party may change its Alliance Manager at any time in its sole discretion with written notice to the other Party.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt;text-decoration:underline">General Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each Alliance Manager will be responsible to ensure a collaborative work environment between the Parties to ensure that the alliance is run smoothly, professionally and productively.  Each Alliance Manager shall act in his or her discretion to facilitate the execution of the collaboration throughout their organization and will oversee and support implementation plans&#59; promote effectiveness of the governance model and implementation of contractual provisions and lead any changes to enhance the alliance between both Parties&#59; and facilitate the JCC (and other bodies) for effective decision making in a timely manner.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;text-decoration:underline">Specific Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Alliance Managers shall be responsible for (i) scheduling meetings of the JCC, (ii) setting agendas for meetings with solicited input from other members and (iii) for acting as secretary at each meeting and preparing the draft minutes of such meeting, which shall provide a description in reasonable detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by the JCC.  Within &#91;***&#93; days after each meeting, the drafting Alliance Manager shall provide the draft minutes to the other Alliance Manager for review and comment.  The drafting Alliance Manager shall reasonably consider all comments from the other Alliance Manager that are provided within &#91;***&#93; days. The drafting Alliance Manager shall prepare and submit revised final draft minutes for approval within &#91;***&#93; days after receipt of such comments or upon the expiration of such &#91;***&#93; day comment period.  Beginning with DS&#8217;s Alliance Manager, such responsibilities shall alternate between the Alliance Managers on a meeting-by-meeting basis after each meeting of the applicable committee.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The JCC shall meet, unless mutually agreed to by the Parties, no less frequently than each &#91;***&#93; during the Term&#59; provided, however, that the frequency of JCC meetings can be adjusted upon the consent of both Parties. Meetings can be conducted in person or by means of teleconference, videoconference or other similar communications equipment. All meetings and proceedings for the JCC shall take place in English.  Each Party shall bear its own expenses relating to attendance at such meetings by its representatives.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">JCC Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The JCC shall have the following responsibilities with respect to the Development, Manufacturing and Commercialization of Licensed Products pursuant to this Agreement&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">discussing, reviewing and approving the Development Plans and amendments or modifications to the Development Plans&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">discussing, reviewing and approving the Development of new formulations of Licensed Products&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">discussing and reviewing the implementation of the Development Plans, and reviewing the status and results of such Development Plans&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">discussing, reviewing and approving Clinical Studies, including post-marketing studies proposed to be sponsored or supported (through supply of Licensed Products) by DS or Esperion (in respect of the Development Pre-Approval Clinical Studies in South Korea and Taiwan), as detailed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development in South Korea and Taiwan)), of Licensed Products in the DS Territory, including the approval of the relevant study design or summary of the relevant protocol and related documentation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">discussing and reviewing the status of Licensed Products, including material Development and Manufacturing matters in the Esperion Territory and the DS Territory&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">discussing and reviewing the Global Branding Strategy&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">discussing, reviewing and approving the DS Territory Commercialization Plans and amendment or modifications to the DS Territory Commercialization Plans&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">discussing and reviewing the implementation of such DS Territory Commercialization Plans, and reviewing the status and results of such DS Territory Commercialization Plans&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">reviewing representative samples of DS Territory Promotional Materials developed for use in the DS Territory as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DS Advertising &#38; Promotional Materials)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">discussing, reviewing and approving Trademarks for the DS Territory pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Product Trademarks)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">reviewing a publication strategy pursuant to which the Parties may publish certain key results achieved in connection with this Agreement as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Publication)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">overseeing the JCC&#8217;s subcommittees and ensuring effective participation in each such committee&#8217;s operations by any of its members&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">addressing any other matters regarding the Development, and Manufacturing of Licensed Products referred to the JCC by the terms of this Agreement&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">performing such other activities as the Parties agree in writing shall be the responsibility of the JCC.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">JCC Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;text-decoration:underline">Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  With respect to decisions of the JCC, the representatives of each Party shall have collectively one (1) vote on behalf of such Party.  For each meeting of the JCC, the attendance of at least &#91;***&#93; representatives of each Party shall constitute a quorum. Action on any matter may be taken at a meeting, by teleconference, by videoconference or by written agreement.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt;text-decoration:underline">Escalation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The JCC shall attempt to resolve any and all decisions and disputes before it by consensus.  If the JCC is unable to reach consensus with respect to a decision or dispute regarding any matter within the JCC&#8217;s responsibilities for a period in excess of &#91;***&#93; days, then the dispute shall be submitted to the Chief Executive Officers of Esperion and DS or his or her designee for resolution.  If such dispute cannot be resolved for a period in excess of &#91;***&#93;) days following escalation (or such other period as the Parties may agree), then </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1.7(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Tie-Breaking) shall apply.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;text-decoration:underline">Tie-Breaking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If a dispute cannot be resolved under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Escalation), then&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">The Chief Executive Officer of DS or his or her designee shall have the deciding vote if the dispute relates to &#91;***&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">The Chief Executive Officer of Esperion shall have the deciding vote if the dispute relates to&#58;</font></div><div style="margin-bottom:9pt;padding-left:216pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:9pt;padding-left:216pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:9pt;padding-left:216pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">&#91;***&#93;.&#91;***&#93;.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">&#91;***&#93;. </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the avoidance of doubt, all matters relating to the Development, Manufacturing and Commercialization of the Licensed Products in the Esperion Territory shall be decided by Esperion and shall not be subject to decision-making by the JCC.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt;text-decoration:underline">Limitation of Power of JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Neither the JCC nor any subcommittee of the JCC shall have decision-making authority regarding any of the following matters, and neither Party shall be permitted to exercise its tie-breaking authority under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1.7(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Tie-Breaking), such that the resulting decision would have any of the following results&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the imposition of any requirements on the other Party to undertake obligations beyond those for which it is responsible, or forgo any rights, under this Agreement&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the imposition of any requirements that the other Party take or decline to take any action that would result in a violation of any Law or any agreement with any Third Party or the infringement of intellectual property rights of Third Parties&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">any matters that would excuse such Party from any of its obligations specifically enumerated under this Agreement&#59; or</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">modifying the terms of this Agreement or taking any action to expand or narrow the responsibilities of the JCC (but excluding amendments and modifications to any schedules or exhibits to this Agreement that are expressly permitted under this Agreement).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Parties or the JCC shall have the right to create such subcommittees of the JCC as they or it may deem appropriate or necessary (such as a finance subcommittee, or other appropriate subcommittees).  Each such subcommittee shall report to the JCC, which shall have authority to approve or reject recommendations or actions proposed thereby, subject to the terms of this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Collaboration Principles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In performing its obligations and exercising its rights hereunder (including acting through its executives, representatives on any of the committees and its Alliance Managers), each Party &#91;***&#93; to undertake and perform its obligations in a timely and efficient manner &#91;***&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All information disclosed by either Party or its representatives to the other Party or its representatives under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Collaboration Management) shall be deemed to be Confidential Information of the disclosing Party and maintained in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Confidentiality and Publication).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Parties may meet from time to time to discuss whether any changes to the governance structure for the Parties&#8217; activities hereunder are necessary or advisable.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">CONFIDENTIALITY AND PUBLICATION</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Nondisclosure Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">All Confidential Information disclosed by one Party to the other Party under this Agreement shall be maintained in confidence by the receiving Party and shall not be disclosed to a Third Party or used for any purpose except as set forth herein without the prior written consent of the disclosing Party, except to the extent that such Confidential Information&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party&#8217;s business records&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">is known to the public before its receipt from the disclosing Party, or thereafter becomes known to the public through no breach of this Agreement by the receiving Party&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">is subsequently disclosed to the receiving Party by a Third Party who is not known by the receiving Party to be under an obligation of confidentiality to the disclosing Party&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">is developed by the receiving Party independently of Confidential Information received from the disclosing Party, as documented by the receiving Party&#8217;s business records.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">Notwithstanding the obligations of confidentiality and non-use set forth above and in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Nondisclosure Obligation) below, a receiving Party may provide Confidential Information disclosed to it, and disclose the existence and terms of this Agreement as may be reasonably required in order to perform its obligations and to exploit its rights under this Agreement, and specifically to (i) Related Parties, and their employees, directors, agents, consultants, advisors or other Third Parties for the performance of its obligations hereunder in accordance with this Agreement in each case who are under an obligation of confidentiality with respect to such information that is no less stringent than the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Nondisclosure Obligation)&#59; (ii) Governmental Authorities or other Regulatory Authorities, Statutory Accountants or tax and legal advisors in order to obtain patents, comply with statutory tax and legal requirements in any country or perform its obligations or exploit its rights under this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that such Confidential Information shall be disclosed only to the extent reasonably necessary to do so&#59; (iii) the extent required by Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or listing entity&#59; and (iv) (a) any bona fide actual or prospective underwriters, investors, lenders or acquirers of a Party or substantially all of its assets and to consultants and advisors of such Third Party, and (b) any bona fide actual or prospective collaborators or strategic partners and to consultants and advisors of such Third Party, in each case of (a) and (b) during bona fide business discussions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the receiving party of such information is under an obligation of confidentiality of reasonable scope and duration with respect to such information.  If a Party is required by Law to disclose Confidential Information that is subject to the non-disclosure provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Nondisclosure Obligation), such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure.  Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Nondisclosure Obligation), Confidential Information that is required to be disclosed by Law shall remain otherwise subject to the confidentiality and non-use provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Nondisclosure Obligation).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If either Party concludes that a copy of any of this Agreement must be filed with the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States, such Party shall provide the other Party with a copy of such agreement showing any provisions hereof as to which the Party proposes to request confidential treatment, shall provide the other Party with an opportunity to comment on any such proposed redactions and to suggest additional redactions, and shall take such Party&#8217;s comments into consideration before filing such agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">Each Party recognizes that the value to the other Party of the transactions under this Agreement depend, in part, on each Party protecting the secrecy of its Know-How. Therefore, without limiting any Party&#8217;s right to license its Know-How, subject to the terms of this Agreement, in any way it chooses, each Party shall use Commercially Reasonable Efforts to protect the confidentiality of its Know-How as determined in such Party&#8217;s reasonable business judgment.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Publication and Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The JCC shall develop a publication strategy pursuant to which the Parties may publish certain key results achieved in connection with this Agreement, including in connection with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development of the Licensed Products.  All publications of such key results shall also be subject to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Publication).  Except for disclosures permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Nondisclosure Obligation) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Publicity), either Party wishing to make a publication or public presentation regarding any such key results, or that contains the Confidential Information of the other Party, shall deliver to the other Party a copy of the proposed written publication or presentation at least &#91;***&#93; days prior to submission for publication or presentation. The reviewing Party shall have the right (i) to require modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons, and the publishing Party shall remove all Confidential Information of the other Party if requested by the reviewing Party, or (ii) to request a reasonable delay in publication or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party shall delay submission or presentation for a period of one hundred and &#91;***&#93; days to enable the non-publishing Party to file patent applications protecting such Party&#8217;s rights in such information.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Nondisclosure Obligation) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Publication) above and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Press Release) below, the terms of any of this Agreement may not be disclosed by either Party.  Neither Party shall use the name,  Trademark or trade name or logo of the other Party or its employees in any publicity, news release or disclosure relating to any of this Agreement, its subject matter, or the activities of the Parties hereunder without the prior express written permission of the other Party, except as may be required by Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in any country other than the United States or of any stock exchange or listing entity, or except as expressly permitted by the terms hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the execution of this Agreement, the Parties may each issue a press release in substantially the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Press Releases) or such other forms mutually agreed by the Parties.  After such initial press releases, neither Party shall issue a press release or public announcement relating to the Parties&#8217; respective rights and obligations under this Agreement without the prior written approval of the other Party, not to be unreasonably withheld, conditioned or delayed, except that the Parties  may (i) once a press release or other public statement is approved in writing by both Parties, make subsequent public disclosure of the information contained in such press release or other written statement without the further approval of the other Party, and (ii) issue a press release or public announcement as required, in the reasonable judgment of such Party, by Law, including by the rules or regulations of the United States Securities and Exchange Commission, or similar regulatory agency in a country other than the United States or of any stock exchange or listing entity on which such Party desires to list or does list its securities.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The provisions in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Confidentiality and Publication) shall survive the expiration or the termination of this Agreement for a period of &#91;***&#93; years thereafter, except that with respect to trade secrets, such provisions and obligations shall survive for as long as the trade secrets remain secret.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">LICENSES</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">License Grants to DS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Exclusive License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, Esperion hereby grants to DS a non-transferable (except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Assignment)), sublicensable (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DS Sublicense Rights)), exclusive (even as to Esperion and its Affiliates, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development in South Korea and Taiwan)) license under the Esperion Technology, Esperion&#8217;s interest in the Joint Technology, and the Esperion Trademarks to Develop (but solely to the extent necessary for DS to conduct the Development activities set forth in the applicable Development Plan in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development Plans), have Developed (but solely to the extent necessary for DS to conduct the Development activities set forth in the applicable Development Plan in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Development Plans)), Manufacture (but solely in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Licensed Products) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Back-Up Manufacturing Rights), have Manufactured (but solely in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Licensed Products) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Back-Up Manufacturing Rights)) and Commercialize Licensed Products in the Field in the DS Territory. The license granted hereunder shall be royalty-bearing for the Royalty Term applicable to each Licensed Product in the DS Territory, and, after the Royalty Term applicable to such Licensed Product, shall convert to a fully-paid, royalty-free perpetual license. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">DS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sublicense Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS shall have the right to sublicense any of its rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Exclusive License Grant) to any of its Affiliates or to any Third Party without the prior consent of Esperion, subject to the requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DS Sublicense Rights). Each sublicense granted by DS pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DS Sublicense Rights) shall be subject and subordinate to the terms of this Agreement and shall contain provisions consistent with those in this Agreement. DS shall promptly provide Esperion with a copy of the fully executed sublicense agreement covering any sublicense granted hereunder to a Third Party (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DS Sublicense Rights)), and each such sublicense agreement shall contain the following provisions&#58; (i) a requirement that the Sublicensee comply with the confidentiality and non-use provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Confidentiality and Publication) with respect to Esperion&#8217;s Confidential Information and (ii) a requirement that the Sublicensee submit applicable sales or other reports to DS to the extent necessary or relevant to the reports required to be made or records required to be maintained under this Agreement. Notwithstanding any sublicense, DS shall remain primarily liable to Esperion for the performance of all of DS&#8217;s obligations under, and DS&#8217;s compliance with all provisions of, this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as specifically set forth in this Agreement, neither Party shall acquire any license or other right or interest, by implication or otherwise, in any intellectual property rights of the other Party or any of its Affiliates.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">License Grants to Esperion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">License Grant for Esperion Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, DS hereby grants Esperion a non-transferable (except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Assignment)), sublicensable (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Esperion Sublicense Rights)), non-exclusive, royalty-free license under the DS Technology for all uses in connection with any Licensed Product in the Esperion Territory.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Esperion Sublicense Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion shall have the right to sublicense any of its rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (License Grant for Esperion Territory) to any of its Affiliates or to any Third Party without the prior consent of DS, subject to the requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Esperion Sublicense Rights). Each sublicense granted by Esperion pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Esperion Sublicense Rights) shall be subject and subordinate to this Agreement and shall contain provisions consistent with those in this Agreement.  Esperion shall promptly provide DS with a copy of the fully executed sublicense agreement covering any sublicense granted hereunder (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Esperion Sublicense Rights)), and each such sublicense agreement shall contain a requirement that the Sublicensee comply with the confidentiality and non-use provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Confidentiality and Publication) of this Agreement with respect to DS&#8217;s Confidential Information.  Notwithstanding any sublicense, Esperion shall remain primarily liable to DS for the performance of all of Esperion&#8217;s obligations under, and Esperion&#8217;s compliance with all provisions of, this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Option to Expand the DS Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">Subject to the terms and conditions of this Agreement, Esperion hereby grants to DS an exclusive option to expand the DS Territory to include the Middle East Option Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Middle East Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). DS may exercise the Middle East Option during the Option Period by providing written notice to Esperion during the Option Period that it elects to exercise the Middle East Option&#59; provided, however, that DS may not exercise the Middle East Option unless and until it has entered into a sublicense agreement with a Third Party, on terms that are approved by Esperion, pursuant to which DS grants such Third Party a sublicense to Develop, Manufacture (but solely to the extent necessary to conduct primary and secondary packaging of the Bulk Tablets) and Commercialize the Licensed Products in the Middle East Option Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Middle East Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). From and after the date on which DS exercises the Middle East Option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Middle East</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and continuing until the expiration or earlier termination of the Middle East Sublicense, the DS Territory shall include the Middle East Option Territory&#59; provided, however, that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Commercial Milestones) will not apply to the Middle East Option Territory&#59; and provided further, that DS shall pay to Esperion fifty percent (50%) of upfront payments and royalty received by DS under the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Middle East Sublicense in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Audits), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Payment), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Late Payment), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Taxes) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Payment of Back Royalties). </font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33pt">Subject to the terms and conditions of this Agreement, Esperion hereby grants to DS an exclusive option to expand the DS Territory to include the Latin American Option Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Latin American Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). DS may exercise the Latin American Option  during the Option Period by providing written notice to Esperion during the Option Period that it elects to exercise the Latin American Option&#59; provided, however, that DS may not exercise the Latin American Option unless and until it has entered into a sublicense agreement with a Third Party to be mutually agreed to by the Parties, on terms that are approved by Esperion, pursuant to which DS grants to such Third Party an exclusive sublicense to Develop, Manufacture (but solely to the extent necessary to conduct primary and secondary packaging of the Bulk Tablets) and Commercialize the Licensed Products in the Latin American Option Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Latin American Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). From and after the date on which DS exercises the Latin American Option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Latin American Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and continuing until the expiration or earlier termination of the Latin American Sublicense, the DS Territory shall include the Latin American Option Territory&#59; provided, however, that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Commercial Milestones) will not apply to the Latin American Option Territory. The specific terms for the Latin American Sublicense between Esperion and DS shall be discussed and agreed during the Option Period, however </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Audits), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Payment), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Late Payment), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Taxes) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Payment of Back Royalties) of this Agreement shall apply.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  For the avoidance of doubt, notwithstanding the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (License Grants to DS) or any other provision of this Agreement, Esperion shall retain rights under the Esperion Patent Rights, Esperion Know-How, Regulatory Documentation, Esperion Trademarks and Esperion house marks to (a) perform its responsibilities under this Agreement or any ancillary agreement&#59; and (b) Develop and Manufacture the Licensed Product in the Territory for purposes of the Development of the Licensed Product worldwide and Commercialization of the Licensed Product outside the DS Territory and the DSE Territory.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as specifically set forth in this Agreement, neither Party shall acquire any license or other right or interest, by implication or otherwise, in any intellectual property rights of the other Party or any of its Affiliates.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Bankruptcy and Section 365(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All rights and licenses granted under or pursuant to this Agreement by a Party to the other, including those set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Licenses) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Right of Reference), are and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or the equivalent of the foregoing in any foreign counterpart thereto, as applicable, (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), licenses of right to &#8220;intellectual property&#8221; as defined under Bankruptcy Code.  The Parties agree that the Parties and their respective Sublicensees, as Sublicensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the Bankruptcy Code. The Parties further agree that upon commencement of a proceeding by or against a Party (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) under the Bankruptcy Code, the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) will be entitled to a complete duplicate of, or complete access to (as the Non-Bankrupt Party deems appropriate), all such intellectual property and all embodiments of such intellectual property.  Such intellectual property and all embodiments of such intellectual property will be promptly delivered to the Non-Bankrupt Party (a) upon any such commencement of a proceeding and upon written request by the Non-Bankrupt Party, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Bankrupt Party and upon written request by the Non-Bankrupt Party. All rights, powers and remedies of a Non-Bankrupt Party hereunder are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at Law in the event of the commencement of a proceeding under a Bankruptcy Code with respect to the Bankrupt Party. The Parties agree that, in addition to the foregoing rights, they intend for the right to contract directly with any Third Party to perform any obligations of the Bankrupted Party hereunder and complete such contracted work to apply to the maximum extent permitted by law and to be enforceable under the Bankruptcy Code. All written agreements entered into or in connection with the Parties&#8217; performance hereunder from time to time are considered agreements &#8220;supplementary&#8221; to this Agreement for purposes of section 365(n).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">No Other Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as otherwise expressly provided in this Agreement, under no circumstances shall a Party, as a result of this Agreement, obtain any ownership interest or other right in any Know-How, Patent Rights or other intellectual property rights of the other Party, including items owned, controlled or developed by the other Party, or provided by the other Party to the receiving Party at any time pursuant to this Agreement.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">FINANCIAL TERMS&#59; ROYALTY REPORTS&#59; PAYMENTS AND AUDITS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As partial consideration for the licenses and rights granted to DS hereunder, DS shall, within &#91;***&#93;) business days after the Effective Date and upon receiving an invoice from Esperion, pay Esperion a one-time, non-creditable, non-refundable (other than as described later in this Section), non-reimbursable upfront fee of Thirty Million United States dollars ($30,000,000).  In accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Taxes), the payment date of the upfront payment can be extended by Esperion at its own discretion for a period of &#91;***&#93;) days without any obligation of DS to pay interest according to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Late Payments).  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline"> Commercial Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  DS shall provide Esperion with written notice of the achievement by DS or any of its Related Parties of any commercial milestone event set forth below in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Commercial Milestones) within &#91;***&#93;&#91;***&#93; days after the end of the Fiscal Quarter in which such event has occurred.  Esperion shall invoice DS within &#91;***&#93;) days of receipt of such written notice by DS, and DS shall remit the associated milestone payment within &#91;***&#93; days of the receipt of such invoice.  The Parties acknowledge that more than one commercial milestone payment may become due and payable in any given Fiscal Year.  Each commercial milestone payment set forth below shall be payable only once, regardless of the number of times a commercial milestone event is achieved.  </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:70.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c4bc96;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commercial Milestone Event</font></td><td colspan="3" style="background-color:#c4bc96;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commercial Milestone Payment (USD)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Royalties Payable to Esperion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Royalty Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, DS shall pay to Esperion royalties on Net Sales for a Fiscal Year by DS and its Related Parties of Licensed Products during the Royalty Term, as follows&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:56.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c4bc96;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Net Sales for a Fiscal Year</font></td><td colspan="3" style="background-color:#c4bc96;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Royalty<br>(as a percentage of Net Sales)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Portion less than or equal to &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Portion greater than &#91;***&#93; and less than or equal to &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Portion greater than &#91;***&#93; and less than or equal to &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Portion greater than &#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20%</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The period during which the royalties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Royalty Rates) and the sales milestones set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Commercial Milestones) shall be payable, on a Licensed Product-by-Licensed Product and country-by-country basis, shall commence with the First Commercial Sale of a Licensed Product in a country and continue until the latest of (a) the date of expiration of the last Valid Claim of the  Esperion Patent Rights that covers such Licensed Product in such country, (b) the expiration of Regulatory Exclusivity for such Licensed Product in such country, and (c) the &#91;***&#93; anniversary of the First Commercial Sale of such Licensed Product in such country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt;text-decoration:underline">Market Entry of Generic Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On a Licensed Product-by-Licensed Product, country-by-country and &#91;***&#93; basis&#58; </font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">if one or more Generic Products have, in the aggregate, obtained a market share in such country in the DS Territory with respect to such Licensed Product during such &#91;***&#93; equals or exceeds &#91;***&#93; percent &#91;***&#93;%) but is less than &#91;***&#93; percent (&#91;***&#93;%) of the combined number of units of such Licensed Product and Generic Product sold, as such Generic Product sales are evidenced by creditable independent market data or other evidence of similar credibility, then DS shall pay to Esperion a reduced royalty rate on Net Sales of such Licensed Product in such country during such &#91;***&#93; equal to &#91;***&#93; percent (&#91;***&#93;%) of the royalty rate applicable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Royalty Rates).</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33pt">If one or more Generic Products have, in the aggregate, obtained a market share in such country in the DS Territory with respect to such Licensed Product during such &#91;***&#93; equals or exceeds &#91;***&#93; percent (&#91;***&#93;%) of the combined number of units of such Licensed Product and Generic Product sold, as such Generic Product sales are evidenced by creditable independent market data or other evidence of similar credibility, then DS shall pay to Esperion a reduced royalty rate on Net Sales of such Licensed Product in such country during such &#91;***&#93; equal to &#91;***&#93; percent (&#91;***&#93;%) of the royalty rate applicable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Royalty Rates).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Reports&#59; Payment of Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DS shall provide Esperion with a written report within &#91;***&#93; days after the end of each &#91;***&#93; showing, on a Licensed Product-by-Licensed Product basis, the Net Sales of each Licensed Product in the DS Territory, the number of units of Licensed Product sold during such &#91;***&#93; in the DS Territory and the royalties payable under this Agreement with respect to each such Licensed Product.  Royalties shown to have accrued by each royalty report shall be due and payable within &#91;***&#93;) days after the end of the applicable Fiscal Quarter.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">Upon the written request of either Party, and not more than &#91;***&#93; in each Calendar Year, the other Party and its Affiliates shall permit an independent certified public accounting firm of internationally-recognized standing selected by the requesting Party and reasonably acceptable to the other Party, at the requesting Party&#8217;s expense except as set forth below, to have access during normal business hours to such of the records of the other Party as may be reasonably necessary to verify the accuracy of the royalty and other amounts payable or reports under this Agreement for any year ending not more than &#91;***&#93;) years prior to the date of such request for the sole purpose of verifying the basis and accuracy of payments made and compliance with the financial terms of this Agreement.  Notwithstanding the foregoing, a Party may not make more than &#91;***&#93; such request in a Calendar Year.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">If such accounting firm identifies a discrepancy made during such period, the appropriate Party shall pay the other Party the amount of the discrepancy, within &#91;***&#93;) days after the date the requesting Party delivers to the other Party such accounting firm&#8217;s written report so concluding, or as otherwise agreed by the Parties in writing. The fees charged by such accounting firm shall be paid by the requesting Party, unless such discrepancy represents an underpayment by the other Party of at least &#91;***&#93; percent (&#91;***&#93;%) of the payments due in the audited period, in which case such fees shall be paid by the other Party.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">Unless an audit for such year has been commenced prior to and is ongoing upon the &#91;***&#93; anniversary of the end of such year, the calculation of royalties, expense reimbursement and other payments payable with respect to such year shall be binding and conclusive upon both Parties, and each Party and its Related Parties shall be released from any further liability or accountability with respect to such royalties or expense reimbursement for such year.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">Each Party shall treat all financial information subject to review under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Audits) or under any sublicense agreement in accordance with the confidentiality and non-use provisions of Section 7 (Confidentiality and Publication), and shall cause its accounting firm to enter into a confidentiality agreement with the other Party or its Related Parties obligating it to retain all such information in confidence pursuant to such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confidentiality agreement, which terms shall be no less stringent than the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Confidentiality and Publication).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Payment&#59; Exchange Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All payments to be made under this Agreement shall be made in United States Dollars (legal tender of the United States of America). In the case of Net Sales made by DS and its Related Parties in currencies other than United States dollars during a Calendar Quarter, the rate of exchange to be used in computing the amount of United States dollars due shall be DS&#8217;s then current standard exchange rate methodology as applied in its external reporting for the conversion of foreign currency sales into United States dollars.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline"> Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If a Party does not receive payment of any sum due to it on or before the due date therefor, simple interest shall thereafter accrue on the sum due to such Party from the due date until the date of payment at a per-annum rate of &#91;***&#93; percent &#91;***&#93;%), or the maximum rate allowable by Applicable Law, whichever is less.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline"> Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party shall use reasonable efforts to minimize tax withholding on payments made to the other Party.  Notwithstanding such efforts, if the Party who pays and remits the amount (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remitter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) concludes that tax withholdings under the Laws of any country are required with respect to payments to the other Party (the Party who receive the amount (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)), the Remitter shall first notify the Recipient and provide the Recipient with &#91;***&#93; days to determine whether there are actions the Recipient can undertake to avoid such withholding.  During this notice period, the Remitter shall refrain from making such payment in accordance with what is stated under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Upfront Payment) above until the Recipient instructs the Remitter that (a) the Recipient intends to take actions (satisfactory to both Parties) that shall obviate the need for such withholding, in which case the Remitter shall make such payment only after it is instructed to do so by the Recipient (but in no event greater than &#91;***&#93; days after the date the payment was originally due) and without any obligation to pay interest under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Late Payments), or (b) the Remitter should make such payment and withhold the required amount and pay it to the appropriate Governmental Authority in accordance with the timelines defined by applicable tax law and the Remitter shall provide the Recipient in a reasonable time period with copies of receipts or other evidence reasonably required and sufficient to allow the Recipient to document such tax withholdings adequately for purposes of claiming foreign tax credits and similar benefits,  the Parties shall cooperate reasonably in completing and filing documents required under the provisions of any applicable tax laws or under any other applicable Law, in connection with the making of any required tax payment or withholding payment, or in connection with any claim to a refund of or credit for any such payment, and the Parties shall cooperate to minimize such taxes in accordance with applicable Laws, including using reasonable efforts to access the benefits of any applicable treaties.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">  Payment of Back Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If DS would owe a royalty payment to Esperion under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Financial Terms&#59; Royalty Reports&#59; Payments and Audits) but for a decision by a court or other governmental agency of competent jurisdiction holding a patent claim unenforceable, unpatentable or invalid and if such decision is later vacated or reversed by a final non-appealable decision by a court or other governmental agency of competent jurisdiction, Esperion may invoice DS for such unpaid royalty payments after such decision is vacated or reversed and DS shall make any such unpaid royalty payments to Esperion within &#91;***&#93; days after receipt of such invoice but without any obligation to pay interest under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Late Payments).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline">  Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  All payments to be made under this Agreement shall be paid by bank wire transfer in immediately available funds to Esperion&#8217;s following designated bank account&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bank Name&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bank Address&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABA #&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Swift&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficiary&#58; &#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficiary Address&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficiary Account #&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFC Account Name&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFC Account Number&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Esperion may from time to time designate formally in writing another bank account in the United States to which DS shall thereafter make all payments hereunder.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt;text-decoration:underline">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Mutual Representations and Warranties as of the Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Party represents and warrants to the other Party that, as of the Effective Date&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">Such Party is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation or formation.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">Such Party has all requisite corporate power and corporate authority to enter into this Agreement and to carry out its obligations under this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">All requisite corporate action on the part of such Party, its directors and stockholders required by applicable Law for the authorization, execution and delivery by such Party of this Agreement, and the performance of all obligations of such Party under this Agreement, has been taken.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">The execution, delivery and performance of this Agreement, and compliance with the provisions of this Agreement, by such Party do not and shall not&#58; (a) violate any provision of applicable Law or any ruling, writ, injunction, order, permit, judgment or decree of any Governmental Authority, (b) constitute a breach of, or default under (or an event which, with notice or lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, any agreement, arrangement or instrument, whether written or oral, by which such Party or any of its assets are bound, or (c) violate or conflict with any of the provisions of such Party&#8217;s organizational documents (including any articles or memoranda of organization or association, charter, bylaws or similar documents).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">No consent, approval, authorization or other order of, or filing with, or notice to, any Governmental Authority or other Third Party is required to be obtained or made by such Party in connection with the authorization, execution and delivery by the Parties of this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Representations, Warranties and Covenants of Esperion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Esperion represents, warrants and covenants to DS that, as of the Effective Date&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">Esperion has sufficient legal or beneficial title and ownership of, or sufficient license rights under, the Esperion Technology to grant the licenses under such Esperion Technology to DS pursuant to this Agreement, free and clear of all liens, claims, security interests or other encumbrances of any kind (including prior license grants) that would interfere, or the exercise of which would interfere, with DS&#8217;s exercise of the licenses or rights granted hereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">the Esperion Third Party Agreements constitute all agreements pursuant to which Esperion has granted licensed rights to DS with respect to the Esperion Technology hereunder, and Esperion has provided DS with a complete, true and correct copy of each Esperion Third Party Agreement existing as of the Effective Date, and (i) each such agreement is, and shall remain during the Term, in full force and effect, (ii) Esperion is, and shall remain during the Term, in compliance with the terms of each such agreement, and (iii) Esperion has not received any written notice that it is not in such compliance.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">Esperion and its Affiliates will not materially breach or be in material default under any contract with any Third Party (i) that is necessary for Esperion and its Affiliates to perform Esperion&#8217;s obligations under this Agreement&#59; (ii) the termination of which would materially diminish the scope, exclusivity or any other right of DS hereunder&#59; or (iii) that is an Esperion Third Party Agreement.  In the event that Esperion receives notice of an alleged material breach by Esperion or its Affiliates under any such Esperion Third Party Agreement, where termination of such Esperion Third Party Agreement or any diminishment of the scope, exclusivity or any other right of DS or obligation of Esperion hereunder is being or could be sought by the counterparty, then Esperion will promptly, but in no event less than &#91;***&#93; days thereafter, provide written notice thereof to DS.  Esperion will not amend any such Esperion Third Party Agreements in any manner than materially adversely affects DS&#8217;s rights hereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Schedule 10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Existing Esperion Patent Rights) sets forth a complete and accurate list of the Esperion Patent Rights owned, either solely or jointly, by Esperion,  (b) to Esperion&#8217;s knowledge, the Esperion Patent Rights are, or, upon issuance, will be, valid and enforceable patents and no Third Party has challenged or threatened to challenge the scope, validity or enforceability of any Esperion Patent Rights (including, by way of example, through opposition or the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority), and (c) Esperion or its Affiliates have timely paid all filing and renewal fees payable with respect to such Esperion Patent Rights for which Esperion controls prosecution and maintenance.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">Esperion has not granted, and shall not grant during the Term, any right to any Third Party or Governmental Authority which would conflict with the rights granted to DS hereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">Esperion shall not enter into any agreement with any Third Party that would conflict with, limit or restrict the rights granted to DS under this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">Esperion is not party to or otherwise subject to any agreement or arrangement which limits the ownership or licensed rights of Esperion or its Affiliates with respect to, or limits the ability of Esperion or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in, to or under, any intellectual property right or material (including any Patent Right, Know-How or other data or information), in each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned to Esperion or its Affiliates pursuant to this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">to Esperion&#8217;s knowledge, Esperion has complied, or timely cured any noncompliance, with all applicable Laws, including any duties of candor to applicable patent offices, in connection with the filing, prosecution and maintenance of the Esperion Patent Rights.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11pt">Esperion has obtained from all inventors of Esperion Technology owned by Esperion valid and enforceable agreements assigning to Esperion each such inventor&#8217;s entire right, title and interest in and to all such Esperion Technology.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">the Development, Manufacture or Commercialization in the DS Territory of any Licensed Product as formulated and manufactured as of the Effective Date does not and will not infringe any patent of any Third Party, whether published as of the Effective Date or issuing at any time thereafter.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">notwithstanding anything to the contrary contained in this Agreement, the representations and warranties of Esperion contained in this Agreement, all materials prepared by Esperion and provided by Esperion to DS and all materials prepared by any Third Party and provided by Esperion to DS do not, to Esperion&#8217;s knowledge, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Warranty Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY TECHNOLOGY, ESPERION TECHNOLOGY (WITH RESPECT TO ESPERION), PRODUCT, PROGRAM, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THE AGREEMENT AND HEREBY </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.  EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY LICENSED PRODUCT PURSUANT TO THIS AGREEMENT SHALL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY LICENSED PRODUCT SHALL BE ACHIEVED.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  For the first &#91;***&#93; years of the Term of this Agreement, neither Party nor their Affiliates shall, either alone or with or through Third Parties, &#91;***&#93;. For the first &#91;***&#93;) years of the Term of this Agreement, neither Party nor their Affiliates shall, either alone or with or through Third Parties, &#91;***&#93;.  Notwithstanding the foregoing limitations, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Exclusivity) shall limit, restrict or impair DS&#8217;s and its Affiliates&#8217; right to continue to develop, manufacture, sell, offer for sale, or have sold &#91;***&#93; during the Term of this Agreement.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Certain Other Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DS and its Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall Develop, Manufacture and Commercialize the Licensed Products in material compliance with this Agreement and all applicable Laws, including current governmental regulations concerning GLP, GCP and cGMP.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Conflicting Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DS shall not enter into any agreement with any Third Party that would conflict with, limit or restrict DS&#8217;s ability to comply with its obligations under this Agreement. Esperion shall not enter into any agreement with any Third Party that would conflict with, limit or restrict Esperion&#8217;s ability to comply with its obligations under this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">No Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each Party shall use Commercially Reasonable Efforts to not use, in any capacity in connection with this Agreement or the performance of its obligations under this Agreement, any Person that has been debarred pursuant to Section 306 of the FD&#38;C Act, or that is the subject of a conviction described in such section.  Each Party agrees to inform the other Party in writing immediately if it or any Person that is performing activities under this Agreement, is debarred or is subject to debarment or is the subject of a conviction described in Section 306, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of such Party&#8217;s knowledge, is threatened, relating to the debarment or conviction of such Party&#8217;s or any Person or entity used in any capacity by such Party or any Affiliates in connection with performance of its other obligations under this Agreement.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt;text-decoration:underline">INDEMNIFICATION&#59; LIMITATION OF LIABILITY&#59; INSURANCE</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General Indemnification by DS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS shall indemnify, hold harmless and defend Esperion, its Related Parties, and their respective directors, officers, employees and agents (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) from and against any and all Third Party claims, suits, losses, liabilities, damages, costs, fees and expenses (including reasonable attorneys&#8217; fees and litigation expenses) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) arising out of or resulting from, directly or indirectly, (a) any breach of, or inaccuracy in, any representation or warranty made by DS in this Agreement, or any breach or violation of any covenant or agreement of DS in or in the performance of this Agreement, (b) the Development or Commercialization of the Licensed Product by or on behalf of DS or its Related Parties in the DS Territory, or (c) the negligence or willful misconduct by or of DS and its Related Parties, and their respective directors, officers, employees and agents in the performance of DS&#8217;s obligations under this Agreement. DS shall have no obligation to indemnify the Esperion Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, any breach of, or inaccuracy in, any representation or warranty made by Esperion in this Agreement, or any breach or violation of any covenant or agreement of Esperion in or in the performance of this Agreement, or the negligence or willful misconduct by or of any of the Esperion Indemnitees, or matters for which Esperion is obligated to indemnify DS Indemnitees under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (General Indemnification by Esperion).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General Indemnification by Esperion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion shall indemnify, hold harmless, and defend DS, its Related Parties and their respective directors, officers, employees and agents (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) from and against any and all Third Party Losses arising out of or resulting from, directly or indirectly (a) any breach of, or inaccuracy in, any representation or warranty made by Esperion in this Agreement, or any breach or violation of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">covenant or agreement of Esperion in or in the performance of this Agreement, (b) the Development or Commercialization of the Licensed Products by or on behalf of Esperion or any of its Affiliates in the Esperion Territory, or (c) the negligence or willful misconduct by or of Esperion and its Related Parties, and their respective directors, officers, employees and agents in the performance of Esperion&#8217;s obligations under this Agreement.  Esperion shall have no obligation to indemnify the DS Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, any breach of, or inaccuracy in, any representation or warranty made by DS in this Agreement, or any breach or violation of any covenant or agreement of DS in or in the performance of this Agreement, or the negligence or willful misconduct by or of any of the DS Indemnitees, or matters for which DS is obligated to indemnify Esperion under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (General Indemnification by DS).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Indemnification Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of any such claim against any DS Indemnitee or Esperion Indemnitee (individually, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the indemnified Party shall promptly notify the other Party in writing of the claim and the indemnifying Party shall manage and control, at its sole expense, the defense of the claim and its settlement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indemnitee shall cooperate with the indemnifying Party and may, at its option and expense, be represented in any such action or proceeding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indemnifying Party shall not be liable for any settlements, litigation costs or expenses incurred by any Indemnitee without the indemnifying Party&#8217;s written authorization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if the indemnifying Party believes that any of the exceptions to its obligation of indemnification of the Indemnitees set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (General Indemnification by DS), or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (General Indemnification by Esperion) may apply, the indemnifying Party shall promptly notify the Indemnitees, which shall then have the right to be represented in any such action or proceeding by separate counsel at their expense, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the indemnifying Party shall be responsible for payment of such expenses if the Indemnitees are ultimately determined to be entitled to indemnification from the indemnifying Party for the matters to which the indemnifying Party notified the Indemnitees that such exception(s) may apply.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. NEITHER PARTY HERETO SHALL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THE AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT AS A RESULT OF A PARTY&#8217;S WILLFUL MISCONDUCT OR A BREACH OF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CONFIDENTIALITY AND PUBLICATION). NOTHING IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (LIMITATION OF LIABILITY) IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party shall, at its own expense, maintain general commercial liability insurance, including products liability insurance, contractual liability, bodily injury, property damage and personal injury coverage adequate to cover its obligations and liabilities under this Agreement and the Supply Agreement, and which are consistent with normal business practices of comparable companies with respect to similar obligations and liabilities.  Such coverage shall be purchased for a minimum limit of &#91;***&#93; U.S. Dollars &#91;***&#93;) for any one (1) claim or all damages combined.  The Parties shall maintain such insurance for so long as this Agreement or the Supply Agreement is in effect, and shall from time to time provide copies of certificates of such insurance to each other upon request.  If the insurance policy is written on a claims-made basis, then the coverage must be kept in place for at least &#91;***&#93; years after the termination of this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt;text-decoration:underline">INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Inventorship&#59; Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Inventorship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Inventorship for inventions made during the course of the performance of this Agreement shall be determined in accordance with applicable patent Laws for determining inventorship.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion shall own the entire right, title and interest in and to all inventions it solely Invents (i.e., solely by one or more employees of Esperion or its Affiliates (or a Third Party acting on any of their behalf)) during the Term.  DS shall own the entire right, title and interest in and to all inventions it solely Invents (i.e., by one or more employees of DS or its Affiliates that are Sublicensees (or a Third Party acting on any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of their behalf)) during the Term. The Parties shall jointly own the entire right, title and interest in and to all inventions they Invent jointly (i.e., by one or more employees of Esperion or its Affiliates (or a Third Party acting on any of their behalf) and one or more employees of DS or its Affiliates that are Sublicensees (or a Third Party acting on any of their behalf)) during the Term.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Employee Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each Party shall ensure that all of its employees and all of its Affiliates&#8217; employees acting under its or its Affiliates&#8217; authority in the performance of this Agreement assign to such Party under a binding written agreement all Know-How and Patent Rights discovered, made, conceived by such employee as a result of such employee&#8217;s employment.  In the case of all Third Parties acting in the performance of a Party&#8217;s obligations under this Agreement, such as consultants, subcontractors, licensees, Sublicensees, outside contractors, clinical investigators, agents, or non-employees working for non-profit academic institutions, the Party that engages such Third Party shall ensure that such Third Party is also so obligated under such an agreement, unless otherwise approved by the Parties.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Right to Practice Joint Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Subject to the rights and licenses granted to, and the obligations (including royalty obligations) of each Party, either Party is entitled to practice Joint Technology for all purposes on a worldwide basis and license Joint Technology without consent of and without a duty of accounting to the other Party.  Each Party will grant and hereby does grant all permissions, consents and waivers with respect to, and all licenses under, the Joint Technology, throughout the world, necessary to provide the other Party with such rights of use and exploitation of the Joint Technology, and will execute documents as necessary to accomplish the foregoing.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Prosecution and Maintenance of Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Prosecution of Esperion Patent Rights and Joint Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">Esperion has the sole responsibility to, at Esperion&#8217;s discretion, file, prosecute, and maintain (including the defense of any interference or opposition proceedings or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and any equivalent proceedings in the Territory), all Esperion Patent Rights and Joint Patent Rights.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33pt">Esperion shall furnish to DS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, via electronic mail or such other method as mutually agreed by the Parties, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">copies of documents received from </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside counsel in the course of filing, prosecution or maintenance of or copies of documents </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed with the relevant national patent offices with respect to the filing, prosecution, and maintenance of all Esperion Patent Rights and Joint Patent Rights in the DS Territory within a reasonable time after the receipt or filing of such documents.  Esperion shall provide DS and its patent counsel with a reasonable opportunity to consult with and provide comments to Esperion and its patent counsel regarding the filing and contents of any such application, amendment, submission or response. All timely advice and suggestions of DS and its patent counsel shall be taken into consideration in good faith by Esperion and its patent counsel in connection with such filing.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">In the event that Esperion elects not to maintain patent protection on any Esperion Patent Rights or Joint Patent Rights in the DS Territory, Esperion shall notify DS at least &#91;***&#93;) days before any such Patent Rights would become abandoned or otherwise forfeited, and Esperion shall assign all of its right, title and interest in and to such Esperion Patent Rights or Joint Patent Rights to DS &#91;***&#93;, and such Esperion Patent Rights or Joint Patent Rights shall become patent rights solely owned by DS&#59; provided that, if such assignment is not possible, then DS shall have the right (but not the obligation), &#91;***&#93;, to prosecute and maintain in any country patent protection on such Esperion Patent Rights or Joint Patent Right in the name of Esperion.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Prosecution of DS Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">DS has the sole responsibility to, at DS&#8217;s discretion, file, prosecute, and maintain (including the defense of any interference or opposition proceedings or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and any equivalent proceedings in the Territory), all DS Patent Rights.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33pt">DS shall furnish to Esperion, via electronic mail or such other method as mutually agreed by the Parties, copies of documents received from outside counsel in the course of filing, prosecution or maintenance of or copies of documents filed with the relevant national patent offices with respect to the filing, prosecution, and maintenance of all DS Patent Rights in the DS Territory within a reasonable time after the receipt or filing of such documents.  DS shall provide Esperion and its patent counsel with a reasonable opportunity to consult with and provide comments to DS and its patent counsel regarding the filing and contents of any such application, amendment, submission or response. All timely advice and suggestions of Esperion and its patent counsel shall be taken into consideration in good faith by DS and its patent counsel in connection with such filing.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">In the event that DS elects not to maintain patent protection on any DS Patent Rights in the DS Territory for other than strategic reasons, DS shall notify Esperion at least &#91;***&#93; days before any such Patent Rights would become abandoned or otherwise forfeited, and DS shall assign all of its right, title and interest in and to such DS Patent Rights to Esperion &#91;***&#93;, and such DS Patent Rights shall become patent rights solely owned by Esperion&#59; provided that, if such assignment is not possible, then Esperion shall have the right (but not the obligation), &#91;***&#93;, to prosecute and maintain in any country patent protection on such DS Patent Rights in the name of DS.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Notice of Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  During the Term, each Party will promptly notify the other Party in writing of any known or suspected infringement or unauthorized use or misappropriation by a Third Party of DS Technology, Esperion Technology, or Joint Technology concerning any product intended for use in preventing, diagnosing or treating any disease or condition in humans (including development, Manufacture, or Commercialization) in the DS Territory (such infringement or unauthorized use or misappropriation, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competing Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of which such Party becomes aware. The notifying Party will provide the other Party with all evidence available to it supporting its belief that there is Competing Infringement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Right to Enforce</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">Subject to the provisions of any Esperion Third Party Agreement, DS shall have the first right, but not the obligation, to take any reasonable measures it deems appropriate with respect to any Competing Infringement in the DS Territory under any DS Technology, Esperion Technology or Joint Technology.  Such measures may include (a) initiating or prosecuting an infringement, misappropriation or other appropriate suit or action (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infringement Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in the DS Territory, or (b) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DS Sublicense Rights), granting adequate rights and licenses to any Third Party necessary to render continued Competing Infringement in the DS Territory non-infringing.  Notwithstanding the foregoing, if DS does not inform Esperion that it intends to either initiate such an Infringement Action or grant adequate rights and licenses to such Third Party within &#91;***&#93;) days after DS&#8217;s receipt of a notice of infringement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Notice of Infringement), then Esperion will have the second right, but not the obligation, to initiate such Infringement Action, but solely with respect to any Esperion Technology or Joint Technology.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33pt">Esperion shall have the first right, but not the obligation, to take any reasonable measures it deems appropriate with respect to any Competing Infringement in the Esperion Territory and South Korea and Taiwan during a period of the Pre-Approval Clinical Studies under any DS Technology, Esperion Technology or Joint Technology. Such measures may include (a) initiating or prosecuting an Infringement Action in the Esperion Territory, or (b) granting adequate rights and licenses to any Third Party necessary to render continued Competing Infringement in the Esperion Territory non-infringing.  Notwithstanding the foregoing, if Esperion does not inform DS that it intends to either initiate such an Infringement Action or grant adequate rights and licenses to such Third Party within &#91;***&#93; days after Esperion&#8217;s receipt of a notice of infringement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Notice of Infringement), then DS will have the second right, but not the obligation, to initiate such Infringement Action, but solely with respect to any DS Technology. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Control&#59; Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Party initiating any Infringement Action (such Party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Responsible Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall have the right to control the initiation and prosecution of any Infringement Action, including the right to select counsel therefor, at its own expense.  If requested by the Responsible Party, the other Party shall join as a party to such Infringement Action and will execute and cause its Affiliates to execute all documents necessary for the Responsible Party to initiate, prosecute, maintain or defend such action or proceeding.  In addition, at the Responsible Party&#8217;s request, the other Party shall provide reasonable assistance to the Responsible Party in connection with an Infringement Action at no charge to the Responsible Party except for reimbursement by the Responsible Party of reasonable Out-of-Pocket Costs incurred in rendering such assistance.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Sharing of Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any amounts recovered by either Party pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Third Party Infringement) will be used first to reimburse the Parties for their reasonable costs and expenses, including attorneys&#8217; fees incurred in making such recovery (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses) with any remainder &#91;***&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If a Third Party sues a Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sued Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) alleging that the Sued Party&#8217;s, or the Sued Party&#8217;s Sublicensee&#8217;s, Development, Manufacture or Commercialization of the Licensed Product infringes or will infringe said Third Party&#8217;s intellectual property, then upon the Sued Party&#8217;s request and in connection with the Sued Party&#8217;s defense of any such Third Party suit, the other Party will provide reasonable assistance to the Sued Party for such defense. The Sued Party will keep the other Party, if such other Party has not joined in such suit, reasonably informed on a quarterly basis, in person or by telephone, prior to and during the pendency of any such suit.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Common Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All information exchanged between the Parties&#8217; representatives pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Intellectual Property Ownership, Protection and Related Matters) regarding the preparation, filing, prosecution, maintenance, or enforcement of Patent Rights will be deemed Confidential Information.  In addition, the Parties acknowledge and agree that, with regard to such preparation, filing, prosecution, maintenance, and enforcement of the Esperion Patent Rights and Joint Patent Rights the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature.  The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning such Patent Rights, including privilege under the common interest doctrine and similar or related doctrines.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Patent Term Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Esperion Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of any Esperion Third Party Agreement, Esperion shall use Commercially Reasonable Efforts to obtain all available extensions of Esperion Patent Rights in the DS Territory, as requested by DS.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Joint Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion shall have the exclusive right in its sole discretion to obtain all available extensions of any Joint Patent Rights.  DS shall provide any reasonably necessary powers of attorney and shall provide any other assistance, &#91;***&#93;, that Esperion reasonably requests to enable Esperion to obtain any such extensions.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">DS Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DS shall use Commercially Reasonable Efforts to obtain all available extensions of DS Patent Rights, as requested by Esperion, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that Esperion shall &#91;***&#93; by DS in connection with seeking and obtaining such extensions.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.57pt;text-decoration:underline">Prosecution of Esperion Trademarks&#59; General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion shall have the sole responsibility to file, prosecute, register and maintain (including the defense of opposition proceedings and any equivalent proceedings) Esperion Trademarks and back-up trademarks (including any logo and local letter associated therewith), which shall not be confusingly similar to any DS mark, on a timely manner &#91;***&#93; in the DS Territory throughout the Term. Notwithstanding anything in the foregoing, Esperion&#8217;s obligation &#91;***&#93;, and DS shall &#91;***&#93; by Esperion in connection with the filing, prosecution, registration and maintenance (including the defense of opposition proceedings and any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalent proceedings) of the Esperion Trademarks &#91;***&#93;. Esperion shall invoice DS from time to time &#91;***&#93;, and DS shall pay Esperion within thirty (30) days of receipt of such invoice. &#91;***&#93;&#58; (i) Esperion shall file Esperion Trademarks and back-up trademarks not only in Latin, but also in local letter in South Korea, Taiwan, Hong Kong, Macao, and Thailand excluding Middle East Option Territory&#58; (ii) Esperion shall execute trademark searches not only for Latin trademarks, but also the local letter trademarks in the DS Territory before the filling of Esperion Trademarks and back-up trademarks&#59; and (iii) Esperion shall file Esperion Trademarks and back-up trademarks in a few different variations of local letter for each Latin trademark as a trade name in Taiwan, Hong Kong and Macao.  Esperion shall consider local letter trademarks in consultation with DS and its Affiliates or request DS and its Affiliate to consider local letter trademarks.  </font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33pt">Consistent with DS&#8217;s exclusive right to such Esperion Trademarks under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Exclusive License Grant), DS shall use any Esperion Trademarks in a manner consistent with this Agreement, including the Global Branding Strategy, and for no other purpose. DS shall use any Esperion Trademarks in a manner consistent with trademark usage guidelines provided by Esperion from time-to-time. Subject to the foregoing&#58; (i) DS shall not use any other marks that are confusingly similar to an Esperion Trademark, (ii) all rights in each of the Esperion Trademarks shall remain at all times the sole property of Esperion, and all use of such Esperion Trademarks shall inure to the benefit of Esperion, and (iii) DS agrees not to contest or attack Esperion&#8217;s ownership of the Esperion Trademarks.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.57pt">Notice of Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  During the Term, each Party will promptly notify the other Party in writing of any known or suspected infringement or unauthorized use or misappropriation by a Third Party of Esperion Trademarks in the DS Territory (such infringement or unauthorized use or misappropriation, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competing Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of which such Party becomes aware. The notifying Party will provide the other Party with all evidence available to it supporting its belief that there is Competing Infringement.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33pt">Right to Enforce</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion shall have the first right, but not the obligation, to take any reasonable measures it deems appropriate with respect to any Competing Infringement in the DS Territory.  Such measures may include initiating or prosecuting an infringement, misappropriation or other appropriate suit or action (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infringement Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in the DS Territory.  Notwithstanding the foregoing, if Esperion does not inform DS that it intends to initiate such an Infringement Action to such Third Party within &#91;***&#93;) days after Esperion&#8217;s receipt of a notice of infringement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.7.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Notice of Infringement), then DS will have the second right, but not the obligation, to initiate such Infringement Action</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.57pt">Control&#59; Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Party initiating any Infringement Action (such Party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Responsible Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall have the right to control the initiation and prosecution of any Infringement Action, including the right to select counsel therefor, at its own expense.  If requested by the Responsible Party, the other Party shall join as a party to such Infringement Action and will execute and cause its Affiliates to execute all documents necessary for the Responsible Party to initiate, prosecute, maintain or defend such action or proceeding.  In addition, at the Responsible Party&#8217;s request, the other Party shall provide reasonable assistance to the Responsible Party in connection with an Infringement Action at no charge to the Responsible Party except for reimbursement by the Responsible Party of reasonable Out-of-Pocket Costs incurred in rendering such assistance.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33pt">Sharing of Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any amounts recovered by either Party pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Third Party Infringement) will be used first to reimburse the Parties for their reasonable costs and expenses, including attorneys&#8217; fees incurred in making such recovery (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses) with &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion shall warrant Esperion Trademarks do not infringe other intellectual property rights in the DS Territory. If the use of Esperion Trademarks infringes any other intellectual property rights in the DS Territory, Esperion shall hold DS, its Affiliates and its Sublicensees harmless and indemnified against any Losses suffered as a result of such Third Party&#8217;s Claims.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Esperion Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Esperion or its designee shall register, own and maintain &#91;***&#93;, the Esperion Domain Names. Notwithstanding the foregoing, DS or its designee may register, own and maintain such mutually agreed to Esperion Domain Names that Esperion is not able to register due to local regulation restrictions. &#91;***&#93;DS relating to the registration and maintenance of the Esperion Domain Names &#91;***&#93;within thirty (30) days from the receipt of an invoice therefor.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">DS Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS or its designee shall register, own and maintain &#91;***&#93; the DS Domain Names. Notwithstanding the foregoing, Esperion or its designee may register, own and maintain such mutually agreed to DS Domain Names that DS is not able to register due to local regulation restrictions. &#91;***&#93;relating to the registration and maintenance of the DS Domain Names &#91;***&#93;within thirty (30) days from the receipt of an invoice therefor.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt;text-decoration:underline">TERM AND TERMINATION&#59; REMEDIES</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement shall be effective as of the Effective Date and, unless terminated earlier pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Termination Rights), this Agreement shall continue in effect until the expiration of the last to expire of the Royalty Terms (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Upon the expiration of the Term without this Agreement being terminated earlier pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Termination Rights), DS&#8217;s rights to the Licensed Products and all license grants to DS hereunder shall continue, shall remain exclusive to DS (even as to Esperion) and shall become fully paid-up, royalty-free, perpetual and irrevocable.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement may not be terminated by either Party except as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Termination Rights).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Termination of Agreement for Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  DS shall have the right to terminate this Agreement in its entirety or on a country-by-country basis at any time after the &#91;***&#93; anniversary of the Effective Date on &#91;***&#93; months&#8217; prior written notice to Esperion.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Termination of Agreement in its Entirety for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement may be terminated in its entirety at any time during the Term upon written notice by either Party if the other Party is in material breach of its obligations hereunder and has not cured such breach within &#91;***&#93; days in the case of any undisputed payment breach, or within &#91;***&#93;) days in the case of all other breaches, after notice requesting cure of the breach&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that if any breach other than a payment breach is not reasonably curable within &#91;***&#93; days and if a Party is making a bona fide effort to cure such breach, such termination shall be delayed for a time period to be agreed by both Parties, not to exceed an additional &#91;***&#93; days, in order to permit such Party a reasonable period of time to cure such breach&#59; provided further, that if the alleged material breach relates to non-payment of any amount due under this Agreement (i.e., a payment breach), the cure period shall be tolled pending resolution of any bona fide dispute between the Parties as to whether such payment is due. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Challenges of Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If, during the Term, DS (a) commences or participates in any action or proceeding (including any patent opposition or re-examination proceeding), or otherwise asserts any claim, challenging or denying the validity or enforceability of any claim of any Esperion Patent Rights that have been specifically identified to DS in writing (including as of the Effective Date, as set forth and identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or (b) actively assists any other Person in bringing or prosecuting any action or proceeding (including any patent opposition or re-examination proceeding) challenging or denying the validity or enforceability of any claim of such Esperion Patent Rights (each of (a) and (b), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then, to the extent permitted by the applicable Laws, Esperion shall have the right, exercisable within &#91;***&#93; days following receipt of notice regarding such Patent Challenge, in its sole discretion, to give notice to DS that Esperion may terminate the license(s) granted under such Esperion Patent Right(s) to DS pursuant to this Agreement &#91;***&#93; days following such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">notice (or such longer period as Esperion may designate in such notice), and, unless DS withdraws or causes to be withdrawn all such challenge(s) (or in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex-parte</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proceedings, multi-party proceedings, or other Patent Challenges that DS does not have the power to unilaterally withdraw or cause to be withdrawn, DS ceases actively assisting any other party to such Patent Challenge and, to the extent DS is a party to such Patent Challenge, it withdraws from such Patent Challenge) within such &#91;***&#93;-day period, Esperion shall have the right to terminate the license(s) granted under such Esperion Patent Right(s) to DS pursuant to this Agreement by providing written notice thereof to DS. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Effect of Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS may terminate this Agreement forthwith upon written notice to Esperion in the event that there is a Change of Control of Esperion. Esperion shall give DS written notice of any such Change of Control prior to the effective date thereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event that the performance of the respective obligations of this Agreement become untenable as a result of a Party filing a petition of bankruptcy, entering into insolvency or liquidation proceedings either voluntarily or involuntarily, or if a receiver is appointed with respect to the assets of such Party, or any similar action is filed under applicable Laws, and such measure is not dismissed &#91;***&#93; days, to the extent permitted by the applicable Laws of such Party&#8217;s Territory, the other Party may terminate this Agreement by written notice to such Party. Notwithstanding the foregoing, the Parties acknowledge that a Party to this Agreement may, from time-to-time, make changes in its corporate structure, including inter alia changes in the shareholdings of Affiliates, which would not constitute a case of bankruptcy under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Bankruptcy).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Consequences of Termination or Expiration of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If this Agreement expires or is terminated by a Party in its entirety (or by DS with respect to a particular country in the DS Territory (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Terminated Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)) prior to its expiration, in each case, at any time and for any reason, then the following terms will apply as specified below&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.57pt;text-decoration:underline">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Upon termination of this Agreement prior to expiration, the licenses granted by Esperion to DS or by DS to Esperion under this Agreement will terminate with respect to the DS Territory or the Terminated Country, as applicable, and DS, its Affiliates and its Sublicensees will cease selling Licensed Products in the DS Territory or the Terminated Country, as applicable.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33pt;text-decoration:underline">Return of Information and Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Upon termination (in its entirety or with respect to a Terminated Country, as applicable) or expiration of this Agreement, the Parties will return (or destroy, as directed by the other Party), as applicable, all data, files, records, and other materials containing or comprising the other Party&#8217;s Confidential Information.  Notwithstanding the foregoing, the Parties will be permitted to retain one copy of such data, files, records, and other materials for archival and legal, financial and tax compliance purposes.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.57pt;text-decoration:underline">Return of Domain Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon termination (in its entirety or with respect to a Terminated Country, as applicable) or expiration of this Agreement, DS will (and will cause its designee to) assign and hereby assigns to Esperion or its designee any Esperion Domain Name owned by DS or its designee as of the effective date of such termination (with respect to the DS Territory or Terminated Country, as applicable) or expiration of this Agreement, if requested by Esperion and permissible under applicable Laws. Where such assignment of Esperion Domain Name is not permissible under applicable Laws, e.g. due to local regulation restrictions (as the case may be), DS will (and will cause its designee to) immediately cease the use of such Esperion Domain Name.  DS will (and will cause its designee to) cooperate with Esperion to effectuate the foregoing assignment, including by promptly executing any documents or providing authorization codes necessary to effectuate such assignment. &#91;***&#93; by DS or its designee in connection with the assignment of the Esperion Domain Name owned by DS or its designee to Esperion &#91;***&#93; by Esperion to DS or its designee within &#91;***&#93; days from receipt of an invoice therefore.  Upon termination (in its entirety or with respect to a Terminated Country, as applicable) or expiration of this Agreement, Esperion will assign and hereby assigns to DS or its designee any DS Domain Name owned by Esperion as of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective date of such expiration or termination (with respect to the DS Territory or Terminated Country, as applicable), if requested by DS and permissible under applicable Laws.  Where such assignment of DS Domain Name is not permissible under applicable Laws, e.g. due to local regulation restrictions (as the case may be), Esperion will immediately cease the use of such DS Domain Name. Esperion will cooperate with DS to effectuate the foregoing assignment, including by promptly executing any documents or providing authorization codes necessary to effectuate such assignment.  &#91;***&#93; by Esperion in connection with the assignment of the DS Domain Name owned by Esperion to DS &#91;***&#93; within &#91;***&#93; days from receipt of an invoice therefore.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33pt;text-decoration:underline">Accrued Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Termination of this Agreement (in its entirety or with respect to a Terminated Country, as applicable) for any reason will be without prejudice to any rights or financial compensation that will have accrued to the benefit of a Party prior to such termination.  Such termination will not relieve a Party from obligations that are expressly indicated to survive the termination of this Agreement.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.57pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The following provisions of this Agreement will survive the expiration or earlier termination (in its entirety or with respect to a Terminated Country, as applicable) of this Agreement&#58; 9.7 through 9.10 (solely to the extent applicable with respect to a payment obligation that accrued prior to expiration or termination), 10.3 (Warranty Disclaimer), 12.1 (Inventorship&#59; Ownership), 12.2 (Prosecution of Esperion Patent Rights and Joint Patent Rights) (solely with respect to Joint Patent Rights), 12.3 (Third Party Infringement) (solely with respect to Joint Patent Rights), 12.4 (Third Party Claims) (solely with respect to Joint Patent Rights), 12.5 (Common Interest) (solely with respect to Joint Patent Rights)&#59; 12.6 (Patent Term Extensions) (solely with respect to Joint Patent Rights), 13.1 (Term), 13.3 (Effect of Termination), 13.4 (Special Consequences of Certain Terminations), 14.1 (Assignment), 14.2 (Governing Law), 14.3 (Jurisdiction), 14.9 (No Implied Waivers&#59; Rights Cumulative), 14.10 (Notices), 14.13 (Independent Parties), and 14.15 (Binding Effect&#59; No Third Party Beneficiaries)&#59; and Articles 1 (Definitions) (to the extent the definitions are used in other surviving provisions), 7 (Confidentiality and Publication) (for the time period set forth in Section 7.4 (Survival)), and 11 (Indemnification&#59; Limitation of Liability&#59; Insurance).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Special Consequences of Certain Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If Esperion terminates this Agreement for any reason&#91;***&#93; then, in addition to the terms set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Consequences of Termination or Expiration of this Agreement), the following additional terms will also apply&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The license granted by DS to Esperion under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (License Grants to Esperion) shall automatically become irrevocable, perpetual and worldwide&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Disclosure of Certain Commercialization Related Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  DS will disclose to Esperion for use with respect to the further Commercialization of the Licensed Product, material information pertaining to pricing and market access strategy and health economic study information, in each case for the Licensed Product in the DS Territory or Terminated Country, as applicable, in the possession of DS as of the date of such reversion that relate to such Licensed Products that is necessary for the continued Commercialization of such Licensed Products in the DS Territory or Terminated Country, as applicable&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Within &#91;***&#93; days following the date of the termination, DS will assign, and hereby does assign, to Esperion all of DS&#8217;s right, title and interest in and to all Regulatory Documentation for the Licensed Products, including any Regulatory Approvals and Pricing and Reimbursement Approvals that relate to the applicable Licensed Product with respect to the DS Territory or Terminated Country, as applicable&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DS will license to Esperion any trademarks that are specific to Licensed Products solely for use with such Licensed Product in the DS Territory or Terminated Country, as applicable&#59; provided, however, that in no event will DS have any obligation to license to Esperion any trademarks used by DS other than in connection with a Licensed Product or any other trademarks of DS&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Stock of Finished Drug Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  For a period of &#91;***&#93; months after the effective date of termination of this Agreement, with respect to the DS Territory or Terminated Country, as applicable, DS will have the right to continue to sell and otherwise Commercialize in the DS Territory or Terminated Country, as applicable, all of the inventory of finished drug product for such Licensed Product held by DS as of the effective date of termination, and DS shall continue to pay to Esperion any applicable royalties due on any such sales.  Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Regulatory Materials), DS or its Sublicensees shall retain the Regulation Approvals and Pricing and Reimbursement Approvals until the time when the inventory of the Licensed Products are sold and consumed. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11pt;text-decoration:underline">Transition Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">The Parties wish to provide a mechanism to ensure that, assuming the Licensed Product is available to patients as of the reversion date, patients who were being treated with the Licensed Product prior to such termination or who desire access to the Licensed Product can continue to have access to such Licensed Product while the regulatory and commercial responsibilities for the Licensed Product are transitioned from DS to Esperion. As such, Esperion may request DS to perform transition activities that are necessary or useful to (1) transition DS&#8217;s Commercialization activities (if any) to Esperion to minimize disruption to sales, (2) provide patients with continued access to the applicable Licensed Products (if applicable), (3) enable Esperion (or Esperion&#8217;s designee) to assume and execute the responsibilities under all Regulatory Approvals and ongoing Clinical Studies for the applicable Licensed Product, and (4) transition any CMO or similar agreements entered into by DS pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Back-Up Manufacturing Right), if applicable and if requested by Esperion (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transition Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), but no longer than &#91;***&#93; year following the effective date of termination.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33pt">Esperion may elect to have DS perform the applicable Transition Activities by providing written notice to DS no later than &#91;***&#93; days following the effective date of the termination of this Agreement in its entirety or with respect to a Terminated Country, as applicable. If Esperion requests Transition Activities, the Parties will mutually agree upon a transition plan for DS to perform the applicable Transition Activities including delivery and transition dates. In addition, the Parties will establish a transition committee consisting of at least each Party&#8217;s Alliance Managers, and up to &#91;***&#93; additional representatives from each Party who are from other relevant functional groups to facilitate a smooth transition. While DS is providing applicable Transition Activities, DS and Esperion will agree on talking points and a communication plan to customers, specialty pharmacies, physicians, regulatory authorities, patient advocacy groups, and clinical study investigators, in each case only if applicable at the time of reversion, and DS will make all such communications to such applicable entities in accordance with the mutually agreed talking points.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">&#91;***&#93;, Esperion will own all revenue derived from the Licensed Product after the termination date and DS will remit all such revenues to Esperion no later than the &#91;***&#93; day following the end of the month in which such revenue was received.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Assignment), this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party&#8217;s written consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate or to a party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party to which the subject matter of this Agreement relates, provided that the assignee assumes all of the assigning Party&#8217;s obligations under this Agreement, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Future Acquisition of a Party or its Business). The assigning Party shall remain responsible for the performance by its assignee of this Agreement or any obligations hereunder so assigned.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any purported assignment in violation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Assignment) shall be void.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline">  Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Agreement shall be construed, and the respective rights of the Parties determined, in accordance with the substantive Laws of the State of New York, notwithstanding any provisions of New York Law or any other Law governing conflicts of laws to the contrary.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline"> Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party by its execution hereof, (a) hereby irrevocably submits to the jurisdiction of the courts sitting in New York City, New York, for the purpose of any dispute arising between the Parties in connection with this Agreement (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), except as otherwise expressly provided in this Agreement&#59; (b) hereby waives, to the extent not prohibited by applicable Law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such Action, any claim that (i) it is not subject personally to the jurisdiction of the above-named court, (ii) its property is exempt or immune from attachment or execution, (iii) any such Action brought in the above-named court should be dismissed on grounds of forum non conveniens, should be transferred or removed to any court other than the above-named court, or should be stayed by reason of the pendency of some other proceeding in any other court other than the above-named court, or (iv) this Agreement or the subject matter hereof may not be enforced in or by such court&#59; and (c) hereby agrees not to commence any such Action other than before the above-named court. Notwithstanding the previous sentence a Party may commence any Action in a court other than the above-named court solely for the purpose of enforcing an order or judgment issued by the above-named court.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline">  Entire Agreement&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement contains the entire understanding of the Parties with respect to the subject matter hereof, and supersedes all previous arrangements with respect to the subject matter hereof, whether written or oral.  This Agreement (other than the Schedules attached hereto) may be amended, or any term hereof modified, only by a written instrument duly-executed by authorized representatives of both Parties hereto.  The Schedules attached hereto may be amended, or any term hereof modified, only by a written instrument duly-executed by authorized representatives of both Parties hereto, except to the extent expressly provided in this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline">  Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any provision hereof should be held invalid, illegal or unenforceable in any respect by a competent court in any jurisdiction, the invalid, illegal or unenforceable provision(s) shall be severed from this Agreement and shall not affect the validity of this Agreement as a whole.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline">  Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The captions to the Sections hereof are not a part of this Agreement but are merely for convenience to assist in locating and reading the several Sections hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline">  Waiver of Rule of Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt;text-decoration:underline">  Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa)&#59; (b) the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221; and shall not be interpreted to limit the provision to which it relates&#59; (c) the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;&#59; (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein)&#59; (e) any reference herein to any Person shall be construed to include the Person&#8217;s successors and permitted assigns&#59; (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in each of their entirety, as the context requires, and not to any particular provision hereof&#59; (g) all references herein to Sections or Schedules shall be construed to refer to Sections or Schedules of this Agreement, and references to this Agreement include all Schedules hereto&#59; (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement&#59; (i) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging)&#59; (j) references to any specific law, rule or regulation, or article, Section or other division thereof, shall be deemed to include the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">then-current amendments thereto or any replacement or successor law, rule or regulation thereof&#59; and (k) the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;and&#47;or.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.5pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">No Implied Waivers&#59; Rights Cumulative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as expressly provided in this Agreement, no failure on the part of Esperion or DS to exercise, and no delay in exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at Law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of any breach of this Agreement or as an acquiescence therein, nor shall any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power, remedy or privilege.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:31.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.782%"><tr><td style="width:1.0%"></td><td style="width:31.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If to Esperion, to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Esperion Therapeutics, Inc.</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3891 Ranchero Drive, Suite 150</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ann Arbor, MI 48108</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S.A.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Attention&#58; Chief Executive Officer</font></div><div></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwin Procter LLP</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100 Northern Avenue</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Boston, Massachusetts 02110</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S.A.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Attention&#58; Christopher Denn</font></div><div></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If to DS, to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Daiichi Sankyo Company, Limited.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">103-8426, Japan</font></div><div style="text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Attention&#58; Vice President, Business Planning, ASCA Company</font></div><div style="text-indent:36pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Daiichi Sankyo Company, Limited.</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">103-8426, Japan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Attention&#58; Vice President, Legal Department</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. In addition, each Party shall deliver a courtesy copy to the other Party&#8217;s Alliance Manager concurrently with such notice. Any such notice shall be deemed to have been given&#58; (a) when delivered if personally delivered or sent by facsimile on a business day (or if delivered or sent on a non-business day, then on the next business day)&#59; (b) on receipt if sent by overnight courier&#59; or (c) on receipt if sent by mail.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:31.5pt;text-decoration:underline">Compliance with Export Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither Party shall export any technology licensed to it by the other Party under this Agreement except in compliance with U.S. export Laws and other applicable foreign export Laws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:31.5pt;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement (except liability of money payment obligations), to the extent that such failure or delay is caused by or results from causes which are enforceable and irresistible, potentially including embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, pandemic, or other acts of God. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:31.5pt;text-decoration:underline">Independent Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is expressly agreed that Esperion and DS shall be independent contractors and that the relationship between Esperion and DS shall not constitute a partnership, joint venture or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agency.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Esperion shall not have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on DS, without the prior written consent of DS, and DS shall not have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on Esperion without the prior written consent of Esperion.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:31.5pt;text-decoration:underline">Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6pt;text-decoration:underline">Use of Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Party acknowledges and accepts that the other Party may exercise its rights and perform its obligations under this Agreement either directly or through one or more of its Affiliates.  A Party&#8217;s Affiliates will have the benefit of all rights (including all licenses) of such Party under this Agreement.  Accordingly, in this Agreement &#8220;DS&#8221; will be interpreted to mean &#8220;DS or its Affiliates&#8221; and &#8220;Esperion&#8221; will be interpreted to mean &#8220;Esperion or its Affiliates&#8221; where necessary to give each Party&#8217;s Affiliates the benefit of the rights provided to such Party in this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that in any event each Party will remain responsible for the acts and omissions, including financial liabilities, of its Affiliates.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6pt;text-decoration:underline">Future Acquisition of a Party or its Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Use of Affiliates) or anything to the contrary in this Agreement, in the event of an acquisition of a Party or its business by a Third Party (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) after the Effective Date, whether by merger, asset purchase or otherwise, as to any such Acquirer, the non-acquired Party shall not obtain rights, licenses, options or access to any Patent Rights, Know-How, product candidates or products that are held by the Acquirer or any Affiliate of the Acquirer that becomes an Affiliate of the acquired Party as a result of such acquisition (but excluding the acquired Party), that were not generated through any use or access to the Know-How or Patent Rights of the acquired Party, or that are not used by the acquired Party in connection with a Licensed Product.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6pt;text-decoration:underline">Acquired Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.57pt">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Use of Affiliates) or anything to the contrary in this Agreement, but subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  (Assignment), in the event of either (a) an acquisition of a Party or its business after the Effective Date by an Acquirer whether by merger, asset purchase or otherwise, or (b) an acquisition by a Party after the Effective Date of the business or assets of a Third Party, whether by merger, asset purchase or otherwise, that includes any program(s) of the acquired Third Party that but for this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Acquired Programs), would violate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Exclusivity) (each such program, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; and such acquired business or assets, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquired Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then, in either case ((a) or (b)), the Acquirer or Acquired Business, and any Affiliate of the Acquirer or Acquired Business that becomes an Affiliate of the acquired or acquiring Party as a result of such acquisition (but excluding the acquired Party), shall not be subject to the restrictions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Exclusivity) as to&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33pt">In addition, notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Use of Affiliates) or anything to the contrary in this Agreement, in the event of an acquisition by a Party after the Effective Date of an Acquired Business that includes a Competing Program that is the lead development program (if such Acquired Business has no commercial products) or lead commercial product (i.e. its product with the highest net sales) for such Acquired Business and its Affiliates, the acquiring Party (a) if DS, &#91;***&#93;&#59; or (b) if Esperion, &#91;***&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:31.5pt;text-decoration:underline">Binding Effect&#59; No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Effective Date, this Agreement shall be binding upon and inure to the benefit of the Parties and their respective permitted successors and permitted assigns. Except as expressly set forth in this Agreement, no Person other than the Parties and their respective Affiliates and permitted assignees hereunder shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:31.5pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement may be executed in two or more counterparts, including by facsimile or PDF signature pages or other electronic means, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Daiichi Sankyo Company, Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ESPERION THERAPEUTICS, INC.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BY&#58; &#91;***&#93; <br>NAME&#58; &#91;***&#93; <br>TITLE&#58; &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BY&#58; &#91;***&#93; <br>NAME&#58; &#91;***&#93; <br>TITLE&#58; &#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.52</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Party Agreements</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.53</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Trademarks*</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.81</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensed Products</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Description of Bempedoic Acid Formulations</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 2.1.2</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreed Development Plan</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.9</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Safety Data Exchange Agreement</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See attachment</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PHARMACOVIGILANCE AGREEMENT</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;***&#93;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 5.4</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Agreement</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See attachment</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Agreement</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; </font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 7.3</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Press Releases</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Esperion Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">DS Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (English Version)&#58;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 10.2</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Schedule</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 10.2.4</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Existing Esperion Patent Rights</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.217%"><tr><td style="width:1.0%"></td><td style="width:15.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102-amendedkoenigemploym.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i48e01668f36b40ebb89257867820a26a_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Amended and Restated Employment Agreement (&#8220;Agreement&#8221;) is made by and between Esperion Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Sheldon Koenig (the &#8220;Executive&#8221;).  Except with respect to the Equity Documents (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the Employment Agreement between the Executive and the Company dated December 14, 2020 (the &#8220;Former Employment Agreement&#8221;). </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> The Company and the Executive desire to continue their employment relationship pursuant to this Agreement commencing as of May 18, 2021 (the &#8220;Effective Date&#8221;) and continuing in effect until terminated by either party in accordance with this Agreement (the &#8220;Term&#8221;). At all times, the Executive&#8217;s employment with the Company will be &#8220;at will,&#8221; meaning that the Executive&#8217;s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement.  If the Executive&#8217;s employment with the Company is terminated for any reason during the Term, the Company shall pay or provide to the Executive (or to his authorized representative or estate) any earned but unpaid base salary, unpaid expense reimbursements, accrued but unused vacation and any vested benefits the Executive may have under any employee benefit plan of the Company (the &#8220;Accrued Benefit&#8221;).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt;text-decoration:underline">Position&#59; Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> During the Term, the Executive will serve as President and Chief Executive Officer (&#8220;CEO&#8221;), and will have such powers and duties as may from time to time be prescribed by the Board of Directors of the Company (the &#8220;Board&#8221;).  The Executive shall devote his full working time and efforts to the business and affairs of the Company.  Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the prior written approval of the Board, and&#47;or engage in religious, charitable or other community activities, as long as such services and activities do not interfere with the Executive&#8217;s performance of his duties to the Company. The Company shall cause the Executive to be nominated for election to the Board and to be recommended to the stockholders for election to the Board as long as the Executive remains the CEO, provided that the Executive shall be deemed to have resigned from the Board and from any related positions upon ceasing to serve as CEO for any reason.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">It is currently anticipated that the Executive&#8217;s normal place of work will be the Executive&#8217;s home office in Pennsylvania, provided that the Executive will be required to regularly travel to the Company&#8217;s office, consistent with business needs and will be required to travel domestically and internationally consistent with business needs.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt;text-decoration:underline">Compensation and Related Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  During the Term, the Executive&#8217;s base salary will be paid at the rate of $600,000 per year, subject to redetermination by the Board or the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;). The annual base salary in effect at any given time is referred to herein as &#8220;Base Salary.&#8221; The Base Salary will be payable in a manner that is consistent with the Company&#8217;s usual payroll practices for senior executives.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  During the Term, the Executive will be eligible to be considered for annual cash bonus as determined by the Board or the Compensation Committee from time to time. The annual bonus will be targeted at 50% of the Executive&#8217;s Base Salary (the &#8220;Target Bonus&#8221;).  The actual bonus is discretionary and will be subject to the Board or the Compensation Committee&#8217;s assessment of the Executive&#8217;s performance as well as business conditions of the Company.  The Executive&#8217;s bonus, if any, will be paid by March 15 following the applicable bonus year.  To earn a bonus, the Executive must be employed by the Company on the day such bonus is paid. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt;text-decoration:underline">PTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#58;  During the Term, the Executive is eligible to earn up to four (4) weeks of paid time off (&#8220;PTO&#8221;) per calendar year, to be accrued on a pro rata basis and subject to the terms and conditions of the Company&#8217;s policies and procedures relating to PTO, which may be amended from time to time.    </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  During the Term, the Executive will be entitled to continue to participate in the Company&#8217;s employee benefit plans, subject to the terms and the conditions of such plans and to the Company&#8217;s ability to amend and modify such plans.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Executive&#8217;s equity compensation shall be governed by the terms and conditions of the Company&#8217;s Stock Option and Incentive Plan, as may be amended, and the applicable stock option, restricted stock and&#47;or restricted stock unit agreements (collectively &#8220;Equity Documents&#8221;)&#59; provided that, and notwithstanding anything to the contrary in the Equity Documents, Section 5 of this Agreement shall apply in the event of a Sale Event.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.01pt;text-decoration:underline">Reimbursement of Business Expenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The Company shall reimburse the Executive for travel, entertainment, business development and other expenses reasonably and necessarily incurred by the Executive in connection with the Company&#8217;s business.  Expense reimbursement shall be subject to such policies the Company may adopt from time to time, including policies related to remote working arrangements and associated travel.    </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt;text-decoration:underline">Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt;text-decoration:underline">Sale Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  A Sale Event shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">transaction other than as a result of the acquisition of securities directly from the Company.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Terminating Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  A &#8220;Terminating Event&#8221; shall mean (i) Termination by the Company other than for Cause&#59; or (ii) Termination by the Executive for Good Reason, both as set forth in this Section 4(b)&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.67pt;text-decoration:underline">Termination by the Company Other Than For Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Termination by the Company of the Executive&#8217;s employment for any reason other than for Cause, death or Disability.  For purposes of this Agreement, &#8220;Cause&#8221; shall mean, as determined by the Board&#58; </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:6.34pt">conviction (including a guilty or no contest plea) on a felony indictment or for any misdemeanor involving moral turpitude that adversely affects the Company&#59;</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:7pt">participation in a fraud or act of dishonesty against the Company&#59;</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:7pt">material breach of Executive&#8217;s duties to the Company, that has not been cured to the reasonable satisfaction of the Board, within thirty (30) days following written notice to Executive (provided that no such notice and cure period will be required if such a breach is not subject to cure)&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:6.34pt">intentional and material damage to the Company&#8217;s property&#59; or </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:7.67pt">material breach of this Agreement or other written agreement with the Company or written policy of the Company.  </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.34pt;text-decoration:underline">Termination by the Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Termination by the Executive of the Executive&#8217;s employment with the Company for Good Reason.  For purposes of this Agreement, &#8220;Good Reason&#8221; shall mean that the Executive has complied with the &#8220;Good Reason Process&#8221; (hereinafter defined) following, the occurrence of any of the following events&#58;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:6.34pt">a material diminution in the Executive&#8217;s position, responsibilities, authority or duties&#59;</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:7pt">a material diminution in the Executive&#8217;s base salary except for across-the-board salary reductions based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company&#59; or</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:7pt">a material change in the geographic location of the principal office to which the Executive is assigned, such that there is an increase of at least 30 miles of driving distance to such location from the Executive&#8217;s principal residence as of such change.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;Good Reason Process&#8221; shall mean that (i) the Executive reasonably determines in good faith that a &#8220;Good Reason&#8221; condition has occurred&#59; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition&#59; (iii) the Executive cooperates in good faith with the Company&#8217;s efforts, for a period not less than 30 days following such notice (the &#8220;Cure Period&#8221;), to remedy the condition&#59; (iv) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (v) the Executive terminates his employment within 60 days after the end of the Cure Period.  If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">A Terminating Event shall not be deemed to have occurred pursuant to this Section 4(b)  as a result of&#58;  (i) the ending of the Executive&#8217;s employment due to the Executive&#8217;s death or Disability, (ii) Executive&#8217;s resignation for any reason, other than for Good Reason, (iii) the Company&#8217;s termination of the employment relationship for Cause&#59; or (iv) solely as a result of the Executive being or becoming an employee of any direct or indirect successor to the business or assets of the Company rather than continuing as an employee of the Company following a Sale Event.  For purposes hereof, the Executive will be considered &#8220;Disabled&#8221; if, as a result of the Executive&#8217;s incapacity due to physical or mental illness, the Executive shall have been absent from his duties or be expected to be absent from his duties to the Company on a full&#8209;time basis for 180 calendar days in the aggregate in any 12-month period.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt;text-decoration:underline">Sale Event&#59; Accelerated Vesting&#59; Severance During the Sale Event Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  In the event of a Sale Event, all stock options and other stock-based awards with time-based vesting held by the Executive shall immediately accelerate and become fully exercisable or nonforfeitable as of the date of the Sale Event.  In addition, in the event a Terminating Event occurs within the twelve (12) month period commencing with a Sale Event (the &#8220;Sale Event Period&#8221;), subject to the Executive signing and complying with a separation agreement in a form and manner satisfactory to the Company containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement and reaffirmation of the Restrictive Covenants (the &#8220;Separation Agreement and Release&#8221;) and the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination, the following shall occur&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">the Company shall pay to the Executive an amount equal to the sum of (i) 1.5 times the Executive&#8217;s Base Salary in effect immediately prior to the Terminating Event (or the Executive&#8217;s Base Salary in effect immediately prior to the Sale Event, if higher), and (ii) the Executive&#8217;s Target Bonus&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">if the Executive was participating in the Company&#8217;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a lump sum cash payment in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company for eighteen (18) months after the Date of Termination.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The amounts payable under Section 5(a) and (b), as applicable, shall be paid out in a lump sum within 60 days after the Date of Termination&#59; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the amounts shall be paid in the second calendar year no later than the last day of the 60-day period.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt;text-decoration:underline">Severance Outside the Sale Event Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  In the event a Terminating Event occurs at any time other than during the Sale Event Period, subject to the Executive signing the Separation Agreement and Release and the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination, the following shall occur&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">the Company shall pay to the Executive an amount equal to twelve (12)  months of the Executive&#8217;s annual Base Salary in effect immediately prior to the Terminating Event&#59; </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">if the Executive was participating in the Company&#8217;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for twelve (12) months or the Executive&#8217;s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The amounts payable under Section 6(a) and (b), as applicable, shall be paid out in substantially equal installments in accordance with the Company&#8217;s payroll practice over twelve (12) months commencing within 60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">days after the Date of Termination&#59; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the severance shall begin to be paid in the second calendar year by the last day of such 60-day period&#59; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The terms of the Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (the &#8220;Restrictive Covenants&#8221;), appended hereto as Exhibit A, are incorporated by reference as material terms of this Agreement.  The Executive hereby agrees to the Restrictive Covenants as material terms of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt;text-decoration:underline">Third-Party Agreements and Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#8217;s use or disclosure of information or the Executive&#8217;s engagement in any business.  The Executive represents to the Company that the Executive&#8217;s execution of this Agreement, the Executive&#8217;s employment with the Company and the performance of the Executive&#8217;s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party.  In the Executive&#8217;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Litigation and Regulatory Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  During and after the Executive&#8217;s employment, the Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information and (iii) occasional transitional duties related to the Executive&#8217;s position.  The Executive&#8217;s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.  During and after the Executive&#8217;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company.  The Company shall reimburse the Executive for any reasonable out&#8209;of&#8209;pocket expenses incurred in connection with the Executive&#8217;s performance of obligations pursuant to this Section 7(b).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt;text-decoration:underline">Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the promises set forth in this Section 7 or in Exhibit A, and that in any event money damages would be an inadequate remedy for any such breach.  Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of this Section 7 or Exhibit A, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company and without the posting of a bond.  The Executive further agrees that if he violates this Section 7 or the Restrictive Covenants, in addition to all other remedies available to the Company at law, in equity, and under contract, the Executive shall pay all of the Company&#8217;s costs of enforcement of this Section 7 or the Restrictive Covenants, including attorneys&#8217; fees and expenses.  In addition, in the event the Executive breaches the Restrictive Covenants during a period when he is receiving Severance, the Company shall have the right to suspend or terminate the severance payments.  Such suspension or termination shall not limit the Company&#8217;s other options with respect to relief for such breach and shall not relieve the Executive of his duties under this Agreement.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Protected Disclosures and Other Protected Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Nothing in this Agreement or Exhibit A shall be interpreted or applied to prohibit the Executive from making any good faith report to any governmental agency or other governmental entity (a &#8220;Government Agency&#8221;) concerning any act or omission that the Executive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">reasonably believes constitutes a possible violation of federal or state law or making other disclosures that are protected under the anti-retaliation or whistleblower provisions of applicable federal or state law or regulation.  In addition, nothing contained in this Agreement or Exhibit A limits the Executive&#8217;s ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency.  In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal or state trade secret law or under this Agreement or Exhibit A for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney&#59; and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt;text-decoration:underline">Additional Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the &#8220;Severance Payments&#8221;), would be subject to the excise tax imposed by Section 4999 of the Code, the following provisions shall apply&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.67pt">If the Severance Payments, reduced by the sum of (A) the Excise Tax and (B) the total of the federal, state, and local income and employment taxes payable by the Executive on the amount of the Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, the Executive shall be entitled to the full amount of Severance Payments.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.34pt">If the Threshold Amount is less than (x) the Severance Payments, but greater than (y) the Severance Payments reduced by the sum of (A) the Excise Tax and (B) the total of the federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount, then the Severance Payments shall be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount.  In such event, the Severance Payments shall be reduced in the following order&#58;  (1) cash payments not subject to Section 409A of the Code&#59; (2) cash payments subject to Section 409A of the Code&#59; (3) equity-based payments and acceleration&#59; and (4) non-cash forms of benefits.  To the extent any payment is to be made over time (e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">For the purposes of this Section 8, &#8220;Threshold Amount&#8221; shall mean three times the Executive&#8217;s &#8220;base amount&#8221; within the meaning of Section 280G(b)(3) of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Code and the regulations promulgated thereunder less one dollar ($1.00)&#59; and &#8220;Excise Tax&#8221; shall mean the excise tax imposed by Section 4999 of the Code, and any interest or penalties incurred by the Executive with respect to such excise tax.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">The determination as to which of the alternative provisions of Section 8(a) above shall apply to the Executive shall be made by a nationally recognized accounting firm selected by the Company (the &#8220;Accounting Firm&#8221;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive.  For purposes of determining which of the alternative provisions of Section 8(a) above shall apply, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of the Executive&#8217;s residence on the Date of Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.  Any determination by the Accounting Firm shall be binding upon the Company and the Executive.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#8217;s &#8220;separation from service&#8221; within the meaning of Section 409A of the Code, the Company determines that the Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive&#8217;s separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive&#8217;s separation from service, or (B) the Executive&#8217;s death.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code.  The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement.  All reimbursements shall be paid as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year.  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#8217;s termination of employment, then such payments or benefits shall be payable only upon the Executive&#8217;s &#8220;separation from service.&#8221;  The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Notice and Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Executive&#8217;s employment with the Company may be terminated by the Company or the Executive at any time and for any reason.  During the Term, any purported termination of the Executive&#8217;s employment (other than by reason of death) shall be communicated by written Notice of Termination from one party hereto to the other party hereto in accordance with this Section 11.  For purposes of this Agreement, a &#8220;Notice of Termination&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  &#8220;Date of Termination&#8221; shall mean&#58;  (i) if the Executive&#8217;s employment is terminated by his death, the date of his death&#59; (ii) if the Executive&#8217;s employment is terminated on account of Executive&#8217;s Disability or by the Company for Cause, the date on which Notice of Termination is given&#59; (iii) if the Executive&#8217;s employment is terminated by the Company without Cause, the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination&#59; (iv) if the Executive&#8217;s employment is terminated by the Executive for any reason except for Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive&#8217;s employment is terminated by the Executive for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period.  Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">No Mitigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Company agrees that, if the Executive&#8217;s employment by the Company is terminated during the term of this Agreement, the Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable to the Executive by the Company pursuant to Section 5 or Section 6 hereof.  Further, the amount of any payment provided for in this Agreement shall not be reduced by any compensation earned by the Executive as the result of employment by another employer.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The parties hereby consent to the jurisdiction of the Superior Court of the State of Michigan and the United States District Court in Michigan.  Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts&#59; (b) consents to service of process&#59; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Agreement constitutes the entire agreement between the parties with respect to compensation, severance pay, benefits and accelerated vesting and supersedes in all respects all prior agreements between the parties concerning such subject matter, including without limitation the Former Employment Agreement and any offer letter relating to the Executive&#8217;s employment relationship with the Company.  Provided, and notwithstanding the foregoing, any agreement relating to confidentiality, noncompetition, nonsolicitation or assignment of inventions shall not be superseded by this Agreement and the Executive acknowledges and agrees that any such agreement shall remain in full force and effect, provided that, in the event of any conflict between any such agreement and the Restrictive Covenants, the most restrictive provision that is enforceable shall govern.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Successor to the Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Agreement shall inure to the benefit of and be enforceable by the Executive&#8217;s personal representatives, executors, administrators, heirs, distributees, devisees and legatees.  In the event of the Executive&#8217;s death after a Terminating Event but prior to the completion by the Company of all payments due him under this Agreement, the Company shall continue such payments to the Executive&#8217;s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If any portion or provision of this Agreement (including, without limitation, any portion or provision of any Section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party.  The failure of any party to require the performance of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight currier service of by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company, or to the Company at its main office, attention of the Board of Directors.  Notice shall also be sufficient if sent and received via email to the Executive&#8217;s Company email address, or, if to the Company, to the Lead Outside Director&#8217;s email address.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Effect on Other Plans and Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company's benefit plans, programs or policies.  Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#8217;s benefit plans, programs or policies except as otherwise provided in Section 7 hereof, and except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise.  In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such agreement and this Agreement, the terms of this Agreement shall govern and Executive may receive payment under this Agreement only and not both.  Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall Executive be entitled to payments or benefits pursuant to Section 5 and Section 6 of this Agreement.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This is a Michigan contract and shall be construed under and be governed in all respects by the laws of the State of Michigan, without giving effect to the conflict of laws principles.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Successor to Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place&#59; provided that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments or vesting pursuant to Section 5 or pursuant to Section 6 of this Agreement solely as a result of such transaction.  Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Gender Neutral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original&#59; but such counterparts shall together constitute one and the same document. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:175.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">                         ESPERION THERAPEUTICS, INC.</font></div><div style="text-indent:175.5pt"><font><br></font></div><div style="text-indent:175.5pt"><font><br></font></div><div style="text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">      &#47;s&#47; Nicole Vitullo                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        </font></div><div style="text-indent:252pt"><font><br></font></div><div style="text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; Nicole Vitullo</font></div><div style="text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Lead Director</font></div><div style="text-indent:175.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        </font></div><div style="text-indent:175.5pt"><font><br></font></div><div style="padding-left:72pt;text-indent:175.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EXECUTIVE&#58;</font></div><div><font><br></font></div><div style="text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Sheldon Koenig                             </font></div><div style="text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Sheldon Koenig</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>espr-ex311x06302021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie9109a114bab470499bce8b6a102e649_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:center"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="margin-bottom:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sheldon L. Koenig, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form&#160;10-Q for the period ended June&#160;30, 2021, of Esperion Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sheldon L. Koenig</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sheldon L. Koenig</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>espr-ex312x06302021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i713f4d86ade84f35af091647a4e80f9a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="margin-bottom:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard B. Bartram, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form&#160;10-Q for the period ended June&#160;30, 2021, of Esperion Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.781%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard B. Bartram</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard B. Bartram</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>espr-ex321x06302021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7f41163f8cd04e5393eb6d4d0e1d82ac_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:right"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form&#160;10-Q of Esperion Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the period ended June&#160;30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;each of the undersigned officers of Esperion Therapeutics, Inc., hereby certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section&#160;1350, that, to my knowledge as of the date hereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Report which this statement accompanies fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.834%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sheldon L. Koenig</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sheldon L. Koenig</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard B. Bartram</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard B. Bartram</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>espr-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d960a0e3-43c0-4beb-a690-4f9d75967096,g:902768da-5c62-49b7-8ede-3e343f3fe2f7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:espr="http://www.esperion.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.esperion.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="espr-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="espr-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="espr-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="espr-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.esperion.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://www.esperion.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://www.esperion.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLossIncome" roleURI="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome">
        <link:definition>1003004 - Statement - Condensed Statements of Operations and Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofStockholdersEquityDeficit" roleURI="http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Condensed Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlows" roleURI="http://www.esperion.com/role/CondensedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentation" roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentation">
        <link:definition>2101101 - Disclosure - The Company and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentationDetails" roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - The Company and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationswithThirdParties" roleURI="http://www.esperion.com/role/CollaborationswithThirdParties">
        <link:definition>2106103 - Disclosure - Collaborations with Third Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationswithThirdPartiesDetails" roleURI="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails">
        <link:definition>2407403 - Disclosure - Collaborations with Third Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.esperion.com/role/Inventories">
        <link:definition>2108104 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.esperion.com/role/InventoriesTables">
        <link:definition>2309301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.esperion.com/role/InventoriesDetails">
        <link:definition>2410404 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.esperion.com/role/CommitmentsandContingencies">
        <link:definition>2111105 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.esperion.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2412405 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.esperion.com/role/Investments">
        <link:definition>2113106 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.esperion.com/role/InvestmentsTables">
        <link:definition>2314302 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" roleURI="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails">
        <link:definition>2415406 - Disclosure - Investments - Summary of Cash Equivalents and Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.esperion.com/role/InvestmentsNarrativeDetails">
        <link:definition>2416407 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.esperion.com/role/FairValueMeasurements">
        <link:definition>2117107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.esperion.com/role/FairValueMeasurementsTables">
        <link:definition>2318303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.esperion.com/role/FairValueMeasurementsDetails">
        <link:definition>2419408 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheRevenueInterestPurchaseAgreement" roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement">
        <link:definition>2120108 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables" roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables">
        <link:definition>2321304 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails">
        <link:definition>2422409 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails">
        <link:definition>2423410 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotes" roleURI="http://www.esperion.com/role/ConvertibleNotes">
        <link:definition>2124109 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesTables" roleURI="http://www.esperion.com/role/ConvertibleNotesTables">
        <link:definition>2325305 - Disclosure - Convertible Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesDetails" roleURI="http://www.esperion.com/role/ConvertibleNotesDetails">
        <link:definition>2426411 - Disclosure - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesSummaryofConvertibleDebtDetails" roleURI="http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails">
        <link:definition>2427412 - Disclosure - Convertible Notes - Summary of Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedLiabilities" roleURI="http://www.esperion.com/role/OtherAccruedLiabilities">
        <link:definition>2128110 - Disclosure - Other Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedLiabilitiesTables" roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesTables">
        <link:definition>2329306 - Disclosure - Other Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedLiabilitiesDetails" roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails">
        <link:definition>2430413 - Disclosure - Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensation" roleURI="http://www.esperion.com/role/StockCompensation">
        <link:definition>2131111 - Disclosure - Stock Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationTables" roleURI="http://www.esperion.com/role/StockCompensationTables">
        <link:definition>2332307 - Disclosure - Stock Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationEmployeeStockPurchasePlanDetails" roleURI="http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2433414 - Disclosure - Stock Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationScheduleofStockOptionsDetails" roleURI="http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails">
        <link:definition>2434415 - Disclosure - Stock Compensation - Schedule of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationStockOptionsAdditionalInformationDetails" roleURI="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails">
        <link:definition>2435416 - Disclosure - Stock Compensation - Stock Options Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationRSUsDetails" roleURI="http://www.esperion.com/role/StockCompensationRSUsDetails">
        <link:definition>2436417 - Disclosure - Stock Compensation - RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationRSUsAdditionalInformationDetails" roleURI="http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails">
        <link:definition>2437418 - Disclosure - Stock Compensation - RSUs Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationPBRSUsDetails" roleURI="http://www.esperion.com/role/StockCompensationPBRSUsDetails">
        <link:definition>2438419 - Disclosure - Stock Compensation - PBRSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.esperion.com/role/IncomeTaxes">
        <link:definition>2139112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.esperion.com/role/IncomeTaxesDetails">
        <link:definition>2440420 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerCommonShare" roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShare">
        <link:definition>2141113 - Disclosure - Net (Loss) Income Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerCommonShareTables" roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShareTables">
        <link:definition>2342308 - Disclosure - Net (Loss) Income Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails" roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails">
        <link:definition>2443421 - Disclosure - Net (Loss) Income Per Common Share - Calculation of Basic and Diluted (Loss) Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerCommonShareDetails" roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShareDetails">
        <link:definition>2444422 - Disclosure - Net (Loss) Income Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="espr_NetSalesThresholdDomain" abstract="true" name="NetSalesThresholdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_RevenueInterestLiability" abstract="false" name="RevenueInterestLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ProceedsFromRevenueInterestPurchaseAgreement" abstract="false" name="ProceedsFromRevenueInterestPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" abstract="false" name="ScheduleOfRevenueInterestLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer" abstract="false" name="ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_CappedCallMember" abstract="true" name="CappedCallMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_LiabilityFromSaleOfFutureRevenuesLineItems" abstract="true" name="LiabilityFromSaleOfFutureRevenuesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" abstract="false" name="PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_DebtInstrumentCovenantRequiredAmountOutstanding" abstract="false" name="DebtInstrumentCovenantRequiredAmountOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" abstract="false" name="AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestPurchaseAgreementAmendmentMember" abstract="true" name="RevenueInterestPurchaseAgreementAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" abstract="false" name="PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" abstract="true" name="RIPAAmendmentToTheSecurityAgreementAndWaiverMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" abstract="false" name="AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" abstract="false" name="MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" abstract="false" name="EmployeeStockPurchasePlanDurationOfOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" abstract="false" name="SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" abstract="false" name="AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" abstract="false" name="EmployeeStockPurchasePlanPercentageDiscountOnShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_PrepaidClinicalDevelopmentCostsCurrent" abstract="false" name="PrepaidClinicalDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_EigerIiiSaLlcMember" abstract="true" name="EigerIiiSaLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_PaymentsFromRevenueInterestPurchaseAgreement" abstract="false" name="PaymentsFromRevenueInterestPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_FutureUpFrontPayment" abstract="false" name="FutureUpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" abstract="true" name="LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_NetSalesThresholdThreeMember" abstract="true" name="NetSalesThresholdThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" abstract="false" name="PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_RevenueInterestPurchaseAgreementMember" abstract="true" name="RevenueInterestPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" abstract="false" name="PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts" abstract="false" name="RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" abstract="false" name="NonCashInterestExpenseRelatedToRevenueInterestLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" abstract="false" name="PercentageOfRoyaltiesToBeReceivedOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_DaiichiSankyoCoLtdMember" abstract="true" name="DaiichiSankyoCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_RevenueInterestLiabilityCurrent" abstract="false" name="RevenueInterestLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" abstract="false" name="NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestRateTierTwo" abstract="false" name="RevenueInterestRateTierTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" abstract="false" name="RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" abstract="false" name="FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestRateInitialRate" abstract="false" name="RevenueInterestRateInitialRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" abstract="false" name="FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RegulatoryPerformanceObligationsMember" abstract="true" name="RegulatoryPerformanceObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_ConvertibleSeniorNotesDue2025Member" abstract="true" name="ConvertibleSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_FuturePaymentMilestoneSalesMilestones" abstract="false" name="FuturePaymentMilestoneSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestLiabilityNoncurrent" abstract="false" name="RevenueInterestLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" abstract="false" name="MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NonCashRightOfUseAsset" abstract="false" name="NonCashRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NetSalesThresholdTwoMember" abstract="true" name="NetSalesThresholdTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" abstract="false" name="ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_DaiichiSankyoEuropeGmbhMember" abstract="true" name="DaiichiSankyoEuropeGmbhMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" abstract="false" name="FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestRateTierThree" abstract="false" name="RevenueInterestRateTierThree" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_NumberOfSourcesOfRevenue" abstract="false" name="NumberOfSourcesOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" abstract="true" name="UnvestedRestrictedStockAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_LiabilityFromSaleOfFutureRevenuesTable" abstract="true" name="LiabilityFromSaleOfFutureRevenuesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember" abstract="true" name="RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" abstract="false" name="RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_AccruedVariableConsiderationCurrent" abstract="false" name="AccruedVariableConsiderationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_UpFrontPayment" abstract="false" name="UpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" abstract="false" name="LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="espr_MilestoneMarketingAuthorizationApprovalNustendiMember" abstract="true" name="MilestoneMarketingAuthorizationApprovalNustendiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_NumberOfBusinessDays" abstract="false" name="NumberOfBusinessDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" abstract="false" name="DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" abstract="false" name="RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_DebtInstrumentAdditionalAmount" abstract="false" name="DebtInstrumentAdditionalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" abstract="false" name="MilestoneAmountForWorldwideSalesToReceiveThirdPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NetSalesThresholdOneMember" abstract="true" name="NetSalesThresholdOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" abstract="false" name="AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ConcentrationRiskNumberOfMajorCustomers" abstract="false" name="ConcentrationRiskNumberOfMajorCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" abstract="false" name="PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" abstract="false" name="ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" abstract="false" name="BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NumberOfConsecutiveTradingDays" abstract="false" name="NumberOfConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" abstract="false" name="PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_PercentageOfCumulativePurchaserPaymentsGuarantee" abstract="false" name="PercentageOfCumulativePurchaserPaymentsGuarantee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_GrossProceedsFromRevenueInterestPurchaseAgreement" abstract="false" name="GrossProceedsFromRevenueInterestPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" abstract="false" name="HypotheticalRepaymentObligationBasedOnSalesGenerated" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_SerometrixMember" abstract="true" name="SerometrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" abstract="false" name="CashPaymentToBeReceivedUponCertainCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_OtsukaPharmaceuticalCoLtdMember" abstract="true" name="OtsukaPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_ExclusiveDevelopmentalActivitiesMember" abstract="true" name="ExclusiveDevelopmentalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_CollaborativeArrangementAbstract" abstract="true" name="CollaborativeArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember" abstract="true" name="CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_HypotheticalSalesGeneratedAmount" abstract="false" name="HypotheticalSalesGeneratedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NetSalesThresholdAxis" abstract="true" name="NetSalesThresholdAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" abstract="false" name="UnamortizedTransactionCostsOnRevenueInterestAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ProductSalesBulkTabletsNilemdoAndNustendiMember" abstract="true" name="ProductSalesBulkTabletsNilemdoAndNustendiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_AccruedClinicalDevelopmentCostsCurrent" abstract="false" name="AccruedClinicalDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_CashPaymentToBeReceivedUponFirstCommercialSales" abstract="false" name="CashPaymentToBeReceivedUponFirstCommercialSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised" abstract="false" name="PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_LiabilityFromSaleOfFutureRevenuesRollForward" abstract="true" name="LiabilityFromSaleOfFutureRevenuesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="espr_DeferredUpFrontPayment" abstract="false" name="DeferredUpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_CollaborativeArrangementLicenseToIntellectualPropertyMember" abstract="true" name="CollaborativeArrangementLicenseToIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="espr_AmendedLicenseAndCollaborationAgreementMember" abstract="true" name="AmendedLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>espr-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d960a0e3-43c0-4beb-a690-4f9d75967096,g:902768da-5c62-49b7-8ede-3e343f3fe2f7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8d04b83e-0118-4d5c-829a-3a43fed06eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a800bb4c-cf51-4ce5-ad2e-aad1041c8731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d04b83e-0118-4d5c-829a-3a43fed06eef" xlink:to="loc_us-gaap_AssetsCurrent_a800bb4c-cf51-4ce5-ad2e-aad1041c8731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4436cfd4-54c0-43cb-88de-e43fa1c09e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d04b83e-0118-4d5c-829a-3a43fed06eef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4436cfd4-54c0-43cb-88de-e43fa1c09e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c84d263-c7ba-458f-9c2d-a6b502277cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d04b83e-0118-4d5c-829a-3a43fed06eef" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c84d263-c7ba-458f-9c2d-a6b502277cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_8dfb0972-9515-42b0-9162-0fef95bace3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d04b83e-0118-4d5c-829a-3a43fed06eef" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_8dfb0972-9515-42b0-9162-0fef95bace3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_08a7da6a-f7a6-4fb9-96ab-8957a03c688d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_24860294-5d38-4f28-925f-1279bc138236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08a7da6a-f7a6-4fb9-96ab-8957a03c688d" xlink:to="loc_us-gaap_LiabilitiesCurrent_24860294-5d38-4f28-925f-1279bc138236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_093b082b-48e8-49b0-888c-6f8a417a4d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08a7da6a-f7a6-4fb9-96ab-8957a03c688d" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_093b082b-48e8-49b0-888c-6f8a417a4d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityNoncurrent_bdda45be-d713-457a-b09d-2492575f6969" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08a7da6a-f7a6-4fb9-96ab-8957a03c688d" xlink:to="loc_espr_RevenueInterestLiabilityNoncurrent_bdda45be-d713-457a-b09d-2492575f6969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac0991a0-dc42-49b8-a420-b9f7ba333667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08a7da6a-f7a6-4fb9-96ab-8957a03c688d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac0991a0-dc42-49b8-a420-b9f7ba333667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6ce1e32e-a814-4f0f-9494-01c39d2f9aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08a7da6a-f7a6-4fb9-96ab-8957a03c688d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6ce1e32e-a814-4f0f-9494-01c39d2f9aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1391d59f-fd01-486d-88e5-40f57d4f0f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08a7da6a-f7a6-4fb9-96ab-8957a03c688d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1391d59f-fd01-486d-88e5-40f57d4f0f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6501f82e-20d8-4b23-b73d-966ab341568d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_011c60c6-d903-4dea-9a12-25dd01311931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6501f82e-20d8-4b23-b73d-966ab341568d" xlink:to="loc_us-gaap_AccountsPayableCurrent_011c60c6-d903-4dea-9a12-25dd01311931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedClinicalDevelopmentCostsCurrent_5099bbd5-ce84-41c4-9a01-3bff37c43b6a" xlink:href="espr-20210630.xsd#espr_AccruedClinicalDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6501f82e-20d8-4b23-b73d-966ab341568d" xlink:to="loc_espr_AccruedClinicalDevelopmentCostsCurrent_5099bbd5-ce84-41c4-9a01-3bff37c43b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_7b260b5e-ecef-473d-a11f-4bd76a7fa877" xlink:href="espr-20210630.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6501f82e-20d8-4b23-b73d-966ab341568d" xlink:to="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_7b260b5e-ecef-473d-a11f-4bd76a7fa877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityCurrent_1a8c04f4-edb3-4ace-9235-9e9970b770b9" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6501f82e-20d8-4b23-b73d-966ab341568d" xlink:to="loc_espr_RevenueInterestLiabilityCurrent_1a8c04f4-edb3-4ace-9235-9e9970b770b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7603467c-948c-408a-b9b1-785401e44cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6501f82e-20d8-4b23-b73d-966ab341568d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7603467c-948c-408a-b9b1-785401e44cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dc56e584-d223-42e1-b096-ca1408f387e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6501f82e-20d8-4b23-b73d-966ab341568d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dc56e584-d223-42e1-b096-ca1408f387e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8ae0f229-24b5-4435-a97b-35b91b0b52bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e472b18-9e56-449d-85e6-112e4c0537bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ae0f229-24b5-4435-a97b-35b91b0b52bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e472b18-9e56-449d-85e6-112e4c0537bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_da8119e6-e9fd-4348-a729-91430b4408af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ae0f229-24b5-4435-a97b-35b91b0b52bb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_da8119e6-e9fd-4348-a729-91430b4408af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PrepaidClinicalDevelopmentCostsCurrent_e6829ade-8bb8-48f1-9313-6ca87f136d7d" xlink:href="espr-20210630.xsd#espr_PrepaidClinicalDevelopmentCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ae0f229-24b5-4435-a97b-35b91b0b52bb" xlink:to="loc_espr_PrepaidClinicalDevelopmentCostsCurrent_e6829ade-8bb8-48f1-9313-6ca87f136d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_33cfcf8e-4ee4-48ad-9da0-e693886e9cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ae0f229-24b5-4435-a97b-35b91b0b52bb" xlink:to="loc_us-gaap_InventoryNet_33cfcf8e-4ee4-48ad-9da0-e693886e9cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2ad1015b-2980-4916-9eec-bd41e441c733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ae0f229-24b5-4435-a97b-35b91b0b52bb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2ad1015b-2980-4916-9eec-bd41e441c733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_08a778f9-d7f4-4c39-b39e-839ac0cf0d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f2a4126e-c9d2-408e-90f5-63b0276a28e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08a778f9-d7f4-4c39-b39e-839ac0cf0d80" xlink:to="loc_us-gaap_PreferredStockValue_f2a4126e-c9d2-408e-90f5-63b0276a28e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2808280c-6524-40af-b50f-36c7c76f6f25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08a778f9-d7f4-4c39-b39e-839ac0cf0d80" xlink:to="loc_us-gaap_CommonStockValue_2808280c-6524-40af-b50f-36c7c76f6f25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ce4b2572-0c2e-48c7-9375-c81ebaa2ddb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08a778f9-d7f4-4c39-b39e-839ac0cf0d80" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ce4b2572-0c2e-48c7-9375-c81ebaa2ddb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8f110535-d5aa-4485-959c-1123d6426d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08a778f9-d7f4-4c39-b39e-839ac0cf0d80" xlink:to="loc_us-gaap_TreasuryStockValue_8f110535-d5aa-4485-959c-1123d6426d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fe43a19a-c42c-4d00-9f1a-744a9a4c41c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08a778f9-d7f4-4c39-b39e-839ac0cf0d80" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fe43a19a-c42c-4d00-9f1a-744a9a4c41c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_272f58b4-c9fd-4b8c-a34a-9b6ebcf785ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0cb6d95a-45e0-4386-ab12-97143a4f5304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_272f58b4-c9fd-4b8c-a34a-9b6ebcf785ba" xlink:to="loc_us-gaap_Liabilities_0cb6d95a-45e0-4386-ab12-97143a4f5304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5aaca260-e5df-4094-9d8e-de7c29328b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_272f58b4-c9fd-4b8c-a34a-9b6ebcf785ba" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5aaca260-e5df-4094-9d8e-de7c29328b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4a8756e7-361e-4d92-8823-ce8a79eaefb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_272f58b4-c9fd-4b8c-a34a-9b6ebcf785ba" xlink:to="loc_us-gaap_StockholdersEquity_4a8756e7-361e-4d92-8823-ce8a79eaefb6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a5b19e2-57d2-4e46-a49a-5d7a9a579113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a559ea09-a768-40e9-a327-00c61c7c8f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a5b19e2-57d2-4e46-a49a-5d7a9a579113" xlink:to="loc_us-gaap_NetIncomeLoss_a559ea09-a768-40e9-a327-00c61c7c8f80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c8acee96-98c4-4471-b0b3-60251955e571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a5b19e2-57d2-4e46-a49a-5d7a9a579113" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c8acee96-98c4-4471-b0b3-60251955e571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c46523fb-536e-470a-b593-d7f5f0bbbec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53dc309a-fc1a-4a57-9a9b-14f0efb166c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c46523fb-536e-470a-b593-d7f5f0bbbec6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53dc309a-fc1a-4a57-9a9b-14f0efb166c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_10381f56-1276-44b6-9595-8c2336378572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c46523fb-536e-470a-b593-d7f5f0bbbec6" xlink:to="loc_us-gaap_OperatingExpenses_10381f56-1276-44b6-9595-8c2336378572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c55fad79-0fda-4d57-8fec-7b88e0054ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_59e2ce71-cf37-46e1-b705-e84fcf0d0e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c55fad79-0fda-4d57-8fec-7b88e0054ae9" xlink:to="loc_us-gaap_OperatingIncomeLoss_59e2ce71-cf37-46e1-b705-e84fcf0d0e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bb64897d-8b30-41b2-b03d-e38d7ced1c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c55fad79-0fda-4d57-8fec-7b88e0054ae9" xlink:to="loc_us-gaap_InterestExpense_bb64897d-8b30-41b2-b03d-e38d7ced1c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ae060323-7016-4792-b428-546d342a9718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c55fad79-0fda-4d57-8fec-7b88e0054ae9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ae060323-7016-4792-b428-546d342a9718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_facf28cf-ed6a-4ff4-8636-21dc7b86a383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_77e2a368-2281-44e8-bdeb-b8d7dcfe69c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_facf28cf-ed6a-4ff4-8636-21dc7b86a383" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_77e2a368-2281-44e8-bdeb-b8d7dcfe69c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f966dd6e-7960-4966-978b-61bfdc09af42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_facf28cf-ed6a-4ff4-8636-21dc7b86a383" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f966dd6e-7960-4966-978b-61bfdc09af42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d5f175bf-0fb1-4217-96a6-bc39ff498c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_facf28cf-ed6a-4ff4-8636-21dc7b86a383" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d5f175bf-0fb1-4217-96a6-bc39ff498c53" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e91aa9a9-a0fb-49f4-b4c0-900714239289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_0aad3d4f-ec62-46dc-ad4c-ab10f26e5284" xlink:href="espr-20210630.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e91aa9a9-a0fb-49f4-b4c0-900714239289" xlink:to="loc_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_0aad3d4f-ec62-46dc-ad4c-ab10f26e5284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b5f2eb06-760d-4b43-b2a8-f5a99ffeaeeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e91aa9a9-a0fb-49f4-b4c0-900714239289" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b5f2eb06-760d-4b43-b2a8-f5a99ffeaeeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_e471ea75-41aa-4da4-a1d8-27a2071c9eec" xlink:href="espr-20210630.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e91aa9a9-a0fb-49f4-b4c0-900714239289" xlink:to="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_e471ea75-41aa-4da4-a1d8-27a2071c9eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_24bb772a-6509-4053-9902-a21864871397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e91aa9a9-a0fb-49f4-b4c0-900714239289" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_24bb772a-6509-4053-9902-a21864871397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a465bf5-134d-48eb-9c5a-77dd1fa02a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_73f6954b-3fb8-4d67-8d60-c4dc07ec40e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a465bf5-134d-48eb-9c5a-77dd1fa02a2c" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_73f6954b-3fb8-4d67-8d60-c4dc07ec40e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_935b0624-0d4b-4f59-b06a-bbb942078b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a465bf5-134d-48eb-9c5a-77dd1fa02a2c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_935b0624-0d4b-4f59-b06a-bbb942078b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fb6d2b37-0246-414f-869a-400af96dfd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a465bf5-134d-48eb-9c5a-77dd1fa02a2c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fb6d2b37-0246-414f-869a-400af96dfd16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_82f4513a-3ec0-43ae-9f65-9299e82e3114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_NetIncomeLoss_82f4513a-3ec0-43ae-9f65-9299e82e3114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7b9c212a-f724-4d95-994b-11376a382767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_Depreciation_7b9c212a-f724-4d95-994b-11376a382767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b1cd21c5-7859-45ca-b1a9-6b6c717d6df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b1cd21c5-7859-45ca-b1a9-6b6c717d6df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9024977e-8772-4c76-be5f-64932fd7a102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9024977e-8772-4c76-be5f-64932fd7a102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_3a9b7716-c296-4b55-a129-beb353c3495a" xlink:href="espr-20210630.xsd#espr_NonCashInterestExpenseRelatedToRevenueInterestLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_3a9b7716-c296-4b55-a129-beb353c3495a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_52560a79-5ae5-4c49-ac8e-16da87fcc818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_ShareBasedCompensation_52560a79-5ae5-4c49-ac8e-16da87fcc818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_24e9f06b-27d1-4c2b-81e0-d58c1b6ee62c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_24e9f06b-27d1-4c2b-81e0-d58c1b6ee62c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fad2ad98-525c-462d-b2df-83fa37e73a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fad2ad98-525c-462d-b2df-83fa37e73a9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9da8b1e5-ca62-4eea-bb25-b359cd41cfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9da8b1e5-ca62-4eea-bb25-b359cd41cfa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_50be3189-5794-483c-9343-07a5fe0ef303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_50be3189-5794-483c-9343-07a5fe0ef303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f6540eb2-fb00-4132-8a50-51ed5c3bdb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f6540eb2-fb00-4132-8a50-51ed5c3bdb4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e2a4b4dd-d47a-4aaa-875c-88759f24822c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e2a4b4dd-d47a-4aaa-875c-88759f24822c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a6e5dca3-ea28-4443-a208-1c69b1e32395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc0d21-5d08-4876-b999-0635caf92181" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a6e5dca3-ea28-4443-a208-1c69b1e32395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d320194-33e2-48df-8bb0-4b6bb381951a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a158c890-ca0a-4703-99d4-5c1ab2f76888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d320194-33e2-48df-8bb0-4b6bb381951a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a158c890-ca0a-4703-99d4-5c1ab2f76888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4b25d7e-60d6-42d2-a6b0-a429033e7e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d320194-33e2-48df-8bb0-4b6bb381951a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4b25d7e-60d6-42d2-a6b0-a429033e7e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4783b243-e905-48c1-a304-c53131e711df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d320194-33e2-48df-8bb0-4b6bb381951a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4783b243-e905-48c1-a304-c53131e711df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InventoriesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7726b63e-4538-4d39-a4c6-4019d6cdda71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ac783a9b-8fea-40e5-b8bd-eebc478db78b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7726b63e-4538-4d39-a4c6-4019d6cdda71" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ac783a9b-8fea-40e5-b8bd-eebc478db78b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0a9d5a98-b4dd-4841-ab8c-5b9e0cd02b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7726b63e-4538-4d39-a4c6-4019d6cdda71" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0a9d5a98-b4dd-4841-ab8c-5b9e0cd02b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7ab77a55-d123-4ff7-ad66-d43d934517e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7726b63e-4538-4d39-a4c6-4019d6cdda71" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7ab77a55-d123-4ff7-ad66-d43d934517e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5a60de5b-f07c-45bf-a9ee-95b878765990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dd5d22bc-6fad-4a19-b8e3-76af537cfa48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5a60de5b-f07c-45bf-a9ee-95b878765990" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dd5d22bc-6fad-4a19-b8e3-76af537cfa48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bed4cbc0-57dc-4676-9839-ad354c59dbdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5a60de5b-f07c-45bf-a9ee-95b878765990" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bed4cbc0-57dc-4676-9839-ad354c59dbdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea224871-6c8d-4f59-9ea3-d8817e9ed876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5a60de5b-f07c-45bf-a9ee-95b878765990" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea224871-6c8d-4f59-9ea3-d8817e9ed876" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#OtherAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_242d7b3e-ecdf-4867-b8e9-0d3ac943deb0" xlink:href="espr-20210630.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_55cbb398-0e3a-4cab-aa2b-cfdbcdafc4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_242d7b3e-ecdf-4867-b8e9-0d3ac943deb0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_55cbb398-0e3a-4cab-aa2b-cfdbcdafc4a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedVariableConsiderationCurrent_2422e371-757a-4a7d-90e6-2d14e1d50f50" xlink:href="espr-20210630.xsd#espr_AccruedVariableConsiderationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_242d7b3e-ecdf-4867-b8e9-0d3ac943deb0" xlink:to="loc_espr_AccruedVariableConsiderationCurrent_2422e371-757a-4a7d-90e6-2d14e1d50f50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f7219bec-96a4-4785-a106-4fd18dc2ffad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_242d7b3e-ecdf-4867-b8e9-0d3ac943deb0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f7219bec-96a4-4785-a106-4fd18dc2ffad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_d82509e5-9fac-40d0-8bb4-0cc55004825c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_242d7b3e-ecdf-4867-b8e9-0d3ac943deb0" xlink:to="loc_us-gaap_InterestPayableCurrent_d82509e5-9fac-40d0-8bb4-0cc55004825c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fefe8212-9e0c-486e-82de-ffb8978b7d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_242d7b3e-ecdf-4867-b8e9-0d3ac943deb0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fefe8212-9e0c-486e-82de-ffb8978b7d10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e55bccb2-108e-4337-849b-bed1bc2ca3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_eb36c535-c97d-4fe0-9f8a-30546f5a3a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e55bccb2-108e-4337-849b-bed1bc2ca3d7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_eb36c535-c97d-4fe0-9f8a-30546f5a3a0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_606a206c-ab2d-41ed-9b72-2ea798a8cc51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_132f861f-b57d-4174-a039-fdc2df9670f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_606a206c-ab2d-41ed-9b72-2ea798a8cc51" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_132f861f-b57d-4174-a039-fdc2df9670f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_488ce8b6-1687-4f46-a43b-5c145602f939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_606a206c-ab2d-41ed-9b72-2ea798a8cc51" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_488ce8b6-1687-4f46-a43b-5c145602f939" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>espr-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d960a0e3-43c0-4beb-a690-4f9d75967096,g:902768da-5c62-49b7-8ede-3e343f3fe2f7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended" id="i53cbcec640004c24a9c23d538a9f183c_CondensedStatementsofOperationsandComprehensiveLossIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f651075-87d9-4d37-8da1-1fda0a9b481a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_RevenuesAbstract_3f651075-87d9-4d37-8da1-1fda0a9b481a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e757776e-8a2a-43aa-9c4a-8a81056397e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_3f651075-87d9-4d37-8da1-1fda0a9b481a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e757776e-8a2a-43aa-9c4a-8a81056397e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_bf040b67-56f0-4c5b-8fdf-b159629e3269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_bf040b67-56f0-4c5b-8fdf-b159629e3269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8b7ef1c1-c395-484f-a75c-a7156d63084c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8b7ef1c1-c395-484f-a75c-a7156d63084c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1e3229ff-49de-49ae-b74e-55f57ca3e557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1e3229ff-49de-49ae-b74e-55f57ca3e557" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c4018eac-dcc8-4abc-9b2e-9d3faa410d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:to="loc_us-gaap_OperatingExpenses_c4018eac-dcc8-4abc-9b2e-9d3faa410d66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_577e21be-5175-4184-adf0-269fde9e4e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_OperatingIncomeLoss_577e21be-5175-4184-adf0-269fde9e4e21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_82fe0879-91d0-4606-b51d-f5819d271c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_InterestExpense_82fe0879-91d0-4606-b51d-f5819d271c6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2b83d3c4-7d3b-4001-a871-d6e607103736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2b83d3c4-7d3b-4001-a871-d6e607103736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_37629617-2c0e-44f0-a8ba-ab990188f769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_NetIncomeLoss_37629617-2c0e-44f0-a8ba-ab990188f769" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e3dd3b88-ad5a-4eb0-94c5-465880e5c4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_EarningsPerShareBasic_e3dd3b88-ad5a-4eb0-94c5-465880e5c4e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b0b1ef96-c88a-4d06-b6a1-46127696cd4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b0b1ef96-c88a-4d06-b6a1-46127696cd4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eb6d1a10-5df5-4589-a718-ecd4c51a6ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eb6d1a10-5df5-4589-a718-ecd4c51a6ebb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11fca1f2-cd5f-4f9b-8dc1-5a3c90573e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11fca1f2-cd5f-4f9b-8dc1-5a3c90573e2b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc72b58a-5601-4f08-8782-91c74e5d018d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc72b58a-5601-4f08-8782-91c74e5d018d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f7ece052-b858-4b41-b663-68bf6416b467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc72b58a-5601-4f08-8782-91c74e5d018d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f7ece052-b858-4b41-b663-68bf6416b467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_888750d0-2a01-4ab6-9559-69cb52fe9c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_888750d0-2a01-4ab6-9559-69cb52fe9c30" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c67e9bb9-6d1a-4145-bb4c-f3ba465bd962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_StatementTable_c67e9bb9-6d1a-4145-bb4c-f3ba465bd962" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2f908c9a-d0e8-454e-b6ee-3713c27dd766" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c67e9bb9-6d1a-4145-bb4c-f3ba465bd962" xlink:to="loc_srt_ProductOrServiceAxis_2f908c9a-d0e8-454e-b6ee-3713c27dd766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2f908c9a-d0e8-454e-b6ee-3713c27dd766_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2f908c9a-d0e8-454e-b6ee-3713c27dd766" xlink:to="loc_srt_ProductsAndServicesDomain_2f908c9a-d0e8-454e-b6ee-3713c27dd766_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e0d4eba7-6967-43c8-a761-6175d5a31428" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2f908c9a-d0e8-454e-b6ee-3713c27dd766" xlink:to="loc_srt_ProductsAndServicesDomain_e0d4eba7-6967-43c8-a761-6175d5a31428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_26ba2303-761c-4e8b-b862-edb7c4af2e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e0d4eba7-6967-43c8-a761-6175d5a31428" xlink:to="loc_us-gaap_ProductMember_26ba2303-761c-4e8b-b862-edb7c4af2e59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborationRevenueMember_6409095e-d37d-4b83-ba45-b1b857e3a66f" xlink:href="espr-20210630.xsd#espr_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e0d4eba7-6967-43c8-a761-6175d5a31428" xlink:to="loc_espr_CollaborationRevenueMember_6409095e-d37d-4b83-ba45-b1b857e3a66f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedStatementsofStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit" xlink:type="extended" id="if52cdf02ee9d4248b7f763ef0ccf4557_CondensedStatementsofStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0e163d9a-fa57-41ed-b407-58ddaa36f6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e163d9a-fa57-41ed-b407-58ddaa36f6e4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_471bd5e0-2234-47f6-a9ed-8068fe888369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_SharesOutstanding_471bd5e0-2234-47f6-a9ed-8068fe888369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c7bf98f-9cc7-4797-b5c7-c1d26084bcac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockholdersEquity_9c7bf98f-9cc7-4797-b5c7-c1d26084bcac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_c2964472-18d8-4dd2-a68a-7c689b1ff073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_c2964472-18d8-4dd2-a68a-7c689b1ff073" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd8e2fd1-43ae-4830-b39e-b7513ea34ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd8e2fd1-43ae-4830-b39e-b7513ea34ea7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_597f1676-856d-4371-b0df-ee9a2fa6016d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_597f1676-856d-4371-b0df-ee9a2fa6016d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bd085b76-e80e-427a-82a1-d27b79366901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bd085b76-e80e-427a-82a1-d27b79366901" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_bd4ed397-7b6d-46b5-a64b-82c5b1e8d78d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_bd4ed397-7b6d-46b5-a64b-82c5b1e8d78d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8bbae939-a2b2-4834-87ce-ee54ef630449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8bbae939-a2b2-4834-87ce-ee54ef630449" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_72cef70d-8ac7-4344-ae33-8fdea7dba2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_72cef70d-8ac7-4344-ae33-8fdea7dba2d2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_af3d87bf-3817-4490-b9d9-241c2b8fd13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_af3d87bf-3817-4490-b9d9-241c2b8fd13b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4f5c61eb-3403-4a27-965b-b8e5390066a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4f5c61eb-3403-4a27-965b-b8e5390066a2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ee6c05b9-cdd7-4387-930b-5585326d9a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_NetIncomeLoss_ee6c05b9-cdd7-4387-930b-5585326d9a82" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_eb9f1de8-591a-4bb6-a098-dddd73345c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e5fe79c7-593a-49c4-bbb8-93fb051b9a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ba506ab-0305-4a19-841f-0303ef1aa3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0e163d9a-fa57-41ed-b407-58ddaa36f6e4" xlink:to="loc_us-gaap_StatementTable_2ba506ab-0305-4a19-841f-0303ef1aa3c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7223ce70-6ff4-40e0-9a1c-1e6fa771fc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2ba506ab-0305-4a19-841f-0303ef1aa3c1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7223ce70-6ff4-40e0-9a1c-1e6fa771fc97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7223ce70-6ff4-40e0-9a1c-1e6fa771fc97_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7223ce70-6ff4-40e0-9a1c-1e6fa771fc97" xlink:to="loc_us-gaap_EquityComponentDomain_7223ce70-6ff4-40e0-9a1c-1e6fa771fc97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7223ce70-6ff4-40e0-9a1c-1e6fa771fc97" xlink:to="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_66e3911a-f769-4fa4-856e-1de1f9bc5384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_CommonStockMember_66e3911a-f769-4fa4-856e-1de1f9bc5384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_183fbe35-dc01-4f1b-adb4-84bbdaa196b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_183fbe35-dc01-4f1b-adb4-84bbdaa196b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dec913ca-851c-42fd-aa8c-4cf44cc20fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_RetainedEarningsMember_dec913ca-851c-42fd-aa8c-4cf44cc20fd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4392dc7d-6dac-4c8f-843e-38a2edda07e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4392dc7d-6dac-4c8f-843e-38a2edda07e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_de2e283f-e2b2-456b-a3b5-3dc13b5812b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_TreasuryStockMember_de2e283f-e2b2-456b-a3b5-3dc13b5812b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_061cd2ab-c370-4cca-9e8a-f6e45c79d8be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2ba506ab-0305-4a19-841f-0303ef1aa3c1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_061cd2ab-c370-4cca-9e8a-f6e45c79d8be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_061cd2ab-c370-4cca-9e8a-f6e45c79d8be_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_061cd2ab-c370-4cca-9e8a-f6e45c79d8be" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_061cd2ab-c370-4cca-9e8a-f6e45c79d8be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cf7f540-bc1d-43c0-8b43-2cd0d81da963" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_061cd2ab-c370-4cca-9e8a-f6e45c79d8be" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cf7f540-bc1d-43c0-8b43-2cd0d81da963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8efafc6d-1b7b-46ff-9f09-f4cf199f7633" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cf7f540-bc1d-43c0-8b43-2cd0d81da963" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8efafc6d-1b7b-46ff-9f09-f4cf199f7633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_bcf6fca0-5ba9-4e33-9220-22bd157f944a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cf7f540-bc1d-43c0-8b43-2cd0d81da963" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_bcf6fca0-5ba9-4e33-9220-22bd157f944a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#TheCompanyandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="extended" id="iedef2d116f0743a69b14819f6e2f72aa_TheCompanyandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UpFrontPayment_0307daaa-e215-48f2-8f6d-170211437a24" xlink:href="espr-20210630.xsd#espr_UpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:to="loc_espr_UpFrontPayment_0307daaa-e215-48f2-8f6d-170211437a24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_3dc3ce6f-ac4d-41f0-ba5e-651064b940c4" xlink:href="espr-20210630.xsd#espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:to="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_3dc3ce6f-ac4d-41f0-ba5e-651064b940c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_dc2e6ce6-6bc8-414a-b6f4-92bd41bde5d0" xlink:href="espr-20210630.xsd#espr_PercentageOfRoyaltiesToBeReceivedOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:to="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_dc2e6ce6-6bc8-414a-b6f4-92bd41bde5d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_cbe2f3f6-dd02-447a-9159-9bab0d54a9aa" xlink:href="espr-20210630.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:to="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_cbe2f3f6-dd02-447a-9159-9bab0d54a9aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1ea6746a-82c4-44ef-a9c9-56975e417c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1ea6746a-82c4-44ef-a9c9-56975e417c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ea6746a-82c4-44ef-a9c9-56975e417c28_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1ea6746a-82c4-44ef-a9c9-56975e417c28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ea6746a-82c4-44ef-a9c9-56975e417c28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93dd45e0-fa33-433a-9d22-e61033fbac1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1ea6746a-82c4-44ef-a9c9-56975e417c28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93dd45e0-fa33-433a-9d22-e61033fbac1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_074ebace-0571-427b-afb9-fc5c22d10051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93dd45e0-fa33-433a-9d22-e61033fbac1c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_074ebace-0571-427b-afb9-fc5c22d10051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_a66b32cb-003a-4d17-a4fb-795d4bba2a52" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93dd45e0-fa33-433a-9d22-e61033fbac1c" xlink:to="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_a66b32cb-003a-4d17-a4fb-795d4bba2a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e2d08c70-1724-41e5-b902-4280d147a26e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:to="loc_srt_CounterpartyNameAxis_e2d08c70-1724-41e5-b902-4280d147a26e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2d08c70-1724-41e5-b902-4280d147a26e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e2d08c70-1724-41e5-b902-4280d147a26e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2d08c70-1724-41e5-b902-4280d147a26e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0286c5a3-e73f-4191-878a-e066eb4639db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e2d08c70-1724-41e5-b902-4280d147a26e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0286c5a3-e73f-4191-878a-e066eb4639db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember_e4422b57-9fce-4ced-8bf1-fd399e89e61e" xlink:href="espr-20210630.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0286c5a3-e73f-4191-878a-e066eb4639db" xlink:to="loc_espr_DaiichiSankyoCoLtdMember_e4422b57-9fce-4ced-8bf1-fd399e89e61e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EigerIiiSaLlcMember_da4fe326-e07c-40a0-aa3b-a24dce5f4425" xlink:href="espr-20210630.xsd#espr_EigerIiiSaLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0286c5a3-e73f-4191-878a-e066eb4639db" xlink:to="loc_espr_EigerIiiSaLlcMember_da4fe326-e07c-40a0-aa3b-a24dce5f4425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a1f386c-77e5-44ab-abcb-0bd6df169aed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:to="loc_srt_RangeAxis_2a1f386c-77e5-44ab-abcb-0bd6df169aed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a1f386c-77e5-44ab-abcb-0bd6df169aed_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2a1f386c-77e5-44ab-abcb-0bd6df169aed" xlink:to="loc_srt_RangeMember_2a1f386c-77e5-44ab-abcb-0bd6df169aed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3771fa39-4a72-48d3-81f0-c3021463b2c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2a1f386c-77e5-44ab-abcb-0bd6df169aed" xlink:to="loc_srt_RangeMember_3771fa39-4a72-48d3-81f0-c3021463b2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a3ceee5a-b2b0-42bb-8b38-f87682184154" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3771fa39-4a72-48d3-81f0-c3021463b2c8" xlink:to="loc_srt_MinimumMember_a3ceee5a-b2b0-42bb-8b38-f87682184154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3494245c-ef4c-43a5-84a2-34e1e597598d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3771fa39-4a72-48d3-81f0-c3021463b2c8" xlink:to="loc_srt_MaximumMember_3494245c-ef4c-43a5-84a2-34e1e597598d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i7cf5be7c5053464aa8e4337795588fd5_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:href="espr-20210630.xsd#espr_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConcentrationRiskNumberOfMajorCustomers_94903312-c258-491a-95b7-1f22912ef49e" xlink:href="espr-20210630.xsd#espr_ConcentrationRiskNumberOfMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_espr_ConcentrationRiskNumberOfMajorCustomers_94903312-c258-491a-95b7-1f22912ef49e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfSourcesOfRevenue_920d2b14-df59-4037-bd5e-a702b99f2ddf" xlink:href="espr-20210630.xsd#espr_NumberOfSourcesOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_espr_NumberOfSourcesOfRevenue_920d2b14-df59-4037-bd5e-a702b99f2ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_120503b5-b7fe-4689-a2e2-83ca0e3a8abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_120503b5-b7fe-4689-a2e2-83ca0e3a8abb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_a6b43548-99a3-4949-ab8b-5be6d5c353a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_a6b43548-99a3-4949-ab8b-5be6d5c353a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45dfd682-f9e8-49f8-91e8-c6affd5f0540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45dfd682-f9e8-49f8-91e8-c6affd5f0540" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f90fddb4-f5f7-4668-b970-c9d12fa316d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f90fddb4-f5f7-4668-b970-c9d12fa316d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:href="espr-20210630.xsd#espr_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51ee018f-61d3-4ae4-94e5-9f87335d91c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51ee018f-61d3-4ae4-94e5-9f87335d91c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_51ee018f-61d3-4ae4-94e5-9f87335d91c0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51ee018f-61d3-4ae4-94e5-9f87335d91c0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_51ee018f-61d3-4ae4-94e5-9f87335d91c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65098ac0-9931-464e-94b9-b905ff773f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51ee018f-61d3-4ae4-94e5-9f87335d91c0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65098ac0-9931-464e-94b9-b905ff773f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_49054039-158f-4a64-9114-ca42e86c20af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65098ac0-9931-464e-94b9-b905ff773f0d" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_49054039-158f-4a64-9114-ca42e86c20af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0803703a-52da-461b-b385-a2bfbfe184ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0803703a-52da-461b-b385-a2bfbfe184ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0803703a-52da-461b-b385-a2bfbfe184ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0803703a-52da-461b-b385-a2bfbfe184ff" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0803703a-52da-461b-b385-a2bfbfe184ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_02f19faf-afbf-45cc-bb90-5604db19509e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0803703a-52da-461b-b385-a2bfbfe184ff" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_02f19faf-afbf-45cc-bb90-5604db19509e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_59884d95-c653-4be9-a4cd-29cd80d894e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_02f19faf-afbf-45cc-bb90-5604db19509e" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_59884d95-c653-4be9-a4cd-29cd80d894e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0f19562-e6ad-4c9b-975e-72913a39b420" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0f19562-e6ad-4c9b-975e-72913a39b420" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0f19562-e6ad-4c9b-975e-72913a39b420_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0f19562-e6ad-4c9b-975e-72913a39b420" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0f19562-e6ad-4c9b-975e-72913a39b420_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_33f5081c-5735-4399-90ac-73b93fd047ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0f19562-e6ad-4c9b-975e-72913a39b420" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_33f5081c-5735-4399-90ac-73b93fd047ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c3e2ad60-a76c-4aaa-8bb4-e893e60aab5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_33f5081c-5735-4399-90ac-73b93fd047ca" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c3e2ad60-a76c-4aaa-8bb4-e893e60aab5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d976afb-cfa1-4e4a-9036-e160332d979a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:to="loc_srt_ProductOrServiceAxis_9d976afb-cfa1-4e4a-9036-e160332d979a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d976afb-cfa1-4e4a-9036-e160332d979a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9d976afb-cfa1-4e4a-9036-e160332d979a" xlink:to="loc_srt_ProductsAndServicesDomain_9d976afb-cfa1-4e4a-9036-e160332d979a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_513432a9-501b-487e-83c5-b24088256b53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9d976afb-cfa1-4e4a-9036-e160332d979a" xlink:to="loc_srt_ProductsAndServicesDomain_513432a9-501b-487e-83c5-b24088256b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ac66f2ca-bbde-4f4e-9f99-cd3b3927bb00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_513432a9-501b-487e-83c5-b24088256b53" xlink:to="loc_us-gaap_ProductMember_ac66f2ca-bbde-4f4e-9f99-cd3b3927bb00" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#CollaborationswithThirdPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" xlink:type="extended" id="i7845ff64a7c14879aed6a26f5b47b1d7_CollaborationswithThirdPartiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UpFrontPayment_d05449b8-ff90-4eb6-9d60-e633c1f27e8c" xlink:href="espr-20210630.xsd#espr_UpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_UpFrontPayment_d05449b8-ff90-4eb6-9d60-e633c1f27e8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FutureUpFrontPayment_29c43d8d-c9ee-49ce-aeea-cbcac5fcdab0" xlink:href="espr-20210630.xsd#espr_FutureUpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FutureUpFrontPayment_29c43d8d-c9ee-49ce-aeea-cbcac5fcdab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales_a0577cc9-f107-490a-8c21-fd91e68ddfbd" xlink:href="espr-20210630.xsd#espr_CashPaymentToBeReceivedUponFirstCommercialSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales_a0577cc9-f107-490a-8c21-fd91e68ddfbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_16669d12-2a99-40e6-a1ba-3a569961c9ae" xlink:href="espr-20210630.xsd#espr_PercentageOfRoyaltiesToBeReceivedOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_16669d12-2a99-40e6-a1ba-3a569961c9ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer_d0985168-1a8b-4fd7-a8df-18652313fd14" xlink:href="espr-20210630.xsd#espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer_d0985168-1a8b-4fd7-a8df-18652313fd14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_40730959-e210-4f71-99d6-3b9b23c99e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_40730959-e210-4f71-99d6-3b9b23c99e21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1567dd7a-dec8-44d8-92a1-aac97f77a454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1567dd7a-dec8-44d8-92a1-aac97f77a454" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_3af79b82-7f29-470e-a33f-29af31bbf40f" xlink:href="espr-20210630.xsd#espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_3af79b82-7f29-470e-a33f-29af31bbf40f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_7dedd9a0-27be-4013-8f07-fc7c0f020212" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_7dedd9a0-27be-4013-8f07-fc7c0f020212" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_de12a19f-d414-4ba1-bcc6-edca1fb6b22e" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_de12a19f-d414-4ba1-bcc6-edca1fb6b22e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_d7ca4323-f032-4362-94c6-9800f1499a8d" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_d7ca4323-f032-4362-94c6-9800f1499a8d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneSalesMilestones_cd56dc31-c0ec-46eb-9a54-c87d91b604fe" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FuturePaymentMilestoneSalesMilestones_cd56dc31-c0ec-46eb-9a54-c87d91b604fe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_ea78d4ad-ccd3-41fc-87ce-6f2e0019ef13" xlink:href="espr-20210630.xsd#espr_CashPaymentToBeReceivedUponCertainCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_ea78d4ad-ccd3-41fc-87ce-6f2e0019ef13" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DeferredUpFrontPayment_10effc36-8e13-49cb-b78a-401f0e4f2015" xlink:href="espr-20210630.xsd#espr_DeferredUpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_DeferredUpFrontPayment_10effc36-8e13-49cb-b78a-401f0e4f2015" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_240319cc-bd9e-47fe-a25f-646ed693e6fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_240319cc-bd9e-47fe-a25f-646ed693e6fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_240319cc-bd9e-47fe-a25f-646ed693e6fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_240319cc-bd9e-47fe-a25f-646ed693e6fa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_240319cc-bd9e-47fe-a25f-646ed693e6fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_240319cc-bd9e-47fe-a25f-646ed693e6fa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_990b5284-005d-4a47-ab1f-fc54990c7282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_990b5284-005d-4a47-ab1f-fc54990c7282" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmendedLicenseAndCollaborationAgreementMember_b6bd575f-276b-4e6e-bee2-d5d9975e5137" xlink:href="espr-20210630.xsd#espr_AmendedLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_espr_AmendedLicenseAndCollaborationAgreementMember_b6bd575f-276b-4e6e-bee2-d5d9975e5137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ExclusiveDevelopmentalActivitiesMember_07cdd6ba-e52a-4219-a8c4-501a28af7812" xlink:href="espr-20210630.xsd#espr_ExclusiveDevelopmentalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_espr_ExclusiveDevelopmentalActivitiesMember_07cdd6ba-e52a-4219-a8c4-501a28af7812" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember_1aa82f8b-49e1-41c3-bb13-94bab2ae9223" xlink:href="espr-20210630.xsd#espr_CollaborativeArrangementLicenseToIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember_1aa82f8b-49e1-41c3-bb13-94bab2ae9223" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember_2a988d04-b593-4a01-8166-7e7f5e919ac1" xlink:href="espr-20210630.xsd#espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember_2a988d04-b593-4a01-8166-7e7f5e919ac1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9ac06b1-82ea-4250-bb7d-273253236b7c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:to="loc_srt_CounterpartyNameAxis_a9ac06b1-82ea-4250-bb7d-273253236b7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ac06b1-82ea-4250-bb7d-273253236b7c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a9ac06b1-82ea-4250-bb7d-273253236b7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ac06b1-82ea-4250-bb7d-273253236b7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a9ac06b1-82ea-4250-bb7d-273253236b7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoEuropeGmbhMember_52882af5-3003-475c-9e3a-d83c8c2781b3" xlink:href="espr-20210630.xsd#espr_DaiichiSankyoEuropeGmbhMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:to="loc_espr_DaiichiSankyoEuropeGmbhMember_52882af5-3003-475c-9e3a-d83c8c2781b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_OtsukaPharmaceuticalCoLtdMember_f5dc1287-b1dc-4c48-8106-56dee2a00ca5" xlink:href="espr-20210630.xsd#espr_OtsukaPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:to="loc_espr_OtsukaPharmaceuticalCoLtdMember_f5dc1287-b1dc-4c48-8106-56dee2a00ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember_5034fbfd-9b03-41c8-aeef-5fb3afe0c257" xlink:href="espr-20210630.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:to="loc_espr_DaiichiSankyoCoLtdMember_5034fbfd-9b03-41c8-aeef-5fb3afe0c257" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SerometrixMember_4ac34f77-b81f-41ea-8a21-5ab1d77155ed" xlink:href="espr-20210630.xsd#espr_SerometrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:to="loc_espr_SerometrixMember_4ac34f77-b81f-41ea-8a21-5ab1d77155ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_91b4f30c-274e-4c5d-af02-2b823cca9265" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:to="loc_srt_ProductOrServiceAxis_91b4f30c-274e-4c5d-af02-2b823cca9265" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91b4f30c-274e-4c5d-af02-2b823cca9265_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_91b4f30c-274e-4c5d-af02-2b823cca9265" xlink:to="loc_srt_ProductsAndServicesDomain_91b4f30c-274e-4c5d-af02-2b823cca9265_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_91b4f30c-274e-4c5d-af02-2b823cca9265" xlink:to="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RegulatoryPerformanceObligationsMember_a5bf1aa1-a16b-4ad5-9f0e-8c9e41929021" xlink:href="espr-20210630.xsd#espr_RegulatoryPerformanceObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_RegulatoryPerformanceObligationsMember_a5bf1aa1-a16b-4ad5-9f0e-8c9e41929021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember_c5cb3fb0-0684-4210-b056-2c50cb1cbbf1" xlink:href="espr-20210630.xsd#espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember_c5cb3fb0-0684-4210-b056-2c50cb1cbbf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember_5a936050-f4d2-4250-8698-cfd355094279" xlink:href="espr-20210630.xsd#espr_ProductSalesBulkTabletsNilemdoAndNustendiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember_5a936050-f4d2-4250-8698-cfd355094279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborationRevenueMember_9ac7a1f4-669e-47c0-9371-fbf83ef25a52" xlink:href="espr-20210630.xsd#espr_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_CollaborationRevenueMember_9ac7a1f4-669e-47c0-9371-fbf83ef25a52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MilestoneMarketingAuthorizationApprovalNustendiMember_b042f13a-41ea-476b-b83a-2b540d7e61e0" xlink:href="espr-20210630.xsd#espr_MilestoneMarketingAuthorizationApprovalNustendiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_MilestoneMarketingAuthorizationApprovalNustendiMember_b042f13a-41ea-476b-b83a-2b540d7e61e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df037dd4-e48f-4199-ada9-bae70f71c4ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:to="loc_srt_RangeAxis_df037dd4-e48f-4199-ada9-bae70f71c4ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df037dd4-e48f-4199-ada9-bae70f71c4ca_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_df037dd4-e48f-4199-ada9-bae70f71c4ca" xlink:to="loc_srt_RangeMember_df037dd4-e48f-4199-ada9-bae70f71c4ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_196f3351-ec68-406c-9da4-0d0649edf333" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_df037dd4-e48f-4199-ada9-bae70f71c4ca" xlink:to="loc_srt_RangeMember_196f3351-ec68-406c-9da4-0d0649edf333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_94e58fef-f844-4351-9690-7f1c13d6211a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_196f3351-ec68-406c-9da4-0d0649edf333" xlink:to="loc_srt_MinimumMember_94e58fef-f844-4351-9690-7f1c13d6211a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cf186939-3e52-492d-bcfc-d8e581478b8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_196f3351-ec68-406c-9da4-0d0649edf333" xlink:to="loc_srt_MaximumMember_cf186939-3e52-492d-bcfc-d8e581478b8d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ice1022b4fa3a484d93e66a34edc8c9c3_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ad932466-1cd6-4378-bc98-92e62a9c7cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ad932466-1cd6-4378-bc98-92e62a9c7cab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c9218c58-7e26-4934-8a71-2f3b3feb154b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c9218c58-7e26-4934-8a71-2f3b3feb154b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb8375af-7a4e-48e1-89d9-08adce9fa6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb8375af-7a4e-48e1-89d9-08adce9fa6a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable_2ee9d6a9-03d3-4dc7-a3b4-1aa92f387ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:to="loc_us-gaap_LossContingencyReceivable_2ee9d6a9-03d3-4dc7-a3b4-1aa92f387ac0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_15c3ba85-4cb5-4863-b917-c61b5f282e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:to="loc_us-gaap_LossContingenciesTable_15c3ba85-4cb5-4863-b917-c61b5f282e13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_6d8a5d27-a057-4a78-80da-31e7302f0f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_15c3ba85-4cb5-4863-b917-c61b5f282e13" xlink:to="loc_us-gaap_LitigationStatusAxis_6d8a5d27-a057-4a78-80da-31e7302f0f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6d8a5d27-a057-4a78-80da-31e7302f0f94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_6d8a5d27-a057-4a78-80da-31e7302f0f94" xlink:to="loc_us-gaap_LitigationStatusDomain_6d8a5d27-a057-4a78-80da-31e7302f0f94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_61017148-dec7-443d-83cf-1f8209fa9279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_6d8a5d27-a057-4a78-80da-31e7302f0f94" xlink:to="loc_us-gaap_LitigationStatusDomain_61017148-dec7-443d-83cf-1f8209fa9279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_ffac5156-fb51-4420-a46d-60e7f814f842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_61017148-dec7-443d-83cf-1f8209fa9279" xlink:to="loc_us-gaap_PendingLitigationMember_ffac5156-fb51-4420-a46d-60e7f814f842" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="extended" id="if61ed6ae680f4a55894a305ed5d5fb4f_InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_719636b2-cc5d-48a3-a64d-6b5e553ff704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_719636b2-cc5d-48a3-a64d-6b5e553ff704" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d8a2ae5-1aa3-4af3-932f-2c8c5e3b28f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d8a2ae5-1aa3-4af3-932f-2c8c5e3b28f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40f84063-3fc3-46ab-b25e-fb0d2cf1a94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40f84063-3fc3-46ab-b25e-fb0d2cf1a94f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e147c92b-e1bd-42a8-ab7b-d721f76da207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e147c92b-e1bd-42a8-ab7b-d721f76da207" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_57eb3347-81c4-477e-b7df-f32fac00ab72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_57eb3347-81c4-477e-b7df-f32fac00ab72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_92dc38b7-e4aa-4751-955d-7fb7a369685a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_57eb3347-81c4-477e-b7df-f32fac00ab72" xlink:to="loc_us-gaap_FinancialInstrumentAxis_92dc38b7-e4aa-4751-955d-7fb7a369685a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92dc38b7-e4aa-4751-955d-7fb7a369685a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_92dc38b7-e4aa-4751-955d-7fb7a369685a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92dc38b7-e4aa-4751-955d-7fb7a369685a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2003fdb8-0365-43ff-80f4-8e0250363420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_92dc38b7-e4aa-4751-955d-7fb7a369685a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2003fdb8-0365-43ff-80f4-8e0250363420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3535f13e-f7dd-44f8-82db-efaa9d0e999f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2003fdb8-0365-43ff-80f4-8e0250363420" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3535f13e-f7dd-44f8-82db-efaa9d0e999f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0726e585-97de-47f1-a807-2f73cf6c1aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_57eb3347-81c4-477e-b7df-f32fac00ab72" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0726e585-97de-47f1-a807-2f73cf6c1aae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0726e585-97de-47f1-a807-2f73cf6c1aae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0726e585-97de-47f1-a807-2f73cf6c1aae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0726e585-97de-47f1-a807-2f73cf6c1aae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7488b8ed-c984-4655-89d6-c52840388184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0726e585-97de-47f1-a807-2f73cf6c1aae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7488b8ed-c984-4655-89d6-c52840388184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f8db1ad0-906e-4dcd-a56c-db9f7dda0882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7488b8ed-c984-4655-89d6-c52840388184" xlink:to="loc_us-gaap_CashEquivalentsMember_f8db1ad0-906e-4dcd-a56c-db9f7dda0882" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#InvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/InvestmentsNarrativeDetails" xlink:type="extended" id="i1c3e06bca07245bdb650c004dfb49d30_InvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8a19f816-a56d-4be8-8a4a-676e6543278d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8a19f816-a56d-4be8-8a4a-676e6543278d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_184271f1-3a32-4a2c-aeff-70fee7dd7181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_184271f1-3a32-4a2c-aeff-70fee7dd7181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f9aca585-5817-4aa6-ab23-c9ac8d3daaba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f9aca585-5817-4aa6-ab23-c9ac8d3daaba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_78ba17b9-3a23-4cb5-8e22-dcfe8309b532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_78ba17b9-3a23-4cb5-8e22-dcfe8309b532" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2d347b61-551d-4ac9-a69a-b30481d19795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2d347b61-551d-4ac9-a69a-b30481d19795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d347b61-551d-4ac9-a69a-b30481d19795_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d347b61-551d-4ac9-a69a-b30481d19795" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d347b61-551d-4ac9-a69a-b30481d19795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8eaa4240-b75e-46cd-a2f4-ed7ebdecb939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d347b61-551d-4ac9-a69a-b30481d19795" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8eaa4240-b75e-46cd-a2f4-ed7ebdecb939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_dd544bc3-5a67-444a-8eaa-168079d757f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8eaa4240-b75e-46cd-a2f4-ed7ebdecb939" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_dd544bc3-5a67-444a-8eaa-168079d757f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_89d3bb78-4d0d-4648-b45c-633cc3f353a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_89d3bb78-4d0d-4648-b45c-633cc3f353a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_89d3bb78-4d0d-4648-b45c-633cc3f353a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_89d3bb78-4d0d-4648-b45c-633cc3f353a8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_89d3bb78-4d0d-4648-b45c-633cc3f353a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2523ea7c-26dc-441f-8c9d-9b552bdf42cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_89d3bb78-4d0d-4648-b45c-633cc3f353a8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2523ea7c-26dc-441f-8c9d-9b552bdf42cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b34e6958-6393-458c-a8b7-043441c52ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2523ea7c-26dc-441f-8c9d-9b552bdf42cf" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b34e6958-6393-458c-a8b7-043441c52ae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6603a48-3abf-4b70-9160-92f993d4ee85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:to="loc_srt_RangeAxis_f6603a48-3abf-4b70-9160-92f993d4ee85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6603a48-3abf-4b70-9160-92f993d4ee85_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f6603a48-3abf-4b70-9160-92f993d4ee85" xlink:to="loc_srt_RangeMember_f6603a48-3abf-4b70-9160-92f993d4ee85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d85beeac-b3b7-4cd5-b431-c0fcbb453588" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f6603a48-3abf-4b70-9160-92f993d4ee85" xlink:to="loc_srt_RangeMember_d85beeac-b3b7-4cd5-b431-c0fcbb453588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_459a752d-c1e3-4992-82b2-81f2d48b0316" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d85beeac-b3b7-4cd5-b431-c0fcbb453588" xlink:to="loc_srt_MaximumMember_459a752d-c1e3-4992-82b2-81f2d48b0316" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i5971bacbda0d4aa5830d38fe05b41d8f_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8385d8b-5da7-4aa4-9fdb-bf2a11aeefb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c127f40b-4c6c-4855-9053-7d3506b3237e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8385d8b-5da7-4aa4-9fdb-bf2a11aeefb8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c127f40b-4c6c-4855-9053-7d3506b3237e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8385d8b-5da7-4aa4-9fdb-bf2a11aeefb8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f115e5e5-5d37-49da-a2d5-82e784f65fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f115e5e5-5d37-49da-a2d5-82e784f65fea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f115e5e5-5d37-49da-a2d5-82e784f65fea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f115e5e5-5d37-49da-a2d5-82e784f65fea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f115e5e5-5d37-49da-a2d5-82e784f65fea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e163d4-a819-479a-80ec-43bb3ab76c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f115e5e5-5d37-49da-a2d5-82e784f65fea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e163d4-a819-479a-80ec-43bb3ab76c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d69494ce-54b9-44b0-b042-bd3b6fbc8d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e163d4-a819-479a-80ec-43bb3ab76c80" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d69494ce-54b9-44b0-b042-bd3b6fbc8d83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0a4d083-1b62-4aa2-94e4-4db01a036976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0a4d083-1b62-4aa2-94e4-4db01a036976" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0a4d083-1b62-4aa2-94e4-4db01a036976_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0a4d083-1b62-4aa2-94e4-4db01a036976" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0a4d083-1b62-4aa2-94e4-4db01a036976_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0a4d083-1b62-4aa2-94e4-4db01a036976" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_770c13df-9824-4e42-81b7-1ae4bf8691c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_770c13df-9824-4e42-81b7-1ae4bf8691c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9dac1792-e1c2-42d7-9257-6a09f02ea664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9dac1792-e1c2-42d7-9257-6a09f02ea664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f623e60a-0d8a-4fcd-accd-26c76fd43b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f623e60a-0d8a-4fcd-accd-26c76fd43b9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fd528c48-2bf6-4bf8-aa9e-47169194508e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fd528c48-2bf6-4bf8-aa9e-47169194508e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd528c48-2bf6-4bf8-aa9e-47169194508e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fd528c48-2bf6-4bf8-aa9e-47169194508e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd528c48-2bf6-4bf8-aa9e-47169194508e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a35b34f-a30e-4c13-8ce7-ab1296903a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fd528c48-2bf6-4bf8-aa9e-47169194508e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a35b34f-a30e-4c13-8ce7-ab1296903a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4df26f71-179a-4446-a408-1e6e126cfaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a35b34f-a30e-4c13-8ce7-ab1296903a5e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4df26f71-179a-4446-a408-1e6e126cfaa7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" xlink:type="extended" id="iea128855982540e3805d2ad70fccc021_LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_435e38f4-6e31-45f3-8ad1-4f3d04dc3b20" xlink:href="espr-20210630.xsd#espr_GrossProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_435e38f4-6e31-45f3-8ad1-4f3d04dc3b20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_ced1935e-99c9-4e79-a045-e2126716398a" xlink:href="espr-20210630.xsd#espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_ced1935e-99c9-4e79-a045-e2126716398a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_e50d780f-c25d-4cbf-a280-d901113e31b6" xlink:href="espr-20210630.xsd#espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_e50d780f-c25d-4cbf-a280-d901113e31b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_1ea86b08-c59e-42da-9372-260d7db61438" xlink:href="espr-20210630.xsd#espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_1ea86b08-c59e-42da-9372-260d7db61438" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_ea13f8aa-aab2-4719-b7dc-23a362eb2a74" xlink:href="espr-20210630.xsd#espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_ea13f8aa-aab2-4719-b7dc-23a362eb2a74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_c30ca3c4-6908-416e-920f-890d9b44382c" xlink:href="espr-20210630.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_c30ca3c4-6908-416e-920f-890d9b44382c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierTwo_027041f2-ab94-4695-9317-58a8763bc03a" xlink:href="espr-20210630.xsd#espr_RevenueInterestRateTierTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestRateTierTwo_027041f2-ab94-4695-9317-58a8763bc03a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateInitialRate_d7d6fced-033a-4a4e-bd67-4c93c13b9280" xlink:href="espr-20210630.xsd#espr_RevenueInterestRateInitialRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestRateInitialRate_d7d6fced-033a-4a4e-bd67-4c93c13b9280" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_c1ef710d-590a-4495-8151-209e6ba73812" xlink:href="espr-20210630.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_c1ef710d-590a-4495-8151-209e6ba73812" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_9a3e5630-efe5-4e2a-8657-6505ec765b32" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_9a3e5630-efe5-4e2a-8657-6505ec765b32" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_75aa73c8-eb55-4082-a5ff-448d54f7229e" xlink:href="espr-20210630.xsd#espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_75aa73c8-eb55-4082-a5ff-448d54f7229e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierThree_f039d997-06b0-46b2-b438-4b9e3da41680" xlink:href="espr-20210630.xsd#espr_RevenueInterestRateTierThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestRateTierThree_f039d997-06b0-46b2-b438-4b9e3da41680" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_23c0e043-d204-443b-9ba2-f2b91a36be47" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_23c0e043-d204-443b-9ba2-f2b91a36be47" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised_fa77c35e-1d0a-4e9f-a673-9bda8219174c" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised_fa77c35e-1d0a-4e9f-a673-9bda8219174c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_1b8b6e35-4532-43bd-994f-f5b4bac49429" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_1b8b6e35-4532-43bd-994f-f5b4bac49429" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_e6ad16fb-d956-4aba-b6db-72eaa4d551b5" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_e6ad16fb-d956-4aba-b6db-72eaa4d551b5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_ec534ce4-0819-4803-8398-a553ca0c70ab" xlink:href="espr-20210630.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_ec534ce4-0819-4803-8398-a553ca0c70ab" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_13f24506-0343-42ce-98a2-55320fe20ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_13f24506-0343-42ce-98a2-55320fe20ab1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_bfd52c45-adb8-4865-9941-8e68296033c4" xlink:href="espr-20210630.xsd#espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_bfd52c45-adb8-4865-9941-8e68296033c4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_632f0392-d3d4-4005-a9ad-e6c44c220df9" xlink:href="espr-20210630.xsd#espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_632f0392-d3d4-4005-a9ad-e6c44c220df9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_ebfc4db8-636b-4472-be44-239379af3045" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestLiability_ebfc4db8-636b-4472-be44-239379af3045" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_952f0f09-2a2a-4c96-aad7-c16845ccd723" xlink:href="espr-20210630.xsd#espr_UnamortizedTransactionCostsOnRevenueInterestAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_952f0f09-2a2a-4c96-aad7-c16845ccd723" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f5542408-e859-4adf-8a8e-981383ff79cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_us-gaap_InterestExpense_f5542408-e859-4adf-8a8e-981383ff79cb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalSalesGeneratedAmount_e7f7010d-fe52-4069-8adf-c5c0e6d994ba" xlink:href="espr-20210630.xsd#espr_HypotheticalSalesGeneratedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_HypotheticalSalesGeneratedAmount_e7f7010d-fe52-4069-8adf-c5c0e6d994ba" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_1746a14d-c24b-4b62-a4e5-981563618bd1" xlink:href="espr-20210630.xsd#espr_HypotheticalRepaymentObligationBasedOnSalesGenerated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_1746a14d-c24b-4b62-a4e5-981563618bd1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_073917d5-0f6b-4e24-b73d-17f6fc9ce6e6" xlink:href="espr-20210630.xsd#espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_073917d5-0f6b-4e24-b73d-17f6fc9ce6e6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_50432e92-8355-4dea-bc6d-9bd6c445a1d4" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_50432e92-8355-4dea-bc6d-9bd6c445a1d4" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_bed54a30-8dbb-403e-b8fb-3c04079803a6" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_bed54a30-8dbb-403e-b8fb-3c04079803a6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_2af6a92b-40d2-4e5b-a2f3-b715a0725f13" xlink:href="espr-20210630.xsd#espr_PercentageOfCumulativePurchaserPaymentsGuarantee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_2af6a92b-40d2-4e5b-a2f3-b715a0725f13" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_7b03ae3d-5e2c-4f22-805b-778ef3f383be" xlink:href="espr-20210630.xsd#espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_7b03ae3d-5e2c-4f22-805b-778ef3f383be" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_096046b0-fb28-4cb1-899b-8c12c7c294a7" xlink:href="espr-20210630.xsd#espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_096046b0-fb28-4cb1-899b-8c12c7c294a7" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_22bc7cf5-932b-48eb-8a33-7857782f5982" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:to="loc_srt_CounterpartyNameAxis_22bc7cf5-932b-48eb-8a33-7857782f5982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22bc7cf5-932b-48eb-8a33-7857782f5982_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_22bc7cf5-932b-48eb-8a33-7857782f5982" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22bc7cf5-932b-48eb-8a33-7857782f5982_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acac852a-16b5-4953-9a11-0191d0c87991" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_22bc7cf5-932b-48eb-8a33-7857782f5982" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acac852a-16b5-4953-9a11-0191d0c87991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EigerIiiSaLlcMember_b40b4d24-f97c-4b6c-93bc-dd52e6a2774f" xlink:href="espr-20210630.xsd#espr_EigerIiiSaLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acac852a-16b5-4953-9a11-0191d0c87991" xlink:to="loc_espr_EigerIiiSaLlcMember_b40b4d24-f97c-4b6c-93bc-dd52e6a2774f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a207740d-26f1-48b4-8a4d-f196d321e33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a207740d-26f1-48b4-8a4d-f196d321e33b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a207740d-26f1-48b4-8a4d-f196d321e33b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a207740d-26f1-48b4-8a4d-f196d321e33b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a207740d-26f1-48b4-8a4d-f196d321e33b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a207740d-26f1-48b4-8a4d-f196d321e33b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember_3dabac75-f45e-44ad-bd5d-a116c82872bc" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:to="loc_espr_RevenueInterestPurchaseAgreementMember_3dabac75-f45e-44ad-bd5d-a116c82872bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_651f4c0e-e6d3-4981-8b98-8b6f0bcbb756" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:to="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_651f4c0e-e6d3-4981-8b98-8b6f0bcbb756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_d03bed7a-9982-42bb-bf00-382c9ff616c6" xlink:href="espr-20210630.xsd#espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:to="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_d03bed7a-9982-42bb-bf00-382c9ff616c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdAxis_90e299b9-02ab-42e4-ad46-81df0f652f40" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:to="loc_espr_NetSalesThresholdAxis_90e299b9-02ab-42e4-ad46-81df0f652f40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdDomain_90e299b9-02ab-42e4-ad46-81df0f652f40_default" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_espr_NetSalesThresholdAxis_90e299b9-02ab-42e4-ad46-81df0f652f40" xlink:to="loc_espr_NetSalesThresholdDomain_90e299b9-02ab-42e4-ad46-81df0f652f40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_espr_NetSalesThresholdAxis_90e299b9-02ab-42e4-ad46-81df0f652f40" xlink:to="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdOneMember_aefc90b0-f3ec-4b4a-85d2-28430a1e06dd" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:to="loc_espr_NetSalesThresholdOneMember_aefc90b0-f3ec-4b4a-85d2-28430a1e06dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdTwoMember_ccb8de26-4e66-4247-9030-0606afe4d624" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:to="loc_espr_NetSalesThresholdTwoMember_ccb8de26-4e66-4247-9030-0606afe4d624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdThreeMember_3b21803a-e30a-467e-a4ef-74d794835334" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:to="loc_espr_NetSalesThresholdThreeMember_3b21803a-e30a-467e-a4ef-74d794835334" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" xlink:type="extended" id="i28dbeb5d17974b0889e87fa656f658e2_LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_4973a04e-410a-43e2-9889-00d25e682839" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_4973a04e-410a-43e2-9889-00d25e682839" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_c4bab576-cdad-47bd-aea7-780f6e3e3a90" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:to="loc_espr_RevenueInterestLiability_c4bab576-cdad-47bd-aea7-780f6e3e3a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts_973592f8-b02c-4b54-b058-48e8cf138aa7" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:to="loc_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts_973592f8-b02c-4b54-b058-48e8cf138aa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_090c6fba-b4e1-4ceb-babf-76a53a6086b4" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:to="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_090c6fba-b4e1-4ceb-babf-76a53a6086b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_0dd2cc19-1159-4c73-85eb-399870255bdb" xlink:href="espr-20210630.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:to="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_0dd2cc19-1159-4c73-85eb-399870255bdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_7fb6919a-b97c-477d-a653-b246cb1a606e" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_b76c1189-6392-46b4-94d6-bcf2c75afca6" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_4973a04e-410a-43e2-9889-00d25e682839" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_b76c1189-6392-46b4-94d6-bcf2c75afca6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6a6a96d3-cbc5-4fed-a708-803d9db730e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_b76c1189-6392-46b4-94d6-bcf2c75afca6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6a6a96d3-cbc5-4fed-a708-803d9db730e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a6a96d3-cbc5-4fed-a708-803d9db730e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a6a96d3-cbc5-4fed-a708-803d9db730e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a6a96d3-cbc5-4fed-a708-803d9db730e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a6fcd5e-8145-422e-a565-db98b87c0344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a6a96d3-cbc5-4fed-a708-803d9db730e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a6fcd5e-8145-422e-a565-db98b87c0344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember_7bda1bd1-3e0b-4371-aeae-15e160ea26b4" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a6fcd5e-8145-422e-a565-db98b87c0344" xlink:to="loc_espr_RevenueInterestPurchaseAgreementMember_7bda1bd1-3e0b-4371-aeae-15e160ea26b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/ConvertibleNotesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#ConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/ConvertibleNotesDetails" xlink:type="extended" id="i9c56e484359e4394a8ff950707deb2d1_ConvertibleNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1fdcb98b-b43b-4616-a5ae-6069e1f92d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1fdcb98b-b43b-4616-a5ae-6069e1f92d53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f19a7a64-b85e-4e25-a992-895dcbc74651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f19a7a64-b85e-4e25-a992-895dcbc74651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6f38ca6f-9176-469d-ba0d-782b6482eb91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6f38ca6f-9176-469d-ba0d-782b6482eb91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentAdditionalAmount_d0693824-126a-4aee-853a-1e466eceee53" xlink:href="espr-20210630.xsd#espr_DebtInstrumentAdditionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_DebtInstrumentAdditionalAmount_d0693824-126a-4aee-853a-1e466eceee53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_344ebdfc-292e-47a1-aff6-6dba08d624df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_344ebdfc-292e-47a1-aff6-6dba08d624df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_9846bbc8-3371-418a-97d1-c64af81eba75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_9846bbc8-3371-418a-97d1-c64af81eba75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20affa99-cc27-491f-8725-51f9c00cb4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20affa99-cc27-491f-8725-51f9c00cb4c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6046d234-659c-4b22-baf3-cec61129ff35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6046d234-659c-4b22-baf3-cec61129ff35" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0b9c35e8-7505-44f1-afc1-f032015c2b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0b9c35e8-7505-44f1-afc1-f032015c2b03" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7d378bc-47e7-4c18-b52c-8420ebfed774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7d378bc-47e7-4c18-b52c-8420ebfed774" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ca064ce4-d756-4af2-ba34-933b6ddaab52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ca064ce4-d756-4af2-ba34-933b6ddaab52" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_45f01338-2548-403e-aa06-333166078e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_45f01338-2548-403e-aa06-333166078e48" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3acaf5a7-8185-4e92-bdb0-86483c25ad1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3acaf5a7-8185-4e92-bdb0-86483c25ad1a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfBusinessDays_bed8f81f-18e8-4800-968a-600fec5d585e" xlink:href="espr-20210630.xsd#espr_NumberOfBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_NumberOfBusinessDays_bed8f81f-18e8-4800-968a-600fec5d585e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfConsecutiveTradingDays_a0adb328-ae72-4442-87b2-f75ffaacb98c" xlink:href="espr-20210630.xsd#espr_NumberOfConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_NumberOfConsecutiveTradingDays_a0adb328-ae72-4442-87b2-f75ffaacb98c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_cd514e49-2c63-4337-a4ad-910e9484297a" xlink:href="espr-20210630.xsd#espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_cd514e49-2c63-4337-a4ad-910e9484297a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f33e7378-5a74-4929-a815-996591387d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f33e7378-5a74-4929-a815-996591387d3b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding_d60d1ba8-4f20-44ec-9760-b8bd08b8a925" xlink:href="espr-20210630.xsd#espr_DebtInstrumentCovenantRequiredAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding_d60d1ba8-4f20-44ec-9760-b8bd08b8a925" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_6256011c-17d4-4ac2-91ca-010ebea8e6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_6256011c-17d4-4ac2-91ca-010ebea8e6d4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_295229cd-aff2-4d1a-b223-3cf5fb699264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentTerm_295229cd-aff2-4d1a-b223-3cf5fb699264" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f087ac08-dd5e-40ca-86fd-51cc9a8e2f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_LongTermDebt_f087ac08-dd5e-40ca-86fd-51cc9a8e2f64" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_10b6ec69-bbd3-4211-8dac-4719dfdac477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_10b6ec69-bbd3-4211-8dac-4719dfdac477" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7daaf7b2-e12d-4c2c-8f97-6969d9b3aea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7daaf7b2-e12d-4c2c-8f97-6969d9b3aea1" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_322da80d-3306-41db-a42d-c97ca9b7fb01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_322da80d-3306-41db-a42d-c97ca9b7fb01" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_45c1fed9-0c7a-4e33-98fd-9e8026308872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_InterestExpenseDebt_45c1fed9-0c7a-4e33-98fd-9e8026308872" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6225e6cb-6e70-4c01-93d6-449b6c6514fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6225e6cb-6e70-4c01-93d6-449b6c6514fc" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aaa37202-3262-4ed4-8bd3-b0a76565ba22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aaa37202-3262-4ed4-8bd3-b0a76565ba22" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_5ded7b2b-1c4e-4265-b269-89888e9b5eec" xlink:href="espr-20210630.xsd#espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_5ded7b2b-1c4e-4265-b269-89888e9b5eec" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_bd64f0e9-733b-496d-a887-50fac0aa02fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_bd64f0e9-733b-496d-a887-50fac0aa02fc" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_96968548-efb1-4e84-9c28-03ba9c399a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_96968548-efb1-4e84-9c28-03ba9c399a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_96968548-efb1-4e84-9c28-03ba9c399a56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_96968548-efb1-4e84-9c28-03ba9c399a56" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_96968548-efb1-4e84-9c28-03ba9c399a56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dcf0ff34-bd67-4717-918e-b0ac6cafb40d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_96968548-efb1-4e84-9c28-03ba9c399a56" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dcf0ff34-bd67-4717-918e-b0ac6cafb40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConvertibleSeniorNotesDue2025Member_03cb11d1-6856-4677-909c-275c59ec06dd" xlink:href="espr-20210630.xsd#espr_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dcf0ff34-bd67-4717-918e-b0ac6cafb40d" xlink:to="loc_espr_ConvertibleSeniorNotesDue2025Member_03cb11d1-6856-4677-909c-275c59ec06dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fc71297b-2e81-4aed-a0a1-f10745c0a52f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fc71297b-2e81-4aed-a0a1-f10745c0a52f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fc71297b-2e81-4aed-a0a1-f10745c0a52f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fc71297b-2e81-4aed-a0a1-f10745c0a52f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fc71297b-2e81-4aed-a0a1-f10745c0a52f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c5c1d3b6-96f5-4e7f-8e23-eb4702b693e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fc71297b-2e81-4aed-a0a1-f10745c0a52f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c5c1d3b6-96f5-4e7f-8e23-eb4702b693e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a3d72d59-5d44-4147-9d6a-6edb6eafc911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c5c1d3b6-96f5-4e7f-8e23-eb4702b693e7" xlink:to="loc_us-gaap_ConvertibleDebtMember_a3d72d59-5d44-4147-9d6a-6edb6eafc911" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3f152bad-bee9-488d-8e3f-f4d2725371de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3f152bad-bee9-488d-8e3f-f4d2725371de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3f152bad-bee9-488d-8e3f-f4d2725371de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3f152bad-bee9-488d-8e3f-f4d2725371de" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3f152bad-bee9-488d-8e3f-f4d2725371de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d8650031-f7ff-4a55-bdaf-c481783ede3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3f152bad-bee9-488d-8e3f-f4d2725371de" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d8650031-f7ff-4a55-bdaf-c481783ede3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_e13e464d-8f02-418f-9c6f-d8cdcc55217e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d8650031-f7ff-4a55-bdaf-c481783ede3d" xlink:to="loc_us-gaap_LongTermDebtMember_e13e464d-8f02-418f-9c6f-d8cdcc55217e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c495ea60-d97a-4f6b-ad9f-a105bb2efb28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d8650031-f7ff-4a55-bdaf-c481783ede3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c495ea60-d97a-4f6b-ad9f-a105bb2efb28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b02436c4-11c2-4b53-9aa9-8fa31865515f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b02436c4-11c2-4b53-9aa9-8fa31865515f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b02436c4-11c2-4b53-9aa9-8fa31865515f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b02436c4-11c2-4b53-9aa9-8fa31865515f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b02436c4-11c2-4b53-9aa9-8fa31865515f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b8ab774d-204d-4e86-b072-935ff8fe8fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b02436c4-11c2-4b53-9aa9-8fa31865515f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b8ab774d-204d-4e86-b072-935ff8fe8fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_a290d4ed-ad23-476c-b181-e491cfd246d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b8ab774d-204d-4e86-b072-935ff8fe8fb1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_a290d4ed-ad23-476c-b181-e491cfd246d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4dd7fcdb-22fc-41ba-86b5-9a4ea7f556a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b8ab774d-204d-4e86-b072-935ff8fe8fb1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4dd7fcdb-22fc-41ba-86b5-9a4ea7f556a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_75703c75-5277-43f6-b0cd-93b908254f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_75703c75-5277-43f6-b0cd-93b908254f1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_75703c75-5277-43f6-b0cd-93b908254f1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_75703c75-5277-43f6-b0cd-93b908254f1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_75703c75-5277-43f6-b0cd-93b908254f1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2329e598-c4fc-4f7d-a806-944d1004227d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_75703c75-5277-43f6-b0cd-93b908254f1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2329e598-c4fc-4f7d-a806-944d1004227d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CappedCallMember_500c4af5-a204-494c-b616-1b70004f3f1c" xlink:href="espr-20210630.xsd#espr_CappedCallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2329e598-c4fc-4f7d-a806-944d1004227d" xlink:to="loc_espr_CappedCallMember_500c4af5-a204-494c-b616-1b70004f3f1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d908f1c1-2c73-4233-ae3d-9a68a6173752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d908f1c1-2c73-4233-ae3d-9a68a6173752" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d908f1c1-2c73-4233-ae3d-9a68a6173752_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d908f1c1-2c73-4233-ae3d-9a68a6173752" xlink:to="loc_us-gaap_ClassOfStockDomain_d908f1c1-2c73-4233-ae3d-9a68a6173752_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_61345265-1aa1-45de-98f9-59095fc7819f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d908f1c1-2c73-4233-ae3d-9a68a6173752" xlink:to="loc_us-gaap_ClassOfStockDomain_61345265-1aa1-45de-98f9-59095fc7819f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9cd15043-e051-4fae-8732-328a613ad26e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61345265-1aa1-45de-98f9-59095fc7819f" xlink:to="loc_us-gaap_CommonClassAMember_9cd15043-e051-4fae-8732-328a613ad26e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3c322402-dc9e-4fd7-9610-92882a1756fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3c322402-dc9e-4fd7-9610-92882a1756fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3c322402-dc9e-4fd7-9610-92882a1756fa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3c322402-dc9e-4fd7-9610-92882a1756fa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3c322402-dc9e-4fd7-9610-92882a1756fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0a0df4c-ddce-413e-bea7-0a5226423c46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3c322402-dc9e-4fd7-9610-92882a1756fa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0a0df4c-ddce-413e-bea7-0a5226423c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_632f5c3e-760b-4cab-9632-dd7cde2a1dac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0a0df4c-ddce-413e-bea7-0a5226423c46" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_632f5c3e-760b-4cab-9632-dd7cde2a1dac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#ConvertibleNotesSummaryofConvertibleDebtDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails" xlink:type="extended" id="i0509a2adca9843349cf43a230c2d82dd_ConvertibleNotesSummaryofConvertibleDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_57cf3a25-c048-4176-b6a8-d584a94ea464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_57cf3a25-c048-4176-b6a8-d584a94ea464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_fa9b088e-adef-487f-a05f-be12077aea22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_fa9b088e-adef-487f-a05f-be12077aea22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_288ecd6c-8109-4b83-adaa-7c8144d65220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:to="loc_us-gaap_LongTermDebt_288ecd6c-8109-4b83-adaa-7c8144d65220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2a2624d1-01ad-4b45-9533-14d61fed3852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:to="loc_us-gaap_DebtInstrumentTable_2a2624d1-01ad-4b45-9533-14d61fed3852" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_90080201-39a9-4a7d-8b51-7d1e6543111d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2a2624d1-01ad-4b45-9533-14d61fed3852" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_90080201-39a9-4a7d-8b51-7d1e6543111d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_90080201-39a9-4a7d-8b51-7d1e6543111d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_90080201-39a9-4a7d-8b51-7d1e6543111d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_90080201-39a9-4a7d-8b51-7d1e6543111d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bc3341e5-ebeb-46ab-ada4-5269ca4aa1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_90080201-39a9-4a7d-8b51-7d1e6543111d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bc3341e5-ebeb-46ab-ada4-5269ca4aa1d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_28dd3ad1-4d59-4819-b2de-5c382288fb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bc3341e5-ebeb-46ab-ada4-5269ca4aa1d9" xlink:to="loc_us-gaap_ConvertibleDebtMember_28dd3ad1-4d59-4819-b2de-5c382288fb3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6970b77-3b54-4d82-8abe-53c4bce5a2d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2a2624d1-01ad-4b45-9533-14d61fed3852" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6970b77-3b54-4d82-8abe-53c4bce5a2d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c6970b77-3b54-4d82-8abe-53c4bce5a2d3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6970b77-3b54-4d82-8abe-53c4bce5a2d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c6970b77-3b54-4d82-8abe-53c4bce5a2d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b367df3-5dcc-4b59-ad4d-6c989d0efe86" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6970b77-3b54-4d82-8abe-53c4bce5a2d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b367df3-5dcc-4b59-ad4d-6c989d0efe86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5168dafc-11eb-4be0-95d6-b3c7233ca0d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b367df3-5dcc-4b59-ad4d-6c989d0efe86" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5168dafc-11eb-4be0-95d6-b3c7233ca0d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_7d666231-0268-4d77-9356-9b2202df5755" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b367df3-5dcc-4b59-ad4d-6c989d0efe86" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_7d666231-0268-4d77-9356-9b2202df5755" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="ia58bc3ea8c4547e48ee73d7464dedab0_StockCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_99877f8f-e5da-4d8f-b45f-5bb194e5393c" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_99877f8f-e5da-4d8f-b45f-5bb194e5393c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_2228699a-313e-43ed-a9c2-fd631701e250" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_2228699a-313e-43ed-a9c2-fd631701e250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_09e0c818-6676-48b3-a210-812546f0af8f" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanPercentageDiscountOnShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_09e0c818-6676-48b3-a210-812546f0af8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_3beb58f5-7d95-4050-bea8-224a83832446" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_3beb58f5-7d95-4050-bea8-224a83832446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dbb9acdf-36fd-4e2e-ac63-757d89296a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dbb9acdf-36fd-4e2e-ac63-757d89296a3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_a2ba5459-fbaa-43f9-8a50-02c5a5c5f41e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_a2ba5459-fbaa-43f9-8a50-02c5a5c5f41e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0df52cac-8d4a-4db5-bbc3-54f437e79d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0df52cac-8d4a-4db5-bbc3-54f437e79d19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_99f9bcdd-56d8-4e58-8cf4-846455c3c613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_99f9bcdd-56d8-4e58-8cf4-846455c3c613" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f69b2b05-065a-4063-ac88-949821c9f5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_99f9bcdd-56d8-4e58-8cf4-846455c3c613" xlink:to="loc_us-gaap_AwardTypeAxis_f69b2b05-065a-4063-ac88-949821c9f5d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f69b2b05-065a-4063-ac88-949821c9f5d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f69b2b05-065a-4063-ac88-949821c9f5d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f69b2b05-065a-4063-ac88-949821c9f5d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a14d83-c2ac-4833-b4aa-eadbb2c9e3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f69b2b05-065a-4063-ac88-949821c9f5d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a14d83-c2ac-4833-b4aa-eadbb2c9e3c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a0aa5f61-4b64-41db-8143-b4a5fb767951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a14d83-c2ac-4833-b4aa-eadbb2c9e3c1" xlink:to="loc_us-gaap_EmployeeStockMember_a0aa5f61-4b64-41db-8143-b4a5fb767951" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationStockOptionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" xlink:type="extended" id="i1ee32f610a6949b48bdd24d9645475e3_StockCompensationStockOptionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28da6ef6-137c-43bc-b10b-64daf458b0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28da6ef6-137c-43bc-b10b-64daf458b0e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cfa4cf52-b7a0-4a32-9fd7-78f71542807f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cfa4cf52-b7a0-4a32-9fd7-78f71542807f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ea1f32ca-980a-4a28-a481-40684dc8f270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ea1f32ca-980a-4a28-a481-40684dc8f270" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4e30f4fb-4d4d-4d25-b646-41581a72a228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4e30f4fb-4d4d-4d25-b646-41581a72a228" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d697a88-97ca-4400-b763-918678addeb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d697a88-97ca-4400-b763-918678addeb4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a1f65da7-f58f-4058-9039-d8cf615737e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d697a88-97ca-4400-b763-918678addeb4" xlink:to="loc_us-gaap_AwardTypeAxis_a1f65da7-f58f-4058-9039-d8cf615737e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1f65da7-f58f-4058-9039-d8cf615737e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a1f65da7-f58f-4058-9039-d8cf615737e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1f65da7-f58f-4058-9039-d8cf615737e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_709845d1-2e38-467b-b560-37246398b089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a1f65da7-f58f-4058-9039-d8cf615737e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_709845d1-2e38-467b-b560-37246398b089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_affbf4ea-cb19-4928-ba57-1b38b4619705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_709845d1-2e38-467b-b560-37246398b089" xlink:to="loc_us-gaap_EmployeeStockOptionMember_affbf4ea-cb19-4928-ba57-1b38b4619705" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationRSUsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockCompensationRSUsDetails" xlink:type="extended" id="ie39f4e9fd51a404ca1321666126edad8_StockCompensationRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfba4702-5fd0-4581-9bf9-faed1772dcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfba4702-5fd0-4581-9bf9-faed1772dcf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0de8db6f-ab66-48c9-a63c-3dbfeab4cf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0de8db6f-ab66-48c9-a63c-3dbfeab4cf8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_006089d3-1c5d-4600-907a-af03bd034b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_006089d3-1c5d-4600-907a-af03bd034b0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_99c2d7eb-6390-46f0-83f5-b3f247e19710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_99c2d7eb-6390-46f0-83f5-b3f247e19710" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ee5654e1-3c66-4f16-bffa-9090e6c838f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ee5654e1-3c66-4f16-bffa-9090e6c838f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a25252f-880f-4b26-80ec-40bb4a2d5b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfba4702-5fd0-4581-9bf9-faed1772dcf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_920e5685-660f-4f48-9816-dd77f7da5b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_920e5685-660f-4f48-9816-dd77f7da5b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8db87a83-4d1b-4247-a53c-17e108628a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8db87a83-4d1b-4247-a53c-17e108628a42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e73e7f11-f86e-4e2b-8c2c-56d421d8cf23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e73e7f11-f86e-4e2b-8c2c-56d421d8cf23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_860fd9fe-6296-4fa2-8552-ca09ff56b5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_860fd9fe-6296-4fa2-8552-ca09ff56b5d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d969cf6a-3016-433e-96d1-6798d6a7fc89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e6f74de-7b6a-4859-b5bf-d203b4708c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfba4702-5fd0-4581-9bf9-faed1772dcf2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e6f74de-7b6a-4859-b5bf-d203b4708c38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5669057c-2a88-4654-b47e-c04d565d629f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e6f74de-7b6a-4859-b5bf-d203b4708c38" xlink:to="loc_us-gaap_AwardTypeAxis_5669057c-2a88-4654-b47e-c04d565d629f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5669057c-2a88-4654-b47e-c04d565d629f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5669057c-2a88-4654-b47e-c04d565d629f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5669057c-2a88-4654-b47e-c04d565d629f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_769c970a-2cb3-4c11-ade0-9d5109466eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5669057c-2a88-4654-b47e-c04d565d629f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_769c970a-2cb3-4c11-ade0-9d5109466eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_35ce048e-88a9-4851-b1da-38a36f4b41c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_769c970a-2cb3-4c11-ade0-9d5109466eda" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_35ce048e-88a9-4851-b1da-38a36f4b41c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationRSUsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails" xlink:type="extended" id="i0863c655d83c415f878f1ec33202e765_StockCompensationRSUsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f5f27111-1002-412a-bcf3-9be7c664b81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f5f27111-1002-412a-bcf3-9be7c664b81f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf623904-0805-4a81-956e-110c61366d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf623904-0805-4a81-956e-110c61366d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_45ca1e9a-ad58-40a5-a612-63b6e0ed73fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_45ca1e9a-ad58-40a5-a612-63b6e0ed73fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2cac2015-fcfa-44e7-91e5-192ed2936142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2cac2015-fcfa-44e7-91e5-192ed2936142" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae46500-eed1-43a7-b665-edc708c5e817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae46500-eed1-43a7-b665-edc708c5e817" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a523ae9d-6d83-47a9-bb2e-f9798beb7891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae46500-eed1-43a7-b665-edc708c5e817" xlink:to="loc_us-gaap_AwardTypeAxis_a523ae9d-6d83-47a9-bb2e-f9798beb7891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a523ae9d-6d83-47a9-bb2e-f9798beb7891_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a523ae9d-6d83-47a9-bb2e-f9798beb7891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a523ae9d-6d83-47a9-bb2e-f9798beb7891_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08432d37-7fad-485d-9aa4-cd02940975b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a523ae9d-6d83-47a9-bb2e-f9798beb7891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08432d37-7fad-485d-9aa4-cd02940975b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4080bb3c-f34b-452e-b43f-e483f9c6096f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08432d37-7fad-485d-9aa4-cd02940975b6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4080bb3c-f34b-452e-b43f-e483f9c6096f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationPBRSUsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationPBRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockCompensationPBRSUsDetails" xlink:type="extended" id="ica56c133504943b9870dc638d8b697e5_StockCompensationPBRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a46b153f-814d-4095-a1c4-aef892b7e16f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a46b153f-814d-4095-a1c4-aef892b7e16f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e67aa3f2-7437-4129-b107-d2268a45ea16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e67aa3f2-7437-4129-b107-d2268a45ea16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2dbc957-2e79-4740-a379-525f6e50d752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2dbc957-2e79-4740-a379-525f6e50d752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb039495-82b0-483e-abec-544f216c6c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb039495-82b0-483e-abec-544f216c6c6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c5d03a51-09f6-4adf-a7aa-e8d2aecfd34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb039495-82b0-483e-abec-544f216c6c6e" xlink:to="loc_us-gaap_AwardTypeAxis_c5d03a51-09f6-4adf-a7aa-e8d2aecfd34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5d03a51-09f6-4adf-a7aa-e8d2aecfd34a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c5d03a51-09f6-4adf-a7aa-e8d2aecfd34a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5d03a51-09f6-4adf-a7aa-e8d2aecfd34a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc8214bc-8dbd-4c62-ba7a-1d8e3d93f505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c5d03a51-09f6-4adf-a7aa-e8d2aecfd34a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc8214bc-8dbd-4c62-ba7a-1d8e3d93f505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0c4904a9-7bf2-4807-818b-bfeaff8a8465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc8214bc-8dbd-4c62-ba7a-1d8e3d93f505" xlink:to="loc_us-gaap_PerformanceSharesMember_0c4904a9-7bf2-4807-818b-bfeaff8a8465" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails" xlink:type="extended" id="i75263d2179554b228788d567e3a7c3fd_NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f6f5881-1a37-4b8b-a9c2-1a08bfbb67db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_NetIncomeLoss_1f6f5881-1a37-4b8b-a9c2-1a08bfbb67db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7ae24ee-4f89-436d-9b20-66fe809a8e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7ae24ee-4f89-436d-9b20-66fe809a8e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_66b0aeac-f6f8-4d89-a8cd-bff79f9cbd7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_66b0aeac-f6f8-4d89-a8cd-bff79f9cbd7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0f4ff87c-4417-4609-aa8b-c5b4b5b626d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0f4ff87c-4417-4609-aa8b-c5b4b5b626d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d5170ab0-2563-496e-8e92-8eb9be370684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d5170ab0-2563-496e-8e92-8eb9be370684" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4d3c2e19-29c4-42d4-94fb-c9ce3f7e5bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_EarningsPerShareBasic_4d3c2e19-29c4-42d4-94fb-c9ce3f7e5bc5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2876b6b2-4e33-4d2f-850f-363a2ac868ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2876b6b2-4e33-4d2f-850f-363a2ac868ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cad178ea-5e6d-4ddf-9529-cdb875193160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cad178ea-5e6d-4ddf-9529-cdb875193160" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a3851b1-3229-41a8-93b0-1979a7c72455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cad178ea-5e6d-4ddf-9529-cdb875193160" xlink:to="loc_us-gaap_AwardTypeAxis_0a3851b1-3229-41a8-93b0-1979a7c72455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a3851b1-3229-41a8-93b0-1979a7c72455_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0a3851b1-3229-41a8-93b0-1979a7c72455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a3851b1-3229-41a8-93b0-1979a7c72455_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8a07d8-c0b7-4c7d-9bd9-ed1a3d4e827a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0a3851b1-3229-41a8-93b0-1979a7c72455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8a07d8-c0b7-4c7d-9bd9-ed1a3d4e827a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f23af18c-9908-4868-8d7c-f86df5b77c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8a07d8-c0b7-4c7d-9bd9-ed1a3d4e827a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f23af18c-9908-4868-8d7c-f86df5b77c7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2318565f-f35f-4942-a51d-a5a994bdb301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8a07d8-c0b7-4c7d-9bd9-ed1a3d4e827a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2318565f-f35f-4942-a51d-a5a994bdb301" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShareDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#NetLossIncomePerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/NetLossIncomePerCommonShareDetails" xlink:type="extended" id="i3966ff8c1b184324aa50d1c2734dccdb_NetLossIncomePerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa993461-f9bd-4bd7-9d34-708bdcfdd884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0ad83e9f-3fdf-4322-97e5-923e01ba5dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa993461-f9bd-4bd7-9d34-708bdcfdd884" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0ad83e9f-3fdf-4322-97e5-923e01ba5dc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7e625a-36de-4013-9963-0a138e9e9b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa993461-f9bd-4bd7-9d34-708bdcfdd884" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7e625a-36de-4013-9963-0a138e9e9b5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4e03f2f-3d2e-4263-aba8-8812a43a04b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7e625a-36de-4013-9963-0a138e9e9b5a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4e03f2f-3d2e-4263-aba8-8812a43a04b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d4e03f2f-3d2e-4263-aba8-8812a43a04b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4e03f2f-3d2e-4263-aba8-8812a43a04b3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d4e03f2f-3d2e-4263-aba8-8812a43a04b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4e03f2f-3d2e-4263-aba8-8812a43a04b3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8efc78c8-70db-4e59-b3a2-5e1fb7df16f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8efc78c8-70db-4e59-b3a2-5e1fb7df16f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_1354655f-61a0-48df-9931-031b7b384dbc" xlink:href="espr-20210630.xsd#espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_1354655f-61a0-48df-9931-031b7b384dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_dc8f28cb-007c-4579-b8a0-997f265bcd45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_us-gaap_PerformanceSharesMember_dc8f28cb-007c-4579-b8a0-997f265bcd45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c9b13049-3464-4c67-ae98-fb8bf5a6df49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_us-gaap_EmployeeStockMember_c9b13049-3464-4c67-ae98-fb8bf5a6df49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_5719335c-801a-4796-9918-305a68b258ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_5719335c-801a-4796-9918-305a68b258ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2bba8ba-59db-453d-b034-5098082408e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7e625a-36de-4013-9963-0a138e9e9b5a" xlink:to="loc_us-gaap_AwardTypeAxis_d2bba8ba-59db-453d-b034-5098082408e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2bba8ba-59db-453d-b034-5098082408e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d2bba8ba-59db-453d-b034-5098082408e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2bba8ba-59db-453d-b034-5098082408e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ee6070-9ce7-4b1f-99ba-600f7b9ffa50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d2bba8ba-59db-453d-b034-5098082408e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ee6070-9ce7-4b1f-99ba-600f7b9ffa50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_21b5014b-cfc4-430b-84e5-39520f5af692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ee6070-9ce7-4b1f-99ba-600f7b9ffa50" xlink:to="loc_us-gaap_EmployeeStockOptionMember_21b5014b-cfc4-430b-84e5-39520f5af692" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>espr-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d960a0e3-43c0-4beb-a690-4f9d75967096,g:902768da-5c62-49b7-8ede-3e343f3fe2f7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a29073e4-b9b0-4da0-8e33-0ce28893af92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_77ea5e80-e941-4e3f-8a4e-7c465eaf8499_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivables</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fcd9c1d7-288c-4b02-950b-b8c3c3b4d5aa_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f0a9cb2b-65cc-4dbd-9236-fcd5405f9d4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8d0be9ad-2d8d-40e2-ae9c-cb1e54d6ab2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PrepaidClinicalDevelopmentCostsCurrent_96b6773a-8631-43d9-8901-cd6d9abc81c0_terseLabel_en-US" xlink:label="lab_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical development costs</link:label>
    <link:label id="lab_espr_PrepaidClinicalDevelopmentCostsCurrent_label_en-US" xlink:label="lab_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Development Costs, Current</link:label>
    <link:label id="lab_espr_PrepaidClinicalDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:href="espr-20210630.xsd#espr_PrepaidClinicalDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:to="lab_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ae837e65-4b81-48a6-bae1-16753f5888be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_335f4dc4-46e5-4aba-85d9-63e786b909de_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_8775f282-4bed-4c4d-ac97-fe2a66320ff8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_08466e34-00a7-473f-b807-f4304805f435_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4509e806-30dd-41f7-9d6a-5fca3c2ac09f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DaiichiSankyoEuropeGmbhMember_83355f2a-d442-4608-81ec-0a812a6384b2_terseLabel_en-US" xlink:label="lab_espr_DaiichiSankyoEuropeGmbhMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Europe GmbH ("DSE")</link:label>
    <link:label id="lab_espr_DaiichiSankyoEuropeGmbhMember_label_en-US" xlink:label="lab_espr_DaiichiSankyoEuropeGmbhMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Europe Gmbh [Member]</link:label>
    <link:label id="lab_espr_DaiichiSankyoEuropeGmbhMember_documentation_en-US" xlink:label="lab_espr_DaiichiSankyoEuropeGmbhMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member stands for the Daiichi Sankyo Europe GmbH ("DSE").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoEuropeGmbhMember" xlink:href="espr-20210630.xsd#espr_DaiichiSankyoEuropeGmbhMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DaiichiSankyoEuropeGmbhMember" xlink:to="lab_espr_DaiichiSankyoEuropeGmbhMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ExclusiveDevelopmentalActivitiesMember_d33bbf08-1e46-423e-bd23-abab9be86ad3_terseLabel_en-US" xlink:label="lab_espr_ExclusiveDevelopmentalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Developmental Activities</link:label>
    <link:label id="lab_espr_ExclusiveDevelopmentalActivitiesMember_label_en-US" xlink:label="lab_espr_ExclusiveDevelopmentalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Developmental Activities [Member]</link:label>
    <link:label id="lab_espr_ExclusiveDevelopmentalActivitiesMember_documentation_en-US" xlink:label="lab_espr_ExclusiveDevelopmentalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to exclusive developmental activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ExclusiveDevelopmentalActivitiesMember" xlink:href="espr-20210630.xsd#espr_ExclusiveDevelopmentalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ExclusiveDevelopmentalActivitiesMember" xlink:to="lab_espr_ExclusiveDevelopmentalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_adb0b3a6-347e-4808-9748-d7307296962d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_MilestoneMarketingAuthorizationApprovalNustendiMember_f48a65ff-cab3-4aaf-880e-7eac62c40553_terseLabel_en-US" xlink:label="lab_espr_MilestoneMarketingAuthorizationApprovalNustendiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NUSTENDI, MAA</link:label>
    <link:label id="lab_espr_MilestoneMarketingAuthorizationApprovalNustendiMember_label_en-US" xlink:label="lab_espr_MilestoneMarketingAuthorizationApprovalNustendiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Marketing Authorization Approval Nustendi [Member]</link:label>
    <link:label id="lab_espr_MilestoneMarketingAuthorizationApprovalNustendiMember_documentation_en-US" xlink:label="lab_espr_MilestoneMarketingAuthorizationApprovalNustendiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to marketing authorization approval (MAA) for NUSTENDI.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MilestoneMarketingAuthorizationApprovalNustendiMember" xlink:href="espr-20210630.xsd#espr_MilestoneMarketingAuthorizationApprovalNustendiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_MilestoneMarketingAuthorizationApprovalNustendiMember" xlink:to="lab_espr_MilestoneMarketingAuthorizationApprovalNustendiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_761f6d77-2d92-4632-8e58-e4f22712a254_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_1e7429e6-e1ca-40d3-841d-d98021c6b450_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_19e51838-f2f5-4982-9709-b9c4ac94f6bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_ca101b04-f382-40a8-9261-644700b7b36f_verboseLabel_en-US" xlink:label="lab_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from revenue interest liability, net of issuance costs</link:label>
    <link:label id="lab_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_label_en-US" xlink:label="lab_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Revenue Interest Purchase Agreement, Net of Issuance Costs</link:label>
    <link:label id="lab_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from a revenue interest purchase agreement, net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:href="espr-20210630.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:to="lab_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NumberOfConsecutiveTradingDays_a9897a54-7128-446c-86d3-8d4e1fff8846_terseLabel_en-US" xlink:label="lab_espr_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days</link:label>
    <link:label id="lab_espr_NumberOfConsecutiveTradingDays_label_en-US" xlink:label="lab_espr_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consecutive Trading Days</link:label>
    <link:label id="lab_espr_NumberOfConsecutiveTradingDays_documentation_en-US" xlink:label="lab_espr_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfConsecutiveTradingDays" xlink:href="espr-20210630.xsd#espr_NumberOfConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NumberOfConsecutiveTradingDays" xlink:to="lab_espr_NumberOfConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3d3757c1-be4d-47c8-ae1d-a7bf64376753_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_292935de-28c5-4ba4-8ac1-de3d044551ac_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25516c0c-c8f9-4ab2-9975-0f32d751860d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_471703d6-575e-4106-8f16-c8904af226a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_920e9134-b7c5-48ce-853d-03445237aeb6_terseLabel_en-US" xlink:label="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone amount for worldwide sales to receive the third payment</link:label>
    <link:label id="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_label_en-US" xlink:label="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Amount for Worldwide Sales to Receive Third Payment</link:label>
    <link:label id="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_documentation_en-US" xlink:label="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone amount for worldwide sales to receive the Third Payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:href="espr-20210630.xsd#espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:to="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b037b249-5e9b-462a-8dad-df8bdd4c5cc5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_cdce745d-5131-409b-9126-84896f2ebc2c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_74673918-4fb9-4bc1-af5f-af428563c329_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d50d2523-dd51-48ed-9366-e50864dd5848_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_13cea90e-0c08-4640-81b2-c98a8461aeec_terseLabel_en-US" xlink:label="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of increase in royalty rate upon drawdown of third payment</link:label>
    <link:label id="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_label_en-US" xlink:label="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Increase in Royalty Rate Upon Drawdown of Third Payment</link:label>
    <link:label id="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_documentation_en-US" xlink:label="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of increase in the Royalty Rate upon drawdown of the Third Payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:href="espr-20210630.xsd#espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:to="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9760987a-8847-40c0-a03e-6337ec816a43_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e1b68766-8a30-44d2-92f5-fd278995d231_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PBRSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_4e32fa89-b9b0-4989-b654-b94a3d0efc74_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested PBRSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_713824fb-e900-4e67-9e79-54125051e178_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aad8321f-1eee-41c1-99e8-854398b206cd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at the beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0338380d-e5f6-447c-bfdd-5b0b85748199_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at the at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_1a0f3e38-64b2-444c-8950-8c211f8ef511_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0ed2230c-a54f-4882-b851-887d9c828676_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_a27d0e3a-f81a-425e-86d0-740e50e6e941_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on modification of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_59d4c457-3063-4939-b4ab-7b5b5049a722_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment of forward stock repurchase transaction</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ab317b3b-23e2-41a3-9db9-5f7260c26b3f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5b4078b3-aef4-486a-b5c9-743d657b3c0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d323155b-f734-49f4-92b7-8720abba7f15_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_6bf19600-44f4-412e-8e4c-5477e8f0b21d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_35c7a9d5-39de-43b6-bcae-7cd597664edb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8bec2ddf-03dc-45fb-a453-873a0953135d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ea1c307a-d43c-458f-b482-f74ebe9072a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3b2efaab-bf03-409a-8c20-0721e9c9a596_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Information About the Company's Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7a4bb2a5-ee98-4688-a57b-925adcfdcb17_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ee0d6f88-71e0-4f90-bf7d-a131024a37ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2318b183-8c4c-490e-bc0e-1a903f1f2de0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_ddc0b8a6-9b95-4348-80aa-4aadf6d7c8df_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_81a48a3d-2d04-4e93-97c5-1d888dcbd642_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_088a8f33-2e8d-4c58-b0b5-27977f437acf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ccf384a1-59f1-42fa-b8ff-b9fe07fa2870_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_131a438c-d68c-4719-9943-8a2a777c6451_terseLabel_en-US" xlink:label="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:href="espr-20210630.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c7ed979f-0eba-40a5-8804-7bf2f5de806f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivable_771c7f11-12e1-490b-9608-aaf8de2d92df_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance settlement recovery</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivable_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivable" xlink:to="lab_us-gaap_LossContingencyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CollaborationRevenueMember_cf2e6803-a952-4b78-a182-3005205efa4e_terseLabel_en-US" xlink:label="lab_espr_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_espr_CollaborationRevenueMember_label_en-US" xlink:label="lab_espr_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_espr_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_espr_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to collaboration revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborationRevenueMember" xlink:href="espr-20210630.xsd#espr_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CollaborationRevenueMember" xlink:to="lab_espr_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_d4237d1c-890d-4244-9d7d-4f6a66442520_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d9b40be5-4178-4615-a7c5-0329e96708b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9aebf415-1b2b-4ccc-a469-f754050efbd5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of June&#160;30, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e534151f-1871-40b2-b3d7-623a4e903f0a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_229ef2b4-ff09-46cd-9696-fd5ed51c484e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7e1a4592-aaac-4858-9c11-443595f824dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e7e073d7-449d-4efa-8d5f-f85f3f46b9be_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember_1c66eacc-ec1f-4d55-b515-39321fccae67_terseLabel_en-US" xlink:label="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi</link:label>
    <link:label id="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember_label_en-US" xlink:label="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi [Member]</link:label>
    <link:label id="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember_documentation_en-US" xlink:label="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:href="espr-20210630.xsd#espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:to="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_743c1aa9-76a1-4cd4-826d-c0ebf959b712_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f035e37f-0f7b-4933-beab-e9d9de504afb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FuturePaymentMilestoneSalesMilestones_afa7d13b-98c4-4635-a9db-4fc143fd18cf_terseLabel_en-US" xlink:label="lab_espr_FuturePaymentMilestoneSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments related to total net sales achievements</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneSalesMilestones_label_en-US" xlink:label="lab_espr_FuturePaymentMilestoneSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payment Milestone, Sales Milestones</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneSalesMilestones_documentation_en-US" xlink:label="lab_espr_FuturePaymentMilestoneSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneSalesMilestones" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FuturePaymentMilestoneSalesMilestones" xlink:to="lab_espr_FuturePaymentMilestoneSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_8a75b5da-4dcf-4343-9123-f1aee0713e0d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_efbb03bd-9a0c-40c2-8341-b589161dc9a0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fd39d902-657a-4276-8ad0-37f875e579e2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_c064a7bc-6308-4e63-99d8-0a858af9e5a9_terseLabel_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of subsequent installment, subject to regulatory approval</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_label_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Subsequent Installment, Subject to Regulatory Approval</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_documentation_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of the subsequent installment which is subject to regulatory approval.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:href="espr-20210630.xsd#espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:to="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_62d54ea8-51db-4508-a177-83aa64f8ac28_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1164e8da-13ea-456e-97e0-320d4b6df77b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_7031e6a1-5b9a-4c14-ae39-6885241e1d6f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a80d4076-23aa-4b84-be06-561f8efafc51_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_322fd029-339e-48bb-8824-4d755b6bb419_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3b0c34ee-5e41-4f0a-8010-e42aec0c2aa2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_f6105fd6-6ba1-4f91-bc9a-068d976a0193_terseLabel_en-US" xlink:label="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive number of months sales must be at or above milestone amount</link:label>
    <link:label id="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_label_en-US" xlink:label="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive Number of Months Sales Must Be At or Above Milestone Amount</link:label>
    <link:label id="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_documentation_en-US" xlink:label="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The consecutive number of months sales must be at or above the milestone amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:href="espr-20210630.xsd#espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:to="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_8f7b9114-7f13-4ea8-8468-aee649ac6beb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b390d887-cea9-4427-b9c5-bd5c35321182_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_94d51c48-7d42-4d39-84d9-a3e69be55bd2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_4ffabfff-02db-4ebd-8fd6-9b919fadf11c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_1ec9d6a1-f7ca-4113-8e24-3819a14c64b0_terseLabel_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount of subsequent installment, subject to RIPA terms and conditions</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_label_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Subsequent Installment, Subject to Revenue Interest Purchase Agreement Terms and Conditions</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_documentation_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:href="espr-20210630.xsd#espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:to="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_80182f54-4487-4f70-a3a6-8ae1207dbb07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_4cb1fd6b-5e48-4a8d-9ac5-cdf4fb81ec57_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest on convertible notes</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dbaf2497-12be-4958-9ee6-680777789e76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FutureUpFrontPayment_2b8bb4c6-1e17-4014-8aaa-4e0ec019aac1_terseLabel_en-US" xlink:label="lab_espr_FutureUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future upfront payment</link:label>
    <link:label id="lab_espr_FutureUpFrontPayment_label_en-US" xlink:label="lab_espr_FutureUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Up-Front Payment</link:label>
    <link:label id="lab_espr_FutureUpFrontPayment_documentation_en-US" xlink:label="lab_espr_FutureUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Up-Front Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FutureUpFrontPayment" xlink:href="espr-20210630.xsd#espr_FutureUpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FutureUpFrontPayment" xlink:to="lab_espr_FutureUpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4e5585df-c2ef-4b30-837f-be5978d2ef4d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember_94d072b4-8e0d-4a2c-ab12-9163cc750e0e_terseLabel_en-US" xlink:label="lab_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License To Intellectual Property</link:label>
    <link:label id="lab_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember_label_en-US" xlink:label="lab_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License To Intellectual Property [Member]</link:label>
    <link:label id="lab_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember_documentation_en-US" xlink:label="lab_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License To Intellectual Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember" xlink:href="espr-20210630.xsd#espr_CollaborativeArrangementLicenseToIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember" xlink:to="lab_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3f239279-45af-4b82-b41d-9da6271e6519_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_6c5afa90-603f-4744-bbd2-3ce5019861a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable upon conversion of convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_291c4064-7bfb-43f8-9dfb-5ef8650c5408_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_58e34cf6-493a-404e-b30c-bedf6ee9ccec_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e563b539-12f8-43ff-982f-8c3e0fdcc9ec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_81e386ce-ecb3-4d5d-91ef-eb76cd37a012_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NumberOfBusinessDays_0673cdba-e6b1-4446-9b63-93bdaacd91b1_terseLabel_en-US" xlink:label="lab_espr_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business days</link:label>
    <link:label id="lab_espr_NumberOfBusinessDays_label_en-US" xlink:label="lab_espr_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Days</link:label>
    <link:label id="lab_espr_NumberOfBusinessDays_documentation_en-US" xlink:label="lab_espr_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfBusinessDays" xlink:href="espr-20210630.xsd#espr_NumberOfBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NumberOfBusinessDays" xlink:to="lab_espr_NumberOfBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestRateTierTwo_79265276-57ed-48c3-b373-15136f0788d1_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestRateTierTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021</link:label>
    <link:label id="lab_espr_RevenueInterestRateTierTwo_label_en-US" xlink:label="lab_espr_RevenueInterestRateTierTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Rate, Tier Two</link:label>
    <link:label id="lab_espr_RevenueInterestRateTierTwo_documentation_en-US" xlink:label="lab_espr_RevenueInterestRateTierTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierTwo" xlink:href="espr-20210630.xsd#espr_RevenueInterestRateTierTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestRateTierTwo" xlink:to="lab_espr_RevenueInterestRateTierTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37c97640-3564-4a8d-9738-be59ede2f54e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_33f66e67-21e1-402a-9dbd-e5cf676a630c_terseLabel_en-US" xlink:label="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of last reported sale price</link:label>
    <link:label id="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_label_en-US" xlink:label="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price</link:label>
    <link:label id="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_documentation_en-US" xlink:label="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:href="espr-20210630.xsd#espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:to="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d3863a1a-9e03-4a77-b1a3-2ce65c652d49_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_abdde30e-4e42-42b6-9a7e-5be64e96b439_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e9a9451c-0da1-4ec6-b0d9-1b2aac1b1768_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_c7ac16bf-e279-4381-a9c2-74508a6fc137_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_685b51dd-3d45-458c-9b11-559ee575d7d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ca5b769e-8e9c-45cd-bb6c-5b9092481b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales/maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_74a8031c-4458-4327-b599-5105baa867e0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_dfa9e545-cf9e-4dbe-a1c9-8cd3a3ab295e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculation of Basic and Diluted (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestRateTierThree_c1037351-77ab-4958-9699-f270560849f8_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestRateTierThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024</link:label>
    <link:label id="lab_espr_RevenueInterestRateTierThree_label_en-US" xlink:label="lab_espr_RevenueInterestRateTierThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Rate, Tier Three</link:label>
    <link:label id="lab_espr_RevenueInterestRateTierThree_documentation_en-US" xlink:label="lab_espr_RevenueInterestRateTierThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierThree" xlink:href="espr-20210630.xsd#espr_RevenueInterestRateTierThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestRateTierThree" xlink:to="lab_espr_RevenueInterestRateTierThree" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_b38ed160-a273-4bff-ae09-67fe56b69fc1_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interests Payment on Which Agreement Terminates After the Third Anniversary Of Closing Date If Put Option Is Exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:to="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_52ae0775-c6a7-46bc-b314-cea177b66049_terseLabel_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment, first JNDA submissions</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_label_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payment Milestone, First Submission of Japanese New Drug Application, Otsuka Territory</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_documentation_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:to="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8491f216-990f-44e0-ac4c-aa7bcc536f27_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_cdf91551-24ed-4c19-8ca3-8e22bf82706c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_829f1306-8e49-4779-af41-c3b72a738530_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ddbd5665-c1ba-4b2e-805a-f1d14fbd8425_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf5015d-a582-475f-92e3-38d11516fc50_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1dc3a31e-268b-45a1-99f8-810fcc87fb4d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment not yet paid</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_03428666-58f2-4fa1-8e87-156d06efb081_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9c52ab19-1aab-40f1-9584-b55b30279184_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6af67cc4-d817-431a-9baa-be7e85c37f0b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_41fef430-bd4f-41d1-8261-727f654187d4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_54f59340-b465-48f1-98ad-8b51868076d7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_32460ded-a81f-43bd-b532-a1518a2a3e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ef555847-e8db-4931-b529-dc04971f3edb_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_16d8a7e5-aa8e-4953-bbc1-cf87333d4928_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable related to the ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_7defa511-3b74-4091-a77b-fcbf86b909a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Relating to the Company's RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8ddd1c03-6ab5-4b20-9729-400d50de2d67_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_969012a5-ec49-4ff0-b6e5-c4ee9d714cfa_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesTable_f19354be-93a8-43f1-8fe4-4b8849a557d0_terseLabel_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability from Sale of Future Revenues [Table]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesTable_label_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability from Sale of Future Revenues [Table]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesTable_documentation_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about liabilities from the sale of future royalty revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:to="lab_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3c003c09-da00-4a56-b34e-1d2358427cf6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4a58731a-4aee-421e-98e4-b9890481996b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c037a10b-895f-43a1-9684-02b56caf6902_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DebtInstrumentAdditionalAmount_f51f0977-2452-43ff-84c6-a10c36c44fb7_terseLabel_en-US" xlink:label="lab_espr_DebtInstrumentAdditionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, additional principal amount</link:label>
    <link:label id="lab_espr_DebtInstrumentAdditionalAmount_label_en-US" xlink:label="lab_espr_DebtInstrumentAdditionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Amount</link:label>
    <link:label id="lab_espr_DebtInstrumentAdditionalAmount_documentation_en-US" xlink:label="lab_espr_DebtInstrumentAdditionalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentAdditionalAmount" xlink:href="espr-20210630.xsd#espr_DebtInstrumentAdditionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DebtInstrumentAdditionalAmount" xlink:to="lab_espr_DebtInstrumentAdditionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_93afb3f4-af01-4ca2-abce-431817e1b5dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8e7cbbb5-441b-4fa6-acd9-bb4e1b3db163_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f670f94a-3ed4-490e-98c8-175230d74e40_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_02cd720c-673a-4f47-aa2d-6a5da5c0d0a9_terseLabel_en-US" xlink:label="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenue Interest Liability Activity During the Period</link:label>
    <link:label id="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_label_en-US" xlink:label="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Interest Liability [Table Text Block]</link:label>
    <link:label id="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of information pertaining to the revenue interest liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:href="espr-20210630.xsd#espr_ScheduleOfRevenueInterestLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:to="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6708f1d6-b04b-4759-ac01-e7aac53148aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at the beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d34ddf53-09c9-4289-af80-9b2319a17f64_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at the ending of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5353310c-292a-41f2-b8c0-d2c6c6b1466e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_139e1b48-1152-496e-b603-f961a4da41db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_839e4a36-f650-45dd-b9df-c1ff47880157_terseLabel_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase discount</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_label_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Percentage Discount on Shares</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_documentation_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanPercentageDiscountOnShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:to="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_98d02b16-1f22-43ed-8dad-a8a1f158562e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cac440d2-d3f8-4403-8f90-f248979c31bb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c7773d75-4271-49c4-a00f-553805289610_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7565b77d-e7c3-4221-ae4a-d3372155c801_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_59d7787d-1a52-407f-b615-d922d7fe3354_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_5af6f9cd-971c-4282-b56e-6d06c577b2cd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_34501210-f6b0-46de-92ff-5b8b5d3896ab_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interest payments to qualify for third payment applicable percentage</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:to="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember_7f33e0a2-c3a1-401a-b0b2-d3fe7209ddbb_terseLabel_en-US" xlink:label="lab_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Ongoing Regulatory And Development Activities</link:label>
    <link:label id="lab_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember_label_en-US" xlink:label="lab_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Ongoing Regulatory And Development Activities [Member]</link:label>
    <link:label id="lab_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Ongoing Regulatory And Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember" xlink:href="espr-20210630.xsd#espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember" xlink:to="lab_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_043fa101-76c4-45e1-997c-0f460cc9efcf_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_521abf8e-6662-4e84-81a5-132251d96925_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_c94b3f39-d4ba-4beb-9ded-591de4b257c2_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interests Payment on Which Agreement Terminates Prior to the Third Anniversary Of Closing Date If Put Option Is Exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:to="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_13ab8343-93bf-42e3-8b68-876e0628265f_terseLabel_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of offering periods</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_label_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Duration of Offering Period</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_documentation_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:to="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_e2044689-814a-49fb-bd05-8a677b53188e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Cash Equivalents and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_db074199-ed04-4c98-8d7e-1ef1050671f0_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1564cb2f-f986-410b-acee-770ecc78e3cd_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c873234-9917-4c97-b4f2-9773b6e0f086_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period over which remaining unrecognized compensation cost will be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_adc29c37-643c-4054-a2f4-10ae28c3861d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_7b63f98e-0ee6-4640-9e8d-eaa19384e0ac_terseLabel_en-US" xlink:label="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="espr-20210630.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_UpFrontPayment_bd5bca70-4615-4aea-bc5c-439bb07991ad_terseLabel_en-US" xlink:label="lab_espr_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment received (paid)</link:label>
    <link:label id="lab_espr_UpFrontPayment_label_en-US" xlink:label="lab_espr_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-Front Payment</link:label>
    <link:label id="lab_espr_UpFrontPayment_documentation_en-US" xlink:label="lab_espr_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of up-front payment received (paid) .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UpFrontPayment" xlink:href="espr-20210630.xsd#espr_UpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_UpFrontPayment" xlink:to="lab_espr_UpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_70251c15-43d0-4d5f-a9a0-95b3ce5f4590_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bcda3aad-409b-4b72-9dc9-46166d67fe22_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2be62986-56d0-4f1b-904d-40df517b8d52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_b3d5f32e-4913-4c64-9c5e-27be6ed702b2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4f22fe0-6277-4dec-89c2-26cbc39fd65c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdAxis_e80765de-0075-4748-9e71-64592fd89b4f_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold [Axis]</link:label>
    <link:label id="lab_espr_NetSalesThresholdAxis_label_en-US" xlink:label="lab_espr_NetSalesThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold [Axis]</link:label>
    <link:label id="lab_espr_NetSalesThresholdAxis_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdAxis" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdAxis" xlink:to="lab_espr_NetSalesThresholdAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_df184661-f8ea-452d-8d4f-e69b6884c01b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcafa694-b11a-4151-9bdc-12bd1bf4c6e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_bc46b21d-bebc-494f-9af7-ad437366b077_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestLiabilityNoncurrent_3a418a3c-9b8b-4d32-9125-92a902fa0070_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityNoncurrent_label_en-US" xlink:label="lab_espr_RevenueInterestLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Liability, NonCurrent</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityNoncurrent_documentation_en-US" xlink:label="lab_espr_RevenueInterestLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityNoncurrent" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestLiabilityNoncurrent" xlink:to="lab_espr_RevenueInterestLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7fd15345-a626-4ff9-a730-00e8951b638d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_03f14835-2671-44cb-a209-a293aef6f742_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SignificantAccountingPoliciesTable_3380fb65-c9a2-4105-a621-7a50dabd1cb9_terseLabel_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_espr_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_espr_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesTable" xlink:href="espr-20210630.xsd#espr_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SignificantAccountingPoliciesTable" xlink:to="lab_espr_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_be2cc87d-bf63-412a-86d5-ab5acc42026b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NumberOfSourcesOfRevenue_1b44f179-ec20-4490-8a85-a216e24e89a3_terseLabel_en-US" xlink:label="lab_espr_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of revenue sources</link:label>
    <link:label id="lab_espr_NumberOfSourcesOfRevenue_label_en-US" xlink:label="lab_espr_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sources Of Revenue</link:label>
    <link:label id="lab_espr_NumberOfSourcesOfRevenue_documentation_en-US" xlink:label="lab_espr_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sources Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfSourcesOfRevenue" xlink:href="espr-20210630.xsd#espr_NumberOfSourcesOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NumberOfSourcesOfRevenue" xlink:to="lab_espr_NumberOfSourcesOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d03f4085-2d6d-4441-a0ee-b45919d71184_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DaiichiSankyoCoLtdMember_45d9cba8-e6d7-4610-88c6-c7f5e5d9f2d8_terseLabel_en-US" xlink:label="lab_espr_DaiichiSankyoCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Co. Ltd</link:label>
    <link:label id="lab_espr_DaiichiSankyoCoLtdMember_label_en-US" xlink:label="lab_espr_DaiichiSankyoCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Co. Ltd [Member]</link:label>
    <link:label id="lab_espr_DaiichiSankyoCoLtdMember_documentation_en-US" xlink:label="lab_espr_DaiichiSankyoCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Co. Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember" xlink:href="espr-20210630.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DaiichiSankyoCoLtdMember" xlink:to="lab_espr_DaiichiSankyoCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_aa607584-0ff3-4dcb-aecf-2a1f5c3b086a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db86bc04-6565-4a31-9d09-5ee3e39a8913_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_706b4e9d-0203-403e-bd68-b77d9c3169fc_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales_9223a35b-b5fe-4ed9-9206-6367a65f3d2d_terseLabel_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment to the Company upon first commercial sales in the DSE Territory</link:label>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales_label_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payment to be Received upon First Commercial Sales</link:label>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales_documentation_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash payment to the Company upon first commercial sales in the DSE Territory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:href="espr-20210630.xsd#espr_CashPaymentToBeReceivedUponFirstCommercialSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:to="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c9c3e8c9-be3a-4fdd-ad85-fa92b256b277_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b91acf2e-5ec4-443e-831f-6cc75046789a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3e9993ff-cf63-47f6-8722-0177823d6330_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_806dcb12-ec59-426f-9c52-ebb3eae72100_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_97a150e4-e01d-46b0-8f4a-0978f32b0ca6_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_f6c1e13c-c3b9-4e8c-be16-5a75460a9cfb_terseLabel_en-US" xlink:label="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential additional future payments</link:label>
    <link:label id="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_label_en-US" xlink:label="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount of Potential Future Revenue, Total Development and Sales Milestones</link:label>
    <link:label id="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_documentation_en-US" xlink:label="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:href="espr-20210630.xsd#espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:to="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_16959400-bea2-4b92-abe1-cb62137fc73e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_ef0aacf7-750d-4d02-857e-e158f5046466_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4e8a3661-7146-48c3-91d3-6d27c559392b_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_732a8201-1d69-4a38-9e6c-a4fcde18eb5c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations with Third Parties</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_23051366-8d23-4eb3-b2eb-a0f07c49b12d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_d9fc366b-32fe-4b81-b029-a9658879a458_terseLabel_en-US" xlink:label="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized issuance costs</link:label>
    <link:label id="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_label_en-US" xlink:label="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Transaction Costs on Revenue Interest Agreement</link:label>
    <link:label id="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_documentation_en-US" xlink:label="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction costs on revenue interest agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:href="espr-20210630.xsd#espr_UnamortizedTransactionCostsOnRevenueInterestAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:to="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_79104d4a-66c8-4b96-9272-de441ed86fba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a53a2b08-e072-433a-abec-c03efc299ccc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_40f46c62-1811-41a3-9b3e-0c0f7386a1bd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0678ee56-b648-4422-8d60-c13e9138cbf7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_990b6010-ce17-4ea9-9b27-e8765caf69da_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_993eb6a5-2307-44fd-a8e8-6e5ac27fd664_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_4692d5c7-947e-45eb-9e56-e207bcc656b5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems_bb38973a-f917-49d9-bbb7-c860aaa3afbb_terseLabel_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems_label_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability from Sale of Future Revenues [Line Items]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems_documentation_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:to="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_OtsukaPharmaceuticalCoLtdMember_a554f143-5fc7-40e8-9eb2-09f5f3badb1b_terseLabel_en-US" xlink:label="lab_espr_OtsukaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka Pharmaceutical Co, Ltd.</link:label>
    <link:label id="lab_espr_OtsukaPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_espr_OtsukaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka Pharmaceutical Co Ltd [Member]</link:label>
    <link:label id="lab_espr_OtsukaPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_espr_OtsukaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Otsuka Pharmaceutical Co, Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_OtsukaPharmaceuticalCoLtdMember" xlink:href="espr-20210630.xsd#espr_OtsukaPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_OtsukaPharmaceuticalCoLtdMember" xlink:to="lab_espr_OtsukaPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f7141a3d-2cba-483c-ad95-f6ba4a55bf1a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CollaborativeArrangementAbstract_2f6affcf-a587-4e07-97b7-138912066a3e_terseLabel_en-US" xlink:label="lab_espr_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations with Third Parties</link:label>
    <link:label id="lab_espr_CollaborativeArrangementAbstract_label_en-US" xlink:label="lab_espr_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations with Third Parties</link:label>
    <link:label id="lab_espr_CollaborativeArrangementAbstract_documentation_en-US" xlink:label="lab_espr_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementAbstract" xlink:href="espr-20210630.xsd#espr_CollaborativeArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CollaborativeArrangementAbstract" xlink:to="lab_espr_CollaborativeArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_b1925c03-e054-4426-a8c9-2e406da0d702_terseLabel_en-US" xlink:label="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RIPA Amendment To The Security Agreement And Waiver</link:label>
    <link:label id="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_label_en-US" xlink:label="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RIPA Amendment To The Security Agreement And Waiver [Member]</link:label>
    <link:label id="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_documentation_en-US" xlink:label="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RIPA Amendment To The Security Agreement And Waiver</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:href="espr-20210630.xsd#espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:to="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_69ba5aeb-4b51-464f-a620-10fd6d53a3d8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ConvertibleSeniorNotesDue2025Member_2d6220b1-b667-4025-93bb-fa6d3aaf7bcc_terseLabel_en-US" xlink:label="lab_espr_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:label id="lab_espr_ConvertibleSeniorNotesDue2025Member_label_en-US" xlink:label="lab_espr_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_espr_ConvertibleSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_espr_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConvertibleSeniorNotesDue2025Member" xlink:href="espr-20210630.xsd#espr_ConvertibleSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ConvertibleSeniorNotesDue2025Member" xlink:to="lab_espr_ConvertibleSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_ff98167c-4197-46b1-af44-b02ab308c390_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021</link:label>
    <link:label id="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_label_en-US" xlink:label="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold To Include Worldwide Sales In Covered Territory</link:label>
    <link:label id="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold To Include Worldwide Sales In Covered Territory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:to="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0d1c9401-b5eb-4ab7-b5a1-581329ac71ad_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dd217e07-aada-4653-856c-aa725b5d5f5d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c0ca7252-41a7-4b0e-8568-d9274cc1858b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestLiability_08f843cf-d266-4a2b-a6a1-2dbb24b92c4d_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability</link:label>
    <link:label id="lab_espr_RevenueInterestLiability_5a765f5e-80b5-477c-88ec-38a4821884b0_periodStartLabel_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability, beginning balance</link:label>
    <link:label id="lab_espr_RevenueInterestLiability_ff4abfe4-77d2-4d0b-97cf-dd63b1f28afb_periodEndLabel_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability, ending balance</link:label>
    <link:label id="lab_espr_RevenueInterestLiability_label_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Liability</link:label>
    <link:label id="lab_espr_RevenueInterestLiability_documentation_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current and non-current portion of the Revenue Interest Liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestLiability" xlink:to="lab_espr_RevenueInterestLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_63518dab-170c-465c-a91c-f6a453a76608_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_4716a636-f512-4770-8628-e0f27921d264_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense recognized</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_label_en-US" xlink:label="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Liability, Increase for Interest Expense Recognized</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_documentation_en-US" xlink:label="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase in the revenue interest liability attributable to interest expense recognized during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:to="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_04dbc871-80ff-437f-ad9e-f74600157a66_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_62b3d83c-90ff-4fd4-96b7-5f6a3b94878c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2802780d-85aa-490d-b01b-2e8cff5083fb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_f45fc622-632b-48fe-a2fb-1d65848474f9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_0d929b1c-471a-44ab-9e1e-256613c383cd_terseLabel_en-US" xlink:label="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_155b7fe7-1d77-4136-9bb7-02780ce0f51f_totalLabel_en-US" xlink:label="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other accrued liabilities</link:label>
    <link:label id="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Employee-related Liabilities, Current</link:label>
    <link:label id="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:href="espr-20210630.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_51af9d35-6b79-4a4b-92b6-aba1b9694b7e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ef321513-60c8-4085-a1a2-c50c53f58bf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_74367f3a-d190-4613-85bb-56bf6adfab35_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized into inventory</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7a908d1b-4086-4b26-b7f9-9acf303c77b7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bebbff97-72dd-4771-bb62-e0852c99dc47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bb7f310d-a9b7-4aaf-b8c2-ade3beeb2a10_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_72a2ff50-46fd-4ef5-b2e1-6b9afec8e5f4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ConcentrationRiskNumberOfMajorCustomers_90341cef-4d2a-47ac-8c34-fe95369ebdde_terseLabel_en-US" xlink:label="lab_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major customers</link:label>
    <link:label id="lab_espr_ConcentrationRiskNumberOfMajorCustomers_label_en-US" xlink:label="lab_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number of Major Customers</link:label>
    <link:label id="lab_espr_ConcentrationRiskNumberOfMajorCustomers_documentation_en-US" xlink:label="lab_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of the Company's major customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:href="espr-20210630.xsd#espr_ConcentrationRiskNumberOfMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:to="lab_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_788a2c87-ae01-474a-8236-96687c49edab_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_0fc79a1a-1ff2-4ce3-a53e-657038f73daa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestLiabilityCurrent_922fc47e-b072-4598-9971-b1e9e33b3dee_verboseLabel_en-US" xlink:label="lab_espr_RevenueInterestLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityCurrent_label_en-US" xlink:label="lab_espr_RevenueInterestLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Liability, Current</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityCurrent_documentation_en-US" xlink:label="lab_espr_RevenueInterestLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityCurrent" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestLiabilityCurrent" xlink:to="lab_espr_RevenueInterestLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_677b2fce-dcd5-4c84-bc60-4c8faf7ff522_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_80fc30fc-1bbd-4edb-be69-c8d99708e716_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_c8b5454b-8393-4ccf-8f58-910aea825137_terseLabel_en-US" xlink:label="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical repayment obligation</link:label>
    <link:label id="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_label_en-US" xlink:label="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical Repayment Obligation Based On Sales Generated</link:label>
    <link:label id="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_documentation_en-US" xlink:label="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical Repayment Obligation Based On Sales Generated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:href="espr-20210630.xsd#espr_HypotheticalRepaymentObligationBasedOnSalesGenerated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:to="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement_47749b4a-6161-473d-bbc7-420fdbd189e9_negatedLabel_en-US" xlink:label="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on revenue interest liability</link:label>
    <link:label id="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement_bfa31013-4b28-4b84-a581-79b377109a7b_negatedTerseLabel_en-US" xlink:label="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interests payments</link:label>
    <link:label id="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement_label_en-US" xlink:label="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments From Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement_documentation_en-US" xlink:label="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from a revenue interest purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:href="espr-20210630.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:to="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_109cd53e-c492-4e91-ab2f-c9fdf6884f93_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of premiums and discounts on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_90b722a9-49bd-4598-beb0-f3df3539028e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_760d5a5b-aa40-462c-91b7-a476c91f7e69_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a4441907-ce76-4abe-aacf-6654f5f31281_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_b31268f9-08c3-4d99-b2f3-fc0e4ad291f3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_895456f3-f670-413d-a131-5481dd2e70e5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e0797253-4256-400b-95b2-be0672b000e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_af82f69f-d8b5-419d-8e6a-6836534888f3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_16828e9c-d519-4dd3-8800-7caa9b08ee1a_terseLabel_en-US" xlink:label="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cumulative purchaser payments</link:label>
    <link:label id="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_label_en-US" xlink:label="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Cumulative Purchaser Payments, Guarantee</link:label>
    <link:label id="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_documentation_en-US" xlink:label="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Cumulative Purchaser Payments, Guarantee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:href="espr-20210630.xsd#espr_PercentageOfCumulativePurchaserPaymentsGuarantee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:to="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_a7625c36-1fa6-4661-a79e-6ad6cd52e152_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ba306bce-7315-4efa-b070-963bbb48f6a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_4fe3e110-3743-412d-99b0-280ab9ec8371_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties to be received on the net sales</link:label>
    <link:label id="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_label_en-US" xlink:label="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Royalties to be Received on Net Sales</link:label>
    <link:label id="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_documentation_en-US" xlink:label="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of royalties to be received on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:href="espr-20210630.xsd#espr_PercentageOfRoyaltiesToBeReceivedOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:to="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_42ce255e-b380-450f-9d2d-ccecb6e68e44_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense, RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b6c7a5cb-0345-4cec-947e-4ef8ef8854b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_658da0c0-9f73-4e4d-acaf-d298d1418943_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be1b3666-1378-4b8f-a7c1-3e59f04890bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_7e756c99-14c1-4318-aa06-399dd941da64_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4926a7db-4030-4a61-b0c6-b1ed57931944_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fd3c348-92dd-4cb4-894d-12125b7edce6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ac64a3ee-f1be-4c91-83e5-c286af1a3b57_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Relating to the Company's Options to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b48f3b2b-0446-4923-8ec9-14e698810848_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_65661759-55ce-4edd-9681-bce5e0d3efd6_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to plaintiff</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5cd44bca-0d92-4498-9d61-200a3c8bbc78_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_9e190c9f-9790-45fd-aaed-18b93769c2cc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_db728303-aa9f-4491-bdb6-03c1be2444f4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_5b7afe62-ba23-4f72-8c14-e28f52e3b74f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer_c4342cb6-603b-4f24-bb30-688960a60baf_terseLabel_en-US" xlink:label="lab_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received upon completion of NUSTENDI MAA transfer</link:label>
    <link:label id="lab_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer_label_en-US" xlink:label="lab_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Achievement of Milestone, Completion of the NUSTENDI Marketing Authorization Approval Transfer</link:label>
    <link:label id="lab_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer_documentation_en-US" xlink:label="lab_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of proceeds received upon achievement of the milestone for completion of the NUSTENDI Marketing Authorization Approval (MAA) transfer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer" xlink:href="espr-20210630.xsd#espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer" xlink:to="lab_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding_341ed23b-6a23-45ce-8b85-ab4b00199014_terseLabel_en-US" xlink:label="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, required amount outstanding</link:label>
    <link:label id="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding_label_en-US" xlink:label="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Required Amount Outstanding</link:label>
    <link:label id="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding_documentation_en-US" xlink:label="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Required Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:href="espr-20210630.xsd#espr_DebtInstrumentCovenantRequiredAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:to="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96745592-4597-4328-b426-7f753248c14c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a122d848-1f27-4631-be5f-9301212f418d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4e95a75f-5708-4606-8466-1a4ceae9b0fe_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_d7228951-0fc4-41f8-9cae-b3994a66978e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_a542d7ce-1d90-4ba5-aab8-c6d23262c2e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_881a79f9-c055-46eb-97e4-09df96aeb111_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_32d6dc65-0b05-4673-8859-aca8a047613a_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective annual imputed interest rate (as a percent)</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_label_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement, Effective Annual Imputed Interest Rate</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_documentation_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of effective annual imputed interest rate under the revenue interest purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:to="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cec1c3ad-1d71-4898-973d-ce3489ff10f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3e4ef3da-d675-4e8a-9874-02de22130bec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_444ccb5b-804d-4025-8291-421ae0de0926_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6055af35-dfbb-4a5c-816f-401c57df79a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a6d3a3df-ce03-4a24-ac0e-56a4b5baa368_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c63b235a-9526-4928-8360-80c0afd48b05_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_34ffc734-fa5a-40aa-976d-a62df54afc2d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementMember_e101e57e-aae2-4a3f-a72b-dedf75c832b0_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement (RIPA)</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementMember_label_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement [Member]</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementMember_documentation_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to revenue interest purchase agreement ("RIPA").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestPurchaseAgreementMember" xlink:to="lab_espr_RevenueInterestPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward_4d192339-1fc6-4654-975c-5f9f536090e6_terseLabel_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Revenues [Roll Forward]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward_label_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Revenues [Roll Forward]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward_documentation_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:to="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_516dd8cf-e15e-46aa-bb84-f23c53946089_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SerometrixMember_9622b036-e77a-47d5-b53d-fae8c7b37631_terseLabel_en-US" xlink:label="lab_espr_SerometrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serometrix</link:label>
    <link:label id="lab_espr_SerometrixMember_label_en-US" xlink:label="lab_espr_SerometrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serometrix [Member]</link:label>
    <link:label id="lab_espr_SerometrixMember_documentation_en-US" xlink:label="lab_espr_SerometrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serometrix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SerometrixMember" xlink:href="espr-20210630.xsd#espr_SerometrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SerometrixMember" xlink:to="lab_espr_SerometrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_17dd69c4-6c26-434e-864a-b10f86e500b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9df26fdb-87d3-4560-b213-40c6ebcec07d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_9c92df4c-1d56-4150-8692-30ce80b080af_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts_49da70a6-07e7-4692-ae9c-621152009261_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oberland funding upon execution of Amendment No. 2, net of issuance costs</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts_label_en-US" xlink:label="lab_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Liability, Increase for Funding Received, Net Of Issuance Costs</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase in the revenue interest liability related to funding received during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts" xlink:to="lab_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_934f6d6c-1a62-4c13-8931-803991051b96_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of capped call options associated with convertible notes</link:label>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_60b20c8d-53b3-4c7b-bc69-c17d2ca694d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_766bcbc8-c5a9-408b-a2df-926dd24f5c83_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from collaborations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_1c40d9d9-d985-42e3-a947-378bc67deed2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_136119a0-50d4-4b41-b857-ca7cad0c70e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_817846d7-5a23-4ff3-b048-53cd70a4553b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_7ac884ca-7adc-48c7-bbdc-4d73fdf4bffa_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a8e795dc-3126-4f7e-82c5-b612d022cf8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_89bfcb2e-d9f2-4c9d-be9a-1df389e6d39b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21e32085-db5c-470c-beb0-02487c2843cd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd619475-26d8-442a-9085-924efdf07d57_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_46cac1a8-6ad6-4a06-b448-409db3793e07_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_997c90f6-276e-44d2-ba28-33c1661ab295_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_45378f9d-a176-43ab-8958-e69a8136cb39_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3d98f38e-0877-43eb-82d4-a9774e089843_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1f6956a8-135d-48b6-8443-49ef361c7574_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d541635e-43fb-4a7e-a5ae-b2b2eb122652_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d99183d3-dcf3-4e6b-96a5-a0fcac44d215_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of ESPP Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9d885534-c1e2-45cd-81ac-568064bfa592_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a34f2a9b-9d2d-48d1-89c2-207a1bab33a1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 120,000,000 shares authorized as of June&#160;30, 2021 and December&#160;31, 2020; 28,268,533 shares issued at June&#160;30, 2021 and 27,910,366 shares issued at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement_5daf8ba0-cae7-42e8-87c7-681994d9aee3_terseLabel_en-US" xlink:label="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement_label_en-US" xlink:label="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement_documentation_en-US" xlink:label="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Revenue Interest Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:href="espr-20210630.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:to="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_e64b6f2a-b03d-4660-88ae-33e2b97cd992_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_69bf260a-1cab-48af-85e1-3f354aae66d1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_57e43701-5b5a-45a7-a798-166fd2fa9d17_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AccruedVariableConsiderationCurrent_0659250b-189e-4bab-95ba-a27aa00d0d96_terseLabel_en-US" xlink:label="lab_espr_AccruedVariableConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued variable consideration</link:label>
    <link:label id="lab_espr_AccruedVariableConsiderationCurrent_label_en-US" xlink:label="lab_espr_AccruedVariableConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Variable Consideration, Current</link:label>
    <link:label id="lab_espr_AccruedVariableConsiderationCurrent_documentation_en-US" xlink:label="lab_espr_AccruedVariableConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedVariableConsiderationCurrent" xlink:href="espr-20210630.xsd#espr_AccruedVariableConsiderationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AccruedVariableConsiderationCurrent" xlink:to="lab_espr_AccruedVariableConsiderationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8fdedcac-4d14-4c39-b5f8-beddf5dc86c4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_baba9a31-1e7a-4f4b-9a38-363831ddd814_terseLabel_en-US" xlink:label="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified net revenue</link:label>
    <link:label id="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_label_en-US" xlink:label="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified Net Revenue Threshold Triggering Deposit In Blocked Account</link:label>
    <link:label id="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_documentation_en-US" xlink:label="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:href="espr-20210630.xsd#espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:to="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_4ad5ae6e-aa7a-427c-b56a-f1d2d3b0ac83_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_382238e4-d099-421c-a9ad-f7de989a9d0e_terseLabel_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, premium percentage</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_label_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_documentation_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:href="espr-20210630.xsd#espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:to="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_57f2e3f8-a431-4bf5-a5e3-7be3a3b9b126_terseLabel_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received</link:label>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_label_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold</link:label>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_documentation_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:href="espr-20210630.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:to="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f9bbab39-73ff-4684-b8ce-0eddcb4269c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a84277eb-9670-4ebf-b042-d6629b6b9ffe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8ad37ff1-8920-40d4-8b04-22f72e95ca11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestRateInitialRate_350f47ab-9726-46ca-8def-3958ebd81c1f_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestRateInitialRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial revenue interest rate</link:label>
    <link:label id="lab_espr_RevenueInterestRateInitialRate_label_en-US" xlink:label="lab_espr_RevenueInterestRateInitialRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Rate, Initial Rate</link:label>
    <link:label id="lab_espr_RevenueInterestRateInitialRate_documentation_en-US" xlink:label="lab_espr_RevenueInterestRateInitialRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateInitialRate" xlink:href="espr-20210630.xsd#espr_RevenueInterestRateInitialRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestRateInitialRate" xlink:to="lab_espr_RevenueInterestRateInitialRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_8e05633c-4bd9-408c-9129-45bd1f4f8514_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6500a50c-b954-40c7-8a11-2539c00918f4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations with Third Parties</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d437be5d-a414-4663-b0a6-bc8b4ab6f3f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_468cc29f-52f6-4eba-988b-c80245119a4e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1f029da-549a-4582-9d68-9ae7d9464ad6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_fe1318ec-23c2-4430-b933-f7a96fc16a15_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1c043d1d-6196-443a-972e-ea267d1b24c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_de57d8ee-1ba9-4f74-a020-cefd47da81f6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3f5b1a1c-6434-4dcd-82d6-a49f4d251781_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_bcd144da-8261-47f2-8c42-9e0813f91369_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_88156898-87af-4a73-8b00-58b9dc79a6e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0953c1c6-a796-4159-b8ed-c708d65bb287_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fa388020-0ad2-4808-88c9-687410500b47_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_d2302afd-65b7-405c-9bbf-fdd9a45a744d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_178ba900-11c9-43b1-ba6c-79df7d550b55_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f64f9387-4bbc-4f85-b9dd-fbe984f3adfc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_acaa28d9-a87d-4960-9bee-0d93b29848aa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AccruedClinicalDevelopmentCostsCurrent_1eaf9439-aeca-4794-87ce-981278298c47_terseLabel_en-US" xlink:label="lab_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical development costs</link:label>
    <link:label id="lab_espr_AccruedClinicalDevelopmentCostsCurrent_label_en-US" xlink:label="lab_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Development Costs, Current</link:label>
    <link:label id="lab_espr_AccruedClinicalDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:href="espr-20210630.xsd#espr_AccruedClinicalDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:to="lab_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_40188525-204b-43d6-9610-88290d9bcbbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f281462d-4fed-413d-92be-24cbcfd8fa91_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NonCashRightOfUseAsset_3be887c6-cf93-4390-b690-3efada1a8476_terseLabel_en-US" xlink:label="lab_espr_NonCashRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash right of use asset</link:label>
    <link:label id="lab_espr_NonCashRightOfUseAsset_label_en-US" xlink:label="lab_espr_NonCashRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Right Of Use Asset</link:label>
    <link:label id="lab_espr_NonCashRightOfUseAsset_documentation_en-US" xlink:label="lab_espr_NonCashRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the difference between the lease asset and the lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashRightOfUseAsset" xlink:href="espr-20210630.xsd#espr_NonCashRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NonCashRightOfUseAsset" xlink:to="lab_espr_NonCashRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_09157015-de48-4000-9dd7-28512b55acc6_terseLabel_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_label_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_documentation_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:href="espr-20210630.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:to="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_01457533-1c0a-4ee6-8524-9003b1daa3c9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48830ea9-4968-45bf-bddd-1ebca2568fa6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_90db17df-5e68-44d1-ac9b-0424440fabe0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdOneMember_c0109871-a0da-4eb4-94da-c3ac3d71705a_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Less Than $250 Million</link:label>
    <link:label id="lab_espr_NetSalesThresholdOneMember_label_en-US" xlink:label="lab_espr_NetSalesThresholdOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold One [Member]</link:label>
    <link:label id="lab_espr_NetSalesThresholdOneMember_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdOneMember" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdOneMember" xlink:to="lab_espr_NetSalesThresholdOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_131b00a0-f606-4fb3-8d75-b2a93ec35afb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_dc5dbd6b-7bdf-402e-a57e-fd2f2bfe3bbf_terseLabel_en-US" xlink:label="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate</link:label>
    <link:label id="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_label_en-US" xlink:label="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Invested Capital Received By December 31, 2024, To Qualify For Second Reduced Revenue Interest Rate</link:label>
    <link:label id="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_documentation_en-US" xlink:label="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:href="espr-20210630.xsd#espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:to="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f23f00ea-930e-4d70-9035-b6ac6fbe5f59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b4439658-b72c-431b-a0e4-ce9503c65480_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ce9553f5-8f77-45fe-8f0a-1174644c3f26_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DeferredUpFrontPayment_9f0a13ac-fa7b-4eba-9858-6d7e7d388a85_terseLabel_en-US" xlink:label="lab_espr_DeferredUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred up-front payment</link:label>
    <link:label id="lab_espr_DeferredUpFrontPayment_label_en-US" xlink:label="lab_espr_DeferredUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Up-Front Payment</link:label>
    <link:label id="lab_espr_DeferredUpFrontPayment_documentation_en-US" xlink:label="lab_espr_DeferredUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Up-Front Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DeferredUpFrontPayment" xlink:href="espr-20210630.xsd#espr_DeferredUpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DeferredUpFrontPayment" xlink:to="lab_espr_DeferredUpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_62170e60-a8cc-4dc7-9f32-6c16247d60c4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f329a56b-6319-498b-acc9-475712316ace_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_aa0d9fea-5250-4d58-8fb3-227798abec0e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b22aefd9-f66e-4793-9b46-45fb1aad6553_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_501661b0-a0fb-4028-8357-68e4793cb2ad_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_82c10c67-d356-461b-aa70-4ea79759e3a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, carrying amount of equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember_0ea1b349-0b06-44f1-bc52-af28a43530ac_terseLabel_en-US" xlink:label="lab_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NILEMDO and NUSTENDI, sales of bulk tablets</link:label>
    <link:label id="lab_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember_label_en-US" xlink:label="lab_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales Bulk Tablets Nilemdo And Nustendi [Member]</link:label>
    <link:label id="lab_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember_documentation_en-US" xlink:label="lab_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to sales of bulk tablets of NILEMDO and NUSTENDI.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:href="espr-20210630.xsd#espr_ProductSalesBulkTabletsNilemdoAndNustendiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:to="lab_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_f53fc978-ba5f-4dae-9b87-5f06361aa577_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_94ecb284-435f-4736-b3cd-39cb3cae225b_terseLabel_en-US" xlink:label="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company deposit value in blocked account</link:label>
    <link:label id="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_label_en-US" xlink:label="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold</link:label>
    <link:label id="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_documentation_en-US" xlink:label="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:href="espr-20210630.xsd#espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:to="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f776e77c-2785-4a09-b9f9-725709e62743_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4f52d7fa-59ce-4084-81ad-d4630e0cb0f2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ad03c62d-c72e-402d-ba99-f6838d6ca895_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_fa61df2c-54b3-4ceb-be8f-595d29138587_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e0af5474-3002-4e2b-98c1-e3badba8217b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_2cb6a8b4-53c3-4d7c-89a1-9cfcd2ec0edb_terseLabel_en-US" xlink:label="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from revenue interest liability</link:label>
    <link:label id="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_label_en-US" xlink:label="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds from Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_documentation_en-US" xlink:label="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from a revenue interest purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:href="espr-20210630.xsd#espr_GrossProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:to="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48cf1f08-158e-4af6-994f-20582eb9e3b0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income Per Common Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_3e23f38d-fe7a-49a4-858f-b5fa3ec9e49a_terseLabel_en-US" xlink:label="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_label_en-US" xlink:label="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payment Milestone, Achievement of Drug Trial Outcomes Studies</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_documentation_en-US" xlink:label="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:to="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_ee57d19a-2033-4408-a574-045aff0208fb_terseLabel_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_label_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to The Revenue Interest Purchase Agreement [Text Block]</link:label>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_documentation_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC ("Oberland").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:href="espr-20210630.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:to="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8c357da8-9c7d-40b7-a579-8473d39d503c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e6a923a5-6baf-4acb-b35b-b670016b4b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2b41c6f5-2c02-4aa1-be2e-276c9eb6a345_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_c124e950-358b-48c8-933a-67b98e8de002_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember_00d767a5-e8c7-4ff7-a492-2706ceac22fe_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RIPA Amendment</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember_label_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement Amendment [Member]</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember_documentation_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:to="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_816492ba-99b1-4ad5-b42e-35a2a8ff1d08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_50c3d507-3554-4167-bba8-b087bb281b1d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from collaborations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e3850334-29fa-4e3c-831f-1dfe6947dfd4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_1f8dc166-21c7-40f0-a92f-e7fec015011a_terseLabel_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee, as a percentage of base salary</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_documentation_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_9ef573dd-d5d0-47b9-a18d-5a9f0338f676_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_41d5fb68-9728-40fd-ae4e-c28ae2f41b19_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of ESPP Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ae7b7069-8928-4e54-9171-4de28e7de90a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_dee24fb1-f37e-4912-b9b6-7eb2e962d7ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_30666a39-2672-4910-b960-35ab4cc3dcf8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3866da6b-ef1e-417a-be19-47088b897f67_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_1c58417e-d640-4f4a-86ad-e617aa89a804_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_d1345ab5-9929-4022-8653-10628769e861_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_fd6a0846-7464-46f5-b055-d94d9130b60c_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment amount expected to pay in next twelve months</link:label>
    <link:label id="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_label_en-US" xlink:label="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months</link:label>
    <link:label id="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_documentation_en-US" xlink:label="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:href="espr-20210630.xsd#espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:to="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_271e2288-1aa6-4b9a-ac2e-1b55117647a4_terseLabel_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of subsequent installment, subject to achievement of sales threshold</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_label_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Subsequent Installment, Subject to Achievement of Sales Threshold</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_documentation_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:href="espr-20210630.xsd#espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:to="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_3010b3b0-892a-4059-84cd-18e9e8ef3d42_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7e9dcf7a-d7d9-4518-ae98-e2304fab7d19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_6ccba05b-054d-45ae-8578-14eccc76a6ce_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AmendedLicenseAndCollaborationAgreementMember_111494d6-ef56-4254-8210-babdb6e34d27_terseLabel_en-US" xlink:label="lab_espr_AmendedLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended License and Collaboration Agreement</link:label>
    <link:label id="lab_espr_AmendedLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_espr_AmendedLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_espr_AmendedLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_espr_AmendedLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to an amended license and collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmendedLicenseAndCollaborationAgreementMember" xlink:href="espr-20210630.xsd#espr_AmendedLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AmendedLicenseAndCollaborationAgreementMember" xlink:to="lab_espr_AmendedLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_9445c628-a538-4c14-b8c4-63cc87cee895_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f0aadd26-cb08-409c-9c30-e2a78e43a2c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_87733117-14f1-4f36-9dea-877e0df5ca81_terseLabel_en-US" xlink:label="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs</link:label>
    <link:label id="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Stock And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to unvested restricted stock and restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:href="espr-20210630.xsd#espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:to="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_HypotheticalSalesGeneratedAmount_07a23362-213a-40ea-b99b-853d1ad80bf0_terseLabel_en-US" xlink:label="lab_espr_HypotheticalSalesGeneratedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical sales generated amount</link:label>
    <link:label id="lab_espr_HypotheticalSalesGeneratedAmount_label_en-US" xlink:label="lab_espr_HypotheticalSalesGeneratedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical Sales Generated Amount</link:label>
    <link:label id="lab_espr_HypotheticalSalesGeneratedAmount_documentation_en-US" xlink:label="lab_espr_HypotheticalSalesGeneratedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical Sales Generated Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalSalesGeneratedAmount" xlink:href="espr-20210630.xsd#espr_HypotheticalSalesGeneratedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_HypotheticalSalesGeneratedAmount" xlink:to="lab_espr_HypotheticalSalesGeneratedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_701f4b1b-df3f-426a-8f93-63b22f84b6de_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9fc7c90b-d217-430c-af0e-5bb632fecdcf_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b271de3-87db-4d15-9572-3be12b61acd0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e172b84c-adc9-4eb2-b5c9-29b89727aecd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares under option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_518bf207-3026-42fd-af79-dd3d2bfda14f_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares under option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1a82847a-cf98-49b4-97de-cccfa77e6b5b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c8031589-0273-4d1c-be96-bb71e06a76f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d66773cc-0df2-4fe0-ae7e-a4784c9de421_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_515c0f55-36cf-44f2-9215-13ed6c7b3bb0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CappedCallMember_8e171136-99e7-4587-a36e-cd461ba53082_terseLabel_en-US" xlink:label="lab_espr_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call</link:label>
    <link:label id="lab_espr_CappedCallMember_label_en-US" xlink:label="lab_espr_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call [Member]</link:label>
    <link:label id="lab_espr_CappedCallMember_documentation_en-US" xlink:label="lab_espr_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CappedCallMember" xlink:href="espr-20210630.xsd#espr_CappedCallMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CappedCallMember" xlink:to="lab_espr_CappedCallMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6f89a10a-6d73-4e80-9a25-8e64746b8e98_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_04f36a4a-25f7-4c47-9d40-c449ce4ed121_terseLabel_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of maximum annual contributions per employee</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_label_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Amount</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_documentation_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount the employee may contribute to an employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_cc2c2968-2feb-4249-a2a3-23c63f27a9e5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3ea3c328-9b45-4b8a-ba7e-d11de8981edf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_712e6740-93e2-4472-8fb4-0c93fdbf61ad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_7f388b91-b01e-439d-a363-73757cfc1af1_terseLabel_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment to be received upon certain commercial milestones</link:label>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_label_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payment To Be Received Upon Certain Commercial Milestones</link:label>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_documentation_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payment To Be Received Upon Certain Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:href="espr-20210630.xsd#espr_CashPaymentToBeReceivedUponCertainCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:to="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_465fde9b-0805-4112-b6df-b3d5a1ed0c15_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_627879ad-cb24-4958-a571-2efb24af8088_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_aecbdfb4-295f-4c9a-ae58-3ce214201f55_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interests Payment on Which Agreement Terminates</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:to="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_214438b2-7458-46db-be48-2f24725a45b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a8fcb2a3-c79c-4069-aa6a-389d3905a971_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_95740807-021b-4078-b3d9-fd43f09d5f60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_8532c8b6-82e0-4b1d-ac23-92e60d222caf_terseLabel_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_label_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payment Milestone, First National Health Insurance Price Listing, Otsuka Territory</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_documentation_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:to="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EigerIiiSaLlcMember_1768140a-8dff-4a3b-886f-cda79cfe4db7_terseLabel_en-US" xlink:label="lab_espr_EigerIiiSaLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oberland</link:label>
    <link:label id="lab_espr_EigerIiiSaLlcMember_label_en-US" xlink:label="lab_espr_EigerIiiSaLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eiger Iii Sa Llc [Member]</link:label>
    <link:label id="lab_espr_EigerIiiSaLlcMember_documentation_en-US" xlink:label="lab_espr_EigerIiiSaLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to revenue interest purchase agreement ("RIPA") with Oberland.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EigerIiiSaLlcMember" xlink:href="espr-20210630.xsd#espr_EigerIiiSaLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EigerIiiSaLlcMember" xlink:to="lab_espr_EigerIiiSaLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0a88d68d-8e58-4bd6-8033-ff3011f3e79e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_503646d4-be1f-481c-befa-cbcd51b19fd1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_777934c9-6024-4139-b47e-fc97394a8f92_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_23902dab-eb87-4db4-86bc-94510f338e8d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_3f039ea1-fda9-4169-a69b-bd02789433b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note, debt balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_a2fb5adc-d56d-4e0f-bd1a-63ee4d0f97b4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_83cc0d35-ddde-4cc8-bcd2-bfce69c1813f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3e7a3f6c-a5e3-45be-8ebb-10a5baa1a768_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_07581e66-d7fa-4584-a3ac-e8f1a31b98e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c41b3e07-1b35-4865-a73e-777e9dafbe6e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_a3ff53a7-dd90-4e9f-8148-521020856683_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_label_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Investment Income Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInvestmentIncomeReceivable" xlink:to="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RegulatoryPerformanceObligationsMember_234e4b64-c1fe-4a4f-b035-9ef836d7c67a_terseLabel_en-US" xlink:label="lab_espr_RegulatoryPerformanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory performance obligations</link:label>
    <link:label id="lab_espr_RegulatoryPerformanceObligationsMember_label_en-US" xlink:label="lab_espr_RegulatoryPerformanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Performance Obligations [Member]</link:label>
    <link:label id="lab_espr_RegulatoryPerformanceObligationsMember_documentation_en-US" xlink:label="lab_espr_RegulatoryPerformanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to performance obligations related to the ongoing regulatory efforts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RegulatoryPerformanceObligationsMember" xlink:href="espr-20210630.xsd#espr_RegulatoryPerformanceObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RegulatoryPerformanceObligationsMember" xlink:to="lab_espr_RegulatoryPerformanceObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SignificantAccountingPoliciesLineItems_c5673e87-3321-4416-a1fa-6a8f02270a71_terseLabel_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_espr_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_espr_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesLineItems" xlink:href="espr-20210630.xsd#espr_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems" xlink:to="lab_espr_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f158a432-a906-4edb-ba4f-9a9caafbdcf5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fa607a30-422b-426d-8f90-9e86954e7ad7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8e54f554-8eac-4487-8b40-7ec42e41128f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_c553d43c-007e-49ff-8287-17fd26b6a09b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0534ed67-dc8a-487e-8928-70dd967058cb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e371f029-d337-48ff-9582-58f683b76e72_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ec1cea8b-030b-4473-9133-20bb14c8f219_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_ff83f197-68e1-4a47-ba89-e6900dac66e3_terseLabel_en-US" xlink:label="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to the revenue interest liability</link:label>
    <link:label id="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_label_en-US" xlink:label="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related to Revenue Interest Liability</link:label>
    <link:label id="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_documentation_en-US" xlink:label="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of non-cash expense included in interest expense associated with the revenue interest liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:href="espr-20210630.xsd#espr_NonCashInterestExpenseRelatedToRevenueInterestLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:to="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9fa4d519-5eb6-428c-9c10-de59ec909946_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7611b470-dca3-4835-96d6-4ce5fe4cee4f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d6bb0a4-5777-4aa9-bac4-891aa333fb79_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_31894378-ba34-44c0-90ad-769cad7b4e4a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2810af-eed3-4c5a-85fe-a0af332b13d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cfe542fe-7b3a-468e-b780-3ed3ff024bb5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_1b2d8caf-9c8c-4cbe-b927-f042e098b900_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e04996bc-3747-49ca-9236-d3d6cdde3175_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9c8f690a-fb37-4803-865a-e4f12ae8ebc7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised_0ef25ee5-8b52-4c43-bba1-25451387d0ad_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interests Payment on Which Agreement Terminates If Prior to the Anniversary Of Closing Date If Put Option Is Exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:to="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_682f5945-002f-49ae-a872-0f5d7429fcee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_efcacd5f-6ed9-46b0-b58c-6e15de017742_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdDomain_f84aec42-d0ed-4dbd-b8ea-a6ef37dc47b8_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold [Domain]</link:label>
    <link:label id="lab_espr_NetSalesThresholdDomain_label_en-US" xlink:label="lab_espr_NetSalesThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold [Domain]</link:label>
    <link:label id="lab_espr_NetSalesThresholdDomain_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdDomain" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdDomain" xlink:to="lab_espr_NetSalesThresholdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_dadbc558-7f92-4ce2-9ee2-ce39e43921e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 1,994,198 shares at June&#160;30, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ffbbc531-ba84-4094-a928-ea3aa6930c93_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdTwoMember_6bd13e73-6c32-457b-bcc5-ca941b81e2cc_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Greater Than $250 Million But Less Than $350 Million</link:label>
    <link:label id="lab_espr_NetSalesThresholdTwoMember_label_en-US" xlink:label="lab_espr_NetSalesThresholdTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold Two [Member]</link:label>
    <link:label id="lab_espr_NetSalesThresholdTwoMember_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdTwoMember" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdTwoMember" xlink:to="lab_espr_NetSalesThresholdTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b691e00-29c6-41fc-bcec-23a19e4b0e68_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdThreeMember_35d001f9-1a3b-485e-a4cf-c084f374ecee_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Greater Than $350 Million</link:label>
    <link:label id="lab_espr_NetSalesThresholdThreeMember_label_en-US" xlink:label="lab_espr_NetSalesThresholdThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold Three [Member]</link:label>
    <link:label id="lab_espr_NetSalesThresholdThreeMember_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdThreeMember" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdThreeMember" xlink:to="lab_espr_NetSalesThresholdThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1cd187c0-b319-410c-9b30-d341160150b2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_75fa2c43-4de1-4b33-ae54-7a1ff09735fc_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d9f62022-f2f5-4b5d-8768-ec4bab3e6a7a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ec254ec1-c22e-4cbc-984c-c7f0adf22013_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_6b747bfd-1ca7-4471-a14f-3ae2228d5804_terseLabel_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021</link:label>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_label_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate</link:label>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_documentation_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:href="espr-20210630.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:to="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_bc4caf56-05ee-4d7a-9acd-431c19a8355e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cb4d3362-1de3-44d8-8fef-c65f60e5ee62_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Implemented Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1c290310-22e1-44eb-b035-e346e576bc84_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>espr-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d960a0e3-43c0-4beb-a690-4f9d75967096,g:902768da-5c62-49b7-8ede-3e343f3fe2f7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.esperion.com/role/CoverPage" xlink:type="simple" xlink:href="espr-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_dcc39b72-b832-4af1-9006-ec53fb41e22f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_DocumentType_dcc39b72-b832-4af1-9006-ec53fb41e22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a4da5642-d5c7-410c-8978-7490666bddb1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_DocumentQuarterlyReport_a4da5642-d5c7-410c-8978-7490666bddb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0f97109f-c2b2-4701-a996-695ac263c867" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_DocumentPeriodEndDate_0f97109f-c2b2-4701-a996-695ac263c867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_baa226a2-d167-4a2d-9a5e-fa77c2c32a2e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_DocumentTransitionReport_baa226a2-d167-4a2d-9a5e-fa77c2c32a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5b5a3691-1d12-4cf0-bcdf-0fff0c37e96c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityFileNumber_5b5a3691-1d12-4cf0-bcdf-0fff0c37e96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_786c81cc-65c6-45f6-9878-320e5fff946f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityRegistrantName_786c81cc-65c6-45f6-9878-320e5fff946f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b6f7cf52-c5fa-4f1e-9b2c-8404e36a8594" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b6f7cf52-c5fa-4f1e-9b2c-8404e36a8594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3c541d46-b822-4718-b3fd-0c95ce5d26f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityTaxIdentificationNumber_3c541d46-b822-4718-b3fd-0c95ce5d26f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c4d09efd-5116-4d46-85ea-bf3ac42621b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityAddressAddressLine1_c4d09efd-5116-4d46-85ea-bf3ac42621b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c164a68b-f6db-4bf5-bdf7-777073f9e83a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityAddressCityOrTown_c164a68b-f6db-4bf5-bdf7-777073f9e83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5bc66795-1104-4af5-832e-b3a6a6221731" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityAddressStateOrProvince_5bc66795-1104-4af5-832e-b3a6a6221731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cca3ff98-999f-4a6a-b1cb-945d12d4c2d2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityAddressPostalZipCode_cca3ff98-999f-4a6a-b1cb-945d12d4c2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b9722ed1-ea10-449b-9fc0-437f025a3abc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_CityAreaCode_b9722ed1-ea10-449b-9fc0-437f025a3abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a6a16691-eb02-409f-85da-b28632cf9d97" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_LocalPhoneNumber_a6a16691-eb02-409f-85da-b28632cf9d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_85591e72-62d5-4c2a-a863-bba2ed973c78" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_Security12bTitle_85591e72-62d5-4c2a-a863-bba2ed973c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_090cc117-087e-4efe-b03f-ee08ed61e7d0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_TradingSymbol_090cc117-087e-4efe-b03f-ee08ed61e7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e5b2d58d-d821-4fbf-8715-f71064c21592" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_SecurityExchangeName_e5b2d58d-d821-4fbf-8715-f71064c21592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6e11365b-dd22-4a81-ae45-28f58510febc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityCurrentReportingStatus_6e11365b-dd22-4a81-ae45-28f58510febc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_012424fe-1a23-40c2-a0c0-8c129fe7a6c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityInteractiveDataCurrent_012424fe-1a23-40c2-a0c0-8c129fe7a6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fc90a9a3-f66c-4af7-9fee-51854fa4a840" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityFilerCategory_fc90a9a3-f66c-4af7-9fee-51854fa4a840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c1409ea0-22e5-48f2-86c4-0c11b88d89e0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntitySmallBusiness_c1409ea0-22e5-48f2-86c4-0c11b88d89e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1affcdac-267a-4e66-9d8b-77bca9b3c6b9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityEmergingGrowthCompany_1affcdac-267a-4e66-9d8b-77bca9b3c6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4c0a27ad-1fa1-48ef-a913-eeb2058ec65c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityShellCompany_4c0a27ad-1fa1-48ef-a913-eeb2058ec65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a69219bb-a3fa-4714-8c89-bd583ad3d034" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a69219bb-a3fa-4714-8c89-bd583ad3d034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d33ee173-2bac-4844-ad3c-a9287d2d3024" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_EntityCentralIndexKey_d33ee173-2bac-4844-ad3c-a9287d2d3024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b40a0b10-75ee-4c8d-ad16-e49fbb4d82ff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_CurrentFiscalYearEndDate_b40a0b10-75ee-4c8d-ad16-e49fbb4d82ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_34962f63-c33b-4ccb-b575-24f7de512a7f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_DocumentFiscalYearFocus_34962f63-c33b-4ccb-b575-24f7de512a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4265aee2-5ce6-468e-a992-9b19779b4f48" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4265aee2-5ce6-468e-a992-9b19779b4f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_656e018d-247a-452a-9190-43bca99f1bd5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3d32e73-96a7-42b1-8c1c-3499fc788c20" xlink:to="loc_dei_AmendmentFlag_656e018d-247a-452a-9190-43bca99f1bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5f6f5a20-68df-40cf-836d-9579266c0c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8a2c4e2d-6984-483f-a419-f890d3df2e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f6f5a20-68df-40cf-836d-9579266c0c58" xlink:to="loc_us-gaap_AssetsAbstract_8a2c4e2d-6984-483f-a419-f890d3df2e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_16988624-8ae2-48c4-b7ff-3e53a2db906c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a2c4e2d-6984-483f-a419-f890d3df2e85" xlink:to="loc_us-gaap_AssetsCurrentAbstract_16988624-8ae2-48c4-b7ff-3e53a2db906c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bd42147-1590-4eaa-ae60-e51229bba94a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_16988624-8ae2-48c4-b7ff-3e53a2db906c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bd42147-1590-4eaa-ae60-e51229bba94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b56bf521-2d72-45dc-a9ef-59b0258c3d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_16988624-8ae2-48c4-b7ff-3e53a2db906c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b56bf521-2d72-45dc-a9ef-59b0258c3d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PrepaidClinicalDevelopmentCostsCurrent_2fb1f787-d094-491b-bae9-7410c6ce91df" xlink:href="espr-20210630.xsd#espr_PrepaidClinicalDevelopmentCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_16988624-8ae2-48c4-b7ff-3e53a2db906c" xlink:to="loc_espr_PrepaidClinicalDevelopmentCostsCurrent_2fb1f787-d094-491b-bae9-7410c6ce91df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0771f555-6d7e-4af6-8417-b89e9b4c1fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_16988624-8ae2-48c4-b7ff-3e53a2db906c" xlink:to="loc_us-gaap_InventoryNet_0771f555-6d7e-4af6-8417-b89e9b4c1fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e68e395f-d630-4872-a49d-5d1931a511d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_16988624-8ae2-48c4-b7ff-3e53a2db906c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e68e395f-d630-4872-a49d-5d1931a511d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_04de096a-b957-4ad2-8bd2-18e0a0666a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_16988624-8ae2-48c4-b7ff-3e53a2db906c" xlink:to="loc_us-gaap_AssetsCurrent_04de096a-b957-4ad2-8bd2-18e0a0666a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b76ef81d-505d-4890-951c-b1a7a1ce59dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a2c4e2d-6984-483f-a419-f890d3df2e85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b76ef81d-505d-4890-951c-b1a7a1ce59dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_daba4094-1c16-464b-932b-b65c6a1ae88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a2c4e2d-6984-483f-a419-f890d3df2e85" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_daba4094-1c16-464b-932b-b65c6a1ae88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_85125746-eda0-4764-be08-0f5a761e8f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a2c4e2d-6984-483f-a419-f890d3df2e85" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_85125746-eda0-4764-be08-0f5a761e8f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dad208ef-7c3f-4f9f-a0fe-491276ab6fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a2c4e2d-6984-483f-a419-f890d3df2e85" xlink:to="loc_us-gaap_Assets_dad208ef-7c3f-4f9f-a0fe-491276ab6fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f6f5a20-68df-40cf-836d-9579266c0c58" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2a6264f6-72c2-42fc-a06d-6d9456b52b10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2a6264f6-72c2-42fc-a06d-6d9456b52b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ceca5ee3-39dd-486c-a48a-c97ccddaf222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a6264f6-72c2-42fc-a06d-6d9456b52b10" xlink:to="loc_us-gaap_AccountsPayableCurrent_ceca5ee3-39dd-486c-a48a-c97ccddaf222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedClinicalDevelopmentCostsCurrent_41521a99-823b-4f2a-8cc1-9dbf7b0d6dff" xlink:href="espr-20210630.xsd#espr_AccruedClinicalDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a6264f6-72c2-42fc-a06d-6d9456b52b10" xlink:to="loc_espr_AccruedClinicalDevelopmentCostsCurrent_41521a99-823b-4f2a-8cc1-9dbf7b0d6dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_4f718228-477a-470f-a3c0-f8b80652d454" xlink:href="espr-20210630.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a6264f6-72c2-42fc-a06d-6d9456b52b10" xlink:to="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_4f718228-477a-470f-a3c0-f8b80652d454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityCurrent_104479bd-21f6-4e14-9728-b2cb777f44ea" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a6264f6-72c2-42fc-a06d-6d9456b52b10" xlink:to="loc_espr_RevenueInterestLiabilityCurrent_104479bd-21f6-4e14-9728-b2cb777f44ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1314e3da-1991-47b9-9989-d100b3ca28c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a6264f6-72c2-42fc-a06d-6d9456b52b10" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1314e3da-1991-47b9-9989-d100b3ca28c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d6ea575d-4eee-49ea-8308-1e0d0f638326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a6264f6-72c2-42fc-a06d-6d9456b52b10" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d6ea575d-4eee-49ea-8308-1e0d0f638326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d53233ef-b9ea-41b8-84a8-867c6fb64d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a6264f6-72c2-42fc-a06d-6d9456b52b10" xlink:to="loc_us-gaap_LiabilitiesCurrent_d53233ef-b9ea-41b8-84a8-867c6fb64d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_1ac10364-2e68-48d7-ab76-f7b4eff37ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_1ac10364-2e68-48d7-ab76-f7b4eff37ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityNoncurrent_f597e6d5-d94d-415e-81c1-b2193f2ffefe" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_espr_RevenueInterestLiabilityNoncurrent_f597e6d5-d94d-415e-81c1-b2193f2ffefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ed18a82a-5ffd-4af7-91ba-fbacaa6988cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ed18a82a-5ffd-4af7-91ba-fbacaa6988cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c4aadbf6-bc69-46e3-b16c-28a889cb9941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c4aadbf6-bc69-46e3-b16c-28a889cb9941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7cff2e3c-b577-43cb-9125-3cf35a9073e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7cff2e3c-b577-43cb-9125-3cf35a9073e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_64d62f1f-eecc-4010-b6ac-882914b8984a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_us-gaap_Liabilities_64d62f1f-eecc-4010-b6ac-882914b8984a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_50aa60fd-d65b-46b8-8665-1eca6dd08956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_50aa60fd-d65b-46b8-8665-1eca6dd08956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_aaa5470a-b9c3-4e66-9ec5-dbca7e004723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_aaa5470a-b9c3-4e66-9ec5-dbca7e004723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c2f25bea-19b6-4bf6-9edf-8e6cb5b34bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa5470a-b9c3-4e66-9ec5-dbca7e004723" xlink:to="loc_us-gaap_PreferredStockValue_c2f25bea-19b6-4bf6-9edf-8e6cb5b34bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6089256b-b1f8-40ca-899a-39a8112f9ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa5470a-b9c3-4e66-9ec5-dbca7e004723" xlink:to="loc_us-gaap_CommonStockValue_6089256b-b1f8-40ca-899a-39a8112f9ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0b401c9d-f4a2-4f9e-b99d-7602b7f3f07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa5470a-b9c3-4e66-9ec5-dbca7e004723" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0b401c9d-f4a2-4f9e-b99d-7602b7f3f07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_18fd9cbe-54c5-41c2-8ed2-181feb58d045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa5470a-b9c3-4e66-9ec5-dbca7e004723" xlink:to="loc_us-gaap_TreasuryStockValue_18fd9cbe-54c5-41c2-8ed2-181feb58d045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3976de84-187c-44d0-8861-4abafd96e5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa5470a-b9c3-4e66-9ec5-dbca7e004723" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3976de84-187c-44d0-8861-4abafd96e5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8bb21fa-8dd2-41f0-abae-cb39cb1a0380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa5470a-b9c3-4e66-9ec5-dbca7e004723" xlink:to="loc_us-gaap_StockholdersEquity_a8bb21fa-8dd2-41f0-abae-cb39cb1a0380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bfb4d94-2aef-462e-a0e6-04b632e34ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96381dc8-5258-4a0d-9e5e-bf4ca99681c7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bfb4d94-2aef-462e-a0e6-04b632e34ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3b92f5ee-1371-4329-b96d-fbbc24a8d9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_21a447dd-4c2a-445d-a829-61a3fe86607c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b92f5ee-1371-4329-b96d-fbbc24a8d9bb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_21a447dd-4c2a-445d-a829-61a3fe86607c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c26ff00a-2f9c-45f4-8521-7c01b2bfc316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b92f5ee-1371-4329-b96d-fbbc24a8d9bb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c26ff00a-2f9c-45f4-8521-7c01b2bfc316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b68c4da7-727b-42b3-b8cf-1ce1c4670301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b92f5ee-1371-4329-b96d-fbbc24a8d9bb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b68c4da7-727b-42b3-b8cf-1ce1c4670301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_770717ba-9462-47bb-8b1e-1768295418cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b92f5ee-1371-4329-b96d-fbbc24a8d9bb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_770717ba-9462-47bb-8b1e-1768295418cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_134448df-449f-4d8e-903b-670f6fe2256a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b92f5ee-1371-4329-b96d-fbbc24a8d9bb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_134448df-449f-4d8e-903b-670f6fe2256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9701219f-76ab-44f1-b9d0-f89aa05fdd7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b92f5ee-1371-4329-b96d-fbbc24a8d9bb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9701219f-76ab-44f1-b9d0-f89aa05fdd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_10c0b283-92d2-4143-ad30-6a88b982895d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b92f5ee-1371-4329-b96d-fbbc24a8d9bb" xlink:to="loc_us-gaap_CommonStockSharesIssued_10c0b283-92d2-4143-ad30-6a88b982895d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_47e31754-bdad-433a-8463-2ebf6de1324b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b92f5ee-1371-4329-b96d-fbbc24a8d9bb" xlink:to="loc_us-gaap_TreasuryStockShares_47e31754-bdad-433a-8463-2ebf6de1324b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cacf2464-c1da-476a-8eb2-468f19753fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c67e9bb9-6d1a-4145-bb4c-f3ba465bd962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cacf2464-c1da-476a-8eb2-468f19753fe9" xlink:to="loc_us-gaap_StatementTable_c67e9bb9-6d1a-4145-bb4c-f3ba465bd962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2f908c9a-d0e8-454e-b6ee-3713c27dd766" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c67e9bb9-6d1a-4145-bb4c-f3ba465bd962" xlink:to="loc_srt_ProductOrServiceAxis_2f908c9a-d0e8-454e-b6ee-3713c27dd766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e0d4eba7-6967-43c8-a761-6175d5a31428" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2f908c9a-d0e8-454e-b6ee-3713c27dd766" xlink:to="loc_srt_ProductsAndServicesDomain_e0d4eba7-6967-43c8-a761-6175d5a31428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_26ba2303-761c-4e8b-b862-edb7c4af2e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e0d4eba7-6967-43c8-a761-6175d5a31428" xlink:to="loc_us-gaap_ProductMember_26ba2303-761c-4e8b-b862-edb7c4af2e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborationRevenueMember_6409095e-d37d-4b83-ba45-b1b857e3a66f" xlink:href="espr-20210630.xsd#espr_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e0d4eba7-6967-43c8-a761-6175d5a31428" xlink:to="loc_espr_CollaborationRevenueMember_6409095e-d37d-4b83-ba45-b1b857e3a66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c67e9bb9-6d1a-4145-bb4c-f3ba465bd962" xlink:to="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f651075-87d9-4d37-8da1-1fda0a9b481a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_RevenuesAbstract_3f651075-87d9-4d37-8da1-1fda0a9b481a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e757776e-8a2a-43aa-9c4a-8a81056397e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3f651075-87d9-4d37-8da1-1fda0a9b481a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e757776e-8a2a-43aa-9c4a-8a81056397e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_bf040b67-56f0-4c5b-8fdf-b159629e3269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_bf040b67-56f0-4c5b-8fdf-b159629e3269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8b7ef1c1-c395-484f-a75c-a7156d63084c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8b7ef1c1-c395-484f-a75c-a7156d63084c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1e3229ff-49de-49ae-b74e-55f57ca3e557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1e3229ff-49de-49ae-b74e-55f57ca3e557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c4018eac-dcc8-4abc-9b2e-9d3faa410d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cab6e992-4885-4efd-8dc7-f580df375112" xlink:to="loc_us-gaap_OperatingExpenses_c4018eac-dcc8-4abc-9b2e-9d3faa410d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_577e21be-5175-4184-adf0-269fde9e4e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_OperatingIncomeLoss_577e21be-5175-4184-adf0-269fde9e4e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_82fe0879-91d0-4606-b51d-f5819d271c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_InterestExpense_82fe0879-91d0-4606-b51d-f5819d271c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2b83d3c4-7d3b-4001-a871-d6e607103736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2b83d3c4-7d3b-4001-a871-d6e607103736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_37629617-2c0e-44f0-a8ba-ab990188f769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_NetIncomeLoss_37629617-2c0e-44f0-a8ba-ab990188f769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e3dd3b88-ad5a-4eb0-94c5-465880e5c4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_EarningsPerShareBasic_e3dd3b88-ad5a-4eb0-94c5-465880e5c4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b0b1ef96-c88a-4d06-b6a1-46127696cd4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b0b1ef96-c88a-4d06-b6a1-46127696cd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eb6d1a10-5df5-4589-a718-ecd4c51a6ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eb6d1a10-5df5-4589-a718-ecd4c51a6ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11fca1f2-cd5f-4f9b-8dc1-5a3c90573e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11fca1f2-cd5f-4f9b-8dc1-5a3c90573e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc72b58a-5601-4f08-8782-91c74e5d018d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc72b58a-5601-4f08-8782-91c74e5d018d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f7ece052-b858-4b41-b663-68bf6416b467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc72b58a-5601-4f08-8782-91c74e5d018d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f7ece052-b858-4b41-b663-68bf6416b467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_888750d0-2a01-4ab6-9559-69cb52fe9c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ac9a942-c921-4dcc-b21f-27dab7c176e7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_888750d0-2a01-4ab6-9559-69cb52fe9c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedStatementsofStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0b98c05f-0238-4e70-a14d-0c5a3a72271d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ba506ab-0305-4a19-841f-0303ef1aa3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0b98c05f-0238-4e70-a14d-0c5a3a72271d" xlink:to="loc_us-gaap_StatementTable_2ba506ab-0305-4a19-841f-0303ef1aa3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7223ce70-6ff4-40e0-9a1c-1e6fa771fc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ba506ab-0305-4a19-841f-0303ef1aa3c1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7223ce70-6ff4-40e0-9a1c-1e6fa771fc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7223ce70-6ff4-40e0-9a1c-1e6fa771fc97" xlink:to="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_66e3911a-f769-4fa4-856e-1de1f9bc5384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_CommonStockMember_66e3911a-f769-4fa4-856e-1de1f9bc5384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_183fbe35-dc01-4f1b-adb4-84bbdaa196b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_183fbe35-dc01-4f1b-adb4-84bbdaa196b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dec913ca-851c-42fd-aa8c-4cf44cc20fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_RetainedEarningsMember_dec913ca-851c-42fd-aa8c-4cf44cc20fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4392dc7d-6dac-4c8f-843e-38a2edda07e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4392dc7d-6dac-4c8f-843e-38a2edda07e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_de2e283f-e2b2-456b-a3b5-3dc13b5812b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0db1b516-b4fe-42a8-a777-4920ef1f580d" xlink:to="loc_us-gaap_TreasuryStockMember_de2e283f-e2b2-456b-a3b5-3dc13b5812b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_061cd2ab-c370-4cca-9e8a-f6e45c79d8be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ba506ab-0305-4a19-841f-0303ef1aa3c1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_061cd2ab-c370-4cca-9e8a-f6e45c79d8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cf7f540-bc1d-43c0-8b43-2cd0d81da963" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_061cd2ab-c370-4cca-9e8a-f6e45c79d8be" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cf7f540-bc1d-43c0-8b43-2cd0d81da963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8efafc6d-1b7b-46ff-9f09-f4cf199f7633" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cf7f540-bc1d-43c0-8b43-2cd0d81da963" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8efafc6d-1b7b-46ff-9f09-f4cf199f7633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_bcf6fca0-5ba9-4e33-9220-22bd157f944a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cf7f540-bc1d-43c0-8b43-2cd0d81da963" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_bcf6fca0-5ba9-4e33-9220-22bd157f944a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0e163d9a-fa57-41ed-b407-58ddaa36f6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ba506ab-0305-4a19-841f-0303ef1aa3c1" xlink:to="loc_us-gaap_StatementLineItems_0e163d9a-fa57-41ed-b407-58ddaa36f6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e163d9a-fa57-41ed-b407-58ddaa36f6e4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_471bd5e0-2234-47f6-a9ed-8068fe888369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_SharesOutstanding_471bd5e0-2234-47f6-a9ed-8068fe888369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c7bf98f-9cc7-4797-b5c7-c1d26084bcac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockholdersEquity_9c7bf98f-9cc7-4797-b5c7-c1d26084bcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_c2964472-18d8-4dd2-a68a-7c689b1ff073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_c2964472-18d8-4dd2-a68a-7c689b1ff073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd8e2fd1-43ae-4830-b39e-b7513ea34ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd8e2fd1-43ae-4830-b39e-b7513ea34ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_597f1676-856d-4371-b0df-ee9a2fa6016d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_597f1676-856d-4371-b0df-ee9a2fa6016d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bd085b76-e80e-427a-82a1-d27b79366901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bd085b76-e80e-427a-82a1-d27b79366901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_bd4ed397-7b6d-46b5-a64b-82c5b1e8d78d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_bd4ed397-7b6d-46b5-a64b-82c5b1e8d78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8bbae939-a2b2-4834-87ce-ee54ef630449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8bbae939-a2b2-4834-87ce-ee54ef630449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_72cef70d-8ac7-4344-ae33-8fdea7dba2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_72cef70d-8ac7-4344-ae33-8fdea7dba2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_af3d87bf-3817-4490-b9d9-241c2b8fd13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_af3d87bf-3817-4490-b9d9-241c2b8fd13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4f5c61eb-3403-4a27-965b-b8e5390066a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4f5c61eb-3403-4a27-965b-b8e5390066a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ee6c05b9-cdd7-4387-930b-5585326d9a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_NetIncomeLoss_ee6c05b9-cdd7-4387-930b-5585326d9a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_eb9f1de8-591a-4bb6-a098-dddd73345c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_SharesOutstanding_eb9f1de8-591a-4bb6-a098-dddd73345c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e5fe79c7-593a-49c4-bbb8-93fb051b9a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63498585-364f-4fbd-a3a4-483d6ea62a28" xlink:to="loc_us-gaap_StockholdersEquity_e5fe79c7-593a-49c4-bbb8-93fb051b9a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="espr-20210630.xsd#CondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_69c15510-6a8b-4c13-ad02-d73fb29b37a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c9832f56-f9dd-436a-a2b3-cee6f9993561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_69c15510-6a8b-4c13-ad02-d73fb29b37a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c9832f56-f9dd-436a-a2b3-cee6f9993561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_baace4c1-1942-489b-9d3d-57d1cb580bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c9832f56-f9dd-436a-a2b3-cee6f9993561" xlink:to="loc_us-gaap_NetIncomeLoss_baace4c1-1942-489b-9d3d-57d1cb580bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d805f598-11e2-4ba1-983b-ccf339c80b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c9832f56-f9dd-436a-a2b3-cee6f9993561" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d805f598-11e2-4ba1-983b-ccf339c80b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_271110be-2fc3-4d23-a725-1499cc724436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d805f598-11e2-4ba1-983b-ccf339c80b2b" xlink:to="loc_us-gaap_Depreciation_271110be-2fc3-4d23-a725-1499cc724436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_92a9fa1e-a8d6-48aa-897a-82b560cf9d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d805f598-11e2-4ba1-983b-ccf339c80b2b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_92a9fa1e-a8d6-48aa-897a-82b560cf9d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9a742fe6-92d2-42fe-b820-3ea5b78a4f10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d805f598-11e2-4ba1-983b-ccf339c80b2b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9a742fe6-92d2-42fe-b820-3ea5b78a4f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_10441e93-8265-46c4-8c7c-fbe1b2789931" xlink:href="espr-20210630.xsd#espr_NonCashInterestExpenseRelatedToRevenueInterestLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d805f598-11e2-4ba1-983b-ccf339c80b2b" xlink:to="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_10441e93-8265-46c4-8c7c-fbe1b2789931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b9d4ef21-2f03-41b3-b705-4bbc39b725b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d805f598-11e2-4ba1-983b-ccf339c80b2b" xlink:to="loc_us-gaap_ShareBasedCompensation_b9d4ef21-2f03-41b3-b705-4bbc39b725b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce67644-7040-4225-a42b-8ff435466488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d805f598-11e2-4ba1-983b-ccf339c80b2b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce67644-7040-4225-a42b-8ff435466488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c0fa7b88-5361-4545-bb46-d61fc5be9f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce67644-7040-4225-a42b-8ff435466488" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c0fa7b88-5361-4545-bb46-d61fc5be9f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3041850e-d0e8-470e-9022-7ee9556eed1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce67644-7040-4225-a42b-8ff435466488" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3041850e-d0e8-470e-9022-7ee9556eed1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f76dedab-b2aa-44b9-b4a0-6ebd23930ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce67644-7040-4225-a42b-8ff435466488" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f76dedab-b2aa-44b9-b4a0-6ebd23930ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_07c46ffc-f2de-4610-9e63-43a1a99fcddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce67644-7040-4225-a42b-8ff435466488" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_07c46ffc-f2de-4610-9e63-43a1a99fcddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_539a2421-b23c-4363-aff7-0aa8fdf0deb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce67644-7040-4225-a42b-8ff435466488" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_539a2421-b23c-4363-aff7-0aa8fdf0deb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c4eb56ca-e72c-4732-9fba-c3bf8a33dc53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce67644-7040-4225-a42b-8ff435466488" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c4eb56ca-e72c-4732-9fba-c3bf8a33dc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_39501dbd-2a3d-4bc7-a91d-58bb6da16d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce67644-7040-4225-a42b-8ff435466488" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_39501dbd-2a3d-4bc7-a91d-58bb6da16d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f69d1c6c-5a54-478e-b239-d26ec2b01413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c9832f56-f9dd-436a-a2b3-cee6f9993561" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f69d1c6c-5a54-478e-b239-d26ec2b01413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e69af25b-941b-4431-ad4d-15ef616c24bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_69c15510-6a8b-4c13-ad02-d73fb29b37a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e69af25b-941b-4431-ad4d-15ef616c24bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_0a03195e-6207-4389-b252-d42e875058d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e69af25b-941b-4431-ad4d-15ef616c24bd" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_0a03195e-6207-4389-b252-d42e875058d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0202a6bd-237a-463c-b91e-f99c8da9fbd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e69af25b-941b-4431-ad4d-15ef616c24bd" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0202a6bd-237a-463c-b91e-f99c8da9fbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635f0698-b365-4f42-8190-cf24e2f46ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e69af25b-941b-4431-ad4d-15ef616c24bd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635f0698-b365-4f42-8190-cf24e2f46ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f3726f12-a592-4dbd-a114-6735280b97c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e69af25b-941b-4431-ad4d-15ef616c24bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f3726f12-a592-4dbd-a114-6735280b97c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56d437ca-5420-4a11-8bb9-b10a0767cba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_69c15510-6a8b-4c13-ad02-d73fb29b37a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56d437ca-5420-4a11-8bb9-b10a0767cba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_67b9f4d7-481f-4579-ba5f-78fe638ef10a" xlink:href="espr-20210630.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56d437ca-5420-4a11-8bb9-b10a0767cba9" xlink:to="loc_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_67b9f4d7-481f-4579-ba5f-78fe638ef10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_85c02731-1841-43e3-8201-b4c92f17a699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56d437ca-5420-4a11-8bb9-b10a0767cba9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_85c02731-1841-43e3-8201-b4c92f17a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_c594a00c-f32b-43cd-bf63-b4517c4ff34a" xlink:href="espr-20210630.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56d437ca-5420-4a11-8bb9-b10a0767cba9" xlink:to="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_c594a00c-f32b-43cd-bf63-b4517c4ff34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_bdd12214-1906-44e4-840a-9d9bd9b476c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56d437ca-5420-4a11-8bb9-b10a0767cba9" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_bdd12214-1906-44e4-840a-9d9bd9b476c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e3b306e-7c40-4882-87a7-ec9dd8eb9b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56d437ca-5420-4a11-8bb9-b10a0767cba9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e3b306e-7c40-4882-87a7-ec9dd8eb9b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb100767-7b00-4687-bb31-e47a6b026f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_69c15510-6a8b-4c13-ad02-d73fb29b37a8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb100767-7b00-4687-bb31-e47a6b026f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc6e2f70-741a-448f-9a23-7efb21780a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_69c15510-6a8b-4c13-ad02-d73fb29b37a8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc6e2f70-741a-448f-9a23-7efb21780a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19742b3a-9630-4432-bd97-9b476a859ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_69c15510-6a8b-4c13-ad02-d73fb29b37a8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19742b3a-9630-4432-bd97-9b476a859ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9b5ca455-21a7-49b0-9630-218383ac1387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_69c15510-6a8b-4c13-ad02-d73fb29b37a8" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9b5ca455-21a7-49b0-9630-218383ac1387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_499a1d1a-4875-469b-81cb-b113a2d6396c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9b5ca455-21a7-49b0-9630-218383ac1387" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_499a1d1a-4875-469b-81cb-b113a2d6396c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashRightOfUseAsset_aa967e24-dfff-401f-a22e-eb8b1b2832c0" xlink:href="espr-20210630.xsd#espr_NonCashRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9b5ca455-21a7-49b0-9630-218383ac1387" xlink:to="loc_espr_NonCashRightOfUseAsset_aa967e24-dfff-401f-a22e-eb8b1b2832c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentation" xlink:type="simple" xlink:href="espr-20210630.xsd#TheCompanyandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/TheCompanyandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c6006cc-8a46-4ed2-92af-95c2efe04fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6a139ad7-8f9c-413f-9f66-01083a8f5403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c6006cc-8a46-4ed2-92af-95c2efe04fdb" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6a139ad7-8f9c-413f-9f66-01083a8f5403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#TheCompanyandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05a1c92f-3f95-40f0-9d85-8506b692a97a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05a1c92f-3f95-40f0-9d85-8506b692a97a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1ea6746a-82c4-44ef-a9c9-56975e417c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1ea6746a-82c4-44ef-a9c9-56975e417c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93dd45e0-fa33-433a-9d22-e61033fbac1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1ea6746a-82c4-44ef-a9c9-56975e417c28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93dd45e0-fa33-433a-9d22-e61033fbac1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_074ebace-0571-427b-afb9-fc5c22d10051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93dd45e0-fa33-433a-9d22-e61033fbac1c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_074ebace-0571-427b-afb9-fc5c22d10051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_a66b32cb-003a-4d17-a4fb-795d4bba2a52" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93dd45e0-fa33-433a-9d22-e61033fbac1c" xlink:to="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_a66b32cb-003a-4d17-a4fb-795d4bba2a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e2d08c70-1724-41e5-b902-4280d147a26e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:to="loc_srt_CounterpartyNameAxis_e2d08c70-1724-41e5-b902-4280d147a26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0286c5a3-e73f-4191-878a-e066eb4639db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e2d08c70-1724-41e5-b902-4280d147a26e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0286c5a3-e73f-4191-878a-e066eb4639db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember_e4422b57-9fce-4ced-8bf1-fd399e89e61e" xlink:href="espr-20210630.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0286c5a3-e73f-4191-878a-e066eb4639db" xlink:to="loc_espr_DaiichiSankyoCoLtdMember_e4422b57-9fce-4ced-8bf1-fd399e89e61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EigerIiiSaLlcMember_da4fe326-e07c-40a0-aa3b-a24dce5f4425" xlink:href="espr-20210630.xsd#espr_EigerIiiSaLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0286c5a3-e73f-4191-878a-e066eb4639db" xlink:to="loc_espr_EigerIiiSaLlcMember_da4fe326-e07c-40a0-aa3b-a24dce5f4425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a1f386c-77e5-44ab-abcb-0bd6df169aed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:to="loc_srt_RangeAxis_2a1f386c-77e5-44ab-abcb-0bd6df169aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3771fa39-4a72-48d3-81f0-c3021463b2c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2a1f386c-77e5-44ab-abcb-0bd6df169aed" xlink:to="loc_srt_RangeMember_3771fa39-4a72-48d3-81f0-c3021463b2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a3ceee5a-b2b0-42bb-8b38-f87682184154" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3771fa39-4a72-48d3-81f0-c3021463b2c8" xlink:to="loc_srt_MinimumMember_a3ceee5a-b2b0-42bb-8b38-f87682184154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3494245c-ef4c-43a5-84a2-34e1e597598d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3771fa39-4a72-48d3-81f0-c3021463b2c8" xlink:to="loc_srt_MaximumMember_3494245c-ef4c-43a5-84a2-34e1e597598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab683f64-599f-45dd-a0b5-f6ce293b1671" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UpFrontPayment_0307daaa-e215-48f2-8f6d-170211437a24" xlink:href="espr-20210630.xsd#espr_UpFrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:to="loc_espr_UpFrontPayment_0307daaa-e215-48f2-8f6d-170211437a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_3dc3ce6f-ac4d-41f0-ba5e-651064b940c4" xlink:href="espr-20210630.xsd#espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:to="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_3dc3ce6f-ac4d-41f0-ba5e-651064b940c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_dc2e6ce6-6bc8-414a-b6f4-92bd41bde5d0" xlink:href="espr-20210630.xsd#espr_PercentageOfRoyaltiesToBeReceivedOnNetSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:to="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_dc2e6ce6-6bc8-414a-b6f4-92bd41bde5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_cbe2f3f6-dd02-447a-9159-9bab0d54a9aa" xlink:href="espr-20210630.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d75ae054-cac5-4d94-bf4e-1565270d373b" xlink:to="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_cbe2f3f6-dd02-447a-9159-9bab0d54a9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="espr-20210630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f98f01ed-1ab8-4a9b-a9c3-327852b3d867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_475eef8c-21d3-4b26-854a-4f7ef2a899c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f98f01ed-1ab8-4a9b-a9c3-327852b3d867" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_475eef8c-21d3-4b26-854a-4f7ef2a899c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="espr-20210630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_675c1944-8ddd-4d2a-a261-43f6d9e5804f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28b1d5de-8fa9-4c89-b182-e407b704feb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_675c1944-8ddd-4d2a-a261-43f6d9e5804f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28b1d5de-8fa9-4c89-b182-e407b704feb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_74c79705-b25d-4ae6-9735-bc247a9e41c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_675c1944-8ddd-4d2a-a261-43f6d9e5804f" xlink:to="loc_us-gaap_UseOfEstimates_74c79705-b25d-4ae6-9735-bc247a9e41c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_63d996ff-60ce-4eca-8d01-7fb1ce93e3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_675c1944-8ddd-4d2a-a261-43f6d9e5804f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_63d996ff-60ce-4eca-8d01-7fb1ce93e3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_917fa654-b1b6-4108-bc93-81911c288ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_675c1944-8ddd-4d2a-a261-43f6d9e5804f" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_917fa654-b1b6-4108-bc93-81911c288ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_51c6786d-1346-4e84-a27e-8d9f2b3f078c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_675c1944-8ddd-4d2a-a261-43f6d9e5804f" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_51c6786d-1346-4e84-a27e-8d9f2b3f078c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_48bd803f-7882-4b13-a863-aa1d79c96bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_675c1944-8ddd-4d2a-a261-43f6d9e5804f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_48bd803f-7882-4b13-a863-aa1d79c96bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a2a7346f-42f2-438e-9277-7bf968797c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:href="espr-20210630.xsd#espr_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2a7346f-42f2-438e-9277-7bf968797c34" xlink:to="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51ee018f-61d3-4ae4-94e5-9f87335d91c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51ee018f-61d3-4ae4-94e5-9f87335d91c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65098ac0-9931-464e-94b9-b905ff773f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51ee018f-61d3-4ae4-94e5-9f87335d91c0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65098ac0-9931-464e-94b9-b905ff773f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_49054039-158f-4a64-9114-ca42e86c20af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65098ac0-9931-464e-94b9-b905ff773f0d" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_49054039-158f-4a64-9114-ca42e86c20af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0803703a-52da-461b-b385-a2bfbfe184ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0803703a-52da-461b-b385-a2bfbfe184ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_02f19faf-afbf-45cc-bb90-5604db19509e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0803703a-52da-461b-b385-a2bfbfe184ff" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_02f19faf-afbf-45cc-bb90-5604db19509e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_59884d95-c653-4be9-a4cd-29cd80d894e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_02f19faf-afbf-45cc-bb90-5604db19509e" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_59884d95-c653-4be9-a4cd-29cd80d894e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0f19562-e6ad-4c9b-975e-72913a39b420" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0f19562-e6ad-4c9b-975e-72913a39b420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_33f5081c-5735-4399-90ac-73b93fd047ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0f19562-e6ad-4c9b-975e-72913a39b420" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_33f5081c-5735-4399-90ac-73b93fd047ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c3e2ad60-a76c-4aaa-8bb4-e893e60aab5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_33f5081c-5735-4399-90ac-73b93fd047ca" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c3e2ad60-a76c-4aaa-8bb4-e893e60aab5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d976afb-cfa1-4e4a-9036-e160332d979a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:to="loc_srt_ProductOrServiceAxis_9d976afb-cfa1-4e4a-9036-e160332d979a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_513432a9-501b-487e-83c5-b24088256b53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9d976afb-cfa1-4e4a-9036-e160332d979a" xlink:to="loc_srt_ProductsAndServicesDomain_513432a9-501b-487e-83c5-b24088256b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ac66f2ca-bbde-4f4e-9f99-cd3b3927bb00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_513432a9-501b-487e-83c5-b24088256b53" xlink:to="loc_us-gaap_ProductMember_ac66f2ca-bbde-4f4e-9f99-cd3b3927bb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:href="espr-20210630.xsd#espr_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesTable_8bd7e5a5-8708-492f-9793-cda4dcce273a" xlink:to="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConcentrationRiskNumberOfMajorCustomers_94903312-c258-491a-95b7-1f22912ef49e" xlink:href="espr-20210630.xsd#espr_ConcentrationRiskNumberOfMajorCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_espr_ConcentrationRiskNumberOfMajorCustomers_94903312-c258-491a-95b7-1f22912ef49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfSourcesOfRevenue_920d2b14-df59-4037-bd5e-a702b99f2ddf" xlink:href="espr-20210630.xsd#espr_NumberOfSourcesOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_espr_NumberOfSourcesOfRevenue_920d2b14-df59-4037-bd5e-a702b99f2ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_120503b5-b7fe-4689-a2e2-83ca0e3a8abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_120503b5-b7fe-4689-a2e2-83ca0e3a8abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_a6b43548-99a3-4949-ab8b-5be6d5c353a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_a6b43548-99a3-4949-ab8b-5be6d5c353a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45dfd682-f9e8-49f8-91e8-c6affd5f0540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45dfd682-f9e8-49f8-91e8-c6affd5f0540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f90fddb4-f5f7-4668-b970-c9d12fa316d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_70c817ae-ce0d-428b-851c-7f097f700977" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f90fddb4-f5f7-4668-b970-c9d12fa316d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CollaborationswithThirdParties" xlink:type="simple" xlink:href="espr-20210630.xsd#CollaborationswithThirdParties"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CollaborationswithThirdParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementAbstract_c264159c-3d86-4d9f-9670-138a0c45b8e7" xlink:href="espr-20210630.xsd#espr_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d8a33b5d-6598-46e1-9480-505ccadb4a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_CollaborativeArrangementAbstract_c264159c-3d86-4d9f-9670-138a0c45b8e7" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d8a33b5d-6598-46e1-9480-505ccadb4a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#CollaborationswithThirdPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementAbstract_1e2e54b6-2630-428a-9838-e94c36957c31" xlink:href="espr-20210630.xsd#espr_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_CollaborativeArrangementAbstract_1e2e54b6-2630-428a-9838-e94c36957c31" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_240319cc-bd9e-47fe-a25f-646ed693e6fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_240319cc-bd9e-47fe-a25f-646ed693e6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_240319cc-bd9e-47fe-a25f-646ed693e6fa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_990b5284-005d-4a47-ab1f-fc54990c7282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_990b5284-005d-4a47-ab1f-fc54990c7282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmendedLicenseAndCollaborationAgreementMember_b6bd575f-276b-4e6e-bee2-d5d9975e5137" xlink:href="espr-20210630.xsd#espr_AmendedLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_espr_AmendedLicenseAndCollaborationAgreementMember_b6bd575f-276b-4e6e-bee2-d5d9975e5137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ExclusiveDevelopmentalActivitiesMember_07cdd6ba-e52a-4219-a8c4-501a28af7812" xlink:href="espr-20210630.xsd#espr_ExclusiveDevelopmentalActivitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_espr_ExclusiveDevelopmentalActivitiesMember_07cdd6ba-e52a-4219-a8c4-501a28af7812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember_1aa82f8b-49e1-41c3-bb13-94bab2ae9223" xlink:href="espr-20210630.xsd#espr_CollaborativeArrangementLicenseToIntellectualPropertyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_espr_CollaborativeArrangementLicenseToIntellectualPropertyMember_1aa82f8b-49e1-41c3-bb13-94bab2ae9223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember_2a988d04-b593-4a01-8166-7e7f5e919ac1" xlink:href="espr-20210630.xsd#espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bcbbd-288c-4094-8c60-7db6a6ab18c4" xlink:to="loc_espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember_2a988d04-b593-4a01-8166-7e7f5e919ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9ac06b1-82ea-4250-bb7d-273253236b7c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:to="loc_srt_CounterpartyNameAxis_a9ac06b1-82ea-4250-bb7d-273253236b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a9ac06b1-82ea-4250-bb7d-273253236b7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoEuropeGmbhMember_52882af5-3003-475c-9e3a-d83c8c2781b3" xlink:href="espr-20210630.xsd#espr_DaiichiSankyoEuropeGmbhMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:to="loc_espr_DaiichiSankyoEuropeGmbhMember_52882af5-3003-475c-9e3a-d83c8c2781b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_OtsukaPharmaceuticalCoLtdMember_f5dc1287-b1dc-4c48-8106-56dee2a00ca5" xlink:href="espr-20210630.xsd#espr_OtsukaPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:to="loc_espr_OtsukaPharmaceuticalCoLtdMember_f5dc1287-b1dc-4c48-8106-56dee2a00ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember_5034fbfd-9b03-41c8-aeef-5fb3afe0c257" xlink:href="espr-20210630.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:to="loc_espr_DaiichiSankyoCoLtdMember_5034fbfd-9b03-41c8-aeef-5fb3afe0c257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SerometrixMember_4ac34f77-b81f-41ea-8a21-5ab1d77155ed" xlink:href="espr-20210630.xsd#espr_SerometrixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a91bdf89-5996-4aec-a487-ca58a50d03bf" xlink:to="loc_espr_SerometrixMember_4ac34f77-b81f-41ea-8a21-5ab1d77155ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_91b4f30c-274e-4c5d-af02-2b823cca9265" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:to="loc_srt_ProductOrServiceAxis_91b4f30c-274e-4c5d-af02-2b823cca9265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_91b4f30c-274e-4c5d-af02-2b823cca9265" xlink:to="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RegulatoryPerformanceObligationsMember_a5bf1aa1-a16b-4ad5-9f0e-8c9e41929021" xlink:href="espr-20210630.xsd#espr_RegulatoryPerformanceObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_RegulatoryPerformanceObligationsMember_a5bf1aa1-a16b-4ad5-9f0e-8c9e41929021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember_c5cb3fb0-0684-4210-b056-2c50cb1cbbf1" xlink:href="espr-20210630.xsd#espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember_c5cb3fb0-0684-4210-b056-2c50cb1cbbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember_5a936050-f4d2-4250-8698-cfd355094279" xlink:href="espr-20210630.xsd#espr_ProductSalesBulkTabletsNilemdoAndNustendiMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_ProductSalesBulkTabletsNilemdoAndNustendiMember_5a936050-f4d2-4250-8698-cfd355094279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborationRevenueMember_9ac7a1f4-669e-47c0-9371-fbf83ef25a52" xlink:href="espr-20210630.xsd#espr_CollaborationRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_CollaborationRevenueMember_9ac7a1f4-669e-47c0-9371-fbf83ef25a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MilestoneMarketingAuthorizationApprovalNustendiMember_b042f13a-41ea-476b-b83a-2b540d7e61e0" xlink:href="espr-20210630.xsd#espr_MilestoneMarketingAuthorizationApprovalNustendiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d0394c-cbb0-4db9-a9f9-644af283347d" xlink:to="loc_espr_MilestoneMarketingAuthorizationApprovalNustendiMember_b042f13a-41ea-476b-b83a-2b540d7e61e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df037dd4-e48f-4199-ada9-bae70f71c4ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:to="loc_srt_RangeAxis_df037dd4-e48f-4199-ada9-bae70f71c4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_196f3351-ec68-406c-9da4-0d0649edf333" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_df037dd4-e48f-4199-ada9-bae70f71c4ca" xlink:to="loc_srt_RangeMember_196f3351-ec68-406c-9da4-0d0649edf333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_94e58fef-f844-4351-9690-7f1c13d6211a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_196f3351-ec68-406c-9da4-0d0649edf333" xlink:to="loc_srt_MinimumMember_94e58fef-f844-4351-9690-7f1c13d6211a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cf186939-3e52-492d-bcfc-d8e581478b8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_196f3351-ec68-406c-9da4-0d0649edf333" xlink:to="loc_srt_MaximumMember_cf186939-3e52-492d-bcfc-d8e581478b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_673e6436-189e-45c1-9b21-93e8c9bf81be" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UpFrontPayment_d05449b8-ff90-4eb6-9d60-e633c1f27e8c" xlink:href="espr-20210630.xsd#espr_UpFrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_UpFrontPayment_d05449b8-ff90-4eb6-9d60-e633c1f27e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FutureUpFrontPayment_29c43d8d-c9ee-49ce-aeea-cbcac5fcdab0" xlink:href="espr-20210630.xsd#espr_FutureUpFrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FutureUpFrontPayment_29c43d8d-c9ee-49ce-aeea-cbcac5fcdab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales_a0577cc9-f107-490a-8c21-fd91e68ddfbd" xlink:href="espr-20210630.xsd#espr_CashPaymentToBeReceivedUponFirstCommercialSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales_a0577cc9-f107-490a-8c21-fd91e68ddfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_16669d12-2a99-40e6-a1ba-3a569961c9ae" xlink:href="espr-20210630.xsd#espr_PercentageOfRoyaltiesToBeReceivedOnNetSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_16669d12-2a99-40e6-a1ba-3a569961c9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer_d0985168-1a8b-4fd7-a8df-18652313fd14" xlink:href="espr-20210630.xsd#espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer_d0985168-1a8b-4fd7-a8df-18652313fd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_40730959-e210-4f71-99d6-3b9b23c99e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_40730959-e210-4f71-99d6-3b9b23c99e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1567dd7a-dec8-44d8-92a1-aac97f77a454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1567dd7a-dec8-44d8-92a1-aac97f77a454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_3af79b82-7f29-470e-a33f-29af31bbf40f" xlink:href="espr-20210630.xsd#espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_3af79b82-7f29-470e-a33f-29af31bbf40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_7dedd9a0-27be-4013-8f07-fc7c0f020212" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_7dedd9a0-27be-4013-8f07-fc7c0f020212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_de12a19f-d414-4ba1-bcc6-edca1fb6b22e" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_de12a19f-d414-4ba1-bcc6-edca1fb6b22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_d7ca4323-f032-4362-94c6-9800f1499a8d" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_d7ca4323-f032-4362-94c6-9800f1499a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneSalesMilestones_cd56dc31-c0ec-46eb-9a54-c87d91b604fe" xlink:href="espr-20210630.xsd#espr_FuturePaymentMilestoneSalesMilestones"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_FuturePaymentMilestoneSalesMilestones_cd56dc31-c0ec-46eb-9a54-c87d91b604fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_ea78d4ad-ccd3-41fc-87ce-6f2e0019ef13" xlink:href="espr-20210630.xsd#espr_CashPaymentToBeReceivedUponCertainCommercialMilestones"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_ea78d4ad-ccd3-41fc-87ce-6f2e0019ef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DeferredUpFrontPayment_10effc36-8e13-49cb-b78a-401f0e4f2015" xlink:href="espr-20210630.xsd#espr_DeferredUpFrontPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a899a89c-422d-473e-87c6-727b00dd8dd1" xlink:to="loc_espr_DeferredUpFrontPayment_10effc36-8e13-49cb-b78a-401f0e4f2015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/Inventories" xlink:type="simple" xlink:href="espr-20210630.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7e1caa65-36b2-4389-968e-5bf912e0e224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_340990d5-34c1-41b5-a94f-9bd8039e6b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7e1caa65-36b2-4389-968e-5bf912e0e224" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_340990d5-34c1-41b5-a94f-9bd8039e6b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InventoriesTables" xlink:type="simple" xlink:href="espr-20210630.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1e01c59a-257c-4d0a-ba2b-3264e26ac25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_04c990e6-f471-460f-b40d-b69c299897e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1e01c59a-257c-4d0a-ba2b-3264e26ac25c" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_04c990e6-f471-460f-b40d-b69c299897e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InventoriesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3728859d-2d2f-4210-b07c-31fc9d8139ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_325ba0f1-738e-45fc-8724-18e1757c6876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3728859d-2d2f-4210-b07c-31fc9d8139ae" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_325ba0f1-738e-45fc-8724-18e1757c6876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_da4f6765-c591-4216-9a44-bbe22976ad3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3728859d-2d2f-4210-b07c-31fc9d8139ae" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_da4f6765-c591-4216-9a44-bbe22976ad3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c46dad7d-5d1a-4e1b-aa15-040a2aeea66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3728859d-2d2f-4210-b07c-31fc9d8139ae" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c46dad7d-5d1a-4e1b-aa15-040a2aeea66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e0e9a850-1ebc-4531-9cbf-7f13a69ca6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3728859d-2d2f-4210-b07c-31fc9d8139ae" xlink:to="loc_us-gaap_InventoryNet_e0e9a850-1ebc-4531-9cbf-7f13a69ca6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="espr-20210630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f509c131-71d1-4e02-ab8c-63f1bc5f1b62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_25cfdc37-41c9-40f3-bcd5-5dcc960de975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f509c131-71d1-4e02-ab8c-63f1bc5f1b62" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_25cfdc37-41c9-40f3-bcd5-5dcc960de975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6f30f2e-77ad-40b5-9b77-bf077490d0fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_15c3ba85-4cb5-4863-b917-c61b5f282e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6f30f2e-77ad-40b5-9b77-bf077490d0fc" xlink:to="loc_us-gaap_LossContingenciesTable_15c3ba85-4cb5-4863-b917-c61b5f282e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_6d8a5d27-a057-4a78-80da-31e7302f0f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_15c3ba85-4cb5-4863-b917-c61b5f282e13" xlink:to="loc_us-gaap_LitigationStatusAxis_6d8a5d27-a057-4a78-80da-31e7302f0f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_61017148-dec7-443d-83cf-1f8209fa9279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_6d8a5d27-a057-4a78-80da-31e7302f0f94" xlink:to="loc_us-gaap_LitigationStatusDomain_61017148-dec7-443d-83cf-1f8209fa9279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_ffac5156-fb51-4420-a46d-60e7f814f842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_61017148-dec7-443d-83cf-1f8209fa9279" xlink:to="loc_us-gaap_PendingLitigationMember_ffac5156-fb51-4420-a46d-60e7f814f842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_15c3ba85-4cb5-4863-b917-c61b5f282e13" xlink:to="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ad932466-1cd6-4378-bc98-92e62a9c7cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ad932466-1cd6-4378-bc98-92e62a9c7cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c9218c58-7e26-4934-8a71-2f3b3feb154b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c9218c58-7e26-4934-8a71-2f3b3feb154b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb8375af-7a4e-48e1-89d9-08adce9fa6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb8375af-7a4e-48e1-89d9-08adce9fa6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable_2ee9d6a9-03d3-4dc7-a3b4-1aa92f387ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_582ea9f0-ef28-492b-9205-356ae6013750" xlink:to="loc_us-gaap_LossContingencyReceivable_2ee9d6a9-03d3-4dc7-a3b4-1aa92f387ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/Investments" xlink:type="simple" xlink:href="espr-20210630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4efe8248-3899-474f-a988-8b99f7311e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_65055fcf-c893-4ff0-bb2e-00f7dbe6974d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4efe8248-3899-474f-a988-8b99f7311e21" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_65055fcf-c893-4ff0-bb2e-00f7dbe6974d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsTables" xlink:type="simple" xlink:href="espr-20210630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0d6fd1f5-1519-4b94-8b4f-1540e7ab2fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_90bdeaf1-ee59-4115-8ffb-983e640a4ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0d6fd1f5-1519-4b94-8b4f-1540e7ab2fb7" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_90bdeaf1-ee59-4115-8ffb-983e640a4ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a56a9d3a-2879-47aa-890e-e17e6649fe6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_57eb3347-81c4-477e-b7df-f32fac00ab72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a56a9d3a-2879-47aa-890e-e17e6649fe6c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_57eb3347-81c4-477e-b7df-f32fac00ab72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_92dc38b7-e4aa-4751-955d-7fb7a369685a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_57eb3347-81c4-477e-b7df-f32fac00ab72" xlink:to="loc_us-gaap_FinancialInstrumentAxis_92dc38b7-e4aa-4751-955d-7fb7a369685a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2003fdb8-0365-43ff-80f4-8e0250363420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_92dc38b7-e4aa-4751-955d-7fb7a369685a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2003fdb8-0365-43ff-80f4-8e0250363420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3535f13e-f7dd-44f8-82db-efaa9d0e999f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2003fdb8-0365-43ff-80f4-8e0250363420" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3535f13e-f7dd-44f8-82db-efaa9d0e999f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0726e585-97de-47f1-a807-2f73cf6c1aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_57eb3347-81c4-477e-b7df-f32fac00ab72" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0726e585-97de-47f1-a807-2f73cf6c1aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7488b8ed-c984-4655-89d6-c52840388184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0726e585-97de-47f1-a807-2f73cf6c1aae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7488b8ed-c984-4655-89d6-c52840388184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f8db1ad0-906e-4dcd-a56c-db9f7dda0882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7488b8ed-c984-4655-89d6-c52840388184" xlink:to="loc_us-gaap_CashEquivalentsMember_f8db1ad0-906e-4dcd-a56c-db9f7dda0882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_57eb3347-81c4-477e-b7df-f32fac00ab72" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_719636b2-cc5d-48a3-a64d-6b5e553ff704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_719636b2-cc5d-48a3-a64d-6b5e553ff704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d8a2ae5-1aa3-4af3-932f-2c8c5e3b28f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d8a2ae5-1aa3-4af3-932f-2c8c5e3b28f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40f84063-3fc3-46ab-b25e-fb0d2cf1a94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40f84063-3fc3-46ab-b25e-fb0d2cf1a94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e147c92b-e1bd-42a8-ab7b-d721f76da207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea832f61-ccde-4219-9371-f9604366c5c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e147c92b-e1bd-42a8-ab7b-d721f76da207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_edd0c49e-c2d0-4411-bdfb-0076610bf3a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_edd0c49e-c2d0-4411-bdfb-0076610bf3a9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2d347b61-551d-4ac9-a69a-b30481d19795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2d347b61-551d-4ac9-a69a-b30481d19795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8eaa4240-b75e-46cd-a2f4-ed7ebdecb939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d347b61-551d-4ac9-a69a-b30481d19795" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8eaa4240-b75e-46cd-a2f4-ed7ebdecb939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_dd544bc3-5a67-444a-8eaa-168079d757f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8eaa4240-b75e-46cd-a2f4-ed7ebdecb939" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_dd544bc3-5a67-444a-8eaa-168079d757f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_89d3bb78-4d0d-4648-b45c-633cc3f353a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_89d3bb78-4d0d-4648-b45c-633cc3f353a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2523ea7c-26dc-441f-8c9d-9b552bdf42cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_89d3bb78-4d0d-4648-b45c-633cc3f353a8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2523ea7c-26dc-441f-8c9d-9b552bdf42cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b34e6958-6393-458c-a8b7-043441c52ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2523ea7c-26dc-441f-8c9d-9b552bdf42cf" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b34e6958-6393-458c-a8b7-043441c52ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6603a48-3abf-4b70-9160-92f993d4ee85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:to="loc_srt_RangeAxis_f6603a48-3abf-4b70-9160-92f993d4ee85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d85beeac-b3b7-4cd5-b431-c0fcbb453588" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f6603a48-3abf-4b70-9160-92f993d4ee85" xlink:to="loc_srt_RangeMember_d85beeac-b3b7-4cd5-b431-c0fcbb453588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_459a752d-c1e3-4992-82b2-81f2d48b0316" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d85beeac-b3b7-4cd5-b431-c0fcbb453588" xlink:to="loc_srt_MaximumMember_459a752d-c1e3-4992-82b2-81f2d48b0316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5ce6652f-c5dc-4875-81da-1e1558725291" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8a19f816-a56d-4be8-8a4a-676e6543278d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8a19f816-a56d-4be8-8a4a-676e6543278d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_184271f1-3a32-4a2c-aeff-70fee7dd7181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_184271f1-3a32-4a2c-aeff-70fee7dd7181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f9aca585-5817-4aa6-ab23-c9ac8d3daaba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f9aca585-5817-4aa6-ab23-c9ac8d3daaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_78ba17b9-3a23-4cb5-8e22-dcfe8309b532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f92678c5-d301-489f-b950-612881865639" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_78ba17b9-3a23-4cb5-8e22-dcfe8309b532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="espr-20210630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_32e626df-e4b4-416c-b7ad-cfd1630e10fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_43ccb693-475c-441f-96b6-a5597804f559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_32e626df-e4b4-416c-b7ad-cfd1630e10fb" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_43ccb693-475c-441f-96b6-a5597804f559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="espr-20210630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c0c23749-a42d-409f-9ab4-69c036f4ec4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_dfda97d4-806d-4d09-a583-ffe64ebacf29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c0c23749-a42d-409f-9ab4-69c036f4ec4d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_dfda97d4-806d-4d09-a583-ffe64ebacf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_90bc1b59-fc2e-4caf-92d7-e5724cd3b7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90bc1b59-fc2e-4caf-92d7-e5724cd3b7aa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f115e5e5-5d37-49da-a2d5-82e784f65fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f115e5e5-5d37-49da-a2d5-82e784f65fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e163d4-a819-479a-80ec-43bb3ab76c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f115e5e5-5d37-49da-a2d5-82e784f65fea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e163d4-a819-479a-80ec-43bb3ab76c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d69494ce-54b9-44b0-b042-bd3b6fbc8d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e163d4-a819-479a-80ec-43bb3ab76c80" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d69494ce-54b9-44b0-b042-bd3b6fbc8d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0a4d083-1b62-4aa2-94e4-4db01a036976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0a4d083-1b62-4aa2-94e4-4db01a036976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0a4d083-1b62-4aa2-94e4-4db01a036976" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_770c13df-9824-4e42-81b7-1ae4bf8691c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_770c13df-9824-4e42-81b7-1ae4bf8691c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9dac1792-e1c2-42d7-9257-6a09f02ea664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9dac1792-e1c2-42d7-9257-6a09f02ea664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f623e60a-0d8a-4fcd-accd-26c76fd43b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4606077f-2439-4b3e-b1e2-af290838e922" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f623e60a-0d8a-4fcd-accd-26c76fd43b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fd528c48-2bf6-4bf8-aa9e-47169194508e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fd528c48-2bf6-4bf8-aa9e-47169194508e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a35b34f-a30e-4c13-8ce7-ab1296903a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fd528c48-2bf6-4bf8-aa9e-47169194508e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a35b34f-a30e-4c13-8ce7-ab1296903a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4df26f71-179a-4446-a408-1e6e126cfaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a35b34f-a30e-4c13-8ce7-ab1296903a5e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4df26f71-179a-4446-a408-1e6e126cfaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8385d8b-5da7-4aa4-9fdb-bf2a11aeefb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d84d1a78-6e03-4600-b437-2bec817eb39a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8385d8b-5da7-4aa4-9fdb-bf2a11aeefb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c127f40b-4c6c-4855-9053-7d3506b3237e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8385d8b-5da7-4aa4-9fdb-bf2a11aeefb8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c127f40b-4c6c-4855-9053-7d3506b3237e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement" xlink:type="simple" xlink:href="espr-20210630.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreement"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_ec35d3a5-ff45-4738-96a4-57b32beeda1b" xlink:href="espr-20210630.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_e5ac5203-1589-47b3-beaf-70f5cc409147" xlink:href="espr-20210630.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_ec35d3a5-ff45-4738-96a4-57b32beeda1b" xlink:to="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_e5ac5203-1589-47b3-beaf-70f5cc409147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables" xlink:type="simple" xlink:href="espr-20210630.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_439fbeb3-58dd-4567-a583-769db8d151b5" xlink:href="espr-20210630.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_a2dc11ce-f445-48a7-b425-d30ced6da066" xlink:href="espr-20210630.xsd#espr_ScheduleOfRevenueInterestLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_439fbeb3-58dd-4567-a583-769db8d151b5" xlink:to="loc_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_a2dc11ce-f445-48a7-b425-d30ced6da066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_905ec300-c994-461d-810f-82a6c7ba09e3" xlink:href="espr-20210630.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_905ec300-c994-461d-810f-82a6c7ba09e3" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_22bc7cf5-932b-48eb-8a33-7857782f5982" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:to="loc_srt_CounterpartyNameAxis_22bc7cf5-932b-48eb-8a33-7857782f5982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acac852a-16b5-4953-9a11-0191d0c87991" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_22bc7cf5-932b-48eb-8a33-7857782f5982" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acac852a-16b5-4953-9a11-0191d0c87991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EigerIiiSaLlcMember_b40b4d24-f97c-4b6c-93bc-dd52e6a2774f" xlink:href="espr-20210630.xsd#espr_EigerIiiSaLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acac852a-16b5-4953-9a11-0191d0c87991" xlink:to="loc_espr_EigerIiiSaLlcMember_b40b4d24-f97c-4b6c-93bc-dd52e6a2774f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a207740d-26f1-48b4-8a4d-f196d321e33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a207740d-26f1-48b4-8a4d-f196d321e33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a207740d-26f1-48b4-8a4d-f196d321e33b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember_3dabac75-f45e-44ad-bd5d-a116c82872bc" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:to="loc_espr_RevenueInterestPurchaseAgreementMember_3dabac75-f45e-44ad-bd5d-a116c82872bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_651f4c0e-e6d3-4981-8b98-8b6f0bcbb756" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:to="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_651f4c0e-e6d3-4981-8b98-8b6f0bcbb756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_d03bed7a-9982-42bb-bf00-382c9ff616c6" xlink:href="espr-20210630.xsd#espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c376088-9344-471c-b61f-9dd9ce8b07fa" xlink:to="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_d03bed7a-9982-42bb-bf00-382c9ff616c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdAxis_90e299b9-02ab-42e4-ad46-81df0f652f40" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:to="loc_espr_NetSalesThresholdAxis_90e299b9-02ab-42e4-ad46-81df0f652f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_NetSalesThresholdAxis_90e299b9-02ab-42e4-ad46-81df0f652f40" xlink:to="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdOneMember_aefc90b0-f3ec-4b4a-85d2-28430a1e06dd" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:to="loc_espr_NetSalesThresholdOneMember_aefc90b0-f3ec-4b4a-85d2-28430a1e06dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdTwoMember_ccb8de26-4e66-4247-9030-0606afe4d624" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:to="loc_espr_NetSalesThresholdTwoMember_ccb8de26-4e66-4247-9030-0606afe4d624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdThreeMember_3b21803a-e30a-467e-a4ef-74d794835334" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_NetSalesThresholdDomain_24cd173a-efd4-4169-aeda-72ab15da64f3" xlink:to="loc_espr_NetSalesThresholdThreeMember_3b21803a-e30a-467e-a4ef-74d794835334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_5c46c114-5c53-45d6-b80c-34442aafab13" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_435e38f4-6e31-45f3-8ad1-4f3d04dc3b20" xlink:href="espr-20210630.xsd#espr_GrossProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_435e38f4-6e31-45f3-8ad1-4f3d04dc3b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_ced1935e-99c9-4e79-a045-e2126716398a" xlink:href="espr-20210630.xsd#espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_ced1935e-99c9-4e79-a045-e2126716398a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_e50d780f-c25d-4cbf-a280-d901113e31b6" xlink:href="espr-20210630.xsd#espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_e50d780f-c25d-4cbf-a280-d901113e31b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_1ea86b08-c59e-42da-9372-260d7db61438" xlink:href="espr-20210630.xsd#espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_1ea86b08-c59e-42da-9372-260d7db61438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_ea13f8aa-aab2-4719-b7dc-23a362eb2a74" xlink:href="espr-20210630.xsd#espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_ea13f8aa-aab2-4719-b7dc-23a362eb2a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_c30ca3c4-6908-416e-920f-890d9b44382c" xlink:href="espr-20210630.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_c30ca3c4-6908-416e-920f-890d9b44382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierTwo_027041f2-ab94-4695-9317-58a8763bc03a" xlink:href="espr-20210630.xsd#espr_RevenueInterestRateTierTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestRateTierTwo_027041f2-ab94-4695-9317-58a8763bc03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateInitialRate_d7d6fced-033a-4a4e-bd67-4c93c13b9280" xlink:href="espr-20210630.xsd#espr_RevenueInterestRateInitialRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestRateInitialRate_d7d6fced-033a-4a4e-bd67-4c93c13b9280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_c1ef710d-590a-4495-8151-209e6ba73812" xlink:href="espr-20210630.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_c1ef710d-590a-4495-8151-209e6ba73812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_9a3e5630-efe5-4e2a-8657-6505ec765b32" xlink:href="espr-20210630.xsd#espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_9a3e5630-efe5-4e2a-8657-6505ec765b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_75aa73c8-eb55-4082-a5ff-448d54f7229e" xlink:href="espr-20210630.xsd#espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_75aa73c8-eb55-4082-a5ff-448d54f7229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierThree_f039d997-06b0-46b2-b438-4b9e3da41680" xlink:href="espr-20210630.xsd#espr_RevenueInterestRateTierThree"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestRateTierThree_f039d997-06b0-46b2-b438-4b9e3da41680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_23c0e043-d204-443b-9ba2-f2b91a36be47" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_23c0e043-d204-443b-9ba2-f2b91a36be47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised_fa77c35e-1d0a-4e9f-a673-9bda8219174c" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised_fa77c35e-1d0a-4e9f-a673-9bda8219174c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_1b8b6e35-4532-43bd-994f-f5b4bac49429" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_1b8b6e35-4532-43bd-994f-f5b4bac49429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_e6ad16fb-d956-4aba-b6db-72eaa4d551b5" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_e6ad16fb-d956-4aba-b6db-72eaa4d551b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_ec534ce4-0819-4803-8398-a553ca0c70ab" xlink:href="espr-20210630.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_ec534ce4-0819-4803-8398-a553ca0c70ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_13f24506-0343-42ce-98a2-55320fe20ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_13f24506-0343-42ce-98a2-55320fe20ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_bfd52c45-adb8-4865-9941-8e68296033c4" xlink:href="espr-20210630.xsd#espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_bfd52c45-adb8-4865-9941-8e68296033c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_632f0392-d3d4-4005-a9ad-e6c44c220df9" xlink:href="espr-20210630.xsd#espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_632f0392-d3d4-4005-a9ad-e6c44c220df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_ebfc4db8-636b-4472-be44-239379af3045" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiability"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestLiability_ebfc4db8-636b-4472-be44-239379af3045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_952f0f09-2a2a-4c96-aad7-c16845ccd723" xlink:href="espr-20210630.xsd#espr_UnamortizedTransactionCostsOnRevenueInterestAgreement"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_952f0f09-2a2a-4c96-aad7-c16845ccd723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f5542408-e859-4adf-8a8e-981383ff79cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_us-gaap_InterestExpense_f5542408-e859-4adf-8a8e-981383ff79cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalSalesGeneratedAmount_e7f7010d-fe52-4069-8adf-c5c0e6d994ba" xlink:href="espr-20210630.xsd#espr_HypotheticalSalesGeneratedAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_HypotheticalSalesGeneratedAmount_e7f7010d-fe52-4069-8adf-c5c0e6d994ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_1746a14d-c24b-4b62-a4e5-981563618bd1" xlink:href="espr-20210630.xsd#espr_HypotheticalRepaymentObligationBasedOnSalesGenerated"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_1746a14d-c24b-4b62-a4e5-981563618bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_073917d5-0f6b-4e24-b73d-17f6fc9ce6e6" xlink:href="espr-20210630.xsd#espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_073917d5-0f6b-4e24-b73d-17f6fc9ce6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_50432e92-8355-4dea-bc6d-9bd6c445a1d4" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_50432e92-8355-4dea-bc6d-9bd6c445a1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_bed54a30-8dbb-403e-b8fb-3c04079803a6" xlink:href="espr-20210630.xsd#espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_bed54a30-8dbb-403e-b8fb-3c04079803a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_2af6a92b-40d2-4e5b-a2f3-b715a0725f13" xlink:href="espr-20210630.xsd#espr_PercentageOfCumulativePurchaserPaymentsGuarantee"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_2af6a92b-40d2-4e5b-a2f3-b715a0725f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_7b03ae3d-5e2c-4f22-805b-778ef3f383be" xlink:href="espr-20210630.xsd#espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_7b03ae3d-5e2c-4f22-805b-778ef3f383be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_096046b0-fb28-4cb1-899b-8c12c7c294a7" xlink:href="espr-20210630.xsd#espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_84da7045-4edd-4d10-b699-86cb8d3a7321" xlink:to="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_096046b0-fb28-4cb1-899b-8c12c7c294a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_778c67b6-8a86-47a2-971a-51532a2558ca" xlink:href="espr-20210630.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_b76c1189-6392-46b4-94d6-bcf2c75afca6" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_778c67b6-8a86-47a2-971a-51532a2558ca" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_b76c1189-6392-46b4-94d6-bcf2c75afca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6a6a96d3-cbc5-4fed-a708-803d9db730e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_b76c1189-6392-46b4-94d6-bcf2c75afca6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6a6a96d3-cbc5-4fed-a708-803d9db730e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a6fcd5e-8145-422e-a565-db98b87c0344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a6a96d3-cbc5-4fed-a708-803d9db730e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a6fcd5e-8145-422e-a565-db98b87c0344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember_7bda1bd1-3e0b-4371-aeae-15e160ea26b4" xlink:href="espr-20210630.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a6fcd5e-8145-422e-a565-db98b87c0344" xlink:to="loc_espr_RevenueInterestPurchaseAgreementMember_7bda1bd1-3e0b-4371-aeae-15e160ea26b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_4973a04e-410a-43e2-9889-00d25e682839" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_b76c1189-6392-46b4-94d6-bcf2c75afca6" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_4973a04e-410a-43e2-9889-00d25e682839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:href="espr-20210630.xsd#espr_LiabilityFromSaleOfFutureRevenuesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_4973a04e-410a-43e2-9889-00d25e682839" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_c4bab576-cdad-47bd-aea7-780f6e3e3a90" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:to="loc_espr_RevenueInterestLiability_c4bab576-cdad-47bd-aea7-780f6e3e3a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts_973592f8-b02c-4b54-b058-48e8cf138aa7" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:to="loc_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts_973592f8-b02c-4b54-b058-48e8cf138aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_090c6fba-b4e1-4ceb-babf-76a53a6086b4" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:to="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_090c6fba-b4e1-4ceb-babf-76a53a6086b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_0dd2cc19-1159-4c73-85eb-399870255bdb" xlink:href="espr-20210630.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:to="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_0dd2cc19-1159-4c73-85eb-399870255bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_7fb6919a-b97c-477d-a653-b246cb1a606e" xlink:href="espr-20210630.xsd#espr_RevenueInterestLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_b25f97ea-6324-425c-87dd-4b6e151fe741" xlink:to="loc_espr_RevenueInterestLiability_7fb6919a-b97c-477d-a653-b246cb1a606e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/ConvertibleNotes" xlink:type="simple" xlink:href="espr-20210630.xsd#ConvertibleNotes"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/ConvertibleNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_290e1763-331e-4c10-b27f-2d425502786f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_afc29224-516b-4c45-a004-d84ac1f9aec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_290e1763-331e-4c10-b27f-2d425502786f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_afc29224-516b-4c45-a004-d84ac1f9aec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/ConvertibleNotesTables" xlink:type="simple" xlink:href="espr-20210630.xsd#ConvertibleNotesTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/ConvertibleNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4bf258e0-4f23-444c-ba2f-ce5088d44ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_47ce61fa-a38f-4678-b884-1bf28324648d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4bf258e0-4f23-444c-ba2f-ce5088d44ec7" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_47ce61fa-a38f-4678-b884-1bf28324648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/ConvertibleNotesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#ConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/ConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_879363f8-7f4e-4fad-aff7-0af0fde91025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_879363f8-7f4e-4fad-aff7-0af0fde91025" xlink:to="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_96968548-efb1-4e84-9c28-03ba9c399a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_96968548-efb1-4e84-9c28-03ba9c399a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dcf0ff34-bd67-4717-918e-b0ac6cafb40d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_96968548-efb1-4e84-9c28-03ba9c399a56" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dcf0ff34-bd67-4717-918e-b0ac6cafb40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConvertibleSeniorNotesDue2025Member_03cb11d1-6856-4677-909c-275c59ec06dd" xlink:href="espr-20210630.xsd#espr_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dcf0ff34-bd67-4717-918e-b0ac6cafb40d" xlink:to="loc_espr_ConvertibleSeniorNotesDue2025Member_03cb11d1-6856-4677-909c-275c59ec06dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fc71297b-2e81-4aed-a0a1-f10745c0a52f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fc71297b-2e81-4aed-a0a1-f10745c0a52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c5c1d3b6-96f5-4e7f-8e23-eb4702b693e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fc71297b-2e81-4aed-a0a1-f10745c0a52f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c5c1d3b6-96f5-4e7f-8e23-eb4702b693e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a3d72d59-5d44-4147-9d6a-6edb6eafc911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c5c1d3b6-96f5-4e7f-8e23-eb4702b693e7" xlink:to="loc_us-gaap_ConvertibleDebtMember_a3d72d59-5d44-4147-9d6a-6edb6eafc911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3f152bad-bee9-488d-8e3f-f4d2725371de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3f152bad-bee9-488d-8e3f-f4d2725371de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d8650031-f7ff-4a55-bdaf-c481783ede3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3f152bad-bee9-488d-8e3f-f4d2725371de" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d8650031-f7ff-4a55-bdaf-c481783ede3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_e13e464d-8f02-418f-9c6f-d8cdcc55217e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d8650031-f7ff-4a55-bdaf-c481783ede3d" xlink:to="loc_us-gaap_LongTermDebtMember_e13e464d-8f02-418f-9c6f-d8cdcc55217e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c495ea60-d97a-4f6b-ad9f-a105bb2efb28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d8650031-f7ff-4a55-bdaf-c481783ede3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c495ea60-d97a-4f6b-ad9f-a105bb2efb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b02436c4-11c2-4b53-9aa9-8fa31865515f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b02436c4-11c2-4b53-9aa9-8fa31865515f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b8ab774d-204d-4e86-b072-935ff8fe8fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b02436c4-11c2-4b53-9aa9-8fa31865515f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b8ab774d-204d-4e86-b072-935ff8fe8fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_a290d4ed-ad23-476c-b181-e491cfd246d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b8ab774d-204d-4e86-b072-935ff8fe8fb1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_a290d4ed-ad23-476c-b181-e491cfd246d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4dd7fcdb-22fc-41ba-86b5-9a4ea7f556a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b8ab774d-204d-4e86-b072-935ff8fe8fb1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4dd7fcdb-22fc-41ba-86b5-9a4ea7f556a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_75703c75-5277-43f6-b0cd-93b908254f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_75703c75-5277-43f6-b0cd-93b908254f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2329e598-c4fc-4f7d-a806-944d1004227d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_75703c75-5277-43f6-b0cd-93b908254f1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2329e598-c4fc-4f7d-a806-944d1004227d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CappedCallMember_500c4af5-a204-494c-b616-1b70004f3f1c" xlink:href="espr-20210630.xsd#espr_CappedCallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2329e598-c4fc-4f7d-a806-944d1004227d" xlink:to="loc_espr_CappedCallMember_500c4af5-a204-494c-b616-1b70004f3f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d908f1c1-2c73-4233-ae3d-9a68a6173752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d908f1c1-2c73-4233-ae3d-9a68a6173752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_61345265-1aa1-45de-98f9-59095fc7819f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d908f1c1-2c73-4233-ae3d-9a68a6173752" xlink:to="loc_us-gaap_ClassOfStockDomain_61345265-1aa1-45de-98f9-59095fc7819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9cd15043-e051-4fae-8732-328a613ad26e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61345265-1aa1-45de-98f9-59095fc7819f" xlink:to="loc_us-gaap_CommonClassAMember_9cd15043-e051-4fae-8732-328a613ad26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3c322402-dc9e-4fd7-9610-92882a1756fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3c322402-dc9e-4fd7-9610-92882a1756fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0a0df4c-ddce-413e-bea7-0a5226423c46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3c322402-dc9e-4fd7-9610-92882a1756fa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0a0df4c-ddce-413e-bea7-0a5226423c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_632f5c3e-760b-4cab-9632-dd7cde2a1dac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0a0df4c-ddce-413e-bea7-0a5226423c46" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_632f5c3e-760b-4cab-9632-dd7cde2a1dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_83144c4a-cb46-4bd4-a3eb-7de1a333de0d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1fdcb98b-b43b-4616-a5ae-6069e1f92d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1fdcb98b-b43b-4616-a5ae-6069e1f92d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f19a7a64-b85e-4e25-a992-895dcbc74651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f19a7a64-b85e-4e25-a992-895dcbc74651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6f38ca6f-9176-469d-ba0d-782b6482eb91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6f38ca6f-9176-469d-ba0d-782b6482eb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentAdditionalAmount_d0693824-126a-4aee-853a-1e466eceee53" xlink:href="espr-20210630.xsd#espr_DebtInstrumentAdditionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_DebtInstrumentAdditionalAmount_d0693824-126a-4aee-853a-1e466eceee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_344ebdfc-292e-47a1-aff6-6dba08d624df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_344ebdfc-292e-47a1-aff6-6dba08d624df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_9846bbc8-3371-418a-97d1-c64af81eba75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_9846bbc8-3371-418a-97d1-c64af81eba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20affa99-cc27-491f-8725-51f9c00cb4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20affa99-cc27-491f-8725-51f9c00cb4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6046d234-659c-4b22-baf3-cec61129ff35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6046d234-659c-4b22-baf3-cec61129ff35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0b9c35e8-7505-44f1-afc1-f032015c2b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0b9c35e8-7505-44f1-afc1-f032015c2b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7d378bc-47e7-4c18-b52c-8420ebfed774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7d378bc-47e7-4c18-b52c-8420ebfed774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ca064ce4-d756-4af2-ba34-933b6ddaab52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ca064ce4-d756-4af2-ba34-933b6ddaab52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_45f01338-2548-403e-aa06-333166078e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_45f01338-2548-403e-aa06-333166078e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3acaf5a7-8185-4e92-bdb0-86483c25ad1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3acaf5a7-8185-4e92-bdb0-86483c25ad1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfBusinessDays_bed8f81f-18e8-4800-968a-600fec5d585e" xlink:href="espr-20210630.xsd#espr_NumberOfBusinessDays"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_NumberOfBusinessDays_bed8f81f-18e8-4800-968a-600fec5d585e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfConsecutiveTradingDays_a0adb328-ae72-4442-87b2-f75ffaacb98c" xlink:href="espr-20210630.xsd#espr_NumberOfConsecutiveTradingDays"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_NumberOfConsecutiveTradingDays_a0adb328-ae72-4442-87b2-f75ffaacb98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_cd514e49-2c63-4337-a4ad-910e9484297a" xlink:href="espr-20210630.xsd#espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_cd514e49-2c63-4337-a4ad-910e9484297a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f33e7378-5a74-4929-a815-996591387d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f33e7378-5a74-4929-a815-996591387d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding_d60d1ba8-4f20-44ec-9760-b8bd08b8a925" xlink:href="espr-20210630.xsd#espr_DebtInstrumentCovenantRequiredAmountOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding_d60d1ba8-4f20-44ec-9760-b8bd08b8a925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_6256011c-17d4-4ac2-91ca-010ebea8e6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_6256011c-17d4-4ac2-91ca-010ebea8e6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_295229cd-aff2-4d1a-b223-3cf5fb699264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentTerm_295229cd-aff2-4d1a-b223-3cf5fb699264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f087ac08-dd5e-40ca-86fd-51cc9a8e2f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_LongTermDebt_f087ac08-dd5e-40ca-86fd-51cc9a8e2f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_10b6ec69-bbd3-4211-8dac-4719dfdac477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_10b6ec69-bbd3-4211-8dac-4719dfdac477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7daaf7b2-e12d-4c2c-8f97-6969d9b3aea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7daaf7b2-e12d-4c2c-8f97-6969d9b3aea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_322da80d-3306-41db-a42d-c97ca9b7fb01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_322da80d-3306-41db-a42d-c97ca9b7fb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_45c1fed9-0c7a-4e33-98fd-9e8026308872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_InterestExpenseDebt_45c1fed9-0c7a-4e33-98fd-9e8026308872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6225e6cb-6e70-4c01-93d6-449b6c6514fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6225e6cb-6e70-4c01-93d6-449b6c6514fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aaa37202-3262-4ed4-8bd3-b0a76565ba22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aaa37202-3262-4ed4-8bd3-b0a76565ba22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_5ded7b2b-1c4e-4265-b269-89888e9b5eec" xlink:href="espr-20210630.xsd#espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_5ded7b2b-1c4e-4265-b269-89888e9b5eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_bd64f0e9-733b-496d-a887-50fac0aa02fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d9a490fb-2f5f-4ed2-a6df-45776f67c072" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_bd64f0e9-733b-496d-a887-50fac0aa02fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#ConvertibleNotesSummaryofConvertibleDebtDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_775f310e-a15f-46cc-833e-89ccc753fe1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2a2624d1-01ad-4b45-9533-14d61fed3852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_775f310e-a15f-46cc-833e-89ccc753fe1e" xlink:to="loc_us-gaap_DebtInstrumentTable_2a2624d1-01ad-4b45-9533-14d61fed3852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_90080201-39a9-4a7d-8b51-7d1e6543111d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a2624d1-01ad-4b45-9533-14d61fed3852" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_90080201-39a9-4a7d-8b51-7d1e6543111d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bc3341e5-ebeb-46ab-ada4-5269ca4aa1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_90080201-39a9-4a7d-8b51-7d1e6543111d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bc3341e5-ebeb-46ab-ada4-5269ca4aa1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_28dd3ad1-4d59-4819-b2de-5c382288fb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bc3341e5-ebeb-46ab-ada4-5269ca4aa1d9" xlink:to="loc_us-gaap_ConvertibleDebtMember_28dd3ad1-4d59-4819-b2de-5c382288fb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6970b77-3b54-4d82-8abe-53c4bce5a2d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a2624d1-01ad-4b45-9533-14d61fed3852" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6970b77-3b54-4d82-8abe-53c4bce5a2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b367df3-5dcc-4b59-ad4d-6c989d0efe86" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6970b77-3b54-4d82-8abe-53c4bce5a2d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b367df3-5dcc-4b59-ad4d-6c989d0efe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5168dafc-11eb-4be0-95d6-b3c7233ca0d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b367df3-5dcc-4b59-ad4d-6c989d0efe86" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5168dafc-11eb-4be0-95d6-b3c7233ca0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_7d666231-0268-4d77-9356-9b2202df5755" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b367df3-5dcc-4b59-ad4d-6c989d0efe86" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_7d666231-0268-4d77-9356-9b2202df5755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a2624d1-01ad-4b45-9533-14d61fed3852" xlink:to="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_57cf3a25-c048-4176-b6a8-d584a94ea464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_57cf3a25-c048-4176-b6a8-d584a94ea464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_fa9b088e-adef-487f-a05f-be12077aea22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_fa9b088e-adef-487f-a05f-be12077aea22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_288ecd6c-8109-4b83-adaa-7c8144d65220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67b3e786-3a01-4ede-b826-d52a2b9f8d91" xlink:to="loc_us-gaap_LongTermDebt_288ecd6c-8109-4b83-adaa-7c8144d65220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/OtherAccruedLiabilities" xlink:type="simple" xlink:href="espr-20210630.xsd#OtherAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/OtherAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8cd3b4ed-3581-4b84-a5be-5e3e4af34ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_a84347f7-f86e-4a8a-9f4e-6398ccf72c89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8cd3b4ed-3581-4b84-a5be-5e3e4af34ed2" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_a84347f7-f86e-4a8a-9f4e-6398ccf72c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesTables" xlink:type="simple" xlink:href="espr-20210630.xsd#OtherAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/OtherAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_de8e6796-c74c-4b8d-afdf-1dec59b72ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fcc42a61-bc4b-4c52-a9e3-7640051f7a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_de8e6796-c74c-4b8d-afdf-1dec59b72ce8" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fcc42a61-bc4b-4c52-a9e3-7640051f7a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#OtherAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5defd16a-157c-438f-91c6-968514adc513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0c087836-4a1e-4cc7-b13c-14719944f1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5defd16a-157c-438f-91c6-968514adc513" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0c087836-4a1e-4cc7-b13c-14719944f1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedVariableConsiderationCurrent_1b1daf2e-a233-41b5-b04c-2c78da8ba058" xlink:href="espr-20210630.xsd#espr_AccruedVariableConsiderationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5defd16a-157c-438f-91c6-968514adc513" xlink:to="loc_espr_AccruedVariableConsiderationCurrent_1b1daf2e-a233-41b5-b04c-2c78da8ba058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_24abffbb-0794-41f2-8932-6fa4347d1127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5defd16a-157c-438f-91c6-968514adc513" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_24abffbb-0794-41f2-8932-6fa4347d1127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_4bdaa14f-3cae-4053-8e83-f24d762172b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5defd16a-157c-438f-91c6-968514adc513" xlink:to="loc_us-gaap_InterestPayableCurrent_4bdaa14f-3cae-4053-8e83-f24d762172b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f8e81bae-ccd8-4731-bd88-54e08950041d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5defd16a-157c-438f-91c6-968514adc513" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f8e81bae-ccd8-4731-bd88-54e08950041d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_fc458bd4-991a-494a-acb1-a97f7b3a5f86" xlink:href="espr-20210630.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5defd16a-157c-438f-91c6-968514adc513" xlink:to="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_fc458bd4-991a-494a-acb1-a97f7b3a5f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensation" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensation"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1371a55-0e85-429f-a6fa-34d0d8dcb33e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60ee743b-7055-484a-a443-675936e3d629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1371a55-0e85-429f-a6fa-34d0d8dcb33e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60ee743b-7055-484a-a443-675936e3d629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationTables" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5636b7f1-284c-4ed1-9c0d-b564a2a18ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b044f48e-9f9a-4535-bd85-1f807e84fe77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5636b7f1-284c-4ed1-9c0d-b564a2a18ef5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b044f48e-9f9a-4535-bd85-1f807e84fe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_c972e0ab-2190-4709-8a06-78cb00aaff6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5636b7f1-284c-4ed1-9c0d-b564a2a18ef5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_c972e0ab-2190-4709-8a06-78cb00aaff6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_fcd4acd8-6260-4f8b-8fd2-418500300e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5636b7f1-284c-4ed1-9c0d-b564a2a18ef5" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_fcd4acd8-6260-4f8b-8fd2-418500300e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686b02eb-5444-4c1d-94c5-3c318c6ed66c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_99f9bcdd-56d8-4e58-8cf4-846455c3c613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686b02eb-5444-4c1d-94c5-3c318c6ed66c" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_99f9bcdd-56d8-4e58-8cf4-846455c3c613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f69b2b05-065a-4063-ac88-949821c9f5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_99f9bcdd-56d8-4e58-8cf4-846455c3c613" xlink:to="loc_us-gaap_AwardTypeAxis_f69b2b05-065a-4063-ac88-949821c9f5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a14d83-c2ac-4833-b4aa-eadbb2c9e3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f69b2b05-065a-4063-ac88-949821c9f5d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a14d83-c2ac-4833-b4aa-eadbb2c9e3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a0aa5f61-4b64-41db-8143-b4a5fb767951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a14d83-c2ac-4833-b4aa-eadbb2c9e3c1" xlink:to="loc_us-gaap_EmployeeStockMember_a0aa5f61-4b64-41db-8143-b4a5fb767951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_99f9bcdd-56d8-4e58-8cf4-846455c3c613" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_99877f8f-e5da-4d8f-b45f-5bb194e5393c" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_99877f8f-e5da-4d8f-b45f-5bb194e5393c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_2228699a-313e-43ed-a9c2-fd631701e250" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_2228699a-313e-43ed-a9c2-fd631701e250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_09e0c818-6676-48b3-a210-812546f0af8f" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanPercentageDiscountOnShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_09e0c818-6676-48b3-a210-812546f0af8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_3beb58f5-7d95-4050-bea8-224a83832446" xlink:href="espr-20210630.xsd#espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_3beb58f5-7d95-4050-bea8-224a83832446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dbb9acdf-36fd-4e2e-ac63-757d89296a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dbb9acdf-36fd-4e2e-ac63-757d89296a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_a2ba5459-fbaa-43f9-8a50-02c5a5c5f41e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_a2ba5459-fbaa-43f9-8a50-02c5a5c5f41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0df52cac-8d4a-4db5-bbc3-54f437e79d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_15bbaebc-6637-45c6-84bc-bf5f951328ee" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0df52cac-8d4a-4db5-bbc3-54f437e79d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationScheduleofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963ca113-3f6e-4d02-a45d-4caa5a2e9e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a3c69e40-5742-4602-8df9-e897b49426c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963ca113-3f6e-4d02-a45d-4caa5a2e9e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a3c69e40-5742-4602-8df9-e897b49426c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dcc30266-be6f-4ea6-b1a8-36c653f9401e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a3c69e40-5742-4602-8df9-e897b49426c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dcc30266-be6f-4ea6-b1a8-36c653f9401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_882b8c16-6c71-4f89-a7e5-b2efb5dcc3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a3c69e40-5742-4602-8df9-e897b49426c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_882b8c16-6c71-4f89-a7e5-b2efb5dcc3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_45a86e0a-dc98-4a70-98ce-e6b66beecd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a3c69e40-5742-4602-8df9-e897b49426c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_45a86e0a-dc98-4a70-98ce-e6b66beecd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e29c90da-6f59-41a6-a05c-cd10b790a69a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a3c69e40-5742-4602-8df9-e897b49426c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e29c90da-6f59-41a6-a05c-cd10b790a69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3c9f1c3-3ef1-4757-ba2b-6e0cfdfb6c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a3c69e40-5742-4602-8df9-e897b49426c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3c9f1c3-3ef1-4757-ba2b-6e0cfdfb6c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d09f5183-e2b6-400d-a40b-cea95615e0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963ca113-3f6e-4d02-a45d-4caa5a2e9e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d09f5183-e2b6-400d-a40b-cea95615e0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2a0e2677-874f-40d0-825f-e74aff7653b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963ca113-3f6e-4d02-a45d-4caa5a2e9e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2a0e2677-874f-40d0-825f-e74aff7653b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dff53cb-3f1f-4790-b6cb-a34af37ac921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963ca113-3f6e-4d02-a45d-4caa5a2e9e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dff53cb-3f1f-4790-b6cb-a34af37ac921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7cf2fbdb-9d69-4c54-bcb2-a4ee0fe39e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dff53cb-3f1f-4790-b6cb-a34af37ac921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7cf2fbdb-9d69-4c54-bcb2-a4ee0fe39e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6a6c3f3d-e2d4-476e-8b83-beb77a1cae46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dff53cb-3f1f-4790-b6cb-a34af37ac921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6a6c3f3d-e2d4-476e-8b83-beb77a1cae46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_90e06748-a4b2-4827-a300-1ea01adb8605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dff53cb-3f1f-4790-b6cb-a34af37ac921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_90e06748-a4b2-4827-a300-1ea01adb8605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f1566849-d9b7-4d21-9960-a71ebe8870e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dff53cb-3f1f-4790-b6cb-a34af37ac921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f1566849-d9b7-4d21-9960-a71ebe8870e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_87ce594d-9a61-453d-bb20-6c94db5aece5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dff53cb-3f1f-4790-b6cb-a34af37ac921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_87ce594d-9a61-453d-bb20-6c94db5aece5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_02547344-4688-4e22-8ed1-c7573bbb38e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963ca113-3f6e-4d02-a45d-4caa5a2e9e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_02547344-4688-4e22-8ed1-c7573bbb38e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03b677f0-1007-4d5c-8cc4-fbfccdfc129a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963ca113-3f6e-4d02-a45d-4caa5a2e9e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03b677f0-1007-4d5c-8cc4-fbfccdfc129a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_ddf600ca-ccbf-4523-90d6-13fb04b12a76" xlink:href="espr-20210630.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963ca113-3f6e-4d02-a45d-4caa5a2e9e00" xlink:to="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_ddf600ca-ccbf-4523-90d6-13fb04b12a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a164d290-6976-4650-bcb8-b80b2f75222a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_ddf600ca-ccbf-4523-90d6-13fb04b12a76" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a164d290-6976-4650-bcb8-b80b2f75222a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c742cb0d-4e7d-4240-9df0-543388510102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_ddf600ca-ccbf-4523-90d6-13fb04b12a76" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c742cb0d-4e7d-4240-9df0-543388510102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_02d0776a-8707-45ab-8e8b-40343f36b528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_ddf600ca-ccbf-4523-90d6-13fb04b12a76" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_02d0776a-8707-45ab-8e8b-40343f36b528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_00bd01ae-1f12-4af8-bce7-2cd81a4da8cf" xlink:href="espr-20210630.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963ca113-3f6e-4d02-a45d-4caa5a2e9e00" xlink:to="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_00bd01ae-1f12-4af8-bce7-2cd81a4da8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_07985c69-751a-4d66-aca3-059d4e88ba48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_00bd01ae-1f12-4af8-bce7-2cd81a4da8cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_07985c69-751a-4d66-aca3-059d4e88ba48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4a7a6c44-3008-4f9d-bbb5-6b7f4f6c8dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_00bd01ae-1f12-4af8-bce7-2cd81a4da8cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4a7a6c44-3008-4f9d-bbb5-6b7f4f6c8dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_feb38c99-e8bf-4e89-b395-a8da4460129c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_00bd01ae-1f12-4af8-bce7-2cd81a4da8cf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_feb38c99-e8bf-4e89-b395-a8da4460129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationStockOptionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cee7e72a-efa1-4c5d-b2fb-141c2871f257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d697a88-97ca-4400-b763-918678addeb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cee7e72a-efa1-4c5d-b2fb-141c2871f257" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d697a88-97ca-4400-b763-918678addeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a1f65da7-f58f-4058-9039-d8cf615737e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d697a88-97ca-4400-b763-918678addeb4" xlink:to="loc_us-gaap_AwardTypeAxis_a1f65da7-f58f-4058-9039-d8cf615737e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_709845d1-2e38-467b-b560-37246398b089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a1f65da7-f58f-4058-9039-d8cf615737e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_709845d1-2e38-467b-b560-37246398b089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_affbf4ea-cb19-4928-ba57-1b38b4619705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_709845d1-2e38-467b-b560-37246398b089" xlink:to="loc_us-gaap_EmployeeStockOptionMember_affbf4ea-cb19-4928-ba57-1b38b4619705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d697a88-97ca-4400-b763-918678addeb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28da6ef6-137c-43bc-b10b-64daf458b0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28da6ef6-137c-43bc-b10b-64daf458b0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cfa4cf52-b7a0-4a32-9fd7-78f71542807f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cfa4cf52-b7a0-4a32-9fd7-78f71542807f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ea1f32ca-980a-4a28-a481-40684dc8f270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ea1f32ca-980a-4a28-a481-40684dc8f270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4e30f4fb-4d4d-4d25-b646-41581a72a228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad7de13d-7b52-4c1e-8c3f-c9b8599d9a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4e30f4fb-4d4d-4d25-b646-41581a72a228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationRSUsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce5f9a0f-d1db-4e03-984c-2b77d850264c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e6f74de-7b6a-4859-b5bf-d203b4708c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce5f9a0f-d1db-4e03-984c-2b77d850264c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e6f74de-7b6a-4859-b5bf-d203b4708c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5669057c-2a88-4654-b47e-c04d565d629f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e6f74de-7b6a-4859-b5bf-d203b4708c38" xlink:to="loc_us-gaap_AwardTypeAxis_5669057c-2a88-4654-b47e-c04d565d629f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_769c970a-2cb3-4c11-ade0-9d5109466eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5669057c-2a88-4654-b47e-c04d565d629f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_769c970a-2cb3-4c11-ade0-9d5109466eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_35ce048e-88a9-4851-b1da-38a36f4b41c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_769c970a-2cb3-4c11-ade0-9d5109466eda" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_35ce048e-88a9-4851-b1da-38a36f4b41c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfba4702-5fd0-4581-9bf9-faed1772dcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e6f74de-7b6a-4859-b5bf-d203b4708c38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfba4702-5fd0-4581-9bf9-faed1772dcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfba4702-5fd0-4581-9bf9-faed1772dcf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0de8db6f-ab66-48c9-a63c-3dbfeab4cf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0de8db6f-ab66-48c9-a63c-3dbfeab4cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_006089d3-1c5d-4600-907a-af03bd034b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_006089d3-1c5d-4600-907a-af03bd034b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_99c2d7eb-6390-46f0-83f5-b3f247e19710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_99c2d7eb-6390-46f0-83f5-b3f247e19710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ee5654e1-3c66-4f16-bffa-9090e6c838f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ee5654e1-3c66-4f16-bffa-9090e6c838f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a25252f-880f-4b26-80ec-40bb4a2d5b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b2c3753-9d8b-42f3-a01a-bb5542c11a6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a25252f-880f-4b26-80ec-40bb4a2d5b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfba4702-5fd0-4581-9bf9-faed1772dcf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_920e5685-660f-4f48-9816-dd77f7da5b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_920e5685-660f-4f48-9816-dd77f7da5b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8db87a83-4d1b-4247-a53c-17e108628a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8db87a83-4d1b-4247-a53c-17e108628a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e73e7f11-f86e-4e2b-8c2c-56d421d8cf23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e73e7f11-f86e-4e2b-8c2c-56d421d8cf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_860fd9fe-6296-4fa2-8552-ca09ff56b5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_860fd9fe-6296-4fa2-8552-ca09ff56b5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d969cf6a-3016-433e-96d1-6798d6a7fc89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4cce3f4a-8c19-47ae-8067-d53531728e93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d969cf6a-3016-433e-96d1-6798d6a7fc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationRSUsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e137e6e9-e061-4db5-9641-59e2f1d49892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae46500-eed1-43a7-b665-edc708c5e817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e137e6e9-e061-4db5-9641-59e2f1d49892" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae46500-eed1-43a7-b665-edc708c5e817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a523ae9d-6d83-47a9-bb2e-f9798beb7891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae46500-eed1-43a7-b665-edc708c5e817" xlink:to="loc_us-gaap_AwardTypeAxis_a523ae9d-6d83-47a9-bb2e-f9798beb7891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08432d37-7fad-485d-9aa4-cd02940975b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a523ae9d-6d83-47a9-bb2e-f9798beb7891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08432d37-7fad-485d-9aa4-cd02940975b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4080bb3c-f34b-452e-b43f-e483f9c6096f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08432d37-7fad-485d-9aa4-cd02940975b6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4080bb3c-f34b-452e-b43f-e483f9c6096f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae46500-eed1-43a7-b665-edc708c5e817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f5f27111-1002-412a-bcf3-9be7c664b81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f5f27111-1002-412a-bcf3-9be7c664b81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf623904-0805-4a81-956e-110c61366d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf623904-0805-4a81-956e-110c61366d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_45ca1e9a-ad58-40a5-a612-63b6e0ed73fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_45ca1e9a-ad58-40a5-a612-63b6e0ed73fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2cac2015-fcfa-44e7-91e5-192ed2936142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45b09ecf-4848-4275-9986-bdc667a465ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2cac2015-fcfa-44e7-91e5-192ed2936142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationPBRSUsDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#StockCompensationPBRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationPBRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_304cc80d-7052-43ae-8760-2065db00df7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb039495-82b0-483e-abec-544f216c6c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_304cc80d-7052-43ae-8760-2065db00df7e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb039495-82b0-483e-abec-544f216c6c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c5d03a51-09f6-4adf-a7aa-e8d2aecfd34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb039495-82b0-483e-abec-544f216c6c6e" xlink:to="loc_us-gaap_AwardTypeAxis_c5d03a51-09f6-4adf-a7aa-e8d2aecfd34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc8214bc-8dbd-4c62-ba7a-1d8e3d93f505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c5d03a51-09f6-4adf-a7aa-e8d2aecfd34a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc8214bc-8dbd-4c62-ba7a-1d8e3d93f505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0c4904a9-7bf2-4807-818b-bfeaff8a8465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc8214bc-8dbd-4c62-ba7a-1d8e3d93f505" xlink:to="loc_us-gaap_PerformanceSharesMember_0c4904a9-7bf2-4807-818b-bfeaff8a8465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb039495-82b0-483e-abec-544f216c6c6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a46b153f-814d-4095-a1c4-aef892b7e16f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a46b153f-814d-4095-a1c4-aef892b7e16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e67aa3f2-7437-4129-b107-d2268a45ea16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e67aa3f2-7437-4129-b107-d2268a45ea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2dbc957-2e79-4740-a379-525f6e50d752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4134c1b0-a314-48f7-b299-408270a97458" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2dbc957-2e79-4740-a379-525f6e50d752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/IncomeTaxes" xlink:type="simple" xlink:href="espr-20210630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_682422f2-ddca-49f5-ba7e-c7e2131ba725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_430d8876-fec7-49ca-96b9-5355e53f3672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_682422f2-ddca-49f5-ba7e-c7e2131ba725" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_430d8876-fec7-49ca-96b9-5355e53f3672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ea4490a4-9782-448b-acd2-c8bec1fa278b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_167c1781-2fad-47f3-82da-d051bacb8284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea4490a4-9782-448b-acd2-c8bec1fa278b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_167c1781-2fad-47f3-82da-d051bacb8284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_304e7164-25e3-4118-ba83-edf28dee4a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_167c1781-2fad-47f3-82da-d051bacb8284" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_304e7164-25e3-4118-ba83-edf28dee4a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShare" xlink:type="simple" xlink:href="espr-20210630.xsd#NetLossIncomePerCommonShare"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/NetLossIncomePerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0e9e2132-2b5d-4ad7-99ae-748d6b306925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0e89d7ed-a7e6-49dc-bfb7-c4e789a816ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0e9e2132-2b5d-4ad7-99ae-748d6b306925" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0e89d7ed-a7e6-49dc-bfb7-c4e789a816ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShareTables" xlink:type="simple" xlink:href="espr-20210630.xsd#NetLossIncomePerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/NetLossIncomePerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_39b9defc-0d4b-48f5-9b19-af4e31c35a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2fd2c503-637c-4a84-b35a-1519576aa93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_39b9defc-0d4b-48f5-9b19-af4e31c35a35" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2fd2c503-637c-4a84-b35a-1519576aa93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_deb91090-b551-4d67-a023-65adf5a59808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_39b9defc-0d4b-48f5-9b19-af4e31c35a35" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_deb91090-b551-4d67-a023-65adf5a59808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3c3079be-e400-4c1a-b25b-a6bb37d4e960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cad178ea-5e6d-4ddf-9529-cdb875193160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3c3079be-e400-4c1a-b25b-a6bb37d4e960" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cad178ea-5e6d-4ddf-9529-cdb875193160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a3851b1-3229-41a8-93b0-1979a7c72455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cad178ea-5e6d-4ddf-9529-cdb875193160" xlink:to="loc_us-gaap_AwardTypeAxis_0a3851b1-3229-41a8-93b0-1979a7c72455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8a07d8-c0b7-4c7d-9bd9-ed1a3d4e827a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0a3851b1-3229-41a8-93b0-1979a7c72455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8a07d8-c0b7-4c7d-9bd9-ed1a3d4e827a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f23af18c-9908-4868-8d7c-f86df5b77c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8a07d8-c0b7-4c7d-9bd9-ed1a3d4e827a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f23af18c-9908-4868-8d7c-f86df5b77c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2318565f-f35f-4942-a51d-a5a994bdb301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8a07d8-c0b7-4c7d-9bd9-ed1a3d4e827a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2318565f-f35f-4942-a51d-a5a994bdb301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cad178ea-5e6d-4ddf-9529-cdb875193160" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f6f5881-1a37-4b8b-a9c2-1a08bfbb67db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_NetIncomeLoss_1f6f5881-1a37-4b8b-a9c2-1a08bfbb67db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7ae24ee-4f89-436d-9b20-66fe809a8e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7ae24ee-4f89-436d-9b20-66fe809a8e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_66b0aeac-f6f8-4d89-a8cd-bff79f9cbd7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_66b0aeac-f6f8-4d89-a8cd-bff79f9cbd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0f4ff87c-4417-4609-aa8b-c5b4b5b626d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0f4ff87c-4417-4609-aa8b-c5b4b5b626d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d5170ab0-2563-496e-8e92-8eb9be370684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d5170ab0-2563-496e-8e92-8eb9be370684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4d3c2e19-29c4-42d4-94fb-c9ce3f7e5bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_EarningsPerShareBasic_4d3c2e19-29c4-42d4-94fb-c9ce3f7e5bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2876b6b2-4e33-4d2f-850f-363a2ac868ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_31b7ae2e-907e-40cc-8535-abcc56171d4a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2876b6b2-4e33-4d2f-850f-363a2ac868ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossIncomePerCommonShareDetails" xlink:type="simple" xlink:href="espr-20210630.xsd#NetLossIncomePerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/NetLossIncomePerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_91913590-9348-433a-b7f8-e0d104ae62a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7e625a-36de-4013-9963-0a138e9e9b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_91913590-9348-433a-b7f8-e0d104ae62a0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7e625a-36de-4013-9963-0a138e9e9b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4e03f2f-3d2e-4263-aba8-8812a43a04b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7e625a-36de-4013-9963-0a138e9e9b5a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4e03f2f-3d2e-4263-aba8-8812a43a04b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4e03f2f-3d2e-4263-aba8-8812a43a04b3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8efc78c8-70db-4e59-b3a2-5e1fb7df16f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8efc78c8-70db-4e59-b3a2-5e1fb7df16f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_1354655f-61a0-48df-9931-031b7b384dbc" xlink:href="espr-20210630.xsd#espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_1354655f-61a0-48df-9931-031b7b384dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_dc8f28cb-007c-4579-b8a0-997f265bcd45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_us-gaap_PerformanceSharesMember_dc8f28cb-007c-4579-b8a0-997f265bcd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c9b13049-3464-4c67-ae98-fb8bf5a6df49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_us-gaap_EmployeeStockMember_c9b13049-3464-4c67-ae98-fb8bf5a6df49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_5719335c-801a-4796-9918-305a68b258ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_923e6dd1-1dbb-4397-9328-38ba7bcc3036" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_5719335c-801a-4796-9918-305a68b258ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2bba8ba-59db-453d-b034-5098082408e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7e625a-36de-4013-9963-0a138e9e9b5a" xlink:to="loc_us-gaap_AwardTypeAxis_d2bba8ba-59db-453d-b034-5098082408e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ee6070-9ce7-4b1f-99ba-600f7b9ffa50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d2bba8ba-59db-453d-b034-5098082408e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ee6070-9ce7-4b1f-99ba-600f7b9ffa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_21b5014b-cfc4-430b-84e5-39520f5af692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ee6070-9ce7-4b1f-99ba-600f7b9ffa50" xlink:to="loc_us-gaap_EmployeeStockOptionMember_21b5014b-cfc4-430b-84e5-39520f5af692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa993461-f9bd-4bd7-9d34-708bdcfdd884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7e625a-36de-4013-9963-0a138e9e9b5a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa993461-f9bd-4bd7-9d34-708bdcfdd884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0ad83e9f-3fdf-4322-97e5-923e01ba5dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa993461-f9bd-4bd7-9d34-708bdcfdd884" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0ad83e9f-3fdf-4322-97e5-923e01ba5dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>espr-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:espr="http://www.esperion.com/20210630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="espr-20210630.xsd" xlink:type="simple"/>
    <context id="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i050ee60691314e20b69ad95578d2607a_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="i1c209f1921c3473dbb64c2533be863bd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i056e612b26e34dd48d60f525e33d62cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9c66ab5008d4c28a2f2a6317075fc61_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib3f1e56095ca4d07a8f77cec69f8a7ba_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id3555938aa014fbda7603991f689d2d4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia332deb386b74a509426822f23273e5e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i338fd57bbd8f4b7b98555b5eedfc71e5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5566a2ae4e074e8aac4a681884d52a3b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic3c9855747284b97950418c5661f9398_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if6ed1002c3524d20bc0a363b109f9831_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i33200b5320234052894888a136145868_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2a5187a56ea64ae79ed566f657f52f0f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e9d11b53c0d4fce938a87352fd5fe47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f8ebc6cecb04f1dbbca266b983b0ee4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia9259ac42a9d4b44a6979f88be43cf44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieb7184bc40e84732a19137ba864fb6b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e0d32b36655400c85ee28b60964a4d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4782e3db8423421e942447fb17c5f321_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib43b6fdc517a411c85647b77372d9e79_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4c1c8ad065e5492490704fc3b9a9d9f6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib618d67da2c4453a8e65d796194636c5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i399ac47076af4f908e42954eee2ad039_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8356b00716a84a1394f6e22c68047217_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i608ba03464564214a1e179c94a81c70c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6eaf0b1998954d038c9b487adfa44c18_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i901e75a34f054bd3a4d7f6dd621b20bb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i01bcadb4b56c4ca1818a0393ce077c11_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2fcaca0841c046a9b25d41c5eeddd739_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibb8bb66820b64eb6a3f3211d247b61e1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibbb9433a1ea14fce9d9a309b864a4811_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0ee76b4784b044ff9b88b671a0c9db61_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib9e46a07eb6b45a69ba79f90d0863355_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib41c95943c0d424c87116966a66887e0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2b16fd3852e84573bb807fbdf4943cb6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7f619499fe244fb9ac621a6969656b01_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib097a985762a42b8972093d71e92f8b8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i26cc47a532c9410ab9a72e3f56e5c255_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icf5c408305464e4a81c9c0971ccc1df0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief3d178aecba4841860608f1ec04b7d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9441fa155214bfa91ca54f2b2d79fdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a70ab68542b4ee4b2ddd235713f530a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i216f52657d874071bb5e106dc1386103_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec380fc9717840dfb890dfb2ccbee359_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedf0d08a05974b498b7f99693e9bb8d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4615107f61ab4ac6a24069635566da77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9bae44f5d32f4368a92888cc0e7ad821_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e73edc56fe64f7eb2572e557a02f296_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i36eefb9d0f774f2b9c2f8ea719313100_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6117ad9e183545289f9791c20580fa73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8aa3399dd3b7433b8d3557e92fc06f12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d6c23d2b97143faa25a7e68488ada74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib32496abb58143b38427f1791a44f20c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87d8e1fc8bdc455ba9db23447bc100f4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icce9fa23f25f427eb9589454600ed4ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibdc069bdc067430e92abc207531d663c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i379ebd88020b47e4b6146efc5bf71137_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i62e792aa7c38468e81e43fe34e5121a0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0d93286758fb4fb0834e3fe5467fd410_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1ca8b35ceea04640b7869eb9e58fee15_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i12e7f1c8a5df44dda88579554a423614_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iacf27721acf74d0ea561cff498784811_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9f2546d188d64d9d93c6334f07c8adcf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e2395549626418da16b8a9ad6037264_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibeed394b634a4b9fb167c86225bdd1d3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i68b9a3b16a7041bd8d34d47e1359ed86_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i733c42004f7f45bf8f40d28a377fb43e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3c790fd04d414722be81c66df421c95d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2b8adaaf631b47b48badf05858b0984f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifbe168eb5b3940b88ace61c5db5c89a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id125fee9cd774cad978f6ae94f446b6b_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="if57aa28556d54b82af658eb81d72b9fb_I20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="i60ff16704c9e4a26864f51907841faaf_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="ica0ff70047d84bf3ac80640f0aca8a46_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="i4efa02bff686461abcceaa2242640380_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="i584f75dd199f4a379657616c6423e8f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e4850b6ddab4d628848b2165151adcd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24321e9e8f7543f590713d54993c4653_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i272c7eba0c41457f84c261e58a1bbedc_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="ife3936cfd95f4b539b5a1cbb4ce8a51a_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="icfdd1264317a4e959d48fae350ca5f6a_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="i52875fa54d2d47d08f43907539a1290b_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:AmendedLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70b05bb32f374749885434ca47747d1a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RegulatoryPerformanceObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib69346e757f3452d8d1aeea2c8017cfc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RegulatoryPerformanceObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5331bb6e27784c98ba83f790214f2d62_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:MilestoneMarketingAuthorizationApprovalNustendiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i22044bf98171420f847fdf469c65b5ac_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:MilestoneMarketingAuthorizationApprovalNustendiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i11df274bc00047b7b2522e08b61ca091_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd1fbd1b685c42ffb9c49c3b31c629df_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i26f9230bab5b44cda5e7265c85d57b66_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:ProductSalesBulkTabletsNilemdoAndNustendiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4dfde8b13e554913935ea8540925afeb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:ProductSalesBulkTabletsNilemdoAndNustendiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3b353fe5393a4dc2bac419bc2aa386d6_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="i232d185de48d4c6baa127c8681fe96ca_I20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-17</instant>
        </period>
    </context>
    <context id="i42d4992daffb433d85ca8fd259ed4e9d_I20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-17</instant>
        </period>
    </context>
    <context id="ic2e95112c7734a5d8292505e37d9fa7f_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="if950ab2c0cae426e871485a272155dd5_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="i42f46b3fae7942db8d62064f916bccae_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9ef4d12805a94033b928a8cef22e81f6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic0ea2e4cbd104e848e494a2b3378dd35_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4170f009274249bfb0d9fad65135d67a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="i93803d292d3b4027976e1b5d23361ad8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i72ae8eed70f84e13942db9d0ab474673_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1fbda9eaced641d493d9cc099814900c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i95b9b936123043afb5dde0d7efbc4dfd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:CollaborativeArrangementLicenseToIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib65202acf8f242f1bd411cf05ccd2003_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2f61d084882445fb054d3e384d280e9_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:SerometrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66cc3f1c51c941f2b162c47f055b97e7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0762115bc2ec4613b524e91fa9b92de0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifecad91fa7424664b1f1f53f4d25e943_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i85239930eaf64704995fff739a828f1c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic2755a874c4a4c48a6b849306fd2464f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5495cad7e02a4bc7ac5c026e15930a48_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i022b72f313384923a430318e5e44d480_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0f3eb84da08544e7858c671a0f89178b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i02ebc26f1dec4284a51f47f1f7bd41c8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id696d6839c0d44a9971fc5c29b5ab6c5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i79c6b9595b0e45e399fbfc89434af8ba_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3014251d4b0c415f885b37eb158bb11f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie7475569334245839b63cf3cc4120cfc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84a310b3100843458cf7b9780be99be8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id74320e4faa84cd1b28ec9a625c98df5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5153d021d85e4ef9b35b24ed9da916ca_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if2ddd957560f42ff8203389517f59eb2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iba2aa44c62434cdca9106c4f4051ff24_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5581113f5e084f04997d0355ded32b7d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4033291bd05c46c28d615917d2bf3476_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4b50f26d3c4740b19924787f56195caa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i17ff88d17c8f4135932357759e2c4415_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a555aa890154f02bec9878d09c55db6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06a780031e57403b91a7034227c9bdaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i559c63b8c37f45c191813cedafe6679c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0655536ac5664cfc9f50beaeae40a963_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9c5f735fcfc445e88a0357b3cff80ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66085bd7806540ba8c194ce5c0187acd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a9b0a5e5b1d4b328310765a841beb27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8270d1b3c55144f89957352d194e823b_D20190626-20190626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-06-26</endDate>
        </period>
    </context>
    <context id="i3fefac52cc164b6e8c114422d7b945c7_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3e34a6464b9342eab9af91553cce8a2c_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="i1e0952b04e3e49f89edda6732c584442_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2090d9c5d7cd408393dabbb49aef53e9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if3a49799960046fabd41ee94341b6178_D20210516-20210516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-16</endDate>
        </period>
    </context>
    <context id="i28e0c72e2cb9467a8d1097badc2d555d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i82b18040c5994d5fb1c1230a7479649f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib5fa732b89bf4e608cb020cdbaed049c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i314c65622530486bbc90177fa464e9a2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i682526a2d76f4aad9318435409bd1702_D20190626-20190626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-06-26</endDate>
        </period>
    </context>
    <context id="i54599248558d4aeabaada2313141952a_D20190626-20190626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-06-26</endDate>
        </period>
    </context>
    <context id="i24cc2d3d09bf4804b7ebe4fcf96e4159_I20190626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-26</instant>
        </period>
    </context>
    <context id="i2b2993300957480c8da25fe45a53a602_D20190626-20190626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-06-26</endDate>
        </period>
    </context>
    <context id="i61206dad37874474a095378d715c7ddc_I20190626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-26</instant>
        </period>
    </context>
    <context id="i3168451b6e8043e7a8c693b76d15d0bb_D20190626-20190626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-06-26</endDate>
        </period>
    </context>
    <context id="i151f5743662f4d9b94b53d5f3aebdc7b_I20190626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-26</instant>
        </period>
    </context>
    <context id="i519246cc64e94185973aeceecf9b0714_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if16e161500f14c968dff53d7b2d6a4eb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if04054e50e094fd9b83c8ea7d483bcc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="iabdf33924b4c4632935947223d1b399b_D20201118-20201118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-18</startDate>
            <endDate>2020-11-18</endDate>
        </period>
    </context>
    <context id="i1e05ade79f0c4479b2b0adfc5aab22f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61bb4d25218d4d74956e512d85225917_D20201116-20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="ieab74430e0d740e2b4be6f36bf9d3cf3_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="i2c80fd5162dd43bcb17ca0bfc7e60a2b_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="i8f1d759f487848f983aa3b9b0cfed648_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="i220604fdf4934041957bde86b350d102_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="ia9f7b2751cd04b7cba61f5f9cda15259_I20201118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-18</instant>
        </period>
    </context>
    <context id="ibe5a302bf0ef4a2ca9960e5cd3087195_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d4607f308bc47208a506b88c7eb9aa4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i975b21eabca94d14af546e0ab124bf30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1d9db700df64698bb10be3cd5969a2d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i93532836fe0e4502b83cb85c9fb2c31a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib008a93c1f5b4185bd24238dd3202fe2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibdbc8b360e6a444da2991d43afe2a07e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5305d0a8f10c49fa886fd702e4c1cc65_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0d2d467fe6c549869f5d62f5f2e70867_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id69054b09ba54731a79fe2fd68c06551_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:CappedCallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ia4a6340c209848789d2ead328753e5dc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2f44623b0aab464f8a2a2de5879f3fc6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i21cebe390d5c4ab1a9dcde2e33388077_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic8fc8a8e135542e79741bc96b14f2509_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i82de142173eb4c029ba076114a0d9dc2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i65c8c52a3f8249128e0061ca20f07e6e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3dd83bfde144490abf8e977beb2d1e13_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i864a800b9e2f4367b5189df3691f74ed_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i059e63457ab0488a8b8926c7af529680_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i898eb34514a14aaca65ddd29c2ba018f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i01e390bfc85947a1b2e04d2d1b168ba2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if90fbea89e414e58b44494d21f429a48_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5f01c8d8eec0472c8f65bc4d927a3971_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id7741b1a7bd54135bcc5b59858d55156_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id7123ad4d0294677ba36fc60acabdec6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i057a47e17f174e828a68dcc68defe7b5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d8118dee83344708fa7b2847e3b49ae_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3300afb8e3844697bef3a62d80174c94_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iada643021f094d168ae1bb38139e79f6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibb9e9630412f44bab00355a379ce951e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i68daaa76952c4522a02c46ae9c9b099d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idf977f7283ba4421a1c44b0fd2d0dd6b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifbfaf88013a0436983a4e2f8e2e3b9a9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9deb65589fd4b818e61af707066a7bd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9113bd66c9034dc5b296e6fd3676426d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5f518e9c8c2e4aa58a673d03a3aca709_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie596161ef3d64bc0b3c096d1474e9499_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia6e64bbef76f49d187ba3ba4bb0a64ae_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie9a360e7e8004cb7a888a243dc4639e3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7ecd3a7b914d4102b067da5c2fed3f4d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6517e0e5ba714e75aef0fa5cdffc38ea_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i594b303f27a441e79f5d86e7922bf49c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6179414809fd40c2899b2bcdf7735820_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="customer">
        <measure>espr:customer</measure>
    </unit>
    <unit id="revenue_source">
        <measure>espr:revenue_source</measure>
    </unit>
    <unit id="day">
        <measure>espr:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF8zLTEtMS0xLTA_71d97125-04bf-41b7-b76b-2f7d42b4a1ef">0001434868</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF80LTEtMS0xLTA_b7d94584-6c8d-4a14-831e-76f409128d63">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF81LTEtMS0xLTA_de3634b0-f29c-426b-b4bc-9c4e403285d9">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF82LTEtMS0xLTA_2a43fe88-1dba-4215-a528-47cc96722099">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180L2ZyYWc6YTdjNjk1OWRmMmIwNDhkZDllM2RlMjIzYjU4MTQ3NzcvdGFibGU6OTVhM2UyNTIzMjI4NGU5ODhiNzFjMDg0NDBjMDU2ODAvdGFibGVyYW5nZTo5NWEzZTI1MjMyMjg0ZTk4OGI3MWMwODQ0MGMwNTY4MF83LTEtMS0xLTA_6b97716d-bcbb-4d32-820c-bb3e42f84e9e">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ifbe168eb5b3940b88ace61c5db5c89a7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xMDUxL2ZyYWc6NzVjNzVhYTFiYTAzNDRlZjliOGRkMjkyMGE2ZmVmOWEvdGV4dHJlZ2lvbjo3NWM3NWFhMWJhMDM0NGVmOWI4ZGQyOTIwYTZmZWY5YV81NDk3NTU4MTM4OTI1_560c1496-cb07-42dd-aca5-0cf59f938839">espr:AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <espr:ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182MS9mcmFnOmRjMWNhZWM3OGM2MzQ1OTc5ZGYzYTYwN2U3MzMxMjYyL3RhYmxlOjJiOWE1YjRkYzgxMTRiOWNiODhjZWVhYjBlYmE2Y2VkL3RhYmxlcmFuZ2U6MmI5YTViNGRjODExNGI5Y2I4OGNlZWFiMGViYTZjZWRfMTMtMS0xLTEtMA_b7a0c8ac-c8e6-475a-be66-e893a4c514bc">P6M</espr:ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount>
    <espr:PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182MS9mcmFnOmRjMWNhZWM3OGM2MzQ1OTc5ZGYzYTYwN2U3MzMxMjYyL3RhYmxlOjJiOWE1YjRkYzgxMTRiOWNiODhjZWVhYjBlYmE2Y2VkL3RhYmxlcmFuZ2U6MmI5YTViNGRjODExNGI5Y2I4OGNlZWFiMGViYTZjZWRfMTQtMS0xLTEtMA_e05aa767-a589-41d1-9e6b-9c4136cd2ce9"
      unitRef="number">0.3333</espr:PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment>
    <dei:DocumentType
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI1_8f534bfa-0104-4afd-9920-931b50ffd8ef">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6YmNiZTEzN2IwMGJjNDI5NTk3ZGEzMjVmZDg3YmYyYjAvdGFibGVyYW5nZTpiY2JlMTM3YjAwYmM0Mjk1OTdkYTMyNWZkODdiZjJiMF8wLTAtMS0xLTA_56226219-c97f-476e-afb8-0b82efd527a9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8xMjg_eb66e5e4-680a-4298-9c10-e91b62d9fd07">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6M2Q5ZDlkYjI3MTA5NDBhM2I0ZDcwODU5YTY3YmVjNmQvdGFibGVyYW5nZTozZDlkOWRiMjcxMDk0MGEzYjRkNzA4NTlhNjdiZWM2ZF8wLTAtMS0xLTA_a108df93-7731-4983-98d8-801f8ac6e82f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI2_ecc54507-6c85-44e5-b3dd-8c428da30f69">001-35986</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTIw_e95c338c-4a26-4258-80b3-809d14564b72">Esperion Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6ZjZhZTg3ODQwNTg3NDkzZmEwNzM1YmJmMGRiZjcxNWEvdGFibGVyYW5nZTpmNmFlODc4NDA1ODc0OTNmYTA3MzViYmYwZGJmNzE1YV8wLTAtMS0xLTA_3cff0e3d-40c0-4abd-b54a-6c4ead1e5cdf">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6ZjZhZTg3ODQwNTg3NDkzZmEwNzM1YmJmMGRiZjcxNWEvdGFibGVyYW5nZTpmNmFlODc4NDA1ODc0OTNmYTA3MzViYmYwZGJmNzE1YV8wLTItMS0xLTA_c695612b-5744-443d-881e-49efdc9b3062">26-1870780</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTIx_7f2188b0-8d82-47c8-a5c9-879a98bc2833">3891 Ranchero Drive, Suite&#160;150</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTIy_3ebfba9d-8b55-45f9-a88b-f3445e5912fe">Ann Arbor</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI3_38e6b954-b95d-4a5b-a1bd-c48c2c4fdd98">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTIz_acdadee4-ec64-45a5-aae8-333b27f4bb5d">48108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTE3_1cb19c69-87a5-4973-a0d5-2cdbe901b958">734</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTE4_25af759e-00cc-4dc7-988b-45ab9accd0c3">887-3903</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NzBiMDhkZTQ0YWI2NGIyMzhkOTc0NTBhOTFjOGQwNGEvdGFibGVyYW5nZTo3MGIwOGRlNDRhYjY0YjIzOGQ5NzQ1MGE5MWM4ZDA0YV8xLTAtMS0xLTA_2b6108d7-10a1-4628-95d5-315c5becafd8">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NzBiMDhkZTQ0YWI2NGIyMzhkOTc0NTBhOTFjOGQwNGEvdGFibGVyYW5nZTo3MGIwOGRlNDRhYjY0YjIzOGQ5NzQ1MGE5MWM4ZDA0YV8xLTItMS0xLTA_45a8d8ea-3e48-40dc-97fe-0beaa91fdc34">ESPR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NzBiMDhkZTQ0YWI2NGIyMzhkOTc0NTBhOTFjOGQwNGEvdGFibGVyYW5nZTo3MGIwOGRlNDRhYjY0YjIzOGQ5NzQ1MGE5MWM4ZDA0YV8xLTQtMS0xLTAvdGV4dHJlZ2lvbjowZWRiMzhjNDg3ZDk0ZmNjOTFiM2Y5MzdmMTVkMzM4NF81_7283f039-05d6-4195-b5fb-b69a7305c4ad">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI4_cb9aaec9-8545-48fa-be60-4597e23a948c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTI0_63d338f6-c656-4ee3-a7ee-856aba7c331b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NGMyY2Y4NzljYmY2NDhiNGI0YmYxZjlkNzgzNjIzZGQvdGFibGVyYW5nZTo0YzJjZjg3OWNiZjY0OGI0YjRiZjFmOWQ3ODM2MjNkZF8wLTAtMS0xLTA_eeeafbf9-77fc-4a80-9edb-872b6e61a453">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NGMyY2Y4NzljYmY2NDhiNGI0YmYxZjlkNzgzNjIzZGQvdGFibGVyYW5nZTo0YzJjZjg3OWNiZjY0OGI0YjRiZjFmOWQ3ODM2MjNkZF8yLTQtMS0xLTA_de28e8a8-abda-4a47-af77-520f6a1fd00c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGFibGU6NGMyY2Y4NzljYmY2NDhiNGI0YmYxZjlkNzgzNjIzZGQvdGFibGVyYW5nZTo0YzJjZjg3OWNiZjY0OGI0YjRiZjFmOWQ3ODM2MjNkZF80LTQtMS0xLTA_71e9d35e-89c8-4219-a4b0-cbc0eb1a669b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMTE5_113e641f-58d5-499b-a873-bc35110b52b0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i050ee60691314e20b69ad95578d2607a_I20210801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xL2ZyYWc6ZmUzNjI1MDc3YTBjNGVjZDkyMDliMTQ5NjBmMThmNTYvdGV4dHJlZ2lvbjpmZTM2MjUwNzdhMGM0ZWNkOTIwOWIxNDk2MGYxOGY1Nl8yMDI2_34f58981-529b-4b69-8a15-7062c1bc6134"
      unitRef="shares">28277493</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNC0xLTEtMS0w_51d2bcc7-2669-4587-bcc9-36e78c1da0c6"
      unitRef="usd">219186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNC0zLTEtMS0w_621ad74b-a11e-412a-86c9-f4f5f7ff482e"
      unitRef="usd">304962000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNy0xLTEtMS00NDA3_eab35158-3289-4aae-9a76-cd3f64e16576"
      unitRef="usd">21854000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNy0zLTEtMS00NDA5_eb6777ae-58ae-4283-b66d-0da0dbe557a5"
      unitRef="usd">12388000</us-gaap:AccountsReceivableNetCurrent>
    <espr:PrepaidClinicalDevelopmentCostsCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNy0xLTEtMS0w_2bded216-15db-45cf-a1f0-6fa7f3e4dcaa"
      unitRef="usd">650000</espr:PrepaidClinicalDevelopmentCostsCurrent>
    <espr:PrepaidClinicalDevelopmentCostsCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNy0zLTEtMS0w_01065716-502e-4c5f-87ab-467a1e3d9d0a"
      unitRef="usd">844000</espr:PrepaidClinicalDevelopmentCostsCurrent>
    <us-gaap:InventoryNet
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfOC0xLTEtMS0w_874cb797-e972-477c-b9fe-aa7c040fecdc"
      unitRef="usd">23714000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfOC0zLTEtMS0w_50244f83-0abb-4462-8434-15238c28e58b"
      unitRef="usd">16136000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfOS0xLTEtMS0w_aeef6936-3d3c-4501-b067-3e3dd939cc3e"
      unitRef="usd">9770000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfOS0zLTEtMS0w_57418d79-4b27-4ac8-954c-888d0bdeb50d"
      unitRef="usd">11566000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTAtMS0xLTEtMA_2e15a4ed-b788-4f03-8005-7a232bc6d3c3"
      unitRef="usd">275174000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTAtMy0xLTEtMA_cb1b5e5c-b49f-4d6a-b5d9-2f01efe4629b"
      unitRef="usd">345896000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTItMS0xLTEtMA_c8bc8ee8-7f16-4208-9f47-174032d94a52"
      unitRef="usd">970000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTItMy0xLTEtMA_34077b9b-6ca5-499d-b43b-da64343479ee"
      unitRef="usd">1276000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTMtMS0xLTEtMA_8e159a80-c6e0-4db1-b15b-779f2c791778"
      unitRef="usd">4261000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTMtMy0xLTEtMA_05026bd7-da87-4708-9945-f53a879c24c9"
      unitRef="usd">6030000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTQtMS0xLTEtMA_01f08770-7d69-4b23-a6d0-31f213aa23d4"
      unitRef="usd">56000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTQtMy0xLTEtMA_58b981d6-3536-49a6-a985-b445d288cdbf"
      unitRef="usd">56000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:Assets
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTUtMS0xLTEtMA_32fa5540-780d-434b-9c99-693fc03aba02"
      unitRef="usd">280461000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTUtMy0xLTEtMA_3ac820f8-6059-4de3-b105-f659ac192747"
      unitRef="usd">353258000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTktMS0xLTEtMA_cb8ea1d6-59ef-45e1-9aee-f7d0b534823b"
      unitRef="usd">29353000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMTktMy0xLTEtMA_48f923f9-072a-4391-963f-e6567f51447f"
      unitRef="usd">51975000</us-gaap:AccountsPayableCurrent>
    <espr:AccruedClinicalDevelopmentCostsCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjAtMS0xLTEtMA_0ff8c9c3-b0ca-4bc7-a712-84e8ec60cb13"
      unitRef="usd">2873000</espr:AccruedClinicalDevelopmentCostsCurrent>
    <espr:AccruedClinicalDevelopmentCostsCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjAtMy0xLTEtMA_cd5a7c16-9408-4280-9d4b-8625bcea669e"
      unitRef="usd">7663000</espr:AccruedClinicalDevelopmentCostsCurrent>
    <espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjEtMS0xLTEtMA_fb50d89f-bb1b-4fee-8a9b-f7bc1f503a67"
      unitRef="usd">31673000</espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjEtMy0xLTEtMA_c0201084-632a-4906-bc29-a21048c1cb52"
      unitRef="usd">24790000</espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <espr:RevenueInterestLiabilityCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjItMS0xLTEtMA_7df11f57-77a5-4a71-843f-9c085fa1f1a9"
      unitRef="usd">12469000</espr:RevenueInterestLiabilityCurrent>
    <espr:RevenueInterestLiabilityCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjItMy0xLTEtMA_b78f2c08-33e8-4aa1-b16b-4ba29b9c2675"
      unitRef="usd">5392000</espr:RevenueInterestLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjMtMS0xLTEtMA_319bc44b-4fd0-4930-8aac-7e190b8c5b61"
      unitRef="usd">3930000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjMtMy0xLTEtMA_79daf03f-73b4-42e1-b83f-3e118fced09b"
      unitRef="usd">1662000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjQtMS0xLTEtMA_e90f7135-5e00-4167-8ca6-ece533ed1365"
      unitRef="usd">2346000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjQtMy0xLTEtMA_1ec7a198-8f7a-4015-8576-7d606694e845"
      unitRef="usd">2587000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjUtMS0xLTEtMA_b48e92c2-ad4a-4af5-9c5b-388e838b676a"
      unitRef="usd">82644000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjUtMy0xLTEtMA_7535a840-3475-4385-a651-00eff2e5a33a"
      unitRef="usd">94069000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjctMS0xLTEtMA_61dd6221-e82a-414f-890a-2c292a0a4402"
      unitRef="usd">272098000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjctMy0xLTEtMA_825fdee5-771f-458f-81d7-a3f121e2753a"
      unitRef="usd">179367000</us-gaap:ConvertibleLongTermNotesPayable>
    <espr:RevenueInterestLiabilityNoncurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjgtMS0xLTEtMA_a63d9690-5724-4c25-8b99-0398a4d77c80"
      unitRef="usd">225762000</espr:RevenueInterestLiabilityNoncurrent>
    <espr:RevenueInterestLiabilityNoncurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjgtMy0xLTEtMA_6b1dd928-cfd5-4d1a-bffa-dda05d5f8f2a"
      unitRef="usd">171212000</espr:RevenueInterestLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjktMS0xLTEtMA_b473e3aa-fc6a-49f6-af00-4f12946d3265"
      unitRef="usd">1920000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMjktMy0xLTEtMA_b6183d71-b9cc-4519-bc7c-7778c9e899ad"
      unitRef="usd">3454000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzAtMS0xLTEtMzY0NA_a04ede93-8dfb-4457-a1fb-d851f4516b55"
      unitRef="usd">1057000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzAtMy0xLTEtMzY0NA_e815b89a-ec29-492d-8d9a-940788d8d8a0"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzAtMS0xLTEtMA_09bd0cf0-d753-4f6e-a371-a3e16c8dfb10"
      unitRef="usd">1290000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzAtMy0xLTEtMA_2b462e6a-bfa9-4741-b6af-9fcceddcf821"
      unitRef="usd">1290000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzEtMS0xLTEtMA_e251c82a-df6a-4ee3-88b2-ea22bf67d1d2"
      unitRef="usd">584771000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzEtMy0xLTEtMA_cc02ef42-3a2e-4040-900f-27acbb274ea0"
      unitRef="usd">449392000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzItMS0xLTEtMA_4d5ca52a-e58a-4031-a2aa-150c4f4f754e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzItMy0xLTEtMA_f02278f1-045d-4984-8f2b-8de747b1f21b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzIx_430ea4cc-b355-428a-946a-653e3f5bc074"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzIx_4893ceed-10c8-4f53-b146-1ae1dff0bb7c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzM1_3145819b-9a73-4b09-b154-05c66ace7a73"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzM1_59b04738-8ce4-4110-93ca-6498c8e0daf6"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzYw_565ae722-6208-4617-bc2a-d9b27bf3bf28"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzYw_7a1dd12e-a94a-4ed8-8fa9-d4fa6fb7e790"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzYw_aa7cb2fb-83ae-4a30-b8a1-fb32fe5f9525"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjdlMmIxOTczZmU3NzQ0NmRhYTFkZjAwZmY1ZjhlZThlXzYw_ee2ea208-ee74-425f-af34-5d558870abed"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMS0xLTEtMA_58efbeb5-c6c4-4a43-804a-89c10d34cd5a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzQtMy0xLTEtMA_7e1f0be4-d0be-4b85-b029-52c602a861bb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzE4_75f80a97-1405-4f99-8ae5-6bc017f937e8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzE4_894eab25-72ef-4185-9a96-d0acdae842b6"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzMy_21ff22c2-95b3-4ce0-a020-2b5cdb7933de"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzMy_51f21f27-6ece-450e-816d-5d64019484b2"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4Xzk3_504f51e6-ab07-4b78-8330-939aff5ae90d"
      unitRef="shares">28268533</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMzYxMzAzY2JiMDQ1ZmVhNDJlNmYwZTY4ZTY3NzU4XzEzNg_79bebdd5-1282-4984-a02a-868b3135a472"
      unitRef="shares">27910366</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMS0xLTEtMA_657023f5-2ac1-45fa-bbd6-961e5d63b9cf"
      unitRef="usd">26000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzUtMy0xLTEtMA_feb134d9-4d57-4bd1-b4fc-e8df6639206f"
      unitRef="usd">26000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzYtMS0xLTEtMA_49e22333-6e8c-4125-8fae-559cffbf02c3"
      unitRef="usd">722534000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzYtMy0xLTEtMA_c05c7eb7-34c8-42b0-81d7-27d5f89da3a7"
      unitRef="usd">797655000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjk2MDI1ZDlhNzdjYjRlNTJhNmQ5MzRhZmVmYTc5NTdkXzI5_25d00df4-b0e6-4e2d-b3ae-364d1e353cad"
      unitRef="shares">1994198</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjk2MDI1ZDlhNzdjYjRlNTJhNmQ5MzRhZmVmYTc5NTdkXzI5_71348a69-51db-4547-a37a-dd2c55544a75"
      unitRef="shares">1994198</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzctMS0xLTEtMA_244ff2b9-b213-4c5a-9066-fcd2b274861c"
      unitRef="usd">54998000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzctMy0xLTEtMA_dc59a6d8-17dc-4af3-bbf9-4e5297e4e74c"
      unitRef="usd">54998000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzktMS0xLTEtMA_138c22c6-b379-4f26-88ca-a04ba7c4c7e7"
      unitRef="usd">-971872000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfMzktMy0xLTEtMA_ac8d9818-cfa7-4c14-9e3d-f798221fcf12"
      unitRef="usd">-838817000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNDAtMS0xLTEtMA_fc47098d-bdb3-4bbc-af9f-7012be419a6b"
      unitRef="usd">-304310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNDAtMy0xLTEtMA_ab0f87c9-8f14-4933-a25a-b07842ec2ad3"
      unitRef="usd">-96134000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNDEtMS0xLTEtMA_23b576a9-6dbb-4305-8162-4c404a644747"
      unitRef="usd">280461000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xNi9mcmFnOmNhZDE1NmY5YjBiNDQ0MGZiM2MxOWVhMDVjMDJkYzA3L3RhYmxlOjYwMzZmOTVkNTYxNDRmMjY5NTVhMDIyZjVhZGUwZTBjL3RhYmxlcmFuZ2U6NjAzNmY5NWQ1NjE0NGYyNjk1NWEwMjJmNWFkZTBlMGNfNDEtMy0xLTEtMA_02ddf246-867e-40dc-acfb-d7f9a3d0d258"
      unitRef="usd">353258000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9c66ab5008d4c28a2f2a6317075fc61_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMy01LTEtMS0xMjU_ab7e8357-cad7-4f62-a037-0fc59c037220"
      unitRef="usd">10610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3f1e56095ca4d07a8f77cec69f8a7ba_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMy03LTEtMS03OA_4858d109-45e5-404c-836d-a555c60e3ede"
      unitRef="usd">609000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3555938aa014fbda7603991f689d2d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMy01LTEtMS0w_fb0f5bbc-e535-460a-b899-aa64b20a88f0"
      unitRef="usd">16960000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia332deb386b74a509426822f23273e5e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMy03LTEtMS0w_50d2eb7e-8203-4cfd-82b3-ce0f8560584a"
      unitRef="usd">1467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i338fd57bbd8f4b7b98555b5eedfc71e5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNC01LTEtMS0xMjg_101c1f96-ff61-4a8c-a4dc-8a8379e91007"
      unitRef="usd">30049000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5566a2ae4e074e8aac4a681884d52a3b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNC03LTEtMS04MQ_40488eb9-460a-4a4a-bfe2-7bb5d3139ba7"
      unitRef="usd">211627000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3c9855747284b97950418c5661f9398_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNC01LTEtMS0w_9ca738c8-4f6a-4efe-a73e-493bade0d3f3"
      unitRef="usd">31677000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6ed1002c3524d20bc0a363b109f9831_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNC03LTEtMS0w_68b9284e-316c-4b04-8905-6302cc249e4b"
      unitRef="usd">212609000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNS01LTEtMS0xMzE_8745d3ea-0a93-4213-a96e-6e3713921297"
      unitRef="usd">40659000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNS03LTEtMS04NA_6a2587b4-baa0-4afc-852f-9ca0e1164690"
      unitRef="usd">212236000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNS01LTEtMS0w_a9806b12-05dc-4884-b969-874c72259bae"
      unitRef="usd">48637000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfNS03LTEtMS0w_a7e4d441-6de5-4434-8017-ded1d4cea0f8"
      unitRef="usd">214076000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOC01LTEtMS0xMzQ_5b05adb3-f709-44ea-b7c3-9524a98ae272"
      unitRef="usd">1800000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOC03LTEtMS04Nw_960842dc-be12-4db0-911e-4a7a10c1f657"
      unitRef="usd">398000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOC01LTEtMS0w_5b3d5be7-789a-4276-8bdf-40d8f8e00b12"
      unitRef="usd">3584000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOC03LTEtMS0w_945de271-dd2a-41a9-b3a2-550f5e3eebdf"
      unitRef="usd">429000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOS01LTEtMS0xMzc_8e4e5ea4-8251-4357-a7a8-f52ba0e5969d"
      unitRef="usd">25074000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOS03LTEtMS05MQ_c972d2c0-994d-42af-8cff-db2ada29672e"
      unitRef="usd">34987000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOS01LTEtMS0w_485a646d-4a79-4c91-9efc-b7968c4f2dc4"
      unitRef="usd">53028000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfOS03LTEtMS0w_852ba023-7f33-474d-9a6b-bf212a250ddb"
      unitRef="usd">69689000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTAtNS0xLTEtMTQw_8e75dbc4-08fb-4c49-a02d-3631cd0d6ba1"
      unitRef="usd">46318000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTAtNy0xLTEtOTQ_5e6b63fa-9990-490b-8f83-8694bd2cebce"
      unitRef="usd">47681000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTAtNS0xLTEtMA_a3c14654-1ac2-4240-8016-6215ba205a57"
      unitRef="usd">107382000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTAtNy0xLTEtMA_ef8c5b04-a910-4368-b780-8bc14e5fcc26"
      unitRef="usd">89234000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTEtNS0xLTEtMTQz_69a41c91-3131-4c4b-9b4f-50b8d1ddda27"
      unitRef="usd">73192000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTEtNy0xLTEtOTc_c6edf2ad-692c-4a5f-b864-0fe98fd2f92b"
      unitRef="usd">83066000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTEtNS0xLTEtMA_04bc35a3-e273-49d4-b1e8-aeb6cefcb3b7"
      unitRef="usd">163994000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTEtNy0xLTEtMA_cba49198-23a1-4efa-8b3f-ca0d9de8031c"
      unitRef="usd">159352000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTMtNS0xLTEtMTQ2_e8b5278b-e5f1-461f-8d5c-e2568b4e3323"
      unitRef="usd">-32533000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTMtNy0xLTEtMTAx_6f1900d8-4ced-418a-a9fb-22968183fe0c"
      unitRef="usd">129170000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTMtNS0xLTEtMA_fb426936-4b4b-44d1-ab04-b1ea59ddc330"
      unitRef="usd">-115357000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTMtNy0xLTEtMA_55a66ec4-c4f7-4860-94ea-d6a5a4936fa0"
      unitRef="usd">54724000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTUtNS0xLTEtMTUz_5e70d91b-28ae-489c-9104-176fc8fe7a07"
      unitRef="usd">11144000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTUtNy0xLTEtMTA0_98a2a26c-6f0e-4dd1-a6a5-66de7415d419"
      unitRef="usd">4640000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTUtNS0xLTEtMA_6c25c598-d115-4030-8f00-f41a216c3780"
      unitRef="usd">19269000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTUtNy0xLTEtMA_622e446c-060d-497f-b302-d4aca1e9a7fa"
      unitRef="usd">8811000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTYtNS0xLTEtMTUy_8e0ef3ad-5e5b-45ed-a91e-32ad347a26e6"
      unitRef="usd">9000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTYtNy0xLTEtMTA3_07edacfe-32b7-4564-ae26-8d8f5296e776"
      unitRef="usd">81000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTYtNS0xLTEtMA_499897a0-eaf3-44fb-8cd0-4c930da9c69c"
      unitRef="usd">23000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTYtNy0xLTEtMA_f9dce7f2-4aed-4347-9b5f-c810c3371c93"
      unitRef="usd">449000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTctNS0xLTEtMTc4_22ba8602-8575-4ec9-a439-ce58bf7a60eb"
      unitRef="usd">-43668000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTctNy0xLTEtMTEw_f359c64c-3b95-4a88-9d88-f24a64e899ee"
      unitRef="usd">124611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTctNS0xLTEtMA_34cf3931-c2d3-4edf-ab12-2b09fb44d7aa"
      unitRef="usd">-134603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTctNy0xLTEtMA_6ebc1bfb-6a67-43eb-9b04-e4d1d12fced3"
      unitRef="usd">46362000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTktNS0xLTEtMTgx_f2601034-800d-4d00-9a9b-9de0bc3ca9dc"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTktNy0xLTEtMTEz_5f199e5b-301f-4d33-b926-94cd59965fdf"
      unitRef="usdPerShare">4.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTktNS0xLTEtMA_62122548-1f5f-490f-9ec6-0817813324ae"
      unitRef="usdPerShare">-5.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMTktNy0xLTEtMA_9101bce7-e85e-47c4-bcbf-85d2c980eb63"
      unitRef="usdPerShare">1.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjAtNS0xLTEtMTkwMw_e5bc23a9-274c-4811-ad61-d42d039225e4"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjAtNy0xLTEtMTg5NQ_e5ea78d0-ac2b-4e26-917d-a64e53dcd327"
      unitRef="usdPerShare">4.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjAtNS0xLTEtMA_a3312486-f30b-4e9a-b5af-ead2ab4c4885"
      unitRef="usdPerShare">-5.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjAtNy0xLTEtMA_3c6643d3-8e7f-41fa-b6a8-6023d3485a68"
      unitRef="usdPerShare">1.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjItNS0xLTEtMTg0_9c9c03de-f657-4463-aad0-66437065b2d9"
      unitRef="shares">26225073</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjItNy0xLTEtMTE2_61887452-5661-4d67-b581-259335bded9b"
      unitRef="shares">27665728</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjItNS0xLTEtMA_9ef10db2-791e-437c-948c-25fad707edbe"
      unitRef="shares">26109089</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjItNy0xLTEtMA_2452a97d-f78f-401e-8b95-88b744ed409f"
      unitRef="shares">27592479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjMtNS0xLTEtMTkxNQ_7261d445-63d5-4996-9786-5ae78bf4ff40"
      unitRef="shares">26225073</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjMtNy0xLTEtMTkxNQ_ff1d3e96-1b79-439b-9570-0f1924fdf011"
      unitRef="shares">28854445</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjMtNS0xLTEtMA_1462d647-fcd8-45ad-b250-096d8e577428"
      unitRef="shares">26109089</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjMtNy0xLTEtMA_5f8d3ff2-e029-4323-8e0e-7f4c76b5ac99"
      unitRef="shares">28948058</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjYtNS0xLTEtMTg3_8d4dc9e0-b546-49ad-92b9-ba817c636668"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjYtNy0xLTEtMTE5_b71aa2a2-89ec-4024-a09c-eebc12a9e746"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjYtNS0xLTEtMA_1c84ca42-fef5-4982-8ce0-7965a83a9b00"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjYtNy0xLTEtMA_d4fb84cb-5048-43bf-aad5-3fbc7fece799"
      unitRef="usd">-23000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjctNS0xLTEtMTkw_e3e8f244-0146-46d4-bb0f-adc9d264b030"
      unitRef="usd">-43668000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjctNy0xLTEtMTIy_425f0317-49b4-4ca0-b308-3f27ce79e0ce"
      unitRef="usd">124602000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjctNS0xLTEtMA_501dd9ca-6f47-4522-b75c-1e0dc7ee1c66"
      unitRef="usd">-134603000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18xOS9mcmFnOjg5YWIwMzk2NTA3YTQyODFhYzhlYTdkZTliMTU0YTMyL3RhYmxlOmQ0MWQwMTM4MTNjMjQ1YTA5NzJiMDYzNmRlMmYzZDYwL3RhYmxlcmFuZ2U6ZDQxZDAxMzgxM2MyNDVhMDk3MmIwNjM2ZGUyZjNkNjBfMjctNy0xLTEtMA_e82b4710-d404-4957-8c1d-a2a5fb6d2873"
      unitRef="usd">46339000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i2a5187a56ea64ae79ed566f657f52f0f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi0xLTEtMS0w_5793628e-8214-4af9-9493-bf2d3118fe7a"
      unitRef="shares">27497911</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2a5187a56ea64ae79ed566f657f52f0f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi0zLTEtMS0w_76ce6c09-ef5c-474a-8261-3467213ae6af"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e9d11b53c0d4fce938a87352fd5fe47_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi01LTEtMS0w_3a167088-523f-4f0e-8fad-80172ee7949a"
      unitRef="usd">715166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f8ebc6cecb04f1dbbca266b983b0ee4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi03LTEtMS0w_52a5100a-6ee2-4a46-891b-c9e287d65c86"
      unitRef="usd">-695266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9259ac42a9d4b44a6979f88be43cf44_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi05LTEtMS0w_046559b8-f475-4aa8-b71b-2710152894e4"
      unitRef="usd">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb7184bc40e84732a19137ba864fb6b1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi0xMS0xLTEtMA_44047113-3c14-49d5-9c3b-f5e8ac9ac48e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e0d32b36655400c85ee28b60964a4d7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMi0xMy0xLTEtMA_03cdcf15-7240-4c67-9842-81e922514882"
      unitRef="usd">19950000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4782e3db8423421e942447fb17c5f321_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMy0xLTEtMS0w_befeb83d-422d-40a3-8706-3c5275c92302"
      unitRef="shares">40133</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4782e3db8423421e942447fb17c5f321_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMy0zLTEtMS0w_f76ebbed-0b97-4fc1-9a94-cb3a40e213bc"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib43b6fdc517a411c85647b77372d9e79_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMy01LTEtMS0w_d4805886-2c5f-4f2b-8afd-29f6ffcf664c"
      unitRef="usd">1013000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMy0xMy0xLTEtMA_248de341-3c01-4979-a80b-f2999324c355"
      unitRef="usd">1014000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i4782e3db8423421e942447fb17c5f321_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNC0xLTEtMS0w_d16606ee-d84b-40d5-a96d-593364c268b4"
      unitRef="shares">10089</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNC0xMy0xLTEtMA_03807656-6bca-4891-b564-be87eb843607"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib43b6fdc517a411c85647b77372d9e79_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNS01LTEtMS0w_96bb16ea-0c97-4a81-a9e7-78b71322aafb"
      unitRef="usd">7053000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNS0xMy0xLTEtMA_86e5c25d-1f0c-4c54-9c17-b8f83a5fcc54"
      unitRef="usd">7053000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4c1c8ad065e5492490704fc3b9a9d9f6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNi05LTEtMS0w_56502c16-0040-4987-9f4c-7653c5cd8e9b"
      unitRef="usd">-14000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNi0xMy0xLTEtMA_771d0c55-fca4-4cdd-96bd-90314f839df0"
      unitRef="usd">-14000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ib618d67da2c4453a8e65d796194636c5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNy03LTEtMS0w_5038a855-93af-4ecf-bd5f-b3b1dd69abe9"
      unitRef="usd">-78249000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4a96f79c53b84a4e80438a13c29eb845_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfNy0xMy0xLTEtMA_f803e5fa-cab8-4824-bb92-5e41e24cf93c"
      unitRef="usd">-78249000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i399ac47076af4f908e42954eee2ad039_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC0xLTEtMS0w_5844fb65-5b66-4fb0-b7b5-3665a0692de0"
      unitRef="shares">27548133</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i399ac47076af4f908e42954eee2ad039_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC0zLTEtMS0w_5a539679-3b6e-4de8-bb5b-56b09de12759"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8356b00716a84a1394f6e22c68047217_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC01LTEtMS0w_024a351e-aab8-4204-8f50-523cf046724f"
      unitRef="usd">723232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i608ba03464564214a1e179c94a81c70c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC03LTEtMS0w_1025ad1b-5cd3-4c98-95f8-38607ea1810d"
      unitRef="usd">-773515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6eaf0b1998954d038c9b487adfa44c18_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC05LTEtMS0w_2c4fe731-4386-4ab9-aa9e-e126f0515fd2"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i901e75a34f054bd3a4d7f6dd621b20bb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC0xMS0xLTEtMA_6d2b685f-5d72-4377-b140-f419dd8c35fa"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01bcadb4b56c4ca1818a0393ce077c11_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOC0xMy0xLTEtMA_f86ef87b-27bd-456a-84c2-9c92557a7727"
      unitRef="usd">-50246000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2fcaca0841c046a9b25d41c5eeddd739_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOS0xLTEtMS0w_ad8a6af5-aec6-47db-a7e9-b13e004283ce"
      unitRef="shares">160024</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibb8bb66820b64eb6a3f3211d247b61e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOS01LTEtMS0w_970960a9-a9e7-48f0-a44c-22317c2be68e"
      unitRef="usd">3738000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfOS0xMy0xLTEtMA_fcae8125-c8db-4c11-803c-4114c4cf1c85"
      unitRef="usd">3738000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i2fcaca0841c046a9b25d41c5eeddd739_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTEtMS0xLTEtMA_450ac986-eaf2-4358-b4e9-c63becac5144"
      unitRef="shares">43498</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTEtMTMtMS0xLTA_e2fec730-c59b-4af3-92f5-8a12ccae208b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibb8bb66820b64eb6a3f3211d247b61e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTItNS0xLTEtMA_b1e186b2-fcb3-4e2f-9419-3ff549b0b339"
      unitRef="usd">7395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTItMTMtMS0xLTA_c26c5ff9-7940-4c2e-b8e3-932dd791e49b"
      unitRef="usd">7395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibbb9433a1ea14fce9d9a309b864a4811_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTMtOS0xLTEtMA_91a7a91b-54c0-4cd1-9472-0ee55e367f73"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTMtMTMtMS0xLTA_0b4c9261-6c39-4bab-8eba-d8855c7a2768"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i0ee76b4784b044ff9b88b671a0c9db61_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTQtNy0xLTEtMA_b13460e9-bb8e-42ea-acc9-aa6d5915e17d"
      unitRef="usd">124611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTQtMTMtMS0xLTA_bd4e4ca8-13bf-4307-a799-4f16a4c680e0"
      unitRef="usd">124611000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib9e46a07eb6b45a69ba79f90d0863355_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtMS0xLTEtMA_086660f0-68ff-4f5d-93ac-b90a3467a8c6"
      unitRef="shares">27751655</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib9e46a07eb6b45a69ba79f90d0863355_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtMy0xLTEtMA_037f81c3-e7bd-4fba-a834-be58dbe6ed3b"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib41c95943c0d424c87116966a66887e0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtNS0xLTEtMA_77490c10-be9c-4465-90fa-9ccbbaaba005"
      unitRef="usd">734365000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib41c95943c0d424c87116966a66887e0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtNS0xLTEtMA_ef89ac82-d342-452f-87a9-0b161f0c3950"
      unitRef="usd">734365000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b16fd3852e84573bb807fbdf4943cb6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtNy0xLTEtMA_43922aa7-41d3-4489-907c-a274122e4614"
      unitRef="usd">-648904000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f619499fe244fb9ac621a6969656b01_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtOS0xLTEtMA_5896b6d1-28fe-4e15-acf3-b9dd79eac0a0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib097a985762a42b8972093d71e92f8b8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTQtMTEtMS0xLTM3MjY_ac4f3fef-2bcb-4f25-afdb-133d665c825f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i26cc47a532c9410ab9a72e3f56e5c255_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjNkYjE2ODRkOWIxNTRlZjRiZTRiMmVlNmE2N2UxYTg4L3RhYmxlcmFuZ2U6M2RiMTY4NGQ5YjE1NGVmNGJlNGIyZWU2YTY3ZTFhODhfMTUtMTMtMS0xLTA_64347f4e-35b9-40bc-b847-67fc8e7660f9"
      unitRef="usd">85489000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="icf5c408305464e4a81c9c0971ccc1df0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi0xLTEtMS0w_b80f96ad-1e0d-4068-97b1-4b0faae7d100"
      unitRef="shares">25916168</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icf5c408305464e4a81c9c0971ccc1df0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi0zLTEtMS0w_7b2f819d-de5c-45e9-9a46-7c99d931a155"
      unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ief3d178aecba4841860608f1ec04b7d7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi01LTEtMS0w_ba127cc9-686a-4d5e-a635-e5aab4854425"
      unitRef="usd">797655000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if9441fa155214bfa91ca54f2b2d79fdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi03LTEtMS0w_754d8dec-0a89-4860-84af-23401cc810a0"
      unitRef="usd">-838817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a70ab68542b4ee4b2ddd235713f530a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi05LTEtMS0w_4625b13d-8911-41eb-a13c-5a8fbce894ac"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i216f52657d874071bb5e106dc1386103_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi0xMS0xLTEtMA_0645e4e3-a1ef-4490-87c2-67fb69fb7320"
      unitRef="usd">-54998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMi0xMy0xLTEtMA_12dc7322-f0aa-4474-940f-9a1c0099960e"
      unitRef="usd">-96134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec380fc9717840dfb890dfb2ccbee359_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMy01LTEtMS0w_56a38efa-3c22-4cd5-9d4f-9f7194dac786"
      unitRef="usd">-93475000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedf0d08a05974b498b7f99693e9bb8d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMy03LTEtMS0w_12f081ca-5326-40b0-ba86-334dccc8c124"
      unitRef="usd">1548000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4615107f61ab4ac6a24069635566da77_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMy0xMy0xLTEtMA_26f9d873-137a-4ca4-9429-33e1edee9738"
      unitRef="usd">-91927000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i9bae44f5d32f4368a92888cc0e7ad821_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC0xLTEtMS0w_ec6dd647-f50a-4910-82c3-d2eb6d492cc8"
      unitRef="shares">25916168</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9bae44f5d32f4368a92888cc0e7ad821_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC0zLTEtMS0w_904e151e-fa7d-47af-ab95-008a1992ff65"
      unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e73edc56fe64f7eb2572e557a02f296_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC01LTEtMS0w_63a80abc-c5d0-408a-a6ea-3839c987835b"
      unitRef="usd">704180000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36eefb9d0f774f2b9c2f8ea719313100_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC03LTEtMS0w_fcab2caf-0415-4768-824a-9c4eecc9809c"
      unitRef="usd">-837269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6117ad9e183545289f9791c20580fa73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC05LTEtMS0w_b0ac7ffa-c520-4975-80d0-b8842a46aa87"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8aa3399dd3b7433b8d3557e92fc06f12_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC0xMS0xLTEtMA_1c7d25c9-ed8b-4e45-ab25-e17b57e308cd"
      unitRef="usd">-54998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d6c23d2b97143faa25a7e68488ada74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNC0xMy0xLTEtMA_eced92cd-f614-49f1-b32f-d2d5e8d77d62"
      unitRef="usd">-188061000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib32496abb58143b38427f1791a44f20c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNS0xLTEtMS0w_f891f796-4b82-4ca7-a820-bb43cf9b8d14"
      unitRef="shares">172268</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i87d8e1fc8bdc455ba9db23447bc100f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNS01LTEtMS0w_bd1c890b-44ed-4a59-bc6b-8c4c9b84e7aa"
      unitRef="usd">2668000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNS0xMy0xLTEtMA_5f77da32-358d-4281-9da2-9e5e82cfba1f"
      unitRef="usd">2668000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ib32496abb58143b38427f1791a44f20c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNi0xLTEtMS0w_5d8d27ab-1a4e-4c58-9531-7d2cee25be4b"
      unitRef="shares">43465</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNi0xMy0xLTEtMA_b0d54e56-e6f5-451a-9b3c-84aa631ccad6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib32496abb58143b38427f1791a44f20c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNy0xLTEtMS0w_9cfc1643-b881-4358-a277-057a90260b9b"
      unitRef="shares">50818</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i87d8e1fc8bdc455ba9db23447bc100f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNy01LTEtMS0w_af7d3f69-4687-4300-8b84-ca72df7d6f77"
      unitRef="usd">1183000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfNy0xMy0xLTEtMA_cf4e08ca-3082-4201-af70-73dbb359baeb"
      unitRef="usd">1183000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i87d8e1fc8bdc455ba9db23447bc100f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfOC01LTEtMS0w_91dbff2a-0f09-44b6-b9c3-84bbafedb45e"
      unitRef="usd">5751000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfOC0xMy0xLTEtMA_a814c4d2-187b-43c6-888c-c90cd8976e31"
      unitRef="usd">5751000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="icce9fa23f25f427eb9589454600ed4ca_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTAtNy0xLTEtMA_179fb87b-597c-4c77-ba22-1a116808babb"
      unitRef="usd">-90935000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieb3c40c61c4f4689b7b8f69c26cd0133_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTAtMTMtMS0xLTA_ffd29394-61f6-42b7-b207-87280b27c017"
      unitRef="usd">-90935000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ibdc069bdc067430e92abc207531d663c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtMS0xLTEtMA_01b9952a-237a-41fc-9e22-e45649564e36"
      unitRef="shares">26182719</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibdc069bdc067430e92abc207531d663c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtMy0xLTEtMA_58fc7a2f-56c4-4fbe-b8ff-a3b56183ab0e"
      unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i379ebd88020b47e4b6146efc5bf71137_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtNS0xLTEtMA_bb152dbb-b254-475e-bf6c-45b4064b4de5"
      unitRef="usd">713782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62e792aa7c38468e81e43fe34e5121a0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtNy0xLTEtMA_fc48090a-c7f8-4aec-8022-0c9148d7f976"
      unitRef="usd">-928204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d93286758fb4fb0834e3fe5467fd410_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtOS0xLTEtMA_4fe57210-cb5d-4772-bdfb-330570545bbd"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ca8b35ceea04640b7869eb9e58fee15_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtMTEtMS0xLTA_7b1604ed-b804-47bf-8e82-ec0664e2d72f"
      unitRef="usd">-54998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i12e7f1c8a5df44dda88579554a423614_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTEtMTMtMS0xLTA_16b092a9-496c-4807-8efa-90425593f6bd"
      unitRef="usd">-269394000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iacf27721acf74d0ea561cff498784811_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTgtMS0xLTEtMA_ac9b07cc-b3b5-43d3-948a-f05470c9dd55"
      unitRef="shares">10477</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9f2546d188d64d9d93c6334f07c8adcf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTgtNS0xLTEtMA_7362a6c5-242f-4ab5-a970-a627f982e223"
      unitRef="usd">168000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTgtMTMtMS0xLTA_47b64909-b9e9-42c3-a41d-1ebfeff27b41"
      unitRef="usd">168000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="iacf27721acf74d0ea561cff498784811_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTktMS0xLTEtMA_425214eb-a55d-4b71-83ee-4e9505805303"
      unitRef="shares">81139</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMTktMTMtMS0xLTA_b7c7910f-9436-4fc3-98fe-ef60c22042e9"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9f2546d188d64d9d93c6334f07c8adcf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjAtNS0xLTEtMA_ea63ce3c-cf28-4b38-afcb-20a78f405b22"
      unitRef="usd">8584000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjAtMTMtMS0xLTA_25170b86-c63c-4963-a4c7-bac2b9e60806"
      unitRef="usd">8584000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjEtMTMtMS0xLTA_48f57107-a518-4af4-acde-996b117dcbdb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i0e2395549626418da16b8a9ad6037264_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjItNy0xLTEtMA_1f7dfdc1-cb7f-4c7f-9159-b7dc725d7de3"
      unitRef="usd">-43668000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjItMTMtMS0xLTA_78a3d212-c46a-4bcb-ad97-9d81c30ff35f"
      unitRef="usd">-43668000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ibeed394b634a4b9fb167c86225bdd1d3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtMS0xLTEtMA_3bbe5c6e-2154-4978-9b75-936260cf92eb"
      unitRef="shares">26274335</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibeed394b634a4b9fb167c86225bdd1d3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtMy0xLTEtMA_ae532617-9b64-468f-a525-a60133630bff"
      unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68b9a3b16a7041bd8d34d47e1359ed86_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtNS0xLTEtMA_7786c167-37e6-43c0-93bd-09f761be800d"
      unitRef="usd">722534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i733c42004f7f45bf8f40d28a377fb43e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtNy0xLTEtMA_3cc73aab-c8be-476f-9264-3e0a88af288c"
      unitRef="usd">-971872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c790fd04d414722be81c66df421c95d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtOS0xLTEtMA_5f967de1-6576-4322-b259-365996bf10ab"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b8adaaf631b47b48badf05858b0984f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtMTEtMS0xLTE5NDM_a0901eca-df09-4af7-8378-a10f55920649"
      unitRef="usd">-54998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yMi9mcmFnOjFkMzIwOTE2ZmRhNDRjY2Q4ZjI5NzAxMTQwYTk0NDZiL3RhYmxlOjZjMjEwNzdhN2ZlNjRjNDZhYzhmODhkYjg5NTE5NDczL3RhYmxlcmFuZ2U6NmMyMTA3N2E3ZmU2NGM0NmFjOGY4OGRiODk1MTk0NzNfMjMtMTMtMS0xLTA_6962551c-7818-4794-a1e9-752be181c1da"
      unitRef="usd">-304310000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMy0xLTEtMS0w_34cf3931-c2d3-4edf-ab12-2b09fb44d7aa"
      unitRef="usd">-134603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMy0zLTEtMS0w_14d78907-ce5d-48ca-9c82-d6e89213f7d7"
      unitRef="usd">46362000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNS0xLTEtMS0w_0baf7803-03e0-4174-8fc9-1608ffd44929"
      unitRef="usd">306000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNS0zLTEtMS0w_cdfcf201-64ff-4c3c-ad46-acea18d4bf41"
      unitRef="usd">224000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNi0xLTEtMS0w_21a0f901-3f1d-4802-bff8-fa33500e60ec"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNi0zLTEtMS0w_db11e0ee-8a41-4088-ae51-69695af0eb1b"
      unitRef="usd">93000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNy0xLTEtMS0w_1afae6d4-0667-47d1-9714-ff5c97c5a6bc"
      unitRef="usd">804000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfNy0zLTEtMS0w_5d9f42cc-edac-4062-9f57-2aef7288a1c9"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <espr:NonCashInterestExpenseRelatedToRevenueInterestLiability
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfOS0xLTEtMS0w_dc1f754b-82dc-4711-a8bc-f14da31a09f4"
      unitRef="usd">12865000</espr:NonCashInterestExpenseRelatedToRevenueInterestLiability>
    <espr:NonCashInterestExpenseRelatedToRevenueInterestLiability
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfOS0zLTEtMS0w_fe084a70-7a1c-49ea-a27b-d48a96bc5b0c"
      unitRef="usd">8811000</espr:NonCashInterestExpenseRelatedToRevenueInterestLiability>
    <us-gaap:ShareBasedCompensation
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTEtMS0xLTEtMA_ac326f2e-76fb-422a-ac15-77223169b987"
      unitRef="usd">14335000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTEtMy0xLTEtMA_a921cefe-ae0e-491f-90b7-a24037b719a9"
      unitRef="usd">14448000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTMtNS0xLTEtNDQxMw_e7757aeb-f111-4bec-bb1d-fef724142d15"
      unitRef="usd">9466000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTMtNy0xLTEtNDQxNQ_75d111d9-c4ab-457e-9e17-c51cefb6c0d2"
      unitRef="usd">2915000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTMtMS0xLTEtMA_ae9221da-38ed-471d-a44d-d676026baffc"
      unitRef="usd">-1990000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTMtMy0xLTEtMA_17a09c30-4cba-42fa-b6cb-1c361fe929ba"
      unitRef="usd">-533000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTQtMS0xLTEtMA_2c269691-d09e-41f7-b3c1-c5a01359ef92"
      unitRef="usd">3325000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTQtMy0xLTEtMA_8986405b-d5ce-4b30-af97-08ef66d24b78"
      unitRef="usd">-1018000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTUtMS0xLTEtMA_5a00f243-b96e-436a-9548-a5769bf260e3"
      unitRef="usd">7578000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTUtMy0xLTEtMA_e245ad57-b3fa-4753-a6bf-babce37ecd3f"
      unitRef="usd">8248000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTYtMS0xLTEtMA_0e71863e-2080-4ae9-ba9e-11593c017c81"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTYtMy0xLTEtMA_4c23f68c-6856-4e2c-9909-5f60d4c1dd90"
      unitRef="usd">1238000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTctMS0xLTEtMA_c3dae4c5-2457-477b-9785-cfa2cc5c51da"
      unitRef="usd">-22182000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTctMy0xLTEtMA_9bac159b-eb84-4e37-b873-1eb2bfc89db3"
      unitRef="usd">921000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTgtMS0xLTEtMA_da7cc4a5-c276-4902-9363-40adf2b9a3af"
      unitRef="usd">3270000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTgtMy0xLTEtMA_eb4dbbf7-64c9-4346-96dc-b447337c9ff0"
      unitRef="usd">12257000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTktMS0xLTEtMA_394d3c70-643a-4af8-87b5-fc6050d48c5d"
      unitRef="usd">-136934000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMTktMy0xLTEtMA_3d096fd2-c352-4406-8172-a9cddf05aff9"
      unitRef="usd">70044000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjItMS0xLTEtMA_140b2d1d-990f-43a1-8d32-af18abd87a15"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjItMy0xLTEtMA_da158bfc-556b-43b5-8643-7778c0a1e0af"
      unitRef="usd">4420000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjMtMS0xLTEtMA_87b31b1f-e4a9-410f-a621-e5eb70c62bf5"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjMtMy0xLTEtMA_b7148ae3-a6f8-4b6e-9443-cf4586e6b66d"
      unitRef="usd">36895000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjQtMS0xLTEtMA_d29651eb-1083-44ee-a44f-6e134bfa58f6"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjQtMy0xLTEtMA_d4a93dfe-0065-413e-87b4-a9c8f8038028"
      unitRef="usd">776000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjUtMS0xLTEtMA_e64de8ae-5124-43cd-824e-3d78e4481391"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjUtMy0xLTEtMA_8f0e50eb-933f-4bce-81f8-27bb2c3a0c18"
      unitRef="usd">31699000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <espr:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjgtMS0xLTEtMA_773295ef-332a-4d3b-9965-9a06535ad477"
      unitRef="usd">49917000</espr:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts>
    <espr:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjgtMy0xLTEtMA_8b0f5ad7-b678-4bf0-b80f-6645105ae7a3"
      unitRef="usd">25000000</espr:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjktMS0xLTEtMA_5dad6dd7-a1a2-4156-8ee1-f54f9ed19698"
      unitRef="usd">2836000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMjktMy0xLTEtMA_90b4b56f-9d31-4cbf-9f53-282661540939"
      unitRef="usd">4752000</us-gaap:ProceedsFromStockOptionsExercised>
    <espr:PaymentsFromRevenueInterestPurchaseAgreement
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzAtMS0xLTEtMA_0c26346a-bf75-4fd2-b03d-cbaf9b593dd5"
      unitRef="usd">1155000</espr:PaymentsFromRevenueInterestPurchaseAgreement>
    <espr:PaymentsFromRevenueInterestPurchaseAgreement
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzAtMy0xLTEtMA_ce52926e-d718-48b2-a4f3-407ccec17db3"
      unitRef="usd">64000</espr:PaymentsFromRevenueInterestPurchaseAgreement>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzEtMS0xLTEtMA_3cb79443-ef48-453b-a400-cf2228e8e17f"
      unitRef="usd">440000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzEtMy0xLTEtMA_bfd65fe6-ff86-42ba-a18b-d3e39519dfa3"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzItMS0xLTEtMA_55717642-220e-45a7-8991-705a0be03f45"
      unitRef="usd">51158000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzItMy0xLTEtMA_bc0c8c50-f09b-4268-9a9f-5bba211abafd"
      unitRef="usd">29688000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzQtMS0xLTEtMA_84700bca-3181-4d33-bd5d-8fde1a06b5fc"
      unitRef="usd">-85776000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzQtMy0xLTEtMA_eaf801de-6305-4bb2-b11d-4ac47e3233be"
      unitRef="usd">131431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzUtMS0xLTEtMA_cfaa39fd-0a07-4d2c-926e-5cf251072429"
      unitRef="usd">304962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1e0d32b36655400c85ee28b60964a4d7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzUtMy0xLTEtMA_b4e006e6-8f7d-436d-bdb5-fa2e0c23428c"
      unitRef="usd">167058000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzYtMS0xLTEtMA_9d0fb2d0-fac7-443a-a54f-64dcf8203163"
      unitRef="usd">219186000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i26cc47a532c9410ab9a72e3f56e5c255_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzYtMy0xLTEtMA_ccfd4e09-2c7a-426c-8a0d-25b7d1eb4c10"
      unitRef="usd">298489000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzgtMS0xLTEtMA_485bbe06-30dc-40f0-bd93-5942f6b0cd1c"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzgtMy0xLTEtMA_5121adb2-2a8a-4f14-a582-4ce05073d14a"
      unitRef="usd">6000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <espr:NonCashRightOfUseAsset
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzktMS0xLTEtMA_c4d4ba1a-380e-4178-99da-a81f79cbaa67"
      unitRef="usd">6000</espr:NonCashRightOfUseAsset>
    <espr:NonCashRightOfUseAsset
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18yOC9mcmFnOjYzNjIwZWJjY2FlNjRjNjM5ZDQ5ZjM4N2FiYjhkOGQyL3RhYmxlOmRjZDE4NjVmMDY3YjQ3Mzg4ZGU3ZDBhNjA0ZWU5NjkwL3RhYmxlcmFuZ2U6ZGNkMTg2NWYwNjdiNDczODhkZTdkMGE2MDRlZTk2OTBfMzktMy0xLTEtMA_f885a489-3fc4-4c3f-93a6-5b1549f8fa50"
      unitRef="usd">-7000</espr:NonCashRightOfUseAsset>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfNjI1NQ_99707d76-2d79-4705-b467-0826bc6c96be">The Company and Basis of Presentation&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Esperion Therapeutics, Inc. ("the Company&#x201d;) is the Lipid Management Company, a pharmaceutical company singularly focused on developing and commercializing affordable, oral, once-daily, non-statin medicines for the treatment of patients struggling with elevated low density lipoprotein cholesterol ("LDL-C"). The Esperion team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. The Company's first two products were approved by the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Swiss Agency for Therapeutic Products ("Swissmedic") in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease ("ASCVD") or heterozygous familial hypercholesterolemia ("HeFH"). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 26, 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd ("DS"). Pursuant to the agreement, the Company granted DS exclusive development and commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. The Company received an upfront cash payment of $30.0&#160;million in May 2021 and is eligible to receive up to an additional $175.0&#160;million in sales milestones. The Company will also receive tiered royalties ranging from 5 percent to 20 percent on net sales in the DS Territory. Refer to Note 3 "Collaborations with Third Parties" for further information. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 26, 2021, the Company entered into Amendment No. 2 (the &#x201c;RIPA Amendment&#x201d;) to the Revenue Interest Purchase Agreement with Eiger III SA LLC (&#x201c;Oberland&#x201d;), an affiliate of Oberland Capital LLC, as agent for the purchaser parties thereto dated as of June 26, 2019 (as amended by the Amendment No. 1 dated as of November 9, 2020, the &#x201c;RIPA&#x201d;). Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50&#160;million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA and the related Security Agreement, which are discussed further in Note 8 "Liability Related to the Revenue Interest Purchase Agreement."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's primary activities since incorporation have been conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. The Company received approval by the FDA in February 2020 to commercialize NEXLETOL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and NEXLIZET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S., and accordingly commenced principal operations on March 30, 2020 with the commercialization of NEXLETOL. The Company is subject to risks and uncertainties which include the need to successfully commercialize its products, research, develop, and clinically test therapeutic products; obtain regulatory approvals for its products; expand its management, commercial and scientific staff; and finance its operations with an ultimate goal of achieving profitable operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has sustained annual operating losses since inception and expects such losses to continue over the foreseeable future. The Company's ability to successfully launch, commercialize and generate revenue from NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI has been and may continue to be adversely affected by the economic impact of the COVID-19 pandemic. In response to the Company&#x2019;s history of operating losses and the uncertainty around the ongoing impact of COVID-19 management has initiated certain cost optimization measures and will implement additional cost reduction measures as needed if additional collaboration or capital funding is not available. Additionally, management may continue to fund operations and advance the development of the Company's products and product candidates through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, and permitted private and public equity offerings or through other sources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If adequate funds are not available, the Company may not be able to continue the development of its current products or future product candidates, or to commercialize its current or future product candidates, if approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods presented. Certain prior year amounts have been &lt;/span&gt;&lt;/div&gt;reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <espr:UpFrontPayment
      contextRef="id125fee9cd774cad978f6ae94f446b6b_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfMTgyNg_8825cc7a-3579-4acf-88a1-3a8f22616725"
      unitRef="usd">30000000.0</espr:UpFrontPayment>
    <espr:AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones
      contextRef="if57aa28556d54b82af658eb81d72b9fb_I20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfMTg4OA_711a9e0c-b461-4928-afeb-b79e239598cc"
      unitRef="usd">175000000.0</espr:AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="i60ff16704c9e4a26864f51907841faaf_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfNTQ5NzU1ODE0NTIyOQ_c6968758-3533-472b-8b3b-ebb4ed098208"
      unitRef="number">0.05</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="ica0ff70047d84bf3ac80640f0aca8a46_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfNTQ5NzU1ODE0NTIzOQ_ee53016a-9f86-4811-9359-73642067537c"
      unitRef="number">0.20</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:ProceedsFromRevenueInterestPurchaseAgreement
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfMjU3Ng_33520b4e-fbfc-4988-a866-9d648ff8f829"
      unitRef="usd">50000000</espr:ProceedsFromRevenueInterestPurchaseAgreement>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N18zNC9mcmFnOjNkODJmZjRhMjEyNzQ2MGU4NjlkOGFkYzE3YTA2Y2ZhL3RleHRyZWdpb246M2Q4MmZmNGEyMTI3NDYwZTg2OWQ4YWRjMTdhMDZjZmFfNjI1Ng_24b487c0-b0e9-47e4-befb-4207162efb85">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods presented. Certain prior year amounts have been &lt;/span&gt;&lt;/div&gt;reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTM_2c1b5990-1396-44ee-b219-1b1b58b7b14b">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of June&#160;30, 2021 nine customers accounted for all of the Company's net trade receivables and as of December 31, 2020 eight customers accounted for all the Company's net trade receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#x201c;API&#x201d;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $10.6 million and $17.0 million for the three and six months ended June&#160;30, 2021 and $0.6 million and $1.5 million for the three and six months ended June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#x2019; distribution facilities, or free on board (&#x201c;FOB&#x201d;) destination, the terms of which are designated in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#x2019;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#x201c;Other accrued liabilities&#x201d; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forms of Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-pay assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company generally offers a right of return based on the product&#x2019;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#x2019;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#x2019;s expectations regarding future payment patterns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Implemented Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")  2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;). This ASU simplifies the accounting for convertible instruments by removing the separation models for convertible debt with cash conversion features and convertible instruments with a beneficial conversion feature, which requires the fair value of the embedded conversion feature of convertible instruments be allocated to equity. Under ASU 2020-06, a convertible debt instrument with those features will generally be reported as a single liability at its amortized cost with no separate accounting for the embedded conversion features in equity. The adoption of this ASU resulted in the reclassification of the portion of the Company's convertible notes from equity to debt, which also reduces reported interest expense and increases reported net income. ASU 2020-06 requires the application of the if-converted method when calculating diluted earnings per share, eliminating the Company&#x2019;s ability to use the treasury stock method when certain conditions are met. The ASU is effective for annual reporting periods beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company early adopted this standard as of January 1, 2021 which resulted in a net increase in the convertible notes of approximately $92.0&#160;million, an adjustment to accumulated deficit of $1.5&#160;million, and a reduction to additional paid-in capital of $93.5&#160;million. The tax impact of the adoption was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTQ_abc4f171-15d2-4990-9f20-4d631b5c460c">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTE_be984c76-b8df-4e84-8cb5-41c2a09c379f">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of June&#160;30, 2021 nine customers accounted for all of the Company's net trade receivables and as of December 31, 2020 eight customers accounted for all the Company's net trade receivables.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <espr:ConcentrationRiskNumberOfMajorCustomers
      contextRef="i584f75dd199f4a379657616c6423e8f0_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfNjIy_49647e87-60c6-4ac3-bf87-4f10e908b3d5"
      unitRef="customer">9</espr:ConcentrationRiskNumberOfMajorCustomers>
    <espr:ConcentrationRiskNumberOfMajorCustomers
      contextRef="i3e4850b6ddab4d628848b2165151adcd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfNjU5NzA2OTc4MTc0MQ_6049a6ff-1d9a-4fe9-ac5b-3157fb34c428"
      unitRef="customer">8</espr:ConcentrationRiskNumberOfMajorCustomers>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTI_423f301f-379b-46ee-95a3-1db2668a9bbc">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#x201c;API&#x201d;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $10.6 million and $17.0 million for the three and six months ended June&#160;30, 2021 and $0.6 million and $1.5 million for the three and six months ended June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#x2019; distribution facilities, or free on board (&#x201c;FOB&#x201d;) destination, the terms of which are designated in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#x2019;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#x201c;Other accrued liabilities&#x201d; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forms of Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-pay assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company generally offers a right of return based on the product&#x2019;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#x2019;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#x2019;s expectations regarding future payment patterns.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <espr:NumberOfSourcesOfRevenue
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTg0NQ_d2cb9cd2-4309-4b96-968d-ed55a9d0c1d8"
      unitRef="revenue_source">2</espr:NumberOfSourcesOfRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9c66ab5008d4c28a2f2a6317075fc61_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTA5OTUxMTY0MjEyMw_bfe8fefb-187d-4ebc-a0e9-837833f0e306"
      unitRef="usd">10600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3555938aa014fbda7603991f689d2d4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTA5OTUxMTY0MjEzMA_07756136-aeea-4a30-9d05-40c29411e395"
      unitRef="usd">17000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3f1e56095ca4d07a8f77cec69f8a7ba_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTA5OTUxMTY0MjAxOQ_99bc8e12-0f34-4695-a25a-026c3e3c7889"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia332deb386b74a509426822f23273e5e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTA5OTUxMTY0MjAyMw_807bbd4b-77cf-405a-ac0b-6b2c4558a716"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNDk_87b9a64a-e798-4efb-86dc-aa00795ecd28">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTQxNTA_d472eb32-3f5e-47bd-9a6b-f8c01f272b00">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Implemented Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")  2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;). This ASU simplifies the accounting for convertible instruments by removing the separation models for convertible debt with cash conversion features and convertible instruments with a beneficial conversion feature, which requires the fair value of the embedded conversion feature of convertible instruments be allocated to equity. Under ASU 2020-06, a convertible debt instrument with those features will generally be reported as a single liability at its amortized cost with no separate accounting for the embedded conversion features in equity. The adoption of this ASU resulted in the reclassification of the portion of the Company's convertible notes from equity to debt, which also reduces reported interest expense and increases reported net income. ASU 2020-06 requires the application of the if-converted method when calculating diluted earnings per share, eliminating the Company&#x2019;s ability to use the treasury stock method when certain conditions are met. The ASU is effective for annual reporting periods beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company early adopted this standard as of January 1, 2021 which resulted in a net increase in the convertible notes of approximately $92.0&#160;million, an adjustment to accumulated deficit of $1.5&#160;million, and a reduction to additional paid-in capital of $93.5&#160;million. The tax impact of the adoption was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i24321e9e8f7543f590713d54993c4653_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTM4MjU_de5aa668-768c-4211-84a3-69d59b39f149"
      unitRef="usd">92000000.0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i24321e9e8f7543f590713d54993c4653_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTM4Njk_6508db37-4005-489c-8396-a7373eae702f"
      unitRef="usd">-1500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i24321e9e8f7543f590713d54993c4653_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180MC9mcmFnOjRjMjYzODZkOGVhMzQ5YjM5Njc2MzY3YTEyYzk2N2E5L3RleHRyZWdpb246NGMyNjM4NmQ4ZWEzNDliMzk2NzYzNjdhMTJjOTY3YTlfMTM5MjI_68879d31-665e-4570-aff5-4e2c565820ae"
      unitRef="usd">-93500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfODM3Mg_4ffc81f0-ba52-4217-9235-2a436c63aa8e">Collaborations with Third Parties&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DSE Agreement Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2019, the Company entered into a license and collaboration agreement with Daiichi Sankyo Europe GmbH ("DSE"). Pursuant to the agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablets in the European Economic Area and Switzerland (&#x201c;DSE Territory&#x201d;). DSE will be responsible for commercialization in the DSE Territory. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the agreement, the consideration consists of a $150.0 million upfront cash payment as well as $150.0 million cash payment to the Company upon first commercial sales in the DSE Territory. The Company also is responsible to supply DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive a substantial additional regulatory milestone payment upon the grant of the marketing authorisation in the European Union for the CV risk reduction label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company will receive tiered fifteen percent (15%) to twenty-five percent (25%) royalties on net DSE Territory sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement calls for both parties to participate in a Joint Collaboration Committee (the &#x201c;DSE JCC&#x201d;). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Agreement Terms Amendment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2020, the Company entered into an amendment to the license and collaboration agreement with DSE, dated as of January 2, 2019. In June 2020, the Company completed the transfer of the MAAs for NILEMDO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and NUSTENDI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Pursuant to the terms of the amendment, DSE paid the Company the second $150.0 million milestone based on completion of the NUSTENDI MAA transfer rather than the first product sale in the EU, as previously agreed. Additionally, the Company and DSE have agreed to expand the DSE Territory, or the territory in which DSE has exclusive commercialization rights to NILEMDO and NUSTENDI to include Turkey. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $150.0 million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company&#x2019;s intellectual property and 2) the obligation to provide ongoing regulatory and development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company&#x2019;s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company&#x2019;s obligation to provide ongoing regulatory and development activities. In the three and six months ended June 30, 2020, the Company recognized approximately $0.7&#160;million and $1.6&#160;million, respectively, related to the on-going performance obligation for the ongoing regulatory efforts related to the MAA in the DSE Territory, which was transferred to DSE in June 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three and six months ended June 30, 2020, the Company recognized the $150.0&#160;million milestone as collaboration revenue based on the successful transfer of the NUSTENDI MAA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in the three and six months ended June&#160;30, 2021, the Company recognized collaboration revenue of approximately $2.0 million and $3.6&#160;million related to royalty revenue from DSE following their European launch of NILEMDO and NUSTENDI as well as the sales of bulk tablets to DSE pursuant to the supply agreement that was executed with DSE. In the three and six months ended June 30, 2020, the Company recognized collaboration revenue of $1.0&#160;million related to the sales of bulk tablets of NILEMDO and NUSTENDI to DSE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All remaining future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to sales-based milestones will be recognized when the subsequent sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Otsuka Agreement Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2020, the Company entered into the Otsuka Agreement with Otsuka Pharmaceutical Co., Ltd. ("Otsuka"). Pursuant to the Otsuka Agreement, the Company granted Otsuka exclusive development and commercialization rights to NEXLETOL and NEXLIZET in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the agreement, the consideration consists of a $60.0 million upfront cash payment and the Company will be eligible to receive additional payments of up to $450.0 million if certain regulatory and commercial milestones are achieved by Otsuka. The potential future milestone payments include up to $20.0 million upon first JNDA submissions in the Otsuka Territory, up to $70.0 million upon the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and up to $50.0 million upon the achievement of the primary major adverse cardiovascular events (&#x201c;MACE&#x201d;) in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments up to $310.0 million related to total net sales achievements for Otsuka in Japan. Finally, the Company will receive tiered fifteen percent (15%) to thirty percent (30%) royalties on net sales in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement calls for both parties to participate in a Joint Collaboration Committee (the "Otsuka JCC"). The Otsuka JCC is comprised of executive management from each company and Otsuka will lead in all aspects related to development and commercialization in the Otsuka Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company did not have any collaboration revenue from the Otsuka Agreement during the three and six months ended June 30, 2021. In the three and six months ended June 30, 2020, the Company recognized $60.0&#160;million of collaboration revenue related to the $60.0&#160;million upfront payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not yet recognized any revenue for milestone payments as the related regulatory and commercial milestones have not yet been achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DS Agreement Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 26, 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Company, Limited ("DS Agreement"). Pursuant to the DS Agreement, the Company granted DS exclusive rights to develop and commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet (the "Products") in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible development and commercialization in these territories. In addition, DS will fund all development costs associated with the program in the DS Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the agreement, the consideration consists of a $30.0&#160;million upfront cash payment that is non-refundable, non-reimbursable and non-creditable. The Company will be eligible to receive additional one-time payments of up to $175.0&#160;million if certain commercial milestones are achieved by DS. Also, the Company will receive tiered royalties of five percent (5%) to twenty percent (20%) of net sales in the DS Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement requires the parties to establish a joint collaboration committee (the "Joint Collaboration Committee" or "JCC"). The Joint Collaboration Committee is composed of six (6) members, with each Party contributing three (3) representatives each who are employees of such Party with main responsibility of overseeing the Development and Commercialization activities relating to the Licensed Products in the Field in the DS Territory and other responsibilities as stated in the Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $30.0&#160;million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company&#x2019;s intellectual property and 2) the obligation to provide ongoing development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company&#x2019;s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company&#x2019;s obligation to provide ongoing development activities. Accordingly, for the three and six months ended June 30, 2021, the Company recognized $28.1&#160;million of collaboration revenue related to the $30.0&#160;million upfront payment. The $28.1&#160;million relates to the performance obligations for the license to the Company&#x2019;s intellectual property and a portion of ongoing regulatory and development activities conducted during the period ended June 30, 2021, in the amounts of $28.0&#160;million and $0.1 million, respectively. The remaining $1.9&#160;million of the upfront payment was deferred as of June 30, 2021 due to an on-going performance obligation related to the developmental activities in South Korea and Taiwan. This deferred revenue will be recognized ratably over the period leading up to the completion of these developmental activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During December 2020, the Company entered into a licensing agreement with Serometrix to in-license a series of early stage compounds known as scaffolds related to its oral, small molecule PCSK9 inhibitor program. PCSK9 is an enzyme responsible for regulating LDL receptors. PCSK9 inhibitors stop LDL receptors from being broken down, increasing the number of LDL receptors present to remove cholesterol from the blood. The agreement allows the Company use of the PCSK9 compounds, which were patented by Serometrix prior to the licensing agreement, to perform further research and development with the goal of developing a small molecule oral PCSK9 inhibitor that can be taken as a tablet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for these rights, the Company agreed to pay Serometrix an upfront payment, milestone payments and royalties on net sales of licensed products under the agreement. The Company is obligated to make milestone payments to Serometrix upon the achievement of specified development, regulatory and commercialization milestones. The development milestone payments due under the agreement depend on the licensed product being developed. As part of the agreement, the Company made an upfront cash payment of $12.5&#160;million in December 2020, which was recorded to research and development expense, to Serometrix, with payments in future years tied to specific milestones. The Company has also agreed to pay tiered royalties based on net sales of all products licensed under the agreement of mid-single-digit to low double-digit percentages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <espr:UpFrontPayment
      contextRef="i272c7eba0c41457f84c261e58a1bbedc_D20190102-20190102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNjcy_55aefc1c-c726-40a7-aea8-6112611039e0"
      unitRef="usd">150000000.0</espr:UpFrontPayment>
    <espr:CashPaymentToBeReceivedUponFirstCommercialSales
      contextRef="i272c7eba0c41457f84c261e58a1bbedc_D20190102-20190102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNzA3_1413768a-4da6-42e1-8934-4e70b5343e43"
      unitRef="usd">150000000.0</espr:CashPaymentToBeReceivedUponFirstCommercialSales>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="ife3936cfd95f4b539b5a1cbb4ce8a51a_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMTM4Mg_ee4daf96-3188-4df5-bb74-cfc852e441ec"
      unitRef="number">0.15</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="icfdd1264317a4e959d48fae350ca5f6a_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMTQxMA_63a1f41a-4097-419f-a531-00612109d602"
      unitRef="number">0.25</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer
      contextRef="i52875fa54d2d47d08f43907539a1290b_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMjA5Ng_82700f16-5624-4a08-af88-a58f3f57ef46"
      unitRef="usd">150000000.0</espr:ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer>
    <espr:UpFrontPayment
      contextRef="i272c7eba0c41457f84c261e58a1bbedc_D20190102-20190102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMjgyNQ_4a1bf8f0-ce76-4972-8fcc-a2287e9a99f9"
      unitRef="usd">150000000.0</espr:UpFrontPayment>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i70b05bb32f374749885434ca47747d1a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU0MA_aa4ef7f4-08aa-42a8-b3ba-1f93dfc26d45"
      unitRef="usd">700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib69346e757f3452d8d1aeea2c8017cfc_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU1NA_856443b6-c002-41ef-a22b-0afa3de75bf1"
      unitRef="usd">1600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5331bb6e27784c98ba83f790214f2d62_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU2OA_9026b46a-a8c1-4450-ac48-005abd763b86"
      unitRef="usd">150000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22044bf98171420f847fdf469c65b5ac_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU2OA_d95eabc0-484c-40a8-8dac-48b8e21e65bc"
      unitRef="usd">150000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11df274bc00047b7b2522e08b61ca091_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMzY1OQ_69ce787d-431e-4baf-bc05-b0c6308ec1ac"
      unitRef="usd">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd1fbd1b685c42ffb9c49c3b31c629df_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfMTA5OTUxMTY0NzU3MQ_6b3d281b-ee28-46a4-aa96-9709d98b009c"
      unitRef="usd">3600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26f9230bab5b44cda5e7265c85d57b66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU4NA_af132915-cd14-42bf-9ee1-4ecf23f2a33e"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dfde8b13e554913935ea8540925afeb_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU4NA_f0b4e64e-c3a2-4610-a281-fc91106c1017"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <espr:UpFrontPayment
      contextRef="i3b353fe5393a4dc2bac419bc2aa386d6_D20200417-20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNDgxMQ_a8abecfa-f470-4395-aa3e-8c70ff222455"
      unitRef="usd">60000000.0</espr:UpFrontPayment>
    <espr:AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones
      contextRef="i232d185de48d4c6baa127c8681fe96ca_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNDkwOA_17064aeb-e3a2-43b0-897e-484c841ef2d8"
      unitRef="usd">450000000.0</espr:AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones>
    <espr:FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory
      contextRef="i42d4992daffb433d85ca8fd259ed4e9d_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTAzNw_51301812-6519-497a-a422-939768f34412"
      unitRef="usd">20000000.0</espr:FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory>
    <espr:FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory
      contextRef="i42d4992daffb433d85ca8fd259ed4e9d_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTA5OQ_83fd63ed-cca4-4aa5-9819-96889df196ad"
      unitRef="usd">70000000.0</espr:FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory>
    <espr:FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies
      contextRef="i42d4992daffb433d85ca8fd259ed4e9d_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTE4Mw_4b5d947a-35c8-4cd9-bd2f-8d7762859b66"
      unitRef="usd">50000000.0</espr:FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies>
    <espr:FuturePaymentMilestoneSalesMilestones
      contextRef="i42d4992daffb433d85ca8fd259ed4e9d_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTUxNA_1070ba86-0839-4aff-8c2e-7d5b8c934ac6"
      unitRef="usd">310000000.0</espr:FuturePaymentMilestoneSalesMilestones>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="ic2e95112c7734a5d8292505e37d9fa7f_D20200417-20200417"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTYzNg_77d6e68b-04ac-48b7-9f1c-9acb7e0b69bf"
      unitRef="number">0.15</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="if950ab2c0cae426e871485a272155dd5_D20200417-20200417"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTY1OQ_f6f5e1e2-a877-44b8-9c51-22013adf4453"
      unitRef="number">0.30</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42f46b3fae7942db8d62064f916bccae_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNjEyOQ_b168f620-0eb0-451d-b1e7-cf5c18641ae7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ef4d12805a94033b928a8cef22e81f6_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNjEyOQ_d02d1663-6b13-4728-8aad-a2cbfa275103"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0ea2e4cbd104e848e494a2b3378dd35_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU1OA_7fdeede7-2198-46a2-a809-850ea3de11aa"
      unitRef="usd">60000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4170f009274249bfb0d9fad65135d67a_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU1OA_dfcda3cd-2d92-4db6-b21d-078dfa466ae8"
      unitRef="usd">60000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <espr:UpFrontPayment
      contextRef="i3b353fe5393a4dc2bac419bc2aa386d6_D20200417-20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU0MQ_3a657f63-9a11-4d88-a330-41e4b273fde9"
      unitRef="usd">60000000.0</espr:UpFrontPayment>
    <espr:FutureUpFrontPayment
      contextRef="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU3Mw_2e5ed9d4-8967-45f4-a18f-b9643110593e"
      unitRef="usd">30000000.0</espr:FutureUpFrontPayment>
    <espr:CashPaymentToBeReceivedUponCertainCommercialMilestones
      contextRef="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODU4OA_aafc18b2-8f4e-446c-991f-273302de899e"
      unitRef="usd">175000000.0</espr:CashPaymentToBeReceivedUponCertainCommercialMilestones>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="i60ff16704c9e4a26864f51907841faaf_D20210426-20210426"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODYwMw_bd8bf485-115a-4932-b252-8b59abf55d68"
      unitRef="number">0.05</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="ica0ff70047d84bf3ac80640f0aca8a46_D20210426-20210426"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODYwNw_e16bda50-aff2-4c23-8463-efda65181462"
      unitRef="number">0.20</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:FutureUpFrontPayment
      contextRef="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE1ODYxMg_b15ebe97-1321-4bf1-a998-4643de59ec1d"
      unitRef="usd">30000000.0</espr:FutureUpFrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93803d292d3b4027976e1b5d23361ad8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU5OA_1e1376a5-6c0d-4188-845a-d6cbf3b986c8"
      unitRef="usd">28100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72ae8eed70f84e13942db9d0ab474673_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTU5OA_6fa00703-8ab8-4545-8b28-bb0419a2d1c2"
      unitRef="usd">28100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <espr:FutureUpFrontPayment
      contextRef="i52a9b8e4f8bc422ab7cb6fde7e6e2163_D20210426-20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTYxMw_f53fddb5-a2fa-4545-bf18-d170d22a1c52"
      unitRef="usd">30000000.0</espr:FutureUpFrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fbda9eaced641d493d9cc099814900c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTYyOA_da61589c-49a8-4a8e-b6af-eb1f2bcf0bc1"
      unitRef="usd">28100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95b9b936123043afb5dde0d7efbc4dfd_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTY0Mw_92660a45-c935-4c59-b83c-6c5397055568"
      unitRef="usd">28000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib65202acf8f242f1bd411cf05ccd2003_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTY1Nw_6cb618d6-e530-4b97-aa7a-d5a7ac14cb25"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <espr:DeferredUpFrontPayment
      contextRef="i72ae8eed70f84e13942db9d0ab474673_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfNTQ5NzU1ODE2NTY2Mw_b49bf6ba-1e19-4c86-ad84-2d66de6cb038"
      unitRef="usd">1900000</espr:DeferredUpFrontPayment>
    <espr:UpFrontPayment
      contextRef="id2f61d084882445fb054d3e384d280e9_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180My9mcmFnOjM0NzQ5OWYyYjY2MDRiMjg4MjQ5OWJiZjBkYjg3MDBlL3RleHRyZWdpb246MzQ3NDk5ZjJiNjYwNGIyODgyNDk5YmJmMGRiODcwMGVfODA1NA_8c61261c-bd9f-4fa1-97a9-8a1abb30d6a2"
      unitRef="usd">12500000</espr:UpFrontPayment>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RleHRyZWdpb246YzcxZDA0MTU1NGU0NGMyM2IyNmQxOGFjYmMzYzM4MDJfNzU_f68e49be-0a7f-44a2-a501-6b18a2982365">Inventories&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RleHRyZWdpb246YzcxZDA0MTU1NGU0NGMyM2IyNmQxOGFjYmMzYzM4MDJfNzY_ac4849de-4e09-45eb-96d3-ccfb10a3a7dc">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMS0xLTEtMS0w_341fed23-50d8-44bc-adf4-36614be3b25f"
      unitRef="usd">21293000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMS0zLTEtMS0w_0556f644-908f-442d-8de0-5ef7e416070c"
      unitRef="usd">13788000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMi0xLTEtMS0w_d061b268-a720-4e33-bda8-cb8d72b4eed6"
      unitRef="usd">703000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMi0zLTEtMS0w_d78566ac-aa82-49f8-af60-4427ac332eaa"
      unitRef="usd">2028000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMy0xLTEtMS0w_b1038810-f300-4073-9627-54eaed1c0632"
      unitRef="usd">1718000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfMy0zLTEtMS0w_f63cfffa-f4db-40cd-b9cc-29be457b8d91"
      unitRef="usd">320000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfNC0xLTEtMS0w_990df683-d95d-41e5-9892-b443e6f96ebe"
      unitRef="usd">23714000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180Ni9mcmFnOmM3MWQwNDE1NTRlNDRjMjNiMjZkMThhY2JjM2MzODAyL3RhYmxlOjQxM2JjYzA3NmVjNTQwMzI4MDZjYzk3NTgxYjZmZTM3L3RhYmxlcmFuZ2U6NDEzYmNjMDc2ZWM1NDAzMjgwNmNjOTc1ODFiNmZlMzdfNC0zLTEtMS0w_57789962-8757-464e-8230-a0a29875bd29"
      unitRef="usd">16136000</us-gaap:InventoryNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfNjAzMw_4c404908-ca89-4f8c-a1ba-c9d2add01ac3">Commitments and Contingencies&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 12, 2016, a purported stockholder of the Company filed a putative class action lawsuit in the United States District Court for the Eastern District of Michigan, against the Company and Tim Mayleben, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Kevin L. Dougherty v. Esperion Therapeutics, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (No. 16-cv-10089). The lawsuit alleges that the Company and Mr. Mayleben violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by allegedly failing to disclose in an August 17, 2015, public statement that the FDA would require a cardiovascular outcomes trial before approving the Company&#x2019;s lead product candidate. The lawsuit seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between August 18, 2015, and September 28, 2015, as well as attorneys&#x2019; fees and costs. On May 20, 2016, an amended complaint was filed in the lawsuit and on July 5, 2016, the Company filed a motion to dismiss the amended complaint. &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On December 27, 2016, the court granted the Company&#x2019;s motion to dismiss with prejudice and entered judgment in the Company&#x2019;s favor. On January 24, 2017, the plaintiffs in this lawsuit filed a motion to alter or amend the judgment. In May 2017, the court denied the plaintiff&#x2019;s motion to alter or amend the judgment. &#160;In May 2017, the court denied the plaintiff&#x2019;s motion to alter or amend the judgment. On June 19, 2017, the plaintiffs filed a notice of appeal to the Sixth Circuit Court of Appeals and on September 14, 2017, they filed their opening brief in support of the appeal. The appeal was fully briefed on December 7, 2017, and it was argued before the Sixth Circuit on March 15, 2018. On September 27, 2018, the Sixth Circuit issued an opinion in which it reversed the district court&#x2019;s dismissal and remanded for further proceedings. On October 11, 2018, the Company filed a petition for rehearing en banc and, on October 23, 2018, the Sixth Circuit Court of Appeals directed plaintiffs to respond to that petition. On December 3, 2018, the Sixth Circuit denied the Company&#x2019;s petition for en banc rehearing, and on December 11, 2018, the case was returned to the federal district court by mandate from the Sixth Circuit. On December 26, 2018, the Company filed an answer to the amended complaint, and on March 28, 2019, the Company filed its amended answer to the amended complaint. On September 15, 2020, the Company filed a motion for summary judgment, and the plaintiffs filed a motion for partial summary judgment, and on October 23, 2020, the parties filed oppositions to both motions for summary judgment. On November 20, 2020, the Company and plaintiffs filed replies in support of their respective motions. On March 12, 2021, the parties agreed to a settlement in principle of the securities class action, and on April 26, 2021, the parties entered into a stipulation of settlement to resolve all legal claims, in which defendants expressly deny that they have committed any act or omission giving rise to any liability under Section 10(b) of the Securities Exchange Act of 1934. Under the terms of the stipulation of settlement, which the court preliminarily approved on May 6, 2021, the Company and certain of the Company's insurance carriers will cause a payment of $18.25&#160;million to be made to the plaintiff class. There is no assurance that the settlement will ultimately become final. If the settlement does not occur and litigation continues, the Company intends to vigorously defend against it. As a result of this settlement agreement, during the three months ended March 31, 2021, the Company recorded a loss on settlement of $13.25&#160;million in selling, general, and administrative expenses on the condensed statement of operations, which represents the litigation settlement of $18.25&#160;million offset by $5.0&#160;million in insurance claim proceeds from our insurance carriers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 15, 2016, a purported stockholder of the Company filed a derivative lawsuit in the Court of Chancery of the State of Delaware against Tim Mayleben, Roger Newton, Mary McGowan, Nicole Vitullo, Dov Goldstein, Daniel Janney, Antonio Gotto Jr., Mark McGovern, Gilbert Omenn, Scott Braunstein, and Patrick Enright. The Company is named as a nominal defendant. The lawsuit alleges that the defendants breached their fiduciary duties to the Company when they made or approved improper statements on August 17, 2015, regarding the Company&#x2019;s lead product candidate&#x2019;s path to FDA approval, and failed to ensure that reliable systems of internal controls were in place at the Company. On February 8, 2019, the Company and defendants filed a motion to dismiss the derivative lawsuit. On April 23, 2019, the plaintiff filed an opposition to the motion to dismiss the derivative lawsuit, and the Company filed a reply brief on May 15, 2019. On November 6, 2019, the court held a hearing on the motion to dismiss. On February 13, 2020, the court granted the motion to dismiss with prejudice and entered judgment in the Company&#x2019;s favor. On March 16, 2020, the plaintiff filed a notice of appeal to the Supreme Court of Delaware. On June 1, 2020, the plaintiff filed his opening brief on appeal to the Supreme Court of Delaware. On July 1, 2020, the Company and the defendants filed an answering brief, and on July 16, 2020, the plaintiff filed a reply brief. On October 14, 2020, the Supreme Court of Delaware held oral arguments on the appeal. On October 29, 2020, the Supreme Court of Delaware issued an order affirming the judgment of the Court of Chancery. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes to the Company&#x2019;s contractual obligations and commitments and contingencies outside the ordinary course of business from those previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 or noted above.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i66cc3f1c51c941f2b162c47f055b97e7_D20210101-20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfMzI3OA_0d449f7c-8c16-4449-b584-9c658f5f5bb1"
      unitRef="usd">18250000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i0762115bc2ec4613b524e91fa9b92de0_D20210101-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfMTA5OTUxMTYzNDAyNA_1dda782a-83a6-43af-8135-936bbea738ad"
      unitRef="usd">-13250000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ifecad91fa7424664b1f1f53f4d25e943_I20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfMzYzMg_3046fd9d-4e5f-4bf7-adc1-57c0d61b17b9"
      unitRef="usd">18250000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyReceivable
      contextRef="ifecad91fa7424664b1f1f53f4d25e943_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N180OS9mcmFnOmFjMjc1MDE5M2RlZDRjZjhiMGNiNGU2ZmUwZDJlYzc3L3RleHRyZWdpb246YWMyNzUwMTkzZGVkNGNmOGIwY2I0ZTZmZTBkMmVjNzdfMzc3NA_75c7cdc2-3718-47b5-b215-25aa53080eab"
      unitRef="usd">5000000.0</us-gaap:LossContingencyReceivable>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfNzk1_b5736904-01e2-4321-a8cc-9d1a364a07ba">Investments&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021, other income, net in the statements of operations includes interest income on investments of less than $0.1 million and less than $0.1 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2020, other income, net in the statements of operations includes interest income on investments of $0.1 million and $0.5 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no unrealized gains or losses on investments reclassified from accumulated other comprehensive income (loss) to other income in the statements of operations during the three and six months ended June&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three and six months ended June&#160;30, 2021, there were no allowances for credit losses and all unrealized gains (losses) for available-for-sale securities were recognized in accumulated other comprehensive income (loss). As of June&#160;30, 2021, the Company had no accrued interest receivables.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfNzk0_17a85700-24ca-46f5-a9d3-eee96b118288">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i85239930eaf64704995fff739a828f1c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfMy0xLTEtMS0w_93b552e6-3e63-4ebb-a7ee-c2708c5d0668"
      unitRef="usd">201734000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i85239930eaf64704995fff739a828f1c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfMy0zLTEtMS0w_ec57f960-8fe1-4829-935b-8c8f4b617eac"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i85239930eaf64704995fff739a828f1c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfMy01LTEtMS0w_579354ca-cfc0-492f-9923-df6896be91e7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85239930eaf64704995fff739a828f1c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfMy03LTEtMS0w_6c090ba5-467f-45cc-ada0-42df25631ef9"
      unitRef="usd">201734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfNi0xLTEtMS0w_b3975997-dae8-4204-a5a4-6a45c1fdb312"
      unitRef="usd">201734000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfNi0zLTEtMS0w_bac9524e-fb50-4664-b0a1-600bcf122e78"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfNi01LTEtMS0w_1bd9bf85-35a0-4b78-94b5-572bd3b889d7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOjU0NzNkNGViMzg5NjQxY2FiZTMyY2IyMDM0ODM4MGRiL3RhYmxlcmFuZ2U6NTQ3M2Q0ZWIzODk2NDFjYWJlMzJjYjIwMzQ4MzgwZGJfNi03LTEtMS0w_f826a279-f37a-423e-8c10-7f71a442294c"
      unitRef="usd">201734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic2755a874c4a4c48a6b849306fd2464f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMy0xLTEtMS0w_c5c32b99-22c7-4500-b4e9-1b549c630fb0"
      unitRef="usd">281783000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic2755a874c4a4c48a6b849306fd2464f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMy0zLTEtMS0w_9c208c1b-19fb-450f-b05e-f419d505eac2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic2755a874c4a4c48a6b849306fd2464f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMy01LTEtMS0w_919483eb-de69-4549-b341-53777121a501"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2755a874c4a4c48a6b849306fd2464f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMy03LTEtMS0w_3016da43-0422-4f4c-a3ff-07e6bf9aadc1"
      unitRef="usd">281783000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMTAtMS0xLTEtMA_9f7f83a9-47b9-4172-80d0-84f81cbbe804"
      unitRef="usd">281783000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMTAtMy0xLTEtMA_f92c7c8c-f3bb-4aed-9871-cceb9bff6e65"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMTAtNS0xLTEtMA_83993292-88c7-42a0-8f3f-ee484f3a6100"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RhYmxlOmM4MmQyOTAxYmQyNTRlOGZhMTJiNDdkYmU2ZWY5MWRiL3RhYmxlcmFuZ2U6YzgyZDI5MDFiZDI1NGU4ZmExMmI0N2RiZTZlZjkxZGJfMTAtNy0xLTEtMA_8af82995-1f6f-4710-8fc8-933d0a1367d7"
      unitRef="usd">281783000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5495cad7e02a4bc7ac5c026e15930a48_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMTA5OTUxMTYyODg5Nw_08a935a5-a3de-427f-8fd1-92e70e99dc17"
      unitRef="usd">100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i022b72f313384923a430318e5e44d480_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMTA5OTUxMTYyODg0Mw_3f252af2-e911-41e6-ae50-068697c03081"
      unitRef="usd">100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0f3eb84da08544e7858c671a0f89178b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMTA5OTUxMTYyODg4Nw_8036cfa9-6cbd-47d0-a65e-e13a3b751e18"
      unitRef="usd">100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i02ebc26f1dec4284a51f47f1f7bd41c8_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMTA5OTUxMTYyODg3OA_5eecf62e-ca90-4f0d-b21b-0b7ebd06d304"
      unitRef="usd">500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id696d6839c0d44a9971fc5c29b5ab6c5_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMzA3_3b16f9a5-15d6-4ac9-bc73-fd2b1ec33656"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i79c6b9595b0e45e399fbfc89434af8ba_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMzA3_9698b28d-e525-41a3-904c-5107febe1743"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3014251d4b0c415f885b37eb158bb11f_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMzA3_a7bddf5a-b42f-43cb-b85a-171a0da085bb"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie7475569334245839b63cf3cc4120cfc_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfMzA3_d0781b0c-84a7-46db-81fd-3a943e98e063"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfNTQ3_033dab22-20df-42aa-b92c-31757ae110d3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181Mi9mcmFnOjkwZTNmMWFhMTYxZjRkODk4OTJhNTMxMTU2YjNlNmJlL3RleHRyZWdpb246OTBlM2YxYWExNjFmNGQ4OTg5MmE1MzExNTZiM2U2YmVfNzYx_78b72e21-59cf-405e-b073-4731b0524583"
      unitRef="usd">0</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RleHRyZWdpb246MGZiZDY2MTA3NWU3NDlhY2E2ZjhhMTc4YjAwZTA5MDRfNjUw_b9981599-b7ae-416f-9719-97e9496f9b65">Fair Value Measurements&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as &#x201c;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201d; Fair value measurements are defined on a three level hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1 inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quoted prices for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2 inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Observable inputs other than Level&#160;1 prices, such as quoted market prices for similar assets or liabilities or other inputs that are observable or can be corroborated by market data; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3 inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable inputs that are supported by little or no market activity and require the reporting entity to develop assumptions that market participants would use when pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s financial assets that have been measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Levels 1, 2 or 3 during the three and six months ended June&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RleHRyZWdpb246MGZiZDY2MTA3NWU3NDlhY2E2ZjhhMTc4YjAwZTA5MDRfNjUx_cec8b86a-21d3-4535-9e31-f8d1466ff0a8">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s financial assets that have been measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84a310b3100843458cf7b9780be99be8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNC0yLTEtMS0w_0ba4e5f3-8b9a-4396-ad5b-3fdd6711fa51"
      unitRef="usd">201734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id74320e4faa84cd1b28ec9a625c98df5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNC00LTEtMS0w_555146fc-4c3a-42ab-8b18-0867e1a97069"
      unitRef="usd">201734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5153d021d85e4ef9b35b24ed9da916ca_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNC02LTEtMS0w_3c86449b-f5f5-4208-a7e9-e577d16a35f3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2ddd957560f42ff8203389517f59eb2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNC04LTEtMS0w_d07ae212-3382-4ea4-b7b2-93ec092cb054"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba2aa44c62434cdca9106c4f4051ff24_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNy0yLTEtMS0w_f71e146b-e8ed-4bc7-bbca-86a7ec0fb0b5"
      unitRef="usd">201734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5581113f5e084f04997d0355ded32b7d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNy00LTEtMS0w_5d41377f-0be1-4f2d-8791-aab797d33196"
      unitRef="usd">201734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4033291bd05c46c28d615917d2bf3476_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNy02LTEtMS0w_3cedb1c3-8ee0-4ffe-acba-f44af45187d7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b50f26d3c4740b19924787f56195caa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfNy04LTEtMS0w_acd6395a-d0f3-4beb-bea1-69a6da956549"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i17ff88d17c8f4135932357759e2c4415_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTAtMi0xLTEtMA_0b546081-f01a-4541-b929-ad116bcabeea"
      unitRef="usd">281783000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a555aa890154f02bec9878d09c55db6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTAtNC0xLTEtMA_fb6fde34-162d-4935-ae22-f0881de6409a"
      unitRef="usd">281783000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06a780031e57403b91a7034227c9bdaf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTAtNi0xLTEtMA_7e34cdf1-8ea2-4bec-8811-6b03924e1271"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i559c63b8c37f45c191813cedafe6679c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTAtOC0xLTEtMA_77ba08b6-5f7f-4ead-b90a-f43b6c7f34b0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0655536ac5664cfc9f50beaeae40a963_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTUtMi0xLTEtMA_4d9901ad-c379-4cbf-b509-d94d78e64e9f"
      unitRef="usd">281783000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if9c5f735fcfc445e88a0357b3cff80ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTUtNC0xLTEtMA_355bea3e-8ddc-4855-993d-30bfd5cd3b4d"
      unitRef="usd">281783000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66085bd7806540ba8c194ce5c0187acd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTUtNi0xLTEtMA_e70c3d7c-73ac-46a9-b5d3-97deea7151b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a9b0a5e5b1d4b328310765a841beb27_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181NS9mcmFnOjBmYmQ2NjEwNzVlNzQ5YWNhNmY4YTE3OGIwMGUwOTA0L3RhYmxlOmRlMzUyN2MxODI4MDRlNjg4YWQ1ZGM4MTgzMmE2YzZlL3RhYmxlcmFuZ2U6ZGUzNTI3YzE4MjgwNGU2ODhhZDVkYzgxODMyYTZjNmVfMTUtOC0xLTEtMA_91050aa6-976c-40bb-939c-50f7f2451284"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNzA3Nw_a1137b40-5ded-4a32-a45d-fcf676936f92">Liability Related to the Revenue Interest Purchase AgreementOn June 26, 2019, the Company entered into a RIPA with Oberland, as agent for purchasers party thereto (the &#x201c;Purchasers&#x201d;), and the Purchasers named therein, to obtain financing in respect to the commercialization and further &lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development of bempedoic acid and the bempedoic acid / ezetimibe combination tablets and other working capital needs. Pursuant to the RIPA, the Company received $125.0 million at closing, less certain issuance costs. The Company was also entitled to receive up to approximately $75.0 million in subsequent installments subject to the terms and conditions set forth in the RIPA: (i) $25.0 million upon certain regulatory approval of its product candidates and (ii) $50.0 million, at the Company&#x2019;s option, upon reaching $100.0 million trailing worldwide six-month net sales any time prior to December 31, 2021 (the &#x201c;Third Payment&#x201d;). In March 2020, the Company received $25.0 million from Oberland upon receiving regulatory approval of NEXLETOL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the &#x201c;Revenue Interests&#x201d;) from the Company based upon net sales of the Company&#x2019;s certain products which will be tiered payments initially ranging from 2.5% to 7.5% of the Company&#x2019;s net sales in the covered territory (the &#x201c;Covered Territory&#x201d;); provided that (a) if annual net sales equal or exceed $350.0 million by December 31, 2021 (the &#x201c;Sales Threshold&#x201d;), the initially tiered revenue interest rate will be decreased to a single rate of 2.5% of the Company&#x2019;s net sales in the Covered Territory, beginning on January 1, 2022, and (b) if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024, the revenue interest rate will be decreased to a single rate of 0.4% of the Company&#x2019;s net sales in the Covered Territory beginning on January 1, 2025. If the Third Payment is drawn down by the Company, the applicable royalty rates will increase by one-third. The Covered Territory is the United States, but is subject to expand to include the world-wide net sales if the Company&#x2019;s annual U.S. net sales are less than $350.0 million for the year ended December 31, 2021. The U.S. net sales milestone thresholds are not to be taken as financial guidance. The Purchasers&#x2019; rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received Revenue Interests payments of 195% of the then aggregate purchase price (the &#x201c;Cumulative Purchaser Payments&#x201d;) paid to the Company, unless the RIPA is terminated earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the RIPA, the Company has an option (the &#x201c;Call Option&#x201d;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#x201c;Put Option&#x201d;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option is exercised prior to the first anniversary of the closing date by the Purchasers (except pursuant to a change of control), the required repurchase price will be 120% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests). In all other cases, if the Put Option or the Call Option are exercised, the required repurchase price will be 175% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 195% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the RIPA contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RIPA Amendments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 26, 2021, the Company entered into Amendment No. 2 (the &#x201c;RIPA Amendment&#x201d;) to the RIPA with Oberland, as agent for the purchaser parties thereto. Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50&#160;million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA such that the purchasers will have a right to receive certain revenue interests (the &#x201c;Revenue Interests&#x201d;) from the Company based on net sales of the Company&#x2019;s certain products, once approved, which will be tiered payments ranging from 3.33% to 10% (the &#x201c;Third Payment Applicable Percentage&#x201d;) of the Company&#x2019;s net sales in the covered territory (the &#x201c;Covered Territory&#x201d;); provided that (a) prior to December 31, 2024, with respect to each country defined in the Daiichi Territory, if the percentage of net sales that Company receives from Daiichi (the &#x201c;Receivables Percentage&#x201d;) is less than the Third Payment Applicable Percentage, then the Revenue Interest for such country payable to the purchasers will be equal to the Receivables Percentages, (b) if annual net sales equal or exceed $350&#160;million and if the Purchasers receive 100% of their invested capital (&lt;br/&gt;Cumulative Purchaser Payments") by December 31, 2024, the revenue interest rate will be decreased to a single rate of 3.33% of the Company&#x2019;s net sales in the Covered Territory for all subsequent calendar quarters and (c) if the Purchasers receive Revenue Interest payments less than 100% of Cumulative Purchaser Payments by December 31, 2024, the Third Payment Applicable Percentage will be increased to a single rate of the Company&#x2019;s net sales that would have provided 100% of Cumulative Purchaser Payments had such rate applied from the initial funding by the Purchasers. The Covered Territory was originally the United States, but has been expanded to worldwide for all calendar years beginning on or after January 1, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the RIPA, the Company has an option (the &#x201c;Call Option&#x201d;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#x201c;Put Option&#x201d;) to terminate &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price will be 200% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 470&#x2011;50, &#x201c;Debt&#x2014;Modifications and Extinguishments,&#x201d; the RIPA Amendment was accounted for as a debt modification. The amendment resulted in a $0.1&#160;million loss on modification of debt, consisting of third-party fees associated with the transaction, which is included in selling, general, and administrative expenses in the statements of operations for the three and six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2021, the Company entered into an Amendment to the Security Agreement and Waiver ("Amendment and Waiver") with the same parties to the Security Agreement, by and among the Company, Eiger Partners II LP (the "Purchaser") and Eiger III SA LLC (the "Purchaser Agent"), dated as of June 26, 2019 (the "Security Agreement"). Pursuant to the Amendment and Waiver, if (i) the net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States (as reported in the Company&#x2019;s financial statements as &#x201c;product sales, net&#x201d; in accordance with GAAP and excluding, for the avoidance of doubt, upfront or milestone payments and other collaboration revenue) (the &#x201c;Specified Net Revenue&#x201d;) for the calendar quarter ending September 30, 2021 does not exceed $15.0 million, or (ii) the Specified Net Revenue for any calendar quarter ending after September 30, 2021 does not exceed $15.0 million, then the Company shall deposit $50.0 million in a deposit account that is subject to a block account control agreement in favor of the Purchase Agent, no later than the earlier of (x) the date the Specified Net Revenue for such calendar quarter has been determined and (y) 45 days after the last day of such calendar quarter. The Purchaser Agent shall have sole dominion and control over all funds deposited in the deposited account and such funds may be withdrawn therefrom only with the consent of the Purchaser Agent. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to apply amounts held in the deposit account in payment of certain secured obligations in the manner provided for in the Security Agreement. The Amendment and Wavier does not substitute, replace or release the Pledgors from any other obligations under the RIPA or Security Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the arrangement, as of June&#160;30, 2021, the Company has recorded a liability, referred to as the &#x201c;Revenue interest liability&#x201d; in the condensed balance sheets, of $238.2 million, net of $0.5 million of capitalized issuance costs in connection with the RIPA. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The Company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant increase or decrease in net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. The Company recorded approximately $8.0&#160;million and $12.9&#160;million in interest expense related to this arrangement for the three and six months ended June&#160;30, 2021, and $4.6&#160;million and $8.8&#160;million for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The repayment of the RIPA to Oberland does not have a fixed repayment schedule, rather it will be completely repaid and extinguished when the Company has repaid 200% of the aggregate purchase price prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments thereafter, unless the RIPA is terminated earlier. Since there is not a fixed repayment schedule, the Company does not project its future repayments by year. Each period, the Company estimates the future expected sales of its products in the covered territory and determines the effective annual imputed interest rate, which updates and changes the timing of the Company&#x2019;s payments. Under the terms of the agreement, every $100&#160;million of net sales generated, less than or equal to $250&#160;million in an annual aggregate year, would result in a repayment obligation of approximately $10.0&#160;million or 10.0% at the stated repayment rate in the first year. Annual Net Sales for a calendar year exceeding $250&#160;million would result in a repayment obligation of approximately $3.3&#160;million or 3.3% for every $100&#160;million of sales above the threshold. If the Company equals or exceeds $350&#160;million of sales in the U.S. in 2021, then the repayment amount would drop to $3.3&#160;million for every $100&#160;million of net sales starting in 2022. If the US net sales are less than $350&#160;million for the year ended December 31, 2021, then the Covered Territory is expanded to include worldwide sales beginning in 2022. The Company&#x2019;s repayments of the RIPA are directly tied to the growth of its net sales, and as the Company&#x2019;s net sales grow, the Company expects the related repayments of the RIPA to grow as well. The Company currently expects to repay $12.5&#160;million in the next twelve months.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective annual imputed interest rate is 17.2% as of June&#160;30, 2021. The Company incurred $0.6 million of issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. Payments made to Oberland as a result of the Company&#x2019;s net sales will reduce the revenue interest liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue interest liability activity during the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue interest liability at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&#160;Oberland funding upon execution of Amendment No. 2, net of issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Interests payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue interest liability at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock>
    <espr:GrossProceedsFromRevenueInterestPurchaseAgreement
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDU1_c62145fa-9036-461e-aca9-7d520a6eb0ab"
      unitRef="usd">125000000.0</espr:GrossProceedsFromRevenueInterestPurchaseAgreement>
    <espr:AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTU5_6b0c8cbd-e569-484d-9a01-b51d39475d80"
      unitRef="usd">75000000.0</espr:AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions>
    <espr:AmountOfSubsequentInstallmentSubjectToRegulatoryApproval
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjUy_f5491952-f766-4a15-9bec-a886bbc0cc53"
      unitRef="usd">25000000.0</espr:AmountOfSubsequentInstallmentSubjectToRegulatoryApproval>
    <espr:AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNzIz_3010fb34-4910-4864-a753-39ee978e5053"
      unitRef="usd">50000000.0</espr:AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold>
    <espr:MilestoneAmountForWorldwideSalesToReceiveThirdPayment
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNzY2_15e142d4-9ff0-40cc-a342-19bd6d990722"
      unitRef="usd">100000000.0</espr:MilestoneAmountForWorldwideSalesToReceiveThirdPayment>
    <espr:ProceedsFromRevenueInterestPurchaseAgreement
      contextRef="i3fefac52cc164b6e8c114422d7b945c7_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfOTAz_96237c78-aa27-4458-8ad0-160ad2765058"
      unitRef="usd">25000000.0</espr:ProceedsFromRevenueInterestPurchaseAgreement>
    <espr:RevenueInterestRateTierTwo
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTIyMA_5768c298-4c8d-4ec0-8d1d-d5e77c04e9b3"
      unitRef="number">0.025</espr:RevenueInterestRateTierTwo>
    <espr:RevenueInterestRateInitialRate
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTIyNg_da12a8b3-880b-4af1-84f2-931b55ed894e"
      unitRef="number">0.075</espr:RevenueInterestRateInitialRate>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTM2Mg_541db255-2798-4007-a16c-e5a3b09f60cd"
      unitRef="usd">350000000.0</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate>
    <espr:RevenueInterestRateTierTwo
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTQ5Mg_01aa3963-2530-4ebb-b57e-bff86751491b"
      unitRef="number">0.025</espr:RevenueInterestRateTierTwo>
    <espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTY3Mg_d1047e61-bd44-48bb-9c9d-3aacdc6e935b"
      unitRef="number">1</espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate>
    <espr:RevenueInterestRateTierThree
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTc4Nw_5bf66a40-c10a-46de-af80-8d2cb107bfa3"
      unitRef="number">0.004</espr:RevenueInterestRateTierThree>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMjEzOA_760167d8-f7eb-449d-a8ad-6fcf37210c96"
      unitRef="usd">350000000.0</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMjQxNA_bcc71e15-91e4-4099-b26c-76e76fc52cca"
      unitRef="number">1.95</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMzE3Nw_c2526fb9-70b1-4b57-9ff5-5e985ac3ecd3"
      unitRef="number">1.20</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMzQyNQ_2adde6a2-5bae-4f91-9dea-e7e9dd954678"
      unitRef="number">1.75</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMzY0Nw_6b23dd36-fb43-4c9e-95be-89d7cd9e3e26"
      unitRef="number">1.95</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised>
    <espr:ProceedsFromRevenueInterestPurchaseAgreement
      contextRef="i3e34a6464b9342eab9af91553cce8a2c_D20210426-20210426"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0NzM4MA_9a98eab1-e6a1-4291-9c9a-56efe399da17"
      unitRef="usd">50000000</espr:ProceedsFromRevenueInterestPurchaseAgreement>
    <espr:RevenueInterestRateTierTwo
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0Nzc1NA_3162db05-ca2b-4a26-89e4-52f14fd60c35"
      unitRef="number">0.0333</espr:RevenueInterestRateTierTwo>
    <espr:RevenueInterestRateInitialRate
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0Nzc2MQ_937ba7c9-5943-40d9-8dc1-602f95232528"
      unitRef="number">0.10</espr:RevenueInterestRateInitialRate>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0ODMwNw_7287b1e5-5859-4b51-90a8-799508053cd0"
      unitRef="usd">350000000</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold>
    <espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0ODM0MQ_aa27502a-3c13-4a69-9def-28343f8fd44b"
      unitRef="number">1</espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate>
    <espr:RevenueInterestRateTierTwo
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0ODQ1Nw_65083a07-c9b0-47de-8251-8cc787fcacb8"
      unitRef="number">0.0333</espr:RevenueInterestRateTierTwo>
    <espr:PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NTQ2Mw_bee654d1-bccf-4996-b128-115731955438"
      unitRef="number">1</espr:PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage>
    <espr:PercentageOfCumulativePurchaserPaymentsGuarantee
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NTQ2OQ_8bad2bf0-8c4d-458d-bd3a-0f5e1341c19f"
      unitRef="number">1</espr:PercentageOfCumulativePurchaserPaymentsGuarantee>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0OTI1NA_7e105283-3ba0-4b3e-98d0-ae16a1bf9cc7"
      unitRef="number">2</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY0OTQ3Nw_1980e211-3855-47d4-be9d-f1231d19ff60"
      unitRef="number">2.25</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="i1e0952b04e3e49f89edda6732c584442_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NjU0OQ_4803522d-6912-47ef-a316-8ad26004b32f"
      unitRef="usd">-100000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="i2090d9c5d7cd408393dabbb49aef53e9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NjU0OQ_c9069bc9-0bbb-422b-b2c7-99a54abd0bc3"
      unitRef="usd">-100000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount
      contextRef="if3a49799960046fabd41ee94341b6178_D20210516-20210516"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY1MTAzMA_18277cb9-279b-4bac-9e87-f73d533200fa"
      unitRef="usd">15000000.0</espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount>
    <espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount
      contextRef="if3a49799960046fabd41ee94341b6178_D20210516-20210516"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY1MTE0Mg_1edd7856-8a4e-402a-92e4-d1c55d41d8b7"
      unitRef="usd">15000000.0</espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount>
    <espr:BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold
      contextRef="if3a49799960046fabd41ee94341b6178_D20210516-20210516"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY1MTE3OA_c4e77bc2-eb04-4b71-9d4d-a21b268ccd28"
      unitRef="usd">50000000.0</espr:BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold>
    <espr:RevenueInterestLiability
      contextRef="i28e0c72e2cb9467a8d1097badc2d555d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDIxMw_9331bdc8-a90d-485f-adf9-6e04a7118b93"
      unitRef="usd">238200000</espr:RevenueInterestLiability>
    <espr:UnamortizedTransactionCostsOnRevenueInterestAgreement
      contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDIyNA_696c5d9f-7ace-4a70-b8e3-28a29a16c238"
      unitRef="usd">500000</espr:UnamortizedTransactionCostsOnRevenueInterestAgreement>
    <us-gaap:InterestExpense
      contextRef="i82b18040c5994d5fb1c1230a7479649f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDM5ODA0NjUzNjI4OQ_877b2389-3308-49fb-8ac1-fee5d9285152"
      unitRef="usd">8000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNDM5ODA0NjUzNjMxNw_b86f3f37-94a2-4762-9f90-a666a8a8a242"
      unitRef="usd">12900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib5fa732b89bf4e608cb020cdbaed049c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NjY1Ng_f6b58b3d-8c7f-4dcf-8cad-e9652c5d5bd2"
      unitRef="usd">4600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i314c65622530486bbc90177fa464e9a2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTQ5NzU1ODE2NjY3MA_fbc39b78-a754-4c00-8179-82f2246425ed"
      unitRef="usd">8800000</us-gaap:InterestExpense>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised
      contextRef="i682526a2d76f4aad9318435409bd1702_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTI5Mg_b4fffa07-bc05-46bb-a6ad-11a867c0962e"
      unitRef="number">2</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised
      contextRef="i4efa02bff686461abcceaa2242640380_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfMTA5OTUxMTY1MjQ2OA_1980e211-3855-47d4-be9d-f1231d19ff60"
      unitRef="number">2.25</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised>
    <espr:HypotheticalSalesGeneratedAmount
      contextRef="i54599248558d4aeabaada2313141952a_D20190626-20190626"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTczOA_ccaacd57-fda0-486c-bbba-c6a0ef66ad94"
      unitRef="usd">100000000</espr:HypotheticalSalesGeneratedAmount>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate
      contextRef="i54599248558d4aeabaada2313141952a_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTc4Nw_86b4f9e0-5cbc-4c7f-8cda-8876d19ae22b"
      unitRef="usd">250000000</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate>
    <espr:HypotheticalRepaymentObligationBasedOnSalesGenerated
      contextRef="i24cc2d3d09bf4804b7ebe4fcf96e4159_I20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTg3NQ_0de68dfd-4331-4a50-8b12-8329998fb570"
      unitRef="usd">10000000.0</espr:HypotheticalRepaymentObligationBasedOnSalesGenerated>
    <espr:RevenueInterestRateInitialRate
      contextRef="i54599248558d4aeabaada2313141952a_D20190626-20190626"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTg4MQ_63810f10-47b5-498e-9532-ea1946447ea0"
      unitRef="number">0.100</espr:RevenueInterestRateInitialRate>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate
      contextRef="i2b2993300957480c8da25fe45a53a602_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNTk3OQ_2aba5305-b67d-4fe5-80a0-241c243d0b93"
      unitRef="usd">250000000</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate>
    <espr:HypotheticalRepaymentObligationBasedOnSalesGenerated
      contextRef="i61206dad37874474a095378d715c7ddc_I20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjAzOA_6a1da402-90ba-4a91-8ae3-906f1655a892"
      unitRef="usd">3300000</espr:HypotheticalRepaymentObligationBasedOnSalesGenerated>
    <espr:RevenueInterestRateTierTwo
      contextRef="i2b2993300957480c8da25fe45a53a602_D20190626-20190626"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjA0NA_b1be8964-06ba-4694-8c97-0f7671f42197"
      unitRef="number">0.033</espr:RevenueInterestRateTierTwo>
    <espr:HypotheticalSalesGeneratedAmount
      contextRef="i2b2993300957480c8da25fe45a53a602_D20190626-20190626"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjA1Nw_ce7d93fc-0ada-4525-9698-75280011c6da"
      unitRef="usd">100000000</espr:HypotheticalSalesGeneratedAmount>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate
      contextRef="i3168451b6e8043e7a8c693b76d15d0bb_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjEyMw_0881d388-356a-4923-b920-d0816b2b7e94"
      unitRef="usd">350000000</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate>
    <espr:HypotheticalRepaymentObligationBasedOnSalesGenerated
      contextRef="i151f5743662f4d9b94b53d5f3aebdc7b_I20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjE5Ng_4ed7c9ae-5fdb-41d8-8f2a-bbc70ea8273d"
      unitRef="usd">3300000</espr:HypotheticalRepaymentObligationBasedOnSalesGenerated>
    <espr:HypotheticalSalesGeneratedAmount
      contextRef="i3168451b6e8043e7a8c693b76d15d0bb_D20190626-20190626"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjIwOQ_7064b6a5-06d1-4a8c-ac11-82fb1b5ef92f"
      unitRef="usd">100000000</espr:HypotheticalSalesGeneratedAmount>
    <espr:NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjI3Nw_c1feeb13-6ca9-418f-aeca-5d8c20871d38"
      unitRef="usd">350000000</espr:NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory>
    <espr:RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths
      contextRef="i519246cc64e94185973aeceecf9b0714_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjYzOA_0c6daf1a-5a73-43e7-ba1a-571d840e5a7e"
      unitRef="usd">12500000</espr:RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths>
    <espr:RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate
      contextRef="if16e161500f14c968dff53d7b2d6a4eb_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjcxNg_e63b3bfd-5041-46b6-b23a-6c306995eed0"
      unitRef="number">0.172</espr:RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate>
    <espr:UnamortizedTransactionCostsOnRevenueInterestAgreement
      contextRef="i8270d1b3c55144f89957352d194e823b_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNjc1MA_d0f97d5f-361e-4145-9ecd-e1c2386af849"
      unitRef="usd">600000</espr:UnamortizedTransactionCostsOnRevenueInterestAgreement>
    <espr:ScheduleOfRevenueInterestLiabilityTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RleHRyZWdpb246NTIxODY0NGI2ZDU5NDMxNGE3YmVmOTNkZWNmYjI2MWRfNzA3OA_31fabf6b-4d61-4c49-baa8-c2dd832d160c">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue interest liability activity during the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue interest liability at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&#160;Oberland funding upon execution of Amendment No. 2, net of issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Interests payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue interest liability at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</espr:ScheduleOfRevenueInterestLiabilityTableTextBlock>
    <espr:RevenueInterestLiability
      contextRef="if04054e50e094fd9b83c8ea7d483bcc9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfMS0xLTEtMS0w_ef8b85fb-a945-4d1e-a7bc-334c0e8c56ae"
      unitRef="usd">176604000</espr:RevenueInterestLiability>
    <espr:RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts
      contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfMi0xLTEtMS0w_65235df9-29cf-420d-b75e-e6023b13e830"
      unitRef="usd">49917000</espr:RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts>
    <espr:RevenueInterestLiabilityIncreaseForInterestExpenseRecognized
      contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfMy0xLTEtMS0w_9e5529d3-f48f-401d-b8d8-9e4b3603f07f"
      unitRef="usd">12865000</espr:RevenueInterestLiabilityIncreaseForInterestExpenseRecognized>
    <espr:PaymentsFromRevenueInterestPurchaseAgreement
      contextRef="i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfNC0xLTEtMS0w_8754821c-5fc1-404a-9b4f-2af7a726e378"
      unitRef="usd">1155000</espr:PaymentsFromRevenueInterestPurchaseAgreement>
    <espr:RevenueInterestLiability
      contextRef="i28e0c72e2cb9467a8d1097badc2d555d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N181OC9mcmFnOjUyMTg2NDRiNmQ1OTQzMTRhN2JlZjkzZGVjZmIyNjFkL3RhYmxlOjdjNGVjYWMzOWE0MTRiMDk5ZTY4YWQ2MzhkOTAzMTBjL3RhYmxlcmFuZ2U6N2M0ZWNhYzM5YTQxNGIwOTllNjhhZDYzOGQ5MDMxMGNfNS0xLTEtMS0w_b98d12d8-5f95-46ca-8fab-b7190521d9eb"
      unitRef="usd">238231000</espr:RevenueInterestLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTIxNzU_5263b05e-8f16-4c37-9c2a-410798062879">Convertible Notes&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 16, 2020, the Company issued $250.0&#160;million aggregate principal amount of 4.0% senior subordinated convertible notes due November 15, 2025. The net proceeds the Company received from the offering of the initial notes was approximately $242.0&#160;million, after deducting the initial purchasers&#x2019; discounts and commissions and offering expenses payable by the Company. In connection with the offering of the senior subordinated convertible notes, the Company granted the initial purchasers of the senior subordinated convertible notes a 30-day option to purchase up to an additional $30.0&#160;million aggregate principal amount of the senior subordinated convertible notes on the same terms and conditions. On November 18, 2020 the option was exercised, which resulted in approximately $29.1&#160;million of additional proceeds, for total aggregate principal of $280.0&#160;million and net proceeds of $271.1&#160;million (the additional notes and, together with the initial notes, collectively called the &#x201c;Convertible Notes&#x201d;). The Company used approximately $46.0&#160;million of the net proceeds from the offering of the notes to pay the cost of the Capped Call (as defined below) and $55.0&#160;million of the net proceeds from the offering of the initial notes to finance the Prepaid Forward (as defined below). The Convertible Notes are the Company's senior unsecured obligations and mature on November 15, 2025 (the &#x201c;Maturity Date&#x201d;), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Convertible Notes are convertible into shares of the Company&#x2019;s common stock, can be repurchased for cash, or a combination thereof, at the Company&#x2019;s election, at an initial conversion rate of 30.2151 shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $33.096 per share of common stock, subject to adjustment. The Company will pay interest on the Convertible Notes semi-annually in arrears on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Convertible Notes are general unsecured obligations of the Company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the Company&#x2019;s RIPA, the revenue interests issued pursuant to such agreement, and any refinancing of the foregoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2025 in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended on March 31, 2021 (and only during such calendar quarter), if the last reported sale price per share of the Company&#x2019;s common stock, par value $0.001 per share (&#x201c;common stock&#x201d;), is greater than or equal to 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five business days after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company&#x2019;s common stock and the conversion rate for the notes on each such trading day; (3) if the Company calls such notes for redemption, any such notes that have been called for redemption may be converted at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption; and (4) upon the occurrence of specified corporate events, as provided in the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after August 15, 2025, to the close of business on the second scheduled trading day immediately before the maturity date, holders may convert all or any portion of their notes at the applicable conversion rate at any time at the option of the holder regardless of the foregoing conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, following certain corporate events or following issuance of a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;corporate event or to convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Convertible Notes will be redeemable, in whole or in part, at the Company&#x2019;s option at any time, and from time to time, on or after November 20, 2023 and before the 41st scheduled trading day immediately before the maturity date, at a cash redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company&#x2019;s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date the Company sends the related redemption notice, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company sends such redemption notice. No sinking fund is provided for the notes. If the Company redeems less than all the outstanding notes, at least $125.0&#160;million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a &#x201c;fundamental change&#x201d; (as defined in the Indenture), holders may require the Company to repurchase their notes for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. The Indenture includes customary terms and covenants, including certain events of default.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred approximately $8.9&#160;million of issuance costs related to the issuance of the Convertible Notes, of which, prior to the adoption of ASU 2020-06 on January 1, 2021, $5.8&#160;million and $3.1&#160;million were allocated and recorded to long-term debt and additional paid-in capital, respectively. The $5.8&#160;million of issuance costs recorded as long-term debt on the condensed balance sheet are amortized over the five-year contractual term of the Convertible Notes using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the adoption of ASU 2020-06 on January 1, 2021, the $271.1&#160;million of proceeds received from the issuance of the Convertible Notes were allocated between long-term debt (the &#x201c;liability component&#x201d;) of $177.6&#160;million and additional paid-in capital (the &#x201c;equity component&#x201d;) of $93.5&#160;million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Convertible Notes and was included in additional paid-in capital in the condensed balance sheet and was not remeasured as long as it did not to meet the conditions for equity classification. The liability component was to be accreted up to the face value of the Convertible Notes of $280.0&#160;million, which resulted in additional non-cash interest expense being recognized through the Maturity Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the adoption of ASU 2020-06 as of January 1, 2021, the Company reports the convertible debt liability at the aggregate principal amount less unamortized issuance costs. This resulted in the reclassification of the $93.5&#160;million of the Company&#x2019;s convertible notes recognized at December 31, 2020 from additional paid in capital to the convertible debt liability. The portion of interest expense previously recognized for the accretion of the convertible debt liability and the true-up of the amortization of the issuance costs of $1.5&#160;million was recorded as an adjustment to accumulated deficit.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarizes the outstanding principal and debt issuance cost balances as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible note, debt balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible notes, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to net principal due to adoption of ASU 2020-06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded $3.2&#160;million and $6.4&#160;million of interest expense during the three and six months ended June&#160;30, 2021, relating to the cash interest on the convertible notes due semi-annually and amortization of the debt issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, no Convertible Notes were convertible pursuant to their terms. The estimated fair value of the Convertible Notes was $233.6&#160;million and $283.4&#160;million as of June&#160;30, 2021 and December 31, 2020, respectively. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. As of June&#160;30, 2021 and December 31, 2020, the if-converted value of the Convertible Notes did not exceed the principal value of those notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capped Call Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the offering of the Convertible Notes, the Company entered into privately-negotiated capped call transactions with one of the initial purchasers of the convertible notes or its affiliate and certain other financial institutions. The Company used approximately $46.0&#160;million of the net proceeds from the offering of the Convertible Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce potential dilution to the Company&#x2019;s common stock upon any conversion of the Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, in the event that the market value per share of the Company&#x2019;s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the Convertible Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $55.16 (which represents a premium of approximately 100% over the last reported sale price of the Company&#x2019;s common stock on November 11, 2020), subject to certain adjustments. The capped call transactions are separate transactions, entered into by the Company and are not part of the terms of the Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given that the transactions meet certain accounting criteria, the convertible note capped call transactions are recorded in stockholders&#x2019; equity, and they are not accounted for as derivatives and are not remeasured each reporting period. As of June&#160;30, 2021 and December 31, 2020, the Company had not purchased any shares under the convertible note capped call transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prepaid Forward&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the offering of the Convertible Notes, the Company entered into a prepaid forward stock repurchase transaction (&#x201c;Prepaid Forward&#x201d;) with a financial institution (&#x201c;Forward Counterparty&#x201d;). Pursuant to the Prepaid Forward, the Company used approximately $55.0&#160;million of the net proceeds from the offering of the Convertible Notes to fund the Prepaid Forward. The aggregate number of shares of the Company&#x2019;s common stock underlying the Prepaid Forward was approximately 1,994,198. The expiration date for the Prepaid Forward is November 15, 2025, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders&#x2019; votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company&#x2019;s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjc_0d1c59a1-029e-47b4-b2c5-3ec7eb14867d"
      unitRef="usd">250000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTAw_3e35ae1e-74c9-49ea-9a2d-cbc2d58eff62"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjU5_9604e8f2-f1c7-46f9-8208-b7f3c25a058c"
      unitRef="usd">242000000.0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <espr:DebtInstrumentAdditionalAmount
      contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNTg5_0583a86f-dd45-4940-878e-2f87abb63f81"
      unitRef="usd">30000000.0</espr:DebtInstrumentAdditionalAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="iabdf33924b4c4632935947223d1b399b_D20201118-20201118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNzc3_b5583f83-f518-407c-b990-1d79a7fe8967"
      unitRef="usd">29100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i1e05ade79f0c4479b2b0adfc5aab22f0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfODM3_3b2dacad-8e96-44d7-afd8-e0dd1b36bcae"
      unitRef="usd">280000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i1e05ade79f0c4479b2b0adfc5aab22f0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfODYw_8eb35a67-ab85-4323-9d11-f5258f2587d4"
      unitRef="usd">271100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTAwMA_220feb3b-5aca-44ab-bccb-2f6c7b5b0b2f"
      unitRef="usd">46000000.0</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTExMg_e34d7f2f-3c41-47ff-99a3-97021cc83554"
      unitRef="usd">55000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTY1OA_e26e9400-02d0-4679-b61b-1b4fe1d93ff6"
      unitRef="number">30.2151</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTgwNg_c26b99a5-299d-498c-a4d7-2601c89a1cf4"
      unitRef="usdPerShare">33.096</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ieab74430e0d740e2b4be6f36bf9d3cf3_I20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjY3Ng_7dd3b98d-051a-49b5-8882-711ff77dbadb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjczNQ_2cd8ae41-5562-4022-a0d2-ae8de37c6135"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjc4Mw_da927341-3d89-419c-b644-b29746922974"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjgzOQ_95739343-c9d7-412c-9e94-a5ab583b9d72"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <espr:NumberOfBusinessDays
      contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMjk3Ng_5310a771-1d55-46ea-81d5-cd69a8e5e63d"
      unitRef="day">5</espr:NumberOfBusinessDays>
    <espr:NumberOfConsecutiveTradingDays
      contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMzAwMw_246f1ec0-963b-4294-a3cf-00bc5da0facf"
      unitRef="day">5</espr:NumberOfConsecutiveTradingDays>
    <espr:NumberOfConsecutiveTradingDays
      contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMzA0Mw_e7927a01-9b47-46fb-91e6-5ed8b1370626"
      unitRef="day">5</espr:NumberOfConsecutiveTradingDays>
    <espr:DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice
      contextRef="i57fb06b778944c5abc8cd12ce2867f89_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMzIyOQ_69a4e89a-2d39-4cf6-b30f-a1d1048c4fd3"
      unitRef="number">0.98</espr:DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNDcxOA_4de82f2e-7748-4512-9442-49ecd2129fab"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNDkxNQ_7d50ffa9-fc6f-4991-ab9a-ca884c3f62b0"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNDk3MA_9cf5a5de-155f-461c-8899-983835f0b2db"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i7069b4456781431ab2d79c7481d14d9b_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNTEzMw_2fdfec84-1253-405a-b4ef-5111b6df458d"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <espr:DebtInstrumentCovenantRequiredAmountOutstanding
      contextRef="i2c80fd5162dd43bcb17ca0bfc7e60a2b_I20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNTQwMw_222990a2-b561-41c1-8c5d-bfe9cf518953"
      unitRef="usd">125000000.0</espr:DebtInstrumentCovenantRequiredAmountOutstanding>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNTc2NQ_7ae69840-6229-4e43-8467-a98bc1f54af0"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjA0Mw_fc3cc4e3-b21f-4b40-b157-d8e069302020"
      unitRef="usd">8900000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i8f1d759f487848f983aa3b9b0cfed648_I20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjE4MQ_dbb570c2-1a17-4b97-87aa-d62fe007e35c"
      unitRef="usd">5800000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i220604fdf4934041957bde86b350d102_I20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjE4OA_be205d3d-dcf6-4fa2-9730-1e71ba282de5"
      unitRef="usd">3100000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i8f1d759f487848f983aa3b9b0cfed648_I20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjI4Nw_be38b466-8dc1-4aed-9166-dd2bdafcdedf"
      unitRef="usd">5800000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentTerm
      contextRef="if78fe7409fb44c45b340cbe6762f1aad_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTIxNzY_e5a19cf2-1aca-421b-8d52-1f6ad9408621">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i1e05ade79f0c4479b2b0adfc5aab22f0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjUzOA_ceebdd58-6307-4e7e-a8cd-8ccb2b5d4641"
      unitRef="usd">271100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:LongTermDebt
      contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjY3NA_691ee1e4-622f-4501-871d-6103ea562e8c"
      unitRef="usd">177600000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i12b40d1dbb7343eba7ae5e7bd91ea790_I20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNjczNg_0772c6f5-718c-4778-a787-7765c3204b69"
      unitRef="usd">93500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia9f7b2751cd04b7cba61f5f9cda15259_I20201118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNzM0OA_43923030-1540-4bab-84ab-ab7c314f7a97"
      unitRef="usd">280000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i24321e9e8f7543f590713d54993c4653_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNzY3MQ_aef81c25-f469-485e-8697-aa02df8bff1a"
      unitRef="usd">-93500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i24321e9e8f7543f590713d54993c4653_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfNzk3NQ_0de5e827-28b3-477b-859f-9a5d65b0c8c9"
      unitRef="usd">-1500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTIxNzc_4cc3952f-f6c4-42a0-84d6-cecc15daf48e">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarizes the outstanding principal and debt issuance cost balances as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible note, debt balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible notes, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to net principal due to adoption of ASU 2020-06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibe5a302bf0ef4a2ca9960e5cd3087195_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMS0xLTEtMS0w_1473db34-9b22-44bb-96bf-c60141986011"
      unitRef="usd">185100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ibe5a302bf0ef4a2ca9960e5cd3087195_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMS0yLTEtMS0w_897598dc-4074-4b31-90bc-e58d9322a93e"
      unitRef="usd">5733000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="ibe5a302bf0ef4a2ca9960e5cd3087195_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMS0zLTEtMS0w_4475fda7-f909-4e3b-aa7a-4b4e12a96b3c"
      unitRef="usd">179367000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2d4607f308bc47208a506b88c7eb9aa4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMi0xLTEtMS0w_04af6d86-ed7d-4b43-a2f2-87632e818b6a"
      unitRef="usd">94900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i2d4607f308bc47208a506b88c7eb9aa4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMi0yLTEtMS0w_d4cbc53f-bf32-4f7c-9dad-6a7469e9ba35"
      unitRef="usd">2973000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i2d4607f308bc47208a506b88c7eb9aa4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMi0zLTEtMS0w_303d39ac-231c-466e-91b0-ea4d976b107e"
      unitRef="usd">91927000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i975b21eabca94d14af546e0ab124bf30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMy0xLTEtMS0w_0850bac5-1444-4a8c-a063-42613008aea3"
      unitRef="usd">280000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i975b21eabca94d14af546e0ab124bf30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMy0yLTEtMS0w_1e14c4e0-52b0-4d38-b602-6d1dbe937b6e"
      unitRef="usd">8706000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i975b21eabca94d14af546e0ab124bf30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfMy0zLTEtMS0w_53232416-f72b-4a25-984f-bd766425beac"
      unitRef="usd">271294000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic1d9db700df64698bb10be3cd5969a2d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNC0xLTEtMS0w_33ab6183-6861-4465-911f-ef3ca6462b13"
      unitRef="usd">280000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ic1d9db700df64698bb10be3cd5969a2d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNC0yLTEtMS0w_d8cf1d58-fa8f-446c-9a08-1e1ffaac94e0"
      unitRef="usd">8306000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="ic1d9db700df64698bb10be3cd5969a2d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNC0zLTEtMS0w_58959a30-2ef2-42d3-b807-d12e06fb6cc6"
      unitRef="usd">271694000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i93532836fe0e4502b83cb85c9fb2c31a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNS0xLTEtMS0yMDg3_32734a97-9611-4431-999d-ee2bbe526ecf"
      unitRef="usd">280000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i93532836fe0e4502b83cb85c9fb2c31a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNS0yLTEtMS0yMDg3_1a751f19-4c8f-4e71-9ccf-f0b1a24bee76"
      unitRef="usd">7902000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i93532836fe0e4502b83cb85c9fb2c31a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RhYmxlOmIwNjA5ODIyNDY5ZjQ4YTU4NmJhNWZjMzQzYTYwMjRiL3RhYmxlcmFuZ2U6YjA2MDk4MjI0NjlmNDhhNTg2YmE1ZmMzNDNhNjAyNGJfNS0zLTEtMS0yMDg3_29cbea43-f009-4d8f-8441-e9f5b634302f"
      unitRef="usd">272098000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ib008a93c1f5b4185bd24238dd3202fe2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTA5OTUxMTY0MDI3OA_010c9871-a0a5-4112-97e2-2c007a47de54"
      unitRef="usd">3200000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ibdbc8b360e6a444da2991d43afe2a07e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTA5OTUxMTY0MDY0OQ_67c6e145-6d99-4fbd-8460-61baa80399f7"
      unitRef="usd">6400000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5305d0a8f10c49fa886fd702e4c1cc65_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfODUwMQ_8693e689-8aa4-4459-9865-cf9cc7e51b2b"
      unitRef="usd">233600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i0d2d467fe6c549869f5d62f5f2e70867_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfODUwOA_62457195-de03-45c9-a9e7-158c1a4c0b42"
      unitRef="usd">283400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfOTEzMg_52a595ac-06db-467e-8559-da1084dd17a2"
      unitRef="usd">46000000.0</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id69054b09ba54731a79fe2fd68c06551_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfOTk3OA_8d5ee224-573b-48c0-af86-059b2d7fb539"
      unitRef="usdPerShare">55.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <espr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage
      contextRef="id69054b09ba54731a79fe2fd68c06551_I20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTAwMjY_c5d702e9-9e6e-436a-bf82-352414253670"
      unitRef="number">1</espr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTA5NDk_46b9c005-992a-4420-a757-23365bff5c98"
      unitRef="usd">55000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i61bb4d25218d4d74956e512d85225917_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182NC9mcmFnOjA2MzhkY2VmZTlmZTRhYmFhZjZiMTdkN2NlN2FiNThkL3RleHRyZWdpb246MDYzOGRjZWZlOWZlNGFiYWFmNmIxN2Q3Y2U3YWI1OGRfMTExNTQ_e14b4ae2-fa3c-4a59-80b5-80642ddebb22"
      unitRef="shares">1994198</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RleHRyZWdpb246NjIyN2Q5NjIzZmZlNDYzNmI1YzhkZDA5ZjUzYzg4YjdfMTc4_b32d66e0-33f4-4a1d-b9d3-049d87020777">Other Accrued Liabilities&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RleHRyZWdpb246NjIyN2Q5NjIzZmZlNDYzNmI1YzhkZDA5ZjUzYzg4YjdfMTgw_533fee29-63d1-42d5-8acf-c9bace183c51">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfMi0xLTEtMS0w_c5572d45-13bb-48f0-83f1-fadfaa528d18"
      unitRef="usd">12419000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfMi0zLTEtMS0w_d84b9f60-7156-486b-bd7f-2873e3eff2d3"
      unitRef="usd">15161000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <espr:AccruedVariableConsiderationCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfMy0xLTEtMS0w_d6d1561f-460e-43c9-9428-74eaec81f7b5"
      unitRef="usd">13700000</espr:AccruedVariableConsiderationCurrent>
    <espr:AccruedVariableConsiderationCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfMy0zLTEtMS0w_d8644c80-8af5-4d14-aaef-c74bb5c868b5"
      unitRef="usd">5025000</espr:AccruedVariableConsiderationCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNC0xLTEtMS0w_e36c1c45-ac49-4c3a-af5c-c7f13f3502be"
      unitRef="usd">4046000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNC0zLTEtMS0w_1c0bca46-e0e3-436e-be80-90c4ce5514d2"
      unitRef="usd">3183000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNS0xLTEtMS0w_645421c4-26fd-4808-bd8f-1da46b35bd29"
      unitRef="usd">1400000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNS0zLTEtMS0w_2d129a3d-c3e5-463f-a6c0-48a99759183d"
      unitRef="usd">1369000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNi0xLTEtMS0w_8d524d15-cb97-441a-b8ed-3abe3fcfd67e"
      unitRef="usd">108000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNi0zLTEtMS0w_6db4624b-a756-4b05-920b-fdeda93c00e4"
      unitRef="usd">52000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNy0xLTEtMS0w_0ed5c6dc-390e-4bb9-a0c8-3e20de2e7f9e"
      unitRef="usd">31673000</espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N182Ny9mcmFnOjYyMjdkOTYyM2ZmZTQ2MzZiNWM4ZGQwOWY1M2M4OGI3L3RhYmxlOjkxNWUxNmEyM2I5YTQ0MjI4YjQzMDQ1OWI2MzIxYWI2L3RhYmxlcmFuZ2U6OTE1ZTE2YTIzYjlhNDQyMjhiNDMwNDU5YjYzMjFhYjZfNy0zLTEtMS0w_c269499f-9781-42f6-a4ee-3b9c339012f8"
      unitRef="usd">24790000</espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI0OQ_fc7e71ca-6600-4c94-b644-7411ef2177cc">Stock Compensation&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the board of directors approved the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") which was approved by the Company's shareholders on May 28, 2020. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary or wages up to $25,000 annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to 15% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in six months increments, commencing on September 1 and March 1 of each calendar year with the administrator having the right to establish different offering periods. In the three and six months ended June&#160;30, 2021, the Company recognized approximately $0.1&#160;million and $0.4&#160;million of stock compensation expense related to the ESPP, respectively. As of June&#160;30, 2021, there have been 50,818 shares issued and 774,182 shares reserved for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s options to purchase common stock for the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,176,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&#160;or&#160;expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the Company&#x2019;s stock option plan as of June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,948,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to stock options was $6.2 million and $9.9 million for the three and six months ended June&#160;30, 2021, respectively, including $0.2 million and $0.5 million that were capitalized into inventory, and $5.5 million and $11.1 million for the three and six months ended June&#160;30, 2020, respectively, including $0.3 million and $0.5 million that were capitalized into inventory. As of June&#160;30, 2021, there was $20.3 million of unrecognized stock-based compensation expense related to unvested options, which will be recognized over a weighted-average period of 2.7 years. The increase in stock option expense for the three months ended June 30, 2021, was primarily due to an equity modification related to the CEO Departure Agreement entered into between the Company and the Company's former CEO on May 16, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units (or RSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s RSUs for the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Fair Value Per &lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to RSUs was approximately $2.2 million and $4.0 million for the three and six months ended June&#160;30, 2021, respectively, including $0.1 million and $0.2 million that were capitalized into inventory, and approximately $1.8 million and $3.3&#160;million for the three and six months ended June 30, 2020, respectively, including $0.1 million and $0.1 million that were capitalized into inventory. As of June&#160;30, 2021, there was $28.2 million of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted-average period of 3.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based Restricted Stock Units ("PBRSUs")&lt;/span&gt;&lt;/div&gt;The Company's PBRSUs vest after a two-year performance period contingent upon the achievement of predetermined performance-based milestones based on the Company's U.S. net product sales. The actual number of units (if any) received under this award will depend on continued employment and actual performance over the two-year performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBRSUs based on the expected performance period to achieve the performance milestone. The fair value of the PBRSUs is based on the quoted market price of our common stock on the date of grant. During the three and six months ended June 30, 2021 the Company granted 64,200 PBRSUs with a weighted-average fair value per share of $22.52. The Company expects the performance criteria to be met.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMzI1_d3961d3e-52e4-4e18-b6b5-d9fa590a4c5f"
      unitRef="number">0.10</espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMzY0_8ea8d560-232b-4d16-ae5b-ce333735c417"
      unitRef="usd">25000</espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount>
    <espr:EmployeeStockPurchasePlanPercentageDiscountOnShares
      contextRef="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNTk2_21909607-1eff-4e94-89c6-686541a0884a"
      unitRef="number">0.15</espr:EmployeeStockPurchasePlanPercentageDiscountOnShares>
    <espr:EmployeeStockPurchasePlanDurationOfOfferingPeriod
      contextRef="i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfODQ5_88d80a27-8e7c-4381-b571-0c1f59f83e56">P6M</espr:EmployeeStockPurchasePlanDurationOfOfferingPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4a6340c209848789d2ead328753e5dc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA3MA_cc919743-5aea-4944-9c71-e0777aa7c219"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f44623b0aab464f8a2a2de5879f3fc6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTU0Mg_a4fb5308-4b49-4fe7-ac65-daef6cb507d5"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i2f44623b0aab464f8a2a2de5879f3fc6_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTE2Mg_df066d07-0790-465e-9236-a523df2cb94c"
      unitRef="shares">50818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i21cebe390d5c4ab1a9dcde2e33388077_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTE4Mw_b7a8684d-2b96-49f6-9474-a0554f5ed128"
      unitRef="shares">774182</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI1MA_544157e1-4ea4-4310-8d79-1bb81254360d">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s options to purchase common stock for the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,176,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&#160;or&#160;expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMi0xLTEtMS0w_c78e3b51-0d0b-4a20-81ee-a767c8af46c8"
      unitRef="shares">4176518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMi0zLTEtMS0w_a21501a3-ca16-4f9c-8106-3eac70725a74"
      unitRef="usdPerShare">40.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ifbe168eb5b3940b88ace61c5db5c89a7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMi01LTEtMS0w_890f0d95-fe5e-4a9d-8a6c-6eea76602fa1">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i056e612b26e34dd48d60f525e33d62cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMi03LTEtMS0w_9fa08423-4211-47dd-81cc-be7ec5be5e74"
      unitRef="usd">18415000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMy0xLTEtMS0w_80bf56bd-6233-4881-b4cf-8afcaaa635be"
      unitRef="shares">757992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfMy0zLTEtMS0w_d14c11a8-d782-4b9e-9567-efb34dbece51"
      unitRef="usdPerShare">28.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNC0xLTEtMS0w_a505cc9b-a275-48f3-8be5-ef8e6a3e8010"
      unitRef="shares">876151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNC0zLTEtMS0w_749950f8-d90b-4c14-8b8d-d656bb3c110d"
      unitRef="usdPerShare">49.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNS0xLTEtMS0w_1fddd63a-7372-431e-b12e-c0b353d727b2"
      unitRef="shares">182745</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNS0zLTEtMS0w_55f5695d-59e2-4179-8d72-942b9f061df5"
      unitRef="usdPerShare">15.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNi0xLTEtMS0w_4b3fade5-2412-4e57-b693-08dbed5a52de"
      unitRef="shares">3875614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNi0zLTEtMS0w_38d73704-3d7c-4c40-aacf-d6dc3a95812e"
      unitRef="usdPerShare">36.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNi01LTEtMS0w_58fd1710-92e2-4ba7-a79a-ce5e00c98edb">P5Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOmYxZDVlMGVjZWFhYzQzYzg5NWI0MDU2OTBhYjIxM2RiL3RhYmxlcmFuZ2U6ZjFkNWUwZWNlYWFjNDNjODk1YjQwNTY5MGFiMjEzZGJfNi03LTEtMS0w_44e4d0cd-9967-4a6f-8396-ece0f52e1aa5"
      unitRef="usd">10405000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI1MQ_878626ff-4dee-4627-9934-5862405fdce9">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the Company&#x2019;s stock option plan as of June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,948,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMi0xLTEtMS0w_910fa1a5-fd64-4244-ade2-c721fc18934d"
      unitRef="shares">3875614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMi0zLTEtMS0w_4a311964-64f4-48c7-a089-77f08b7d9e06"
      unitRef="usdPerShare">36.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMi01LTEtMS0w_102b137e-80db-49a7-8797-70e7f500427a">P5Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMi03LTEtMS0w_16543bc9-6848-4896-a7a8-e0759fadab9d"
      unitRef="usd">10405000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMy0xLTEtMS0w_c57a9984-33cf-433b-b4dc-b8c0395d8031"
      unitRef="shares">2948732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMy0zLTEtMS0w_6e1a1543-2e9c-4b8e-b4e1-c468543c6831"
      unitRef="usdPerShare">36.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMy01LTEtMS0w_6297eda3-478e-4175-adc4-5d18caf9434a">P3Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i1c209f1921c3473dbb64c2533be863bd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjA5NjZkYTQ3YmU4NjQ3M2M4YWY3ZDQwMTI1ODY2YjA4L3RhYmxlcmFuZ2U6MDk2NmRhNDdiZTg2NDczYzhhZjdkNDAxMjU4NjZiMDhfMy03LTEtMS0w_46c8ddca-b607-4574-a6ef-306aee739594"
      unitRef="usd">10371000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTUyMg_33bcd399-fe5f-4e78-b141-bfafc45525fb"
      unitRef="usd">6200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMDA5MQ_b8d6a126-c904-468c-9f39-2caf79b9da07"
      unitRef="usd">9900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMDEwNw_f1cbcebf-a40d-4b0c-8826-07c2077fbc16"
      unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMDExMQ_123e6132-91ab-4249-a316-809705977763"
      unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic8fc8a8e135542e79741bc96b14f2509_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTM3Mg_35253f0b-b911-4ae7-b85d-6115de571f0d"
      unitRef="usd">5500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i82de142173eb4c029ba076114a0d9dc2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTM4Ng_6bf58fcf-e1dd-4d9c-a699-8f765e45e731"
      unitRef="usd">11100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ic8fc8a8e135542e79741bc96b14f2509_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTg2NQ_70a701da-b98f-47c1-bbc4-f699b1aa7389"
      unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i82de142173eb4c029ba076114a0d9dc2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTg4Mg_9bc2f533-2371-4145-8a6d-82c5c07db5ef"
      unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i65c8c52a3f8249128e0061ca20f07e6e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTY2MQ_18ff31cf-b691-42a7-988e-fcec53cd48ce"
      unitRef="usd">20300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTgwMQ_7b535588-c7e6-4c9d-9c24-bdf22eb6a40b">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI1Mg_af9fa1bb-a036-4cde-a650-8dcc3fe0cc67">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s RSUs for the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Fair Value Per &lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3dd83bfde144490abf8e977beb2d1e13_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMS0xLTEtMS0w_ba80107f-98a8-4391-89e6-161aeb8f7005"
      unitRef="shares">401234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3dd83bfde144490abf8e977beb2d1e13_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMS0zLTEtMS0w_2ab95e75-5e36-4e95-a6a4-2bb7e216dd35"
      unitRef="usdPerShare">46.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMi0xLTEtMS0w_b36ca0ec-d5af-44e2-88de-e1204da3a043"
      unitRef="shares">823301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMi0zLTEtMS0w_ad216278-cb76-4c37-a4ec-7a7624860407"
      unitRef="usdPerShare">26.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMy0xLTEtMS0w_d3f8b629-8ff7-4b1f-a1bd-473fb4731973"
      unitRef="shares">115616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfMy0zLTEtMS0w_f3c11f56-8a3a-4e70-b298-7afa49022e0a"
      unitRef="usdPerShare">42.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfNC0xLTEtMS0w_c20a44ff-3d8e-4d7a-b29b-60df9e78351d"
      unitRef="shares">124604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfNC0zLTEtMS0w_d3e9f5b2-bf6a-411f-b449-d1898e2be9a0"
      unitRef="usdPerShare">45.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i864a800b9e2f4367b5189df3691f74ed_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfNS0xLTEtMS0w_9ef8d42d-1496-4ac5-951a-d0fe4aac959e"
      unitRef="shares">984315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i864a800b9e2f4367b5189df3691f74ed_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RhYmxlOjU3NGY2NTVlNmM0ZjQyZGE4M2NlNWNjZGI5YTZmYzg4L3RhYmxlcmFuZ2U6NTc0ZjY1NWU2YzRmNDJkYTgzY2U1Y2NkYjlhNmZjODhfNS0zLTEtMS0w_541fad61-0e9b-49d6-b0b6-175d114715c1"
      unitRef="usdPerShare">30.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i059e63457ab0488a8b8926c7af529680_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTk4Ng_f08a1d10-6ecb-4e7b-82b9-67df63eb4bb2"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTk5Mw_8b0f95ad-a03b-4718-99fc-3011ba175232"
      unitRef="usd">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i059e63457ab0488a8b8926c7af529680_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjAzMg_63efab7f-4164-410f-a85d-8ed1a8df2d6e"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjA0OQ_52f6d008-c1d6-4001-b2a8-efaebc4504eb"
      unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i898eb34514a14aaca65ddd29c2ba018f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMzI5ODUzNDg4NzU4MQ_2c45b7f4-13a3-411f-b0a0-53110b63849f"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i01e390bfc85947a1b2e04d2d1b168ba2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMzI5ODUzNDg4NzU5Ng_544ad3f0-99d0-42f3-ba1e-2602d91d211c"
      unitRef="usd">3300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i898eb34514a14aaca65ddd29c2ba018f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTkwMA_caf1df03-2309-47b4-8812-386532cfa041"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i01e390bfc85947a1b2e04d2d1b168ba2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMTA5OTUxMTYzMTkxNQ_96f6adab-7b7d-40ab-b74b-c4a68a12f5b2"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i864a800b9e2f4367b5189df3691f74ed_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjExMA_d32d50b9-0102-4970-bac6-0e549453999c"
      unitRef="usd">28200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfMjI0Nw_230ba33b-c2db-445b-a848-c37c1747bd7d">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if90fbea89e414e58b44494d21f429a48_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODkyNg_de1e4a0d-cba6-46a2-8fc0-f1320c162b82">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if90fbea89e414e58b44494d21f429a48_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODkyNw_f9de9e9e-7b78-401e-ade1-66b4f12b3249">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5f01c8d8eec0472c8f65bc4d927a3971_D20210401-20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODg1MQ_4244a602-5096-41c6-995b-6be3ebaf253a"
      unitRef="shares">64200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if90fbea89e414e58b44494d21f429a48_D20210101-20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODg1MQ_e2586d52-3f4d-4cc1-8686-11aabba1a518"
      unitRef="shares">64200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if90fbea89e414e58b44494d21f429a48_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODg0Mw_159958e5-25c7-4b9e-abb1-777c819ec1af"
      unitRef="usdPerShare">22.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5f01c8d8eec0472c8f65bc4d927a3971_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183MC9mcmFnOmYxYjZmYzEyNWUzZTRhMzlhYjk5YzcxYzc3MjQ0M2IxL3RleHRyZWdpb246ZjFiNmZjMTI1ZTNlNGEzOWFiOTljNzFjNzcyNDQzYjFfNjU5NzA2OTc3ODg0Mw_20d2be34-ea81-4046-bb75-3d5f763ec418"
      unitRef="usdPerShare">22.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfNDM5_cbde8eda-8913-41f8-a2bc-1043399d1ca9">Income TaxesThere was no provision for income taxes for the three and six months ended June&#160;30, 2021 and 2020, because the Company has incurred annual operating losses since inception. At June&#160;30, 2021, the Company continues to conclude that it is not more likely than not that the Company will realize the benefit of its deferred tax assets due to its history of losses. Accordingly, a full valuation allowance has been applied against the net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfMzI_3f4aa625-8415-406a-8a51-7598e2320c8b"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfMzI_8e8ab965-10ae-46cf-ab8b-6674beb84251"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfMzI_9542a880-963b-4436-a014-9a77bcafc6d3"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183My9mcmFnOmRjZDE3OGYzM2FjYzQ5ZDc4MWQyMTY1NTMwMTIwNWQwL3RleHRyZWdpb246ZGNkMTc4ZjMzYWNjNDlkNzgxZDIxNjU1MzAxMjA1ZDBfMzI_cce1f458-561b-4a89-b2fe-c8769db02423"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RleHRyZWdpb246MmE4ZWE4YjZiMDMzNGIyNDg5OWE2OWI3YjY5NThiYzJfMTA0Mg_c5a6c2fb-23a7-456b-9ea3-dc1b450ede39">Net (Loss) Income Per Common Share&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net (loss) income per share is calculated by dividing net (loss) income by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common stock equivalents outstanding for the period, including shares that potentially could be dilutive if they were exercised or vested during the period, determined using the treasury-stock method. For purposes of this calculation, stock options, unvested RSUs, unvested PBRSUs, shares issuable under the ESPP and shares issuable upon conversion of the convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the calculation of basic and diluted net (loss) income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,225,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,665,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,109,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,592,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares under option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,139,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,225,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,854,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,109,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,948,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per common share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net (loss) income per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares under option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,391,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested PBRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable related to the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,460,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,460,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total potential dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,417,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,722,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,417,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,581,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RleHRyZWdpb246MmE4ZWE4YjZiMDMzNGIyNDg5OWE2OWI3YjY5NThiYzJfNTQ5NzU1ODE0MDAzNQ_66861a14-b05e-48e4-86d6-9c7cfba30fd1">The following table summarizes the calculation of basic and diluted net (loss) income per share:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,225,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,665,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,109,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,592,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares under option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,139,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,225,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,854,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,109,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,948,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per common share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMi0xLTEtMS0yNTE5_22ba8602-8575-4ec9-a439-ce58bf7a60eb"
      unitRef="usd">-43668000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMi0zLTEtMS0yNTE5_f359c64c-3b95-4a88-9d88-f24a64e899ee"
      unitRef="usd">124611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMi01LTEtMS0yNTE5_34cf3931-c2d3-4edf-ab12-2b09fb44d7aa"
      unitRef="usd">-134603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMi03LTEtMS0yNTE5_6ebc1bfb-6a67-43eb-9b04-e4d1d12fced3"
      unitRef="usd">46362000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNC0xLTEtMS0yNTE5_9c9c03de-f657-4463-aad0-66437065b2d9"
      unitRef="shares">26225073</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNC0zLTEtMS0yNTE5_3bb9684b-dc7b-4131-b4e8-783ac7552e89"
      unitRef="shares">27665728</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNC01LTEtMS0yNTE5_9ef10db2-791e-437c-948c-25fad707edbe"
      unitRef="shares">26109089</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNC03LTEtMS0yNTE5_20691f81-ee48-4b1a-bc66-96a9ea29307c"
      unitRef="shares">27592479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNy0xLTEtMS0yNTE5_38857131-9a9c-48cc-947e-a9d3e865b41a"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic8fc8a8e135542e79741bc96b14f2509_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNy0zLTEtMS0yNTE5_05397151-5bb9-4e4c-8d8a-f94008268da4"
      unitRef="shares">1139280</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia73f0f9b861345959bab6a14de83db22_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNy01LTEtMS0yNTE5_4a5b7926-4475-4bad-8bad-de64a4d31eae"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i82de142173eb4c029ba076114a0d9dc2_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfNy03LTEtMS0yNTE5_dc39e86c-def7-437f-b8e4-56f9a13a058e"
      unitRef="shares">1291353</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i059e63457ab0488a8b8926c7af529680_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOC0xLTEtMS0yNTE5_aaf30b78-ad40-4677-925b-4f279cd09d91"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i898eb34514a14aaca65ddd29c2ba018f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOC0zLTEtMS0yNTE5_4d84cace-2f77-47a3-bb9a-158b4fcca985"
      unitRef="shares">49437</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i83c661c6afcd4ac9b6e8b6188830e219_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOC01LTEtMS0yNTE5_a9edfd7b-a8c3-4b03-ba87-0277320180fc"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i01e390bfc85947a1b2e04d2d1b168ba2_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOC03LTEtMS0yNTE5_0048fc13-e3b8-4bc1-9889-9b516775277b"
      unitRef="shares">64226</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOS0xLTEtMS0yNTE5_283d8d28-7f26-4562-add7-380ed4085370"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOS0zLTEtMS0yNTE5_b4080040-c366-4ed9-a44c-c5c764fcf144"
      unitRef="shares">1188717</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOS01LTEtMS0yNTE5_92a7e080-7cf5-4c81-93bb-3fc1620dbc43"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfOS03LTEtMS0yNTE5_c910842a-d07e-49d2-9795-24b6f64dc96b"
      unitRef="shares">1355579</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTAtMS0xLTEtMjUxOQ_f53974a7-7ec9-4fd8-bbd3-54b0add273cd"
      unitRef="shares">26225073</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTAtMy0xLTEtMjUxOQ_99b2d5df-d578-40e8-bb28-8990e47a831c"
      unitRef="shares">28854445</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTAtNS0xLTEtMjUxOQ_88b4d8f6-78f3-4042-8364-59571e2a68b4"
      unitRef="shares">26109089</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTAtNy0xLTEtMjUxOQ_a615e86b-0623-47c0-a4a1-cb0a339aa2dc"
      unitRef="shares">28948058</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTItMS0xLTEtMjUxOQ_73626918-800d-4c54-9ade-28618a15628a"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTItMy0xLTEtMjUxOQ_b3c4d113-7d41-460c-9ea6-d5dc7251e5eb"
      unitRef="usdPerShare">4.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTItNS0xLTEtMjUxOQ_4e11a946-7b1e-450f-9fc5-cdc8edd03cbe"
      unitRef="usdPerShare">-5.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTItNy0xLTEtMjUxOQ_6e6dcf91-f3cf-4909-8204-9d3b1deab2a3"
      unitRef="usdPerShare">1.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTMtMS0xLTEtMjUxOQ_a80a1487-146b-49b3-ae32-ab47ec58e4aa"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTMtMy0xLTEtMjUxOQ_bca99bb7-6f24-4db3-8f1f-fe99d384a542"
      unitRef="usdPerShare">4.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTMtNS0xLTEtMjUxOQ_9bc49f44-4e5e-4d4f-979a-72c70458401f"
      unitRef="usdPerShare">-5.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjEzOGMwMzNiYTZmZTQyMzViMzEyNDEwZjdiOTFiM2E5L3RhYmxlcmFuZ2U6MTM4YzAzM2JhNmZlNDIzNWIzMTI0MTBmN2I5MWIzYTlfMTMtNy0xLTEtMjUxOQ_9293fc20-a56d-4ddf-ab54-f3fe073d84eb"
      unitRef="usdPerShare">1.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RleHRyZWdpb246MmE4ZWE4YjZiMDMzNGIyNDg5OWE2OWI3YjY5NThiYzJfMTA0Mw_e1165f00-2c08-4c0f-a0b1-ddf298fd226d">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net (loss) income per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares under option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,391,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested PBRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable related to the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,460,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,460,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total potential dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,417,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,722,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,417,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,581,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id7741b1a7bd54135bcc5b59858d55156_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMi0xLTEtMS0w_d6c0727d-a50b-4b87-98e6-488227375d33"
      unitRef="shares">3875614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id7123ad4d0294677ba36fc60acabdec6_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMi0zLTEtMS0w_25a2e338-e2d8-4610-b055-cc50bfde9550"
      unitRef="shares">2427074</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i057a47e17f174e828a68dcc68defe7b5_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMi01LTEtMS0w_ee513ab6-5d3b-47b8-b28c-13e07e4365d3"
      unitRef="shares">3875614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2d8118dee83344708fa7b2847e3b49ae_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMi03LTEtMS0w_23b29909-0988-4657-bd1d-5702605c45c5"
      unitRef="shares">2391374</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3300afb8e3844697bef3a62d80174c94_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMy0xLTEtMS0w_badbd252-0a26-445c-a3c6-1801f13323fb"
      unitRef="shares">984315</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iada643021f094d168ae1bb38139e79f6_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMy0zLTEtMS0w_17332fda-7061-4b22-b4d4-99227d287eac"
      unitRef="shares">295423</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibb9e9630412f44bab00355a379ce951e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMy01LTEtMS0w_aa788a53-e79e-4c0d-a548-aade7ffdcb3e"
      unitRef="shares">984315</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i68daaa76952c4522a02c46ae9c9b099d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfMy03LTEtMS0w_f6b5cd49-65ba-4752-9610-6aeb4094bdce"
      unitRef="shares">190565</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf977f7283ba4421a1c44b0fd2d0dd6b_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC0xLTEtMS00NDIw_dbf8ed2a-c42b-4f3c-bc9f-999712405868"
      unitRef="shares">64200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifbfaf88013a0436983a4e2f8e2e3b9a9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC0zLTEtMS00NDIy_2b204976-be51-4fe7-ab08-96d902e5c249"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic9deb65589fd4b818e61af707066a7bd_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC01LTEtMS00NDI2_c285d923-e7d2-40dc-85f9-5ba2d7f6572b"
      unitRef="shares">64200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9113bd66c9034dc5b296e6fd3676426d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC03LTEtMS00NDI2_488b2972-ca18-41f9-9510-280c6bd72fb4"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f518e9c8c2e4aa58a673d03a3aca709_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC0xLTEtMS0w_fa8bae10-6c45-4c9a-a76d-5b65339bb63e"
      unitRef="shares">33412</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie596161ef3d64bc0b3c096d1474e9499_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC0zLTEtMS0w_3e55c0cb-0017-468b-b670-36112ab89aa6"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia6e64bbef76f49d187ba3ba4bb0a64ae_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC01LTEtMS0yNTQ0_681fca50-f323-4b02-98db-2d7fb915bc29"
      unitRef="shares">33412</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie9a360e7e8004cb7a888a243dc4639e3_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNC03LTEtMS0yNTQ0_6f42af65-e077-430f-9b57-3417b2340080"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7ecd3a7b914d4102b067da5c2fed3f4d_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNS0xLTEtMS0w_d2fad463-ecde-439c-9d2c-946458f136d2"
      unitRef="shares">8460237</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6517e0e5ba714e75aef0fa5cdffc38ea_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNS0zLTEtMS0w_06702607-5e7d-473e-9500-582df324bc5d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i594b303f27a441e79f5d86e7922bf49c_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNS01LTEtMS0yNTQ0_85ea034f-083a-4f3e-9107-4fe1e1be5e0d"
      unitRef="shares">8460237</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6179414809fd40c2899b2bcdf7735820_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNS03LTEtMS0yNTQ0_ac3eeae1-1b7e-4878-8d28-6cce3a22c34a"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNi0xLTEtMS0w_9ad526a1-2148-47a3-bd75-2d2f98e1048e"
      unitRef="shares">13417778</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i33200b5320234052894888a136145868_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNi0zLTEtMS0w_2c7f3cf0-2a25-4e1f-aa3e-2c72cfde8225"
      unitRef="shares">2722497</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNi01LTEtMS0w_8aef5e19-cdba-4165-b6c7-7451fd31ffbc"
      unitRef="shares">13417778</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i21ac6ffd6c4e4f9aab61fb7ac5b23647_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1NTIzM2E5YzMwMTQzZjc4OGMyY2IzMGJmN2I3YTc3L3NlYzoxNTUyMzNhOWMzMDE0M2Y3ODhjMmNiMzBiZjdiN2E3N183Ni9mcmFnOjJhOGVhOGI2YjAzMzRiMjQ4OTlhNjliN2I2OTU4YmMyL3RhYmxlOjBlNDQxOTgxZWM1ZjQ2YjA5OGUwZDczMzliNTVlOGRiL3RhYmxlcmFuZ2U6MGU0NDE5ODFlYzVmNDZiMDk4ZTBkNzMzOWI1NWU4ZGJfNi03LTEtMS0w_c57a73ad-3ce9-49b3-a5f4-928bcf58b221"
      unitRef="shares">2581939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347851091624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Esperion Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1870780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3891 Ranchero Drive, Suite&#160;150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ann Arbor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">887-3903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ESPR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,277,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001434868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847649320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 219,186<span></span>
</td>
<td class="nump">$ 304,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">21,854<span></span>
</td>
<td class="nump">12,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PrepaidClinicalDevelopmentCostsCurrent', window );">Prepaid clinical development costs</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">23,714<span></span>
</td>
<td class="nump">16,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other prepaid and current assets</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">11,566<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">275,174<span></span>
</td>
<td class="nump">345,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">1,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use operating lease assets</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">6,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">280,461<span></span>
</td>
<td class="nump">353,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">29,353<span></span>
</td>
<td class="nump">51,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AccruedClinicalDevelopmentCostsCurrent', window );">Accrued clinical development costs</a></td>
<td class="nump">2,873<span></span>
</td>
<td class="nump">7,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">31,673<span></span>
</td>
<td class="nump">24,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestLiabilityCurrent', window );">Revenue interest liability</a></td>
<td class="nump">12,469<span></span>
</td>
<td class="nump">5,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue from collaborations</a></td>
<td class="nump">3,930<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,346<span></span>
</td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">82,644<span></span>
</td>
<td class="nump">94,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes, net of issuance costs</a></td>
<td class="nump">272,098<span></span>
</td>
<td class="nump">179,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestLiabilityNoncurrent', window );">Revenue interest liability</a></td>
<td class="nump">225,762<span></span>
</td>
<td class="nump">171,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">3,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue from collaborations</a></td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">584,771<span></span>
</td>
<td class="nump">449,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of June&#160;30, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 120,000,000 shares authorized as of June&#160;30, 2021 and December&#160;31, 2020; 28,268,533 shares issued at June&#160;30, 2021 and 27,910,366 shares issued at December&#160;31, 2020</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">722,534<span></span>
</td>
<td class="nump">797,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 1,994,198 shares at June&#160;30, 2021 and December 31, 2020</a></td>
<td class="num">(54,998)<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(971,872)<span></span>
</td>
<td class="num">(838,817)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(304,310)<span></span>
</td>
<td class="num">(96,134)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 280,461<span></span>
</td>
<td class="nump">$ 353,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AccruedClinicalDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AccruedClinicalDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PrepaidClinicalDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PrepaidClinicalDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347860083224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">28,268,533<span></span>
</td>
<td class="nump">27,910,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">1,994,198<span></span>
</td>
<td class="nump">1,994,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847138392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive (Loss) Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 40,659<span></span>
</td>
<td class="nump">$ 212,236<span></span>
</td>
<td class="nump">$ 48,637<span></span>
</td>
<td class="nump">$ 214,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Cost of goods sold</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">3,584<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">25,074<span></span>
</td>
<td class="nump">34,987<span></span>
</td>
<td class="nump">53,028<span></span>
</td>
<td class="nump">69,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">46,318<span></span>
</td>
<td class="nump">47,681<span></span>
</td>
<td class="nump">107,382<span></span>
</td>
<td class="nump">89,234<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">73,192<span></span>
</td>
<td class="nump">83,066<span></span>
</td>
<td class="nump">163,994<span></span>
</td>
<td class="nump">159,352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(32,533)<span></span>
</td>
<td class="nump">129,170<span></span>
</td>
<td class="num">(115,357)<span></span>
</td>
<td class="nump">54,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(11,144)<span></span>
</td>
<td class="num">(4,640)<span></span>
</td>
<td class="num">(19,269)<span></span>
</td>
<td class="num">(8,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (43,668)<span></span>
</td>
<td class="nump">$ 124,611<span></span>
</td>
<td class="num">$ (134,603)<span></span>
</td>
<td class="nump">$ 46,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per common share - basic (in dollars per share)</a></td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="num">$ (5.16)<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="num">$ (5.16)<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares)</a></td>
<td class="nump">26,225,073<span></span>
</td>
<td class="nump">27,665,728<span></span>
</td>
<td class="nump">26,109,089<span></span>
</td>
<td class="nump">27,592,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares)</a></td>
<td class="nump">26,225,073<span></span>
</td>
<td class="nump">28,854,445<span></span>
</td>
<td class="nump">26,109,089<span></span>
</td>
<td class="nump">28,948,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">(43,668)<span></span>
</td>
<td class="nump">124,602<span></span>
</td>
<td class="num">(134,603)<span></span>
</td>
<td class="nump">46,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">10,610<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">16,960<span></span>
</td>
<td class="nump">1,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=espr_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 30,049<span></span>
</td>
<td class="nump">$ 211,627<span></span>
</td>
<td class="nump">$ 31,677<span></span>
</td>
<td class="nump">$ 212,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=espr_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=espr_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347765940440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjusted Balance</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th">
<div>Common&#160;Stock </div>
<div>Cumulative Effect, Period of Adoption, Adjusted Balance</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjusted Balance</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjusted Balance</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Income (Loss) </div>
<div>Cumulative Effect, Period of Adoption, Adjusted Balance</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th">
<div>Treasury Stock </div>
<div>Cumulative Effect, Period of Adoption, Adjusted Balance</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,497,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 19,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 715,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (695,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(78,249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,548,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="num">(50,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(773,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,497,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">19,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(695,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">46,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,751,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">85,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">734,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(648,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,497,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 19,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(695,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">espr:AccountingStandardsUpdate202006Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,916,168<span></span>
</td>
<td class="nump">25,916,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="num">$ (96,134)<span></span>
</td>
<td class="num">$ (91,927)<span></span>
</td>
<td class="num">$ (188,061)<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">797,655<span></span>
</td>
<td class="num">$ (93,475)<span></span>
</td>
<td class="nump">$ 704,180<span></span>
</td>
<td class="num">(838,817)<span></span>
</td>
<td class="nump">$ 1,548<span></span>
</td>
<td class="num">$ (837,269)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
<td class="num">$ (54,998)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,548,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="num">(50,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(773,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">124,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,751,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">85,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">734,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(648,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,916,168<span></span>
</td>
<td class="nump">25,916,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(96,134)<span></span>
</td>
<td class="num">(91,927)<span></span>
</td>
<td class="num">(188,061)<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">797,655<span></span>
</td>
<td class="num">(93,475)<span></span>
</td>
<td class="nump">704,180<span></span>
</td>
<td class="num">(838,817)<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="num">(837,269)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Vesting of ESPP Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Vesting of ESPP Shares</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(90,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,182,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="num">(269,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">713,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(928,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,916,168<span></span>
</td>
<td class="nump">25,916,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (96,134)<span></span>
</td>
<td class="num">$ (91,927)<span></span>
</td>
<td class="num">$ (188,061)<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">797,655<span></span>
</td>
<td class="num">$ (93,475)<span></span>
</td>
<td class="nump">$ 704,180<span></span>
</td>
<td class="num">(838,817)<span></span>
</td>
<td class="nump">$ 1,548<span></span>
</td>
<td class="num">$ (837,269)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
<td class="num">$ (54,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">182,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (134,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,274,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="num">(304,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(971,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,182,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="num">(269,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">713,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(928,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(43,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,274,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="num">$ (304,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 722,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (971,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (54,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347844508136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (134,603)<span></span>
</td>
<td class="nump">$ 46,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of premiums and discounts on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability', window );">Non-cash interest expense related to the revenue interest liability</a></td>
<td class="nump">12,865<span></span>
</td>
<td class="nump">8,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14,335<span></span>
</td>
<td class="nump">14,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(9,466)<span></span>
</td>
<td class="num">(2,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other assets</a></td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">3,325<span></span>
</td>
<td class="num">(1,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(7,578)<span></span>
</td>
<td class="num">(8,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(22,182)<span></span>
</td>
<td class="nump">921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">3,270<span></span>
</td>
<td class="nump">12,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(136,934)<span></span>
</td>
<td class="nump">70,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales/maturities of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(776)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts', window );">Proceeds from revenue interest liability, net of issuance costs</a></td>
<td class="nump">49,917<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">2,836<span></span>
</td>
<td class="nump">4,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PaymentsFromRevenueInterestPurchaseAgreement', window );">Payments on revenue interest liability</a></td>
<td class="num">(1,155)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(440)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">51,158<span></span>
</td>
<td class="nump">29,688<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(85,776)<span></span>
</td>
<td class="nump">131,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">304,962<span></span>
</td>
<td class="nump">167,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">219,186<span></span>
</td>
<td class="nump">298,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment not yet paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_NonCashRightOfUseAsset', window );">Non cash right of use asset</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash expense included in interest expense associated with the revenue interest liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NonCashInterestExpenseRelatedToRevenueInterestLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NonCashRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the difference between the lease asset and the lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NonCashRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PaymentsFromRevenueInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from a revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PaymentsFromRevenueInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a revenue interest purchase agreement, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843409512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text">The Company and Basis of Presentation<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Esperion Therapeutics, Inc. ("the Company&#8221;) is the Lipid Management Company, a pharmaceutical company singularly focused on developing and commercializing affordable, oral, once-daily, non-statin medicines for the treatment of patients struggling with elevated low density lipoprotein cholesterol ("LDL-C"). The Esperion team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. The Company's first two products were approved by the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Swiss Agency for Therapeutic Products ("Swissmedic") in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease ("ASCVD") or heterozygous familial hypercholesterolemia ("HeFH"). </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 26, 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd ("DS"). Pursuant to the agreement, the Company granted DS exclusive development and commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. The Company received an upfront cash payment of $30.0&#160;million in May 2021 and is eligible to receive up to an additional $175.0&#160;million in sales milestones. The Company will also receive tiered royalties ranging from 5 percent to 20 percent on net sales in the DS Territory. Refer to Note 3 "Collaborations with Third Parties" for further information. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2021, the Company entered into Amendment No. 2 (the &#8220;RIPA Amendment&#8221;) to the Revenue Interest Purchase Agreement with Eiger III SA LLC (&#8220;Oberland&#8221;), an affiliate of Oberland Capital LLC, as agent for the purchaser parties thereto dated as of June 26, 2019 (as amended by the Amendment No. 1 dated as of November 9, 2020, the &#8220;RIPA&#8221;). Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50&#160;million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA and the related Security Agreement, which are discussed further in Note 8 "Liability Related to the Revenue Interest Purchase Agreement."</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's primary activities since incorporation have been conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. The Company received approval by the FDA in February 2020 to commercialize NEXLETOL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NEXLIZET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., and accordingly commenced principal operations on March 30, 2020 with the commercialization of NEXLETOL. The Company is subject to risks and uncertainties which include the need to successfully commercialize its products, research, develop, and clinically test therapeutic products; obtain regulatory approvals for its products; expand its management, commercial and scientific staff; and finance its operations with an ultimate goal of achieving profitable operations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has sustained annual operating losses since inception and expects such losses to continue over the foreseeable future. The Company's ability to successfully launch, commercialize and generate revenue from NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI has been and may continue to be adversely affected by the economic impact of the COVID-19 pandemic. In response to the Company&#8217;s history of operating losses and the uncertainty around the ongoing impact of COVID-19 management has initiated certain cost optimization measures and will implement additional cost reduction measures as needed if additional collaboration or capital funding is not available. Additionally, management may continue to fund operations and advance the development of the Company's products and product candidates through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, and permitted private and public equity offerings or through other sources. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available, the Company may not be able to continue the development of its current products or future product candidates, or to commercialize its current or future product candidates, if approved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods presented. Certain prior year amounts have been </span></div>reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843084104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of June&#160;30, 2021 nine customers accounted for all of the Company's net trade receivables and as of December 31, 2020 eight customers accounted for all the Company's net trade receivables.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#8220;API&#8221;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt">Product Sales, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $10.6 million and $17.0 million for the three and six months ended June&#160;30, 2021 and $0.6 million and $1.5 million for the three and six months ended June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#8217; distribution facilities, or free on board (&#8220;FOB&#8221;) destination, the terms of which are designated in the contract.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#8217;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#8220;Other accrued liabilities&#8221; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forms of Variable Consideration</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-pay assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company generally offers a right of return based on the product&#8217;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#8217;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#8217;s expectations regarding future payment patterns.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Implemented Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")  2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;). This ASU simplifies the accounting for convertible instruments by removing the separation models for convertible debt with cash conversion features and convertible instruments with a beneficial conversion feature, which requires the fair value of the embedded conversion feature of convertible instruments be allocated to equity. Under ASU 2020-06, a convertible debt instrument with those features will generally be reported as a single liability at its amortized cost with no separate accounting for the embedded conversion features in equity. The adoption of this ASU resulted in the reclassification of the portion of the Company's convertible notes from equity to debt, which also reduces reported interest expense and increases reported net income. ASU 2020-06 requires the application of the if-converted method when calculating diluted earnings per share, eliminating the Company&#8217;s ability to use the treasury stock method when certain conditions are met. The ASU is effective for annual reporting periods beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company early adopted this standard as of January 1, 2021 which resulted in a net increase in the convertible notes of approximately $92.0&#160;million, an adjustment to accumulated deficit of $1.5&#160;million, and a reduction to additional paid-in capital of $93.5&#160;million. The tax impact of the adoption was not material.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843403368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations with Third Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_CollaborativeArrangementAbstract', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations with Third Parties</a></td>
<td class="text">Collaborations with Third Parties<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DSE Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2019, the Company entered into a license and collaboration agreement with Daiichi Sankyo Europe GmbH ("DSE"). Pursuant to the agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablets in the European Economic Area and Switzerland (&#8220;DSE Territory&#8221;). DSE will be responsible for commercialization in the DSE Territory. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the consideration consists of a $150.0 million upfront cash payment as well as $150.0 million cash payment to the Company upon first commercial sales in the DSE Territory. The Company also is responsible to supply DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive a substantial additional regulatory milestone payment upon the grant of the marketing authorisation in the European Union for the CV risk reduction label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company will receive tiered fifteen percent (15%) to twenty-five percent (25%) royalties on net DSE Territory sales.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement calls for both parties to participate in a Joint Collaboration Committee (the &#8220;DSE JCC&#8221;). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement Terms Amendment</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2020, the Company entered into an amendment to the license and collaboration agreement with DSE, dated as of January 2, 2019. In June 2020, the Company completed the transfer of the MAAs for NILEMDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NUSTENDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pursuant to the terms of the amendment, DSE paid the Company the second $150.0 million milestone based on completion of the NUSTENDI MAA transfer rather than the first product sale in the EU, as previously agreed. Additionally, the Company and DSE have agreed to expand the DSE Territory, or the territory in which DSE has exclusive commercialization rights to NILEMDO and NUSTENDI to include Turkey. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $150.0 million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company&#8217;s intellectual property and 2) the obligation to provide ongoing regulatory and development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company&#8217;s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company&#8217;s obligation to provide ongoing regulatory and development activities. In the three and six months ended June 30, 2020, the Company recognized approximately $0.7&#160;million and $1.6&#160;million, respectively, related to the on-going performance obligation for the ongoing regulatory efforts related to the MAA in the DSE Territory, which was transferred to DSE in June 2020.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three and six months ended June 30, 2020, the Company recognized the $150.0&#160;million milestone as collaboration revenue based on the successful transfer of the NUSTENDI MAA. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the three and six months ended June&#160;30, 2021, the Company recognized collaboration revenue of approximately $2.0 million and $3.6&#160;million related to royalty revenue from DSE following their European launch of NILEMDO and NUSTENDI as well as the sales of bulk tablets to DSE pursuant to the supply agreement that was executed with DSE. In the three and six months ended June 30, 2020, the Company recognized collaboration revenue of $1.0&#160;million related to the sales of bulk tablets of NILEMDO and NUSTENDI to DSE.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All remaining future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Otsuka Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, the Company entered into the Otsuka Agreement with Otsuka Pharmaceutical Co., Ltd. ("Otsuka"). Pursuant to the Otsuka Agreement, the Company granted Otsuka exclusive development and commercialization rights to NEXLETOL and NEXLIZET in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the consideration consists of a $60.0 million upfront cash payment and the Company will be eligible to receive additional payments of up to $450.0 million if certain regulatory and commercial milestones are achieved by Otsuka. The potential future milestone payments include up to $20.0 million upon first JNDA submissions in the Otsuka Territory, up to $70.0 million upon the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and up to $50.0 million upon the achievement of the primary major adverse cardiovascular events (&#8220;MACE&#8221;) in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments up to $310.0 million related to total net sales achievements for Otsuka in Japan. Finally, the Company will receive tiered fifteen percent (15%) to thirty percent (30%) royalties on net sales in Japan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement calls for both parties to participate in a Joint Collaboration Committee (the "Otsuka JCC"). The Otsuka JCC is comprised of executive management from each company and Otsuka will lead in all aspects related to development and commercialization in the Otsuka Territory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company did not have any collaboration revenue from the Otsuka Agreement during the three and six months ended June 30, 2021. In the three and six months ended June 30, 2020, the Company recognized $60.0&#160;million of collaboration revenue related to the $60.0&#160;million upfront payment.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet recognized any revenue for milestone payments as the related regulatory and commercial milestones have not yet been achieved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Agreement Terms</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 26, 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Company, Limited ("DS Agreement"). Pursuant to the DS Agreement, the Company granted DS exclusive rights to develop and commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet (the "Products") in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible development and commercialization in these territories. In addition, DS will fund all development costs associated with the program in the DS Territory.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the consideration consists of a $30.0&#160;million upfront cash payment that is non-refundable, non-reimbursable and non-creditable. The Company will be eligible to receive additional one-time payments of up to $175.0&#160;million if certain commercial milestones are achieved by DS. Also, the Company will receive tiered royalties of five percent (5%) to twenty percent (20%) of net sales in the DS Territory.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement requires the parties to establish a joint collaboration committee (the "Joint Collaboration Committee" or "JCC"). The Joint Collaboration Committee is composed of six (6) members, with each Party contributing three (3) representatives each who are employees of such Party with main responsibility of overseeing the Development and Commercialization activities relating to the Licensed Products in the Field in the DS Territory and other responsibilities as stated in the Agreement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $30.0&#160;million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company&#8217;s intellectual property and 2) the obligation to provide ongoing development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company&#8217;s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company&#8217;s obligation to provide ongoing development activities. Accordingly, for the three and six months ended June 30, 2021, the Company recognized $28.1&#160;million of collaboration revenue related to the $30.0&#160;million upfront payment. The $28.1&#160;million relates to the performance obligations for the license to the Company&#8217;s intellectual property and a portion of ongoing regulatory and development activities conducted during the period ended June 30, 2021, in the amounts of $28.0&#160;million and $0.1 million, respectively. The remaining $1.9&#160;million of the upfront payment was deferred as of June 30, 2021 due to an on-going performance obligation related to the developmental activities in South Korea and Taiwan. This deferred revenue will be recognized ratably over the period leading up to the completion of these developmental activities.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Agreements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2020, the Company entered into a licensing agreement with Serometrix to in-license a series of early stage compounds known as scaffolds related to its oral, small molecule PCSK9 inhibitor program. PCSK9 is an enzyme responsible for regulating LDL receptors. PCSK9 inhibitors stop LDL receptors from being broken down, increasing the number of LDL receptors present to remove cholesterol from the blood. The agreement allows the Company use of the PCSK9 compounds, which were patented by Serometrix prior to the licensing agreement, to perform further research and development with the goal of developing a small molecule oral PCSK9 inhibitor that can be taken as a tablet.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for these rights, the Company agreed to pay Serometrix an upfront payment, milestone payments and royalties on net sales of licensed products under the agreement. The Company is obligated to make milestone payments to Serometrix upon the achievement of specified development, regulatory and commercialization milestones. The development milestone payments due under the agreement depend on the licensed product being developed. As part of the agreement, the Company made an upfront cash payment of $12.5&#160;million in December 2020, which was recorded to research and development expense, to Serometrix, with payments in future years tied to specific milestones. The Company has also agreed to pay tiered royalties based on net sales of all products licensed under the agreement of mid-single-digit to low double-digit percentages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843917224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,136&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843328376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 12, 2016, a purported stockholder of the Company filed a putative class action lawsuit in the United States District Court for the Eastern District of Michigan, against the Company and Tim Mayleben, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Kevin L. Dougherty v. Esperion Therapeutics, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (No. 16-cv-10089). The lawsuit alleges that the Company and Mr. Mayleben violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by allegedly failing to disclose in an August 17, 2015, public statement that the FDA would require a cardiovascular outcomes trial before approving the Company&#8217;s lead product candidate. The lawsuit seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between August 18, 2015, and September 28, 2015, as well as attorneys&#8217; fees and costs. On May 20, 2016, an amended complaint was filed in the lawsuit and on July 5, 2016, the Company filed a motion to dismiss the amended complaint. </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 27, 2016, the court granted the Company&#8217;s motion to dismiss with prejudice and entered judgment in the Company&#8217;s favor. On January 24, 2017, the plaintiffs in this lawsuit filed a motion to alter or amend the judgment. In May 2017, the court denied the plaintiff&#8217;s motion to alter or amend the judgment. &#160;In May 2017, the court denied the plaintiff&#8217;s motion to alter or amend the judgment. On June 19, 2017, the plaintiffs filed a notice of appeal to the Sixth Circuit Court of Appeals and on September 14, 2017, they filed their opening brief in support of the appeal. The appeal was fully briefed on December 7, 2017, and it was argued before the Sixth Circuit on March 15, 2018. On September 27, 2018, the Sixth Circuit issued an opinion in which it reversed the district court&#8217;s dismissal and remanded for further proceedings. On October 11, 2018, the Company filed a petition for rehearing en banc and, on October 23, 2018, the Sixth Circuit Court of Appeals directed plaintiffs to respond to that petition. On December 3, 2018, the Sixth Circuit denied the Company&#8217;s petition for en banc rehearing, and on December 11, 2018, the case was returned to the federal district court by mandate from the Sixth Circuit. On December 26, 2018, the Company filed an answer to the amended complaint, and on March 28, 2019, the Company filed its amended answer to the amended complaint. On September 15, 2020, the Company filed a motion for summary judgment, and the plaintiffs filed a motion for partial summary judgment, and on October 23, 2020, the parties filed oppositions to both motions for summary judgment. On November 20, 2020, the Company and plaintiffs filed replies in support of their respective motions. On March 12, 2021, the parties agreed to a settlement in principle of the securities class action, and on April 26, 2021, the parties entered into a stipulation of settlement to resolve all legal claims, in which defendants expressly deny that they have committed any act or omission giving rise to any liability under Section 10(b) of the Securities Exchange Act of 1934. Under the terms of the stipulation of settlement, which the court preliminarily approved on May 6, 2021, the Company and certain of the Company's insurance carriers will cause a payment of $18.25&#160;million to be made to the plaintiff class. There is no assurance that the settlement will ultimately become final. If the settlement does not occur and litigation continues, the Company intends to vigorously defend against it. As a result of this settlement agreement, during the three months ended March 31, 2021, the Company recorded a loss on settlement of $13.25&#160;million in selling, general, and administrative expenses on the condensed statement of operations, which represents the litigation settlement of $18.25&#160;million offset by $5.0&#160;million in insurance claim proceeds from our insurance carriers.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2016, a purported stockholder of the Company filed a derivative lawsuit in the Court of Chancery of the State of Delaware against Tim Mayleben, Roger Newton, Mary McGowan, Nicole Vitullo, Dov Goldstein, Daniel Janney, Antonio Gotto Jr., Mark McGovern, Gilbert Omenn, Scott Braunstein, and Patrick Enright. The Company is named as a nominal defendant. The lawsuit alleges that the defendants breached their fiduciary duties to the Company when they made or approved improper statements on August 17, 2015, regarding the Company&#8217;s lead product candidate&#8217;s path to FDA approval, and failed to ensure that reliable systems of internal controls were in place at the Company. On February 8, 2019, the Company and defendants filed a motion to dismiss the derivative lawsuit. On April 23, 2019, the plaintiff filed an opposition to the motion to dismiss the derivative lawsuit, and the Company filed a reply brief on May 15, 2019. On November 6, 2019, the court held a hearing on the motion to dismiss. On February 13, 2020, the court granted the motion to dismiss with prejudice and entered judgment in the Company&#8217;s favor. On March 16, 2020, the plaintiff filed a notice of appeal to the Supreme Court of Delaware. On June 1, 2020, the plaintiff filed his opening brief on appeal to the Supreme Court of Delaware. On July 1, 2020, the Company and the defendants filed an answering brief, and on July 16, 2020, the plaintiff filed a reply brief. On October 14, 2020, the Supreme Court of Delaware held oral arguments on the appeal. On October 29, 2020, the Supreme Court of Delaware issued an order affirming the judgment of the Court of Chancery. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the Company&#8217;s contractual obligations and commitments and contingencies outside the ordinary course of business from those previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 or noted above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841530888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s cash equivalents and short-term investments (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, other income, net in the statements of operations includes interest income on investments of less than $0.1 million and less than $0.1 million, respectively. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2020, other income, net in the statements of operations includes interest income on investments of $0.1 million and $0.5 million, respectively. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unrealized gains or losses on investments reclassified from accumulated other comprehensive income (loss) to other income in the statements of operations during the three and six months ended June&#160;30, 2021 and 2020.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three and six months ended June&#160;30, 2021, there were no allowances for credit losses and all unrealized gains (losses) for available-for-sale securities were recognized in accumulated other comprehensive income (loss). As of June&#160;30, 2021, the Company had no accrued interest receivables.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843355864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three level hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1 inputs:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices for identical assets or liabilities in active markets;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2 inputs:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level&#160;1 prices, such as quoted market prices for similar assets or liabilities or other inputs that are observable or can be corroborated by market data; and</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3 inputs:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that are supported by little or no market activity and require the reporting entity to develop assumptions that market participants would use when pricing the asset or liability.</span></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets that have been measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2 or 3 during the three and six months ended June&#160;30, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841525784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Revenue Interest Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock', window );">Liability Related to the Revenue Interest Purchase Agreement</a></td>
<td class="text">Liability Related to the Revenue Interest Purchase AgreementOn June 26, 2019, the Company entered into a RIPA with Oberland, as agent for purchasers party thereto (the &#8220;Purchasers&#8221;), and the Purchasers named therein, to obtain financing in respect to the commercialization and further <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of bempedoic acid and the bempedoic acid / ezetimibe combination tablets and other working capital needs. Pursuant to the RIPA, the Company received $125.0 million at closing, less certain issuance costs. The Company was also entitled to receive up to approximately $75.0 million in subsequent installments subject to the terms and conditions set forth in the RIPA: (i) $25.0 million upon certain regulatory approval of its product candidates and (ii) $50.0 million, at the Company&#8217;s option, upon reaching $100.0 million trailing worldwide six-month net sales any time prior to December 31, 2021 (the &#8220;Third Payment&#8221;). In March 2020, the Company received $25.0 million from Oberland upon receiving regulatory approval of NEXLETOL.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from the Company based upon net sales of the Company&#8217;s certain products which will be tiered payments initially ranging from 2.5% to 7.5% of the Company&#8217;s net sales in the covered territory (the &#8220;Covered Territory&#8221;); provided that (a) if annual net sales equal or exceed $350.0 million by December 31, 2021 (the &#8220;Sales Threshold&#8221;), the initially tiered revenue interest rate will be decreased to a single rate of 2.5% of the Company&#8217;s net sales in the Covered Territory, beginning on January 1, 2022, and (b) if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024, the revenue interest rate will be decreased to a single rate of 0.4% of the Company&#8217;s net sales in the Covered Territory beginning on January 1, 2025. If the Third Payment is drawn down by the Company, the applicable royalty rates will increase by one-third. The Covered Territory is the United States, but is subject to expand to include the world-wide net sales if the Company&#8217;s annual U.S. net sales are less than $350.0 million for the year ended December 31, 2021. The U.S. net sales milestone thresholds are not to be taken as financial guidance. The Purchasers&#8217; rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received Revenue Interests payments of 195% of the then aggregate purchase price (the &#8220;Cumulative Purchaser Payments&#8221;) paid to the Company, unless the RIPA is terminated earlier.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RIPA, the Company has an option (the &#8220;Call Option&#8221;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#8220;Put Option&#8221;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option is exercised prior to the first anniversary of the closing date by the Purchasers (except pursuant to a change of control), the required repurchase price will be 120% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests). In all other cases, if the Put Option or the Call Option are exercised, the required repurchase price will be 175% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 195% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the RIPA contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RIPA Amendments</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 26, 2021, the Company entered into Amendment No. 2 (the &#8220;RIPA Amendment&#8221;) to the RIPA with Oberland, as agent for the purchaser parties thereto. Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50&#160;million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA such that the purchasers will have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from the Company based on net sales of the Company&#8217;s certain products, once approved, which will be tiered payments ranging from 3.33% to 10% (the &#8220;Third Payment Applicable Percentage&#8221;) of the Company&#8217;s net sales in the covered territory (the &#8220;Covered Territory&#8221;); provided that (a) prior to December 31, 2024, with respect to each country defined in the Daiichi Territory, if the percentage of net sales that Company receives from Daiichi (the &#8220;Receivables Percentage&#8221;) is less than the Third Payment Applicable Percentage, then the Revenue Interest for such country payable to the purchasers will be equal to the Receivables Percentages, (b) if annual net sales equal or exceed $350&#160;million and if the Purchasers receive 100% of their invested capital (<br/>Cumulative Purchaser Payments") by December 31, 2024, the revenue interest rate will be decreased to a single rate of 3.33% of the Company&#8217;s net sales in the Covered Territory for all subsequent calendar quarters and (c) if the Purchasers receive Revenue Interest payments less than 100% of Cumulative Purchaser Payments by December 31, 2024, the Third Payment Applicable Percentage will be increased to a single rate of the Company&#8217;s net sales that would have provided 100% of Cumulative Purchaser Payments had such rate applied from the initial funding by the Purchasers. The Covered Territory was originally the United States, but has been expanded to worldwide for all calendar years beginning on or after January 1, 2022. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the RIPA, the Company has an option (the &#8220;Call Option&#8221;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#8220;Put Option&#8221;) to terminate </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price will be 200% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 470&#8209;50, &#8220;Debt&#8212;Modifications and Extinguishments,&#8221; the RIPA Amendment was accounted for as a debt modification. The amendment resulted in a $0.1&#160;million loss on modification of debt, consisting of third-party fees associated with the transaction, which is included in selling, general, and administrative expenses in the statements of operations for the three and six months ended June 30, 2021.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2021, the Company entered into an Amendment to the Security Agreement and Waiver ("Amendment and Waiver") with the same parties to the Security Agreement, by and among the Company, Eiger Partners II LP (the "Purchaser") and Eiger III SA LLC (the "Purchaser Agent"), dated as of June 26, 2019 (the "Security Agreement"). Pursuant to the Amendment and Waiver, if (i) the net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States (as reported in the Company&#8217;s financial statements as &#8220;product sales, net&#8221; in accordance with GAAP and excluding, for the avoidance of doubt, upfront or milestone payments and other collaboration revenue) (the &#8220;Specified Net Revenue&#8221;) for the calendar quarter ending September 30, 2021 does not exceed $15.0 million, or (ii) the Specified Net Revenue for any calendar quarter ending after September 30, 2021 does not exceed $15.0 million, then the Company shall deposit $50.0 million in a deposit account that is subject to a block account control agreement in favor of the Purchase Agent, no later than the earlier of (x) the date the Specified Net Revenue for such calendar quarter has been determined and (y) 45 days after the last day of such calendar quarter. The Purchaser Agent shall have sole dominion and control over all funds deposited in the deposited account and such funds may be withdrawn therefrom only with the consent of the Purchaser Agent. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to apply amounts held in the deposit account in payment of certain secured obligations in the manner provided for in the Security Agreement. The Amendment and Wavier does not substitute, replace or release the Pledgors from any other obligations under the RIPA or Security Agreement.</span></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the arrangement, as of June&#160;30, 2021, the Company has recorded a liability, referred to as the &#8220;Revenue interest liability&#8221; in the condensed balance sheets, of $238.2 million, net of $0.5 million of capitalized issuance costs in connection with the RIPA. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The Company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant increase or decrease in net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. The Company recorded approximately $8.0&#160;million and $12.9&#160;million in interest expense related to this arrangement for the three and six months ended June&#160;30, 2021, and $4.6&#160;million and $8.8&#160;million for the three and six months ended June 30, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment of the RIPA to Oberland does not have a fixed repayment schedule, rather it will be completely repaid and extinguished when the Company has repaid 200% of the aggregate purchase price prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments thereafter, unless the RIPA is terminated earlier. Since there is not a fixed repayment schedule, the Company does not project its future repayments by year. Each period, the Company estimates the future expected sales of its products in the covered territory and determines the effective annual imputed interest rate, which updates and changes the timing of the Company&#8217;s payments. Under the terms of the agreement, every $100&#160;million of net sales generated, less than or equal to $250&#160;million in an annual aggregate year, would result in a repayment obligation of approximately $10.0&#160;million or 10.0% at the stated repayment rate in the first year. Annual Net Sales for a calendar year exceeding $250&#160;million would result in a repayment obligation of approximately $3.3&#160;million or 3.3% for every $100&#160;million of sales above the threshold. If the Company equals or exceeds $350&#160;million of sales in the U.S. in 2021, then the repayment amount would drop to $3.3&#160;million for every $100&#160;million of net sales starting in 2022. If the US net sales are less than $350&#160;million for the year ended December 31, 2021, then the Covered Territory is expanded to include worldwide sales beginning in 2022. The Company&#8217;s repayments of the RIPA are directly tied to the growth of its net sales, and as the Company&#8217;s net sales grow, the Company expects the related repayments of the RIPA to grow as well. The Company currently expects to repay $12.5&#160;million in the next twelve months.  </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual imputed interest rate is 17.2% as of June&#160;30, 2021. The Company incurred $0.6 million of issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. Payments made to Oberland as a result of the Company&#8217;s net sales will reduce the revenue interest liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the six months ended June&#160;30, 2021:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;Oberland funding upon execution of Amendment No. 2, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interests payments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC ("Oberland").</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841765464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text">Convertible Notes<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2020, the Company issued $250.0&#160;million aggregate principal amount of 4.0% senior subordinated convertible notes due November 15, 2025. The net proceeds the Company received from the offering of the initial notes was approximately $242.0&#160;million, after deducting the initial purchasers&#8217; discounts and commissions and offering expenses payable by the Company. In connection with the offering of the senior subordinated convertible notes, the Company granted the initial purchasers of the senior subordinated convertible notes a 30-day option to purchase up to an additional $30.0&#160;million aggregate principal amount of the senior subordinated convertible notes on the same terms and conditions. On November 18, 2020 the option was exercised, which resulted in approximately $29.1&#160;million of additional proceeds, for total aggregate principal of $280.0&#160;million and net proceeds of $271.1&#160;million (the additional notes and, together with the initial notes, collectively called the &#8220;Convertible Notes&#8221;). The Company used approximately $46.0&#160;million of the net proceeds from the offering of the notes to pay the cost of the Capped Call (as defined below) and $55.0&#160;million of the net proceeds from the offering of the initial notes to finance the Prepaid Forward (as defined below). The Convertible Notes are the Company's senior unsecured obligations and mature on November 15, 2025 (the &#8220;Maturity Date&#8221;), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Convertible Notes are convertible into shares of the Company&#8217;s common stock, can be repurchased for cash, or a combination thereof, at the Company&#8217;s election, at an initial conversion rate of 30.2151 shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $33.096 per share of common stock, subject to adjustment. The Company will pay interest on the Convertible Notes semi-annually in arrears on May 15 and November 15 of each year.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes are general unsecured obligations of the Company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the Company&#8217;s RIPA, the revenue interests issued pursuant to such agreement, and any refinancing of the foregoing.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2025 in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended on March 31, 2021 (and only during such calendar quarter), if the last reported sale price per share of the Company&#8217;s common stock, par value $0.001 per share (&#8220;common stock&#8221;), is greater than or equal to 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five business days after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company&#8217;s common stock and the conversion rate for the notes on each such trading day; (3) if the Company calls such notes for redemption, any such notes that have been called for redemption may be converted at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption; and (4) upon the occurrence of specified corporate events, as provided in the Indenture.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 15, 2025, to the close of business on the second scheduled trading day immediately before the maturity date, holders may convert all or any portion of their notes at the applicable conversion rate at any time at the option of the holder regardless of the foregoing conditions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, following certain corporate events or following issuance of a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corporate event or to convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after November 20, 2023 and before the 41st scheduled trading day immediately before the maturity date, at a cash redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company&#8217;s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date the Company sends the related redemption notice, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company sends such redemption notice. No sinking fund is provided for the notes. If the Company redeems less than all the outstanding notes, at least $125.0&#160;million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the Indenture), holders may require the Company to repurchase their notes for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. The Indenture includes customary terms and covenants, including certain events of default.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $8.9&#160;million of issuance costs related to the issuance of the Convertible Notes, of which, prior to the adoption of ASU 2020-06 on January 1, 2021, $5.8&#160;million and $3.1&#160;million were allocated and recorded to long-term debt and additional paid-in capital, respectively. The $5.8&#160;million of issuance costs recorded as long-term debt on the condensed balance sheet are amortized over the five-year contractual term of the Convertible Notes using the effective interest method. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASU 2020-06 on January 1, 2021, the $271.1&#160;million of proceeds received from the issuance of the Convertible Notes were allocated between long-term debt (the &#8220;liability component&#8221;) of $177.6&#160;million and additional paid-in capital (the &#8220;equity component&#8221;) of $93.5&#160;million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Convertible Notes and was included in additional paid-in capital in the condensed balance sheet and was not remeasured as long as it did not to meet the conditions for equity classification. The liability component was to be accreted up to the face value of the Convertible Notes of $280.0&#160;million, which resulted in additional non-cash interest expense being recognized through the Maturity Date. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the adoption of ASU 2020-06 as of January 1, 2021, the Company reports the convertible debt liability at the aggregate principal amount less unamortized issuance costs. This resulted in the reclassification of the $93.5&#160;million of the Company&#8217;s convertible notes recognized at December 31, 2020 from additional paid in capital to the convertible debt liability. The portion of interest expense previously recognized for the accretion of the convertible debt liability and the true-up of the amortization of the issuance costs of $1.5&#160;million was recorded as an adjustment to accumulated deficit.  </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the outstanding principal and debt issuance cost balances as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible note, debt balance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt issuance cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible notes, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,733)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to net principal due to adoption of ASU 2020-06</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,902)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $3.2&#160;million and $6.4&#160;million of interest expense during the three and six months ended June&#160;30, 2021, relating to the cash interest on the convertible notes due semi-annually and amortization of the debt issuance costs. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, no Convertible Notes were convertible pursuant to their terms. The estimated fair value of the Convertible Notes was $233.6&#160;million and $283.4&#160;million as of June&#160;30, 2021 and December 31, 2020, respectively. The </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. As of June&#160;30, 2021 and December 31, 2020, the if-converted value of the Convertible Notes did not exceed the principal value of those notes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capped Call Transactions</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into privately-negotiated capped call transactions with one of the initial purchasers of the convertible notes or its affiliate and certain other financial institutions. The Company used approximately $46.0&#160;million of the net proceeds from the offering of the Convertible Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce potential dilution to the Company&#8217;s common stock upon any conversion of the Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, in the event that the market value per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the Convertible Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $55.16 (which represents a premium of approximately 100% over the last reported sale price of the Company&#8217;s common stock on November 11, 2020), subject to certain adjustments. The capped call transactions are separate transactions, entered into by the Company and are not part of the terms of the Convertible Notes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that the transactions meet certain accounting criteria, the convertible note capped call transactions are recorded in stockholders&#8217; equity, and they are not accounted for as derivatives and are not remeasured each reporting period. As of June&#160;30, 2021 and December 31, 2020, the Company had not purchased any shares under the convertible note capped call transactions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Forward</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into a prepaid forward stock repurchase transaction (&#8220;Prepaid Forward&#8221;) with a financial institution (&#8220;Forward Counterparty&#8221;). Pursuant to the Prepaid Forward, the Company used approximately $55.0&#160;million of the net proceeds from the offering of the Convertible Notes to fund the Prepaid Forward. The aggregate number of shares of the Company&#8217;s common stock underlying the Prepaid Forward was approximately 1,994,198. The expiration date for the Prepaid Forward is November 15, 2025, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders&#8217; votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company&#8217;s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843623384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Accrued Liabilities</a></td>
<td class="text">Other Accrued Liabilities<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued variable consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,673&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841753784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Compensation</a></td>
<td class="text">Stock Compensation<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the board of directors approved the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") which was approved by the Company's shareholders on May 28, 2020. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary or wages up to $25,000 annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to 15% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in six months increments, commencing on September 1 and March 1 of each calendar year with the administrator having the right to establish different offering periods. In the three and six months ended June&#160;30, 2021, the Company recognized approximately $0.1&#160;million and $0.4&#160;million of stock compensation expense related to the ESPP, respectively. As of June&#160;30, 2021, there have been 50,818 shares issued and 774,182 shares reserved for future issuance under the ESPP.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s options to purchase common stock for the six months ended June&#160;30, 2021:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,176,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited&#160;or&#160;expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the Company&#8217;s stock option plan as of June&#160;30, 2021:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,948,732&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.94</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options was $6.2 million and $9.9 million for the three and six months ended June&#160;30, 2021, respectively, including $0.2 million and $0.5 million that were capitalized into inventory, and $5.5 million and $11.1 million for the three and six months ended June&#160;30, 2020, respectively, including $0.3 million and $0.5 million that were capitalized into inventory. As of June&#160;30, 2021, there was $20.3 million of unrecognized stock-based compensation expense related to unvested options, which will be recognized over a weighted-average period of 2.7 years. The increase in stock option expense for the three months ended June 30, 2021, was primarily due to an equity modification related to the CEO Departure Agreement entered into between the Company and the Company's former CEO on May 16, 2021. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (or RSUs)</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s RSUs for the six months ended June&#160;30, 2021:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value Per <br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,604)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to RSUs was approximately $2.2 million and $4.0 million for the three and six months ended June&#160;30, 2021, respectively, including $0.1 million and $0.2 million that were capitalized into inventory, and approximately $1.8 million and $3.3&#160;million for the three and six months ended June 30, 2020, respectively, including $0.1 million and $0.1 million that were capitalized into inventory. As of June&#160;30, 2021, there was $28.2 million of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted-average period of 3.2 years.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based Restricted Stock Units ("PBRSUs")</span></div>The Company's PBRSUs vest after a two-year performance period contingent upon the achievement of predetermined performance-based milestones based on the Company's U.S. net product sales. The actual number of units (if any) received under this award will depend on continued employment and actual performance over the two-year performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBRSUs based on the expected performance period to achieve the performance milestone. The fair value of the PBRSUs is based on the quoted market price of our common stock on the date of grant. During the three and six months ended June 30, 2021 the Company granted 64,200 PBRSUs with a weighted-average fair value per share of $22.52. The Company expects the performance criteria to be met.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843407848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThere was no provision for income taxes for the three and six months ended June&#160;30, 2021 and 2020, because the Company has incurred annual operating losses since inception. At June&#160;30, 2021, the Company continues to conclude that it is not more likely than not that the Company will realize the benefit of its deferred tax assets due to its history of losses. Accordingly, a full valuation allowance has been applied against the net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841801448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income Per Common Share</a></td>
<td class="text">Net (Loss) Income Per Common Share<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated by dividing net (loss) income by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common stock equivalents outstanding for the period, including shares that potentially could be dilutive if they were exercised or vested during the period, determined using the treasury-stock method. For purposes of this calculation, stock options, unvested RSUs, unvested PBRSUs, shares issuable under the ESPP and shares issuable upon conversion of the convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net (loss) income per share:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:43.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income (in thousands)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,668)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,225,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,109,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,592,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,225,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,854,445&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,109,089&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,948,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share - diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net (loss) income per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,391,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested PBRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable related to the ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,460,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,460,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,417,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,722,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,417,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,581,939&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841893928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods presented. Certain prior year amounts have been </span></div>reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of June&#160;30, 2021 nine customers accounted for all of the Company's net trade receivables and as of December 31, 2020 eight customers accounted for all the Company's net trade receivables.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#8220;API&#8221;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt">Product Sales, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $10.6 million and $17.0 million for the three and six months ended June&#160;30, 2021 and $0.6 million and $1.5 million for the three and six months ended June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#8217; distribution facilities, or free on board (&#8220;FOB&#8221;) destination, the terms of which are designated in the contract.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#8217;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#8220;Other accrued liabilities&#8221; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forms of Variable Consideration</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-pay assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company generally offers a right of return based on the product&#8217;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#8217;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#8217;s expectations regarding future payment patterns.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Implemented Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Implemented Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")  2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;). This ASU simplifies the accounting for convertible instruments by removing the separation models for convertible debt with cash conversion features and convertible instruments with a beneficial conversion feature, which requires the fair value of the embedded conversion feature of convertible instruments be allocated to equity. Under ASU 2020-06, a convertible debt instrument with those features will generally be reported as a single liability at its amortized cost with no separate accounting for the embedded conversion features in equity. The adoption of this ASU resulted in the reclassification of the portion of the Company's convertible notes from equity to debt, which also reduces reported interest expense and increases reported net income. ASU 2020-06 requires the application of the if-converted method when calculating diluted earnings per share, eliminating the Company&#8217;s ability to use the treasury stock method when certain conditions are met. The ASU is effective for annual reporting periods beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company early adopted this standard as of January 1, 2021 which resulted in a net increase in the convertible notes of approximately $92.0&#160;million, an adjustment to accumulated deficit of $1.5&#160;million, and a reduction to additional paid-in capital of $93.5&#160;million. The tax impact of the adoption was not material.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843231656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,136&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841860872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Company's Cash Equivalents and Short-Term Investments</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s cash equivalents and short-term investments (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843392904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets that have been measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,734&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843300008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Revenue Interest Purchase Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock', window );">Summary of Revenue Interest Liability Activity During the Period</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the six months ended June&#160;30, 2021:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;Oberland funding upon execution of Amendment No. 2, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interests payments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to the revenue interest liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ScheduleOfRevenueInterestLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843444120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Convertible Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the outstanding principal and debt issuance cost balances as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible note, debt balance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt issuance cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible notes, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,733)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to net principal due to adoption of ASU 2020-06</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,902)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841541624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued variable consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,673&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347852012968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Relating to the Company's Options to Purchase Common Stock</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s options to purchase common stock for the six months ended June&#160;30, 2021:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,176,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited&#160;or&#160;expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Summary of Information About the Company's Stock Option Plan</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the Company&#8217;s stock option plan as of June&#160;30, 2021:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,948,732&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.94</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Activity Relating to the Company's RSUs</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s RSUs for the six months ended June&#160;30, 2021:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value Per <br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,604)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841794504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculation of Basic and Diluted (Loss) Income Per Share</a></td>
<td class="text">The following table summarizes the calculation of basic and diluted net (loss) income per share:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:43.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income (in thousands)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,668)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,225,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,109,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,592,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,225,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,854,445&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,109,089&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,948,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share - diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net (loss) income per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,391,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested PBRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable related to the ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,460,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,460,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,417,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,722,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,417,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,581,939&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347843682280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Daiichi Sankyo Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_UpFrontPayment', window );">Upfront cash payment received (paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones', window );">Potential additional future payments</a></td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Daiichi Sankyo Co. Ltd | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Daiichi Sankyo Co. Ltd | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember', window );">RIPA Amendment | Oberland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ProceedsFromRevenueInterestPurchaseAgreement', window );">Proceeds from Revenue Interest Purchase Agreement</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalties to be received on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRoyaltiesToBeReceivedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ProceedsFromRevenueInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Revenue Interest Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ProceedsFromRevenueInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of up-front payment received (paid) .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847168424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>customer </div>
<div>revenue_source</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_SignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_NumberOfSourcesOfRevenue', window );">Number of revenue sources | revenue_source</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 40,659<span></span>
</td>
<td class="nump">$ 212,236<span></span>
</td>
<td class="nump">$ 48,637<span></span>
</td>
<td class="nump">$ 214,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes, net of issuance costs</a></td>
<td class="nump">272,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="nump">971,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="num">(722,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(722,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (797,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_SignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 10,610<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 16,960<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_SignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Receivables | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_SignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ConcentrationRiskNumberOfMajorCustomers', window );">Number of major customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ConcentrationRiskNumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's major customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ConcentrationRiskNumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NumberOfSourcesOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Sources Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NumberOfSourcesOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347767188136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations with Third Parties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2021</div></th>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,659,000<span></span>
</td>
<td class="nump">$ 212,236,000<span></span>
</td>
<td class="nump">$ 48,637,000<span></span>
</td>
<td class="nump">$ 214,076,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=espr_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,049,000<span></span>
</td>
<td class="nump">211,627,000<span></span>
</td>
<td class="nump">31,677,000<span></span>
</td>
<td class="nump">212,609,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember', window );">Daiichi Sankyo Europe GmbH ("DSE") | Regulatory performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Upfront payment, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember', window );">Daiichi Sankyo Europe GmbH ("DSE") | Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember', window );">Daiichi Sankyo Europe GmbH ("DSE") | NILEMDO and NUSTENDI, sales of bulk tablets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember', window );">Daiichi Sankyo Europe GmbH ("DSE") | NUSTENDI, MAA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember', window );">Daiichi Sankyo Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Daiichi Sankyo Europe GmbH ("DSE")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_UpFrontPayment', window );">Upfront cash payment received (paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_CashPaymentToBeReceivedUponFirstCommercialSales', window );">Cash payment to the Company upon first commercial sales in the DSE Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Daiichi Sankyo Europe GmbH ("DSE") | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Daiichi Sankyo Europe GmbH ("DSE") | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Daiichi Sankyo Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_UpFrontPayment', window );">Upfront cash payment received (paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_FutureUpFrontPayment', window );">Future upfront payment</a></td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones', window );">Potential additional future payments</a></td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones', window );">Cash payment to be received upon certain commercial milestones</a></td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_DeferredUpFrontPayment', window );">Deferred up-front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Daiichi Sankyo Co. Ltd | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Daiichi Sankyo Co. Ltd | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaboration Agreement | Serometrix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_UpFrontPayment', window );">Upfront cash payment received (paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_AmendedLicenseAndCollaborationAgreementMember', window );">Amended License and Collaboration Agreement | Daiichi Sankyo Europe GmbH ("DSE")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer', window );">Proceeds received upon completion of NUSTENDI MAA transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember', window );">Exclusive Developmental Activities | Otsuka Pharmaceutical Co, Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_UpFrontPayment', window );">Upfront cash payment received (paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones', window );">Potential additional future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember', window );">Exclusive Developmental Activities | Otsuka Pharmaceutical Co, Ltd. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember', window );">Exclusive Developmental Activities | Otsuka Pharmaceutical Co, Ltd. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory', window );">Milestone payment, first JNDA submissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory', window );">Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies', window );">Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_FuturePaymentMilestoneSalesMilestones', window );">Milestone payments related to total net sales achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember', window );">Exclusive Developmental Activities | Otsuka Pharmaceutical Co, Ltd. | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_CollaborativeArrangementLicenseToIntellectualPropertyMember', window );">Collaborative Arrangement, License To Intellectual Property | Daiichi Sankyo Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember', window );">Collaborative Arrangement, Ongoing Regulatory And Development Activities | Daiichi Sankyo Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Payment To Be Received Upon Certain Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CashPaymentToBeReceivedUponCertainCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CashPaymentToBeReceivedUponFirstCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash payment to the Company upon first commercial sales in the DSE Territory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CashPaymentToBeReceivedUponFirstCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_DeferredUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Up-Front Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_DeferredUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FuturePaymentMilestoneSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FuturePaymentMilestoneSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FutureUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Up-Front Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FutureUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalties to be received on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRoyaltiesToBeReceivedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds received upon achievement of the milestone for completion of the NUSTENDI Marketing Authorization Approval (MAA) transfer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of up-front payment received (paid) .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=espr_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=espr_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=espr_RegulatoryPerformanceObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=espr_RegulatoryPerformanceObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=espr_ProductSalesBulkTabletsNilemdoAndNustendiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=espr_ProductSalesBulkTabletsNilemdoAndNustendiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=espr_MilestoneMarketingAuthorizationApprovalNustendiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=espr_MilestoneMarketingAuthorizationApprovalNustendiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_SerometrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_SerometrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_AmendedLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_AmendedLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_OtsukaPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_OtsukaPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_CollaborativeArrangementLicenseToIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_CollaborativeArrangementLicenseToIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841633208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 21,293<span></span>
</td>
<td class="nump">$ 13,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">2,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory</a></td>
<td class="nump">$ 23,714<span></span>
</td>
<td class="nump">$ 16,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841708216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Pending Litigation - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payment to plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss related to litigation settlement</a></td>
<td class="nump">$ 13,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation settlement</a></td>
<td class="nump">18,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivable', window );">Insurance settlement recovery</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847925368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Cash Equivalents and Short-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 201,734<span></span>
</td>
<td class="nump">$ 281,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">201,734<span></span>
</td>
<td class="nump">281,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">201,734<span></span>
</td>
<td class="nump">281,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 201,734<span></span>
</td>
<td class="nump">$ 281,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847499800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 449,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Accrued interest receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income on investments</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847450872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 201,734<span></span>
</td>
<td class="nump">$ 281,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">201,734<span></span>
</td>
<td class="nump">281,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">201,734<span></span>
</td>
<td class="nump">281,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">201,734<span></span>
</td>
<td class="nump">281,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">201,734<span></span>
</td>
<td class="nump">281,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347767097528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 16, 2021</div></th>
<th class="th"><div>Apr. 26, 2021</div></th>
<th class="th"><div>Jun. 26, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,144,000<span></span>
</td>
<td class="nump">$ 4,640,000<span></span>
</td>
<td class="nump">$ 19,269,000<span></span>
</td>
<td class="nump">$ 8,811,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement (RIPA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestLiability', window );">Revenue interest liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,604,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement', window );">Capitalized issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember', window );">RIPA Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Loss on modification of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember', window );">Oberland | Revenue Interest Purchase Agreement (RIPA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_GrossProceedsFromRevenueInterestPurchaseAgreement', window );">Gross proceeds from revenue interest liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions', window );">Total amount of subsequent installment, subject to RIPA terms and conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval', window );">Amount of subsequent installment, subject to regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold', window );">Amount of subsequent installment, subject to achievement of sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment', window );">Milestone amount for worldwide sales to receive the third payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ProceedsFromRevenueInterestPurchaseAgreement', window );">Proceeds from Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestRateTierTwo', window );">Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestRateInitialRate', window );">Initial revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate', window );">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory', window );">Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate', window );">Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestRateTierThree', window );">Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates', window );">Percentage of revenue interests payment on which agreement terminates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised', window );">Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised', window );">Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised', window );">Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement', window );">Capitalized issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths', window );">Repayment amount expected to pay in next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate', window );">Effective annual imputed interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount', window );">Consecutive number of months sales must be at or above milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment', window );">Percentage of increase in royalty rate upon drawdown of third payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember', window );">Oberland | Revenue Interest Purchase Agreement (RIPA) | Net Sales Less Than $250 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestRateInitialRate', window );">Initial revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate', window );">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_HypotheticalSalesGeneratedAmount', window );">Hypothetical sales generated amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated', window );">Hypothetical repayment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember', window );">Oberland | Revenue Interest Purchase Agreement (RIPA) | Net Sales Greater Than $250 Million But Less Than $350 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestRateTierTwo', window );">Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate', window );">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_HypotheticalSalesGeneratedAmount', window );">Hypothetical sales generated amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated', window );">Hypothetical repayment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember', window );">Oberland | Revenue Interest Purchase Agreement (RIPA) | Net Sales Greater Than $350 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate', window );">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_HypotheticalSalesGeneratedAmount', window );">Hypothetical sales generated amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated', window );">Hypothetical repayment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember', window );">Oberland | RIPA Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ProceedsFromRevenueInterestPurchaseAgreement', window );">Proceeds from Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestRateTierTwo', window );">Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestRateInitialRate', window );">Initial revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate', window );">Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised', window );">Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised', window );">Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold', window );">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage', window );">Percentage of revenue interest payments to qualify for third payment applicable percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PercentageOfCumulativePurchaserPaymentsGuarantee', window );">Percentage of cumulative purchaser payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember', window );">Oberland | RIPA Amendment To The Security Agreement And Waiver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount', window );">Specified net revenue</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold', window );">Company deposit value in blocked account</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the subsequent installment which is subject to regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consecutive number of months sales must be at or above the milestone amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_GrossProceedsFromRevenueInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_GrossProceedsFromRevenueInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hypothetical Repayment Obligation Based On Sales Generated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_HypotheticalRepaymentObligationBasedOnSalesGenerated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_HypotheticalSalesGeneratedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hypothetical Sales Generated Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_HypotheticalSalesGeneratedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityFromSaleOfFutureRevenuesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone amount for worldwide sales to receive the Third Payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Threshold To Include Worldwide Sales In Covered Territory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfCumulativePurchaserPaymentsGuarantee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Cumulative Purchaser Payments, Guarantee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfCumulativePurchaserPaymentsGuarantee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of increase in the Royalty Rate upon drawdown of the Third Payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue interests payment on which agreement terminates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ProceedsFromRevenueInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Revenue Interest Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ProceedsFromRevenueInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the current and non-current portion of the Revenue Interest Liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of effective annual imputed interest rate under the revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestRateInitialRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestRateInitialRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestRateTierThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestRateTierThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestRateTierTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestRateTierTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction costs on revenue interest agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_UnamortizedTransactionCostsOnRevenueInterestAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NetSalesThresholdAxis=espr_NetSalesThresholdOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NetSalesThresholdAxis=espr_NetSalesThresholdOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NetSalesThresholdAxis=espr_NetSalesThresholdTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NetSalesThresholdAxis=espr_NetSalesThresholdTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NetSalesThresholdAxis=espr_NetSalesThresholdThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NetSalesThresholdAxis=espr_NetSalesThresholdThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847074616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesRollForward', window );"><strong>Liability From Sale Of Future Revenues [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PaymentsFromRevenueInterestPurchaseAgreement', window );">Revenue Interests payments</a></td>
<td class="num">$ (1,155)<span></span>
</td>
<td class="num">$ (64)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement (RIPA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesRollForward', window );"><strong>Liability From Sale Of Future Revenues [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestLiability', window );">Revenue interest liability, beginning balance</a></td>
<td class="nump">176,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts', window );">Oberland funding upon execution of Amendment No. 2, net of issuance costs</a></td>
<td class="nump">49,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized', window );">Interest expense recognized</a></td>
<td class="nump">12,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_PaymentsFromRevenueInterestPurchaseAgreement', window );">Revenue Interests payments</a></td>
<td class="num">(1,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_RevenueInterestLiability', window );">Revenue interest liability, ending balance</a></td>
<td class="nump">$ 238,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityFromSaleOfFutureRevenuesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability From Sale Of Future Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityFromSaleOfFutureRevenuesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PaymentsFromRevenueInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from a revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PaymentsFromRevenueInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the current and non-current portion of the Revenue Interest Liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in the revenue interest liability related to funding received during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in the revenue interest liability attributable to interest expense recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347844088712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 18, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Purchase of capped call options associated with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Prepayment of forward stock repurchase transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (722,534,000)<span></span>
</td>
<td class="num">$ (722,534,000)<span></span>
</td>
<td class="num">$ (797,655,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971,872,000<span></span>
</td>
<td class="nump">971,872,000<span></span>
</td>
<td class="nump">838,817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Underlying common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,994,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=espr_CappedCallMember', window );">Capped Call | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage', window );">Class of warrant or right, premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 280,000,000.0<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt, net of issuance costs</a></td>
<td class="nump">$ 29,100,000<span></span>
</td>
<td class="nump">$ 242,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_DebtInstrumentAdditionalAmount', window );">Debt instrument, additional principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.2151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt instrument, convertible, carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,600,000<span></span>
</td>
<td class="nump">$ 233,600,000<span></span>
</td>
<td class="nump">$ 283,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt | Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_NumberOfBusinessDays', window );">Number of business days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice', window );">Debt instrument, convertible, threshold percentage of last reported sale price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt | Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_DebtInstrumentCovenantRequiredAmountOutstanding', window );">Debt instrument, required amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt | Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_DebtInstrumentAdditionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_DebtInstrumentAdditionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_DebtInstrumentCovenantRequiredAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Required Amount Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_DebtInstrumentCovenantRequiredAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NumberOfBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NumberOfBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=espr_CappedCallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=espr_CappedCallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847277192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Notes - Summary of Convertible Debt (Details) - Convertible Debt - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible note, debt balance</a></td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="nump">$ 185,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="num">(7,902)<span></span>
</td>
<td class="num">(8,306)<span></span>
</td>
<td class="num">(5,733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Convertible notes, net</a></td>
<td class="nump">$ 272,098<span></span>
</td>
<td class="nump">$ 271,694<span></span>
</td>
<td class="nump">179,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ConvertibleDebtMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible note, debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Convertible notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ConvertibleDebtMember', window );">Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible note, debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Convertible notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347879471320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 12,419<span></span>
</td>
<td class="nump">$ 15,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AccruedVariableConsiderationCurrent', window );">Accrued variable consideration</a></td>
<td class="nump">13,700<span></span>
</td>
<td class="nump">5,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">4,046<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on convertible notes</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Total other accrued liabilities</a></td>
<td class="nump">$ 31,673<span></span>
</td>
<td class="nump">$ 24,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AccruedVariableConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AccruedVariableConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347851168648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Employee Stock Purchase Plan (Details) - Shares issuable related to the ESPP - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Purchase Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee, as a percentage of base salary</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount', window );">Amount of maximum annual contributions per employee</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares', window );">Purchase discount</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod', window );">Duration of offering periods</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774,182<span></span>
</td>
<td class="nump">774,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_EmployeeStockPurchasePlanPercentageDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847601096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Schedule of Stock Options (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of period (in shares) | shares</a></td>
<td class="nump">4,176,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">757,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares) | shares</a></td>
<td class="num">(876,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(182,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares) | shares</a></td>
<td class="nump">3,875,614<span></span>
</td>
<td class="nump">4,176,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares) | shares</a></td>
<td class="nump">3,875,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">2,948,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 40.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">28.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">49.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">15.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">36.87<span></span>
</td>
<td class="nump">$ 40.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">36.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">5 years 21 days<span></span>
</td>
<td class="text">5 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">5 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">3 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding | $</a></td>
<td class="nump">$ 10,405<span></span>
</td>
<td class="nump">$ 18,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest | $</a></td>
<td class="nump">10,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable | $</a></td>
<td class="nump">$ 10,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847067672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Stock Options Additional Information (Details) - Common shares under option - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized into inventory</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense, options</a></td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which remaining unrecognized compensation cost will be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347848167928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - RSUs (Details) - Unvested RSUs<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested at the beginning of period (in shares) | shares</a></td>
<td class="nump">401,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">823,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited or expired (in shares) | shares</a></td>
<td class="num">(115,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(124,604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested at the ending of period (in shares) | shares</a></td>
<td class="nump">984,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at the beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 46.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">26.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">42.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">45.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at the at the end of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 30.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847067672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - RSUs Additional Information (Details) - Unvested RSUs - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized into inventory</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense, RSUs</a></td>
<td class="nump">$ 28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which remaining unrecognized compensation cost will be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347841632648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - PBRSUs (Details) - PBRSUs - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">64,200<span></span>
</td>
<td class="nump">64,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value (in dollars per share)</a></td>
<td class="nump">$ 22.52<span></span>
</td>
<td class="nump">$ 22.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347860713416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Provision for income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347847103928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Common Share - Calculation of Basic and Diluted (Loss) Income Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (43,668)<span></span>
</td>
<td class="num">$ (90,935)<span></span>
</td>
<td class="nump">$ 124,611<span></span>
</td>
<td class="num">$ (78,249)<span></span>
</td>
<td class="num">$ (134,603)<span></span>
</td>
<td class="nump">$ 46,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares)</a></td>
<td class="nump">26,225,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,665,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,109,089<span></span>
</td>
<td class="nump">27,592,479<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,188,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,355,579<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares)</a></td>
<td class="nump">26,225,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,854,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,109,089<span></span>
</td>
<td class="nump">28,948,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per common share - basic (in dollars per share)</a></td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5.16)<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5.16)<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common shares under option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,139,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,291,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347844877096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">13,417,778<span></span>
</td>
<td class="nump">2,722,497<span></span>
</td>
<td class="nump">13,417,778<span></span>
</td>
<td class="nump">2,581,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common shares under option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">3,875,614<span></span>
</td>
<td class="nump">2,427,074<span></span>
</td>
<td class="nump">3,875,614<span></span>
</td>
<td class="nump">2,391,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">984,315<span></span>
</td>
<td class="nump">295,423<span></span>
</td>
<td class="nump">984,315<span></span>
</td>
<td class="nump">190,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Unvested PBRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">64,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares issuable related to the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">33,412<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,412<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Shares issuable upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">8,460,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,460,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4327&\X O1: YVL!_-S=Z&\@^V]>BW\!4$L#!!0    (  )' U-*11P1X@(
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M'Z1_A=(*3_T*OX=+E"WI_IQ%M:Y3OZ[OEK.ZH$,7*0"S<A:UO0#,60"'<Q8
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M=@QP^'8,@*9K\4+ZLZ@5BOFK']O<CAU+# H@V/IO@NP/0PL?\PO?T#W:L1]
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M@6-0F&->6D2?J"A8%Z"Z?ZUUYRI-2ZO+HVEC_0:XS((R/.[8/%+Q,IF8:M%
M0"A,0/?DN3\1:7YQ3$ NS\PA3,;MD4\LG2KB QFA,!GUL']A0D,>WHEC)Z%<
MJ8D(P0/AX/!,XRT"Z[,9UL'&[M22:"^/VSR/&,K3;**#P@.GX3"GV8.9DNIQ
M7E==>SACK\RP8TTRM==>F *\UUPRP1G80V99<EIA>SM<.8CU-#?1:.&!]7"8
M]<QIWSL'JL5O0EVPPLS+G4T*K.B&-8W9'4,T5#!>>JWRT%P4Y^FX=_3(P709
M)5/;<W(:%^;#7[.*FIDL:(_+@@CF,'-VR2.79W$VP3MXX$L<!WGGH=WM*GM$
M2RI[5E1QV8JNFAHCUI76R)KN;%_7T]!HC0>VP^%)ZWQ7 1JNP+/.!3/<>CWG
MCEGCTN(1F>@O\$"G.$RG7WB?A\*<Y1O\NC?O9C$ORM0Y&G6VUA69CT>'Q<EA
M?$W%QGZCD,#.6MW)]O'I\3O(C3W]'SV_A1=WW=>,04WW<>4S$3H#):CH6JN,
MWB^UVT3WO:*[47QGC_Q77"E>V\LM)2451D#_ON9<'6[,"XY?C:[_!U!+ P04
M    "  "1P-3X1JK/RL+  "0&@  &    'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;*U9:7,;-Q+]*RAN:E>IHBB*OI+(=A5U>,VU9&E-.7O5?@!G0 YB## !
M,*+I7[^O&W.1/I*MRA>) P)]]^N'X?.M\Q]"H504'TMCPXM1$6/UT\E)R I5
MRC!QE;+X9NU\*2,>_>8D5%[)G ^5YF0VG3X]*:6VHY?/>>W.OWSNZFBT57=>
MA+HLI=^=*^.V+T:GHW;AG=X4D19.7CZOY$8M57Q?W7D\G712<ETJ&[2SPJOU
MB]'\]*?SQ[2?-_RLU38,/@OR9.7<!WI8Y"]&4S)(&95%DB#Q[T%=*&-($,SX
MM9$YZE32P>'G5OHK]AV^K&10%\[\0^>Q>#'Z821RM9:UB>_<]K5J_'E"\C)G
M O\5VV;O="2R.D17-H=A0:EM^B\_-G'X/0=FS8$9VYT4L967,LJ7S[W;"D^[
M(8T^L*M\&L9I2TE91H]O-<[%E_>%$A>NK*3="6ES<2Z##L*MQ9U70=DH*7;/
M3R)4T8&3K!%[GL3.OB+VJ;AQ-A9!7-E<Y?OG3V!B9^>LM?-\]DV!?ZOM1#R:
MCL5L.CO]AKQ'G=^/6-ZCK\B[]1MI]2=V;XP(V.",SF6J%,1AZ#Z%XY6VTF9:
M&K'$HD)9QB#^,U^%Z%%8__V&18\[BQZS18__Z$Q\4RPU]4^ADIEZ,:I(D']0
MH]^G2UR%2GGZ@.U>5JJ..@MCL;#91!R-8B_CSW_Z838[/?M>0 @M7^M*Y^)&
M6K0U1:K=-Q925(5$,V4L#-',&BN"MIO:2&]V8NU0]RH74)RK!\!&A>_83&PN
ME:<LZ$^\M@8JY7)EU%@X+PW^VDP=YU(;Z++.'@=RQ8I2Y3I#8 *$>S8Q L$B
MVP:O*VSBA"*;]69C2/96QT( /!Z0[5P NV ,H"CNA-&5J[R+"H*SPAD5HO)H
MW*/1]>7U\<7H^PD%K(]>5+(D+8:CHCYB&:JD5Y (LUA^=*0"^Z%Y)?,]N;'P
MKMX4;':N0^8>E(=[36S8A\/@=&6KK77P , WB 'MAC#MZ<P*A4V[0^,Q(K8R
M&H"2]R>20TT2_X(@:A^BB%LG$(>\SN .;%="5GA^P,G5CJU]/UE.Q"OG<E9Y
MB=B*>0X0T]0U;.+1Z-7E?/3]6%S5'H-&6G'3F3G?*)OML.7J!EM8Q'*K0_<%
MI7)0F:C=QI:C$>]C\W$0:0)H3"?B7)65RAVVRDSG;1C$:G_Y1*A/*NI2K]0P
M/H+BHIK$?:O8QH++H,_G?O%UM<;AEC# NY 9_"4?,NESC8R%C)J!TJTP<N#1
M?'GQ\R6<@81"45U\VFU<#9&RU(9@J=BAK@9EHTHM<>ZU>O6:*O+6BGGEM1&S
MIPE#QV+0P (6(8$Y8H5*E"C5#,6NFKHR1JY<DS"Y\2KU--M_*;7."BV6TG[8
M.8B;B.N80^_EDK3>U3[4$ILAE=1UI_>U;SSV0/OE$NV1F3I0O?YV?7N:N(%D
MK_Z S%*=+$%;"O'& 1S&XE[JK40Z7SLD\0W^8*E MB%]+$ /HI7E6)Q[^4FC
M&&YD)ATFB2Q7+D?HR8:;G;2@.N*(8JB8?YC4&8B/N%?>Z^C\KD6,/K;2H'J:
M>@'0V$@9!G+(1(9DAIH)8J,<(E<5&J6E+>*64[DM)?Z+N9<K#2?>U%NI$>[;
MDEQY/[\:B[^#)W@8+@LOJ5S_13II!AJ*2;+<45V*:P;/.<(.F +8N=I&KPD/
MKCYFJHIL8 8X@YS]?)&O.B;#AE%EX6U@$8.M-@9I KT+%3!((Q$L]+>3#[FP
M$34:FS#J YR"S$QI0B.87E=K#T*"_@H%6G#7(O]WCZ:3*7B5,8W,&[GC]F"M
M&&?*Z U;A2IK!$(8/4&JS'--QB YWYT^>[(O*4BT(BV@(=TAB";'I0F]5$2+
M.M"[G30<.33%AA(*RTOQ1%![J]1*LVGW!%T6M9N4I9B(86U-Q#NU1BIQZBTJ
M23P2HXMA0S<X=%]H#](C/6D><0K6M><BT#91?VS^_V $=6-S#O1;P,),'-%.
MI@K3LW>+NWF_H>,/#4R\0_9MK< T2!Q&#7 D*P@(Y_OP<Z4WL'"Q6(CE7%Q?
M7XBC1O[M2GEJU%;RF-.U7A-6(@K(?+L#'5OIB SB.'8!WS<DON4)5:.9@)N#
M0ZM>P="<![=DV@1VJIJ0G/XHCD@*^=9/POU8G.X=?HN16<(:\2.'=)I".@A4
MZ\3G>+H?QG'O%)J>*I_VH#-01G 0,U<SM0GZXW%)])QN3"8_QHU##:HH<S:5
M=:LE<G%HB_EF##O1=E -'WUO"6GVX$PR-+K7K/B[)WUCM"?Q7S9M-2R@7B R
M7W)X6NG[_4.J.F^YCQ@]F4EQ[(?-^9FL;D+ 6L[$4F6U)W(W[R?4ML!H2SP-
MK*L.Y%3?%*F=?A"C:PVD-73V72/L]U?Q9'3 K-!;=#<> BB8<:8(WYVOVBE<
MR >:;LIRLD!Z**U$W:4GD^'<E]%X/)@38"P9RH%8^!AZ5?N0\+9]B#!<T^@#
MX! .,$'%@ :@)2*Y[BY&%7)A>2^$^5JS43@6G+7*C%-U2$U,'SC,3?<UP&8>
M"9%-]X C4L1?J96O*3K4)13EX510XNW5/Z^O[F^OT3JGSQZ?L3Y:6_S[ZKY=
M:Q"2B&DR2&:(*\4#@YG%(=@YI0$^5;  I+0%2D?3@>+;7$.G"8-(WA>Y=VO/
MOI.8*:%>_0(VP"-%AP\ICK5M!BDG/=5>2I9B%;8I[E!G&6*_KDUK<1< '4-'
MR,==.70WA?%>9HF(4%'& 8-N#Y\)M^*9[A5=RFB.=#E)K&2HZBPQDYP7R^[2
M-QY8QYI#1L17KZ$(2+)>GPWJ)QD_"'9BQQC<F(4E0?;&43;62!CXS@.7EG=K
MS=QM<' _V.@V!"R0+\P#;-VG%!(,6-2PPT!IVOL_7=/H+H%P%^T^KCAX0$U-
ME[ $<8X"K=B,=1UKKPYO2RT\'";/2.2\&!\DD91C I&)!$\)0I@"M/4T[JH:
MGQ;75S>7MZG6WR_OK]Y>+MAK!@=:+>6NMYJI,I 1Q@>BHL@"O.S'E,).5R)!
M&L9GL87,B]N?%Y?'F&R49EPL</]?V):S'6(X3:O39V=!%+CF4>5 R&<A;_&W
MKWH8@VMNLPRR[6AW;T9G0E]@[">*.6I&W9:'9@Y5[2KB^4TOEAA(R$O2RL0+
M<DW#M/LIP0?!7NKLX%3@YB-:L][?/[P8$1-NF,0:;K#U..B@XH$N#:B/"6Z_
M[6FZ,PY<.<P2B1BV T-5_L"=PN\!!O#>)FDP1)J+,)UJ'F <C"+:$;H7"G+O
M%@0QV1>881K^#?D9"[ZYJPU=J3#0R1XLINLBOY'QQ%K3ZS&>&:6.E)Q<K6([
M*NQF[ZM$>'?'*V8-PSUL?K</F$SO8M)JO8).H7ZMJ;$<JIANVD$P:4O.I1M,
M<)BYQ+T7E#KL)PD4W'2/WTO//I6EC-#7U"\-4>D3]'D&"+Y (3QSFS;^S*()
M$KZ0A3$;>SC#AF*^?9IJL7G=,OG*^SN^4V;-&S:>NB +=*]G@HZ0E8/I'?K7
MFA29VM(UDDDJ-8UB*Q3*H >+;J+99HIR=7+1)  CD,,W0%65!FUM$R=(TW5P
M8WEO616_6F4_FCMGQ^?_.I_?]31XD4[1B\&F<H=C)QX,@!*)IVI% ?R"6=#4
MYOZ$==90NG'/,41#D &NYOX (("0F]@'S3\IUE)[41V\)?X2# X(D@NZ&S X
MB=D6!NA(+==>.]K\\"O$/+2**-<7#<XABMB\PXP'X:70A@$M_-+[Z)/!KP0(
M[X9_"PGI5I]^,.A6NY];YNE7AGY[^JT&/ AWBB",6N/H=/+LR2B]C6D?HJOX
M-X>5B]&5_+%0R(.G#4_H@@GVW#R0@NY'J)?_ U!+ P04    "  "1P-3:>MK
MZI@4  !'/   &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;-5;:Y/;N'+]
M*ZS)5G:F2J-Y^+%[_:H:/R8[-]YKEV?MFTHJ'T 2DA!3A R0,];^^ISN!D"0
MDNR]F^1#JK;6&@D$&HWNTZ>[P6?WUGWV*ZV[XNNZ:?WSHU77;9Z<G?EJI=?*
MS^U&M_AE8=U:=?C3+<_\QFE5\T/KYNSR_/SQV5J9]NC%,_[NO7OQS/9=8UK]
MWA6^7Z^5V[[4C;U_?G1Q%+_X8):KCKXX>_%LHY;Z5G<?-^\=_CI+L]1FK5MO
M;%LXO7A^='7QY.5#&L\#/AE][[//!>VDM/8S_7%3/S\Z)X%THZN.9E#XYTZ_
MTDU#$T&,+V'.H[0D/9A_CK-?\]ZQEU)Y_<HV?S=UMWI^]/-14>N%ZION@[W_
M18?]/*+Y*MMX_G]Q+V,?/C@JJMYW=AT>A@1KT\J_ZFO00_; S^<''K@,#URR
MW+(02_E:=>K%,V?O"T>C,1M]X*WRTQ#.M'0HMYW#KP;/=2]NY3 *NRANS;(U
M"U.IMBNNJLKV;6?:9?'>-J8RVC\[Z[ >/756A;E?RMR7!^9^7/QJVV[EBS=M
MK>OQ\V>0,PE[&85]>?G-"?_:M_/BP?FLN#R_O/C&? _2YA_P? \.S+=GE\5_
M7)6^<S"6__S& @_3 @]Y@8?_)]K]WYJ[^.@U#7OC.P,[QA>_K70!']XHI]@W
M\./"M*JMC&H*WV$,_*[SA2&WJ:RK\9.&97:K8JE;[533;.D7O>ETS4/"DAMG
M,,FFT?QLAV4^MH;&W':\L--?>N/P8:U:^#RM4G06?WW6A4[BJ1:3>N#$AJ3S
MF$=UA5HLX,D\)R2WCE=>T\*>Y,=XW?E9T1A5FL9TV/>L:(%J3M_IMJ>_]%=
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M/01V1UC'+('=0ORVLQVL5/2K:QZ-?1M S(AQ0^E?.RW'!*T"+ C [;URS"
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M<54B$1PH"7XH"+9#E9]ZC>R^ .&>TXP H('+T&^84%?*,XF/-E[VVUB3#14
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M;^XW47>X\QF##3:SS_*1-J?D5)I<,8,*KA#+RGM:90>Z*ZGM%)LG=/.*&CC
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M@Z=/>CY(RR\ 5?[QU=3DN4GYXP*T1%EZ /=G!LPB?*$%JE_CO?H?4$L#!!0
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MJ&5X"<)!ZND OI\;&)O>D(+VU[BK_P!02P,$%     @  D<#4[[K';2P P
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MAH,\0!.0<6,;!+:J0GW-P3U+YW*()#J"(C!L3 0#7FGD6:'7+-;HN4I)VXF
MH%E?'YZ[9R>APRV5"YTL)L3+ C,@(^7B3D(()5#ZS0+8SL$W$=7#2#.3%$,7
ME/A[BRB37)/G>K^_2.I6FH89A-]3.2*HZ72VZ"I-0"#?Z2"D:9!#'K9]3GH@
MQ;F%0ZN3UNP*-'41&L(,'O&(V-;Y^)M<WLKFTC!5J(:C2A8^UI/W9<3P0-#%
M:UGAV@VDV8 \M,S;=M$Z;:&8G?U+3D]&_=[(T60Z>MK=@_<FKKN7Z;3KQLFO
MYO"A8C@Z'UWVE7@R>K)W5OV5,L?#U&C#*IEM\$)V2J_-"@MRDS:#;^RNSO5=
M*.SC.+I#7#:&$%DRTF+'2%5^ 1\;Q?Z,21:(9"H'"1=VF4] 3'ZYVR2X]\#Y
MCZ_0VQKYJ\^E;S3!* ^D5\A]#WFN:W_V-Z*1F1QE8FP1Y;&.BB>ZHS 2KZEC
M&L)\I\[#5KG*"1\E4*P6I&JN2CIWYAYH_G(D))KF=C [-AK#-E#VL255R,VZ
MO8L7.DTN96FNO?<+F61N]Z2_=RH@VW(2& %%Z9I>=W]K\274XIYZ5&T;EYJA
MJ:=Z-+WHD^PJ6=8&'_E\&'>3T',(=+R31YEH,#OK@\JDR^,Q-WW^)MU#Y%JM
M&R!A>PM+$@ZZPY)?!:V(9=\D6*8&7B+$X?(*%QI\<[%KUV]6_6QTUM4<'[_A
M>0^[/5ZUF=E(-_.EF-Q4S&%*[G=M5]KUV])95BJ&Z=H-_LY4*^[TV8C 9*.=
M96WY FM/^_NU;H,%:U'[>&68+IIEM3_>/'B5Z%==).K5?0>N284;4*IW!ZIS
MW915:&][94T_'$BD#G)T@9X,*#6V0!_N^N6+.(O:;D#8(CYDBV,CRQU,UDZJ
M8?0.&#'NN+A6IA_H;G?SH?$TRT89T]^M(R4Q'8DV".(-^J*;OZ$;<X?D@APB
M)KPS[I+)A\"+%F'R>#3]YA#1W^' %:M6$L&^[,;4UY/JW<- 1#)B\'-:_QVV
MD6EJPOFRQRD#2\][6.HBMV>OCE.?8>"+9X*L$8QK"O4%/A:<,K?&V V30R;<
MX>= ,,5]87CX!0_]T:'*#S,ENBM.:VT;![O<B?A@Z43JH3G\7BJ.Q1$6^G)X
M.3YO742E/>D0CF'N4"(F:-RY29"+JYVU/G\Z?#IYW![XM42QL&#&M+*3Z?#)
MY<5#M^^.Q/%D.+FX^#K#>J[!6!2!P^G91!SZX<IIYR=%*U4O^(=3+IQ&AE\7
MY:?YMUE7X2=)[>OAAUWO9+V@FR5&S3%T/'I\,0@=AO3!VS7_0&EFO;<K_G.I
M$),UO8#OY];Z]($FR+]8>_D_4$L#!!0    (  )' U.HEO/ILQ   #DW   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;+5;67/C.)+^*PB/9\>.H&4=
M/KN.B#IF=ZHC>K>BCYF'C7V 2$A"%P\U2-K6_OK],@&0 $FY7-V]+U662"3R
MSB\3T.O'RGRI=THUXJG(R_K-R:YI]M]=7M;I3A6RGE5[5>+)IC*%;/#1;"_K
MO5$RXT5%?KF<SV\N"ZG+D[>O^;O/YNWKJFUR7:K/1M1M44AS>*_RZO'-R>+$
M?_&CWNX:^N+R[>N]W*J?5//+_K/!I\N.2J8+5=:Z*H51FS<G[Q;?O;^B]_F%
M?VKU6 =_"Y)D755?Z,.G[,W)G!A2N4H;HB#QWX/ZH/*<"(&-WQS-DVY+6AC^
M[:G_.\L.6=:R5A^J_%\Z:W9O3NY.1*8VLLV;'ZO'?R@GSS712ZN\YG_%HWUW
M>7LBTK9NJL(M!@>%+NW_\LGI(5AP-S^R8.D6+)EONQ%S^5$V\NUK4ST*0V^#
M&OW!HO)J,*=+,LI/C<%3C77-VP]5^:!,H]>Y$O]9-:I^?=F +#V\3!V)]Y;$
M\@B)&_%#53:[6OR]S%06K[\$.QU/2\_3^^6S!+]ORYE8S1.QG"\7S]!;=3*N
MF-[J"+V/:MV(C[I.\ZINC1+__6Y=-P;^\#_/$+_JB%\Q\:L_HL!O)"'^J\0?
M#ZI8*R,6-ZP(J*/9*?&A*O:R/ A=UZW*Q.GR>CZ;PS'RG'U\NS5J*QLE]D:7
MJ=[+7,BB:LM&5!MQ-9O_5=2JU!5%Y;HRF2[Q;B;2@(&2&<A:%7!PS1Q<S\3/
MX*!$IMB;*E4JJR.6C$H5(BP3&U,5_*3:;!3XV-+F]%F7NM%@R>[Q*&LA]R#U
MI!%=*C] FJME+TTBY*;!]G"J%K$+,B&-?6O2'<+1U/_VE[OEXO:5R&!A$A54
M2Y*I** DT+&?.U[4$Q):C?WW\B!)XO4A%&,F/I6DD-*EC4?=[":%>9$B8Z-M
MC2SIM6DYOHFPD(B0BTP>1+5G/INJ(R7:/7V4\(<LT_04^YRN7NXH+^>"-J:7
M9:$$;%5XW9=VWWH6N_*==66K3\LW>8%Z4B;5M<H2\;C3Z0ZN5".K8D==CESD
M?K;HQ "O@8C>*Q.!8@4--"34A*!8=;J\B]0!IB._YE=N%\%69\1SL)FS0@F>
MFVJK\-3TOA(Y>@)]Y%R%'DB"5.*#]0'RW.7\U2C^^?O%JW,;<-Y[6BAHJ(VK
MFT *9[E(D*.Q:/DGKY'6_].J[HS_ =M@LP]@59S!0"ASR%F96%,1/V=UG5Y?
M_]ZMXS0 %D!<EJGBAY^-VDN="=3<1VFRB>V]5H9)4QH51MO?:N_#+<(]1>)'
M$ECG&L[0)06HD0I"58Z3G36XL] /])YN#@(U5GGK)""<JQKN*TVNL12<NPC$
M3L9'"WLQA*QW8) ]BU(3MD1M3[^ 1H:E*5X$@A*I-FE;U VI@^2N4Z/77O+G
M! ]#<[!=H!.7*NN(!?@G4L5:1?Q3!*6RWB4DB:3WUY0$M UXHZH-TG,S2=LC
M+GX!E+VY+8L6S5% @C7DI.7B>G%,-WMHYG21S.?SHVEJI V?0C08^:W5#S)7
M>-NFPPE.0#=E5@:!M5K-YO<WS $S-^0MH<SX*P1ETMFO0&J JDT<L8^(#HXO
M6 0ZH_@JI[F&JQ;Z0I9EBY [<-HSP-B&,^P/H+"X9H<-W)0X4A*2'O#><ZZQ
M5:4RD'HZ#&('P=]D-*R*$C_X,01OZ6W(4SB5:OCN&L]+1$$R"JZ*<V*NY5KG
MT#NXL;X^Y3,_?OK\SM9*HQY4V:I.9;6'.O#-NI5VX[J%W!*971$K"6]G(8A-
M)4&R@2.K;84O9N(?59Y1G2V@3Q<O](HV4XKSCUR98E>&>M"0D,]P?;%I$Z"2
MO6/=UIH4X6W<?:8BK8M"9=KZUIZ 4D8LOFNW\)L^Y>C2L9PCVNF%*!U\)\X6
MYT!FG$J)F91\.Y-&_-9*0TB)'%19Z2UT8@:';RF"Z=:O$.UBM;! &YF6C%:"
M0[<':WFX'&E/6\WF$KPC9U2<XVJ\YZ(I"IJO9Y\]B"-,8?-3U.3Y(EA_YO)O
MN*!/OPAQN("T@B*\812$/#P=IEFL@'7=]J-PI^3&H4-QWXA<D20$2XQDN\!B
MG$=L5<?+J%1$A>*'JGCB-4345_/P442#5,VN6%H710K+6_HFZ148O-_5QTEG
M&1KBE3A;GH>,;&C[T.MJYP7D*_SP")^D<%VAU++!7_!F$J*7 MI#5N&<8!][
M"Y$_VV1,KWLRO8\\D]HM-.CL-*&D\;8,);D@LS?<WW4.@,Q.+83_^.<X+EMT
MX%Y<UQA\[@*$S"*P;@,Y8+[5N0\EGWT)&];VU5X#R-BJV+N*BI>"QYRM=Y+L
MKE3IH66\B-/=6@5PY-MS&7P!D%[02"AK&;T&!IEV5YO+.R8R/$] M[$9AI$R
MTOO>5=!>7Y,RO&)EGUV=H[5Q+%4I:IE1I:W>1$AO-/<H!H8E.U A:1#'\ HX
MP(/.;"&CQ9^0 DN"?MR?$,+A0!GDX^3/T\M:41VRCNNQI%7);J(H$>RN;-R2
MD_8 6QO?=UCH!="2ZY2[V*$7AD9V;[M2YGS;;BRH.S(9A\VP8D9]W*>^FTS"
M"N6!ZT#MQ'__%I5PZ4PE200'ND+7#N. @%-"QIK$Q?0D1>*OU='XDUZ\QUUE
M 2DW&E[!&A^M(O6XV;?@8BB1L&$RIN <]JRB207R4>:^.1_&89"JC<H95P5/
M?6:5M:O:M7*1>PS;,;I<VRA3!3E!8C-NA5>P-?Y&:6V.XO0QLK%5RO9MY#?D
M_OQU%01)!T&7=D*WXD6!@U\M$$-_)"2((VX^(OUPAN[K^WP>I/?IWJ#K+SLE
MT81AG[>(GS0U!"J)];;DAM,#3L8WT$B0K?Y4P(-\7=MTW4&/9\$*OJ3.12AT
MT4B6[-U',(LX.XY9SI,>?D3U^/D43A:)0A,]M9O[33BQC>PD!*G'X9$OV\^#
MI&]@LPKA1LPOQ_2(T1F<62"C?R$RFY8V#VI%5,>1 .-2;1TJ!!R4M3G-M@TE
M*N;-#8 Z@YTNEM<O'L-9_RVH)*UCLCRO@GV#'C003G:I'"92#]0SC41GC8V$
MX@9M6_%XT<$[4HLDE$5],\3<^OE'-)D9UM7SN+ 9:L7C\8SEN1M9AL7-SQY>
M5@>E&+,84O[#B:,;BKPD=S25S1OJ*?+BYUFTMO@Y5* + ZHO? @DS2$:L*(D
M248W?5#[6ND+\,:?3L5#"2P@X#0:)=[-[L-Q7E>R:2Y8=\'N$%%8T(^,8?"$
MHS&),:;,>ACR[J=?>!Y\,;^AX/U>EBW)Z1K21)Q>S^ZB&>WI*IC(/D+EY")5
MRIS1<^2$RF26S;PJMQ>D,D%#"CLB"&;%,-L%%7^YUS!*XL$HSVBMPJ+=IS3B
M]J*N(][+H4."3W34@.HH<UYISUFI4,#AH*[_I4;\P37JU'A=T#"'%O+Y%+LL
M43VF94%XU&9 6QXHQ7;#I@*UH,IFXO/OU3^]/QB#TP#(#WC'!SY?=8NAT=:J
M>:12.%!@.'OU R2"QP70/YR[:S!I3+^XO9W=1%YRW,P18<I)1ZG>KV;7GJAU
MAXW4?D[A^\@Q9]R#NM8T<]8A#$F9DL3C9$GYK=8@+HT55Y=U8]J"PY8@*%(]
M ] ."6R4M-W*SPP-C3EP%8B2UE <<FD42=2_[NPLH%@YU/TH(];6A\%QV\ND
M[AR@+V@;"3>(%DX,V4K;M+M<9X][CAM/?R6L'#4JC#08<$9PX4G_ZT9DVE9.
M1$-!BSQ!V^;8B8-3).!>C9XRY9&F5?TQB]M2085!D5?;\S>KOJ]K870<-7D*
M%IX\E1=<'KM =T>:X(']#8EI6W)N:7:F:K<6$$5G&#/Q+W]6=2PA6!0QF1-Z
M#$1EN0Y\R\K%3MWKRC>KQ\$.@ZBV[)-BG&M)^;J.]&'136PCK^(H>(]#\N%9
M9J W</P1R8W;'#<?G5LG'[BG"-S3#PN.*L+Z4(!D1@9$O#[HJJWS0\B-!Z+6
MOP*9GM.Y&TXAKZ@+^*-;X30<J6M0USBG!OHC_PYK'1\K^_,./OU(T9JW%AX0
M'DRU0QQ]_]]0=UJ[FS^0J1X!Y< ERLQEQ9 O'^LUL6 )H]UA1X"^L*8^_RZ*
M+;)I8@GY-/%Q3'6X KB%SC#?NQ63?K"XNTZ (L79=7*[6IV+Q>U]LKJY%>\Z
MK7!"L&>A7BJZ4,$G1=/!=G^5W!/)97)_"Y+WB^1^>1NR,8A#@83!P].SN^1V
M?G,N4*63Y?U5N&0PW@]6K/R*FWC%]VVINHLW_8);\+:D!<MD?G\7@<G.,8#,
MEC%4NYE=1>AIZ.O!. 1I2BE>5>LG4=C;1/:8(F(IL3"4EU5^3!+DP1YW35QG
MB4_8&"=,!,/8\Y!]WME4&+-25L?@3;A_>&IE&Q=&\39 P#/#[VRBS$[0AN>?
M+E>K =I![5@%JI9C7OFUD1]/0=YO9RC #K[84+N/!MIT>OVMK8@D0O^+C8E4
M32OU&*.<I387_03[*XSY(H\F3+FK%GTD!FMIJNNZ^_#&P\]&EK5,+2)XX6V@
MB08HK)2*7=3=!  O#]QT791JBV[<WJVQ#*0\10@9X"T!-8:W)\87AR:NYQ@>
M5,K-!E6!I\+4/+H^T9[/N@-3AE>P?M.Z>6\8Y7_NS9.QO8[<0CFF$@^#CRB,
MVBM*,BFIU1U^YV[> &A+%;@A4$Q96>>MOSWUU;D='SWP*4T HY^!MI?0/F2O
M5>-.:Y&JW.%Y?'&.H0T/2+AQ+>07Q0,_>&\_E9^:5?0!X>=,H^%QXL&2'6+S
M@9$=N7(PVF#XQ@/;J,7ICO3M=.(KIO-8D,?+=('!W?P:'^;R\4IC]!<_P?D:
MY3-W[\.&!UVTJ@QEN(KGE544.U,70(Y$L;13P6#2YN.G1T'U>1(<'1C;0-GT
M'#A!>&&$Q A8[:93@R"[OIXM;KQD73M'TSG\6>BV&-]<L?,M/U,X.K)^R: Z
MNA;EDO%Y\A55O" X:[67?+ 2/DGB'!E?RK3EVG!:XT,-SW_D="/KS<1_H+B5
MO=='K'#_UTF0\MU1GJ.A2T+"DLED4GU>M X/::=$-P7U=U1M;YEX>'[HA'+[
M.[3/A96K!/BO(^F#SI;/E:UQ&4+S./V;"ZM7\4[:HMG? >/QN;V9U8?YB_4Q
M&UWE^W\HI1P(O,G&;6)=-YPL]SQU]TD&G'63'^9)3M?$;K$7YP,;S) ['OH;
MFY]CP#=40BS+5&']_?<J)PLK'VM,,&+CM._)RY9]@\[27WQST+I%?O X?FCP
M\0UO]#5H=1;W=PYO/NVUPXE9>'5B2 @)>'1!$T&44_,'Q*D;?\D!>;;).33L
ME<R)\]"9^(4*N7V3>U@GZ<A2L@D9I(ND'@$0^4- PEIURC'L*6VF<LTI.8(9
MUK03>O\6'3N-^:E"8R]GNE%0J X'\=TN?93WH3TDS1=JN29SXT]_(O$<@NLO
ME"_"+I[L!\K[JE8!%,A3F@XX=U[+6J>VR2?P99DKL;CN88@]0F'-(=TQ5AUL
MTA_.Y_*QVS(\#1FRPI>@6CY:F4K,#S;14 G(CQO3V=&BK# U'K=/;/((5W<Q
M-5RS4]DV3ESP0Q8D\A[47R1".+_1]1>_D7IJ.J!'V#\-^7=1TI9\922<@4:%
M--@Y;@0* ):MM#>/"+72OJC4N:8'=,]CN"&GZ$+^6AUI-&93O\"Y#'[.5"BS
MY1]M.<+VETW=M]WOPM[9GT/UK]L?E?T@S1;;B5QML'0^N[T^L3=9_8>FVO./
MH]95TU0%_[E3$A:E%_!\4\$QW ?:H/NUW-O_ U!+ P04    "  "1P-3:6;X
M@:,"  #-!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RM5,ENVS 0
M_96!T$,+"-'J)89MP$Y:M$6#&DF70]$#+8UL(A2IDI2=_'V'E**Z0.U3+]*0
M,^_-(KV9'Y5^-'M$"T^UD&81[*UM9E%DBCW6S%RI!B5Y*J5K9NFH=Y%I-++2
M@VH1I7$\CFK&9;"<^[N-7LY5:P67N-%@VKIF^GF-0AT701*\7-SSW=ZZBV@Y
M;]@.']!^;3::3M' 4O(:I>%*@L9J$:R2V3IW\3[@&\>C.;'!=;)5ZM$=/I2+
M('8%H<#".@9&KP/>H!".B,KXU7,&0TH'/+5?V-_YWJF7+3-XH\1W7MK](I@&
M4&+%6F'OU?$]]OV,'%^AA/%/.':Q619 T1JKZAY,%=1<=F_VU,_A!#"-SP#2
M'I#ZNKM$OLI;9MERKM41M(LF-F?X5CV:BN/2?90'J\G+"6>7G^T>-:R*0K=8
MPB?.MEQPR]',(TOT+B@J>JIU1Y6>H1K#G9)V;^"M++'\&Q]164-MZ4MMZ_0B
MX<=67D$6AY#&:7*!+QMZS3Q?=H9OPY[95J !)LNN928,_%AMC=7T=_R\D"(?
M4N0^1?X_QGF1RJEQ9AI6X"(@N1G4!PS.\T/G8;U'G'@*11(R%E0%% .5$J1$
M+G?PFDNZ4:VA>9@W,Z!YHY_W+198;XDN2\(A6:%JV@2&>3&]@B0-\^3:&:,P
M&2=#V(%I[J;<I2U1=X D"R=Q#*,P3D=#;*-5A<;IFPFHD&K-PS@?0Q8FTVR(
MXM(B#8 :D([T@-IRET J2X@DS(DW";/Q]8!0?A9)/(51"E^4)79U=CRO7)?C
M249&FH>3ZQC^]1]$)Q*K4>_\(G&S;:7MU#;<#KMJU4GT3WBWZ.Z8WG%I0&!%
MT/AJ,@I =\NC.UC5>,%NE27Y>W-/^Q:U"R!_I:CS_N 2#!M\^1M02P,$%
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M_-90MA@YY)M &87\JW LAD8]CF$8<,,(9MM>C<<*?;*Z(<&3\\_=34Q'-S^
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M@1(KT2E_8_I/N*OGF/D*HUSXAC[&3B8)%)WSIMF!24$C=?P5C[L^' !.LQ<
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MS5C4*$TTY$<XXX'_+JW$.*K<^'),D$Y>" FI$:I>>.CE6$Y*:<&>$$M!Y8R
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M!F]\-5:J'+R)78#R[YR?FA4NNB7U)O7UEJOX7DCRW(V' Y>]E@SNY.KBYC4
MQ#C7#9?HAWZNV?,?3"YN/F,H+7%$N?$W>BX\X>PY??3-Y[:BU%-P:A+Z?_#O
M@QS<=//6UC##AX]/CLY.#GG,&^I)Y724.(1?=+&$!'[JOKD=1_J6FY"CF_@
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MI?Y>B 6F6":HH=_SO*(W> T):MC?L?Z7U[L@7BKI<*MKE*B7OC<:2%4M;=-
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MTHA'91WH?",ID;UA+QC^-.;_ 5!+ P04    "  "1P-3+)2?$;("  #(!0
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M\Z6R-!OX94[C&VIW@<Y7BCIKO7$#0C,03O\ 4$L#!!0    (  )' U,U663
M7@0  -P0   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;+U8;6_;-A#^
M*X31#RV01J)DO06.@<2RLPYH821I]W%@)-IF(Y$>2=D=L!\_4E(D6Y88%]GZ
M)9:HN^?NX1WOCIGL&7\6&XPE^)%G5%R/-E)NKRQ+)!N<(W')MIBJ+RO&<R35
M*U];8LLQ2DNE/+,<V_:M'!$ZFD[*M26?3E@A,T+QD@-1Y#GB?]_BC.VO1W#T
MLG!/UANI%ZSI9(O6^ '+K]LE5V]6@Y*2'%-!& 4<KZY'-_#J#D9:H93X1O!>
M'#P#3>6)L6?]\BF]'MG:(YSA1&H(I'YV>(:S3",I/_ZJ04>-3:UX^/R"OBC)
M*S)/2. 9R_X@J=Q<C\(12/$*%9F\9_O?<$W(TW@)RT3Y%^PK65\))X60+*^5
ME0<YH=4O^E%OQ(&" P<4G%K!.5?!K17<CL+8'5 8UPKC<RUXM8+758@&%/Q:
MP3_70E K!&6PJMTM0Q,CB:83SO: :VF%IA_*^);:*B*$ZE1\D%Q])4I/3A^J
M% 1L!1[(FI(521"5X"9)6$$EH6NP9!E)"!;@?8PE(IGX -X!0L'CAA4"T51,
M+*D<T7!64AN]K8PZ T9=\)E1N1%@3E.<]NC'9GW_-?V%61\Z!@!+[6"SC<[+
M-MXZ1L3?"WH)7/L".+8#OS[$X/V[#SU^S<Y'L8=1XI_WI<HDS#G>85K@/P4K
M>()[L.?_B8<+,TJ,$X4"CU!>/.Q!NWO%)Z1\LJ%A[X]"ZC8GPRUAW3>?#(.Q
M<6-L7!H;#QC[4N1/F&M;=81 %2$!_@&OQBRNL+T26_>>W=296+L>=[S&'<_H
MSB.3* /WE>'> U[I^P<FQ[;O18W9*MU/I1SH.*Y_+!;W@(6^&QQ+S?O QG;@
M]U/U&ZJ^D>J,T1WFDCQE&% FL;@ 5$T *A)$B +1!(.$"=F["?[IO@>.'84=
M>N>)+?P3?C"(7#_HYQ<T_ (C/Y6O15YD2.(4Q%@E,9%]5((3'Z, AH'3H7*>
MV.)4+'3#$ Y0"1LJH9E*FA(]OZC47"*2ZB8T0UNB4K6/47CBP\? <3QWW*%T
MIMPB/ G/QR *?,_K)Q4UI"(CJ25G:9%((%!6YYZAG$"[;>OV_U^]X,$4 =]8
M,&J H_2V?6AW*D:/F&]WRDK<A^5'?@=KWB<V'CI/T&FY.N:*49TG-4&#^6JE
M1NH+L,2<L%1O]DW*MCI'+]33=]72U-1N#&C;C> O:$>P[4?0W)#>4!;O:NC#
M?8_4U<@>V/BV*4%S5SJOE-W5*(<G&GJ#UML^ <V-XJ>JSQT\K>:1.^Q%6\VA
MN9P_<I1B== 23'9(!4</"+-Z= (J:(G*-X[*6]X]$<^F7&C++@Q_0>JU!1&:
M*V(["^7H.^/@93+45 U38ES#'C6G3@WO$0D[$;$.[E+*T+J\)@M04JV&QV:U
MN8K?E!?0SOHMO)K!GO487LVKBW8+7]W[/R.^)E2 #*^4*?LR4'[RZBI=O4BV
M+6]R3TRJ72@?-UCE ]<"ZON*J9-:OV@#S3\TIO\"4$L#!!0    (  )' U-_
ME4(?20@  +PO   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;+U:;6_B
MN!;^*Q:Z5YJ19B&O#JS:2A28;3M]0=-V=[^:Q(#5).8Z3EM6^^.O'0(.37#2
MELR70JC/B_T</^?XQ"<OE#TE2XPY>(W".#GM+#E?_=[K)?X21RCITA6.Q7_F
ME$6(BT>VZ"4KAE&0"45ASS(,V(L0B3MG)]EO4W9V0E,>DAA/&4C2*$)L?8Y#
M^G+:,3O;'WZ2Q9++'WIG)RNTP/>8/ZZF3#SU=EH"$N$X(30&#,]/.T/S]Q^>
M(P6R$7\2_)(4O@,YE1FE3_+A,CCM&-(C'&*?2Q5(?#SC$0Y#J4GX\;]<:6=G
M4PH6OV^U?\\F+R8S0PD>T? O$O#E::?? 0&>HS3D/^G+!<XGY$I]/@V3["]X
MR<<:'>"G":=1+BP\B$B\^42O^4(4!$QX0,#*!:RF G8N8#<5<'(!YZV >T#
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MX)@\W%^1PX,C<D"8(#]+V6A#HN<^&FM6P$\[&Y>MC7"/C8C<&N%2DZ\B@VP
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M4MQ.)V1W9X_L$):1FT3D"H%JZ&H4:[9T9Z6PDT)8\(&P'WEV0$+O&PF\P&^
MC]OA$Y@AW+=P;Q/N8HBJ. 55G ++%WX>IQ:VL&(++5OG [;C%./(7F!.QD+I
MIN 4^)[%FU)<18'G]\/.T%W5@]!@-O#[@[ RVY#7J>1U6N6=2Z$4N<VP+W"K
M\AS[06,."YYN;7_O+X5M%AOBNI6X[K^)^XES:%37_51=F\6&NEZEKM>J[E1I
MALT%99U1)LD=Y3DT2>N]V[@QOPUF+?GM5R+[K2(O10;/V$7D YX3<8[U27Z_
M*_B6WWQ0[3/80M$<5FR'_UDTAU\+:H-92U!][ZV5>ELJFY*H[<]L-=D46.OU
M_K9*IV1J5=AFLJGPK<OZP5;*IZ3YM#\VV37EVJV=H.;Z<DGE G-'.,0(] [Z
MZ*4L;@3%1(NE/53OA<8CV@X3O$6!- :X'@NA7R?FG*[N9=$?4$L#!!0    (
M  )' U,IY"\J60,  #P,   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;*U7VV[C. S]%<&8AQ;HU->D%R0!FLMB.T!GBQ:S\ZS:3"Q4EK*2G'2 _?BE
M9,=)&M?I;/L26S+/X2$I4,Q@+=6SS@$,>2FXT$,O-V9Y[?LZS:&@^EPN0>"7
MN50%-;A4"U\O%=#,@0KN1T'0]PO*A#<:N+U[-1K(TG FX%X1718%5;_&P.5Z
MZ(7>9N.!+7)C-_S18$D7\ CFQ_)>X<IO6#)6@-!,"J)@/O1NPNM9V+, 9_$W
M@[7>>2<VE"<IG^WB-AMZ@54$'%)C*2@^5C !SBT3ZOBG)O4:GQ:X^[YA_\,%
MC\$\40T3R7^RS.1#[](C&<QIR<V#7/\)=4!.8"JY=K]D7=GV8X^DI3:RJ,&H
MH&"B>M*7.A$[ .1I!T0U('H-2-X Q#4@?J^'I 8D[_70JP$N=+^*W25N2@T=
M#91<$V6MD<V^N.P[-.:+"7M0'HW"KPQQ9G0K5J -5MYH\I5\ITI16SER,@5#
M&=>GN/OC<4I.OIP.?(,.+<Q/:_)Q11Z]01Z3.RE,KLE,9)"UX*?=^'X'WL=
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M>;^1C;.M!LB,9+<TIUF5;:7,CLXA%*36Z7Q51PHG214#[FAEZ:]ZK^-DOCG
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M)(_W,W)^=D'."*O)0RDVBM:%2EV-!,:/F[?1;IMHP9%H7S?U)0F]#R3P G]
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M@6\64F74X%8M?9TKH(D#9=R/@J#G9Y0);]AW9_=JV)<KPYF >T7T*LNHVHZ
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M9FYEJH3>I5I.C::*SY_0-<_U-4MB W6![J;W$IW=@"(TD^=ZX9ZM02I([,[
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M7&[I1YLWM&C<W5T);2:!6U;F;P#2!IC]M1!Z;]@$_?\E>P%02P,$%     @
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M>V&@YE><R^-+X:#^Y6/X'U!+ P04    "  "1P-3: BE*)\#  ###P  &0
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M)(JJ]^#.^RA<OZ?"]G]\H]]02P,$%     @  D<#4Y>*NQS     $P(   L
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M@J"G\D%3")J6#Y(QRC@F2+K!FD!K0:Z%P&M!L(5 ;$&RA<!L0;2%0&U!MH7
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M;%!+ 0(4 Q0    (  )' U.[A63%[@   "L"   1              "  :\
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M2P$"% ,4    "  "1P-32D4<$>("  "!"0  &               @(%/%
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @  D<#4Y:W<(/J
M!0  E1@  !@              ("!9Q<  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    (  )' U-?ZE('6 H  --!   8              "
M@8<=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  "1P-3
M_#W*?Y\&  !!&@  &               @($5*   >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @  D<#4^$:JS\K"P  D!H  !@
M     ("!ZBX  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M  )' U-IZVOJF!0  $<\   8              " @4LZ  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    "  "1P-3GD#DWQ /  "9-P  &
M            @($93P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#
M%     @  D<#4W^5QI)@ @  $04  !D              ("!7UX  'AL+W=O
M<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  "1P-36;@-3"0*  "9
M&P  &0              @('V8   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;%!+ 0(4 Q0    (  )' U.^ZQVTL ,  /\)   9              " @5%K
M  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @  D<#4\P.
M;RA'!   0PH  !D              ("!.&\  'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6Q02P$"% ,4    "  "1P-3=)E2E8(0  "]-@  &0
M    @(&V<P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M  )' U.HEO/ILQ   #DW   9              " @6^$  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @  D<#4VEF^(&C @  S04  !D
M             ("!694  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    "  "1P-3OY&0+TX'  !D%   &0              @($SF   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  )' U.!>DV]Q0(
M !0&   9              " @;B?  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @  D<#4QW;0CPH!0  8@T  !D              ("!
MM*(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  "1P-3
MD*0E6+85  #N0   &0              @($3J   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    (  )' U/VJ/:Z<0(  !H%   9
M      " @0"^  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @  D<#4[.QN_/' @  J 8  !D              ("!J,   'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  "1P-35R5(KM,"  "@!@
M&0              @(&FPP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    (  )' U/@.27LU0(  &T&   9              " @;#&  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @  D<#4\]%9+WI
M @  0 8  !D              ("!O,D  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    "  "1P-3+)2?$;("  #(!0  &0
M@('<S   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (  )'
M U-5MYSR(P0  !0+   9              " @<7/  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @  D<#4P6=UI1D!   \ H  !D
M         ("!']0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    "  "1P-3^BRT!Q$#   <"@  &0              @(&ZV   >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  )' U,U663 7@0  -P0
M   9              " @0+<  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @  D<#4W^50A])"   O"\  !D              ("!E^
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  "1P-3*DLS
M)F8"   L!@  &0              @($7Z0  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    (  )' U-/EVLDC@(  +X&   9
M  " @;3K  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M D<#4QXO@W3- @  HPD  !D              ("!>>X  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    "  "1P-3*>0O*ED#   \#   &0
M            @(%]\0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    (  )' U/4=S/L-P,  "T0   9              " @0WU  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @  D<#4U%Q;R-,"0
MZS0  !D              ("!>_@  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    "  "1P-3_=KI?C@#  !'"0  &0              @('^
M 0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (  )' U-M
M\W0Q;P<   4E   9              " @6T% 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @  D<#4S:[L9XO P  C0L  !D
M     ("!$PT! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  )' U,U\JV"*0,  *4*   9              "
M@0L? 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @  D<#
M4RZH&%@5 P  :PD  !D              ("!:R(! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    "  "1P-3T-[3VFL"  !Z!@  &0
M        @(&W)0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   (  )' U-H!<SR.@(  &L&   9              " @5DH 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @  D<#4[LVS=E(!   !1$
M !D              ("!RBH! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    "  "1P-3: BE*)\#  ###P  &0              @(%)+P$
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (  )' U/@4\Y[
M-0,  / 3   -              "  1\S 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @  D<#4Y>*NQS     $P(   L              ( !?S8! %]R96QS
M+RYR96QS4$L! A0#%     @  D<#4R@B(WXM!   :R$   \
M ( !:#<! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  )' U,X@V\FQ $
M  T>   :              "  <([ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    (  )' U. A/B=P $    >   3              "
M ;X] 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Z #H S0\  *\_ 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>220</ContextCount>
  <ElementCount>350</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Statements of Operations and Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedStatementsofCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/TheCompanyandBasisofPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Collaborations with Third Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CollaborationswithThirdParties</Role>
      <ShortName>Collaborations with Third Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111105 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113106 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120108 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement</Role>
      <ShortName>Liability Related to the Revenue Interest Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124109 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.esperion.com/role/ConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128110 - Disclosure - Other Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/OtherAccruedLiabilities</Role>
      <ShortName>Other Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131111 - Disclosure - Stock Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensation</Role>
      <ShortName>Stock Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2141113 - Disclosure - Net (Loss) Income Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/NetLossIncomePerCommonShare</Role>
      <ShortName>Net (Loss) Income Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.esperion.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/Inventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/Investments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables</Role>
      <ShortName>Liability Related to the Revenue Interest Purchase Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Convertible Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.esperion.com/role/ConvertibleNotesTables</Role>
      <ShortName>Convertible Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/ConvertibleNotes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Other Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/OtherAccruedLiabilitiesTables</Role>
      <ShortName>Other Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/OtherAccruedLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Stock Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationTables</Role>
      <ShortName>Stock Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/StockCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2342308 - Disclosure - Net (Loss) Income Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/NetLossIncomePerCommonShareTables</Role>
      <ShortName>Net (Loss) Income Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/NetLossIncomePerCommonShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - The Company and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails</Role>
      <ShortName>The Company and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/TheCompanyandBasisofPresentation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Collaborations with Third Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CollaborationswithThirdPartiesDetails</Role>
      <ShortName>Collaborations with Third Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/CollaborationswithThirdParties</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/InventoriesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/CommitmentsandContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Investments - Summary of Cash Equivalents and Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails</Role>
      <ShortName>Investments - Summary of Cash Equivalents and Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails</Role>
      <ShortName>Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails</Role>
      <ShortName>Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2426411 - Disclosure - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.esperion.com/role/ConvertibleNotesDetails</Role>
      <ShortName>Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/ConvertibleNotesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - Convertible Notes - Summary of Convertible Debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails</Role>
      <ShortName>Convertible Notes - Summary of Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2430413 - Disclosure - Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/OtherAccruedLiabilitiesDetails</Role>
      <ShortName>Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/OtherAccruedLiabilitiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2433414 - Disclosure - Stock Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2434415 - Disclosure - Stock Compensation - Schedule of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails</Role>
      <ShortName>Stock Compensation - Schedule of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2435416 - Disclosure - Stock Compensation - Stock Options Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails</Role>
      <ShortName>Stock Compensation - Stock Options Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2436417 - Disclosure - Stock Compensation - RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationRSUsDetails</Role>
      <ShortName>Stock Compensation - RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Stock Compensation - RSUs Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails</Role>
      <ShortName>Stock Compensation - RSUs Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Stock Compensation - PBRSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationPBRSUsDetails</Role>
      <ShortName>Stock Compensation - PBRSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2440420 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/IncomeTaxes</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2443421 - Disclosure - Net (Loss) Income Per Common Share - Calculation of Basic and Diluted (Loss) Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Common Share - Calculation of Basic and Diluted (Loss) Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/NetLossIncomePerCommonShareTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="espr-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2444422 - Disclosure - Net (Loss) Income Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/NetLossIncomePerCommonShareDetails</Role>
      <ShortName>Net (Loss) Income Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/NetLossIncomePerCommonShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="espr-20210630.htm">espr-20210630.htm</File>
    <File>espr-20210630.xsd</File>
    <File>espr-20210630_cal.xml</File>
    <File>espr-20210630_def.xml</File>
    <File>espr-20210630_lab.xml</File>
    <File>espr-20210630_pre.xml</File>
    <File>espr-ex311x06302021.htm</File>
    <File>espr-ex312x06302021.htm</File>
    <File>espr-ex321x06302021.htm</File>
    <File>ex101-licenseandcollaborat.htm</File>
    <File>ex102-amendedkoenigemploym.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "espr-20210630.htm": {
   "axisCustom": 1,
   "axisStandard": 22,
   "contextCount": 220,
   "dts": {
    "calculationLink": {
     "local": [
      "espr-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "espr-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "espr-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "espr-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "espr-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "espr-20210630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 447,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://www.esperion.com/20210630": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 8
   },
   "keyCustom": 67,
   "keyStandard": 283,
   "memberCustom": 23,
   "memberStandard": 32,
   "nsprefix": "espr",
   "nsuri": "http://www.esperion.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.esperion.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - Inventories",
     "role": "http://www.esperion.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111105 - Disclosure - Commitments and Contingencies",
     "role": "http://www.esperion.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113106 - Disclosure - Investments",
     "role": "http://www.esperion.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117107 - Disclosure - Fair Value Measurements",
     "role": "http://www.esperion.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120108 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement",
     "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement",
     "shortName": "Liability Related to the Revenue Interest Purchase Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124109 - Disclosure - Convertible Notes",
     "role": "http://www.esperion.com/role/ConvertibleNotes",
     "shortName": "Convertible Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128110 - Disclosure - Other Accrued Liabilities",
     "role": "http://www.esperion.com/role/OtherAccruedLiabilities",
     "shortName": "Other Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131111 - Disclosure - Stock Compensation",
     "role": "http://www.esperion.com/role/StockCompensation",
     "shortName": "Stock Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139112 - Disclosure - Income Taxes",
     "role": "http://www.esperion.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141113 - Disclosure - Net (Loss) Income Per Common Share",
     "role": "http://www.esperion.com/role/NetLossIncomePerCommonShare",
     "shortName": "Net (Loss) Income Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://www.esperion.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Inventories (Tables)",
     "role": "http://www.esperion.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Investments (Tables)",
     "role": "http://www.esperion.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.esperion.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:ScheduleOfRevenueInterestLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement (Tables)",
     "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables",
     "shortName": "Liability Related to the Revenue Interest Purchase Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:ScheduleOfRevenueInterestLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Convertible Notes (Tables)",
     "role": "http://www.esperion.com/role/ConvertibleNotesTables",
     "shortName": "Convertible Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Other Accrued Liabilities (Tables)",
     "role": "http://www.esperion.com/role/OtherAccruedLiabilitiesTables",
     "shortName": "Other Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Stock Compensation (Tables)",
     "role": "http://www.esperion.com/role/StockCompensationTables",
     "shortName": "Stock Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342308 - Disclosure - Net (Loss) Income Per Common Share (Tables)",
     "role": "http://www.esperion.com/role/NetLossIncomePerCommonShareTables",
     "shortName": "Net (Loss) Income Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id125fee9cd774cad978f6ae94f446b6b_D20210501-20210531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "espr:UpFrontPayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - The Company and Basis of Presentation (Details)",
     "role": "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails",
     "shortName": "The Company and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "espr:NumberOfSourcesOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "revenue_source",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "espr:NumberOfSourcesOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "revenue_source",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Collaborations with Third Parties (Details)",
     "role": "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
     "shortName": "Collaborations with Third Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i70b05bb32f374749885434ca47747d1a_D20200401-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Inventories (Details)",
     "role": "http://www.esperion.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i66cc3f1c51c941f2b162c47f055b97e7_D20210101-20210630",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.esperion.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i66cc3f1c51c941f2b162c47f055b97e7_D20210101-20210630",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Investments - Summary of Cash Equivalents and Short-Term Investments (Details)",
     "role": "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails",
     "shortName": "Investments - Summary of Cash Equivalents and Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Investments - Narrative (Details)",
     "role": "http://www.esperion.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeExpense",
       "us-gaap:OtherNonoperatingIncomeExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i3014251d4b0c415f885b37eb158bb11f_D20210401-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.esperion.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "iba2aa44c62434cdca9106c4f4051ff24_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)",
     "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
     "shortName": "Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "espr:UnamortizedTransactionCostsOnRevenueInterestAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "espr:PaymentsFromRevenueInterestPurchaseAgreement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)",
     "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails",
     "shortName": "Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "espr:ScheduleOfRevenueInterestLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i3b6d49a2de7d453bb5f3efdd8de4f460_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "espr:RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i61bb4d25218d4d74956e512d85225917_D20201116-20201116",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForDerivativeInstrumentFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426411 - Disclosure - Convertible Notes (Details)",
     "role": "http://www.esperion.com/role/ConvertibleNotesDetails",
     "shortName": "Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i61bb4d25218d4d74956e512d85225917_D20201116-20201116",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForDerivativeInstrumentFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Statements of Operations and Comprehensive (Loss) Income",
     "role": "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
     "shortName": "Condensed Statements of Operations and Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherCostAndExpenseOperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i93532836fe0e4502b83cb85c9fb2c31a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - Convertible Notes - Summary of Convertible Debt (Details)",
     "role": "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails",
     "shortName": "Convertible Notes - Summary of Convertible Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i93532836fe0e4502b83cb85c9fb2c31a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430413 - Disclosure - Other Accrued Liabilities (Details)",
     "role": "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails",
     "shortName": "Other Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i1c209f1921c3473dbb64c2533be863bd_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433414 - Disclosure - Stock Compensation - Employee Stock Purchase Plan (Details)",
     "role": "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i2dee4bb080eb434ea68e0693b8ca612c_D20200401-20200430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i056e612b26e34dd48d60f525e33d62cb_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434415 - Disclosure - Stock Compensation - Schedule of Stock Options (Details)",
     "role": "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails",
     "shortName": "Stock Compensation - Schedule of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435416 - Disclosure - Stock Compensation - Stock Options Additional Information (Details)",
     "role": "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails",
     "shortName": "Stock Compensation - Stock Options Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "ia035057e90e8414782c002bfa3d7dfe7_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i3dd83bfde144490abf8e977beb2d1e13_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436417 - Disclosure - Stock Compensation - RSUs (Details)",
     "role": "http://www.esperion.com/role/StockCompensationRSUsDetails",
     "shortName": "Stock Compensation - RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i3dd83bfde144490abf8e977beb2d1e13_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i059e63457ab0488a8b8926c7af529680_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Stock Compensation - RSUs Additional Information (Details)",
     "role": "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails",
     "shortName": "Stock Compensation - RSUs Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i059e63457ab0488a8b8926c7af529680_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "if90fbea89e414e58b44494d21f429a48_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Stock Compensation - PBRSUs (Details)",
     "role": "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
     "shortName": "Stock Compensation - PBRSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "if90fbea89e414e58b44494d21f429a48_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440420 - Disclosure - Income Taxes (Details)",
     "role": "http://www.esperion.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443421 - Disclosure - Net (Loss) Income Per Common Share - Calculation of Basic and Diluted (Loss) Income Per Share (Details)",
     "role": "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails",
     "shortName": "Net (Loss) Income Per Common Share - Calculation of Basic and Diluted (Loss) Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i2a5187a56ea64ae79ed566f657f52f0f_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Statements of Stockholders' Equity (Deficit)",
     "role": "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit",
     "shortName": "Condensed Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i4782e3db8423421e942447fb17c5f321_D20200101-20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444422 - Disclosure - Net (Loss) Income Per Common Share (Details)",
     "role": "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails",
     "shortName": "Net (Loss) Income Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "id1f0fba619444e1b94070818a3bd0a60_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Statements of Cash Flows",
     "role": "http://www.esperion.com/role/CondensedStatementsofCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - The Company and Basis of Presentation",
     "role": "http://www.esperion.com/role/TheCompanyandBasisofPresentation",
     "shortName": "The Company and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.esperion.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Collaborations with Third Parties",
     "role": "http://www.esperion.com/role/CollaborationswithThirdParties",
     "shortName": "Collaborations with Third Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20210630.htm",
      "contextRef": "i6b05cb1eb61c4baab24e4798050ea035_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "espr_AccruedClinicalDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).",
        "label": "Accrued Clinical Development Costs, Current",
        "terseLabel": "Accrued clinical development costs"
       }
      }
     },
     "localname": "AccruedClinicalDevelopmentCostsCurrent",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities and Employee-related Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "Total other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AccruedVariableConsiderationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees",
        "label": "Accrued Variable Consideration, Current",
        "terseLabel": "Accrued variable consideration"
       }
      }
     },
     "localname": "AccruedVariableConsiderationCurrent",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.",
        "label": "Aggregate Amount of Potential Future Revenue, Total Development and Sales Milestones",
        "terseLabel": "Potential additional future payments"
       }
      }
     },
     "localname": "AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AmendedLicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to an amended license and collaboration agreement.",
        "label": "Amended License And Collaboration Agreement [Member]",
        "terseLabel": "Amended License and Collaboration Agreement"
       }
      }
     },
     "localname": "AmendedLicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement.",
        "label": "Amount of Subsequent Installment, Subject to Achievement of Sales Threshold",
        "terseLabel": "Amount of subsequent installment, subject to achievement of sales threshold"
       }
      }
     },
     "localname": "AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the subsequent installment which is subject to regulatory approval.",
        "label": "Amount of Subsequent Installment, Subject to Regulatory Approval",
        "terseLabel": "Amount of subsequent installment, subject to regulatory approval"
       }
      }
     },
     "localname": "AmountOfSubsequentInstallmentSubjectToRegulatoryApproval",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement.",
        "label": "Amount of Subsequent Installment, Subject to Revenue Interest Purchase Agreement Terms and Conditions",
        "terseLabel": "Total amount of subsequent installment, subject to RIPA terms and conditions"
       }
      }
     },
     "localname": "AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold",
        "label": "Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold",
        "terseLabel": "Company deposit value in blocked account"
       }
      }
     },
     "localname": "BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_CappedCallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped Call",
        "label": "Capped Call [Member]",
        "terseLabel": "Capped Call"
       }
      }
     },
     "localname": "CappedCallMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_CashPaymentToBeReceivedUponCertainCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Payment To Be Received Upon Certain Commercial Milestones",
        "label": "Cash Payment To Be Received Upon Certain Commercial Milestones",
        "terseLabel": "Cash payment to be received upon certain commercial milestones"
       }
      }
     },
     "localname": "CashPaymentToBeReceivedUponCertainCommercialMilestones",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_CashPaymentToBeReceivedUponFirstCommercialSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash payment to the Company upon first commercial sales in the DSE Territory.",
        "label": "Cash Payment to be Received upon First Commercial Sales",
        "terseLabel": "Cash payment to the Company upon first commercial sales in the DSE Territory"
       }
      }
     },
     "localname": "CashPaymentToBeReceivedUponFirstCommercialSales",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage",
        "terseLabel": "Class of warrant or right, premium percentage"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_CollaborativeArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Collaborations with Third Parties",
        "terseLabel": "Collaborations with Third Parties"
       }
      }
     },
     "localname": "CollaborativeArrangementAbstract",
     "nsuri": "http://www.esperion.com/20210630",
     "xbrltype": "stringItemType"
    },
    "espr_CollaborativeArrangementLicenseToIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, License To Intellectual Property",
        "label": "Collaborative Arrangement, License To Intellectual Property [Member]",
        "terseLabel": "Collaborative Arrangement, License To Intellectual Property"
       }
      }
     },
     "localname": "CollaborativeArrangementLicenseToIntellectualPropertyMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Ongoing Regulatory And Development Activities",
        "label": "Collaborative Arrangement, Ongoing Regulatory And Development Activities [Member]",
        "terseLabel": "Collaborative Arrangement, Ongoing Regulatory And Development Activities"
       }
      }
     },
     "localname": "CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_ConcentrationRiskNumberOfMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of the Company's major customers.",
        "label": "Concentration Risk, Number of Major Customers",
        "terseLabel": "Number of major customers"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfMajorCustomers",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consecutive number of months sales must be at or above the milestone amount.",
        "label": "Consecutive Number of Months Sales Must Be At or Above Milestone Amount",
        "terseLabel": "Consecutive number of months sales must be at or above milestone amount"
       }
      }
     },
     "localname": "ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "espr_ConvertibleSeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2025",
        "label": "Convertible Senior Notes Due 2025 [Member]",
        "terseLabel": "Convertible Senior Notes Due 2025"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2025Member",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_DaiichiSankyoCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daiichi Sankyo Co. Ltd",
        "label": "Daiichi Sankyo Co. Ltd [Member]",
        "terseLabel": "Daiichi Sankyo Co. Ltd"
       }
      }
     },
     "localname": "DaiichiSankyoCoLtdMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_DaiichiSankyoEuropeGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for the Daiichi Sankyo Europe GmbH (\"DSE\").",
        "label": "Daiichi Sankyo Europe Gmbh [Member]",
        "terseLabel": "Daiichi Sankyo Europe GmbH (\"DSE\")"
       }
      }
     },
     "localname": "DaiichiSankyoEuropeGmbhMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_DebtInstrumentAdditionalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Additional Amount",
        "label": "Debt Instrument, Additional Amount",
        "terseLabel": "Debt instrument, additional principal amount"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalAmount",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price",
        "label": "Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price",
        "terseLabel": "Debt instrument, convertible, threshold percentage of last reported sale price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_DebtInstrumentCovenantRequiredAmountOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Required Amount Outstanding",
        "label": "Debt Instrument, Covenant, Required Amount Outstanding",
        "terseLabel": "Debt instrument, required amount outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRequiredAmountOutstanding",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_DeferredUpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Up-Front Payment",
        "label": "Deferred Up-Front Payment",
        "terseLabel": "Deferred up-front payment"
       }
      }
     },
     "localname": "DeferredUpFrontPayment",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_EigerIiiSaLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to revenue interest purchase agreement (\"RIPA\") with Oberland.",
        "label": "Eiger Iii Sa Llc [Member]",
        "terseLabel": "Oberland"
       }
      }
     },
     "localname": "EigerIiiSaLlcMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Stock Purchase Plan, Duration of Offering Period",
        "terseLabel": "Duration of offering periods"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanDurationOfOfferingPeriod",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to an employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Amount of maximum annual contributions per employee"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee, as a percentage of base salary"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_EmployeeStockPurchasePlanPercentageDiscountOnShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period.",
        "label": "Employee Stock Purchase Plan, Percentage Discount on Shares",
        "terseLabel": "Purchase discount"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanPercentageDiscountOnShares",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_ExclusiveDevelopmentalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to exclusive developmental activities.",
        "label": "Exclusive Developmental Activities [Member]",
        "terseLabel": "Exclusive Developmental Activities"
       }
      }
     },
     "localname": "ExclusiveDevelopmentalActivitiesMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.",
        "label": "Future Payment Milestone, Achievement of Drug Trial Outcomes Studies",
        "terseLabel": "Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label"
       }
      }
     },
     "localname": "FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.",
        "label": "Future Payment Milestone, First National Health Insurance Price Listing, Otsuka Territory",
        "terseLabel": "Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory"
       }
      }
     },
     "localname": "FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.",
        "label": "Future Payment Milestone, First Submission of Japanese New Drug Application, Otsuka Territory",
        "terseLabel": "Milestone payment, first JNDA submissions"
       }
      }
     },
     "localname": "FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_FuturePaymentMilestoneSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.",
        "label": "Future Payment Milestone, Sales Milestones",
        "terseLabel": "Milestone payments related to total net sales achievements"
       }
      }
     },
     "localname": "FuturePaymentMilestoneSalesMilestones",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_FutureUpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Up-Front Payment",
        "label": "Future Up-Front Payment",
        "terseLabel": "Future upfront payment"
       }
      }
     },
     "localname": "FutureUpFrontPayment",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_GrossProceedsFromRevenueInterestPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a revenue interest purchase agreement.",
        "label": "Gross Proceeds from Revenue Interest Purchase Agreement",
        "terseLabel": "Gross proceeds from revenue interest liability"
       }
      }
     },
     "localname": "GrossProceedsFromRevenueInterestPurchaseAgreement",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_HypotheticalRepaymentObligationBasedOnSalesGenerated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hypothetical Repayment Obligation Based On Sales Generated",
        "label": "Hypothetical Repayment Obligation Based On Sales Generated",
        "terseLabel": "Hypothetical repayment obligation"
       }
      }
     },
     "localname": "HypotheticalRepaymentObligationBasedOnSalesGenerated",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_HypotheticalSalesGeneratedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hypothetical Sales Generated Amount",
        "label": "Hypothetical Sales Generated Amount",
        "terseLabel": "Hypothetical sales generated amount"
       }
      }
     },
     "localname": "HypotheticalSalesGeneratedAmount",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_LiabilityFromSaleOfFutureRevenuesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liability from Sale of Future Revenues [Line Items]",
        "terseLabel": "Liability Related to the Revenue Interest Purchase Agreement"
       }
      }
     },
     "localname": "LiabilityFromSaleOfFutureRevenuesLineItems",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_LiabilityFromSaleOfFutureRevenuesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability From Sale Of Future Revenues",
        "label": "Liability From Sale Of Future Revenues [Roll Forward]",
        "terseLabel": "Liability From Sale Of Future Revenues [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityFromSaleOfFutureRevenuesRollForward",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_LiabilityFromSaleOfFutureRevenuesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about liabilities from the sale of future royalty revenues.",
        "label": "Liability from Sale of Future Revenues [Table]",
        "terseLabel": "Liability from Sale of Future Revenues [Table]"
       }
      }
     },
     "localname": "LiabilityFromSaleOfFutureRevenuesTable",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition.",
        "label": "Liability Related to the Revenue Interest Purchase Agreement",
        "terseLabel": "Liability Related to the Revenue Interest Purchase Agreement"
       }
      }
     },
     "localname": "LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract",
     "nsuri": "http://www.esperion.com/20210630",
     "xbrltype": "stringItemType"
    },
    "espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC (\"Oberland\").",
        "label": "Liability Related to The Revenue Interest Purchase Agreement [Text Block]",
        "terseLabel": "Liability Related to the Revenue Interest Purchase Agreement"
       }
      }
     },
     "localname": "LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone amount for worldwide sales to receive the Third Payment.",
        "label": "Milestone Amount for Worldwide Sales to Receive Third Payment",
        "terseLabel": "Milestone amount for worldwide sales to receive the third payment"
       }
      }
     },
     "localname": "MilestoneAmountForWorldwideSalesToReceiveThirdPayment",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_MilestoneMarketingAuthorizationApprovalNustendiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to marketing authorization approval (MAA) for NUSTENDI.",
        "label": "Milestone Marketing Authorization Approval Nustendi [Member]",
        "terseLabel": "NUSTENDI, MAA"
       }
      }
     },
     "localname": "MilestoneMarketingAuthorizationApprovalNustendiMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021.",
        "label": "Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate",
        "terseLabel": "Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021"
       }
      }
     },
     "localname": "MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold",
        "label": "Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold",
        "terseLabel": "Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received"
       }
      }
     },
     "localname": "MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_NetSalesThresholdAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold",
        "label": "Net Sales Threshold [Axis]",
        "terseLabel": "Net Sales Threshold [Axis]"
       }
      }
     },
     "localname": "NetSalesThresholdAxis",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_NetSalesThresholdDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold",
        "label": "Net Sales Threshold [Domain]",
        "terseLabel": "Net Sales Threshold [Domain]"
       }
      }
     },
     "localname": "NetSalesThresholdDomain",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_NetSalesThresholdOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold One",
        "label": "Net Sales Threshold One [Member]",
        "terseLabel": "Net Sales Less Than $250 Million"
       }
      }
     },
     "localname": "NetSalesThresholdOneMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_NetSalesThresholdThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold Three",
        "label": "Net Sales Threshold Three [Member]",
        "terseLabel": "Net Sales Greater Than $350 Million"
       }
      }
     },
     "localname": "NetSalesThresholdThreeMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold To Include Worldwide Sales In Covered Territory",
        "label": "Net Sales Threshold To Include Worldwide Sales In Covered Territory",
        "terseLabel": "Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021"
       }
      }
     },
     "localname": "NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_NetSalesThresholdTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold Two",
        "label": "Net Sales Threshold Two [Member]",
        "terseLabel": "Net Sales Greater Than $250 Million But Less Than $350 Million"
       }
      }
     },
     "localname": "NetSalesThresholdTwoMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_NonCashInterestExpenseRelatedToRevenueInterestLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-cash expense included in interest expense associated with the revenue interest liability.",
        "label": "Non Cash Interest Expense Related to Revenue Interest Liability",
        "terseLabel": "Non-cash interest expense related to the revenue interest liability"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToRevenueInterestLiability",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_NonCashRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the difference between the lease asset and the lease liability.",
        "label": "Non Cash Right Of Use Asset",
        "terseLabel": "Non cash right of use asset"
       }
      }
     },
     "localname": "NonCashRightOfUseAsset",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_NumberOfBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Business Days",
        "label": "Number Of Business Days",
        "terseLabel": "Number of business days"
       }
      }
     },
     "localname": "NumberOfBusinessDays",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "espr_NumberOfConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Consecutive Trading Days",
        "label": "Number Of Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDays",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "espr_NumberOfSourcesOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Sources Of Revenue",
        "label": "Number Of Sources Of Revenue",
        "terseLabel": "Number of revenue sources"
       }
      }
     },
     "localname": "NumberOfSourcesOfRevenue",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "espr_OtsukaPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Otsuka Pharmaceutical Co, Ltd.",
        "label": "Otsuka Pharmaceutical Co Ltd [Member]",
        "terseLabel": "Otsuka Pharmaceutical Co, Ltd."
       }
      }
     },
     "localname": "OtsukaPharmaceuticalCoLtdMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_PaymentsFromRevenueInterestPurchaseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from a revenue interest purchase agreement.",
        "label": "Payments From Revenue Interest Purchase Agreement",
        "negatedLabel": "Payments on revenue interest liability",
        "negatedTerseLabel": "Revenue Interests payments"
       }
      }
     },
     "localname": "PaymentsFromRevenueInterestPurchaseAgreement",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_PercentageOfCumulativePurchaserPaymentsGuarantee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Cumulative Purchaser Payments, Guarantee",
        "label": "Percentage Of Cumulative Purchaser Payments, Guarantee",
        "terseLabel": "Percentage of cumulative purchaser payments"
       }
      }
     },
     "localname": "PercentageOfCumulativePurchaserPaymentsGuarantee",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of increase in the Royalty Rate upon drawdown of the Third Payment.",
        "label": "Percentage of Increase in Royalty Rate Upon Drawdown of Third Payment",
        "terseLabel": "Percentage of increase in royalty rate upon drawdown of third payment"
       }
      }
     },
     "localname": "PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate.",
        "label": "Percentage of Invested Capital Received By December 31, 2024, To Qualify For Second Reduced Revenue Interest Rate",
        "terseLabel": "Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate"
       }
      }
     },
     "localname": "PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage",
        "label": "Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage",
        "terseLabel": "Percentage of revenue interest payments to qualify for third payment applicable percentage"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue interests payment on which agreement terminates.",
        "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates",
        "terseLabel": "Percentage of revenue interests payment on which agreement terminates"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised.",
        "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates After the Third Anniversary Of Closing Date If Put Option Is Exercised",
        "terseLabel": "Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised.",
        "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates If Prior to the Anniversary Of Closing Date If Put Option Is Exercised",
        "terseLabel": "Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised.",
        "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates Prior to the Third Anniversary Of Closing Date If Put Option Is Exercised",
        "terseLabel": "Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRoyaltiesToBeReceivedOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalties to be received on net sales.",
        "label": "Percentage of Royalties to be Received on Net Sales",
        "terseLabel": "Percentage of royalties to be received on the net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesToBeReceivedOnNetSales",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PrepaidClinicalDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Clinical Development Costs, Current",
        "terseLabel": "Prepaid clinical development costs"
       }
      }
     },
     "localname": "PrepaidClinicalDevelopmentCostsCurrent",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds received upon achievement of the milestone for completion of the NUSTENDI Marketing Authorization Approval (MAA) transfer.",
        "label": "Proceeds From Achievement of Milestone, Completion of the NUSTENDI Marketing Authorization Approval Transfer",
        "terseLabel": "Proceeds received upon completion of NUSTENDI MAA transfer"
       }
      }
     },
     "localname": "ProceedsFromAchievementOfMilestoneCompletionOfNustendiMarketingAuthorizationApprovalTransfer",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_ProceedsFromRevenueInterestPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Revenue Interest Purchase Agreement",
        "label": "Proceeds from Revenue Interest Purchase Agreement",
        "terseLabel": "Proceeds from Revenue Interest Purchase Agreement"
       }
      }
     },
     "localname": "ProceedsFromRevenueInterestPurchaseAgreement",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a revenue interest purchase agreement, net of issuance costs.",
        "label": "Proceeds from Revenue Interest Purchase Agreement, Net of Issuance Costs",
        "verboseLabel": "Proceeds from revenue interest liability, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_ProductSalesBulkTabletsNilemdoAndNustendiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to sales of bulk tablets of NILEMDO and NUSTENDI.",
        "label": "Product Sales Bulk Tablets Nilemdo And Nustendi [Member]",
        "terseLabel": "NILEMDO and NUSTENDI, sales of bulk tablets"
       }
      }
     },
     "localname": "ProductSalesBulkTabletsNilemdoAndNustendiMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RIPA Amendment To The Security Agreement And Waiver",
        "label": "RIPA Amendment To The Security Agreement And Waiver [Member]",
        "terseLabel": "RIPA Amendment To The Security Agreement And Waiver"
       }
      }
     },
     "localname": "RIPAAmendmentToTheSecurityAgreementAndWaiverMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RegulatoryPerformanceObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to performance obligations related to the ongoing regulatory efforts.",
        "label": "Regulatory Performance Obligations [Member]",
        "terseLabel": "Regulatory performance obligations"
       }
      }
     },
     "localname": "RegulatoryPerformanceObligationsMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RevenueInterestLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current and non-current portion of the Revenue Interest Liability.",
        "label": "Revenue Interest Liability",
        "periodEndLabel": "Revenue interest liability, ending balance",
        "periodStartLabel": "Revenue interest liability, beginning balance",
        "terseLabel": "Revenue interest liability"
       }
      }
     },
     "localname": "RevenueInterestLiability",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to Revenue Interest Purchase Agreement (\"RIPA\"), classified as current.",
        "label": "Revenue Interest Liability, Current",
        "verboseLabel": "Revenue interest liability"
       }
      }
     },
     "localname": "RevenueInterestLiabilityCurrent",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in the revenue interest liability related to funding received during the period.",
        "label": "Revenue Interest Liability, Increase for Funding Received, Net Of Issuance Costs",
        "terseLabel": "Oberland funding upon execution of Amendment No. 2, net of issuance costs"
       }
      }
     },
     "localname": "RevenueInterestLiabilityIncreaseForFundingReceivedNetOfIssuanceCosts",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in the revenue interest liability attributable to interest expense recognized during the period.",
        "label": "Revenue Interest Liability, Increase for Interest Expense Recognized",
        "terseLabel": "Interest expense recognized"
       }
      }
     },
     "localname": "RevenueInterestLiabilityIncreaseForInterestExpenseRecognized",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to Revenue Interest Purchase Agreement (\"RIPA\"), classified as noncurrent.",
        "label": "Revenue Interest Liability, NonCurrent",
        "terseLabel": "Revenue interest liability"
       }
      }
     },
     "localname": "RevenueInterestLiabilityNoncurrent",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestPurchaseAgreementAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Purchase Agreement Amendment",
        "label": "Revenue Interest Purchase Agreement Amendment [Member]",
        "terseLabel": "RIPA Amendment"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAgreementAmendmentMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of effective annual imputed interest rate under the revenue interest purchase agreement.",
        "label": "Revenue Interest Purchase Agreement, Effective Annual Imputed Interest Rate",
        "terseLabel": "Effective annual imputed interest rate (as a percent)"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_RevenueInterestPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to revenue interest purchase agreement (\"RIPA\").",
        "label": "Revenue Interest Purchase Agreement [Member]",
        "terseLabel": "Revenue Interest Purchase Agreement (RIPA)"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAgreementMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RevenueInterestRateInitialRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory.",
        "label": "Revenue Interest Rate, Initial Rate",
        "terseLabel": "Initial revenue interest rate"
       }
      }
     },
     "localname": "RevenueInterestRateInitialRate",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_RevenueInterestRateTierThree": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024.",
        "label": "Revenue Interest Rate, Tier Three",
        "terseLabel": "Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024"
       }
      }
     },
     "localname": "RevenueInterestRateTierThree",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_RevenueInterestRateTierTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021.",
        "label": "Revenue Interest Rate, Tier Two",
        "terseLabel": "Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021"
       }
      }
     },
     "localname": "RevenueInterestRateTierTwo",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months",
        "label": "Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months",
        "terseLabel": "Repayment amount expected to pay in next twelve months"
       }
      }
     },
     "localname": "RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi",
        "label": "Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi [Member]",
        "terseLabel": "Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi"
       }
      }
     },
     "localname": "RoyaltyRevenueAndProductSalesBulkTabletsNilemdoAndNustendiMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_ScheduleOfRevenueInterestLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to the revenue interest liability.",
        "label": "Schedule of Revenue Interest Liability [Table Text Block]",
        "terseLabel": "Summary of Revenue Interest Liability Activity During the Period"
       }
      }
     },
     "localname": "ScheduleOfRevenueInterestLiabilityTableTextBlock",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "espr_SerometrixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Serometrix",
        "label": "Serometrix [Member]",
        "terseLabel": "Serometrix"
       }
      }
     },
     "localname": "SerometrixMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account",
        "label": "Specified Net Revenue Threshold Triggering Deposit In Blocked Account",
        "terseLabel": "Specified net revenue"
       }
      }
     },
     "localname": "SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_UnamortizedTransactionCostsOnRevenueInterestAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction costs on revenue interest agreement.",
        "label": "Unamortized Transaction Costs on Revenue Interest Agreement",
        "terseLabel": "Capitalized issuance costs"
       }
      }
     },
     "localname": "UnamortizedTransactionCostsOnRevenueInterestAgreement",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to unvested restricted stock and restricted stock units.",
        "label": "Unvested Restricted Stock And Restricted Stock Units [Member]",
        "terseLabel": "Unvested RSUs"
       }
      }
     },
     "localname": "UnvestedRestrictedStockAndRestrictedStockUnitsMember",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_UpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of up-front payment received (paid) .",
        "label": "Up-Front Payment",
        "terseLabel": "Upfront cash payment received (paid)"
       }
      }
     },
     "localname": "UpFrontPayment",
     "nsuri": "http://www.esperion.com/20210630",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r52",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "auth_ref": [
      "r104",
      "r111",
      "r188",
      "r290",
      "r291",
      "r292",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r104",
      "r111",
      "r188",
      "r290",
      "r291",
      "r292",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit",
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r104",
      "r111",
      "r188",
      "r290",
      "r291",
      "r292",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit",
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r104",
      "r111",
      "r188",
      "r290",
      "r291",
      "r292",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit",
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r258",
      "r259",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r383",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/InvestmentsNarrativeDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r258",
      "r259",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r383",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r168",
      "r245",
      "r248",
      "r384",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r168",
      "r245",
      "r248",
      "r384",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r249",
      "r258",
      "r259",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r383",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/InvestmentsNarrativeDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r249",
      "r258",
      "r259",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r383",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/InvestmentsNarrativeDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r304",
      "r305",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of premiums and discounts on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInvestmentIncomeReceivable": {
     "auth_ref": [
      "r20",
      "r386",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.",
        "label": "Accrued Investment Income Receivable",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "AccruedInvestmentIncomeReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r37"
     ],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r101",
      "r102",
      "r103",
      "r322",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r293"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "negatedTerseLabel": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit",
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r260",
      "r262",
      "r295",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r262",
      "r281",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails",
      "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r66",
      "r85",
      "r349"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total potential dilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net (Loss) Income Per Common Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r157",
      "r160",
      "r166",
      "r184",
      "r319",
      "r323",
      "r338",
      "r387",
      "r402"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r51",
      "r96",
      "r184",
      "r319",
      "r323",
      "r338"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r176",
      "r196"
     ],
     "calculation": {
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r174",
      "r177",
      "r196",
      "r391"
     ],
     "calculation": {
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r263",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails",
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r100",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "The Company and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/TheCompanyandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment not yet paid"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r34",
      "r87"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r82",
      "r87",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r82",
      "r339"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r95",
      "r96",
      "r119",
      "r123",
      "r124",
      "r126",
      "r128",
      "r137",
      "r138",
      "r139",
      "r184",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r241",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r313",
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations with Third Parties"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborations with Third Parties",
        "verboseLabel": "The Company and Basis of Presentation"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r213",
      "r392",
      "r408"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 120,000,000 shares authorized as of June\u00a030, 2021 and December\u00a031, 2020; 28,268,533 shares issued at June\u00a030, 2021 and 27,910,366 shares issued at December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r64",
      "r394",
      "r410"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r170",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r170",
      "r336",
      "r337",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r170",
      "r336",
      "r337",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r142",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r170",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r242",
      "r243",
      "r246"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue from collaborations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r242",
      "r243",
      "r246"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue from collaborations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Upfront payment, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Shares issuable upon conversion of convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes, net of issuance costs"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r145",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r388",
      "r389",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r226",
      "r389",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Convertible note, debt balance"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Debt instrument, convertible, carrying amount of equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r41",
      "r233",
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r99",
      "r233",
      "r235",
      "r236",
      "r237",
      "r347",
      "r348",
      "r350",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r178",
      "r196",
      "r199",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "negatedTerseLabel": "Debt issuance cost",
        "terseLabel": "Debt issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r85",
      "r207"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r117",
      "r119",
      "r126",
      "r127",
      "r128",
      "r132",
      "r133",
      "r395",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net (loss) income per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r65",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r119",
      "r126",
      "r127",
      "r128",
      "r132",
      "r133",
      "r395",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net (loss) income per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net (Loss) Income Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "verboseLabel": "Stock-based compensation capitalized into inventory"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period over which remaining unrecognized compensation cost will be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense, RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares issuable related to the ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Common shares under option",
        "verboseLabel": "Common shares under option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r106",
      "r114",
      "r116",
      "r136",
      "r188",
      "r232",
      "r238",
      "r290",
      "r291",
      "r292",
      "r304",
      "r305",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r328",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r327",
      "r328",
      "r330",
      "r331",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r250",
      "r251",
      "r256",
      "r257",
      "r328",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r250",
      "r251",
      "r256",
      "r257",
      "r328",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r328",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring fair value measurement"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r201",
      "r202",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Loss related to litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "negatedTerseLabel": "Loss on modification of debt"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r306",
      "r308",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r115",
      "r116",
      "r156",
      "r300",
      "r307",
      "r309",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaids and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r128"
     ],
     "calculation": {
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive shares (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r62",
      "r155",
      "r346",
      "r349",
      "r396"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r70",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Debt interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r37"
     ],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest on convertible notes"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r205"
     ],
     "calculation": {
      "http://www.esperion.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r49"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.esperion.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r50",
      "r92",
      "r135",
      "r203",
      "r204",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r205"
     ],
     "calculation": {
      "http://www.esperion.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r205"
     ],
     "calculation": {
      "http://www.esperion.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r69",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income on investments"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r183",
      "r385",
      "r397",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r96",
      "r161",
      "r184",
      "r320",
      "r323",
      "r324",
      "r338"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r96",
      "r184",
      "r338",
      "r390",
      "r405"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r96",
      "r184",
      "r320",
      "r323",
      "r324",
      "r338"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Payment to plaintiff"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r227",
      "r389",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Convertible notes, net",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/ConvertibleNotesSummaryofConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyReceivable": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable",
        "terseLabel": "Insurance settlement recovery"
       }
      }
     },
     "localname": "LossContingencyReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r56",
      "r59",
      "r63",
      "r86",
      "r96",
      "r105",
      "r109",
      "r110",
      "r111",
      "r112",
      "r115",
      "r116",
      "r125",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r184",
      "r338",
      "r393",
      "r409"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows",
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Implemented Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r157",
      "r159",
      "r162",
      "r165",
      "r167"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "(Loss) income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r37"
     ],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r317",
      "r318",
      "r321"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r57",
      "r60",
      "r317",
      "r318",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r79",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Payments for Derivative Instrument, Financing Activities",
        "terseLabel": "Purchase of capped call options associated with convertible notes"
       }
      }
     },
     "localname": "PaymentsForDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "terseLabel": "Prepayment of forward stock repurchase transaction"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PBRSUs",
        "verboseLabel": "Unvested PBRSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of June\u00a030, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Other prepaid and current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r72",
      "r73",
      "r175"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales/maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r285"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r208",
      "r407"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails",
      "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r238",
      "r293",
      "r404",
      "r423",
      "r428"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r106",
      "r114",
      "r116",
      "r188",
      "r290",
      "r291",
      "r292",
      "r304",
      "r305",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r153",
      "r158",
      "r163",
      "r164",
      "r168",
      "r169",
      "r170",
      "r244",
      "r245",
      "r384"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total Revenues",
        "verboseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Calculation of Basic and Diluted (Loss) Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the details pertaining to each employee stock ownership plan.",
        "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]",
        "terseLabel": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r263",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r266",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of Activity Relating to the Company's Options to Purchase Common Stock"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Relating to the Company's RSUs"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Performance period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value (in dollars per share)",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding and unvested at the ending of period (in shares)",
        "periodStartLabel": "Outstanding and unvested at the beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding and unvested at the at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding and unvested at the beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r268",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "verboseLabel": "Summary of Information About the Company's Stock Option Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationEmployeeStockPurchasePlanDetails",
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsAdditionalInformationDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r95",
      "r96",
      "r119",
      "r123",
      "r124",
      "r126",
      "r128",
      "r137",
      "r138",
      "r139",
      "r184",
      "r232",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r101",
      "r102",
      "r103",
      "r106",
      "r114",
      "r116",
      "r136",
      "r188",
      "r232",
      "r238",
      "r290",
      "r291",
      "r292",
      "r304",
      "r305",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r136",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Vesting of ESPP Shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r232",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r238",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Vesting of ESPP Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r232",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r96",
      "r173",
      "r184",
      "r338"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services  that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Receivables"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r46",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r46",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r19",
      "r232",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Underlying common stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r46",
      "r239",
      "r240"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 1,994,198 shares at June\u00a030, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Company's Cash Equivalents and Short-Term Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r144",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r118",
      "r128"
     ],
     "calculation": {
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - diluted (in shares)",
        "totalLabel": "Weighted-average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r117",
      "r128"
     ],
     "calculation": {
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.esperion.com/role/NetLossIncomePerCommonShareCalculationofBasicandDilutedLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r431": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r432": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r433": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r434": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r435": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r436": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(1),(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3505-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001628280-21-015248-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-015248-xbrl.zip
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MD1(0-T8*"7Y?:0C//,YT (X'] Y3X3QQ :P-I2N4CM$RAL=J\<:U*+P;8H"
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M:1")1"^.HR@1S[@O>N<&0R*$:+5'4<H4DFN7UM8:B37%%*,YSFXMDNTI:>)
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MR#',N(R*.2)PX,I@:X,O%I- 7(L1R<9_S)L$2Q0G; RZG9/PKF4/G]?&8%T
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M3DP.CPH?I7L"/?H6FIV3U D*GK_WDXS[S\S3?</F4INGQW.,H0T*O9/NZY$
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MTBI=UG.URKY*:Y2'9U2:_)R:?,4WI/8F(H@1)+4L8R0 WU#PD@:,573!H]0
M%2\+\62^4:4Q'CV7<JL'UU-G4UY$$#3U1ER567J26;K162-H%"6F/.,! <'
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M6K(VN5]&L"79H8XFM='V2%\8M8J02$ #@-I^_:T"N(#B(H  P0.@IL<T31P
MYU16/OED5B[9]3$H V<E?8:V#:OYN6NLQ@^7/E/5^.YJ/%$,)*GF05%PQGM
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M:\<@6L9<DBK0P+:VA<:V4G//IYU)*U8HBK&I:K[<PI^JYK.J^42+5D]83,B
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M_1D>*)$TL48!12( DS&@;10@G2=4)<-5O"T6M(1CW[I]&KQ]M,%H'1.@6$R
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M9R.>%5Q5!5]C!4\RAOPFYKE@&!AQGE@NN:/$)*,YK=&/E5+PB^B'U,YDS([
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MX< X3""(TX&&$"S+!$GQ-C5S\Z.-:VNSYFJ_S A(5?NYU?X\V.$/O(PA,1M
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M8BH9(CH#F\]L31DIK.;6.$(J/:O(UHAGFX6>+6!*7*5GJX%F%X=G 9/+>.9
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MI13C5%U>+5WF4?$8O) I2DPJ.B84BT(H2UABI@;8FJ#F%R%QR:TFUGGP(A#
MK-Q@9;3 -3?>:*6Y<%O;BF";:E)U?0-T?99  I?Y^9T))"E5ZC.,9TE'JZCA
ME.>/JX&$)FG]15@]>>N8SR:=(!79N$N="3N6Z>,8H\]Z3XPOA1JJS>35\2KK
MF?&WL0H_@[Y+2C,C-Y%FLX"":9.,,M0S(C3)//&6%-]:MK ,#;\H6W#$>I62
MS7:=9;MNE !-LH5W6B.S**W5:FEE"U7-&Z#FL]AU;2WGQH3 G4+.G0X\,_@R
M;](3F2BK=KU)6C^9RD^]"DQX S%H!QA19+>="8A4N2Q!3K0/&Y;*7S5^&HT/
MTC,>,H57%'FRE@FKHM2HM0U68=7X9FG\Q9%@]#$8Y@,D23%;^D3!<98@L""B
M#DH%R;:VJ=9M(FG357[#,MN??8U]WQG$DMD^*%K1&F>ZW]S8<SV3%V8['<S;
M&XVTS@F=L<KQS&A5HMD1L8B)$7_PM!R]DOP_&/W"YSHF+&)Y/AB<Q/#TI)_7
M]65^Q%X8GQZ.7GPQ%MF9+$,]1YP%S-Y,G",F;6A21@(Z7?)SK0*KL_OB''*?
M3*:AM&3[*=9F\Q\BU@REFDA6Q317.$BKH"--7KO@40AG37",(RKG\V<E_ D0
MSW[H<Q6'_[)')_%V&*Z<<BH8GFA7%JC7AF3W$6, M,* \]*!]N@S"&-4UFYM
ML[:L(+QRVEU!N(JIBJF*::/$-$M]F.,>B9?48T*IC5-.)VD\DSX0RGFE-"M$
M:2;#9"(I%2QGP(7.I(9I"B98!B:*J)E/SM+4/%*SH.SY58F'_14'H[8.O=3J
MYU_['5\&3XTC8T5I[Q87NV9-5AVX&AX7>WTNO-%E.U]L/_S1[PT&-38V"X)-
MCO@000>FK(,LS0CHA08C. 456-[>3+B(;FL;>1OEHEI(K^@9W@KJ^=UX9!53
M%5,54Q53%5,54Q73AHOIX6(<MZ;SWA#>^+F#4$,<TSD($R$.1X+ *"1$F02@
MH!9,%G69P6 EI][;(!>=\UN3?N8)<CQ[\_)EZR>C?#<L)-OPR,:SXT]'O6]Q
M')]]>=+WAW807Q[EE:BAC5F0Z]M$:,/XY*E$7HH3*" 7&BQ3"HA0UA FB3-N
M:UN0MJ9-BLW6LY=Z1+8V8EK!K)\;H;ARR-F0^"+SQR85>'8%(+L%*B,Q(:"=
M1O!6L9!?DTFITFZ1:EZ!>,4TO )Q%5,54Q731HEI!3-_*JU9E(,Y$1KS"2/1
MW@(GI;*$92%FKD- \> <%Z4!F6L>L=FP[)_1C@>7MWMYW.-/L3NP10(;EO13
M#URJF*J8UCRPL1,^G R&96K58+^WDU>UW)P]>FD[X7GWB?W4&=JC4<1Y!(=/
M)M#P=?S?D\Z@,XQO8O]SQ\<Q=7@=?>]]=_0I(Q91R<(,9.'%9$<\0X-+B5D@
MB1A =!*<\1PT.F=3# Y%W-H6;26N5M-7,&@V&%3,KF*J8JIBVB@Q-30&4AE0
MLQC09+C$:HH> P.JE0/D7D)IR [>$!^T43)FP3>. _TD7!(Z@T]']ENYV7@[
M@M0KZY4;FIRV%X>MH]Y@T]+1ZG%.%5,54Q731HEIEOZ@F::99!E/3"1D*CHC
MM$&!DI 8T-LI/(/9&X5F8_2\ZWO'\3^U,F#&L8'[.\.]"SY/E4FN4'EAE ?T
M2H&S+--[2ZG41#OKW-:V(6W#Z^#K%=+@"K153%5,#V$/%Q IJ_9PN?9P=W]W
M..Z4OW.04F"&&P1)DP1D+AM$1A1HQ31Q3'E"5;,,XB;-T=VU?7_8XO<Y0Y>L
M9DO_&<OF@B?2C'XJY"0:9IW/VUQP&J3D?M34?]YJN3I&=RY<>C:<F-Y!J#-&
M, ML--Z;)@\F9IX>44@T^9_(91FZV:::M16].IIKP8-[?M22!SZHNU]M;QP<
M_O>]R7$&^34*Y:[RL+M!7!T=?!\X-M%L42>O+$L@I$? Y")D>IS <B<DU=PZ
M$I<Q/+CB5\6O9N,75R:ZH#5AQ*&*Z"1%&9,7+BE*N;H9O^JXI>5!V]X%17..
M"A:<R_ZBR-"F1(:V)#V@<$@D.@Q1;&TKRMM*LXIO%=_6$-]F"91)%E4F959Y
MKE'JJ&E$GB+'*"BCEMP,<'6PW$,@W06)2QXU,<2"5TD#VN@AFRD&Q!N*.JAD
M5'9&#=-M1O >!\M5D*L@UVP21X+A3$N5W1Z7G1VB,[IEC!,H50I(;\&X.A9[
M*:CVXH*_89:+RL( [T3(_$TQ<"$YX)P(142F<2XL;3!VA;8*;0WG;]1;[;C(
M"V )2B1.:9E=5A,SV,5(1>5OC4*ZBP.%G0/E,EB5$6Y.D^*JN@29?S.(GDB)
MD07%TA)F@5>0JR#7=)#+3FJB7EL1$F((5FNAC!!HD7%)L8)<PT#N(I.#2D<,
MLP;0E"B<+DD<,5DP!)D0AB=9^!R3ILW-*GBIM8BI7KGL(J;FW7"]LOE7UDU5
MKZR;JE[9_"OKIJI7UDU5KVS^E1O6;>!LLG69A3.>\ML;C[R>I_W A(O.\U*$
MWHD[BB,???TS_JU/3"E&\[\5!A*MD-2GA$8KC9K2T[(D/"M+DIS<TZ"<VP>8
MU]J :2)=[R=K ZPWCBCOP7$G 'G@8%!;2$2@(MZ$(,36-B5M5&I!/8RGU*05
MJDI<+VR8JZZT"K?9PIWA^,(D)E &JG60&$PPW$O.,66XT#;X]!/4OZ$:XH;^
M]+<#>SW"F [8)S**%9?,2B^ (4N -J.[-8J E4PEHUEDC&=@EXN:?585O]F*
M7U&]"K<*MPJW"K=1PIV!CP6:2')64H.(D3J#1!%-M>4N$"M)Y6.-XV.3*26H
MG$1###@3#2#S'"S2 #2Z%%-BRB%=(4*V85.$)L9K]\^GS)]&%XO.WBVVN(;M
MOQL>0'Q]+KS193M?;#_\T9]L?%2#B--@V\?)("(RP2A&!U:4Z@>G*&@>(V T
M@@A-!"?9U]2T3?FBFHLT*/5WS36]SF.H8JIBJF*J8JIBJF*J8FI\D&/JZN<;
M0A\_=Q%J^&-*%V$B_.&45X:2! :Y!$R>@]$I0DR2>,8(LF@672']('&.U<Z=
M6NBTY-5MVEQ[:U<Q53&M9M))G16XDGSAP\YD^DJTDOO(/?C$-*#C&FSR+@O=
M*IV0",?8UK9N"WVU_+;"0;/AH*)V%5,54Q731HGIX6(@E0.M$@>:C)DP015Q
M6D+FP+ZT(BDI([Y,6?/,F2B))K)Y)&C#,D-># ]C?Q0KZ<?#K!R=S_'NLVY7
M-\9;0_%53%5,54Q53%5,54Q53%5,ZRJFYIWFCRCXDTD&?C'0="\.7Z1]^_5E
MKU_N=F<X['?<R="ZH[C?>YD=V^ZP^J@S^:B7.V6B3D)1HL *6N8Y) 3K0P1C
MI*-4!>^"J^?Z#ZZT60WN[I6N;M2M!D>KF*J8JI@V2DRS]"@GD?'2DMQ()I'J
M8*ETVAH;).$J_VD*AE8GSB^3?3V?'*9%DPHI> K>J03H\P]#A0&7>9=B(J@0
M^=8V\K:\IJST00;.5PVN0%O%5,745'NX@(A%M8?+M8>3T0B5!16R3H)':0&=
M=V"#46""IIZ3E+A(S3*("XI#-#KX\"][9+L^MNRP]>^3;FQQTFX5[9GGB/S&
MD2FKB%"S=5-P,09NT$F.%IU)CDKEM61,N!!HX*=SA>9KHC#ZXA<GP\'0=LMR
MUOX(,\'2[F1_!.Y<%%Y&8+1,]S9*@W%*@.'9ZR(^&19=F2;49@K;G(O['A#9
MI,.2>]3SQN'@XJ:FK=+(M!G8U]V0[8;.5G4:VESP=1%EL%%P)FEF44YF^)(Z
M@15,0*;#E/,L#)=2@:\*6Q6V-A*VI'8F.XA46D60NJ #QX J4BY,#%K>#%MU
MON/R$&VR.;+2TF?; EQ%"<@]R5S,!2 F*4E=U(2$K6W%6%OPN5.K*ZQ56&O.
M4\\2#%.<>V2$8%()A4NE\#(P;;E2R2&/-^-:'6#[$ !W0=FX]XI;Z\!K%P&5
M3&!8)F\\$JNU34QKO[5M%&UKQ>YQ?FW%MHIMC:1LW"M#4B"9IU',AC[;?.JE
M# D9]4:$Z2C;K>V%*IC- V8O+MB:2$:J$"E(H0I;8PP<$P:X%"7+,%%B%YYB
M6!&M(EH#GGH6ML:<ML':)#EUJ!QJ9T,B0@OMB-&8*EMK%,#M%G ;@US^O-T#
M2PRAT5O(0C,ED5J!YDJ#I20)81B1:+:V!;:-F>?HLN);Q;?F//4L^$8](R91
MDPD:1\6#<Q(]$YQG[B:YNX6R57Q[$'R[2,N01C(AJ >E2Y&(,IAA+1I0(A-O
MFIDW#79KFQ-L<TJ:#FZG&1MG=W&VG\4(NA:=D37%9TPQZ&.>CZ^W6&^Q*;>X
MVA__$+<X JM?1^6.ERW\7#9]]!F/2V^@CK_=RK-17.8,OT/G\_8_\X^SFSBV
M_?>=[ABHV66"YF,V_?W[HR4S/L*;&%O6ERXOMONM# +J]H;Y^X:]UO P%IX2
M8K?TS$V=KNWZCCW*MVR'<=18Z=&-SW_Z%<C&!82?>H-1YZ3'_7ADAYW/\;<O
MG3 \/(MN3;QQ;)$>DXNW6)?-W,GPYK<L<6UO74EQ>34F?Y:['7$K*@3CW!K/
M"46>E-:>>5<2#9135JD#IK?.WG1X;HD_V?<17#_:CV!3?L#']NB+_3;8^O7R
MGLL;[H=U_W');ER8E.YM8<9[/]/17G_47NMQUOW8+U?E>[*-N9?68;^0\?_Z
MN8C4UO9^@9TR,NM)X?%9$UK__-5N7R?_!]VGZMI]^FSPJ70TZ[;V#V/??HHG
MF1$.VN-HXO.NOUFI?_8 ]Z=:9[?T$,OUY!P"WYP#WTCT=G#8^OVH]V5PYP5;
MUB/\TNEF-.^=Y,\(@W\T_W9/NO8D=(8QS':O(S)P84A&?"+?\Y']-(B/SW[Y
M+70&GX[LM\>=[NB;1V_Z[=1>GUJ? IT_>$JC[QN_?(JJ6CU")LOF/$UR/_WB
M4\Q]--ZWEQV[\6M2/S)2WO@R>43_S^TDZNP1LB\9&W/EU(]/^2-$/>WCS_":
MY%,OZDPW*VY^>?)C?U+P, -)7IS4S)6OOR9D.%:@Y83/],\08#RLH?.UM9NO
M.ARTGF7T#>?5%9<")DU<\/N]\L;XSS4AH&9+^-8JF1D?>!JW<YT6CLRB!=/V
MFFG(&<+U#_TB,U8[&E-;(J>?LV,8;V[XTA1EG4&M9X[WSAVYF;;3U[W<Y":4
M!I:^1+^4QD3_:'5&);"M5=VPLTAEW8XDKWO$]3EXE(X([VATDGITUCJ&$971
M1)!H"1>G->%T VK"7SPY.WQ\^WWOP_,O[_[^]X>W[/?Q0>*'7?'NZ2OQ[L,N
M[K'?.V\_''Y\\<>K;^>'C\>O/[Q[^@SW/OQUO/OT+7_[X17?_?X>W_WQ)W_W
M]%^'>Q]VR+N__Q1['SY^^?'P\=T?>Q]W]]^SO;_??MDK]_/4?R\'EN_VP\?=
M/YZQW:>OC][M?V0O]O^5SBN7WI O!QQ]XH93\"QPP!@26$<9,$=,<HA!6;NU
M33FV)>'-J A?T*E"Q:-5PJ-9\KRH]3*E('V&H60R'DF:G+)>.,8EJA$<D3,X
M(G.5'544F@.%OI^C$,TXHPU1X*,(@-I;,%XS"#)JPRA/*JBM;91M+J]FXZ_\
M)(=&@\K$ )1RFM>/6==\YRBVNJ<=,\M?R^^^!+)/2H"[TVWUKO&T'J\J<UVV
M)W1OG[%A/5V?QD]YNW9&1W2M^+5,YHDKOP?7LP75<KV-RS9\<IM4$SZ#"3\O
M&"XFG#B;E"8<"(\$D"H$G;R!;)MU)F.(AIF2PCAW%X3F>1)5-Q=(O:MN+DHW
M+^BU#\DGEA==8BIM4+D'&U""]=%2'= EI%O;C-4I:0]'L[WOQY%Z]5(K[_GC
MSLGQH&6[H94)@<_/6;)%NIE:?XZG;'RMF<Q&3/]8 ).9IMCV?&OM')<9']]'
M8/HB/3W;5SO=\/)TPSV_V%X5;6=!V\X$$\I&D"23A<83+<$,PL"EI/-VXUP0
M$B6)OHD3/Q;MI:ZG?L]4<;IH.E15>1FJ?$&<@J,TDAA!6Z2 1&NP460>9:01
M-I'HJ-O:-O,<C-21/7>F3!,Z4%A3B&[8Z@P&)Z->NKXW6'..M!$>Y<*C/9>1
M\_=Q.4KW_9.R72I0S@*4D\?(U"8;94 @4BI %2@811%2$MXH+ZQTF?-HTB0/
MLT9_FA?]F<J?J1J\, V^H#HBF(3,>XC!^DQU) .3A )F8U),:TN]69C7LKPX
M4;/->Y.OW+  W%ZO"Z,C[$Y)U<ZNT]F)86M4;!K#62UK/WZ.W9-X<=U1Q[K.
M46?X;:W9YNIZ[ \7D;LV=2@./O4?Y]U6"O^>G^ZA9^.M]GJ\T_9[K\=[[.SE
M_YSML&K>9C!O+R:/)X.G20ETH%G(YDU1"E8[#XEBL)Q:DJW?UC9E;2T7-5ZB
MQN0:J.'+2 ZL&KX\#;\@L"D2C5814)FJ IIHP3+E(*"V)KN?PI'B@K8UI0U2
M\$I?FT)?5SL8.FK(!LZ6_,O2A26#3<U[6RO+M0QN>FFZV;_*9GHRL9>J;9HE
MO_VB?>EH1I#G3"860<GD !G+ULE3 4HQQJDTSFB5^>="QIO5&&ESM7B9Q2E5
MBQ>CQ1.3ODISU9@BV$ABYI@T@2%.9:*)A"NGJ+%FI,6(5WL0-S9&NFZAO">'
MMOL^?URGV[*#01R.\^C.PG2U$J4!G[%(=D[9(];T+;GC3W,X^]''SN?2+&KE
M]^!ZVO(E%[Y/;<R?=WT_9EO^-([__;Q[MJ=>GV^I:MIG,NT7(^_VGK[ZNOOE
M("HEE(T.$J44T$4/SM$ J1R!(D46J-C:-FV45ZM85KD4OJKT@_#SJM+WH=+?
M+E1Z[]6!$B'K<C#@T6:_6Z@()E(%7A0B[Z0G@6UML[:A5]WN!U'I17+U56!&
M+_OQD^V$,4?O#0]C_Y2TKS4_VHBSM@?I"W055$]WV-/LM_?[,9R>Q.UTPXNR
MVW9&FZW"[(PP.QG:C(8Q&BQP'4,Y6@]@$0,$J21ATMF4_-8V;1MS=71)/5E?
M&VU? ',ZU_:JT@^ATA=Q3JHL*9WK ;VS@"Q9R%3) ?4\"S7KNW%V:UOPJX4O
MC3U)7[N0TMGF/TM(7&N^M+K.Y\J$D\H,BG*3?W>&AT].!GG%8K^F)=T-3%]-
M\B/F6:D7I!"(B8 T*7#<T^R"6D*Y,#&9[(+R-F?UY'?5M'O)H:5%N$-5SQ>J
MYQ>D21LMD0@'0?BLYR[3)YN, J)CDC(P=$H7/XC0>>;3UE#3G96UE,1WA[W^
M.G1]7T]W<W4.WR;V4L7,F3#SSTENE"D020PY.",S9G)IP0C48(62QB4F2>1;
MVZHMU )F>M>P41/U^&%/W*H>SZ''%]PG,A0VB.+9) NH! <K70)GG8]<11]X
M*L47[)J\N)7OE;(*W&<4&&T=];KO81C[QYMPQK:Z7F7S>LA=!<[1AMKK=?U)
MOY\1M,;<[P"A;R>I$(F*:LECEI,F@#::C)XF J7"<$^H\IHVL0%##12M%R.J
MBKT0Q;[@1N@93U)[D%I(P,@\_#_VWG2YC1QI&[V5"GWO.>..(-2UH+;N]SB"
M;<D]ZC$EVY*[C_U'@54JFV1I6*1E^>J_3 "U<;$DKY+%'],CD\4J%)#(#4\^
MF>=^3F*=^)**0,K<Q[Q0&&WS0C\6G'W!KGYZ9/;#""KO"/2HEJSG5K"V6O16
M6E1TW2,12::HB E$FL@PEW*2IUE,A&:A$+&( \F0PWP09*LM@K:IHCN[JW\D
MG>YVPW[U#=NZ/3G' N><$\4S"FY/E!*>I1$!I1QR+;)<\FCG<1[>(S:.GS0K
MQ(28+52O0O*G=H'N;Q1Y;X['+ [3RM6S5JRV^O16^O2LZP!)E@I!&7@\80IA
M9.Z')(^2B%"?21WRG$5,(XPH3+\89KW-#MW=?7T'DD/;??WE^[IS=,:IY%RG
M)*$B)S2B"<D3*0BG-(VB5.1:^X:9,(S3.[2Q'QBGQ&'=X?21:W'ZBW<Q*]\7
M$O[!K];V._VI?2BWFKR<234C\_+B-W\7UM"KRG$A/5R/^ZB'[WR*"<00626?
M.]'[X^H52".HY5K\AHWT;57RK53RNZZK%>541B+U025'C%"F,Y*E/"9:)+"Z
MDF8BEJ"2HV201ZL=#6Z=;+KI)KI'B:B?3"_<4?]LJPV^G39H';1(^GFB94A$
M%(>$4C\A69"&A.5"2NW'3.M\YW'J#WSZQ>U-OI-&<,Y;/8Y:UF.SW[]VR'9?
MW)VO^Z[?_QY?R2._(VYXNA'"7_UL?O:6S.TN"=X&FI+%3)RS"FY8Z@?3A?=!
M)-2^$X+R.;LR G-2#L5_%\5,;1MT?J9W]O:@&ZL%U.>A#"1BJC2!>"T@F8S
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MFLG$UW$8JRB222CXZ0'JZB",@A^CJ[>J]U:JM\?6(S1C4:XE\9F?@D\6"F)
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MXZ4:O?BF/2Q>73S%P3J>V"87FSPPEWYT<G9U>'::96$L$*P;Q>C2,Z%)EK&
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M#?P_<S%"5WFTP@3+,#%;HY:LOO.'8M9(NG$"38;#9&/-ONM&&BOW:K(X!E<
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M-E<U:POE$%S:*1W#FMJZ0J/=(FJPLD-Z%1X=T>\;$L5FQE%<IP@L F"J.@
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M_0^V#0\^I^'!IED;"C!MF-W',]&:(ORF0*ZO@LO*H\R/9)B',N+4#],\353
M8PDV-0F8S+;<J3]</2'16XR%] J;=+.8),*7A&)WW(S&C,A$<!WQ/$M$=BM<
M5AHRE2DE4V2\AIL;9'$N?<9I2I,TVK*DWIFU3S3S_=2/2,8X&*28QB0#%Y2
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M['ZDLOO8*#L_CA.=4$IR/\/<22A))I5/8J5314&7I;[8>1Q$@S3+[HNRNV'
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M&,OW9)>_@4/RJ<7ZUEY)6SZ<=G6 ,/Y"W>EQG8Y=U0JV9GBFWBYDS7Q=4WG
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MMRRV\\/*Y70 \A@ Y',:CR+PLEMB1PC3XVG)+BW^PG+<^Y]E_].^^]0!RNT
M95[F)@6ELZTH,3DQ(@VWQ KEB0DF2U\QG5QX\EN)#/-?.T#I .6G!10,/W2
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M/M 0P*/X[6H<FY[ 7RUVC6<#7.,0C##:VCZ(%OP4IR!: <2I'P&=:L%ZVG\
M<K,5COH 5/@[.!3D9;(/_&QR-!K$QRM G[<_'P II4 4)0$YH@!'E21.*T&
M'2:K35(4!4C1*P1H RWA A\J$4W]ZZ0W*DW%-VH! V\#Y@#HU8\3E9T^S/OI
M:)AJF?E]-/Y[-!Y$<&I2+1( +\40[Q_UQ_%/=_ZXB=+GM_R J<0DCY+8G$$\
M $^($Y(3\!-BA9E9FG,@2O0J^<# :G^ 4W_6#C?&3$F)F0++/NU-</1[2(^
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M/@0TY'Y!7V?/]E\ID#+*G!.V$H0K 2Y2\IYXI1/Q.9M*P]A;YB^S9S>%O0O
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MM1^?URI!5K"X/("1JQ)JFIYBZ*,\6[,M< :_M]E&Q8.A.2I6\1BE\ '\LN#
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MXD279O1!0-Q3* A;T] O>E@&CWON($1;%?8GL+&0-U>MR]_5LKQHKDJ+5#=
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M -GN]086A[W:'\ H9W\T8_'9PP2#FY\,P;$=?0+(MBY5"KM_@<?O<TD,Y93
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MN=H<//E29O]MAK\^1]UYPJ6G%@MUA3EYJ<MA+$ 5BIF%SY8KFCV%.D!SK8S
M:YFZ^3O>^B!'*8V!]34T-GJB?8M2YV1J"HP'<ZX2;0KI59X;#]26>IJ&$%Q"
M64I_PJ&PW> &O^H#2YN$9G@'&&<\/-;]*O V#8<\JL-B[]+]/SZP_<._>_NG
M>\G'DS<7'__8Y7L,.-O[_9./?[P2'P[QGD=+V:#[AQ:N_T#A6>S#M[].]W?^
M\_G#X=&W#^P=A3M^_G#2.T8.>(#9H,V6G49CK_B\($IJ27BJ*)'*9X1F5'LC
M"\ O\>PY3VB7I6ON9O3@FQ7=#D V#G6O?<K_ZN__0('S\E-N-T//]9URNSI
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MPG@ME>>4>R$-EL< ]D4+SI3F\JJ0<3X ???]M>UHAC\PS0V<CH@03PT3]D_
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M9T)F3C"2%MP1;BTE,I,9H51K8S35@LIGSS/>9<ER#L%RS*!"R_-R?+S*G6_
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M<_[*R%C&R%AN=L A7!=3 HVW>C+R<P'88V !\)#)$!M9ZGX?=UH&X ?$/ES
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M)Q0W:9(6+-><4SS:)9S,X+^,F8(KV\8M'K;6S\<MI, ZZ;P@B4PU9E*"YE,
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MXO\C84=V@X+Z9WD&_L(L'-JI!!?L2^?L6 -LVR"1(;@7O@&STC^: ']"FS(
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M2CDU]G +_'DWDH;=\@A,SJM7KSIOMSM__ODB?']@0'V"C<5%+W##O0I:U-^
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M#;@9(4DY/,1;-X[=$ V513H&\0%O@3> J9%P9'P.A"Y?QEF,20H_$$Z(K/$
MQT"Y(;"2K8/A.?%;D3<0V081;E<DO("[O$'&4 ^VK"]IG*2P3"G[-\B+)"HM
M04]Q @!M7 MXV_("_YH.!7DZ2<>@.3A-:F@A/E5>XW4*'(HG5[)'G3,!Z^]Q
M:Z7UQ=[$ Y,6]9/*<4S<Y$8E.BAR;.8P? SAK/2 J^UVN/V6W#G+O:).+6S
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M)B7!AACU84[S!$V=2I,=$.JFO-\YZZ>]AAB&\:N/<J B7E(5;:'4ZAT0=ZW
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M1E^1,V'(Y792'C(7POX;;>S" 1N!+?!]G)SEDGJO]D42B;#DF+1"8_O&$^
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MB-YRG/AJ6+4O]MQ[2^I27^5;3P'U'H9IB?/Y2HJI-U6GS"KN^H8WDOS^ 7?
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MQNG!^QF>?+8_8/GY =UI@*ID9B2K"/YVQ9T>?D:6PBP=SE:">$[?K^]7830
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M]K2GQ99:N,"&OS^\**_G]/W6C27>+&DA7U%W4=8OCA?S,50:'[P?<)\NFG[
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ME^EHF"8]$8,(26<"0>*)P#*>#: 2*8U2M?1.TM",(ZU!>JGT.HQ.6W0)YK-
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MK"X+#L[:2"7QRI4RFFB06*8U,<EDE1QS$-A>]-H2T ND6DV5M9P]O[:K-."
M5'M$P5/9617%96!0/D9P);C0WH0&EG*SXAIK +SP^Z!6]-+BB;==,^,F(%OO
M^'K8KNV/5H+:6Y$[M6W?10MM-X[= BSS,5M7NAWK4ODY$)#6D #*@J*1"M^D
MQ.USH,IC): .Q93FPF_;M;K7E?ZW63'&_G[ASZ_K(N)YS"$K(BC%8]&H0%P2
M0*(5P0:.]KUO9B@_.LRQ-H7?2B^C*D)M^\IE$3+WX1S&%Q#2;-H/,'@U>CN-
M2VQ9Q< XSM&SB(98D!;M(*J)TA&=?: 4Y]Y(X4\,='(J;U.P5=?X75"*"IE]
MCF@0%2:R8$LF=B8J>P$YT<!5LRNU32.<G)I;$67;5R&?$HHA3<?][]>U]"$@
M&H-DLRPC&#RW+*#)JZ"4)C%,J=0LH'3UDT].GWN)KN4BK^MK1C$OLZ !S0V)
MWDM0D4"FG'!ON0@!'-=-.JT]F]IY1^@([JV7.CR9K"D$UP#4BRNWMXVBFI7;
MVT'*G97;PUV*"B<#"=Y3(J-W!%QV1$L)F5LAI&G2\.@85;]UN;W6-;^-<-LV
MXFZO,C^D<1ZAF3D,Z;T?]+_ W9M44#XS*#FNK#S302S=FV@BN,,ER1QW=#6?
M?L/1WVR\8RFWMY5F1G7%VK;/MJAA<IUKCW-?BF&>7_#K;/#G_'B;3M[U!^DB
MCLJQ>%TQ8ED/6 4O,LJ%:BO+,QTEGBI->% T>(8BRPTYL2>2Y\^6+E71]@ZR
M+58%3FBJ*,DR\L7%E]7.DI"C4(HZR8UK1)N7QI*:@J[XC#X:+GE]'1H$P0#+
MDF@]CULK7=^$803=7"M2Y@I4LW"*S6,\>U6W)+ZV7[)O<H(>KQFTPD-/)<],
MP,+ME27.QUO\*_=*TFB29JE9"<2=AG_V7*@O])9?GC\67WEN*L=,A8E1DB1+
M\T7F<,X1'/&0#,V&!=E>^X^;47]<+>RH@1HT6+*Q"8S6GXYOQ^_^SF!'#:SJ
M< _QM?WF>P<.<SH+H1A)05LBJ0[$19"$1JJE2Q%_V%KM_>I:?,3];U>)VTBM
M9>7]@9*ZF%U<6Q R*9M3)ME*=!8*)*<=)2:SP$34G+'6=N5[(W=\S;^K[$=M
M"*[E!CA_P/<[0$)F:,D+1T12O'1XB<2''$BT")!)8_UJ98\]-'AWY&>HP9T%
MMW$-MMSTX.*B/^^R-($2*C_OYY.&8=^.!T]^:BOM#K;#OM+K("1&.?<R@P!9
M^F2BL:-!R!0#6C=!]!I\_GYY16]'D\F]CWU[DY^L2EB.RY2@2S5OHN2)XU01
MH30D39DPJDK7D<V0]DVB>HL:7MP^?DK3Z2(7>5%P[NP;(,'CY]'[Z7D:EU82
M5SU =7"IT?0,4>->9RRN%%<*'2;-P043P%>9_S8HNX] ;HDQJ]E4]733XCET
M#?;O**@BAX]I -,";1WZ7G"<V: L,8DC2"<DL6 8X5EXD9-G2E8A4"-T)T.<
M]G51(7WS_MROSD(8SV!P-GT%X_$5?O._8#!+/>\MSA0R,5#>U6QBQ+KH"+40
M0W(9-%3I5MT(W<D0IGU=M'AUO 'DHD[1_$:$I^0B#DZH**6(8C $A)>$ 3AD
MLS40.CB6[R Z56+L*/,6;YPWSG=Q-\94$!ZL(C)X_&*U(-XQ0X)F7N'T>5HM
M(5;)0.NT!D\GRM])QL=2%>?. 3B%Z6PRO[_1T8**'(E+E2$2T&*R- +J-AE!
M>:;95:DNL0[,H>ZGV]#Q9K-U-UG7,#96,"V?7YJ@JEF]9CVLPQ2IV5]M3_!@
M#YEWR A&F6'2EBK^B$Z*6%II9L*RY11-'/<@#N'Y,>&)PC*=$6$+4=?H)UO>
M18=?;L%=)T]D"(HI3;)7#&&AND#J2#1-)ELFLY55ZL9LP', 4[(%=:TVF6U!
MUMVTFWTS_)H6_>TGGV87%S"^&N52(/6W?\W0\!TL;QT_G8_&T\]I?''GU_>X
MF-U_T!;N;5N>^<JU;M:L-*U-VM(L02GK) BJ4E1192]S;__AVRHF>O85/ZY8
M0;^/QB6LZE,*L_$\?__6K$Y@!<<YE>*W:5&,9!%OXS250NN@0I5C8BN4>U=K
M6QGB=?+3VV'.+E 5I0W3J]%D^BM,\) PS&FA/4>IE/I.%@0!+7$Y>Y64$CD;
M6J=<VY9 N]]3Z['K01&WFDJK<&_\!-X09A>S^2WFW\?HJOQC.$XP*!,H=YR_
MICP:I])\2:)YPB&I<OU02FID@1+CF?!@@TK"<YO- 9C7#/T+IF,%]=8H6[GC
M)(IS?6<2%,T9//.)R $GH<$3SU5"VX=&'C(#)YN4/>B,H_?0_^!HF^JM<#N^
M64CWI]-+3)I0[@$3\[C?<[ $O/$D&LZRT1$X[62KW 3P)3&M%255N%U?60$K
MJ!=7A,HD7^*3B65!$FE,(M[$3#)*!P*EB+>*G]P 6U?W[MT1IVV%',N]_._]
M(0Q+8Y$WPPF.=U/&V/$8A/6&) DE4+T$U2DT3TWV!H1VVJHJ]>HWX#G4[7SK
M:A^U+_X*]M9U>^G;A(G2@"VO03LI5; GZW]TG4'=8"XU[_C;G,QA7@9:8<EJ
M\X-#J_C8:<LI%3EZ2ZC0BDCTPTFY.B,V4:[P>T+R*C$-QT_7)YXOCIZMVVBV
M DO_& W3U2)K[/?9,%XGG0LE5&8"_143T>*4V1++(QJ@&<!%FIQS5;S3]7"Z
M=P(.I^)1Z_JI<$WW*PQ*L8)/YRE-WXX6C7OGRXH:KI.RBC@3YPTG& %+#>'9
MB)!U8 !5.F9M G2JIEHK"JAP[[ .UW(5-$%6T_+:#.TP=E0[*FS BSWD7^'
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M?RKB%0Q)(.^NCD\IC(;QD35B%*#,@B7)*YP;M7@(JYQQM=BH9#:<NR??5;H
M>H*,/";5KKDSW.]:>Y.UAQQ*O4R%B\X90K6G:.^AZ^?1F"?2NR0BR%+L=B\#
MNHQR@HQI3:AKU+W?'?%=+J^@G"Q]_??#?Y[WP_F]6^[^$*<PZ7$1:*)2D,@I
MVO]2>.(\<)*Y=PR$]DF:K3>AK6&<(&&Z4\L:1NUW9[P7]#?YP[@_&G\>H=V(
M^^AX N.K]_G58#3I#[^\+IY(_C";OK\LZGTS^>T[CM6?I-C+8$PHSRPL%HLQ
MN4Q &X'3CF Y<\S(AK<\!T#_@[_=DV -[?>[S=YKQLOYSF]8MYPT\];K)%!%
MJO2)$SX2YV0F67GI(4@GN:O/_-TG\(/\!Z'"&O[O>2F_SZ3/\K180]M/.6F(
M3&=/HE.:2/" .HJ>&%[Z/42EF%?UV;\K_!_</P -UC!_OP>'%FZ\7HV&I:](
M$<;-TVP*2LB0)*'S6@Z6"F*%L^@**A& !D/!=W5/N0;?"7+W"!2YAIP[OY)<
MQQ?_'84[*2T^TZ3D%Y70Y8"2FT<[EWI_/28REXIJ0@7Z#)*'1)Q%=P'Q<9H3
M1WQ5\H&? G9:%*NBCC5\V>^%Y=-E"OW<3Q%YOYSW[<7KN/_E2RI(7Z=+W)*G
M;X:_XC_\,\6S$,J:Z?F2<Q%0+A"]1:IK52P01FS2ECM-A0C-@C/V@G%:O.E8
M+6L8M=^#RGTL2XB+/?9-7C.OUZ,T>3>:_I'2G3U4"UZNR3B)I;J1I!3GXB"2
MI(.4@7,:<S,OIPTT)\BOSI6TAF;[O;>L',8W0NLEGX,LO-=">R*EX<0G*0D7
M3A@'6:"\=KFSOAGA!.G0BC#7!*/N]S3QCR%<C,;3_O^D.$_>@E#$_&J$KD4Y
M2>]!OHU%<@I9F:DC'#B4* 5- *(A@6DK50C1<-%(_SL-?X+DJ*^&-<QIH=WJ
M M&R:V,O*U7Z05J2K$*K'&(F%FPQM9BP(F?C@J]A]*[@."U^M"'L-<K?[T'B
M/Z\N2X[<M!]@,'?E_IZ&I9$G'G?S ZZ73#:TA)ODI#B>6]J5+*+2NR?0I".:
M2KY96.!3(YV6LML7[AK5[W<I?Q?=QW2YO'_R@_Z7>:NM7V%2:F[<Q]UC1FI@
M,I+ )9YQI5 8R*0*614>>\SZV"QK<9?13YPB592PAC;[W66O7NP\!+T@=]G>
M J)],WR7OD\_?TN#K^F/T7!Z/NE1(QPS41&:BZ&4N"3>B$B8R3H'%Y).S5*H
M]L=R@I3J6$%K"-9JC/J# /K?<D;<_:]I<0?YYN)R-I_%G2 A1:7@J30R$B5(
M*"8@/NC2<C 6=TL!B\VN6O;'<OH$JZV@-03;+SC^D6>8Y2O,I$FHVMV4G[/+
MRP%NX7Z0;C^\YU-4$@0E-GI<1;34,K/9$Q&HI,99*J#9-M<1X!.DZC&J>@V?
M][N6OCO)5XO.J#BAZV4YOI[HWV> 'NDTI1Z'K,'Q C2BV9F4)\"SP#V>*:"&
MJ\R:>?W;CGSB#&M=^&NHLM]]\ZL1>IQA5B"^FQ7)O<^+(W]N8?XQFTQ_36?3
M]^,S/T)CX'[R8\]XI'%",T E'HC,'+=OBO"-L2F+C,ZJ;Q95O0^*$Z109TI9
M0Z<VX_C#."'EWPP_CJY@,+TJ!_T_+D?#UV/X%D??AN_SO219ZC25):@W>VY+
MZCXCUCE/;& \F,"=7"VQU2A&?RL0)TBFKE2R)N%]OPOL)X5SW3Q:ZL"8)"JH
MTM([:CQI:2!"2LD!,OB&9U>S\6JWENN,%Q7$>^AV<*65[:NR":;Q)8RG5^_@
M8M'7F'./=,TEW[:<LS8AA4$(8JS";9'G4D"LP?5UHU; ZP!T74:WFH)'+0JZ
M[<[=Z7+5[UR%N"P_V 1DZUW:FZ+KOH?[_HH<=:6%@U$& @2K.!"F/6ZU#E>*
M \90R8Y%&JQQKDG0UW.@RB.-X@_$E&V$WW95L-_Z7]+X3;__"=X.PK+6J)?4
MR\@ER<Z$<ML><.X^D!@53QJX,3(WLCC6?'C'O>/KZ&#4H@ K]/$H!6K?Y[,Q
M^M]?TDT!9. 4QZ6E T!FR&,OD<<RDLR<CFA$)2&J/'&O17-J!D-[HJ_0B^$.
MG,FBD0#<?N=.T,9UK>$F<&N6S-\2[V&JXK>@Z=4^[!VHJ4)!\6UAZR",IM;B
MEBAEJ146T*%CF;@874C64Y.K](@Y"E8]4;S^\*3:1CMMVR)//;,M(8H('H)1
M)$N5B)00B8\J$CRN=;#<&C386GGK/%0M^JHZV^9=<P>!MUU7^2F(9_@EWL&J
M%<LRT$02+@VTXRPCUCN+7W2F/GAOU$Z1%D\-_()9LH\*6M]"WGPXN\%3\F;3
MI](S"6V^6[C#^$\HZ83738RI\"D:( X=.2*Y]\1G2DFI2NARULCQAHS9>NQ3
M)DU=1;1=VOA!6:GYP>MHXLYY1R@'=/UYD@2BU,2RF&G6BF?9K,#-VH\_-1^H
M)4&V75CX :*EQ]\$TWHOIZF2#W'AV982'M7I'A)L>\/?A(W+$)D10%(NV4=,
M.P(I C$(E:D(6N9FKV:=:G6#>]"E4K<17'5EOA^F:V<WY>!H>:D5J5RI22!6
M14ZXE8("2U3'N)L^;\;H^&V\%04\JM'=I->V!?^P8N.WT1)6*$^XB6LBD\8O
M7!KBJ$#G75,-.<FH>;.HU<UCG)Q2=Y->]94Z+UYW[2]ZSDH ($FB5%[2)I5H
M_4R,C,9)*Y00NZKU=I334^R.$MQH"A^^V]NGV<4%C*]&JY&H-Q_6=1>XQH .
MU1UN-XFM=(WC-OKD%?+2&>G1>W/)HI^FE4:#P":^6]>XQM"ZZ28G':XZ*A.N
MN;)$1.+$X4P)I9&K4LG BF8U #KJ)O?D,!]'@\'OH_$W&,>>YRH[DX!HP7%7
MX2H0:TKXD]>)*9:3D2VURKLSZO'&!FZCZ^UBP'85>N5KSML4^R ]>&4T"1$0
MBO$1SQ<PI/2 TDDD 6ZG&KM'6Z]@9XTTJEBPC3@K/V_<@+H.6L59EXZO_>&7
MZPP-M!'>YS>3R0R&(<U3ZGNX$I3CV1)/2_2S5Q+_I$H9EV1#9L(^Z-.[)1^V
M0?.BN%--36W?93:8P$I&/DYD]&582CCTJ*-!YU(Q3R9&9$B>X(I!RU.#$J"I
MU7ZG1,*M4+Q47K6CEK8O4*\S>AKU>J(Q\A"8(XR5V@[!"&(5HA7.64.Y4CXV
MJU.XS:@GR9=J8F^[ =O&P]9DKQUS2-IY&)PQ>-AJ)8CG4@?/D+:Z6?I4,]NE
M3OJ%-^4A!(U-76I925QGQ,GR'!(R#T9!#@US6I]G^D4]TWM[\1XZ_>+Q*!T-
M&DH\#@D^*")S0K8;:HFE(KKHC:!IQ2%]H?&56ZF\47SE-J(_A@BX!G!_Q%?N
MK^E]0^%V4-,1L(N#SB&J1"PK67.<)P)**Q*]L]Z:0(64)\NJG>(KNR35-MHY
M4'RE\1&8CZC@1#T>^8:5.Y)$F$I,TP1\1Q?PV<97;J6S'>(KMQ'XQHO'5E][
M7HV&7]-XVL?C^MUHFB9[O--L^J@67E@:H5QY&W%!Z22M%,HE*9P$F[-3U% 3
MD^>1]39]Z'Z;>"GE7;JQCV=%[[?F=70@'<V>\*QR27'FZ")%_),R1F>-W#)-
M$G>WWJPWX-GWK+K_L;]#N"[:P'(,9;647F9(<<TT+B&D.+J +K'L>%2B_CQO
M 76_Z;3!@-7#IQ5Q5TA NX_K;AVL3]/RWGBGCE!F#@QH2;PML>6)ERK1I4R6
M4SB%8*165;H--(=XBE1I3245[-V[K>4+ZC6WZSH+BTYB)HX971J-1^*!1F(L
M]UI:GGRC;.6M2?,TM-,@2\LJ:/N!X_Z4SV*<BQ@&R\TOXB8G+)>$<5U:DB<T
MW)0 PI+4.N'$TNI9L\%^?7R<YZWJM@79XJ/#.A9>DV_9% 4-[N1C#H0[-,:E
M ;28<]9$1R2A+8%O,=?> .Y#>MYL:%GD+;XPW""[?@T9C5^C&_!U7G3NCNW3
M'R+6_O#+6:G#B9)/DYZS4GL?+!'%HY+, G$&O:R@)63+D@>CJI!D:Z@G0IZZ
M*GI(JIVK[JY!?%LIXGU^-;JX& T_34?ASQZGR'(T?T@(W!#I6";6H$6DT(H.
ME 8O5WL8M4ZB#=!.CC1MJ. A2?9NF'9_UG>N!Q9_+/>.'TN1:=8KM>0B%Y)H
MY4K0!^=H$V5!0@J:,>YR%E4VG,8(3X,R=13RD#D[UZC= NB'<3\DUJ/>E5;%
MEAA%%9$RE\,U,)*IX)2IP#WMX'KD$80OACD[*.0A<W8N67L-],[V]P'&[\<+
M'_V_8# K-9@_G<.X/*-&8:PO@14)M\7 +/&*!V(EI\GG%(VI<C(UP'8:;&E;
M"0]YLG,MVB<)?9-5<K<ZZF(JA>#+)H&] %3/FY%&,^^4F\L&B?NE$\+K& %P
M,IWN.\UPGP:_NE3>FGNZEF]YU^'_/(8X;]5\->E)E2D3PA*NI%T4C >< %K^
M@FE-C4W2'H9J=U"^%&+MJI@U--K[OO=IM'?*A=\!SGH" F0%AEAF2WU@APL@
M>DJLEE8$KB"R*I6D=D;\4NC5AL+64&W/$A_+2O._SB8HALED3GZ?HLT6/4IF
M4XG.IY0X;8%H2G,**BJKFH6HKOOTYZWN=H2V1HU[EO-8(EK/L1Y0B%YP2R 9
M3DJU$F*-YR0;E3- >15M5ASL\7%.2+4M"'*-DO<+*=_.-'H+\Z9?HS&:YR7L
M=&XE]4)43";I" ]:$"F$(5!*ESE&DY-HH#O3K(]C"V!.@"Y=JV0-I_:^[[T_
MAX\IIHO+Z;73?_<%7(ADT*\C>%9)(AUW!"PK;=*U<DQ8=/JJE,IMB.]YLZFF
M,M:09K_.::NL_YJ&4,#^:]8?7S<U?3^;3J8PSPCL14TC\V!+7QJ*NV8*Q!E-
MB;<^4NLM.-ZLO?B6 S]O2E07]1I>M'"[F],8D2W>M19A$7\?CR:3GN9*4\8"
M8:;4!(' <8<+@ N>)I_ )KW:C+&M[6,#HN?-CG8%OH8*>U_7WI_MYS2^Z'&G
M.'<AED=R7MK6 /&<"R("3KPTL.&Z$@=6H9R*\O<2\1JM[WWY^G8T_%* S,,C
M,K4& K6EQG\BDB+[K,Z1*!:"0P;R7$??=T&<AJ9W%NN:,+-Z=YRO8#R^*L$,
MBW,I?SY/O^%)-;UZ-;JX' U+3BZC7J>@'?&^U,'EC!$;H3P5,!<S_DD:4W\+
MV KS:3"H*Z6M(=S^V5XW07@?H!_?#%_!97\*@YZ) +GXWXGQ2&0H;TS9&:*=
M=M%Y 0FJA+QNP',:1&E#V&M(L'?#CH\EYV28XF\P'B)=)V<A+!JMIHA&4#_T
MISW!>01+(Q&":B)9].A*(]C@3 #G3?:T"A^>AG8:U&A9!6M8LG=\[$JUD/EY
M*55@.45':#" 4Q:".(OGI4N6<G0PK:V33[0&RVGP8%\AKU'\WK&PJVD__?$\
M* '=H%*2(7BBDT&/.*":G(A(3>F\#EHQF4-]@^,&SVD0H UAKR'!WG>9KP8P
MF;S/_YRGKD[?CS_VOYPC2],X]">+Z]:;'TZ6/YVP'@ (@VHD@NO2BQO=95L,
M'4_!:*65!UYE?]@)[6D0J+ZBUM!KOUO/72!_&*>+_NSBSL6MBBFB$>4)"Z5^
M#-<*_7.TK*VSUB;G54K-GN):@?.\R70@M:QAUM[WII]+M;/9^&H>T#2/HD/C
M:G')V_-1RTR3(T:4O%6G(P$\38FB&0(%H+S."?8(IN?-F[:%OH80;=^>SFL$
M6<&D#!)(\!+/5(_;'XCDB8F)@1 B)AKKFS*=5.3J\-9T:]$>2\6ME43%>>,+
M=,9MB5A+V3,4BY7$!6X)%1Y<$,[!:J.O&@PY1*VMUI3[*%FV%G*%5/#[B.YT
MZVV"JV8%K4W #E,J:U_%/<J#/:7>)2MBR#1G(0F>:*;<V!KBF$W%9@XZ0/:R
MBT/C0/W+NR;#-L)NNY#5G2O]3VG8'XT7E7IF"16DED65J B>L<@(3KT4*#"E
M.XH+A!L5E$NA<<.@!H,=VD;<52VCBC*M4%:FO Q.ER^#I9+;G-PY&,:=0?,H
M65:*%*#U2H&1S*B1"NU7Q:N4 E@'YE0L@;T%W6+%CTV8EGQO@JJF); >UF'L
M@/W5]@0/]I!Y!3M@ [J@ HO":^)T+DD&)A.;N"#)2T.YUTZD*L_N73+A"1N@
M*R)L(^H*!+AS9!5@U[WN1#0\*D=4+"UK66F+%C40G:+7"7)PK,K+Z%HTW5L&
M;:CJ02+LOG*N8 S\"H,2!?CI/*7IV_+;1:J%YR(SQ7WI49Z2(]+:B#,5F609
MN>%*&!93#?UO G0J1D$K J]0)FH=KB7IFR"K:1QLAG88 Z$=%3;@Q1[RKW!.
M/((P6JTH%7@*FISQ4%0*'2?()$C+C!4I)E'ERJ!K9CQA,'1-C&W$7LERO XQ
M79YFB8DDM<3I9<I+):I,7-"91!MB"$IQ9JJ<&@^A=&\RM*6H1P)Y=Y!R!9MA
M0[S?=3]=Z50"34ET):PG:T\@NDR 4>4]3]GS*A4*'D5U,FQH3_;5KY3OY**5
MBN.+1NN><BETD(2QP$M'-T$<@$,F@V H%\54E7NFIZ&=BH'9LA(J%*%\'.%R
MD33!V-W;U'J0Q_!.M;^"M^+/'MKI?,.YQFK!&X.G):?X12:KB:>&$R=4SC8G
MFWT'M=&[9-!6;UL'(M 62NF<..^'UQWD@3L:9;GCBUP0:70@GEE&DG0LY,BE
MCAW4HMR([] O9FTH=ROV[*:9ZKT95F%^_C9:PI0QFARB)YSG@*:Z+YEW7N%J
MD@E,5DI#!_6Z-N)[<03:33,U;MW71:'.]UZC#!7!***X,42*7"8?(D[>.VJY
MDIE5B=[<B.A4+.-V1%ZA@/9:8,NET 1:33OX$6R',7];TF(3;NRA@JYVC"5$
M+KA+RED29-G,<ND1;*DF3LK(*)6<FRH7L)VSXPG3MGMR;"/YU@.XX/(RQ5<P
MN+[_493BWI@5 3PXB702C:+2M8IY0Q%+%@^.CDW16BN?W+V=T)K,1VT)K((5
M.:^%/,^N7\QVGE<PIVM$4N+8C/#2A%QR(0@D@70%;4$S(TR=DL(;$9V*$=".
MR"LT2+B+Y_JBN &B#L[^.Y .<^2WI+/UN_J^ J]WTM]%IIF0JB29,0!&I(JI
M)$L[HAQU*@=CF:MR;]X5!9XXUSMCP#9RKA*+58KESW&=+8\H%R)35 J2J$)$
M&1*Q1I2,UC(_ 9'K*D^J#Z$<S C864%K6Q'L+-T6#8#)>-I[M:B$T?^:?LLY
MA>GRABN?Q='E;>1 $)Q+RDD,+B&^:(C3C!+'K>7 C-*Y27%N'.^.YO%OJUIO
M"NBYFP%5!-]BTYLF^*[#@AH@W,(Z:(4BA[ 2ZJAT"[[LH8\6CY MD'H*-&;T
M=6(,B)2)1'P"0TKP,M=XA@;9).GSZ!FSP:@X%L)LHX:.B7(6_WLVF9:M=GE.
M:L&S"HC0:.J)#.!1%'A.QFA"3"B,"$TNI=LYAU; =6>7U%+N-H?3/IK9:,'\
M^R\KLGN+?YW_8/[](IN/*?]4_O<?']_<R/';MV]_29/+ G'XES"Z^&4NQ#N!
M[O/LMT^SBPL87XWR2@3\ZU(<;#"Y#V[2O[@</-DL8MLA?KF=R_TY+L>YQXX*
MLTK?IVD8$YHC_?BWG_M440<<8@!GI1#2A2P%<$$#CY;'V-MVL#8?,]_>U$S0
MQHMDK"8":,EX15O;6ZY)5!RX=]G&.@W"-^!IN0KIO2J6/65"1A4H$FCIWU/:
M<7L-%N=J)3B90'91:?@^J$._SN[&A"?JB.XN]BK/^)N*86=PGEJ;"*#<B;0F
M$Z JXR;..#4&4J427\^@^OA^9&A#X)6#V7MHWZ40=2"648>>I16("H"88-'E
MC!J/<%H[C/TT]+VS6"OD/J^[0\ 9E)[K#)4!$2%)19P2@C"$4ZI3"MM%Z\:C
MJ)#4WAZ_O6B/I4+2Q@P>1ZE%3:(>'2!UP41BO6+$1):TDH(QUEF&T['=PVVE
MZ*;ID-L(O-MDMR;(?J1#;JO"YEEON\B_6X;X@#X=2XHDG] EUU#2<$ 2Q;4+
M( %]<G<*S-@U';(2,;81>V=U%+B-40!NCK(D^4O+'/$<CU85A.5H$&5?IPG:
MD=11:$M=C6HI;"/K0SSF!>T,]<80X95$D)83BQ]#E C2AZ2 1_%2'_-V,2*J
M"+Y%QV.+Z^(F"'\\YNVJTNW?9G;1QV$>\X07VL0LB(HAE%0MA]NHC$0'9UVD
M*2?[XS&O/F&V4<.A'_,4TS9"#H2Q<O+Z1'&OC9IX$0P7(@!ME-7V<A[SME+N
M/H]YVVBF:PMFCC7%I46W!&RBUIH+/+:YMKBJ2BU+H31QGB,98E9&=4RE%80O
MD$_[Z&CCUM3J"_$\H*]TB\/-?>X2_'9Q.1A=I33_P8?9.)S#)'W 2>SQ1KS]
M("V\$N\YLY5W8E 6O:0$-D@E39(V)2.B*;5?4@1/>]L/MY^/>^_CWW\;IO'D
MO']9/O^W3^\_O.Y/RF7M;)PFM]?*3'D/R0>BM3!$JJ")Q0.7^*RR4TQPG%0-
M!WA[J'OEXFP4_!_PO7\QNS@;#F<P0+]U.N[[65'5!%?O];]:-A;I.6>-R3:3
MI"(4(R43](0R01DR)Y,23C1+X&D%3O?7!97Y=2\9J'N-M7ABMS"#Y0L\Y]QJ
MYP#7CTA$BI)2[P(G.6K!#&6)*]H!Y0X5\?!\&+>#OMI..-PX@=O&2$5B\[:P
MPT5_G!YUB0;++$K+:"*M%P20.L0RKJ3.%'#Q[,>OS8._4#JUI(T6;\(>Q_MZ
M-IX;+^_S>S1KQ_WAEX5ABW9R\LIF14QTBDBJ: FBM(1S"598P>5JH/*VW-DT
M] ME3BN:J%"=]FPP_YT4YS3^%='&>U;OHJUH+WKO(,1,1.EN+A-/!((6Q"@3
MK>-.@ZB2)=<,WLERJJ*6*I2?6P_NK.29?YE'D_QZ=?LK'^!JW@#F&XP7LYJ\
MF4QF*;Y9UI/I ?>@)#KPV0.4N@*.6,#507E0H(+*DE5Q;UJ=Q<DS\W ZKU$N
M9I[&N'#]%^4_%R@_IDD:?TWQ]]'X]]D4A5=@EWN@'HU9\0"!V"B+D^(5\3X(
MHF26PB3C(JL2D+ UTI,G8EW=52A+\"F<IS@;I/>YL:06#[K.9>=#C$3I:'&7
M5Y;8D"6*2DNE@@B:-7GLWGYCW!%P5^&77>]\7>CO6,(WYUOV;:L6[3SW5!&J
M%:X<] C0SK"6..DL9\%E52<,ZQZ*0\58=*/W50-P9_E7B,=Z\LR?;#KT;Z<Q
MC$5.=QK#-9E3S>#/&I,Z3-CH'ES9UKCK2M'/A<3& )/1"A(XVA72"D&\1$LV
M ;IF/+@D0I6\ON=#WB<B6X^<N]OHMP)G[QTXU^5Z*8#*FA'I=6ES%3VQ3,YQ
MJ>R--FC'5'\%/%00[.&5/&I70]WDD3]XW%Y8,/-(A\EM(XPWPSP:7RPBBUN,
M%F@\6(VH@=UFNA(]P%(2'#5*0>-6Y*7U,7(9G2[!!"J)A]$#C8<]T W<K4L$
ML53Y$9$8KSB1@26T4D4FP7FKG(L.9)WZB'M#[^@JG-L(.F5-F#"X/8CB+C+J
MB981LE36TU3%_3[6J_"..;?CU?@V6JN0#G]S+J3QUW[)VE@KL\54YJ]$'U,8
M?1GV_P=%-K\:G>=S+R^VRG>7;]8A@PP9A>8-4")!<.)*-1UCLV%*<DM-E7>9
M2O-Y<>P]!E[4-%0?F]:[DFI4@BKG\IQ\'DU+B,;MS\O4WHVF_U^:WD[Z[CG:
M2\"RX &(LQ3= ^"6@"R]@ZFV,@:;N:E23*"3V?U8"@?G3(5*"=4FN=@-?A^-
ME]\JO\=Z,@F:9?9$EB!H&;DBZ(-H=$*496 X\#HM [N=YH^E<CPLJA"B<GOA
MOKN[O[B!5U$[ ^4"R> .("6E>#YJ01RSVEB(,?DJI:A:FT%73VD'YO=A-'Z<
M;VUX7FD5P9"L;"[Q83@7*EQI29LU4T:85*51VI&]M75*A$<?W[91R'-YMV@R
MIQ^/;]L_OFW%E2X>,'91]',AL:'.2A49X4E8(K7QQ"M-B3!<:N&LI[9*5,+S
M(>]6CV]'Q]UM]%O[\6WA3EX_\.3LLTRE7#YS1#KT*3TH0Y@7UDO-G*%5CNB-
MB([0(:JN\,<>XG;6UH&>XSY^^L>DS1>WNY]7XU%M(]Z5=[,D'$K>Y:@82"H#
M,,&9UIIQG2)$^_#=[.XG'_QI+&0/TE!.5(Z42'1^B?/9D0PI,F-X#/E$G\9V
M1O#;OV;]Z=5M2:+)^^EY&G\^A^'R0N[FEN+C:##X?30N_ZC'/ _"E-;8T7HB
M>18$* /BO5*2!\9 5RGMU>TTCW"7;G<-M)8K4)]%-5H0UI_MN]G\1*,QV>AU
M)N!U23T,CH 6@8CH<P(O0[;/=;DL9OB,5DH'5.U^5>W LT,XC3M/].^E$^KD
M)@N)4HV6912$!171[J04/1\#!#(5/E(A/:WRJ-[5!'\LIX,LISU85N$ELMX\
M40LY]:=WTOJ<"SR:Y EZ;6@TZ$R)%5D1+S*7)J'+Q:H\U'<XQQ]KZB!K:C^N
MU7BLK#;5_YJKY&:>*2FM9$+.AW(89Z:)SQEP#W$TZ6"%S>9YK:G[$_RQH ZR
MH/9@V3%5%-C:MC7 %?XG$VMI)M)S32Q-@4CJO00>E9>'R=RIXT,=I2K^F?I?
MSDO RM<TAB]I;B^]AFGZ'?KC_X+!+-U=/C*$)+($8D.YQC6EOS#5AD0EE&"&
MV^3J9$$?EQR>T3;Y;"Z1JO'P63G%S<71<YSB.6$5T;ILGEE:XBP>%3$:DTT$
MY>NT,SR&R3^C!7@,*^ (5_-6]'U62_C^C</3@K#16P-6$!E9,4FE(:!$( S]
M)FHUM\>6^]6V!'XLYN-<S#6)_!SOUDI1D:>ED(Q()C-&LM6IE(/SJ%4>2OT1
MR5F)X^'/S$3>9OH_UO)QKN5J%'[&MWD-=C0T3:++B6CNRD4,<&*5XB0 =3DK
M[56LDLES-!+XL9R/<SG7)/+SO%%\6@;1:1>R!B(HNAE2B$2<CHQHXVS48'(X
M4*1RY_[R(;/!=-+9R)B(\:@*:94C7OE,(J?"2T-M$'6VU!>8#;;7C=]!-'Z<
MV6!*:T>5"8277":IE20(/)% 951:1=Q4Z]3A/JULL*V(\&@VV#8*>2Z)-$WF
M]",;;/MLL*VXTD5&S2Z*?BXD-FAB.4.!\.!%R3]F!&+I^A<5HT[JDG'PLLF[
M53;8_]_>E?4VDAOA]_R7 G@4R>)+@-DC3T$2[&:>#1:/A1<3&[#E(/GW*<K:
M[(['AUIJMEJV8$#P"&.IR.\CN^Y:'7>GX#N LS^)MGMWG3>[]B*?!9#[GW[^
MO*LQLBY7A20&&O4Y[.0TL"ZB[U.ROB&CSD-4RU>E6J$%/1SXVU&HG; R;'B#
MQC>_9%0-V<$-&15YF[USA6Q&[1H%:KIF:V6A-7CW?&'9NALQHF,5:VY"1)0;
MUP0',9('+MG[D.0*YM,\P-;2B+&Y9H*6XZ^5&):H30+.S8IA68-L$3+I#S63
M:&'.'=B(<0IJ9]2(D9LW-BH$1<H!IN[@<+Z"UJKW]?>^Z'V&Q1]> WYIQ'@4
M>]? B[-JQ/C_3WK\HZ<.80$C)UUC$N7,"1@J.4A>&_"6?56U!-N&%"6>;,67
M([-*;IU_$\<^H\HH[:#EUEM7U0!15P<ZFEI,M%Z/R<JZ-'$\S^-S/(M6W<21
M4I5]50IJ+1K0I@#LO8-:<G?<NTIZ3.'3!PS;'</OTR"^SK!=<L:F&@OX/E<$
M0XK ;"JT&")QY4!C$N3?6=AN$A%>;^(X 9!SB7CLLZ9+V.Z )HY3N+)($\<#
M@#X7$BM":XH-$%HJW0=?(*:$D(LR$54,CH?X4<Z'O-.:.*Z-NU/P73QLAXH4
ML\W0+#*@DXUBM TJDFTQ>Q7]$(_R1PC;30)^4MAN"FHG"MO]X[NY6SI^_8DC
M G*OR/PD^I:3\UE;ZQ1&M!PI*+$/+!5B'WM#X3<^^_2A-FTQ:U:0K$;A9A.]
MTL0(PBP35(H!W;J2ZV<+M1TLP?:EYWY?W_SRZ'#05V(/LG9R\DCW.1$J.D@Z
M(Z3:*!H.58^Y/N=<Q IOVWGY.UMEP+$,.*N6BT]Z=U4?4K+-0, ^-UZ;V*?)
M!2C&>$KH:AH3[5MJ@9=3L ;FO.M:\V0*Y^@"F!IZ-1-VW.0W9USSU:D2W*76
M_'+&3LZ]$>7ALSE$&RL;49ZR9 03L7<JR-=E<(C-:)_EIPXY1!\Q%G(,]4^"
M^#IC(=D599/3H&+S@*DT2*&/5Z=B4LVM6!R2U_C.8B&3B/!J+&0*(.?B1MYG
M39=8R/18R"2N+.%//@3HLR%Q)J.1,U!AL::S-\"R.-"%JBW1-C=FKM#YD'=2
M+&1]W)V [P#.BK:\K7JXV24?W>_\Z2IC5)@B!!8[%4FL4]+$T)O\MT:)T ^A
MW0ORK-!.&@[V[?Q(+1/Y^%O=_/7V7DPQ>:>*V+*!_[J]V0K]??J2'[YLM_*V
MR<Y=YW13?KC^\B"FVE=_L_W?1\1*9I=AANC*V'UY$H\1Z]7;8G2(SB$;0X&H
M.!^J32';5JYFE^9(^^!F<UWZ5US_N_Y<\\.=;'"]__$_^<N#+.HO<C[[.7S8
M[#+O?TQW-]<WO]S_)L3O)IK5'%(UM0]2J&*893EMSCI1C'-V7@==!ID6,RW@
MV!M=<'W$IR-UI9MOCDB#3MW5R'(QI)B-_%,1-V8?RI ,_*^D6/[V/@F;GM[8
MAR,Q("SRQ"'VV ]\9X'>__UA<[^1,RY[L#WN5]M%8Y45-XJ UA>(+$![WRJI
MF*CJ(8=HDI0?E%;CD!R@7\H!N-NJ2]N4]=\>,/>?-IN[:Y:-XB_UG[??ZE%_
M4+.NO&>5:LH@!X@ BRPC42Y]!D&(+68N84A$^7C1/RA!%\9\@'/^V2.V4X"^
M.6>?RJ\/]YLN]Y5J*"IWR("H0Q_G)&(GN>BS8V3'WO@RI-GJ@?)^4'XN@>Z
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M06MJDZ'=V_V%9:%__M/_ %!+ P04    "  "1P-3UFD5Z.KC   2.@D %0
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M4XX3AT.'.M*2")$#8Y=XD"8QCE'H8LZUPJ N%61IKH*=*G661:N,*A55-.J
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MD@@VG0&&J]I)1_CG-*L+*,O=9R/6PGMX&+QLCN_'?NPPR ,1RKU*1"$1C,&
M."0.(A1+^-J7[6W&_CN_:IUZ+_>BM?_A\D^M?_B_V]NF9TLL0=0%&2OS]8G9
MPO/?J4&,^9PO(M_5IE[?1L;L!#,Y7T>8$;*-,U&O*2TV4K@B%[PLY=!X_8[O
M0G1<[ B?^S$,$?'D>HXHC)/ @3'U7%?$7 2ND>]Q>+BE[8Y;:>7^>"<N$-PT
M].D,QGJKF#WD)EY?.M#ZD@(EZ@2[8#U0;!+PF1%GI48][0])2_.N<70B>? A
M;5K,J_[Q>:;"NGE&4UZN',X\SW<HQ $2$,6Q!^6>P(5Q'+&$QEX<1EH)NQIC
M+8U(>J(V3K:^L.#[][DT@P)#"WP(:CU*L03@Q'QRB-V>G/:H1 ,,FSPR--RL
M)**A]R&#Z-PRCC[^BM.L5/D?O+S-/G)E'M%J4\C'M[4ML!<QA_L8BMC%$'D!
M5Y5V'1@AAP<.#WF"W!')&^?&U?H<YL_@4!(#N7-[R%DOKJ%)YS CD[/ ZS&*
M%1SGH95:U":[BY<_*!3WY+5?8T07&YLL<W;,6:E&%X%#OM&^[[)DL7=Y\9%W
M->-5I=N'ASRKBZ"M@H0ABH((^D[H0Y3X"20($QB1@ 0.2G#D>48GA6>'7)H%
M4Q^6;//%1%[4I<;JJI>@V*J@"G_+73 U+Q:G,0F:)X=6H9WZX+!+)U,U*7;B
M*H@;@4$ML?VTLO/H3)%=-C#JBR29G4?A5*Z9QITC_3'U\>.VRBLFOAL1GT#/
MYQY$+O9APD@" Q%YH4.]D/C"R/^R]_BED<SUB)B# \ TG2FC89C:>5(+-DFQ
MV^,Z6_6-[(\PKR_DJ';/?!_'KYKY=+_^']7S6UHP3<MO=Q40Y$0Q\2'F D$4
MAQB2@"9R8^.S,) 40!VC#]VF<$NCB7[47G.D.=/9Y;&)F_@,\L+I6/Y98E.S
MMM40?!B>SOG. 0=P7\1YWC'YOHUSN0%DK9VO#8TQ^IQ,%1Q3S\O7J7)U;4T.
MYGN^&P0$BLB7U)U(_DX\$L$X\AQ,"(Z$JU4.[/Q02R/BG:2@$U7'=#$%6/N
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MH;Y+C%Q*^D,OC=5[DC=1B_4197L"M<<8XWJL&4R*'G%/ _7$/&P1Y1'!HZ:
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MLJ8FO3L^ -E6TY(53ZV'S,8)Z6_Y#+S!K[(H POQCB=PV[DKMVM4\]5F6M^
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MK^XX>Z)6=)-+FX1$8AXG,*49AH@@I?!%-(6$DI#B%".:&55S]D/.U'2_0V[
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MB,. 0X)I!A$A$M*<19!P$5,A:$1"H]KCUY$Q-1GS=T6H=A<NI8XE;FBN^]V
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MPCB$"<I#SB.1!2*Q:H=^%3E3DU072D\Y1V=>N6AF FZ\I1A8]GE8!?M.Z5[
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M:4RC."$0)U'57"B'>9P&ZF;+ B(YRFF0F!JXSDTR-5'9T@FVA(*:4G/+UEE
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M41QC&$JF;IYI@I0"FC"82"P3=07%@3!RHEK//#7IW]%>5X76U(,["6KZ0<L
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MWM6GN;!#7^0U1Y!JEL NWV OV8B^@-T'&^9!Q?T-:/B_ 34"VE%68W #6A1
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M#ZU%YIU\IT.U!*\$<+DC4F=1*.(HR!/(:<(@R@*FA!Q5*Q.A/&-1CF)F51[
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M8#3*$51JJ!(J69Q"&C,.8\S4_Q(118E1DKTWBJ8F>?2%@2Q> *^Y:9I3%0M
M:V8!J;FU4)Z\+)R!!COV<@PLX!IV0,,/:!AJ[_P?)>AXTF'F76:I9@LHOH!F
M;%L+9.P%LU"!QUZXD?3BL1;03B?V"7:OHNQEHO&T9Y^X[*G47@=VT[,_+1??
M=&JAMA\]J"&J KXRRU*190Q&69Y 1 (,*9889E&2!5BD48:LG/JG)IG:Z?:I
M2[+45-X 3:=35>23B)KIU]?B-/"QXP*1M4;=AX%/3?KD/*-JT'V<'FK.O<\Z
MUD"NW-=M6U4DDXAGDL $,P%1H/3@/"0<<J0DMP@8#61D$S^V-_K4XL?JFL1M
MXJ]+4O4^>&:[VQF2@;=U3=< /<-/,NRU*._>!.,6USW%VU&1W),/V2<6-B-\
M4+=F,O]/05;O%_R=+LE"N,X[CCAD6:1WK?J)$JR#\?(XYRDC.39*'>J;9&H'
M=4,GJ D%FE*@2 7OC*OE]$+:OY=] 37PEG;"R"IY\!((5^0-GAUZM)3!2\SM
M9@M>?-;M=.Y"9=[_T''EHNS"P"1)0RXC!A-$8XB8H)"*7*J#.^$1#N,\R:V,
MWV=GFMK&WT:#B892RUB[\YB:'>!>D!IXYV]!:HD<)&;N(A0^C_GSDXUZY%_D
M^?#XO_R"8Y'8PV+Z[6<L B(3E"$8!T$$D8@HQ#D+H8@IX93D49C9U8D],]'4
M),-Q9PJ3C]X.6S,1X0.Q@26$&UCVA6,O(.&U=NRYN<8M'WN!XZ,*LI>>=_"$
M_6VU+,O[U9()P4O=A>-2B[59Q&A*<HI@$K-8UUUC,,<DA)A)QB.=_,3-W5[6
MTT]-DE0,@.>&@[H-SE'YQ:[AK(7CQ'YA#-Q:@\(]L!BJD;[?0]IO*TU[R"T<
M4X-"/Y(7ZN%1U*V\BX6<+_^HUX <?^_/[2J0EAE?45C.*/:ZE^Q''<^7Y,SQ
MGN/(?917Z9?WJ5B(CVOQ5,Y0SF0H@QR&22X@(C*%&".I%C')(T&QTE2M2NCY
M(FQJYU"5:5KG5399EEI;4[P\+1>UTC9JL[SM AJ:NE]A68:VDOMIF0=^T\R!
MBCN/VK9OP"?4.F]+V[]2][PC1#TWT#L>W^&V\&&SWJQ$4YCBEV*N3H[E0MRR
MQT(=)_IW=_+=:O/M8560^=UFK>50^76]X8K062RB6,8YAU)D!"),$,R37$*:
M2!(+AH7ZE?&]X0I"IB:Y.^K;DF8W@&SYT$)!-XU_7A5/9/4"?KE]^UZ'T.G?
MO?WT_O8+:-D#I>*O+K?Z]N]@592_U_7@*]&B"\"#9?W:KW_Y^A=0 6JA&U^S
M\@87DY'6<V"17W/1U?GI^+@!M_LKJGD!%3/;Y6O8&6E-+&XN(ZW-B'>8;0;J
MMLVPK->NV8/@C\>"/0(JZK7AZG;S1[%^K/;/M;NS^J/A#KW1P;,Z1V+QK?UC
M53M*3[S258.T<G$P4L_\OJYA'CZ)W@O9->./=S7S@,+>)<W'> Z'^J?6.M64
MH7I87KH<;M- A$@R'F*BUC".(4+JHD:2#,$ )41*I=[E9HWFKB5D:H=ZQPIH
M>-%Y:WI7^K587;-T!J?R2 LR\*E\<BT>S-;"+ O([\)8',TC+="(1[,^C=4Q
MS+=Y6.JDVZF64Y]Z5OM)CRETM==BH5ZB+_7IV.2F5*?Z^^*;NFY__/@1?+T%
MGSZ]!6_^=$?%2A''__23KS/3PUKUGIG7C#_>F>D!A;TST\=X;B;.JI*J#JA7
MQTE=(*%S_>8L5L<BR2%F&8<HH)D^%3',41;S&'/=_,/&:'E^JJF=>[N4_ON_
MZ?B!OS957BQ#;WK0-;,H^L%LX*-IE\@_MW573M?%&\3G?ADDGW:]GME&M=1=
MYOK0]F;PAJ,0Z:J][M:#W2D0_//+44'8VS_(BM\]ZP=+=0THUZ2Z'WY9SN<?
MEBO]QYE("8YBDL"4$@D18132.%'_2;,@"%.**#)JW3HLF5,37G7#!JUP-&1;
MBJQAUM)0W+WZ"@TM*G<*:>^RN%=-6REW)PMN:UYNVE6] 3O,@M\TNZ#AUZ=H
M'71!O(KE82@=5Z0/BO;1<3#L;/;Y'N^:"UH=5'XO5L62?U"_*V<112%+90(C
MIB,\"0DA%9& 498R+&A*8F2<\'%VEJD)\I;0-IVA)A54M)IG?)P'M5\D>X-J
M8(GJA))5SL=%%*Y(^C@_]FA9'Q?9VTW[N/SP%=?0CV6Y$?S=9J4D2CWTWW6M
MC2_J_KLJF+H65T]5(JB*!)JQ,$*Z"26,DYQ"E#-U5XUC M.,XESD7 1!9'U#
MM:5B:F+C[XK0RM&B?2LMS:"L.J9L%H5MRJ?;REC<;H?$>XR++Z@9 #4'C?RY
M 143-V#+!JB?;K2XBA7/5V!7)+W?CJT)&?_B[(K5R3NU\V .?JY+AL%;]1]>
MN=Z:TJ,!S]),7:)%SC*(I,P@03A2JE.0,D%8%$EA[-NRG'QJHO'+Q_M;T-%H
MX0BQ!=W *S4@E -+/1-G14>]2VU16[0M7$T#HCY:;5$+]#TY?1Q1ZW7TV(XY
MGG/'D=L]AX[K&&[:\]](L=!1TYWWZ%.Q+KY5'^)7L5[/ZS2//$R5X-=M5C$-
MU26:)Y B=8F.$Q*17,J0!_EL(;Y50Y@KS4:3&VTD7&^D(Q(&=*KK9)P=7^R\
M(QV4'>UV^K+96ICIQ_Z@'2FY2=';QN_O1"ELJ09?+Z-JK?M:H>13US6;>%3=
MU@J+0UW6[F4W4?5VN:@\3O\HUH]O-^I6^B16G??[LV*RJ2V4!"SF29 IZ90@
MB,(T@Y22'-(@SRB-\I"&W.9J;SCOU#36KL=OFYU6I5NPY5SQMEP1!_^.Z0*8
M2:@!8!U81K44US$S+<TWH*/Z!FSI]B>D+('R*:9,IQY54%GB<2BJ;%]WM$IN
MGI]KJ4?F;TGY^&&^_./CMJ#_M@!%G"=!'",884D@$C&#>1Q*&'(I4HPR+KE5
MMV;#>:<FK';)/HA]J_)MJVS;G88(ML$TAJMA:'OTC_'0UL9=>#7)0-,,=H@>
M)KK&#BBOQD3#J<<U']KA<60PM'S=P43X_NEYOGP1HK(ZME?/>_4M_4)^%$^;
MI]O%8J,FUR)41VAI'>)>K-JWU(],*P"AS#D+TQ1&H38<!C* !$<2BDP*%H1)
M$(;FF6Y>2)J:O&MH!Z0B7O>)VU*OF[T T=!_ T@)B/Z59H/4B2\ZN$,W@2$K
MFX(:?M;6P#XY^HH-+#U;RAHW3&<UTRS=@'8I:Z[ 'EM5%O/[;BD;UD9?,PLK
MY^AK-Y+MLUVE_8W4[C+PK:YB0^K8^.[73^1ENS>K6%2RV/ZU=HQVM3Z>U82^
M8N6]+D.O,=7/3..96+TBLV=X]3NRC\:L7P17'YN>Z7Y5L'8*]>W.L)!)%G,.
M><(#B#**(0ES#A."I;I.Y#+-4O<FK&?GG=HQ>M1P==51KE-2F9*YVPU_37/5
M\RMA=F48 -^!#[VCIJE;HL%]#>W]96BO;)!Z$:CAFJ&>G_H5&Y]>Q*._R>GE
MU[V&8%4AH.59L5K.4,@32=,<XBS*]3V!0R*0@"S*B8@D"FF(/01A7:)C:E)M
M)PSK_=?[^SJBNP1OB@4HJQ]_\A*'=7%Y#*TAPX,^M'6D)Q:K9N,&]-T!A@_&
M,@5SA'"LBZ1,(2#+%"_#D"SCX>P#U]\OUL7ZY4,Q%ZNW9"V^+5<O,R(RF@4I
MACG68E$D".(P"R'B(LI%Q@4.C,PG9\:?FKBK2005C: ETCQ*_12"_9++ RY#
M6QRL(+$*2>]A_(I@]%.CCA:&WL/2;@!ZWV.N'FE=7;"2!VT\F1 1DC2$,LX$
M1#B,(,4TA9F@D<!IQ#-A%#)Y=H:I;=Z:P'__MS -_EJ1:>M2/D30U'E\!2Z#
MNXGKFI.5HG QAM'!'7R&=;^.W\-)1G;QGN'QV)E[[D&['5VNUFV[[O)VP;^*
MU7=U02K?+9](L9C%09JF),8P2K-([^I [>I4YXX0BAB+.9.YR:[NG65J.[LA
MM*K8U5 *?JM)-8S([0>U?Z-[@VK@S>Z$DO&>-T*A9]^K]W?VO/K7X7[OGV"4
M/6_$8[OOS1YVCB_3YI Z-.I+4?[^LUBPQR>R^KT5 WF:<I)2*&2H#O<P(Y"*
M$$.4!7E.<YS)U*J/T*4)IR81]N@%FF#046PI&HPQ-U4'_"$YN'9P#8@NP6-&
MR'B.&NN?<^QP,2,$3L2)F;WG+&V^B]6ZH'.AC;2-]ANR)%>"14">HO^_NB_K
MC1Q7TGV?7T',O1AT ^:,)%+;'6  U]+G>%!5]E2YSQF@'Q)<;4VG,WU2F=7E
M^?67U)*IW)2D1"G5#]WE<DEBQ!=2,"(8BP>QQ 0F$>%01$K;D"0EB6>5#G9R
ME0GJE9K(8DZNM0HY :2QWN@'S_#*8@^90=R)%@@<:X43"XVM"L[S>N+[;[FX
MVT=?3B9X)#^J^69*I0B9K?69<K;89(NG:@#:<K&;M,=]A)6?$<(T#5(]L310
M*B%$T/>B((FC5"21;Z,2.M P-86A+,#O6:[W3[E<@:P<][ F/TR;1_<1AYEB
M&1CD@=5.-4!#D5_/1 0_51S\? -V3( =%X/DC_9 T:7FZD+&J'JM!TZ'6J_/
MH_J7I'\55?OQ>SJORH=NBU;EFAI=#7^W^")^K!__$//OXK.BZ3F?21X1+\$1
MC'&$(=:M?J@7AI"GF*<^\FCD&?6:=$3/U'3EEH6ZZ;NH2-?9;#KA+5N A6[Q
MNRZ8 "\%%]U+KKN(L%VG7D$P ^O7PT)LG5Q32VG'$"@Y C5+ZG*@F0(E5^#S
M%235O5Y^8(E=J81^$,GUJK#O@;--T7V79:Y6A]\#D[;2_#Z/[;!7EL^^E]\V
M-!?_V*AU=687F<\U">J7_Z/6?%SN34OX1N8B?U1RS77OUED0^R((D@3ZA$00
MTY1 P@(!?1J&OA]'."9&T04WY$QMI[S=#D7)MRP5R:453S?Z]YJK(@]\?P9*
MKCD#ZYHU"Z7<7ZH&N^>HLAIX\]R):<<-N&N*Z=M.3 =CAPJFP.-5Q&2Q=8XJ
MKJN,'=)5%J>_LFKP4)8WO[8S4X<.Q*E+I;CR5A;%J /3Z0BN2C:<":UU&^Z_
MRGB[L#-$]C9A=T_M%L.[5^_5ZLMRL2P=X<53Z3)7_G(5?D:>[U%$/9W"1R#V
M0CW[@''H)R(5B9"(8ZOVDB:+3FT_+6@&3:+KR:P_571;YC$;(6\6GW.-Y\![
MG@&4 QP-V(#D,MYFM.ZH 38;) XC:E;WNJ@:V[HG9"V^K74[GD:Y4BQ2SF1,
M((]Y"G'H)Y"(-($B0!Z6A.IA9MT+Q]J6GIIZ.JH=RPN"=T/<]4#"/C5CK7(P
M4U/#H#NPLCJJ'-L:7YIP99Z7. ]?/6:"UW %9*VK7[&&S 25]C(RHR=TTV2?
MEPOQ]IFL?A?K7S8+GE>;>L08)5Y(H1=BKK06$3 )XP3Z6##&XHA$S"JM^O0R
M4]-0!97@I2 32$VGG3HZ Z:9ZND/T<!JID2GI! 4) Y@ K6CX%)YG%EI5$71
MSNVA4KAP=:<(IUAPP3]E3)M&MPO^OMFM;NNQU[E2OH]3S",H9!A!'(08)H%.
MS2:4TT@@S .C=$S[I:>F*"KB045].0*]27^GV:IVTC"*0@Z$\> 1QWUX;\_#
MVZ5GM1W.5F'$@? >[;#M53U.K9,W6[_IC@YKDBVT$UPV9"&5?.:-UW^OSR4@
M[H-]':"]$-BS>>*80;P.G!X$[+H\H4]%WOLYR?/;ZH-),0Y9%.BYW"B!F/D8
MTH1A&"'&DI@)D:1& Z#.+S&U[: J0,N[EN/MP6=F+?8#96#]7>%14 =N!RO)
M.\6]^YJ\O56N4)1WBLO357DGK[S.E%#=44-PI7KJD_G'I?Y58PS=[9/20[IY
M_)UN[[3(,U;,89E)CQ#.@P@RZND6)2F#*4,>% &)$X$1"1@:<Y!H9TZFIJ1*
M1HJ]NIF1]EW]>MRIH]W?#3/5^*>0^, :V.7LTL:+\['QXORMR,9JH'(#MKB
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M4]N6[Q5-ZA>&T9FSL!GLBCW!&'AO*Z@#BCSPC0!%8)<.&J> L:F@[ ?0^%-
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M.","F KU/R90*C!* U]$=0WDH[D5=+R2T8NZ7_[X.,JQ;$GHMCOXNI@P\._
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M3)3FYLM--NKR;![?+]+%='VQ?#W_FG8ZF%CF;'8T@3-1X2GD'!B[R4'Q4I&
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MPD16QL*48;QX_$6;I"&BRE3:>J9L5XIU;X'+[=>;#<.,IU'&A*&ZLR!"&=1
M#8,DB/8:N4Z^2E)\/_*:-67[X.5!Z=SPFFG@/OKO2PQH?EVNIA<8=2\G6@1M
M-9%E[ <*R&$08S7'/P:&?J1-@H8J76'ODC%R[F<=_!PAZ09P\@)CG50F]Q8M
M?)@N?W^!-$Q7Y;N)XM%:E3,H4M)W4G H']2QSIZ&9'GBL4I-WS,TC7ME40E!
M0^F@ 3CM@M@/*73H5A1^[MM12W5V"F-E3[T"08G!K6'+$Z&E-#!CG*]24_Y=
MRL:]CZ@$K6'UT0# KN8]/SB?)0U*F_*^P3?5\T:@E#0>U]%F#&8RT:9*_=93
M!(W;BJ\2G :1?@,H>IO^N"6A13?';\/V_N]Q[T\8'PWA93( ^GS"EXY;IHQV
M=C1J&ZSR=29P[TOHN#WT*J&NJK8&?"$?Y>+AB!87^RUPPFN'FNTNGL&H8TZC
M^<H@6&9E2F("RW1I=YNM,NC5!UZE:^;PMPZ;QX7G[^@V.2VX3W22);5*X[DO
M2H<#J_'P#]&)&$)BFO=[^/G^6LW>'>RC]3N/-P/+MX%C\4$@\LOE+VD>/N.6
M_7V3U"MI2H0:C$8V][DN"; B2;#9:,YEM+3.3?OW"!L'7%50\+W8\!B5- FQ
M*VYV-2=*$FM<(& M1_= "=R.HDP%L$3FK#7ZDE4&67^/L+$SS(:$P7<Q=H1.
M&L#8^<+%M-N,RVT>1]F'N\1B@40+PBU0B>(23J&DRI#$X,HP9!48<57>%IZE
MJC5T'0. ^]UD!M-& ]!Z9!^6GBB;+4@PY-"E>E^R6.844P^>&XEQCL\^)VI$
MK@*L9V@:Y\)]I'/Q($6TB*G"R'4%9J8VNUSZCI2D\Q# XZ8#J8B(GEK<EWW:
M*AR/J1N:6C-5!^K]>W@Z4 DMX&F]7'47:?& I9W)E=88$:V$H&1)RD@6G @1
MF W1D&C0;ZCR%O@=NAK#U:'ZOX^K 94Q=M^7]<5ZMDF(W,X#V@X0>I?/8K=M
M.%OVH"<H*ZE*AQP7003KH30! \TLY8Y;+UB?"+%?'Y@>!(WS8%CS!*RBBL:A
MM=N(G&=)# T@RXNZX-:")2Z YM[R'(G0H<^#]"#@&KW=R^ 0V -?!^BC<82=
MQ7]'2WVK(5?@B;FH"#BM @8FSI7IA *2L3PIXIR7PS6TVI.X=E%W"##VL6O'
M:&ED!+Y?='$=5N\6']/BZS1L758;K5;H5D#(#@/K)!P*BBM(5!'.&?ZM'<RB
M/4; .$D/M8_'HT7=!E1*+<J.@^5N8TG*!6?.@B08W0A3GMAY*,EF@AC#I/*R
M3_;,/GAY2,5XYN=XQ3Y$R9%2;B#@VS%RU38C*)59<!BCQ 2BU"'9C 8X1.ZY
M9=I[4N6-Y@X5HT/D6*W>GWU]L(C'+@1\ULR^N2YATR08JEV"D$@L[0$]&(D'
MN,[$ZJP)?KU7/'3(2_";O;I##)X=5?/<J27LL?'SX.+B[;KL@7?Y-_?OW>+J
M>@.ML$"CRRF#P&21&44K++T&FAD&&RQE<?^F\@D ]5RPU2?? [7<51;YV#"Z
M8N%CMUZ@27Z7=YFI$\M(9)Z686[2@B!<@X\8HCI-F+<VLQAS+]P\M4*K;R #
M &40H3;@P.S(+E70B/U-6LX_IJO/5TC_]=MN)GD9_X?_B^?NVX0R(@GW>'SK
MG,HP<@N.)5:.=$<2=\;Y*CV2#J"UU3O(XQ!X*N4U@$_DZVM:K*;H&[SIYI_.
MT^+B;;=*R_?N<ML:2GG!I3!@K>-HB 6RXU&&TB<59>"2NRI5>]^AJ]7@?AC<
M#:F4!C#VH>2\SE/\U2WF**LEBFU[&9;BRX22G*XF0L8<E6&0;2KG?4;>*'X7
M,/K-4>:225''Y'V/M%;=^:$LW*"JV1]L=@NV^::%4CP?;D92C)N:(#<K\Y9?
MSW>3F2?9DARC%Y!EUFB>E0%O-8%@(V79<8H;J$HB]./TC%/4<"IT#:&$H2$U
M<"7#K68[W7SY!WH'YY^GB_C>+58'MDSXSB<.4JNP#]5'%B?LPK['>PY=9ZH'
MI@25-D!IS5':#&6PJLQVX,:1(*0WJ=\=S?=6JM4,]>5T&6;=<KU(-[4ZT3B.
MGF $)2U:3I4H6&$(2")#<(A_IRMES?6F<<2KAD$QT;<KZ;%J:K63R_,;^HA"
MJGX?? *C5*-PJA\.:6))"J^ H5#*">C &FX@61&XLE('3INP314Z RO-DQ)<
M 34VE?PPW!N>X1>>3+ ^&^JK)&G^66;U#H^P$\S@W4?I#827CT_N9()P:DL^
M8RQ,E,L8QV0&A08^JI)"D:MT^/BO,8-W+XCTFL&[C[X: -V^TQ8UD3YX'X$9
M4T8$60$F* (Z>N64\]3<;]X\4-SYX\_@W0L91\[@W4=-#:#P.T->K25>,B.
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M']?^8KI<;IRK_\=]<<A:>IO^>+E8?T)O:C8-&X!L"ZG.D?!IR3J=Z)ABM(X
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M(ANTJO#/.<]Y+V <,\]Y'RF=!0)SVKH<VP/:9(P1DFX(81QI,.FRE]J #X*
ME(JV^L0P?$#A-)=J-U@\1EX=! "[7HR-#3);9T B841E\D*#$P:2)I<E^.)2
MF^FJQPP8/U'9UO'O$&,PO3OLW*]IG&D;BT2A(;(Z)Z .A0T&'9W%*?0JHSI%
M^?M]HGIZS3I0ZD]7F!XN@B[@M*L9I* /S+E,=CL7BHMM 62Z0,A<,&LQ-ZI_
M.*X5Y^2ERL<!:0SF]U/>=Z_T7Q#Y,9D(CC-/MMK)^E*#8*/CBNRU%K?=+Y.V
M5YR\\/@8R!S,XEXSP6\O?\NK5S&NKHB>.8;YQ?60VP,ROKL^:I3,[B Z1\K@
MOL.OU=U9OUJDS3?BQ?I;$L_%)$-=$R^UXU7F"E#7QX4LL\(B:YU!"[5Z@J9C
MS<:&M7=X>INZ_$@,_>&BCF-%IZ2RQ4)Q)H/".N^WJ Q&>A=CL2*Z)BF6 ;1-
MZ^",A96'AF9LH9R9_=G$&V-:H>T'MK1%C]%\ HN4LLO&>@/1JAKJN]H-F@KP
ME*/V@5"0FXR0:VB1/L3?<KJZR&_+#B[?ZD")40DT'$)4=;>9%H ^2[!&,:9Y
ML6B:3"P;3F*_]FD?Y'RW_[F-B,[,3!U1'_?,)[8T5"VKWY["FZ9@*G&#P"E*
M!R5=79P339U0IKG"%#5O,H2ZH:7ZB42]_)H)29OVL#M,?GVUJOHY8Y$YZV2=
M7,KIDH[10N R J]-K;X.>\Y--J<\2UF_=FD?G#RT2^,*9.H6A:WN_@-7<[R>
M'+Z>DUPV4KHY#P\\81$9L*YA5SQH"(SLN8C6)70!F7;/&:.A7S;M&]#8F&G"
MX@X>%;='>K=:EKQ>;]JD?\ZW"B 4AE)" &:]HM.4NA%/"C %:SR1.!=-YB0\
M3=:T;T6MS-&(HN@ 6#?=K%MNW9Q"A83(50$9L4X9T1)<=A**4,D:P:T(32*0
MQ\F9=L5<*R"-P/H. +3#(;TY32':>:"#Q)@<*"LI9DC.@5:9.:\94VTJP9\F
M:]I-<ZT -:(H)IT<=/<2OW,.8M?SKF")2KNZ)MM[CJ"\0L 8.(6GMM@@49>'
MI75/NTY[?O^TF^1:>E,M!7&X&5M>XD6[)X)-KV"=9907Z\V''?(J\/V'C/(0
M\ QM8W6^?7NCWNQR^_9E6[EO\JN;9LJ :_*)MDO@OH$.N;0<M0:6Z_AZX0L@
M.4(@56+)I1BD;-,A=Q391U< #/WV'^Y^^^WKFF$YV[I8W3)BG7)5=9228*SV
MTF29C&B2F3F2[HG+4DZ'U.^*#DXH[UY?4[\S1X>G>W9]5!NSV3#%<R0DM9$F
MV,)!N/J6GQ,''UF"H(U"@=SETF:MY*3&\S8+<:LR=ZG8"/#MIG)UO=U>^_5!
M=B(PI8IR&7SQY'IHJ:NCJX$7QVQVJN0V4R./)_VL3>@^>-V=>SJ)U+L8C/KX
M25_5R2>?<F7M#U^_NS5>_0M7:<N'?^1:MEV=\3^^Y%C+SI;UM^Y,,=_\V6:P
MRH95]_D5O16980#!/:-PD'EP=0.6=3$PAG49>9/(?-IC3USR.*&&G0_:^M#.
M^Q8I/.3<>SK\:EX9L;%-=/@'O_/WQ?QREZTJ,2FLKS!&&.)&<0%<2:)N7==T
M&L:R.<4-->JA)JX,[>;NF@XI9Q,;W+P>76\&W2Z+?W>!BR.*+_;_DC;QQ'YG
MZR/2,,X$)G( K92JBX03>!4UR"BYBR8G8]K,_>PDTK@GL[?_6I Z_#;_4H7V
MTX>W[VZIO"Z#FGGR,$-,";2I#^E9.W"Q*'#***VCC*9-T<NA!)]U5+$/-G=;
MYH82[B 'M_'3/M)?WC3+%^.#"$P#,YH"(;*0@-$Y8IMW@D=?=)O9.?>HF!9S
MIQ'\P\* @Z70 82>#0_6N^*#VV,O4N7KK_@Y;UN6K46NDI,015WYX*2$H! A
M8PI!1)]E;-)]V^(PTP+Z"&SM&P>V%G0'8+]G%+8-[TA!J"ZF-G48=3W^WW&U
M.8<NP1KK=1.L/D++Q+9S<H#LJ/\\5%J] >ZI6^B7;RV-7(> .40P1EI0.AJZ
MA.@_0]&%#B>%RTU2I_N3.NV3VB17?6-Y3EVCO#.&_7?\8_[YZO.KQ>(*+UXO
M%Y>K>;C:/ ^^RZN;?[6=TDT,=M865R#KA'5H4R'UU 6($=P3OZ67P\:HCT+.
MM$:U-6"6DTKOO/&Z'3,AA'#&>R2#*#,HF1.@CP)*,I);QK/0[ 1PW6/$1S.;
M>CYH/4!VW8+U=KM!Y?!FH][B>E#]C/G,HN..N&L-N4^!''Z"'?D\0BM3&)*B
M'H?-W5\^[;M^%U <23+=(N_'J^OFF+?E;2&RYHM/UT/"9C+DH%W18)/7M1:=
M0=U:#$(H=-))H=2P:MJ]OWK:DO\N4#>*5#H(?EY=;/Y.3H]'EML]:C,*!#W&
M5$#6=;8JU]ZL:"18;9/SPAN43;HJAY$W;<? B?#84&(=X/#@"HAK4_]FO;[*
MZ<UBJX0H FJE/92 Y!_+4@L:2!.9B!IUU$6U6?XQZBFF;5<X,:JGDW\'X*<C
M?]Z6T6TWZUZ?ZCV)?/5[3C\O5S]?71*SZS'KZ+092T6+B!%<4C4 K!VR(4K0
MJBAIL_6)-TDC[4WI(! W6]1W8A"WE>/95)#<O/HMR]W*T#'+1Y[^AC:U(WN<
MJH_"$6]D1,XER%+'524F )6N:[H1-8I,P5&3B803%XX<64IYIV;R_?+B@E2V
M_N$,930^*P;:*@'*$#-=HFLE.V^#\DJ8V*3>O\UQSKKH9!]<CUUH.P(Z.O W
M1N3"KU>;E%^*43)A#,6ZIBY_1/J)4]0KZWYD<K\4Z\SAWG62SM.[)X!G.XTY
M "L'*\OF.D\?+G%UV87*_&VS,O<F0+F>>NR<""YR R9:7LN'/:#-=5=N+J$N
M$I"A265G@[-,G&9^>6IS+%Y>P"U#8BAY7L.E]75GR_SZR?4;5V9*HS.9(:3H
M7=VOQ\"[F"&;8$S(=5CTD%5-)U>@9T\V;5KG!:K3N%@Z=@3]..I5H]#K=Z\?
MKVX3$-<O#G=#U)OU[6F6A8^>)013ZNX_3C<O,ATA)LZ"]0R-;S.\=6]2I\TP
M]:@ ;:7=!Z)'=S6)X[[P2*%B+G1C6FTAH A BAY+*L%$UV12VC1A2;,,5X_Z
M,"E6C@Q+?EKTH3#/MPW?A&S,%\V=A"R" <58 E0L0,SHM>&:6-1E>#_T@&?=
M>#[E>U@3!+V V.5.K_V6 0)9%L9:<%858D!BX(0ND*W"4JS1,DS3;K/O2<ZZ
ME7Q*73D.$WW,71COUOV///_T6[4=1!]^RC=NZ[O5/.;J))2MDZ!3*5K&0!+C
MQ"/R6X&NX@ HZTH7B]&++O5F_Z-.&_.<L6(U1M4+N(X&<FAF8Q$EI  ^&5]7
MAR@(,511YLQ*EC[;+L<.#3S?BTGN-('Y-%JY%^;.)QVTLP_ST??])QEDT$19
M9"+7.2D2(ME75W<?AAQJYV;$_+#.>^I&[;W/^&+21UTHYD38>P'WY+-I@B>9
MY5EFQBI'IHOLEW+"DCP9 YZQ+O .SK N:X2..O6+255UH;K=X/,<E/DY.W=S
M^F'<*5P;XY2'Y(.E"$9P\-XP0,MSR,Y9BM6[O&;W.N:+2:QUH:[3(? <]'.D
M ,'9F+57"7Q=:JDT>2,AD"J9Z&O!/&;ZXQZOU3&#TG-([76AD1-@[D^3#'R2
M8TQH966= FA<G=@B!+@ZJ35:;64(0;H^M?2X8T^KO&?\9GM"M+V J_).ZNAI
MMLA@K"WDTC-6/0@=P<6HH(028RJ1BT8%7J<YW[0=L6>L;2WP,_7 C&-Y\H 1
M[W.=A4=V9S/-A@1VA1<?\^KS[?;V5 QC$2'&0&Z+%A(\2P:X+(&IP 7:8>,V
M3DSXM!VX$RA-]^CHY4(*S[,G[.U'[^*4F"$W%-.2MV]\G<9CZF24&!P$QX(H
M5@LAVEU.ISWK-(G&_H'_V+76,0I?@*+N[6?OXAR?1:M$#*P.D['TBU ,?")?
M02LIG=.<<=;N@;0+%DR3IOS3J?5$F'T!VK[;S]_-(B82L]8@.%M]?HVAKC0/
MH)A4LD@3M&C7(W':LTZ3J_S3Z6]K%)YMY/GJTZ?5IE_J31V8NEC/XS_PXBI_
M$QIC(3&.&7CA A06<DMBMB!B<AQ50A>'31)M1>$@!7)_Q9(-Y-W+[31.\N4^
M0V;,>J>C\6!UW4>?C &,*(%IGU1V+J#JO4_O_HG.,0 <%:WM\G9'0.<%Z-"
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M]Z)R6C/9!23;2;4#R)*RK39>U69DU<VS]OK5);D\@1A;$WO+[]VM.][8S)C
M,"-YX*:00Y[HV.AB@E"*]<7'D&R3^I'C29^V5Z4+<)]8_AT@_E%UWJ9LOM/I
M5^D_K]:7]9P40JA27$UH*TYWD6%T3*0+*>J@@@Y&F-1D6^N!]$X[MJ\+;)]"
MTH<#NDX);.EU[#KH+&EN&08&0AM)$:O)X+(7]$OP(4O+3)LZ]SWIG'8A8+\
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MD$!?VP&K2FP/$7W@DBD/4AE5IZ!;P.P=E.!"T6A24;[Y!;@'A$Z<'VQQ]1W
M^0[LT.NZ4FQU.:>HZ<<<+F]9M#V.MMQ+J2,XQA&4]884@1-[&)W%!:%=3BV
M] Q=/>;L1@+5F!+I &#W^TR2"!2M! 3MJTNH98+ I +-:N>R4,SE-@'CWOUE
MYU*1>]13Q\&RZ0!83<KWE<W9,$NW?<RU#I17+Y)88A@K-OA24+=ITGWA_65[
M8>L4_67["+H#L.\.L@4/FG$5()::'Y<L@*-0&Z37@I'#48QONQNVKZ>.Z<$R
M^'ED'\EU ,'1DO:(%)@KPZ'XNJ$IU/%FB6R!92ZD6%)R;<K"3MK0TV[P?$?N
MPQ2(.']->/5Y>56+/S$YF7T!65(A]1<"O"7UK[$#XP%UBK9#-;BFOL?W[-;
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MTD[#'*(BTXBMI%,A,0E:"&=$THQU5E^ZE&=I1)8=GAA0S*3N;>+H-OQ"Y\&
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M@Z;.G>9*44<"(L0D'(E$3@)FX2@8WEQ!9*';4S!\$&64"1&F=$<<TR).*)Z
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MMB+YHCP50R'Q4$@\%!(/A<0[4$B\I4FF$M,([0HX61K:.(V<?K1XB:4'O\G
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M'6]?'M\]:#[&?KLM0_%+TX'9)=S,#L<@8!]OF73%-3(NHPD6PW&]VTVN>DW
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M5WHB'0@A[A]6#YK-O )+)O88EZ=%2[1Y!K@_<>#.C:B)I(H.O<M),6[L9IG
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MX7:(02ZUO%DRWBQ<XNY)Q$,C170%16GG2ZN1S7B _E+Y=75 G"QFX$[23>H
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MB+]J,!\;[%5XA8FD:D[!;($23@*<1"J5%4F0>CZ8 #'-LUX*G=25.1?"@54
M5_0F&H$F1F?,SW4FQBFB #2I3-Q]&]2[K9YF+9+?8BC8N(6I3::D:AQ@94O
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MU$)NG4Q'/%C!<>.[>7POF^KWN0(4J3IHEQ1]$$ST!)6A3MU2]2<&APP(%@M
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MLW>O7Y_^].[Z]!:S/&].WY[^?(&9K[Z6.'6(['JM>?QK#.:9=X;QF;'^FM(
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M0XL!%P6Y.%BGK,@IR6I3.UI.EA:G)U9C*BG\)*[1O:?[P4U.Q*.@F^#"69,
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MKTG?F_ZZ^VX@'C[1%("N/(&^LVOI-+Z!)47-9;L"SB/P?.%_7*8=36$^..U
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M-PIW;$+'$BZ<G Q1">:/.>F<\X:)'<V1(ZR#CF_%I]C>9+W!3PU(1TXP:;4
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M7*+FDSQ.# -1_R] N5P\X.W,C!C6EEBEH(F$C;CG13&F0ON<J1J(>&7)AB>
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M"DJ\.J50_)(<$,*",P'J3%39(#7N@JG0>^@J,HQUH&5ET3[>.SOOU\<5ZBX
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M8]TY3[_%%GQ04_#[SM5==86IKGCFS\6NNF)77;&KKMA55^RJ*WA*']8#^]X
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MVI\L";5.ZAJU[\RE&Y7EY"PW;N1.'#K9;7MQ,-A5$KBZ,2)/VS2/E=NLPQ]
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M0,$4ODR><[=48;9%SS5,WCS)ZDKYQ21P&-9XUNNR?G4PCY)4GD0H*I"&LHS
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MOR865+KV%^.3!^[1">$ <E(!.2'_;>@>VX]YI8 [6PV64R;LMB>9G8J:49'
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M[ ES#)@ D^HQ@2^&/6&. 1-@4CTF\,6P)\PQ8 ),JL<$OACVA#D&3(!)]9C
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M;*:<);^IBV3_^82%><3&9C.XZ?C^8[B!CLGB]&0:. AP&DT_3%KX+$^ *X"
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MJC?IAO6B@+6_ZMWK&V()R%+&,!&'0N=P1T":40RGG_[A;\Y42R[7%*&$N"S
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M)4X<)#3\GB2>C,\G5&N5?U-WR$8E%SV_+<E%A\(*@()_1:9V\T&+^W24;UQ
M<6B[!?>%7+=_< ?SJV>0BG(G2>$VQ!/T<9ZXQ$/VR/NT\$Y])X='+:>SC<R[
MN0P^IL+)Q)5+2 Z'9\W9_4G?=X792#)4)(HGF&":MAP=,=R3C^ O"(8(HU42
M@;"N@(/G>[]X7T+F:Y,"[<1K(:0_5)K98PPI84WI#V)*^UPSYT3K%$_I+RDJ
M#XWZDI@EIWG #CNHK1<O7H03ZQ8Q!;I4T/WYOKG2#=U4::[TX+4@V/4)8L+H
MLCYZ8O$B#BW( I'#*9 #:1-O^..F;)3S=G55&?PAZS*8KKADZ@T2$H"VM*\
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M07&GR,AWQQ6_O[<QOOA'ZWWQOP,WPK02^/T-UU4>AIX &\L-#9C>-5EO!TE
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M\W!:9A?PGT6SS%__+U!+ 0(4 Q0    (  )' U/":M?#YM ! #02$P 1
M          "  0    !E<W!R+3(P,C$P-C,P+FAT;5!+ 0(4 Q0    (  )'
M U,9_O%K_A(  )#)   1              "  171 0!E<W!R+3(P,C$P-C,P
M+GAS9%!+ 0(4 Q0    (  )' U,"Q(9RS14  %O'   5              "
M 4+D 0!E<W!R+3(P,C$P-C,P7V-A;"YX;6Q02P$"% ,4    "  "1P-38#?Z
M+F57  #5V@, %0              @ %"^@$ 97-P<BTR,#(Q,#8S,%]D968N
M>&UL4$L! A0#%     @  D<#4]9I%>CJXP  $CH) !4              ( !
MVE$" &5S<'(M,C R,3 V,S!?;&%B+GAM;%!+ 0(4 Q0    (  )' U-_>588
M$H$  $KN!0 5              "  ?<U P!E<W!R+3(P,C$P-C,P7W!R92YX
M;6Q02P$"% ,4    "  "1P-3WLXC5"X(  "Z*@  %P              @ $\
MMP, 97-P<BUE>#,Q,7@P-C,P,C R,2YH=&U02P$"% ,4    "  "1P-3^K#\
M/#,(   "*P  %P              @ &?OP, 97-P<BUE>#,Q,G@P-C,P,C R
M,2YH=&U02P$"% ,4    "  "1P-3F_CZ[(8%  !$'0  %P
M@ $'R , 97-P<BUE>#,R,7@P-C,P,C R,2YH=&U02P$"% ,4    "  "1P-3
M9>ICB@WX  !,\PD '@              @ '"S0, 97@Q,#$M;&EC96YS96%N
M9&-O;&QA8F]R870N:'1M4$L! A0#%     @  D<#4X<_*&]Q+P  ZR(! !X
M             ( !"\8$ &5X,3 R+6%M96YD961K;V5N:6=E;7!L;WEM+FAT
7;5!+!08     "P + /$"  "X]00    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
